DocCode - SCORE

Placeholder Sheet for Supplemental Content

Application Number: 19043303 Document Date: 01/31/2025

The presence of this form indicates that the following document type was received in electronic format on the date identified above. This document is stored separately from the typical case contents which are stored in image format.

Since this was an electronic submission, there is no physical artifact folder, no artifact folder is recorded and no paper documents or physical media exist.

- Drawing

At the time of document entry (noted above):

- USPTO employees may access this supplemental content via Docket Application Viewer (DAV) or Supplemental Content Viewer (SCV).
- External customers may access this supplemental content via Patent Center.

Form Revision Date: March 1, 2024

METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS

CROSS-REFERENCE

[0001] This application is a continuation of U.S. Application No. 18/941,832, filed November 8, 2024, which is a continuation of U.S. Application No. 17/667,285, filed on February 8, 2022, which is a continuation of U.S. Application No. 17/081,694 filed on October 27, 2020, which issued as U.S. Pat. No. 11,304,950 on April 19, 2022, and which is a continuation of International Application No. PCT/US2019/029486 filed on April 26, 2019, which claims the benefit of U.S. Provisional Patent Application No. 62/663,951, filed April 27, 2018, and U.S. Provisional Patent Application No. 62/822,815, filed March 23, 2019, each of which is entirely incorporated herein by reference.

BACKGROUND

[0002] Corticotropes are basophilic cells in the anterior pituitary that produce melanocyte-stimulating hormone, adrenocorticotropic hormone (ACTH) and lipotropin. The cells produce pro-opiomelanocortin (POMC) which undergoes cleavage to ACTH and β-lipotropin (β-LPH). These cells respond to corticotropin-releasing factor (CRF) and make up about 20% of the cells in the anterior pituitary. CRF is a releasing hormone that belongs to the corticotropin-releasing factor family and is the primary physiological regulator of proopiomelanocortin (POMC).

[0003] CRF is produced by parvocellular neuroendocrine cells within the paraventricular nucleus of the hypothalamus and is released at the median eminence from neurosecretory terminals of these neurons into the primary capillary plexus of the hypothalamo-hypophyseal portal system. The portal system carries the CRF to the anterior lobe of the pituitary, where it stimulates corticotropes to secrete ACTH and other biologically-active substances. ACTH, in turn, stimulates the synthesis of cortisol, glucocorticoids, mineralocorticoids and DHEA.

[0004] Testicular adrenal rest tumors (TART) and ovarian adrenal rest tumors (OART) are ACTH-responsive lesions of the testes and ovaries derived from adrenal tissue interchelated within these organs during embryogenesis. In response to high ACTH, hyperplasia of this tissue occurs, resulting in single or multiple lesions that may cause pain and infertility. The identification of compounds that modulate CRF function and downstream processes is an ongoing challenge. Currently, there are no non-steroidal, non-surgical solutions to control, shrink, or reduce TART. Disclosed herein, *inter alia*, are solutions to these and other problems in the art.

SUMMARY


[0005] Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a serious genetic disorder characterized by impaired adrenal synthesis of cortisol and consequent overproduction of adrenocorticotropic hormone (ACTH), 17-hydroxyprogesterone (17OHP), and adrenal androgens such as androstenedione (A4). CAH is an orphan condition with no FDA-approved therapy. To suppress androgen production, patients are often prescribed long-term supraphysiologic doses of glucocorticoid (GC), which has adverse effects and fail to suppress 17OHP and A4 in the majority of patients.

[0006] Compound 1 may be a potent, selective, nonsteroidal, oral corticotropin-releasing factor type-1 (CRF1) receptor antagonist that reduces excess ACTH, 17OHP, and A4 to improve clinical and biochemical sequelae of CAH. This may obviate the need for high dose steroids.

[0007] One aspect provided herein is a method of treating or preventing testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a corticotropin-releasing factor type-1 (CRF_1) antagonist or a pharmaceutically acceptable salt thereof.

[0008] In some embodiments, the subject has congenital adrenal hyperplasia (CAH). In some embodiments, the size and/or number of the tumors is decreased or reduced.

[0009] One aspect provided herein is a method of treating or preventing testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a compound of structural Formula (I):







(I), or a pharmaceutically acceptable salt thereof,



wherein:

R^1 and R^2 are independently ethyl or n-propyl;


R^3 is hydrogen, Cl, Br, methyl, trifluoromethyl, or methoxy; and

R^4 is hydrogen, Br, R^aR^bN–, methoxymethyl, n-butyl, acetamido, pyridin-4-yl, morpholin-4-yl,  ,  ,  , or  ;


R^a and R^b are independently hydrogen, C_1-C_3alkyl, $H_2NCH_2CH_2$–, $(CH_3)_3COC(O)NHCH_2CH_2$–, or $CH_3CH_2CH_2NHCH_2CH_2$–.

[0010] In some embodiments, R^3 is Cl, Br, methyl, or trifluoromethyl. In some embodiments, R^3 is Cl, Br, or methyl. In some embodiments, R^4 is Br, R^aR^bN–, pyridin-4-yl, morpholin-4-yl, or  . In some embodiments, R^4 is morpholin-4-yl or  .


[0011] In some embodiments, R^4 is hydrogen, Br, R^aR^bN– and R^a and R^b are independently C_1-C_3alkyl. In some embodiments, the compound is

 , or a pharmaceutically acceptable salt thereof.

[0012] In some embodiments, the compound is

 , or a pharmaceutically acceptable salt thereof.

[0013] In some embodiments, the compound is

 , or a pharmaceutically acceptable salt thereof.

[0014] In some embodiments, the subject has congenital adrenal hyperplasia (CAH). In some embodiments, the size and/or number of the tumors is decreased or reduced.

[0015] In some embodiments, from about 5 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In some embodiments, from about 5 mg to about 25 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In some embodiments, from about 10 mg to about 400 mg of a compound of Formula (I), or a pharmaceutically


acceptable salt thereof, is administered to the subject. In some embodiments, from about 100 mg to about 600 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject.

[0016] In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 5 mg/day to about 1000 mg/day is administered to the subject. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose from about 5 mg/day to about 25 mg/day is administered to the subject. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose from about 10 mg/day to about 400 mg/day is administered to the subject. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 100 mg/day to about 600 mg/day is administered to the subject.

[0017] In some embodiments, the compound is administered orally. In some embodiments, the compound is formulated as a capsule or tablet. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in the fed state. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in the fasted state.

[0018] In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at least once per day. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at bedtime. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 4 hours before sleep. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 2 hours before sleep. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 30 minutes before sleep. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in the evening. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at about 10 pm at night.





[0019] One aspect described herein is a method of treating or preventing testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a pharmaceutical composition, comprising a compound of structural Formula (I) and a pharmaceutically acceptable excipient:


(I), or a pharmaceutically acceptable salt thereof,

wherein:


R^1 and R^2 are independently ethyl or n-propyl;

R^3 is hydrogen, Cl, Br, methyl, trifluoromethyl, or methoxy; and

R^4 is hydrogen, Br, R^aR^bN–, methoxymethyl, n-butyl, acetamido, pyridin-4-yl, morpholin-4-yl,  ,  ,  , or  ;

R^a and R^b are independently hydrogen, C_1-C_3alkyl, $H_2NCH_2CH_2$–, $(CH_3)_3COC(O)NHCH_2CH_2$–, or $CH_3CH_2CH_2NHCH_2CH_2$–.

[0020] In some embodiments, the compound of Formula (I) has the structure:


, or a pharmaceutically acceptable salt thereof.

[0021] In some embodiments, the pharmaceutical composition comprises from about 5 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises from about 5 mg to about 25 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises from about 10 mg to about 400 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises from about 100 mg to about 600 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0022] In some embodiments, the pharmaceutical composition comprises about 5 mg, about 10 mg, about 15 mg, about 20 mg, 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265

mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg about 500 mg, or about 600 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.







[0023] In some embodiments, the pharmaceutical composition is administered at a dose of from about 5 mg/day to about 1000 mg/day. In some embodiments, the pharmaceutical composition is administered at a dose of from about 5 mg/day to about 25 mg/day. In some embodiments, the pharmaceutical composition is administered at a dose of from about 10 mg/day to about 400 mg/day. In some embodiments, the pharmaceutical composition is administered at a dose of from about 100 mg/day to about 600 mg/day.

[0024] In some embodiments, the pharmaceutical composition is administered orally. In some embodiments, the pharmaceutical composition is formulated as capsule or a tablet. In some embodiments, the pharmaceutical composition is administered in the fed state. In some embodiments, the pharmaceutical composition is administered in the fasted state. In some embodiments, the pharmaceutical composition is administered at least once per day.


[0025] In some embodiments, the pharmaceutical composition is administered at bedtime. In some embodiments, the pharmaceutical composition is administered less than about 4 hours before sleep. In some embodiments, the pharmaceutical composition is administered less than about 2 hours before sleep. In some embodiments, the pharmaceutical composition is administered less than about 30 minutes before sleep. In some embodiments, the pharmaceutical composition is administered in the evening. In some embodiments, the pharmaceutical composition is administered at about 10 pm at night.

[0026] In some embodiments, the method further comprises administering to the subject an additional chemotherapeutic agent. In some embodiments, the additional chemotherapeutic agent is a glucocorticoid, a mineralocorticoid, an ACAT1 inhibitor, or an anti-androgen. In some embodiments, the glucocorticoid is beclomethasone, betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, or triamcinolone. In some embodiments, the mineralocorticoid is fludrocortisone.

[0027] In some embodiments, the additional chemotherapeutic agent is another CRF_1 antagonist. In some embodiments, the CRF_1 antagonist is

 ,  ,  , SSR-126374,  ,  , or  , or a pharmaceutically acceptable salt thereof.

[0028] In some embodiments, the CRF_1 antagonist is

 , or a pharmaceutically acceptable salt thereof.

[0029] In some embodiments, the method further comprises an additional treatment selected from surgical resection of the tumors and radiation therapy, or a combination thereof.

[0030] In some embodiments, the additional therapy is surgical resection and the surgical resection is prior to, after, and/or concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition, or any combination thereof.

[0031] In some embodiments, the surgical resection is prior to administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In some embodiments, the surgical resection is after administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In some embodiments, the surgical resection is concurrent with

administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition.

[0032] In some embodiments, the additional treatment is radiation therapy and the radiation therapy is prior to, after, and/or concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition, or any combination thereof. In some embodiments, the radiation therapy is prior to administration of the CRF_1 antagonist of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition.

[0033] In some embodiments, the radiation therapy is after administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In some embodiments, the radiation therapy is concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition.

[0034] Additional aspects and advantages of the present disclosure will become readily apparent to those skilled in this art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be realized, the present disclosure is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.

INCORPORATION BY REFERENCE

[0035] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.

BRIEF DESCRIPTION OF THE DRAWINGS

[0036] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also “Figure” and “FIG.” herein), of which:

[0037] FIG. 1A-1B. A schematic representation of intra-patient dose escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics **(A).** A schematic representation of inhibition of CRF_1 with a CRF_1 antagonist (Compound 1) **(B)**.

[0038] FIG. 2. Graphic representation of pharmacokinetics (dose-proportional, adequate exposure at safe doses) in patients with CAH following 14-days of once daily dosing at each dose level with a CRF_1 antagonist (Compound 1).

[0039] FIG. 3. Graphic representation of pharmacokinetics (dose-proportional, adequate exposure at safe doses) in patients with CAH following 14-days of once daily dosing at each dose level with a CRF_1 antagonist (Compound 1).

[0040] FIG. 4. Graphic representation of patient-level response (measuring ACTH levels) to a CRF_1 antagonist (Compound 1).

[0041] FIG. 5A-5B. Graphic representation of patient-level response of sample responders (measuring ACTH levels) to a CRF_1 antagonist [Subject 003001 **(A)**; Subject 007002 **(B)**].

[0042] FIG. 6. Graphic representation of patient-level response (measuring 17-OHP levels) to a CRF_1 antagonist (Compound 1).

[0043] FIG. 7A-7B. Graphic representation of patient-level response of sample responders (measuring 17-OHP levels) to a CRF_1 antagonist [Subject 003001 **(A)**; Subject 007002 **(B)**].

[0044] FIG. 8. Graphic representation of patient-level response (measuring androstenedione levels) to a CRF_1 antagonist (Compound 1).

[0045] FIG. 9A-9B. Graphic representation of patient-level response of sample responders (measuring androstenedione levels) to a CRF_1 antagonist (Compound 1) [Subject 003001 **(A)**; Subject 007002 **(B)**].

[0046] FIG. 10A-10B. Images of a patient with TART pre-treatment with a CRF_1 antagonist (Compound 1) **(A)** and 6-weeks post-treatment with a CRF_1 antagonist (Compound 1) **(B)**.

[0047] FIG. 11A-11B. Graphic representation of an *in vitro* binding assay of a CRF_1 antagonist (Compound 1); ^{125}I-sauvagine binding to rat cerebellar membranes one hour after oral administration of increasing Compound 1 doses **(A)** and *in vivo* inhibition of CRF-induced activity after treatment with a CRF_1 antagonist; Compound 1 (oral, 10 mg/kg) **(B)**.

[0048] FIG. 12A-12B. Graphic representation of ACTH levels **(A)** and 17-OHP levels **(B)** after treatment with a CRF_1 antagonist (Compound 1).

[0049] FIG. 13. Graphic representation of hormone responses after treatment with a CRF_1 antagonist (Compound 1).

[0050] FIG. 14 depicts the proof of concept and escalating QD dosing at 10 pm.

[0051] FIG. 15A-15D are graphic representations of changes in androstenedione seen in participants in Cohort A and Cohort B.

[0052] FIG. 16A-16D are graphic representations of changes in 17-hydroxyprogesterone seen in participants in Cohort A and Cohort B.

[0053] FIG. 17A-17D are graphic representations of changes in adrenocorticotropic hormone seen in participants in Cohort A and Cohort B.

DETAILED DESCRIPTION

[0054] While various embodiments of the invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions may occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed.

I. Definitions

[0055] The abbreviations used herein have their conventional meaning within the chemical and biological arts. The chemical structures and formulae set forth herein are constructed according to the standard rules of chemical valency known in the chemical arts.

[0056] Where substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., $-CH_2O-$ is equivalent to $-OCH_2-$.

[0057] The term "alkyl," by itself or as part of another substituent, means, unless otherwise stated, a straight (i.e., unbranched) or branched carbon chain (or carbon), or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include mono-, di- and multivalent radicals, having the number of carbon atoms designated (i.e., C_1-C_{10} means one to ten carbons). Alkyl is an uncyclized chain. Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, (cyclohexyl)methyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers. An alkoxy is an alkyl attached to the remainder of the molecule via an oxygen linker (-O-).

[0058] The term "alkylene," by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited by, $-CH_2CH_2CH_2CH_2-$. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred herein. A "lower alkyl" or "lower alkylene" is a shorter chain alkyl or alkylene group, generally having eight or fewer

carbon atoms. The term “alkenylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkene.

[0059] The term “heteroalkyl,” by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or combinations thereof, including at least one carbon atom and at least one heteroatom (e.g., O, N, P, Si, and S), and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) (e.g., N, S, Si, or P) may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Heteroalkyl is an uncyclized chain. Examples include, but are not limited to: $-CH_2-CH_2-O-CH_3$, $-CH_2-CH_2-NH-CH_3$, $-CH_2-CH_2-N(CH_3)-CH_3$, $-CH_2-S-CH_2-CH_3$, $-CH_2-CH_2$, $-S(O)-CH_3$, $-CH_2-CH_2-S(O)_2-CH_3$, $-CH=CH-O-CH_3$, $-Si(CH_3)_3$, $-CH_2-CH=N-OCH_3$, $-CH=CH-N(CH_3)-CH_3$, $-O-CH_3$, $-O-CH_2-CH_3$, and -CN. Up to two or three heteroatoms may be consecutive, such as, for example, $-CH_2-NH-OCH_3$ and $-CH_2-O-Si(CH_3)_3$. A heteroalkyl moiety may include one heteroatom (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include two optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include three optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include four optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include five optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include up to 8 optionally different heteroatoms (e.g., O, N, S, Si, or P).

[0060] Similarly, the term “heteroalkylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not limited by, $-CH_2-CH_2-S-CH_2-CH_2-$ and $-CH_2-S-CH_2-CH_2-NH-CH_2-$. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula $-C(O)_2R'-$ represents both $-C(O)_2R'-$ and $-R'C(O)_2-$. As described above, heteroalkyl groups, as used herein, include those groups that are attached to the remainder of the molecule through a heteroatom, such as -C(O)R', -C(O)NR', -NR'R", -OR', -SR', and/or $-SO_2R'$. Where “heteroalkyl” is recited, followed by recitations of specific heteroalkyl groups, such as -NR'R" or the like, it will be understood that the terms heteroalkyl and -NR'R" are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term “heteroalkyl” should not be interpreted herein as excluding specific heteroalkyl groups, such as -NR'R" or the like.

[0061] The terms “cycloalkyl” and “heterocycloalkyl,” by themselves or in combination with other terms, mean, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl,”

respectively. Cycloalkyl and heterocycloalkyl are not aromatic. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like. A "cycloalkylene" and a "heterocycloalkylene," alone or as part of another substituent, means a divalent radical derived from a cycloalkyl and heterocycloalkyl, respectively. "Cycloalkyl" is also meant to refer to bicyclic and polycyclic hydrocarbon rings such as, for example, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, etc.

[0062] The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as "haloalkyl" are meant to include monohaloalkyl and polyhaloalkyl. For example, the term "halo(C_1-C_4)alkyl" includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.

[0063] The term "acyl" means, unless otherwise stated, -C(O)R where R is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0064] The term "aryl" means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently. A fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring. The term "heteroaryl" refers to aryl groups (or rings) that contain at least one heteroatom such as N, O, or S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. Thus, the term "heteroaryl" includes fused ring heteroaryl groups (i.e., multiple rings fused together wherein at least one of the fused rings is a heteroaromatic ring). A 5,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. Likewise, a 6,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. And a 6,5-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 5 members, and wherein at least one ring is a heteroaryl ring. A heteroaryl group can be attached to the remainder of the molecule through a carbon or heteroatom. Non-


limiting examples of aryl and heteroaryl groups include phenyl, naphthyl, pyrrolyl, pyrazolyl, pyridazinyl, triazinyl, pyrimidinyl, imidazolyl, pyrazinyl, purinyl, oxazolyl, isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidyl, benzothiazolyl, benzoxazoyl benzimidazolyl, benzofuran, isobenzofuranyl, indolyl, isoindolyl, benzothiophenyl, isoquinolyl, quinoxalinyl, quinolyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below. An “arylene” and a “heteroarylene,” alone or as part of another substituent, mean a divalent radical derived from an aryl and heteroaryl, respectively. A heteroaryl group substituent may be -O- bonded to a ring heteroatom nitrogen.

[0065] Spirocyclic rings are two or more rings wherein adjacent rings are attached through a single atom. The individual rings within spirocyclic rings may be identical or different. Individual rings in spirocyclic rings may be substituted or unsubstituted and may have different substituents from other individual rings within a set of spirocyclic rings. Possible substituents for individual rings within spirocyclic rings are the possible substituents for the same ring when not part of spirocyclic rings (e.g. substituents for cycloalkyl or heterocycloalkyl rings). Spirocylic rings may be substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heterocycloalkylene and individual rings within a spirocyclic ring group may be any of the immediately previous list, including having all rings of one type (e.g. all rings being substituted heterocycloalkylene wherein each ring may be the same or different substituted heterocycloalkylene). When referring to a spirocyclic ring system, heterocyclic spirocyclic rings means a spirocyclic rings wherein at least one ring is a heterocyclic ring and wherein each ring may be a different ring. When referring to a spirocyclic ring system, substituted spirocyclic rings means that at least one ring is substituted and each substituent may optionally be different.

[0066] The symbol “  ” denotes the point of attachment of a chemical moiety to the remainder of a molecule or chemical formula.

[0067] The term “oxo,” as used herein, means an oxygen that is double bonded to a carbon atom.

[0068] The term “alkylarylene” as an arylene moiety covalently bonded to an alkylene moiety (also referred to herein as an alkylene linker). In embodiments, the alkylarylene group has the formula:



[0069] An alkylarylene moiety may be substituted (e.g. with a substituent group) on the alkylene moiety or the arylene linker (e.g. at carbons 2, 3, 4, or 6) with halogen, oxo, $-N_3$, $-CF_3$, $-CCl_3$, $-CBr_3$, $-CI_3$, -CN, -CHO, -OH, $-NH_2$, -COOH, $-CONH_2$, $-NO_2$, -SH, $-SO_2CH_3$ $-SO_3H$, $-OSO_3H$, $-SO_2NH_2$, $–NHNH_2$, $–ONH_2$, $–NHC(O)NHNH_2$, substituted or unsubstituted C_1-C_5 alkyl or substituted or unsubstituted 2 to 5 membered heteroalkyl). In embodiments, the alkylarylene is unsubstituted.

[0070] Each of the above terms (e.g., “alkyl,” “heteroalkyl,” “cycloalkyl,” “heterocycloalkyl,” “aryl,” and “heteroaryl”) includes both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.

[0071] Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one or more of a variety of groups selected from, but not limited to, -OR', =O, =NR', =N-OR', -NR'R", -SR', -halogen, -SiR'R"R'", -OC(O)R', -C(O)R', $-CO_2R'$, -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR'-C(O)NR"R'", $-NR"C(O)_2R'$, -NR-C(NR'R"R'")=NR"", -NR-C(NR'R")=NR'", $-S(O)R'$, $-S(O)_2R'$, $-S(O)_2NR'R"$, $-NRSO_2R'$, –NR'NR"R'", –ONR'R", –NR'C(O)NR"NR'"R"", -CN, $-NO_2$, $-NR'SO_2R"$, -NR'C(O)R", -NR'C(O)-OR", -NR'OR", in a number ranging from zero to (2m'+1), where m' is the total number of carbon atoms in such radical. R, R', R", R'", and R"" each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, alkoxy, or thioalkoxy groups, or arylalkyl groups. When a compound described herein includes more than one R group, for example, each of the R groups is independently selected as are each R', R", R'", and R"" group when more than one of these groups is present. When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example, -NR'R" includes, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term “alkyl” is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., $-CF_3$ and $-CH_2CF_3$) and acyl (e.g., $-C(O)CH_3$, $-C(O)CF_3$, $-C(O)CH_2OCH_3$, and the like).

[0072] Similar to the substituents described for the alkyl radical, substituents for the aryl and heteroaryl groups are varied and are selected from, for example: -OR', -NR'R", -SR', -halogen, -

SiR'R"R'", -OC(O)R', -C(O)R', -CO_2R', -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR'-C(O)NR"R'", -NR"C(O)$_2$R', -NR-C(NR'R"R'")=NR"", -NR-C(NR'R")=NR'", -S(O)R', -S(O)$_2$R', -S(O)$_2$NR'R", -NRSO$_2$R', –NR'NR"R'", –ONR'R", –NR'C(O)NR"NR'"R"", -CN, -NO_2, -R', -N_3, -CH(Ph)$_2$, fluoro(C_1-C_4)alkoxy, and fluoro(C_1-C_4)alkyl, -NR'SO$_2$R", -NR'C(O)R", -NR'C(O)-OR", -NR'OR", in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R', R", R'", and R"" are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. When a compound described herein includes more than one R group, for example, each of the R groups is independently selected as are each R', R", R'", and R"" groups when more than one of these groups is present.

[0073] Substituents for rings (e.g. cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene) may be depicted as substituents on the ring rather than on a specific atom of a ring (commonly referred to as a floating substituent). In such a case, the substituent may be attached to any of the ring atoms (obeying the rules of chemical valency) and in the case of fused rings or spirocyclic rings, a substituent depicted as associated with one member of the fused rings or spirocyclic rings (a floating substituent on a single ring), may be a substituent on any of the fused rings or spirocyclic rings (a floating substituent on multiple rings). When a substituent is attached to a ring, but not a specific atom (a floating substituent), and a subscript for the substituent is an integer greater than one, the multiple substituents may be on the same atom, same ring, different atoms, different fused rings, different spirocyclic rings, and each substituent may optionally be different. Where a point of attachment of a ring to the remainder of a molecule is not limited to a single atom (a floating substituent), the attachment point may be any atom of the ring and in the case of a fused ring or spirocyclic ring, any atom of any of the fused rings or spirocyclic rings while obeying the rules of chemical valency. Where a ring, fused rings, or spirocyclic rings contain one or more ring heteroatoms and the ring, fused rings, or spirocyclic rings are shown with one more floating substituents (including, but not limited to, points of attachment to the remainder of the molecule), the floating substituents may be bonded to the heteroatoms. Where the ring heteroatoms are shown bound to one or more hydrogens (e.g. a ring nitrogen with two bonds to ring atoms and a third bond to a hydrogen) in the structure or formula with the floating substituent, when the heteroatom is bonded to the floating substituent, the substituent will be understood to replace the hydrogen, while obeying the rules of chemical valency.

[0074] Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups. Such so-called ring-forming substituents are typically, though not

necessarily, found attached to a cyclic base structure. In one embodiment, the ring-forming substituents are attached to adjacent members of the base structure. For example, two ring-forming substituents attached to adjacent members of a cyclic base structure create a fused ring structure. In another embodiment, the ring-forming substituents are attached to a single member of the base structure. For example, two ring-forming substituents attached to a single member of a cyclic base structure create a spirocyclic structure. In yet another embodiment, the ring-forming substituents are attached to non-adjacent members of the base structure.

[0075] Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally form a ring of the formula -T-C(O)-$(CRR')_q$-U-, wherein T and U are independently -NR-, -O-, -CRR'-, or a single bond, and q is an integer of from 0 to 3. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-$(CH_2)_r$-B-, wherein A and B are independently -CRR'-, -O-, -NR-, -S-, -S(O) -, -$S(O)_2$-, -$S(O)_2$NR'-, or a single bond, and r is an integer of from 1 to 4. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -$(CRR')_s$-X'- $(C"R"R"')_d$-, where s and d are independently integers of from 0 to 3, and X' is -O-, -NR'-, -S-, -S(O)-, -$S(O)_2$-, or -$S(O)_2$NR'-. The substituents R, R', R'', and R''' are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.

[0076] As used herein, the terms “heteroatom” or “ring heteroatom” are meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).

[0077] A “substituent group,” as used herein, means a group selected from the following moieties:

(A) oxo, halogen, -CF_3, -CN, -OH, -NH_2, -COOH, -$CONH_2$, -NO_2, -SH, -SO_3H, -SO_4H, -SO_2NH_2, –$NHNH_2$, –ONH_2, –NHC=(O)$NHNH_2$, –NHC=(O) NH_2, -$NHSO_2H$, -NHC= (O)H, -NHC(O)-OH, -NHOH, -OCF_3, -$OCHF_2$, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and

(B) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, substituted with at least one substituent selected from:

(i) oxo, halogen, -CF_3, -CN, -OH, -NH_2, -COOH, -$CONH_2$, -NO_2, -SH, -SO_3H, -SO_4H, -SO_2NH_2, –$NHNH_2$, –ONH_2, –NHC=(O)$NHNH_2$, –NHC=(O) NH_2, -$NHSO_2H$, -NHC= (O)H, -NHC(O)-OH, -NHOH, -OCF_3, -$OCHF_2$, unsubstituted alkyl, unsubstituted heteroalkyl,

unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and

(ii) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, substituted with at least one substituent selected from:

(a) oxo, halogen, -CF_3, -CN, -OH, -NH_2, -COOH, -$CONH_2$, -NO_2, -SH, -SO_3H, -SO_4H, -SO_2NH_2, –$NHNH_2$, –ONH_2, –NHC=(O)$NHNH_2$, –NHC=(O) NH_2, -$NHSO_2H$, -NHC=(O)H, -NHC(O)-OH, -NHOH, -OCF_3, -$OCHF_2$, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and

(b) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, substituted with at least one substituent selected from: oxo,

halogen, -CF_3, -CN, -OH, -NH_2, -COOH, -$CONH_2$, -NO_2, -SH, -SO_3H, -SO_4H, -SO_2NH_2, –$NHNH_2$, –ONH_2, –NHC=(O)$NHNH_2$, –NHC=(O) NH_2, -$NHSO_2H$, -NHC=(O)H, -NHC(O)-OH, -NHOH, -OCF_3, -$OCHF_2$, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl.

[0078] A “size-limited substituent” or “ size-limited substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C_1-C_{20} alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C_3-C_8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C_6-C_{10} aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl.

[0079] A “lower substituent” or “ lower substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C_1-C_8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C_3-C_7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C_6-C_{10} aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl.

[0080] In some embodiments, each substituted group described in the compounds herein is substituted with at least one substituent group. More specifically, in some embodiments, each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene described in the compounds herein are substituted with at least one substituent group. In other embodiments, at least one or all of these groups are substituted with at least one size-limited substituent group. In other embodiments, at least one or all of these groups are substituted with at least one lower substituent group.

[0081] In other embodiments of the compounds herein, each substituted or unsubstituted alkyl may be a substituted or unsubstituted C_1-C_{20} alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C_3-C_8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C_6-C_{10} aryl, and/or each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl. In some embodiments of the compounds herein, each substituted or unsubstituted alkylene is a substituted or unsubstituted C_1-C_{20} alkylene, each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 20 membered heteroalkylene, each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C_3-C_8 cycloalkylene, each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene, each substituted or unsubstituted arylene is a substituted or unsubstituted C_6-C_{10} arylene, and/or each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 10 membered heteroarylene.

[0082] In some embodiments, each substituted or unsubstituted alkyl is a substituted or unsubstituted C_1-C_8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C_3-C_7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C_6-C_{10} aryl, and/or each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl. In some embodiments, each substituted or unsubstituted alkylene is a substituted or unsubstituted C_1-C_8 alkylene, each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 8 membered heteroalkylene, each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C_3-C_7 cycloalkylene, each substituted or unsubstituted heterocycloalkylene is a

substituted or unsubstituted 3 to 7 membered heterocycloalkylene, each substituted or unsubstituted arylene is a substituted or unsubstituted C_6-C_{10} arylene, and/or each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 9 membered heteroarylene. In some embodiments, the compound is a chemical species set forth in the Examples section, figures, or tables below.

[0083] Certain compounds of the present invention possess asymmetric carbon atoms (optical or chiral centers) or double bonds; the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisometric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids, and individual isomers are encompassed within the scope of the present invention. The compounds of the present invention do not include those that are known in art to be too unstable to synthesize and/or isolate. The present invention is meant to include compounds in racemic and optically pure forms. Optically active (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.

[0084] As used herein, the term “isomers” refers to compounds having the same number and kind of atoms, and hence the same molecular weight, but differing in respect to the structural arrangement or configuration of the atoms.

[0085] The term “tautomer,” as used herein, refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one isomeric form to another.

[0086] It will be apparent to one skilled in the art that certain compounds of this invention may exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the invention.

[0087] Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention.

[0088] Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by ^{13}C- or ^{14}C-enriched carbon are within the scope of this invention.

[0089] The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the

compounds may be radiolabeled with radioactive isotopes, such as for example tritium (^{3}H), iodine-125 (^{125}I), or carbon-14 (^{14}C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.

[0090] It should be noted that throughout the application that alternatives are written in Markush groups, for example, each amino acid position that contains more than one possible amino acid. It is specifically contemplated that each member of the Markush group should be considered separately, thereby comprising another embodiment, and the Markush group is not to be read as a single unit.

[0091] "Analog" or "analogue" is used in accordance with its plain ordinary meaning within Chemistry and Biology and refers to a chemical compound that is structurally similar to another compound (i.e., a so-called "reference" compound) but differs in composition, e.g., in the replacement of one atom by an atom of a different element, or in the presence of a particular functional group, or the replacement of one functional group by another functional group, or the absolute stereochemistry of one or more chiral centers of the reference compound. Accordingly, an analog is a compound that is similar or comparable in function and appearance but not in structure or origin to a reference compound.

[0092] The terms "a" or "an," as used in herein means one or more. In addition, the phrase "substituted with a[n]," as used herein, means the specified group may be substituted with one or more of any or all of the named substituents. For example, where a group, such as an alkyl or heteroaryl group, is "substituted with an unsubstituted C_1-C_{20} alkyl, or unsubstituted 2 to 20 membered heteroalkyl," the group may contain one or more unsubstituted C_1-C_{20} alkyls, and/or one or more unsubstituted 2 to 20 membered heteroalkyls.

[0093] Moreover, where a moiety is substituted with an R substituent, the group may be referred to as "R-substituted." Where a moiety is R-substituted, the moiety is substituted with at least one R substituent and each R substituent is optionally different. Where a particular R group is present in the description of a chemical genus (such as Formula (I)), a Roman alphabetic symbol may be used to distinguish each appearance of that particular R group. For example, where multiple R^{13} substituents are present, each R^{13} substituent may be distinguished as R^{13A}, R^{13B}, R^{13C}, R^{13D}, etc., wherein each of R^{13A}, R^{13B}, R^{13C}, R^{13D}, etc. is defined within the scope of the definition of R^{13} and optionally differently.

[0094] A "detectable moiety" as used herein refers to a moiety that can be covalently or noncovalently attached to a compound or biomolecule that can be detected for instance, using techniques known in the art. In embodiments, the detectable moiety is covalently attached. The detectable moiety may provide for imaging of the attached compound or biomolecule. The detectable moiety may indicate the contacting between two compounds. Exemplary detectable

moieties are fluorophores, antibodies, reactive dies, radio-labeled moieties, magnetic contrast agents, and quantum dots. Exemplary fluorophores include fluorescein, rhodamine, GFP, coumarin, FITC, Alexa fluor, Cy3, Cy5, BODIPY, and cyanine dyes. Exemplary radionuclides include Fluorine-18, Gallium-68, and Copper-64. Exemplary magnetic contrast agents include gadolinium, iron oxide and iron platinum, and manganese.

[0095] Descriptions of compounds of the present invention are limited by principles of chemical bonding known to those skilled in the art. Accordingly, where a group may be substituted by one or more of a number of substituents, such substitutions are selected so as to comply with principles of chemical bonding and to give compounds which are not inherently unstable and/or would be known to one of ordinary skill in the art as likely to be unstable under ambient conditions, such as aqueous, neutral, and several known physiological conditions. For example, a heterocycloalkyl or heteroaryl is attached to the remainder of the molecule via a ring heteroatom in compliance with principles of chemical bonding known to those skilled in the art thereby avoiding inherently unstable compounds.

[0096] The term "pharmaceutically acceptable salts" is meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, oxalic, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (*see,* for example, Berge *et al.*, "Pharmaceutical Salts", *Journal of Pharmaceutical Science,* **1977**, *66,* 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

[0097] Thus, the compounds of the present invention may exist as salts, such as with pharmaceutically acceptable acids. The present invention includes such salts. Non-limiting examples of such salts include hydrochlorides, hydrobromides, phosphates, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, proprionates, tartrates (e.g., (+)-tartrates, (-)-tartrates, or mixtures thereof including racemic mixtures), succinates, benzoates, and salts with amino acids such as glutamic acid, and quaternary ammonium salts (e.g. methyl iodide, ethyl iodide, and the like). These salts may be prepared by methods known to those skilled in the art.

[0098] The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound may differ from the various salt forms in certain physical properties, such as solubility in polar solvents. In embodiments, compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts. The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in a conventional manner. The parent form of the compounds differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but, unless specifically indicated, the salts disclosed herein are equivalent to the parent form of the compound for the purposes of the present invention.

[0099] In addition to salt forms, the present invention provides compounds, which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Prodrugs of the compounds described herein may be converted *in vivo* after administration. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an *ex vivo* environment, such as, for example, when contacted with a suitable enzyme or chemical reagent.

[0100] Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.

[0101] "Pharmaceutically acceptable excipient" and "pharmaceutically acceptable carrier" refer to a substance that aids the administration of a compound to and absorption by a subject and can be included in the compositions of the present invention without causing a significant adverse toxicological effect on the patient. Non-limiting examples of pharmaceutically acceptable

excipients include water, NaCl, normal saline solutions, lactated Ringer's, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, and the like. Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present invention.

[0102] The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

[0103] A "CRF1 inhibitor" refers to a compound (e.g., compounds described herein) that reduces the activity of CRF1 when compared to a control, such as absence of the compound or a compound with known inactivity.

[0104] The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues, wherein the polymer may optionally be conjugated to a moiety that does not consist of amino acids. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer. In embodiments, the terms "polypeptide," "peptide," and "protein", used interchangeably herein, refer to a polymeric form of amino acids of any length, which can include genetically coded and non-genetically coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified polypeptide backbones. The terms include fusion proteins, including, but not limited to, fusion proteins with a heterologous amino acid sequence; fusion proteins with heterologous and homologous leader sequences, with or without N-terminus methionine residues; immunologically tagged proteins; and the like.

[0105] A polypeptide, or a cell is "recombinant" when it is artificial or engineered, or derived from or contains an artificial or engineered protein or nucleic acid (*e.g.* non-natural or not wild type). For example, a polynucleotide that is inserted into a vector or any other heterologous location, *e.g.*, in a genome of a recombinant organism, such that it is not associated with nucleotide sequences that normally flank the polynucleotide as it is found in nature is a

recombinant polynucleotide. A protein expressed *in vitro* or *in vivo* from a recombinant polynucleotide is an example of a recombinant polypeptide. Likewise, a polynucleotide sequence that does not appear in nature, for example a variant of a naturally occurring gene, is recombinant.

[0106] "Contacting" is used in accordance with its plain ordinary meaning and refers to the process of allowing at least two distinct species (e.g. chemical compounds including biomolecules or cells) to become sufficiently proximal to react, interact or physically touch. It should be appreciated; however, the resulting reaction product can be produced directly from a reaction between the added reagents or from an intermediate from one or more of the added reagents that can be produced in the reaction mixture.

[0107] The term "contacting" may include allowing two species to react, interact, or physically touch, wherein the two species may be a compound as described herein and a protein or enzyme. In some embodiments contacting includes allowing a compound described herein to interact with a protein or enzyme that is involved in a signaling pathway (e.g., MAP kinase pathway).

[0108] As defined herein, the term "activation", "activate", "activating" and the like in reference to a protein refers to conversion of a protein into a biologically active derivative from an initial inactive or deactivated state. The terms reference activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein decreased in a disease.

[0109] The terms "agonist," "activator," "upregulator," etc. refer to a substance capable of detectably increasing the expression or activity of a given gene or protein. The agonist can increase expression or activity 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more in comparison to a control in the absence of the agonist. In certain instances, expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or higher than the expression or activity in the absence of the agonist. In embodiments, an agonist is a molecule that interacts with a target to cause or promote an increase in the activation of the target. In embodiments, activators are molecules that increase, activate, facilitate, enhance activation, sensitize, or up-regulate, e.g., a gene, protein, ligand, receptor, or cell.

[0110] As defined herein, the term "inhibition", "inhibit", "inhibiting" and the like in reference to a protein-inhibitor interaction means negatively affecting (e.g. decreasing) the activity or function of the protein relative to the activity or function of the protein in the absence of the inhibitor. In embodiments inhibition means negatively affecting (e.g. decreasing) the concentration or levels of the protein relative to the concentration or level of the protein in the absence of the inhibitor. In embodiments inhibition refers to reduction of a disease or symptoms of disease. In embodiments, inhibition refers to a reduction in the activity of a particular protein

target. Thus, inhibition includes, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating signal transduction or enzymatic activity or the amount of a protein. In embodiments, inhibition refers to a reduction of activity of a target protein resulting from a direct interaction (e.g. an inhibitor binds to the target protein). In embodiments, inhibition refers to a reduction of activity of a target protein from an indirect interaction (e.g. an inhibitor binds to a protein that activates the target protein, thereby preventing target protein activation).

[0111] The terms "inhibitor," "repressor" or "antagonist" or "downregulator" interchangeably refer to a substance capable of detectably decreasing the expression or activity of a given gene or protein. The antagonist can decrease expression or activity 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more in comparison to a control in the absence of the antagonist. In certain instances, expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or lower than the expression or activity in the absence of the antagonist. An antagonist prevents, reduces, inhibits, or neutralizes the activity of an agonist, and an antagonist can also prevent, inhibit, or reduce constitutive activity of a target, e.g., a target receptor, even where there is no identified agonist. In embodiments, inhibitors are molecules that decrease, block, prevent, delay activation, inactivate, desensitize, or down-regulate, e.g., a gene, protein, ligand, receptor, or cell. An inhibitor may also be defined as a molecule that reduces, blocks, or inactivates a constitutive activity. An "antagonist" is a molecule that opposes the action(s) of an agonist.

[0112] The terms "corticotropin-releasing factor type-1," "CRF_1," "corticotropin-releasing hormone receptor 1," and "CHHR1" refer to a protein (including homologs, isoforms, and functional fragments thereof) and is a receptor for corticotropin releasing-hormone. The terms include any recombinant or naturally-occurring form of CRF_1 variants thereof that maintain CRF_1 activity (e.g. within at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% activity compared to wildtype CRF1). The terms include any mutant form of CRF_1 variants (e.g., frameshift mutations) thereof that maintain CRF_1 activity (e.g. within at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% activity compared to wildtype CRF_1). In embodiments, the CRF_1 protein encoded by the *CRHR1* gene has the amino acid sequence set forth in or corresponding to Entrez 1233, UniProt P34998.

[0113] The term "expression" includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion. Expression can be detected using conventional techniques for detecting protein (*e.g.*, ELISA, Western blotting, flow cytometry, immunofluorescence, immunohistochemistry, *etc.*).

[0114] The terms “disease” or “condition” refer to a state of being or health status of a patient or subject capable of being treated with the compounds or methods provided herein. The disease may be a malignant or benign tumor (e.g., testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART)). The disease may be cancer. In some further instances, “cancer” refers to human cancers and carcinomas, sarcomas, adenocarcinomas, lymphomas, leukemias, etc., including solid and lymphoid cancers, kidney, breast, lung, bladder, colon, ovarian, prostate, pancreas, adrenal, stomach, brain, head and neck, skin, uterine, testicular, glioma, esophagus, and liver cancer, including hepatocarcinoma, lymphoma, including B-acute lymphoblastic lymphoma, non-Hodgkin’s lymphomas (*e.g.*, Burkitt’s, Small Cell, and Large Cell lymphomas), Hodgkin’s lymphoma, leukemia (including MDS, AML, ALL, ATLL and CML), or multiple myeloma.

[0115] As used herein, the term “cancer” refers to all types of cancer, neoplasm or malignant tumors found in mammals (e.g. humans), including leukemia, carcinomas and sarcomas. Exemplary cancers that may be treated with a compound or method provided herein include adrenal cancer and tumors (e.g., testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART)) brain cancer, glioma, glioblastoma, neuroblastoma, prostate cancer, colorectal cancer, pancreatic cancer, cervical cancer, gastric cancer, ovarian cancer, lung cancer, and cancer of the head. Exemplary cancers that may be treated with a compound or method provided herein include cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head & neck, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus, Medulloblastoma, colorectal cancer, pancreatic cancer. Additional examples include, thyroid carcinoma, cholangiocarcinoma, pancreatic adenocarcinoma, skin cutaneous melanoma, colon adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, breast invasive carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, or prostate cancer.

[0116] The term “congenital adrenal hyperplasia” or “CAH” are any of several autosomal recessive diseases resulting from mutations of genes for enzymes mediating the biochemical

steps of production of mineralocorticoids, glucocorticoids or sex steroids from cholesterol by the adrenal glands (steroidogenesis). These conditions involve excessive or deficient production of sex steroids and can alter development of primary or secondary sex characteristics in some affected infants, children, or adults.

[0117] "Adrenal rest tumor" refers to a neoplasm of the testis (or ovaries) consisting of adrenal tissue. It may be secondary to hyperplasia of an adrenal gland.

[0118] "Testicular adrenal rest tumor(s)" or "TART" and/or ovarian adrenal rest tumor(s) are a complication of congenital adrenal hyperplasia (CAH), which may develop from ectopic remnants of intra-testicular adrenal tissue stimulated by adrenocorticotropic hormone (ACTH) hypersecretion. TART lesions are typically located within the rete testis and are bilateral, synchronous, nodular and multiple. TART can lead to testicular structural damage, spermatogenesis disorders, infertility and mass-forming lesions.

[0119] The term "leukemia" refers broadly to progressive, malignant diseases of the blood-forming organs and is generally characterized by a distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemia is generally clinically classified on the basis of (1) the duration and character of the disease-acute or chronic; (2) the type of cell involved; myeloid (myelogenous), lymphoid (lymphogenous), or monocytic; and (3) the increase or non-increase in the number abnormal cells in the blood-leukemic or aleukemic (subleukemic). Exemplary leukemias that may be treated with a compound or method provided herein include, for example, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, a leukocythemic leukemia, basophylic leukemia, blast cell leukemia, bovine leukemia, chronic myelocytic leukemia, leukemia cutis, embryonal leukemia, eosinophilic leukemia, Gross' leukemia, hairy-cell leukemia, hemoblastic leukemia, hemocytoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenous leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblastic leukemia, myelocytic leukemia, myeloid granulocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, multiple myeloma, plasmacytic leukemia, promyelocytic leukemia, Rieder cell leukemia, Schilling's leukemia, stem cell leukemia, subleukemic leukemia, or undifferentiated cell leukemia.

[0120] The term "sarcoma" generally refers to a tumor which is made up of a substance like the embryonic connective tissue and is generally composed of closely packed cells embedded in a fibrillar or homogeneous substance. Sarcomas that may be treated with a compound or method

provided herein include a chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, chorio carcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic multiple pigmented hemorrhagic sarcoma, immunoblastic sarcoma of B cells, lymphoma, immunoblastic sarcoma of T-cells, Jensen's sarcoma, Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma, leukosarcoma, malignant mesenchymoma sarcoma, parosteal sarcoma, reticulocytic sarcoma, Rous sarcoma, serocystic sarcoma, synovial sarcoma, or telangiectaltic sarcoma.

[0121] The term “melanoma” is taken to mean a tumor arising from the melanocytic system of the skin and other organs. Melanomas that may be treated with a compound or method provided herein include, for example, acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungal melanoma, or superficial spreading melanoma.

[0122] The term “carcinoma” refers to a malignant new growth made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. Exemplary carcinomas that may be treated with a compound or method provided herein include, for example, thyroid carcinoma, cholangiocarcinoma, pancreatic adenocarcinoma, skin cutaneous melanoma, colon adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, breast invasive carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocellulare, basaloid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, carcinoma durum, embryonal carcinoma, encephaloid carcinoma, epiermoid carcinoma, carcinoma epitheliale adenoides, exophytic carcinoma, carcinoma ex ulcere, carcinoma fibrosum, gelatiniforni carcinoma, gelatinous carcinoma, giant cell carcinoma, carcinoma gigantocellulare, glandular carcinoma, granulosa cell carcinoma, hair-matrix carcinoma, hematoid carcinoma, hepatocellular carcinoma, Hurthle cell carcinoma, hyaline carcinoma, hypernephroid carcinoma,

infantile embryonal carcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma, Krompecher's carcinoma, Kulchitzky-cell carcinoma, large-cell carcinoma, lenticular carcinoma, carcinoma lenticulare, lipomatous carcinoma, lymphoepithelial carcinoma, carcinoma medullare, medullary carcinoma, melanotic carcinoma, carcinoma molle, mucinous carcinoma, carcinoma muciparum, carcinoma mucocellulare, mucoepidermoid carcinoma, carcinoma mucosum, mucous carcinoma, carcinoma myxomatodes, nasopharyngeal carcinoma, oat cell carcinoma, carcinoma ossificans, osteoid carcinoma, papillary carcinoma, periportal carcinoma, preinvasive carcinoma, prickle cell carcinoma, pultaceous carcinoma, renal cell carcinoma of kidney, reserve cell carcinoma, carcinoma sarcomatodes, schneiderian carcinoma, scirrhous carcinoma, carcinoma scroti, signet-ring cell carcinoma, carcinoma simplex, small-cell carcinoma, solanoid carcinoma, spheroidal cell carcinoma, spindle cell carcinoma, carcinoma spongiosum, squamous carcinoma, squamous cell carcinoma, string carcinoma, carcinoma telangiectaticum, carcinoma telangiectodes, transitional cell carcinoma, carcinoma tuberosum, tuberous carcinoma, verrucous carcinoma, or carcinoma villosum.

[0123] The terms “treating” or “treatment” refer to any indicia of success in the therapy or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient’s physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation. The term “treating” and conjugations thereof, may include prevention of an injury, pathology, condition, or disease. In embodiments, treating is preventing. In embodiments, treating does not include preventing.

[0124] “Treating” or “treatment” as used herein (and as well-understood in the art) also broadly includes any approach for obtaining beneficial or desired results in a subject’s condition, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of the extent of a disease, stabilizing (*i.e.*, not worsening) the state of disease, prevention of a disease’s transmission or spread, delay or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission, whether partial or total and whether detectable or undetectable. In other words, “treatment” as used herein includes any cure, amelioration, or prevention of a disease. Treatment may prevent the disease from occurring; inhibit the disease’s spread; relieve the disease’s symptoms (*e.g.*, ocular pain, seeing

halos around lights, red eye, very high intraocular pressure), fully or partially remove the disease's underlying cause, shorten a disease's duration, or do a combination of these things.

[0125] "Treating" and "treatment" as used herein include prophylactic treatment. Treatment methods include administering to a subject a therapeutically effective amount of a compound described herein. The administering step may consist of a single administration or may include a series of administrations. The length of the treatment period depends on a variety of factors, such as the severity of the condition, the age of the patient, the concentration of the compound, the activity of the compositions used in the treatment, or a combination thereof. It will also be appreciated that the effective dosage of an agent used for the treatment or prophylaxis may increase or decrease over the course of a particular treatment or prophylaxis regime. Changes in dosage may result and become apparent by standard diagnostic assays known in the art. In some instances, chronic administration may be required. For example, the compositions are administered to the subject in an amount and for a duration sufficient to treat the patient.

[0126] The term "prevent" refers to a decrease in the occurrence of disease symptoms in a patient. As indicated above, the prevention may be complete (no detectable symptoms) or partial, such that fewer symptoms are observed than would likely occur absent treatment. In embodiments, prevent refers to slowing the progression of the disease, disorder or condition or inhibiting progression thereof to a harmful or otherwise undesired state.

[0127] "Patient" or "subject in need thereof" refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a pharmaceutical composition as provided herein. Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals. In some embodiments, a patient is human.

[0128] An "effective amount" is an amount sufficient for a compound to accomplish a stated purpose relative to the absence of the compound (e.g., achieve the effect for which it is administered, treat a disease, reduce enzyme activity, increase enzyme activity, reduce a signaling pathway, or reduce one or more symptoms of a disease or condition). An example of an "effective amount" is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which could also be referred to as a "therapeutically effective amount." A "reduction" of a symptom or symptoms (and grammatical equivalents of this phrase) means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s). A "prophylactically effective amount" of a drug is an amount of a drug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology or condition, or reducing the likelihood of the onset (or reoccurrence) of an injury, disease, pathology, or

condition, or their symptoms. The full prophylactic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a prophylactically effective amount may be administered in one or more administrations. An "activity decreasing amount," as used herein, refers to an amount of antagonist required to decrease the activity of an enzyme relative to the absence of the antagonist. A "function disrupting amount," as used herein, refers to the amount of antagonist required to disrupt the function of an enzyme or protein relative to the absence of the antagonist. The exact amounts will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (*see, e.g.*, Lieberman, *Pharmaceutical Dosage Forms* (vols. 1-3, 1992); Lloyd, *The Art, Science and Technology of Pharmaceutical Compounding* (1999); Pickar, *Dosage Calculations* (1999); and *Remington: The Science and Practice of Pharmacy*, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins). The therapeutically effective amount can be ascertained by measuring relevant physiological effects, and it can be adjusted in connection with the dosing regimen and diagnostic analysis of the subject's condition, and the like. By way of example, measurement of the serum level of a CRF1 inhibitor (or, e.g., a metabolite thereof) at a particular time post-administration may be indicative of whether a therapeutically effective amount has been administered.

[0129] For any compound described herein, the therapeutically effective amount can be initially determined from cell culture assays. Target concentrations will be those concentrations of active compound(s) that are capable of achieving the methods described herein, as measured using the methods described herein or known in the art.

[0130] Therapeutically effective amounts for use in humans can also be determined from animal models. For example, a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals. The dosage in humans can be adjusted by monitoring compounds effectiveness and adjusting the dosage upwards or downwards, as described above. Adjusting the dose to achieve maximal efficacy in humans based on the methods described above and other methods is well within the capabilities of the ordinarily skilled artisan. Adjusting the dose to achieve maximal therapeutic window efficacy or toxicity in humans based on the methods described above and other methods is well within the capabilities of the ordinarily skilled artisan.

[0131] The term "therapeutically effective amount," as used herein, refers to that amount of the therapeutic agent sufficient to ameliorate the disorder, as described above. For example, for the given parameter, a therapeutically effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Therapeutic efficacy can also be expressed as "-fold" increase or decrease. For example, a therapeutically

effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control.

[0132] The terms “QD,” “qd,” and “q.d.” refer to once a day, i.e., a drug or therapeutic agent is administered once a day for the duration of the therapeutic regimen.

[0133] The terms “BD,” “bd,” and “b.i.d.” refer to twice a day, i.e., a drug or therapeutic agent is administered two times a day for the duration of the therapeutic regimen.

[0134] The terms “QID,” “qid,” and “q.i.d.” refer to three times a day, i.e., a drug or therapeutic agent is administered three times a day for the duration of the therapeutic regimen.

[0135] Dosages may be varied depending upon the requirements of the patient and the compound being employed. The dose administered to a patient, in the context of the present invention should be sufficient to effect a beneficial therapeutic response in the patient over time. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. Dosage amounts and intervals can be adjusted individually to provide levels of the administered compound effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.

[0136] As used herein, the term “administering” means oral administration, administration as a suppository, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intracranial, intranasal or subcutaneous administration, or the implantation of a slow-release device, *e.g.,* a mini-osmotic pump, to a subject. Administration is by any route, including parenteral and transmucosal (*e.g.*, buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, *e.g.,* intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, *etc.* By “co-administer” it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies (e.g. anti-cancer agent, chemotherapeutic, or treatment for a neurodegenerative disease). The compound of the invention can be administered alone or can be coadministered to the patient. Coadministration is meant to include simultaneous or sequential administration of the compound individually or in combination (more than one compound or agent). Thus, the preparations can also be combined, when desired, with other active substances (e.g. to reduce metabolic degradation). The compositions of the present invention can be

delivered by transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols. Oral preparations include tablets, pills, powder, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions. The compositions of the present invention may additionally include components to provide sustained release and/or comfort. Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Pat. Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes. The compositions of the present invention can also be delivered as microspheres for slow release in the body. For example, microspheres can be administered via intradermal injection of drug-containing microspheres, which slowly release subcutaneously (see Rao, *J. Biomater Sci. Polym. Ed.* 7:623-645, 1995; as biodegradable and injectable gel formulations (see, e.g., Gao *Pharm. Res*. 12:857-863, 1995); or, as microspheres for oral administration (see, e.g., Eyles, *J. Pharm. Pharmacol.* 49:669-674, 1997). In another embodiment, the formulations of the compositions of the present invention can be delivered by the use of liposomes which fuse with the cellular membrane or are endocytosed, *i.e.*, by employing receptor ligands attached to the liposome, that bind to surface membrane protein receptors of the cell resulting in endocytosis. By using liposomes, particularly where the liposome surface carries receptor ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the compositions of the present invention into the target cells in vivo. (See, *e.g.*, Al-Muhammed, *J. Microencapsul.* 13:293-306, 1996; Chonn, *Curr. Opin. Biotechnol.* 6:698-708, 1995; Ostro, *Am. J. Hosp. Pharm.* 46:1576-1587, 1989). The compositions of the present invention can also be delivered as nanoparticles.

[0137] By “co-administer” it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies. The compounds of the invention can be administered alone or can be coadministered to the patient. Coadministration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound). The compositions of the present invention can be delivered transdermally, by a topical route, or formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.

[0138] For any compound described herein, the therapeutically effective amount can be initially determined from cell culture assays. Target concentrations will be those concentrations of active compound(s) that are capable of achieving the methods described herein, as measured using the methods described herein or known in the art.

[0139] Utilizing the teachings provided herein, an effective prophylactic or therapeutic treatment regimen can be planned that does not cause substantial toxicity and yet is effective to treat the clinical symptoms demonstrated by the particular patient. This planning should involve the careful choice of active compound by considering factors such as compound potency, relative bioavailability, patient body weight, presence and severity of adverse side effects, preferred mode of administration and the toxicity profile of the selected agent.

[0140] The compounds described herein can be used in combination with one another, with other active agents known to be useful in treating cancer (e.g. colon cancer), cardiovascular disease, metabolic disease, immune or inflammatory disease or disorder.

[0141] In some embodiments, co-administration includes administering one active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, 24 hours, 2 days, 4 days, 1 week or 1 month of a second active agent. Co-administration includes administering two active agents simultaneously, approximately simultaneously (e.g., within about 1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order. In some embodiments, co-administration can be accomplished by co-formulation, i.e., preparing a single pharmaceutical composition including both active agents. In other embodiments, the active agents can be formulated separately. In another embodiment, the active and/or adjunctive agents may be linked or conjugated to one another. In some embodiments, the compounds described herein may be combined with treatments for cancer (e.g. colon cancer), cardiovascular disease, metabolic disease, immune or inflammatory disease or disorder.

[0142] The compounds described herein can be administered to treat a fertility disease or disorder and/or cancer. In this regard, the compounds disclosed herein may be administered either alone to treat such diseases or disorders or may be co-administered with another therapeutic agent to treat such diseases or disorders.

[0143] The compounds disclosed herein may be co-administered with an agonist or antagonist of CRF_1 function. The compounds described herein can be co-administered with conventional anti-cancer/chemotherapeutic.

[0144] "Anti-cancer agent" is used in accordance with its plain ordinary meaning and refers to a composition (e.g. compound, drug, antagonist, inhibitor, modulator) having antineoplastic properties or the ability to inhibit the growth or proliferation of cells. In some embodiments, an anti-cancer agent is a chemotherapeutic. In some embodiments, an anti-cancer agent is an agent

identified herein having utility in methods of treating cancer. In some embodiments, an anti-cancer agent is an agent approved by the FDA or similar regulatory agency of a country other than the USA, for treating cancer. Examples of anti-cancer agents include, but are not limited to, MEK (e.g. MEK1, MEK2, or MEK1 and MEK2) inhibitors (e.g. XL518, CI-1040, PD035901, selumetinib/ AZD6244, GSK1120212/ trametinib, GDC-0973, ARRY-162, ARRY-300, AZD8330, PD0325901, U0126, PD98059, TAK-733, PD318088, AS703026, BAY 869766), alkylating agents (*e.g.*, cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, meiphalan), ethylenimine and methylmelamines (e.g., hexamethlymelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin), triazenes (decarbazine)), anti-metabolites (*e.g.*, 5-azathioprine, leucovorin, capecitabine, fludarabine, gemcitabine, pemetrexed, raltitrexed, folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., fluorouracil, floxouridine, Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin), *etc.*), plant alkaloids (*e.g.*, vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel, docetaxel, *etc.*), topoisomerase inhibitors (*e.g.*, irinotecan, topotecan, amsacrine, etoposide (VP16), etoposide phosphate, teniposide, *etc.*), antitumor antibiotics (*e.g.*, doxorubicin, adriamycin, daunorubicin, epirubicin, actinomycin, bleomycin, mitomycin, mitoxantrone, plicamycin, *etc.*), platinum-based compounds (*e.g.* cisplatin, oxaloplatin, carboplatin), anthracenedione (e.g., mitoxantrone), substituted urea (e.g., hydroxyurea), methyl hydrazine derivative (e.g., procarbazine), adrenocortical suppressant (e.g., mitotane, aminoglutethimide), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), inhibitors of mitogen-activated protein kinase signaling (e.g. U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002, Syk inhibitors, mTOR inhibitors, antibodies (e.g., rituxan), gossyphol, genasense, polyphenol E, Chlorofusin, all trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2'-deoxycytidine, all trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (Gleevec.RTM.), geldanamycin, 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 11-7082, PKC412, PD184352, 20-epi-1, 25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense

oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9-dioxamycin; diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone;

miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylerie conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen-binding protein; sizofuran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem

cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; zinostatin stimalamer, Adriamycin, Dactinomycin, Bleomycin, Vinblastine, Cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; fluorocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; iimofosine; interleukin I1 (including recombinant interleukin II, or rlL.sub.2), interferon alfa-2a; interferon alfa-2b; interferon alfa-n1; interferon alfa-n3; interferon beta-1a; interferon gamma-1b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazoie; nogalamycin; ormaplatin; oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone

hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride, agents that arrest cells in the G2-M phases and/or modulate the formation or stability of microtubules, (e.g. Taxol.TM (i.e. paclitaxel), Taxotere.TM, compounds comprising the taxane skeleton, Erbulozole (i.e. R-55104), Dolastatin 10 (i.e. DLS-10 and NSC-376128), Mivobulin isethionate (i.e. as CI-980), Vincristine, NSC-639829, Discodermolide (i.e. as NVP-XX-A-296), ABT-751 (Abbott, i.e. E-7010), Altorhyrtins (e.g. Altorhyrtin A and Altorhyrtin C), Spongistatins (e.g. Spongistatin 1, Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and Spongistatin 9), Cemadotin hydrochloride (i.e. LU-103793 and NSC-D-669356), Epothilones (e.g. Epothilone A, Epothilone B, Epothilone C (i.e. desoxyepothilone A or dEpoA), Epothilone D (i.e. KOS-862, dEpoB, and desoxyepothilone B), Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone A N-oxide, 16-aza-epothilone B, 21-aminoepothilone B (i.e. BMS-310705), 21-hydroxyepothilone D (i.e. Desoxyepothilone F and dEpoF), 26-fluoroepothilone, Auristatin PE (i.e. NSC-654663), Soblidotin (i.e. TZT-1027), LS-4559-P (Pharmacia, i.e. LS-4577), LS-4578 (Pharmacia, i.e. LS-477-P), LS-4477 (Pharmacia), LS-4559 (Pharmacia), RPR-112378 (Aventis), Vincristine sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, i.e. WS-9885B), GS-164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy of Sciences), BSF-223651 (BASF, i.e. ILX-651 and LU-223651), SAH-49960 (Lilly/Novartis), SDZ-268970 (Lilly/Novartis), AM-97 (Armad/Kyowa Hakko), AM-132 (Armad), AM-138 (Armad/Kyowa Hakko), IDN-5005 (Indena), Cryptophycin 52 (i.e. LY-355703), AC-7739 (Ajinomoto, i.e. AVE-8063A and CS-39.HCl), AC-7700 (Ajinomoto, i.e. AVE-8062, AVE-8062A, CS-39-L-Ser.HCl, and RPR-258062A), Vitilevuamide, Tubulysin A, Canadensol, Centaureidin (i.e. NSC-106969), T-138067 (Tularik, i.e. T-67, TL-138067 and TI-138067), COBRA-1 (Parker Hughes Institute, i.e. DDE-261 and WHI-261), H10 (Kansas State University), H16 (Kansas State University), Oncocidin A1 (i.e. BTO-956 and DIME), DDE-313 (Parker Hughes Institute), Fijianolide B, Laulimalide, SPA-2 (Parker Hughes Institute), SPA-1 (Parker Hughes Institute, i.e. SPIKET-P), 3-IAABU (Cytoskeleton/Mt. Sinai School of Medicine, i.e. MF-569), Narcosine (also known as NSC-5366), Nascapine, D-24851 (Asta Medica), A-105972 (Abbott), Hemiasterlin, 3-BAABU (Cytoskeleton/Mt. Sinai School of Medicine, i.e. MF-191), TMPN (Arizona State University), Vanadocene acetylacetonate, T-138026 (Tularik), Monsatrol, lnanocine (i.e. NSC-698666), 3-IAABE (Cytoskeleton/Mt. Sinai

School of Medicine), A-204197 (Abbott), T-607 (Tuiarik, i.e. T-900607), RPR-115781 (Aventis), Eleutherobins (such as Desmethyleleutherobin, Desaetyleleutherobin, lsoeleutherobin A, and Z-Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, D-64131 (Asta Medica), D-68144 (Asta Medica), Diazonamide A, A-293620 (Abbott), NPI-2350 (Nereus), Taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott), Diozostatin, (-)-Phenylahistin (i.e. NSCL-96F037), D-68838 (Asta Medica), D-68836 (Asta Medica), Myoseverin B, D-43411 (Zentaris, i.e. D-81862), A-289099 (Abbott), A-318315 (Abbott), HTI-286 (i.e. SPA-110, trifluoroacetate salt) (Wyeth), D-82317 (Zentaris), D-82318 (Zentaris), SC-12983 (NCI), Resverastatin phosphate sodium, BPR-OY-007 (National Health Research Institutes), and SSR-250411 (Sanofi)), steroids (*e.g.*, dexamethasone), finasteride, aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRH) such as goserelin or leuprolide, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethlystilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogen (e.g., flutamide), immunostimulants (*e.g.*, Bacillus Calmette-Guérin (BCG), levamisole, interleukin-2, alpha-interferon, *etc.*), monoclonal antibodies (*e.g.*, anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR, and anti-VEGF monoclonal antibodies), immunotoxins (*e.g.*, anti-CD33 monoclonal antibody-calicheamicin conjugate, anti-CD22 monoclonal antibody-pseudomonas exotoxin conjugate, *etc.*), radioimmunotherapy (*e.g.*, anti-CD20 monoclonal antibody conjugated to ^{111}In, ^{90}Y, or ^{131}I, *etc.*), triptolide, homoharringtonine, dactinomycin, doxorubicin, epirubicin, topotecan, itraconazole, vindesine, cerivastatin, vincristine, deoxyadenosine, sertraline, pitavastatin, irinotecan, clofazimine, 5-nonyloxytryptamine, vemurafenib, dabrafenib, erlotinib, gefitinib, EGFR inhibitors, epidermal growth factor receptor (EGFR)-targeted therapy or therapeutic (e.g. gefitinib (Iressa ™), erlotinib (Tarceva ™), cetuximab (Erbitux™), lapatinib (Tykerb™), panitumumab (Vectibix™), vandetanib (Caprelsa™), afatinib/BIBW2992, CI-1033/canertinib, neratinib/HKI-272, CP-724714, TAK-285, AST-1306, ARRY334543, ARRY-380, AG-1478, dacomitinib/PF299804, OSI-420/desmethyl erlotinib, AZD8931, AEE788, pelitinib/EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626), sorafenib, imatinib, sunitinib, dasatinib, or the like.

[0145] "Chemotherapeutic" or "chemotherapeutic agent" is used in accordance with its plain ordinary meaning and refers to a chemical composition or compound having antineoplastic properties or the ability to inhibit the growth or proliferation of cells.

[0146] The compounds disclosed herein may be co-administered with an antiproliferative/antineoplastic drug or a combination thereof, as used in medical oncology, such as an alkylating agent (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard,

melphalan, chlorambucil, busulphan or a nitrosourea); an antimetabolite (for example an antifolate such as a fluoropyrimidine like 5-fluorouracil or tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, gemcitabine or paclitaxel); an antitumour antibiotic (for example an anthracycline such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin or mithramycin); an antimitotic agent (for example a vinca alkaloid such as vincristine, vinblastine, vindesine or vinorelbine, or a taxoid such as taxol or taxotere); or a topoisomerase inhibitor (for example an epipodophyllotoxin such as etoposide, teniposide, amsacrine, topotecan or a camptothecin); (ii) a cytostatic agent such as an antioestrogen (for example tamoxifen, toremifene, raloxifene, droloxifene or iodoxyfene), an oestrogen receptor down regulator (for example fulvestrant), an antiandrogen (for example bicalutamide, flutamide, nilutamide or cyproterone acetate), a LHRH antagonist or LHRH agonist (for example goserelin, leuprorelin or buserelin), a progestogen (for example megestrol acetate), an aromatase inhibitor (for example as anastrozole, letrozole, vorazole or exemestane) or an inhibitor of 5.alpha.-reductase such as finasteride; (iii) an agent which inhibits cancer cell invasion (for example a metalloproteinase inhibitor like marimastat or an inhibitor of urokinase plasminogen activator receptor function); (iv) an inhibitor of growth factor function, for example: a growth factor antibody (for example the anti-erbb2 antibody trastuzumab, or the anti-erbb1 antibody cetuximab [C225]), a farnesyl transferase inhibitor, a tyrosine kinase inhibitor or a serine/threonine kinase inhibitor, an inhibitor of the epidermal growth factor family (for example an EGFR family tyrosine kinase inhibitor such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazoli- n-4-amine (gefitinib, AZD 1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) or 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazoli- n-4-amine (CI 1033)), an inhibitor of the platelet-derived growth factor family, or an inhibitor of the hepatocyte growth factor family; (v) an antiangiogenic agent such as one which inhibits the effects of vascular endothelial growth factor (for example the anti-vascular endothelial cell growth factor antibody bevacizumab, a compound disclosed in WO 97/22596, WO 97/30035, WO 97/32856 or WO 98/13354), or a compound that works by another mechanism (for example linomide, an inhibitor of integrin .alpha.v.beta.3 function or an angiostatin); (vi) a vascular damaging agent such as combretastatin A4, or a compound disclosed in WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 or WO 02/08213; (vii) an agent used in antisense therapy, for example one directed to one of the targets listed above, such as ISIS 2503, an anti-ras antisense; (viii) an agent used in a gene therapy approach, for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a

bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; or (ix) an agent used in an immunotherapeutic approach, for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.

[0147] In embodiments, the compounds disclosed herein can be co-administered with an antibody, such as a monoclonal antibody targeting B-Lymphocytes (such as CD20 (rituximab), MRA-aIL16R and T-Lymphocytes, CTLA4-Ig, HuMax I1-15) or antibody modulating Ig function such as anti-IgE (for example omalizumab).

[0148] In embodiments, treatment of cancer includes administration of an effective amount of at least two of the following: a CRF1 inhibitor, an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4, an agonistic antibody of CD137 (4-1BB). In some embodiments, the method may comprise the use of two or more combinations.

[0149] In a further embodiment, the compounds described herein can be co-administered with conventional radiotherapeutic agents including, but not limited to, radionuclides such as ^{47}Sc, ^{64}Cu, ^{67}Cu, ^{89}Sr, ^{86}Y, ^{87}Y, ^{90}Y, ^{105}Rh, ^{111}Ag, ^{111}In, ^{117m}Sn, ^{149}Pm, ^{153}Sm, ^{166}Ho, ^{177}Lu, ^{186}Re, ^{188}Re, ^{211}At, and ^{212}Bi, optionally conjugated to antibodies directed against tumor antigens.

[0150] In addition, a CRF_1 inhibitor may be combined with the therapeutic administration of immune cells, sometimes referred to as adoptive cell transfer. These cells may be cells from the patient, a genetically related or unrelated donor, they may be genetically modified (e.g. CAR-T cells, NK cells, etc), cell lines, genetically modified cell lines and live or dead versions of the above. CRF1 inhibitors may also be combined with vaccines of any kind (e.g. protein/peptide, viral, bacterial, cellular) to stimulate immune responses to cancer.

[0151] The CRF_1 inhibitors/CRF_1 antagonists disclosed herein can be administered by any acceptable route, such oral, intraadiposal, intraarterial, intraarticular, intracranial, intradermal, intralesional, intramusculay, intranasal, intraocularal, intrapericardial, intraperitoneal, intrapleural, intraprostatical, intrarectal, intrathecal, intratracheal, intratumoral, intraumbilical, intravaginal, intravenousl, intravesicullar, intravitreal, liposomal, local, mucosal, parenteral, rectal, subconjunctival, subcutaneous, sublingual, topical, transbuccal, transdermal, vaginal, in cremes, in lipid compositions, via a catheter, via a lavage, via continuous infusion, via infusion, via inhalation, via injection, via local delivery, via localized perfusion, bathing target cells directly, or any combination thereof.

[0152] The CRF_1 inhibitors/CRF_1 antagonists disclosed herein can be administered by any acceptable route, such oral, intraadiposal, intraarterial, intraarticular, intracranial, intradermal, intralesional, intramusculay, intranasal, intraocularal, intrapericardial, intraperitoneal, intrapleural, intraprostatical, intrarectal, intrathecal, intratracheal, intratumoral, intraumbilical, intravaginal, intravenousl, intravesicullar, intravitreal, liposomal, local, mucosal, parenteral, rectal, subconjunctival, subcutaneous, sublingual, topical, transbuccal, transdermal, vaginal, in cremes, in lipid compositions, via a catheter, via a lavage, via continuous infusion, via infusion, via inhalation, via injection, via local delivery, via localized perfusion, bathing target cells directly, or any combination thereof.

[0153] The CRF_1 inhibitors/CRF_1 antagonists disclosed herein may be administered once daily until study reached endpoint. The CRF_1 inhibitors/CRF_1 antagonists disclosed herein may be administered at least three times but in some studies four or more times depending on the length of the study and/or the design of the study.

[0154] The methods disclosed herein may be used in combination with additional cancer therapy. In some embodiments, the distinct cancer therapy comprises surgery, radiotherapy, chemotherapy, toxin therapy, immunotherapy, cryotherapy or gene therapy. In some embodiments, the cancer is a chemotherapy-resistant or radio-resistant cancer.

[0155] A “cell” as used herein, refers to a cell carrying out metabolic or other function sufficient to preserve or replicate its genomic DNA. A cell can be identified by well-known methods in the art including, for example, presence of an intact membrane, staining by a particular dye, ability to produce progeny or, in the case of a gamete, ability to combine with a second gamete to produce a viable offspring. Cells may include prokaryotic and eukaroytic cells. Prokaryotic cells include but are not limited to bacteria. Eukaryotic cells include but are not limited to yeast cells and cells derived from plants and animals, for example mammalian, insect (*e.g.*, spodoptera) and human cells. Cells may be useful when they are naturally nonadherent or have been treated not to adhere to surfaces, for example by trypsinization.

[0156] “Control” or “control experiment” is used in accordance with its plain ordinary meaning and refers to an experiment in which the subjects or reagents of the experiment are treated as in a parallel experiment except for omission of a procedure, reagent, or variable of the experiment. In some instances, the control is used as a standard of comparison in evaluating experimental effects. In some embodiments, a control is the measurement of the activity of a protein in the absence of a compound as described herein (including embodiments and examples).

[0157] The term “modulator” refers to a composition that increases or decreases the level of a target molecule or the function of a target molecule or the physical state of the target of the molecule. In some embodiments, a CRF1 associated disease modulator is a compound that

reduces the severity of one or more symptoms of a disease associated with CRF_1 (e.g. an endocrine disorder, a cancer including but not limited to TART or OART). A CRF_1 modulator is a compound that increases or decreases the activity or function or level of activity or level of function of CRF_1. A modulator may act alone, or it may use a cofactor, e.g., a protein, metal ion, or small molecule. Examples of modulators include small molecule compounds and other bioorganic molecules. Numerous libraries of small molecule compounds (e.g., combinatorial libraries) are commercially available and can serve as a starting point for identifying a modulator. The skilled artisan is able to develop one or more assays (e.g., biochemical or cell-based assays) in which such compound libraries can be screened in order to identify one or more compounds having the desired properties; thereafter, the skilled medicinal chemist is able to optimize such one or more compounds by, for example, synthesizing and evaluating analogs and derivatives thereof. Synthetic and/or molecular modeling studies can also be utilized in the identification of an activator.

[0158] The term "modulate" is used in accordance with its plain ordinary meaning and refers to the act of changing or varying one or more properties. "Modulation" refers to the process of changing or varying one or more properties. For example, as applied to the effects of a modulator on a target protein, to modulate means to change by increasing or decreasing a property or function of the target molecule or the amount of the target molecule. In embodiments, the terms "modulate", "modulation" and the like refer to the ability of a molecule (e.g., an activator or an inhibitor) to increase or decrease the function or activity of CRF_1, either directly or indirectly, relative to the absence of the molecule.

[0159] The term "associated" or "associated with" in the context of a substance or substance activity or function associated with a disease (e.g. a protein associated disease, an endocrine disorder, a disease associated with CRF_1 activity, a CRF_1 associated disease (e.g., testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART)) means that the disease (e.g., testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART)) is caused by (in whole or in part), or a symptom of the disease is caused by (in whole or in part) the substance or substance activity or function. For example, an endocrine disorder associated with CRF_1 activity or function may be an endocrine disorder that results (entirely or partially) from aberrant CRF_1 function (e.g. enzyme activity, protein-protein interaction, signaling pathway) or an endocrine disorder wherein a particular symptom of the disease is caused (entirely or partially) by aberrant CRF_1 activity or function. As used herein, what is described as being associated with a disease, if a causative agent, could be a target for treatment of the disease. For example, an endocrine disorder associated with CRF_1 activity or function or a CRF_1 associated disease (e.g., an endocrine disorder including but not limited to TART or OART), may be treated with a

compound described herein (e.g., CRF_1 modulator, CRF_1 inhibitor, or CRF_1 antagonist), in the instance where increased CRF_1 activity or function (e.g. signaling pathway activity) causes the disease (e.g., an endocrine disorder such as TART or OART). For example, an endocrine disorder associated with CRF_1 activity or function or a CRF_1 associated endocrine disorder, may be treated with an CRF_1 modulator or CRF_1 inhibitor, in the instance where increased CRF_1 activity or function (e.g. signaling pathway activity) causes the disease.

[0160] The term "aberrant" as used herein refers to different from normal. When used to describe enzymatic activity or protein function, aberrant refers to activity or function that is greater or less than a normal control or the average of normal non-diseased control samples. Aberrant activity may refer to an amount of activity that results in a disease, wherein returning the aberrant activity to a normal or non-disease-associated amount (e.g. by administering a compound or using a method as described herein), results in reduction of the disease or one or more disease symptoms.

[0161] The term "signaling pathway" as used herein refers to a series of interactions between cellular and optionally extra-cellular components (e.g. proteins, nucleic acids, small molecules, ions, lipids) that conveys a change in one component to one or more other components, which in turn may convey a change to additional components, which is optionally propogated to other signaling pathway components. For example, binding of a CRF_1 with a compound as described herein may reduce the level of a product of the CRF_1 catalyzed reaction or the level of a downstream derivative of the product or binding may reduce the interactions between the CRF_1 or a reaction product and downstream effectors or signaling pathway components (e.g., MAP kinase pathway), resulting in changes in cell growth, proliferation, or survival.

[0162] As used herein, the terms "corticotropin-releasing factor type-1," "CRF_1," "corticotropin-releasing hormone receptor 1," and "CHHR1" and all other related art-accepted terms, many of which are set forth below, refer to a compound capable of modulating, either directly or indirectly, the CRF_1 receptor in an *in vitro* assay, an *in vivo* model, and/or other means indicative of therapeutic efficacy. The terms also refer to a compound that exhibits at least some therapeutic benefit in a human subject.

[0163] The phrase "in a sufficient amount to effect a change" means that there is a detectable difference between a level of an indicator measured before (e.g., a baseline level) and after administration of a particular therapy. Indicators include any objective parameter (e.g., serum concentration) or subjective parameter (e.g., a subject's feeling of well-being).

[0164] The "activity" of a molecule may describe or refer to the binding of the molecule to a ligand or to a receptor; to catalytic activity; to the ability to stimulate gene expression or cell signaling, differentiation, or maturation; to antigenic activity; to the modulation of activities of

other molecules; and the like. The term "proliferative activity" encompasses an activity that promotes, that is necessary for, or that is specifically associated with, for example, normal cell division, as well as cancer, tumors, dysplasia, cell transformation, metastasis, and angiogenesis.

[0165] "Substantially pure" indicates that a component makes up greater than about 50% of the total content of the composition, and typically greater than about 60% of the total polypeptide content. More typically, "substantially pure" refers to compositions in which at least 75%, at least 85%, at least 90% or more of the total composition is the component of interest. In some cases, the polypeptide will make up greater than about 90%, or greater than about 95% of the total content of the composition (percentage in a weight per weight basis).

[0166] The terms "specifically binds" and "selectively binds," when referring to a ligand/receptor, antibody/antigen, or other binding pair, indicates a binding reaction which is determinative of the presence of the protein in a heterogeneous population of proteins and other biologics. Thus, under designated conditions, a specified ligand binds to a particular receptor and does not bind in a significant amount to other proteins present in the sample. The antibody, or binding composition derived from the antigen-binding site of an antibody, of the contemplated method binds to its antigen, or a variant or mutein thereof, with an affinity that is at least two-fold greater, at least 10-times greater, at least 20-times greater, or at least 100-times greater than the affinity with any other antibody, or binding composition derived therefrom. In embodiments, the antibody will have an affinity that is greater than about 10^9 liters/mol, as determined by, e.g., Scatchard analysis (Munsen, et al. (1980) Analyt. Biochem. 107:220-239).

[0167] The terms "DNA," "nucleic acid," "nucleic acid molecule," "polynucleotide" and the like are used interchangeably herein to refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Non-limiting examples of polynucleotides include linear and circular nucleic acids, messenger RNA (mRNA), complementary DNA (cDNA), recombinant polynucleotides, vectors, probes, primers and the like.


[0168] As used herein, the terms "variants" and "homologs" are used interchangeably to refer to amino acid or nucleic acid sequences that are similar to reference amino acid or nucleic acid sequences, respectively. The term encompasses naturally-occurring variants and non-naturally-occurring variants. Naturally-occurring variants include homologs (polypeptides and nucleic acids that differ in amino acid or nucleotide sequence, respectively, from one species to another), and allelic variants (polypeptides and nucleic acids that differ in amino acid or nucleotide sequence, respectively, from one individual to another within a species). Thus, variants and homologs encompass naturally occurring amino acid and nucleic acid sequences encoded thereby and their isoforms, as well as splice variants of a protein or gene. The terms also





encompass nucleic acid sequences that vary in one or more bases from a naturally-occurring nucleic acid sequence but still translate into an amino acid sequence that corresponds to the naturally-occurring protein due to degeneracy of the genetic code. Non-naturally-occurring variants and homologs include polypeptides and nucleic acids that comprise a change in amino acid or nucleotide sequence, respectively, where the change in sequence is artificially introduced (e.g., muteins); for example, the change is generated in the laboratory by human intervention ("hand of man"). Therefore, non-naturally occurring variants and homologs may also refer to those that differ from the naturally-occurring sequences by one or more conservative substitutions and/or tags and/or conjugates.

[0169] The term "muteins" as used herein refers broadly to mutated recombinant proteins. These proteins usually carry single or multiple amino acid substitutions and are frequently derived from cloned genes that have been subjected to site-directed or random mutagenesis, or from completely synthetic genes.

II. Compounds


[0170] In an aspect provided herein, is a compound of Formula (I):




, or a pharmaceutically acceptable salt thereof. R^1 and R^2 are independently ethyl or n-propyl. R^3 is hydrogen, Cl, Br, methyl, trifluoromethyl, or methoxy. R^4 is hydrogen, Br, R^aR^bN–, methoxymethyl, n-butyl, acetamido, pyridin-4-yl, morpholin-4-yl,  ,  ,  , or  . R^a and R^b are independently hydrogen, C_1-C_3alkyl, $H_2NCH_2CH_2$–, $(CH_3)_3COC(O)NHCH_2CH_2$–, or $CH_3CH_2CH_2NHCH_2CH_2$–In embodiments, the inhibitor forms an irreversible bond with the amino acid residue. In embodiments, the bond is a covalent bond.


[0171] In certain embodiments, R^3 is Cl, Br, methyl, or trifluoromethyl.

[0172] In certain embodiments, R^3 is Cl, Br, or methyl.


[0173] In certain embodiments, R^4 is Br, R^aR^bN–, pyridin-4-yl, morpholin-4-yl, or  .

[0174] In certain embodiments, R^4 is morpholin-4-yl or  .


[0175] In certain embodiments, R^4 is hydrogen, Br, R^aR^bN– and R^a and R^b are independently C_1-C_3alkyl.

[0176] In certain embodiments, the compound is  , or a pharmaceutically acceptable salt thereof.

[0177] In certain embodiments, the compound is

 , or a pharmaceutically acceptable salt thereof.

[0178] In certain embodiments, the compound is

 , or a pharmaceutically acceptable salt thereof.

[0179] In one aspect described herein, there is a method of treating a subject in need thereof comprising administering an astressin or a pharmaceutically acceptable salt or solvate thereof. An astressin generally refers to a nonselective corticotropin releasing hormone antagonist that reduces the synthesis of ACTH and cortisol.

[0180] In one aspect described herein, there is a method of treating congenital adrenal hyperplasia (CAH) in a subject in need thereof, comprising administering an astressin or a variant having at least about 70% identity thereto or a pharmaceutically acceptable salt or solvate thereof. In one aspect described herein, there is a method of treating congenital adrenal hyperplasia (CAH) in a subject in need thereof, the method comprising: (i) measuring a hormone

level in the subject in need thereof; (ii) administering an astressin or a variant having at least about 70% identity thereto, or a pharmaceutically acceptable salt or solvate thereof; and repeating steps (i) and (ii) until the hormone level reaches a pre-determined range followed by a maintenance therapy of a daily dosing of said astressin.

[0181] In one aspect described herein, there is a method of improving hyperandrogenic symptoms in a subject in need thereof, comprising administering an astressin or a variant having at least about 70% identity thereto, or a pharmaceutically acceptable salt or solvate thereof. In one aspect described herein, there is a method of treating menstrual irregularity, ovulatory dysfunction or infertility, in a subject in need thereof, comprising administering an astressin or a variant having at least about 70% identity thereto, or a pharmaceutically acceptable salt or solvate thereof. In one aspect described herein, there is a method of improving metabolic symptoms in a subject in need thereof, comprising administering an astressin or a variant having at least about 70% identity thereto; or a pharmaceutically acceptable salt or solvate thereof.

[0182] In one aspect described herein, there is a method of improving quality of life in a subject in need thereof, comprising administering an astressin or a variant having at least about 70% identity thereto, or a pharmaceutically acceptable salt or solvate thereof.

III. Pharmaceutical Compositions

[0183] In an aspect, there is provided a pharmaceutical composition, including a compound as described herein, including embodiments, or the structural Formula (I), and a pharmaceutically acceptable excipient.

[0184] The compounds (e.g., CRF_1 inhibitors/antagonists) of the present disclosure may be in the form of compositions suitable for administration to a subject. In general, such compositions are "pharmaceutical compositions" comprising a compound (e.g., CRF_1 inhibitor(s)/ antagonist(s)) and one or more pharmaceutically acceptable or physiologically acceptable diluents, carriers or excipients. In certain embodiments, the compound (e.g., CRF_1 inhibitor/antagonist) are present in a therapeutically acceptable amount. The pharmaceutical compositions may be used in the methods of the present disclosure; thus, for example, the pharmaceutical compositions can be administered *ex vivo* or *in vivo* to a subject in order to practice the therapeutic and prophylactic methods and uses described herein.

[0185] In one aspect described herein, there is a pharmaceutical composition in the form of a capsule comprising an astressin or a variant having at least about 70% identity thereto, or a pharmaceutically acceptable salt or solvate thereof. In one aspect described herein, there is a pharmaceutical composition in the form of a tablet comprising an astressin or a variant having at least about 70% identity thereto, or a pharmaceutically acceptable salt or solvate thereof.

[0186] The pharmaceutical compositions of the present disclosure can be formulated to be compatible with the intended method or route of administration; exemplary routes of administration are set forth herein.

[0187] The pharmaceutical compositions containing the active ingredient (e.g., an inhibitor of CRF_1 function) may be in a form suitable for oral use, for example, as tablets, capsules, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups, solutions, microbeads or elixirs. Pharmaceutical compositions intended for oral use may be prepared for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents such as, for example, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets, capsules and the like contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture thereof. These excipients may be, for example, diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.

[0188] The tablets, capsules and the like suitable for oral administration may be uncoated or coated to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action. For example, a time-delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated to form osmotic therapeutic tablets for controlled release. Additional agents include biodegradable or biocompatible particles or a polymeric substance such as polyesters, polyamine acids, hydrogel, polyvinyl pyrrolidone, polyanhydrides, polyglycolic acid, ethylene-vinylacetate, methylcellulose, carboxymethylcellulose, protamine sulfate, or lactide/glycolide copolymers, polylactide/glycolide copolymers, or ethylenevinylacetate copolymers in order to control delivery of an administered composition. For example, the oral agent can be entrapped in microcapsules prepared by coacervation techniques or by interfacial polymerization, by the use of hydroxymethylcellulose or gelatin-microcapsules or poly(methylmethacrolate) microcapsules, respectively, or in a colloid drug delivery system. Colloidal dispersion systems include macromolecule complexes, nano-capsules, microspheres, microbeads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes. Methods for the preparation of the above-mentioned formulations will be apparent to those skilled in the art.

[0189] Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium

phosphate, kaolin or microcrystalline cellulose, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

[0190] Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture thereof. Such excipients can be suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents, for example a naturally-occurring phosphatide (e.g., lecithin), or condensation products of an alkylene oxide with fatty acids (e.g., polyoxy-ethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols (e.g., for heptadecaethyleneoxycetanol), or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol (e.g., polyoxyethylene sorbitol monooleate), or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides (e.g., polyethylene sorbitan monooleate). The aqueous suspensions may also contain one or more preservatives.

[0191] Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.

[0192] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, and optionally one or more suspending agents and/or preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified herein.

[0193] The pharmaceutical compositions of the present disclosure may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example, liquid paraffin, or mixtures of these. Suitable emulsifying agents may be naturally occurring gums, for example, gum acacia or gum tragacanth; naturally occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids; hexitol anhydrides, for example, sorbitan monooleate; and condensation products of partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate.

[0194] The pharmaceutical compositions typically comprise a therapeutically effective amount of a CRF_1 inhibitor/antagonist contemplated by the present disclosure and one or more pharmaceutically and physiologically acceptable formulation agents. Suitable pharmaceutically acceptable or physiologically acceptable diluents, carriers or excipients include, but are not limited to, antioxidants (e.g., ascorbic acid and sodium bisulfate), preservatives (e.g., benzyl

alcohol, methyl parabens, ethyl or n-propyl, p-hydroxybenzoate), emulsifying agents, suspending agents, dispersing agents, solvents, fillers, bulking agents, detergents, buffers, vehicles, diluents, and/or adjuvants. For example, a suitable vehicle may be physiological saline solution or citrate-buffered saline, possibly supplemented with other materials common in pharmaceutical compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. Those skilled in the art will readily recognize a variety of buffers that can be used in the pharmaceutical compositions and dosage forms contemplated herein. Typical buffers include, but are not limited to, pharmaceutically acceptable weak acids, weak bases, or mixtures thereof. As an example, the buffer components can be water soluble materials such as phosphoric acid, tartaric acids, lactic acid, succinic acid, citric acid, acetic acid, ascorbic acid, aspartic acid, glutamic acid, and salts thereof. Acceptable buffering agents include, for example, a Tris buffer; N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES); 2-(N-Morpholino)ethanesulfonic acid (MES); 2-(N-Morpholino)ethanesulfonic acid sodium salt (MES); 3-(N-Morpholino)propanesulfonic acid (MOPS); and N-tris[Hydroxymethyl]methyl-3-aminopropanesulfonic acid (TAPS).

[0195] After a pharmaceutical composition has been formulated, it may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder. Such formulations may be stored either in a ready-to-use form, a lyophilized form requiring reconstitution prior to use, a liquid form requiring dilution prior to use, or other acceptable form. In some embodiments, the pharmaceutical composition is provided in a single-use container (e.g., a single-use vial, ampule, syringe, or autoinjector (similar to, e.g., an EpiPen®)), whereas a multi-use container (e.g., a multi-use vial) is provided in other embodiments.

[0196] Formulations can also include carriers to protect the composition against rapid degradation or elimination from the body, such as a controlled release formulation, including liposomes, hydrogels, prodrugs and microencapsulated delivery systems. For example, a time-delay material such as glyceryl monostearate or glyceryl stearate alone, or in combination with a wax, may be employed. Any drug delivery apparatus may be used to deliver a CRF_1 inhibitor/antagonist, including implants (e.g., implantable pumps) and catheter systems, slow injection pumps and devices, all of which are well known to the skilled artisan.

[0197] Depot injections, which are generally administered subcutaneously or intramuscularly, may also be utilized to release the compound (e.g., CRF_1 inhibitor/antagonist) disclosed herein over a defined period of time. Depot injections are usually either solid- or oil-based and generally comprise at least one of the formulation components set forth herein. One of ordinary skill in the art is familiar with possible formulations and uses of depot injections.

[0198] The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents mentioned herein. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Acceptable diluents, solvents and dispersion media that may be employed include water, Ringer's solution, isotonic sodium chloride solution, Cremophor® EL (BASF, Parsippany, NJ) or phosphate buffered saline (PBS), ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. In addition, sterile fixed oils are conventionally employed as a solvent or suspending medium; for this purpose, any bland fixed oil may be employed, including synthetic mono- or diglycerides. Moreover, fatty acids, such as oleic acid, find use in the preparation of injectables. Prolonged absorption of particular injectable formulations can be achieved by including an agent that delays absorption (e.g., aluminum monostearate or gelatin).

[0199] The present disclosure contemplates the administration of the compound (e.g., CRF_1 inhibitor/antagonist) in the form of suppositories for rectal administration. The suppositories can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include, but are not limited to, cocoa butter and polyethylene glycols.

[0200] The compound (e.g., CRF_1 inhibitor/antagonist) contemplated by the present disclosure may be in the form of any other suitable pharmaceutical composition (e.g., sprays for nasal or inhalation use) currently known or developed in the future.

IV. Methods

[0201] In certain embodiments, provided herein are methods for treating or preventing a disease comprising administering an effective amount of a compound of Formula (I), or an isotopic variant thereof or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[0202] In one embodiment, provided herein are methods for treating or preventing a tumor, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for treating or preventing a benign tumor, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for treating or preventing a malignant tumor, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for treating or preventing an adrenal

tumor, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for treating or preventing an adrenal rest tumor, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[0203] In one embodiment, provided herein are methods for treating or preventing infertility, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for treating or preventing male infertility, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for improving or increasing sperm count, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for improving or increasing sperm motility, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for improving or increasing sperm morphology, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for treating or preventing female infertility, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[0204] In one embodiment, provided herein are methods for treating or preventing a proliferative or hyperproliferative disease or disorder, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, the proliferative disease is cancer. In certain embodiments, the proliferative disease is a cancer of the breast, skin, prostate, cervix, uterus, ovary, testes, bladder, lung, liver, larynx, oral cavity, colon and gastrointestinal tract (e.g., esophagus, stomach, pancreas), brain, thyroid, blood, and lymphatic system.

[0205] In certain embodiments, the cancer treatable with the methods provided herein includes, but is not limited to, (1) leukemias, including, but not limited to, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemias such as myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia leukemias and myelodysplastic syndrome or a symptom thereof (such as anemia, thrombocytopenia, neutropenia, bicytopenia or pancytopenia), refractory anemia (RA), RA with ringed sideroblasts (RARS), RA with excess blasts (RAEB),

RAEB in transformation (RAEB-T), preleukemia, and chronic myelomonocytic leukemia (CMML), (2) chronic leukemias, including, but not limited to, chronic rnyelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, and hairy cell leukemia; (3) polycythemia vera; (4) lymphomas, including, but not limited to, Hodgkin's disease and non-Hodgkin's disease; (5) multiple myelomas, including, but not limited to, smoldering multiple myeloma, nonsecretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma, and extramedullary plasmacytoma; (6) Waldenstrom's macroglobulinernia; (7) monoclonal gammopathy of undetermined significance; (8) benign monoclonal gammopathy; (9) heavy chain disease; (10) bone and connective tissue sarcomas, including, but not limited to, bone sarcoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma, soft-tissue sarcomas, angiosarcoma (hemangiosarcoma), fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, metastatic cancers, neurilemmoma, rhabdomyosarcoma, and synovial sarcoma; (11) brain tumors, including, but not limited to, glioma, astrocytoma, brain stem glioma, ependymoma, aligodendrogliorna, nonglial tumor, acoustic neurinoma, craniopharyngioma, medulloblastoma, meningioma, pineocytoma, pineoblastoma, and primary brain lymphoma; (12) breast cancer, including, but not limited to, adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast cancer, mutinous breast cancer, tubular breast cancer, papillary breast cancer, primary cancers, Paget's disease, and inflammatory breast cancer; (13) adrenal cancer, including, but not limited to, pheochromocytom and adrenocortical carcinoma; (14) thyroid cancer, including, but not limited to, papillary or follicular thyroid cancer, medullary thyroid cancer, and anaplastic thyroid cancer; (15) pancreatic cancer, including, but not limited to, insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumor, and carcinoid or islet cell tumor; (16) pituitary cancer, including, but limited to, Cushing's disease, prol actin-secreting tumor, acromegaly, and diabetes insipius; (17) eye cancer, including, but not limited, to ocular melanoma such as iris melanoma, choroidal melanoma, and cilliary body melanoma, and retinoblastoma; (18) vaginal cancer, including, but not limited to, squamous cell carcinoma, adenocarcinoma, and melanoma; (19) vulvar cancer, including, but not limited to, squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease; (20) cervical cancers, including, but not limited to, squamous cell carcinoma, and adenocarcinoma; (21) uterine cancer, including, but not limited to, endometrial carcinoma and uterine sarcoma; (22) ovarian cancer, including, but not limited to, ovarian epithelial carcinoma, borderline tumor, germ cell tumor, and stromal tumor; (23) esophageal cancer, including, but not limited to, squamous cancer, adenocarcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, adenosquamous

carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma; (24) stomach cancer, including, but not limited to, adenocarcinoma, fungating (polypoid), ulcerating, superficial spreading, diffusely spreading, malignant lymphoma, liposarcoma, fibrosarcoma, and carcinosarcoma; (25) colon cancer; (26) rectal cancer; (27) liver cancer, including, but not limited to, hepatocellular carcinoma and hepatoblastoma; (28) gallbladder cancer, including, but not limited to, adenocarcinoma; (29) cholangiocarcinomas, including, but not limited to, pappillary, nodular, and diffuse; (30) lung cancer, including, but not limited to, non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large-cell carcinoma, and small-cell lung cancer; (31) testicular cancer, including, but not limited to, germinal tumor, seminoma, anaplastic, classic (typical), spermatocytic, nonserninoma, embryonal carcinoma, teratoma carcinoma, and choriocarcinoma (yolk-sac tumor); (32) prostate cancer, including, but not limited to, adenocarcinoma, leiomyosarcoma, and rhabdomyosarcorna; (33) penal cancer; (34) oral cancer, including, but not limited to, squamous cell carcinoma; (35) basal cancer; (36) salivary gland cancer, including, but not limited to, adenocarcinoma, mucoepidermoid carcinoma, and adenoidcystic carcinoma; (37) pharynx cancer, including, but not limited to, squamous cell cancer and verrucous; (38) skin cancer, including, but not limited to, basal cell carcinoma, squamous cell carcinoma and melanoma, superficial spreading melanoma, nodular melanoma, lentigo malignant melanoma, and acral lentiginous melanoma; (39) kidney cancer, including, but not limited to, renal cell cancer, adenocarcinoma, hypernephroma, fibrosarcoma, and transitional cell cancer (renal pelvis and/or uterer); (40) Wilms' tumor; (41) bladder cancer, including, but not limited to, transitional cell carcinoma, squamous cell cancer, adenocarcinoma, and carcinosarcoma; and other cancer, including, not limited to, myxosarcoma, osteogenic sarcoma, endotheliosarcoma, lymphangio-endotheliosarcoma, mesothelioma, synovioma, hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, and papillary adenocarcinomas (*See* Fishman *et al.*, 1985, *Medicine*, 2d Ed., J.B. Lippincott Co., Philadelphia and Murphy *et al.*, 1997, *Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery*, Viking Penguin, Penguin Books U.S.A., Inc., United States of America).

[0206] Depending on the disorder, disease, or condition to be treated, and the subject's condition, the compounds or pharmaceutical compositions provided herein can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracistemal injection or infusion, subcutaneous injection, or implant), inhalation, nasal, vaginal, rectal, sublingual, or topical (e.g., transdermal or local) routes of administration and can be formulated, alone or

together, in suitable dosage unit with pharmaceutically acceptable excipients, carriers, adjuvants, and vehicles appropriate for each route of administration as described elsewhere herein.

[0207] The suitability of a particular route of administration employed for a particular active agent will depend on the active agent itself (e.g., whether it can be administered orally without decomposing prior to entering the blood stream) and the disease being treated. Recommended routes of administration for the second active agents are known to those of ordinary skill in the art. See, e.g., Physicians' Desk Reference, 1755-1760 (56th ed., 2002).


[0208] In one embodiment, provided herein are methods for treating or preventing testicular adrenal rest tumors (TART) in a subject, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein the subject has congenital adrenal hyperplasia (CAH).


[0209] In one embodiment, provided herein are methods for treating or preventing ovarian adrenal rest tumors (OART) in a subject, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein the subject has congenital adrenal hyperplasia (CAH).




[0210] In an aspect provided herein, is a method of treating or preventing testicular adrenal rest tumors (TART), comprising administering to a subject in need thereof a corticotropin-releasing factor type-1 (CRF_1) antagonist or a pharmaceutically acceptable salt thereof.

[0211] In an aspect provided herein, is a method of treating or preventing ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a corticotropin-releasing factor type-1 (CRF_1) antagonist or a pharmaceutically acceptable salt thereof.


[0212] In an aspect provided herein, is a method of treating or preventing testicular adrenal rest tumors (TART), comprising administering to a subject in need thereof a compound of structural Formula (I):




, or a pharmaceutically acceptable salt thereof. R^1 and R^2 are independently ethyl or n-propyl. R^3 is hydrogen, Cl, Br, methyl, trifluoromethyl, or methoxy. R^4 is hydrogen, Br, R^aR^bN–, methoxymethyl, n-butyl, acetamido, pyridin-4-yl, morpholin-4-yl,  ,

 ,  , or  . R^a and R^b are independently hydrogen, C_1-C_3alkyl, $H_2NCH_2CH_2$–, $(CH_3)_3COC(O)NHCH_2CH_2$–, or $CH_3CH_2CH_2NHCH_2CH_2$–.

[0213] In an aspect provided herein, is a method of treating or preventing ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a compound of structural Formula (I):

 , or a pharmaceutically acceptable salt thereof. R^1, R^2, R^3 and R^4 are as described herein, including embodiments.


[0214] In an aspect provided herein, is a method of decreasing or reducing adrenocorticotropic hormone (ACTH) levels in a subject in need thereof, comprising administering to the subject contacting the ACTH with a compound of structural Formula (I):

 , or a pharmaceutically acceptable salt thereof. R^1, R^2, R^3 and R^4 are as described herein, including embodiments. R^1, R^2, R^3 and R^4 are as described herein, including embodiments. In certain embodiments, at least about 50% of the subjects demonstrate reduction in ACTH.In certain embodiments, at least about 60% of the subjects demonstrate reduction in ACTH.In certain embodiments, at least about 70% of the subjects demonstrate reduction in ACTH. In certain embodiments, at least about 80% of the subjects demonstrate reduction in ACTH. In embodiments, at least about 10% of subjects were in the standard or normal range for ACTH after treatment.

[0215] In embodiments, at least about 20% of subjects were in the standard or normal range for ACTH after treatment. In embodiments, at least about 30% of subjects were in the standard or normal range for ACTH after treatment. In certain embodiments, ACTH levels are decreased or reduced within about 30 minutes post dosing. In certain embodiments, ACTH levels are decreased or reduced within about 1 hour post dosing. In certain embodiments, ACTH levels are


decreased or reduced within about 90 minutes post dosing. In certain embodiments, ACTH levels are decreased or reduced within about 2 hours post dosing.

[0216] In an aspect provided herein, is a method of decreasing or reducing 17α-hydroxyprogesterone (17-OHP) levels in a subject in need thereof, comprising administering to the subject a compound of structural Formula (I):




, or a pharmaceutically acceptable salt thereof. R^1, R^2, R^3 and R^4 are as described herein, including embodiments. R^1, R^2, R^3 and R^4 are as described herein, including embodiments. In certain embodiments, at least about 50% of the subjects demonstrate reduction in 17-OHP. In certain embodiments, at least about 60% of the subjects demonstrate reduction in 17-OHP. In certain embodiments, at least about 70% of the subjects demonstrate reduction in 17-OHP. In certain embodiments, at least about 80% of the subjects demonstrate reduction in 17-OHP. In embodiments, at least about 30% of subjects were in the standard or normal range of 1200 ng/dL after treatment. In embodiments, at least about 40% of subjects were in the standard or normal range of 1200 ng/dL after treatment. In embodiments, at least about 50% of subjects were in the standard or normal range of 1200 ng/dL after treatment. In embodiments, at least about 60% of subjects were in the standard or normal range of 1200 ng/dL after treatment. In embodiments, at least about 30% of subjects demonstrated an at least about 25% reduction in 17-OHP after treatment. In embodiments, at least about 40% of subjects demonstrated an at least about 25% reduction in 17-OHP after treatment. In embodiments, at least about 50% of subjects demonstrated an at least about 25% reduction in 17-OHP after treatment. In embodiments, at least about 60% of subjects demonstrated an at least about 25% reduction in 17-OHP after treatment.


[0217] In an aspect provided herein, is a method of decreasing or reducing androstenedione levels in a subject in need thereof, comprising administering to the subject a compound of structural Formula (I):

 , or a pharmaceutically acceptable salt thereof. R^1, R^2, R^3 and R^4 are as described herein, including embodiments. R^1, R^2, R^3 and R^4 are as described herein, including embodiments. In certain embodiments, at least about 50% of the subjects demonstrate reduction in androstenedione.In certain embodiments, at least about 60% of the subjects demonstrate reduction in androstenedione.In certain embodiments, at least about 70% of the subjects demonstrate reduction in androstenedione. In certain embodiments, at least about 80% of the subjects demonstrate reduction in androstenedione. In certain embodiments, at least about 90% of the subjects demonstrate reduction in androstenedione. In certain embodiments, at least 100% of the subjects demonstrate reduction in androstenedione. In embodiments, at least about 30% of subjects demonstrated an at least about 25% reduction in androstenedione after treatment. In embodiments, at least about 40% of subjects demonstrated an at least about 25% reduction in androstenedione after treatment. In embodiments, at least about 50% of subjects demonstrated an at least about 25% reduction in androstenedione after treatment. In embodiments, at least 60% of subjects demonstrated an at least about 25% reduction in androstenedione after treatment. In embodiments, at least about 30% of subjects were in the standard or normal range for androstenedione after treatment. In embodiments, at least about 40% of subjects were in the standard or normal range for androstenedione after treatment. In embodiments, at least about 50% of subjects were in the standard or normal range for androstenedione after treatment.


[0218] In certain embodiments, R^3 is Cl, Br, methyl, or trifluoromethyl.

[0219] In certain embodiments, R^3 is Cl, Br, or methyl.

[0220] In certain embodiments, R^4 is Br, R^aR^bN–, pyridin-4-yl, morpholin-4-yl, or  .


[0221] In certain embodiments, R^4 is morpholin-4-yl or  .

[0222] In certain embodiments, R^4 is hydrogen, Br, R^aR^bN– and R^a and R^b are independently C_1-C_3alkyl.




[0223] In certain embodiments, the compound is , or a pharmaceutically acceptable salt thereof.

[0224] In certain embodiments, the compound is



, or a pharmaceutically acceptable salt thereof.

[0225] In certain embodiments, the compound is



, or a pharmaceutically acceptable salt thereof.

[0226] In certain embodiments, a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is cyclically administered to a patient. Cycling therapy involves the administration of an active agent or a combination of active agents for a period of time, followed by a rest for a period of time, and repeating this sequential administration. Cycling therapy can reduce the development of resistance to one or more of the therapies, avoid or reduce the side effects of one of the therapies, and/or improves the efficacy of the treatment.

[0227] In certain embodiments, in the treatment, prevention, or amelioration of one or more symptoms of the disorders, diseases, or conditions described herein (e.g., treatment or prevention of testicular adrenal rest tumors (TART) or treatment or prevention of ovarian adrenal rest tumors (OART)), an appropriate dosage level of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof generally is ranging from about 1 mg to 3000 mg, from about 1 mg to 2000 mg, from about 1 mg to 1000 mg, from about 1 mg to about 500 mg, from about 5 mg to about 500 mg,

from about 5 mg to about 400 mg, from about 5 mg to about 300 mg, from about 5 mg to about 250 mg, from about 5 mg to about 200 mg, from about 50 mg to about 200 mg, from about 10 mg to about 400 mg, from about 5 mg to about 25 mg, from about 10 mg to about 25 mg, or from about 25 to about 200 mg, which can be administered in single or multiple doses. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1 mg, about 5 mg, about 10 mg mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 800 mg, or about 1000 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1 mg, about 5 mg, about 10 mg mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 800 mg, or about 1000 mg/day.

[0228] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 5 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 10 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 15 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 20 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 25 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 220 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 260 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an

amount of about 270 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 280 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 370 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is

administered in an amount of about 600 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg.

[0229] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, about 200 mg, or about 1000 mg.

[0230] For oral administration, the pharmaceutical compositions provided herein can be formulated in the form of tablets or capsules containing from about 1.0 mg to about 1,000 mg of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, for oral administration, the pharmaceutical compositions provided herein can be formulated in the form of tablets or capsules containing about 1 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about

350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 405 mg, about 410 mg, about 415 mg, about 420 mg, about 425 mg, about 430 mg, about 435 mg, about 440 mg, about 445 mg, about 450 mg, about 455 mg, about 460 mg, about 465 mg, about 470 mg, about 475 mg, about 480 mg, about 485 mg, about 490 mg, about 495 mg, about 500 mg, about 505 mg, about 510 mg, about 515 mg, about 520 mg, about 525 mg, about 530 mg, about 535 mg, about 540 mg, about 545 mg, about 550 mg, about 555 mg, about 560 mg, about 565 mg, about 570 mg, about 575 mg, about 580 mg, about 585 mg, about 590 mg, about 595 mg, about 600 mg, about 605 mg, about 610 mg, about 615 mg, about 620 mg, about 625 mg, about 630 mg, about 635 mg, about 640 mg, about 645 mg, about 650 mg, about 655 mg, about 660 mg, about 665 mg, about 670 mg, about 675 mg, about 680 mg, about 685 mg, about 690 mg, about 695 mg, about 700 mg, about 705 mg, about 710 mg, about 715 mg, about 720 mg, about 725 mg, about 730 mg, about 735 mg, about 740 mg, about 745 mg, about 750 mg, about 755 mg, about 760 mg, about 765 mg, about 770 mg, about 775 mg, about 780 mg, about 785 mg, about 790 mg, about 795 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 990 mg, about 990 mg, or about 1000 mg of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof for the symptomatic adjustment of the dosage to the patient to be treated. In certain embodiments, for oral administration, the pharmaceutical compositions provided herein can be formulated in the form of tablets or capsules containing about 50 mg of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, for oral administration, the pharmaceutical compositions provided herein can be formulated in the form of tablets or capsules containing about 200 mg of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.The pharmaceutical compositions can be administered on a regimen of one (1) to four (4) times per day, including once, twice, three times, and four times per day. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered once per day. In some embodiments, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about

310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 405 mg, about 410 mg, about 415 mg, about 420 mg, about 425 mg, about 430 mg, about 435 mg, about 440 mg, about 445 mg, about 450 mg, about 455 mg, about 460 mg, about 465 mg, about 470 mg, about 475 mg, about 480 mg, about 485 mg, about 490 mg, about 495 mg, about 500 mg, about 505 mg, about 510 mg, about 515 mg, about 520 mg, about 525 mg, about 530 mg, about 535 mg, about 540 mg, about 545 mg, about 550 mg, about 555 mg, about 560 mg, about 565 mg, about 570 mg, about 575 mg, about 580 mg, about 585 mg, about 590 mg, about 595 mg, about 600 mg, about 605 mg, about 610 mg, about 615 mg, about 620 mg, about 625 mg, about 630 mg, about 635 mg, about 640 mg, about 645 mg, about 650 mg, about 655 mg, about 660 mg, about 665 mg, about 670 mg, about 675 mg, about 680 mg, about 685 mg, about 690 mg, about 695 mg, about 700 mg, about 705 mg, about 710 mg, about 715 mg, about 720 mg, about 725 mg, about 730 mg, about 735 mg, about 740 mg, about 745 mg, about 750 mg, about 755 mg, about 760 mg, about 765 mg, about 770 mg, about 775 mg, about 780 mg, about 785 mg, about 790 mg, about 795 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 990 mg, about 990 mg, or about 1000 mg of the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered once per day. In some embodiments, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 405 mg, about 410 mg, about 415 mg, about 420 mg, about 425 mg, about 430 mg, about 435 mg, about 440 mg, about 445 mg, about 450 mg, about 455 mg, about 460 mg, about 465 mg, about 470 mg, about 475 mg, about 480 mg, about 485 mg, about 490 mg, about 495 mg, about 500 mg, about 505 mg, about 510 mg, about 515 mg, about 520 mg, about 525 mg, about 530 mg, about 535 mg, about 540 mg, about 545 mg, about 550 mg, about 555 mg, about 560 mg, about 565 mg, about 570 mg, about 575 mg, about 580 mg, about 585 mg, about 590 mg, about 595 mg, about 600 mg, about 605 mg,

about 610 mg, about 615 mg, about 620 mg, about 625 mg, about 630 mg, about 635 mg, about 640 mg, about 645 mg, about 650 mg, about 655 mg, about 660 mg, about 665 mg, about 670 mg, about 675 mg, about 680 mg, about 685 mg, about 690 mg, about 695 mg, about 700 mg, about 705 mg, about 710 mg, about 715 mg, about 720 mg, about 725 mg, about 730 mg, about 735 mg, about 740 mg, about 745 mg, about 750 mg, about 755 mg, about 760 mg, about 765 mg, about 770 mg, about 775 mg, about 780 mg, about 785 mg, about 790 mg, about 795 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, or about 1000 mg of the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered twice per day. In some embodiments, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 405 mg, about 410 mg, about 415 mg, about 420 mg, about 425 mg, about 430 mg, about 435 mg, about 440 mg, about 445 mg, about 450 mg, about 455 mg, about 460 mg, about 465 mg, about 470 mg, about 475 mg, about 480 mg, about 485 mg, about 490 mg, about 495 mg, about 500 mg, about 505 mg, about 510 mg, about 515 mg, about 520 mg, about 525 mg, about 530 mg, about 535 mg, about 540 mg, about 545 mg, about 550 mg, about 555 mg, about 560 mg, about 565 mg, about 570 mg, about 575 mg, about 580 mg, about 585 mg, about 590 mg, about 595 mg, about 600 mg, about 605 mg, about 610 mg, about 615 mg, about 620 mg, about 625 mg, about 630 mg, about 635 mg, about 640 mg, about 645 mg, about 650 mg, about 655 mg, about 660 mg, about 665 mg, about 670 mg, about 675 mg, about 680 mg, about 685 mg, about 690 mg, about 695 mg, about 700 mg, about 705 mg, about 710 mg, about 715 mg, about 720 mg, about 725 mg, about 730 mg, about 735 mg, about 740 mg, about 745 mg, about 750 mg, about 755 mg, about 760 mg, about 765 mg, about 770 mg, about 775 mg, about 780 mg, about 785 mg, about 790 mg, about 795 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, or about 1000 mg of the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered three times per day.

[0231] In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered for a period of one day. In some embodiments, the compound of Formula (I), or an isotopic variant

thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of two days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of three days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of four days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of five days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of six days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of seven days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of eight days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of nine days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of ten days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 11 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 12 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 13 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 14 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered for a period of 15 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 16 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 17 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically

acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 18 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 19 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 20 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 21 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 22 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 23 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 24 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 25 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 26 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 27 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 28 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 29 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered for a period of 30 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 31 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 32 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 33 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate,

hydrate, or prodrug thereof is administered over a period of 34 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 35 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 36 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 37 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 38 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 39 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 40 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 41 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 42 days or more.

[0232] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 25 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg once daily for a period of up to at least about 14 days.

[0233] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically

acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 220 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 260 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 270 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 140 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg once daily for a period of up to at least

about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 370 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically

acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 600 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg once daily for a period of up to at least about 14 days.

[0234] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 5 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 10 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 15 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 20 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 25 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg twice daily

for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 220 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 260 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 270 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 140 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a

pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 370 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 600 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg twice daily

for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg twice daily for a period of up to at least about 14 days.

[0235] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 5 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 10 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 15 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 20 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 25 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant

thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 220 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 260 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 270 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 280 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330

mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 370 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 600 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant

thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg once daily for a period of up to at least about 28 days.

[0236] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 5 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 10 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 15 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 20 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 25 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an

amount of about 220 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 260 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 270 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 280 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula

(I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 370 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 600 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a

pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg twice daily for a period of up to at least about 28 days.

[0237] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 255 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 10 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 15 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 20 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 25 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 220 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230

mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 260 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 270 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 420 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant

thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 370 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 600 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg once daily for a period of up to at least about 42 days.

[0238] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an

amount of about 5 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 10 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 15 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 20 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 25 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 220 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula

(I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 260 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 270 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 420 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an

amount of about 370 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 600 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg twice daily for a period of up to at least about 42 days.

[0239] In some embodiments, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, or about 400 mg of the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered twice per day. In some embodiments, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 150 mg, about 200

mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, or about 800 mg of the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered at least once per day.

[0240] In certain embodiments, from about 5 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In certain embodiments, from about 25 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In certain embodiments, from about 5 mg to about 25 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In certain embodiments, from about 10 mg to about 400 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In certain embodiments, from about 100 mg to about 600 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject.

[0241] In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered orally.

[0242] In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is formulated as a capsule or tablet.

[0243] In certain embodiments, from about 25 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject.


[0244] In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 5 mg/day to about 1000 mg/day is administered to the subject. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 25 mg/day to about 1000 mg/day is administered to the subject. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 5 mg/day to about 25 mg/day is administered to the subject. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 10 mg/day to about 400 mg/day is administered to the subject.In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 100 mg/day to about 600 mg/day.

[0245] In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in the fed state. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in the fasted state. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at least once per day.

[0246] In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at bedtime. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 6 hours before sleep. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 5 hours before sleep. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 4 hours before sleep. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 3 hours before sleep. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 2 hours before sleep. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 1 hour before sleep. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 30 minutes before sleep.

[0247] In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in the evening. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at about 10 pm at night.

[0248] In another aspect is provided a method of treating or preventing testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a pharmaceutical composition, comprising a compound of structural Formula (I): and a pharmaceutically acceptable excipientcomprising with a compound as described herein, including embodiments, or the structural Formulae (I) and a pharmaceutically acceptable excipient:



, or a pharmaceutically acceptable salt thereof. R^1, R^2, R^3, and R^4 are as described herein, including embodiments.

[0249] In certain embodiments, the pharmaceutical composition comprises from about 25 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In certain embodiments, the pharmaceutical composition comprises from about 25 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In certain embodiments, the pharmaceutical composition comprises from about 5 mg to about 25 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In certain embodiments,

the pharmaceutical composition comprises from about 10 mg to about 400 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In certain embodiments, the pharmaceutical composition comprises from about 100 mg to about 600 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0250] In certain embodiments, the pharmaceutical composition comprises about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg about 500 mg, or about 600 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0251] In certain embodiments, the pharmaceutical composition is administered orally.

[0252] In certain embodiments, the pharmaceutical composition is formulated as a capsule or tablet. In certain embodiments, the capsule or tablet comprises about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, or about 400 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In certain embodiments, the capsule or tablet comprises about 50 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In certain embodiments, the capsule or tablet comprises about 200 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0253] In certain embodiments, the pharmaceutical composition is administered at a dose of from about 5 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 25 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 5 mg to about 25 mg of a compound of Formula (I), or a pharmaceutically

acceptable salt thereof, is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 10 mg to about 400 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject.

[0254] In certain embodiments, the pharmaceutical composition is administered at a dose of from about 5 mg/day to about 1000 mg/day is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 25 mg/day to about 1000 mg/day is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 5 mg/day to about 25 mg/day is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 10 mg/day to about 400 mg/day is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 100 mg/day to about 600 mg/day.

[0255] In certain embodiments, the pharmaceutical composition is administered in the fed state. In certain embodiments, the pharmaceutical composition is administered in the fasted state. In certain embodiments, the pharmaceutical composition is administered at least once per day.

[0256] In certain embodiments, the pharmaceutical composition is administered at bedtime. In certain embodiments, the pharmaceutical composition is administered less than about 6 hours before sleep. In certain embodiments, the pharmaceutical composition is administered less than about 5 hours before sleep. In certain embodiments, the pharmaceutical composition is administered less than about 4 hours before sleep. In certain embodiments, the pharmaceutical composition is administered less than about 3 hours before sleep. In certain embodiments, the pharmaceutical composition is administered less than about 2 hours before sleep. In certain embodiments, the pharmaceutical composition is administered less than about 1 hour before sleep. In certain embodiments, the pharmaceutical composition is administered less than about 30 minutes before sleep.







[0257] In certain embodiments, the pharmaceutical composition is administered in the evening. In certain embodiments, the pharmaceutical composition is administered at about 10 pm at night.


[0258] In certain embodiments, the subject has congenital adrenal hyperplasia (CAH).

[0259] In certain embodiments, the size and/or number of the tumors is decreased or reduced. In certain embodiments, the size of the tumors is decreased or reduced. In certain embodiments, the size of the tumors is decreased or reduced.

[0260] In certain embodiments of the methods disclosed herein, the method further comprises administering to the subject an additional chemotherapeutic agent.

[0261] In certain embodiments, the the additional chemotherapeutic agent is a glucocorticoid, a mineralocorticoid, an ACAT1 inhibitor, or an anti-androgen. In certain embodiments, the glucocorticoid is beclomethasone, betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, or triamcinolone. In certain embodiments, the mineralocorticoid is fludrocortisone. In certain embodiments, the additional chemotherapeutic agent is another CRF_1 antagonist. In certain embodiments, the CRF_1 antagonist is:


,

,

, SSR-126374,

,

, or

, or a pharmaceutically acceptable salt thereof. In certain embodiments, the CRF_1 antagonist is


, or a pharmaceutically acceptable salt thereof.

[0262] In certain embodiments of the methods disclosed herein, the method further comprises an additional treatment selected from surgical resection of the tumors and radiation therapy, or a combination thereof. In certain embodiments, the additional therapy is surgical resection and the surgical resection is prior to, after, and/or concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition, or any combination thereof. In certain embodiments, the surgical resection is prior

to administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In certain embodiments, the surgical resection is after administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In certain embodiments, the surgical resection is concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition.

[0263] In certain embodiments, the additional treatment is radiation therapy and the radiation therapy is prior to, after, and/or concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition, or any combination thereof. In certain embodiments, the radiation therapy is prior to administration of the CRF_1 antagonist of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In certain embodiments, the radiation therapy is after administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In certain embodiments, the radiation therapy is concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition.

[0264] In one embodiment, the pharmaceutical compositions are provided in a dosage form for oral administration, which comprise a compound provided herein, and one or more pharmaceutically acceptable excipients or carriers. The pharmaceutical compositions provided herein that are formulated for oral administration may be in tablet, capsule, powder, or liquid form. In some embodiments, a tablet comprises a solid carrier or an adjuvant. Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil, or synthetic oil. Physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol, or polyethylene glycol may be included. In some embodiments, a capsule comprises a solid carrier such as gelatin.

[0265] In another embodiment, the pharmaceutical compositions are provided in a dosage form for parenteral administration, which comprise a compound provided herein, and one or more pharmaceutically acceptable excipients or carriers. Where pharmaceutical compositions may be formulated for intravenous, cutaneous or subcutaneous injection, the active ingredient will be in the form of a parenterally acceptable aqueous solution, which is pyrogen-free and has a suitable pH, isotonicity, and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles, such as Sodium Chloride injection, Ringer's injection, or Lactated Ringer's injection. In some embodiments, preservatives, stabilisers, buffers, antioxidants, and/or other additives are included as required.

[0266] In yet another embodiment, the pharmaceutical compositions are provided in a dosage form for topical administration, which comprise a compound provided herein, and one or more pharmaceutically acceptable excipients or carriers.

[0267] The pharmaceutical compositions can also be formulated as modified release dosage forms, including delayed-, extended-, prolonged-, sustained-, pulsatile-, controlled-, accelerated-, fast-, targeted-, and programmed-release, and gastric retention dosage forms. These dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art (*see, Remington: The Science and Practice of Pharmacy*, supra; *Modified-Release Drug Delivery Technology*, 2nd Edition, Rathbone *et al.*, Eds., Marcel Dekker, Inc.: New York, NY, 2008).

[0268] The pharmaceutical compositions provided herein can be provided in a unit-dosage form or multiple-dosage form. A unit-dosage form, as used herein, refers to physically discrete a unit suitable for administration to a human and animal subject, and packaged individually as is known in the art. Each unit-dose contains a predetermined quantity of an active ingredient(s) sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carriers or excipients. Examples of a unit-dosage form include an ampoule, syringe, and individually packaged tablet and capsule. A unit-dosage form may be administered in fractions or multiples thereof. A multiple-dosage form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dosage form. Examples of a multiple-dosage form include a vial, bottle of tablets or capsules, or bottle of pints or gallons.

[0269] The pharmaceutical compositions provided herein can be administered at once, or multiple times at intervals of time. It is understood that the precise dosage and duration of treatment may vary with the age, weight, and condition of the patient being treated, and may be determined empirically using known testing protocols or by extrapolation from *in vivo* or *in vitro* test or diagnostic data. It is further understood that for any particular individual, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations.

[0270] In certain embodiments, the pharmaceutical compositions provided herein further comprise one or more chemotherapeutic agents as defined herein.

A. Oral Administration

[0271] The pharmaceutical compositions provided herein for oral administration can be provided in solid, semisolid, or liquid dosage forms for oral administration. As used herein, oral administration also includes buccal, lingual, and sublingual administration. Suitable oral dosage

forms include, but are not limited to, tablets, fastmelts, chewable tablets, capsules, pills, strips, troches, lozenges, pastilles, cachets, pellets, medicated chewing gum, bulk powders, effervescent or non-effervescent powders or granules, oral mists, solutions, emulsions, suspensions, wafers, sprinkles, elixirs, and syrups. In addition to the active ingredient(s), the pharmaceutical compositions can contain one or more pharmaceutically acceptable carriers or excipients, including, but not limited to, binders, fillers, diluents, disintegrants, wetting agents, lubricants, glidants, coloring agents, dye-migration inhibitors, sweetening agents, flavoring agents, emulsifying agents, suspending and dispersing agents, preservatives, solvents, non-aqueous liquids, organic acids, and sources of carbon dioxide.

[0272] Binders or granulators impart cohesiveness to a tablet to ensure the tablet remaining intact after compression. Suitable binders or granulators include, but are not limited to, starches, such as corn starch, potato starch, and pre-gelatinized starch (e.g., STARCH 1500); gelatin; sugars, such as sucrose, glucose, dextrose, molasses, and lactose; natural and synthetic gums, such as acacia, alginic acid, alginates, extract of Irish moss, panwar gum, ghatti gum, mucilage of isabgol husks, carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone (PVP), Veegum, larch arabogalactan, powdered tragacanth, and guar gum; celluloses, such as ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), hydroxypropyl methyl cellulose (HPMC); microcrystalline celluloses, such as AVICEL-PH-101, AVICEL-PH-103, AVICEL RC-581, AVICEL-PH-105 (FMC Corp., Marcus Hook, PA); and mixtures thereof. Suitable fillers include, but are not limited to, talc, calcium carbonate, microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof. The amount of a binder or filler in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The binder or filler may be present from about 50 to about 99% by weight in the pharmaceutical compositions provided herein.

[0273] Suitable diluents include, but are not limited to, dicalcium phosphate, calcium sulfate, lactose, sorbitol, sucrose, inositol, cellulose, kaolin, mannitol, sodium chloride, dry starch, and powdered sugar. Certain diluents, such as mannitol, lactose, sorbitol, sucrose, and inositol, when present in sufficient quantity, can impart properties to some compressed tablets that permit disintegration in the mouth by chewing. Such compressed tablets can be used as chewable tablets. The amount of a diluent in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art.

[0274] Suitable disintegrants include, but are not limited to, agar; bentonite; celluloses, such as methylcellulose and carboxymethylcellulose; wood products; natural sponge; cation-exchange

resins; alginic acid; gums, such as guar gum and Veegum HV; citrus pulp; cross-linked celluloses, such as croscarmellose; cross-linked polymers, such as crospovidone; cross-linked starches; calcium carbonate; microcrystalline cellulose, such as sodium starch glycolate; polacrilin potassium; starches, such as corn starch, potato starch, tapioca starch, and pre-gelatinized starch; clays; aligns; and mixtures thereof. The amount of a disintegrant in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The amount of a disintegrant in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The pharmaceutical compositions provided herein may contain from about 0.5 to about 15% or from about 1 to about 5% by weight of a disintegrant.

[0275] Suitable lubricants include, but are not limited to, calcium stearate; magnesium stearate; mineral oil; light mineral oil; glycerin; sorbitol; mannitol; glycols, such as glycerol behenate and polyethylene glycol (PEG); stearic acid; sodium lauryl sulfate; talc; hydrogenated vegetable oil, including peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil; zinc stearate; ethyl oleate; ethyl laureate; agar; starch; lycopodium; silica or silica gels, such as AEROSIL® 200 (W.R. Grace Co., Baltimore, MD) and CAB-O-SIL® (Cabot Co. of Boston, MA); and mixtures thereof. The pharmaceutical compositions provided herein may contain about 0.1 to about 5% by weight of a lubricant.

[0276] Suitable glidants include, but are not limited to, colloidal silicon dioxide, CAB-O-SIL® (Cabot Co. of Boston, MA), and asbestos-free talc. Suitable coloring agents include, but are not limited to, any of the approved, certified, water soluble FD&C dyes, and water insoluble FD&C dyes suspended on alumina hydrate, and color lakes and mixtures thereof. A color lake is the combination by adsorption of a water-soluble dye to a hydrous oxide of a heavy metal, resulting in an insoluble form of the dye. Suitable flavoring agents include, but are not limited to, natural flavors extracted from plants, such as fruits, and synthetic blends of compounds which produce a pleasant taste sensation, such as peppermint and methyl salicylate. Suitable sweetening agents include, but are not limited to, sucrose, lactose, mannitol, syrups, glycerin, and artificial sweeteners, such as saccharin and aspartame. Suitable emulsifying agents include, but are not limited to, gelatin, acacia, tragacanth, bentonite, and surfactants, such as polyoxyethylene sorbitan monooleate (TWEEN® 20), polyoxyethylene sorbitan monooleate 80 (TWEEN® 80), and triethanolamine oleate. Suitable suspending and dispersing agents include, but are not limited to, sodium carboxymethylcellulose, pectin, tragacanth, Veegum, acacia, sodium carbomethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Suitable preservatives include, but are not limited to, glycerin, methyl and propylparaben, benzoic add,

sodium benzoate and alcohol. Suitable wetting agents include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether. Suitable solvents include, but are not limited to, glycerin, sorbitol, ethyl alcohol, and syrup. Suitable non-aqueous liquids utilized in emulsions include, but are not limited to, mineral oil and cottonseed oil. Suitable organic acids include, but are not limited to, citric and tartaric acid. Suitable sources of carbon dioxide include, but are not limited to, sodium bicarbonate and sodium carbonate.

[0277] It should be understood that many carriers and excipients may serve several functions, even within the same formulation.

[0278] The pharmaceutical compositions provided herein for oral administration can be provided as compressed tablets, tablet triturates, chewable lozenges, rapidly dissolving tablets, multiple compressed tablets, or enteric-coating tablets, sugar-coated, or film-coated tablets. Enteric-coated tablets are compressed tablets coated with substances that resist the action of stomach acid but dissolve or disintegrate in the intestine, thus protecting the active ingredients from the acidic environment of the stomach. Enteric-coatings include, but are not limited to, fatty acids, fats, phenyl salicylate, waxes, shellac, ammoniated shellac, and cellulose acetate phthalates. Sugar-coated tablets are compressed tablets surrounded by a sugar coating, which may be beneficial in covering up objectionable tastes or odors and in protecting the tablets from oxidation. Film-coated tablets are compressed tablets that are covered with a thin layer or film of a water-soluble material. Film coatings include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000, and cellulose acetate phthalate. Film coating imparts the same general characteristics as sugar coating. Multiple compressed tablets are compressed tablets made by more than one compression cycle, including layered tablets, and press-coated or dry-coated tablets.

[0279] The tablet dosage forms can be prepared from the active ingredient in powdered, crystalline, or granular forms, alone or in combination with one or more carriers or excipients described herein, including binders, disintegrants, controlled-release polymers, lubricants, diluents, and/or colorants. Flavoring and sweetening agents are especially useful in the formation of chewable tablets and lozenges.

[0280] The pharmaceutical compositions provided herein for oral administration can be provided as soft or hard capsules, which can be made from gelatin, methylcellulose, starch, or calcium alginate. The hard gelatin capsule, also known as the dry-filled capsule (DFC), consists of two sections, one slipping over the other, thus completely enclosing the active ingredient. The soft elastic capsule (SEC) is a soft, globular shell, such as a gelatin shell, which is plasticized by the addition of glycerin, sorbitol, or a similar polyol. The soft gelatin shells may contain a

preservative to prevent the growth of microorganisms. Suitable preservatives are those as described herein, including methyl- and propyl-parabens, and sorbic acid. The liquid, semisolid, and solid dosage forms provided herein may be encapsulated in a capsule. Suitable liquid and semisolid dosage forms include solutions and suspensions in propylene carbonate, vegetable oils, or triglycerides. Capsules containing such solutions can be prepared as described in U.S. Pat. Nos. 4,328,245; 4,409,239; and 4,410,545. The capsules may also be coated as known by those of skill in the art in order to modify or sustain dissolution of the active ingredient.

[0281] Coloring and flavoring agents can be used in all of the above dosage forms.

[0282] The pharmaceutical compositions provided herein for oral administration can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed-release forms.

B. Parenteral Administration

[0283] The pharmaceutical compositions provided herein can be administered parenterally by injection, infusion, or implantation, for local or systemic administration. Parenteral administration, as used herein, include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial, intravesical, and subcutaneous administration.

[0284] The pharmaceutical compositions provided herein for parenteral administration can be formulated in any dosage forms that are suitable for parenteral administration, including solutions, suspensions, emulsions, micelles, liposomes, microspheres, nanosystems, and solid forms suitable for solutions or suspensions in liquid prior to injection. Such dosage forms can be prepared according to conventional methods known to those skilled in the art of pharmaceutical science (*see, Remington: The Science and Practice of Pharmacy*, supra).

[0285] The pharmaceutical compositions intended for parenteral administration can include one or more pharmaceutically acceptable carriers and excipients, including, but not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, cryoprotectants, lyoprotectants, thickening agents, pH adjusting agents, and inert gases.

[0286] Suitable aqueous vehicles include, but are not limited to, water, saline, physiological saline or phosphate buffered saline (PBS), sodium chloride injection, Ringers injection, isotonic dextrose injection, sterile water injection, dextrose and lactated Ringers injection. Suitable non-aqueous vehicles include, but are not limited to, fixed oils of vegetable origin, castor oil, corn oil, cottonseed oil, olive oil, peanut oil, peppermint oil, safflower oil, sesame oil, soybean oil,

hydrogenated vegetable oils, hydrogenated soybean oil, and medium-chain triglycerides of coconut oil, and palm seed oil. Suitable water-miscible vehicles include, but are not limited to, ethanol, 1,3-butanediol, liquid polyethylene glycol (e.g., polyethylene glycol 300 and polyethylene glycol 400), propylene glycol, glycerin, *N*-methy1-2-pyrrolidone, *N*,*N*-dimethylacetamide, and dimethyl sulfoxide.

[0287] Suitable antimicrobial agents or preservatives include, but are not limited to, phenols, cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoates, thimerosal, benzalkonium chloride (e.g., benzethonium chloride), methyl-and propyl-parabens, and sorbic acid. Suitable isotonic agents include, but are not limited to, sodium chloride, glycerin, and dextrose. Suitable buffering agents include, but are not limited to, phosphate and citrate. Suitable antioxidants are those as described herein, including bisulfite and sodium metabisulfite. Suitable local anesthetics include, but are not limited to, procaine hydrochloride. Suitable suspending and dispersing agents are those as described herein, including sodium carboxymethylcelluose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Suitable emulsifying agents are those described herein, including polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate 80, and triethanolamine oleate. Suitable sequestering or chelating agents include, but are not limited to EDTA. Suitable pH adjusting agents include, but are not limited to, sodium hydroxide, hydrochloric acid, citric acid, and lactic acid. Suitable complexing agents include, but are not limited to, cyclodextrins, including α-cyclodextrin, β-cyclodextrin, hydroxypropyl-β-cyclodextrin, sulfobutylether-β-cyclodextrin, and sulfobutylether 7-β-cyclodextrin (CAPTISOL®, CyDex, Lenexa, KS).

[0288] When the pharmaceutical compositions provided herein are formulated for multiple dosage administration, the multiple dosage parenteral formulations must contain an antimicrobial agent at bacteriostatic or fungi static concentrations. All parenteral formulations must be sterile, as known and practiced in the art.

[0289] In one embodiment, the pharmaceutical compositions for parenteral administration are provided as ready-to-use sterile solutions. In another embodiment, the pharmaceutical compositions are provided as sterile dry soluble products, including lyophilized powders and hypodermic tablets, to be reconstituted with a vehicle prior to use. In yet another embodiment, the pharmaceutical compositions are provided as ready-to-use sterile suspensions. In yet another embodiment, the pharmaceutical compositions are provided as sterile dry insoluble products to be reconstituted with a vehicle prior to use. In still another embodiment, the pharmaceutical compositions are provided as ready-to-use sterile emulsions.

[0290] The pharmaceutical compositions provided herein for parenteral administration can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed-release forms.

[0291] The pharmaceutical compositions provided herein for parenteral administration can be formulated as a suspension, solid, semi-solid, or thixotropic liquid, for administration as an implanted depot. In one embodiment, the pharmaceutical compositions provided herein are dispersed in a solid inner matrix, which is surrounded by an outer polymeric membrane that is insoluble in body fluids but allows the active ingredient in the pharmaceutical compositions diffuse through.

[0292] Suitable inner matrixes include, but are not limited to, polymethylmethacrylate, polybutyl-methacrylate, plasticized or unplasticized polyvinylchloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinyl acetate copolymers, silicone rubbers, polydimethylsiloxanes, silicone carbonate copolymers, hydrophilic polymers, such as hydrogels of esters of acrylic and metliacrylic acid, collagen, cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate.

[0293] Suitable outer polymeric membranes include but are not limited to, polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, ethylene/vinyl acetate copolymers, silicone rubbers, polydimethyl siloxanes, neoprene rubber, chlorinated polyethylene, polyvinylchloride, vinyl chloride copolymers with vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, and ethylene/vinyloxyethanol copolymer.

V. Examples

[0294] While preferred embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.


Example 1. A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Compound 1 in Subjects with Testicular Adrenal Rest Tumors

[0295] Testicular adrenal rest tumors (TART) is a common complication in congenital adrenal hyperplasia (CAH) that is caused by adrenocorticotropin hormone (ACTH)–driven

overstimulation of aberrant adrenal cells within the testes and results in impaired spermatogenesis and infertility. TARTS can be found anywhere on the testes, though a typical (very common) location is within the mediastinum. This is a particularly problematic location. Because of the central location of TARTs being in the mediastinum, compression of the nearby seminiferous tubules is common and can lead to obstructive azoospermia, irreversible damage to surrounding tissue, and permanent infertility in males.

[0296] Current treatment for TART consists of chronic high-dose glucocorticoids, a problematic therapy with significant side effects and a narrow therapeutic window. Given the serious nature of TART and the limitations and risks of chronic steroid therapy, new treatment modalities are needed for patients with TART. Compound 1, a high-affinity and selective small-molecule antagonist of the corticotropin-releasing factor type-1 (CRF_1) receptor, may be effective in blocking ACTH synthesis, thereby reducing the size of testicular lesions in TART and reducing the need for chronic supraphysiologic doses of glucocorticoids. This mechanism of action has been validated in a previous proof-of-concept study using a similar small-molecule CRF_1 receptor antagonist, which produced dose-dependent reductions in ACTH and 17-hydroxyprogesterone (17-OHP) in subjects with CAH. Compound 1 has been shown to have an acceptable safety and tolerability profile in nonclinical toxicology studies and in 2 completed Phase 1 clinical studies in healthy volunteers. These promising results provide a rationale for investigating the use of Compound 1 in the treatment of TART, in combination with replacement glucocorticoids and mineralocorticoids.

[0297] The structure of Compound 1 is:



.

[0298] Building upon the 2 completed Phase 1 studies of Compound 1 in healthy volunteers and the ongoing Phase 2 proof-of-concept study of Compound 1 in subjects with CAH, this Phase 2 will study Compound 1 specifically in male CAH subjects with TART for the first time. A sample size of approximately 12 subjects was selected to provide sufficient data for an initial evaluation of efficacy and safety in subjects with TART while maintaining feasible subject recruitment goals for this rare condition. Given the rarity of the disease and thus the small sample size that can be recruited, this study will be open label, and all enrolled subjects will

receive active study drug. Subjects will serve as their own controls in that their outcome measures after 12 weeks of study drug dosing will be compared to their baseline measures.

[0299] The schedule of study visits (every 2 weeks through Week 4, then every 4 weeks for the remainder of the study) provides an appropriate balance between minimizing subject burden and closely monitoring subject safety and response to therapy. The 4-week post-treatment washout period will allow for adequate safety follow-up and analysis of any HPA axis rebound after the last dose of study drug.

[0300] The specification of study drug dosing at 10pm and after consumption of a snack is based on information from the Phase 1 studies in healthy volunteers. The plasma C_{max} (maximum concentration) for Compound 1 in the Phase 1 studies occurred approximately 5 hours after dosing. Therefore, Compound 1 will be dosed daily at 10pm in this study in order to achieve peak plasma study drug concentration at the time of day when most adrenal androgens are produced. Subjects will consume a standardized snack before taking study drug because the Phase 1 studies showed minimal study drug absorption when subjects were dosed in a fasted state. Specific dose reduction criteria, strict individual treatment stopping criteria, and appropriate laboratory and medical assessments have been established to ensure subject safety. (**FIGS. 1A-1B**).

Objectives	**Endpoints**
Primary	
• To assess the efficacy of Compound 1 in subjects with TART	• Reduction in the size/volume of TART on testicular ultrasound from screening to Week 12
Secondary	
• To evaluate the safety of Compound 1 in subjects with TART	• Adverse events (AEs), serious adverse events (SAEs), AEs leading to withdrawal, AEs of special interest (AESIs) • Physical examination findings • Vital signs • Changes in electrocardiogram (ECG) • Changes in clinical laboratory values
• To assess the pharmacodynamic (PD) biomarker effects of Compound 1	• Changes in plasma concentrations of key PD biomarkers, including ACTH, 17-OHP, testosterone, androstenedione, luteinizing hormone (LH),

	follicle-stimulating hormone (FSH), inhibin B, sex hormone–binding globulin (SHBG), renin, and aldosterone from baseline to Week 12
• To assess changes on semen analysis	• Changes in sperm count, morphology, and motility from baseline to Week 12
• To assess changes in metabolism	• Changes in metabolic parameters, including fasting glucose, HbA1c, insulin sensitivity, and lipid profile (including LDL cholesterol, HDL cholesterol, and triglycerides), from baseline to Week 12 • Changes in body weight, body mass index (BMI), waist circumference, and blood pressure
• To evaluate changes in quality of life (QoL) and mood	• Changes in QoL measured using the Short Form 36 (SF-36) • Changes in mood measured using the Hospital Anxiety and Depression Scale (HADS)

Study Population

[0301] Approximately 12 male subjects with TART will be enrolled at approximately 6 investigative sites in the United States, United Kingdom, and possibly other countries. Up to 12 additional subjects may be added to further evaluate specific safety, PD, or efficacy findings.

Eligibility Criteria

Inclusion Criteria

- Adult male subjects aged 18 to 30, inclusive
- Documented historical diagnosis of CAH based on documented genetic mutation or historical documentation of elevated 17-OHP
- Diagnosis of TART via testicular ultrasound and/or magnetic resonance imaging (MRI) at screening with ≥1 lesion(s) measuring ≥2 cm in diameter
- On a stable regimen of GC replacement for ≥30 days before baseline
- Agree to follow contraception guidelines and refrain from donating sperm throughout the treatment period and for 90 days after the last dose of study drug
- Subject is able to understand all study procedures and risks involved and provides written informed consent indicating willingness to comply with all aspects of the protocol

Exclusion Criteria

- Any clinically significant unstable medical condition, medically significant illness, or chronic disease within 30 days of screening, including but not limited to:

  - A malignancy or <3 years of remission history from any malignancy, other than successfully treated localized skin cancer
  - Presence of clinically significant renal disease, as evidenced by an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73m^2
  - Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  - Confirmed positive test at screening for active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
- Any clinically significant psychiatric disorders, including any current major depressive episode, bipolar disorder, schizophrenia, schizoaffective disorder, major depressive disorder with psychotic features, or any other psychotic disorder within the preceding 6 months
- HADS score >12 for either depression or anxiety
- At increased risk of suicide on the basis of the Investigator's judgment or the results of the Columbia-Suicide Severity Rating Scale (C-SSRS) conducted at screening and baseline (eg, C-SSRS Type 3, 4, or 5 ideation during the preceding 6 months or any suicidal behavior within the past 12 months)
- Clinically significant and abnormal clinical or laboratory assessments must be discussed with the Medical Monitor to determine eligibility for this study. Abnormal assessments that must be reviewed to determine eligibility include but are not limited to:
  - Clinically meaningful abnormal ECG results, in the opinion of the Investigator
  - Fridericia-corrected QT interval (QTcF) >450 msec
  - Alanine aminotransferase (ALT) >2x upper limit of normal (ULN)
  - Bilirubin >1.5x ULN (isolated bilirubin >1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%)
- A history that includes bilateral adrenalectomy or hypopituitarism
- Use of any other investigational drug within 30 days or 5 half-lives, whichever is longer, before initial screening
- Require use of prohibited concomitant medications, including strong inhibitors and/or inducers of CYP3A4 (with the exception of glucocorticoids, hydrocortisone, and dexamethasone) within 30 days or 5 half-lives (whichever is longer) of first dose of study drug. Medications that are sensitive substrates or substrates with narrow therapeutic ranges (metabolized by CYP3A4, 2C8, 2C9, or 2C19) should be discussed on a case-by-case basis with the Medical Monitor to determine whether the medication should be discontinued or may be continued with caution. If washout is feasible, then the medication should be

withdrawn at least 30 days or 5 half-lives (whichever is longer) before the first dose of study drug.

- Donation of blood within 60 days before first dose of study drug, or donation of platelets, white blood cells, or plasma within 15 days before first dose of study drug.

Study Duration

[0302] The expected duration of study participation for each subject is up to approximately 20 weeks. This includes a screening period of ≤4 weeks, a treatment period of 12 weeks, and a safety follow-up period of 4 weeks.

Study Design

[0303] This is a Phase 2, open-label efficacy and safety study of Compound 1 for the treatment of TART. All subjects will receive a daily oral dose of Compound 1 for 12 weeks.In-clinic study visits will occur for screening and at Day 1 (baseline) and Weeks 2, 4, 8, 12 (end of treatment), and 16 (follow-up).

Dose, Route, Regimen

[0304] All subjects will receive a daily oral dose of Compound 1 for 12 weeks. Subjects will receive 600 mg/day during the first 2 weeks and 1000 mg/day during the remaining 10 weeks of the treatment period. Study drug will be taken daily at 10pm (or bedtime, if earlier), 5 to 15 minutes after consumption of a standardized snack.

[0305] On mornings of study visits with 8am blood draws for laboratory assessments, subjects should take their morning glucocorticoid replacement after the blood draws. For all other days during the study, subjects may take their morning glucocorticoid replacement at their usual time (generally between 6am and 8am).

[0306] If a subject experiences a Grade 3 or higher TEAE considered at least possibly related to study drug, the Investigator may reduce the subject's daily dose of Compound 1 down in increments of 200 mg. Study drug will be discontinued in subjects who experience clinically significant liver chemistry, QTcF, or other individual treatment stopping criteria.

Investigational Drug

[0307] Compound 1 is a small-molecule CRF_1 receptor antagonist and will be supplied as 200-mg, size 1, white, hard gelatin capsules.

Example 2.

[0308] Since elevated ACTH is the primary driver for TART growth, blocking ACTH synthesis using Compound 1, a small-molecule antagonist of the CRF_1 receptor, may be effective in reducing ACTH levels, thereby reducing the size of testicular lesions in TART and reducing the need for chronic supraphysiologic doses of GCs. In CAH, this mechanism of action has been

validated in a previous proof-of-concept study using a similar small-molecule CRF_1 receptor antagonist, which produced dose-dependent reductions in ACTH and 17-OHP in subjects with CAH. The safety profile of Compound 1 has been established in nonclinical toxicology studies and in 2 completed Phase 1 clinical studies in healthy volunteers. A Phase 2 study in subjects with CAH is currently ongoing.

Nonclinical Toxicology of Compound 1

[0309] The nonclinical safety profile of Compound 1 has been evaluated in repeat-dose range-finding and definitive toxicology studies of up to 91 days in duration in rats and dogs using the clinically relevant route (oral) and schedule of administration (once daily). In rats and beagle dogs administered oral Compound 1 once daily for 91 consecutive days at doses up to 2000 mg/kg/day, toxicologic findings were all mild and limited to the male reproductive tract, and all Compound 1-related findings were reversible following a 6-week treatment-free recovery period.

[0310] Additionally, a fertility toxicology study was conducted in rats. In this study, male rats were administered oral Compound 1 once daily at 0, 5, 20, or 1000 mg/kg for 85 to 87 days (70 days before mating, during mating, and ≤4 days between mating and necropsy). Male reproductive performance (mean day of mating, mating and fertility indices, and conception rates) was unaffected by Compound 1 treatment. Untreated females mated with the Compound 1-treated males had no ovarian and uterine effects.

[0311] In addition, a complete battery of standard genotoxicity tests consisting of in vitro bacterial reverse mutation and chromosome aberration assays and an in vivo (rat) bone marrow micronucleus assay has been conducted. Exploratory and definitive embryo-fetal development studies in rabbits and a bovine corneal opacity and permeability assay have also been conducted.

Clinical Experience with Compound 1

[0312] To date, a total of 53 subjects, all healthy adults aged 21 to 65 years, have been treated with at least 1 dose of Compound 1 in 2 Phase 1 studies. The first-in-human study of Compound 1 (Study I3C-FW-BLAA) evaluated single ascending doses of 2 mg to 800 mg. In this study, a small number of subjects experienced diarrhea and headache of mild or moderate severity. A subsequent study (Study I3C-FW-BLAB) evaluated repeat doses of 50 mg, 100 mg, or 200 mg Compound 1 once daily for 14 consecutive days. A small number of subjects in the repeat-dose study experienced dyspnea, rhinorrhea, palpitations, and headache. The Phase 1 studies showed no clinically significant alterations in safety laboratory values, vital signs, or electrocardiograms (ECGs). Compound 1 has been well tolerated in healthy human subjects, with no SAEs, AEs leading to discontinuation, or dose-limiting toxicities (DLTs). A maximum tolerated dose has not been reached in humans.

[0313] An ongoing Phase 2 open-label study (Study Compound 2) is currently evaluating the safety and efficacy of Compound 1 dosed once daily for 6 weeks in adults with classic CAH. In the initial Cohort A of this study, all subjects are dosed starting at 200 mg/day for 14 days, escalating for each subject to 600 mg/day for 14 days, then 1000 mg/day for 14 days if the subject experiences no DLTs at the previous dose level. (**FIGS. 2-3**).

Known Potential Risks

[0314] Because the reversible testicular effects (degeneration/atrophy) observed in rats and dogs treated with high-dose Compound 1 (2,000 mg/kg/day) are likely associated with on-target (mechanism-driven) effects, these effects are likely to be relevant to human risk. However, male reproductive studies in rodents showed no impairment in fertility at the highest dose tested (1,000 mg/kg/day). Additionally, there were no effects on clinical laboratory markers of testicular function (LH and FSH) when Compound 1 was administered to healthy male volunteers at doses up to 200 mg per day for 14 consecutive days. Clinical laboratory measures of testicular function (LH, FSH, inhibin B, and SHBG) will be assessed throughout this study to monitor the risk of testicular injury. Testicular ultrasounds and semen analysis will also be performed at screening/baseline and the end of the treatment period.

[0315] Laboratory abnormalities in liver function tests (LFTs) have been observed at significantly higher doses in nonclinical studies. However, these events were not observed in the Phase 1 clinical studies. Clinical laboratory measures of liver chemistry will be assessed throughout this study, and strict individual treatment stopping criteria for liver chemistry findings are in place.

[0316] Compound 1-induced effects on the thyroid gland were noted in dogs after 91 days of high-dose (2,000 mg/kg/day) treatment but not in any other nonclinical studies. Clinical pathology parameters of thyroid function (eg, T4, T3, thyroid-stimulating hormone [TSH]) were not evaluated in the Phase 1 studies but will be monitored throughout this study.

Known Potential Benefits

[0317] Early clinical studies suggests that Compound 1 is effective as a CRF_1 receptor antagonist, a mechanism of action that supports the clinical investigation of Compound 1 for treatment of TART. In CAH, this mechanism of action has been validated in a previous proof-of-concept study using a similar small-molecule CRF_1 receptor antagonist, which produced dose-dependent reductions in ACTH and 17-OHP in subjects with CAH.

Assessment of Potential Risks and Benefits

[0318] The mild and reversible toxicologic effects of Compound 1 on the male reproductive tract in nonclinical studies occurred in the context of animals with normal, rather than elevated, baseline hormone function. As a CRF_1 receptor antagonist, Compound 1 is intended to reduce

abnormally elevated ACTH levels, which in TART drives overstimulation of aberrant adrenal cells within the testes. In nonclinical models where baseline hormone levels are within normal ranges, clinical benefits are not expected, and indeed, toxicities may be expected as a result of androgen reduction outside of the normal range. In TART, where baseline ACTH and androgen levels are pathologically elevated, androgen reduction would be considered a positive, therapeutic effect.

[0319] Given the serious nature of TART and the limitations (and risks) of chronic steroid therapy, new treatment modalities are needed for patients with TART. Given the acceptable safety and tolerability profile of Compound 1 in healthy volunteers from the Phase 1 program, the low probability of demonstrating meaningful PD marker changes in healthy subjects, and the lack of any clear benefit to exposing more healthy subjects to study drug, the Sponsor believes the benefit-to-risk profile favors the entry of Compound 1 into Phase 2 in subjects with TART.

Example 3. Congenital Andrenal Hyperplasia (CAH)

[0320] CAH results from a genetic defect in the 21-hydroxylase enzyme. CAH patients are thus unable to produce cortisol. Without cortisol to provide negative feedback, patients over-produce ACTH. High ACTH promotes the overproduction of potent androgens (male sex hormones). Without wishing to be bound by theory, Compound 1 blocks CRF_1 receptor to prevent ACTH release by the pituitary and associated drive on the hypothalamic-pituitary-adrenal axis. Replacement of cortisol to physiological levels will correct cortisol deficiency, however, will not lower ACTH, resulting in hyperplasia of adrenal gland and associated overproduction of adrenal androgens.

[0321] As shown in **FIGS. 4** and **5A-5B**, the attenuation of ACTH demonstrates target engagement and functional CRF_1 receptor antagonism. 80% of subjects demonstrated reduction in ACTH. 70% of subjects demonstrated > 25% reduction in ACTH. 30% of subjects were in the normal range (*) after treatment with a CRF_1 receptor antagonist.

[0322] **FIGS. 6** and **7A-7B** demonstrate “control” of disease based on standard guidelines, which would then allow steroid taper. 80% of subjects demonstrated reduction in 17-OHP. 50% of subjects demonstrated > 25% reduction in ACTH. 50% of subjects were in the guideline range (*; 1200 ng/dL) after treatment with a CRF_1 receptor antagonist.

[0323] **FIGS. 8** and **9A-9B** demonstrate attenuation of morning rise in A4 upon treatment with a CRF1 antagonist, indicative of its ability to control excess andreogen production and associated symptoms. 100% of subjects demonstrated reduction in androstenedione (at various doses). 60% of subjects demonstrated > 25% reduction in androstenedione. 50% of subjects were within the normal reference range after treatment with a CRF_1 receptor antagonist.

[0324] FIGS. 10A-10B show approximately 25% shrinkage in TART in a 25 year old male with classic congenital adrenal hyperplasia following 6 weeks treatment with a CRF_1 receptor antagonist.

[0325] FIGS. 11A-11B demonstrate Compound 1 is a potent, selective, and functional CRF_1 receptor antagonist. In in vitro and ex vivo studies, Compound 1 was determined to be a potent and selective CRF_1 receptor antagonist with high affinity and selective for the $hCRF_1$ receptor. Compound 1 was found to have functional potency to inhibit adenylate cyclase activity (CRF_1 receptor-mediated downstream cascade), demonstrating in vitro efficacy as a CRF_1 receptor antagonist. Compound 1 was found to significantly inhibit CRF-induced locomotor behavior in response to i.c.v. administration of CRF (**FIG. 11B**).

[0326] FIGS. 12A-12B demonstrate single pill of CRF_1 receptor antagonist improves ACTH and 17-OHP in CAH patients.

[0327] FIG. 13 shows the subject level hormone changes (ACTH, 17-OHP, and androstenedione) by dose of a CRF_1 receptor antagonist.

Example 4. Assess reduction in excess ACTH and adrenal steroid production

[0328] The objectives of the study are: to assess the ability of Compound 1 to reduce excess ACTH and adrenal steroid production in participants with classic CAH on a stable gluococorticoid regimen; to evaluate the safety and tolerability of tildacerfont in participants with classic CAH; and to evaluate the pharmacokinetics (PK) of tildacerfont.

ELIGIBILITY CRITERIA

[0329] Inclusion Criteria:

- Adult males and females 18 years or older
- Diagnosis of classic CAH due to 21-hydroxylase deficiency
- Morning 17OHP ≥800 ng/dL, before taking any morning GC dose
- On a stable regimen of gluococorticoid replacement for ≥30 days before enrollment

[0330] Exclusion Criteria:

- Clinically significant unstable medical condition, illness, or chronic disease within 30 days of screening
- Clinically significant psychiatric disorder
- History of bilateral adrenalectomy or hypopituitarism

STUDY DESIGN

[0331] FIG. 14 depicts the proof of concept and escalating QD dosing at 10 PM for Cohort A and the single dose level and BID dosing at 10 AM and 10 pm for Cohort B.

BASELINE CHARACTERISTICS

[0332] Table 1 provides a description of the baseline characteristics displayed by Cohort A and Cohort B. In Cohort A, 10 partcipants were enrolled and received at least 1 dose of Compound 1. One participant withdrew early because of an occupation-related scheduling conflict. In Cohort B, 9 participants were enrolled and received at least one dose of Compound 1. One participant was withdrawn upon discovery of a major protocol violation at Baseline and did not have postbaseline efficacy/PK data. Thus, baseline characteristics are calculated for n=8 in Cohort B. One participant in Cohort B was taking both HC and prednisone.

Table 1 – Baseline characteristics of each cohort

Parameter	Cohort A (n=10)	Cohort B (n=8)
Demographics		
Age (years), mean (range)	39.3 (24-66)	36.8 (19-66)
Sex	5M, 5F	1M, 7F
Bmi (kg/m^2), mean ± SD	31.5 ± 12.0	31.1 ± 6.7
Daily GC dose (mg HC equivalents), mean range	28 (13-40)	35 (20-50)
Types of GCs	4 JC, 3 pred, 3 dex	2HC, 4 pred, 3 dex
17OHP at screening[a] (ng/dl), mean ± SD	5,985 ± 6,347	4,592 ±4,624

Abbreviations: 17OHP: 17-hydroxyprogesterone; BMI: body mass index; dex: dexamethasone; F: female; GC: glucocorticoid; HC: hydrocortisone; M: male; pred: prednisone; SD: standard deviation.
a 17OHP reference ranges: 27-199 ng/dL males, 15-290 ng/dL females.

SAFETY

[0333] Across both cohorts, Compound 1 was generally well tolerated. The most common type of adverse event (AE) was gastrointestinal disorders There were no serious AEs and no AEs leading to withdrawal.

PHARMACOKINETICS

[0334] Over a wide range of doses (200 to 1000 mg QD), Compound 1exhibited a predictable, dose-dependent PK profile.

EFFICACY

[0335] FIG. 15A-15D show the changes in levels of Androstenedione (A4) across both cohorts. Levels of A4 improved at ≥1 dose level for 10 out of 10 participants in Cohort A and 6 out of 8 participants in Cohort B. Excess A4 is associated with clinical sequelae in CAH. Attenuation of A4 demonstrates control of adrenal androgen.

[0336] FIG. 16A-16D show the changes in levels of 17-hydroxyprogesterone (17-OHP) across both cohorts. Levels of 17OHP improved at ≥1 dose level for 8 out of 10 participants in Cohort A and 6 out of 7 participants in Cohort B. 17OHP is a critical hormone in CAH diagnosis and management. Attenuation of 17OHP demonstrates control of adrenal steroid production.

[0337] FIG. 17A-17D show the changes in levels of adrenocorticotropic hormone (ACTH) across both cohorts. Levels of ACTH improved at ≥1 dose level for 8 out of 10 participants in

Cohort A and 5 out of 7 participants in Cohort B. Attenuation of ACTH demonstrates target engagement and fucntional CRF_1 receptor antagonism.

Table 2 – Percentage change from baseline in ACTH, 17OHP and A4.

	Cohort A			Cohort B
	200 mg QD (Week 2)	600 mg QD (Week 4)	1000 mg QD (Week 6)	200 mg BID (Weed 2)
ACTH	-25.7 (±51.6)	-60.1 (±37.5)	-32.7 (±47.0)	-36.5 (±58.0)
17OHP	+22.2 (±172.3)	-23.7 (±64.2)	-13.8 (±74.7)	-47.8 (±63.3)
A4	-12.1 (±47.4)	-33.2 (±36.5)	-28.6 (±44.6)	-16.0 (±81.4)

CONCLUSIONS










[0338] Compound 1, a potent and selective CRF_1 receptor antagonist, offers a novel nonsteroidal oral treatment approach for CAH. Compound 1 was well tolerated and efficacious in reducing excess ACTH, 17OHP, and androstenedione in patients with classic CAH. Compound 1 exhibited a predictable, dose-dependent PK profile suitable for the target population.

[0339] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. It is not intended that the invention be limited by the specific examples provided within the specification. While the invention has been described with reference to the aforementioned specification, the descriptions and illustrations of the embodiments herein are not meant to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. Furthermore, it shall be understood that all aspects of the invention are not limited to the specific depictions, configurations or relative proportions set forth herein which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is therefore contemplated that the invention shall also cover any such alternatives, modifications, variations or equivalents. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby

CLAIMS


WHAT IS CLAIMED IS:

1. A method of changing a metabolic parameter of a subject having a testicular adrenal rest tumor (TART) or an ovarian adrenal rest tumor (OART), comprising administering to the subject in need thereof a small molecule corticotropin-releasing factor type-1 (CRF_1) antagonist, or a pharmaceutically acceptable salt thereof, wherein the small molecule CRF_1 antagonist is:


,

,

,

,

,

, SSR-126374,

,

, or

, or a pharmaceutically acceptable salt thereof, and


wherein the metabolic parameter comprises fasting glucose, HbA1c level, insulin sensitivity, or a lipid profile, or a combination thereof.

2. The method of claim 1, wherein the small molecule CRF_1 antagonist is:



, or a pharmaceutically acceptable salt thereof.

3. The method of claim 1, wherein the small molecule CRF_1 antagonist is:



, or a pharmaceutically acceptable salt thereof.

4. The method of claim 1, wherein the metabolic parameter is insulin sensitivity.
5. The method of claim 1, wherein the subject has congenital adrenal hyperplasia (CAH).
6. The method of claim 1, wherein the administering reduces a size of the TART or the OART.
7. The method of claim 1, wherein the administering reduces a number of the TART or the OART.
8. The method of claim 1, wherein the small molecule CRF_1 antagonist is administered at a dose of about 10 mg/day to about 400 mg/day to the subject.
9. The method of claim 8, wherein the small molecule CRF_1 antagonist is administered at a dose of about 50 mg.
10. The method of claim 8, wherein the small molecule CRF_1 antagonist is administered at a dose of about 100 mg.
11. The method of claim 8, wherein the small molecule CRF_1 antagonist is administered at a dose of about 200 mg.
12. The method of claim 8, wherein the small molecule CRF_1 antagonist is administered at a dose of about 400 mg.
13. The method of claim 1, wherein the small molecule CRF_1 antagonist is administered to the subject once per day.
14. The method of claim 1, wherein the small molecule CRF_1 antagonist is administered to the subject twice per day.
15. The method of claim 1, wherein the small molecule CRF_1 antagonist is administered orally.
16. The method of claim 1, wherein the small molecule CRF_1 antagonist is formulated as a capsule or tablet.

17. The method of claim 1, wherein the administering reduces a plasma concentration of a biomarker comprising 17α-hydroxyprogesterone (17-OHP), adrenocorticotropic hormone (ACTH), testosterone, androstenedione (A4), luteinizing hormone (LH), follicle-stimulating hormone (FSH), inhibin B, sex hormone-binding globulin (SHBG), renin, or aldosterone, or a combination thereof.
18. The method of claim 1, wherein the biomarker is selected from the group consisting of 17-OHP, ACTH, and A4.
19. The method of claim 1, wherein the plasma concentration of the biomarker is at least 10% from baseline.

ABSTRACT OF THE DISCLOSURE

Provided herein are compounds and pharmaceutical compositions for the prevention and treatment of testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART).



Baseline (AM) & PK/PD (Overnight)
PK/PD (Overnight)
PK/PD (Overnight)
PK/PD (Overnight)
Washout / Follow-Up (AM)
Cohort A: Open Label
Strength 1
Strength 2
Strength 3
14 Days
14 Days
14 Days
30 days

FIG. 1A



SPR001
Inhibits CRF1 receptor to reduce ACTH
ACTH
17 OHP
21 Hydroxylase Deficiency
Aldosterone
Cortisol
Androgens
COI

FIG. 1B



Treatment
200 mg single-dose, Day 1
200 mg Q24h Day 14
600 mg Q24h Day 28
1000 mg Q24h Day 42
Mean SPR001 Concentration (ng/mL)
900
600
300
0
0
2
4
6
8
10
Time from Dose (hr)

FIG. 2



Concentration (ng/mL)
300
200
100
0
0
2
4
6
8
10
12
14
Time after first dose (days)
100 mg bid
200 mg bid
300 mg bid
200 mg qd
600 mg qd

FIG. 3



ACTH
% Change from Baseline
100
50
0
-50
-100
*
*
*
004-001
006-003
005-003
005-002
007-001
005-001
004-004
007-002
006-004
003-001

FIG. 4




FIG. 5A




FIG. 5B





FIG. 6






FIG. 7A *FIG. 7B*




FIG. 8




FIG. 9A




FIG. 9B




FIG. 10A




FIG. 10B

In Vitro Binding Assay




FIG. 11A




FIG. 11B




FIG. 12A




FIG. 12B




FIG. 13

ACTH: 7.2-63.3 pg/mL 17-OHP: <1200 ng/dL A4: 41-262 ng/dL (M) 27-152 ng/dL (F)




FIG. 13 (Cont.)

ACTH: 7.2-63.3 pg/mL 17-OHP: <1200 ng/dL A4: 41-262 ng/dL (M) 27-152 ng/dL (F)



Cohort A: Proof of concept, escalating QD dosing at 10 PM
(n=10 enrolled)
Baseline PD (Overnight);
Day 1 PK/PD (Overnight)
Week 2 PK/PD
(Overnight)
Week 4 PK/PD
(Overnight)
Week 6 PK/PD
(Overnight)
Follow-up
(Outpatient)
200 mg QD
600 mg QD
1000 mg QD
14 days
14 days
14 days
30 days
Cohort B: Single dose level, BID dosing at 10 AM and 10 PM
(n=9 enrolled)
Baseline PD
(Overnight)
Outpatient
Week 2 PK/PD
(Overnight)
Follow-up
(Outpatient)
200 mg BID
14 days
30 days

FIG. 14




FIG. 15A




FIG. 15B




FIG. 15C




FIG. 15D




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D




FIG. 17A




FIG. 17B




FIG. 17C




FIG. 17D

PTO/AIA/14 (01-22)
Approved for use through 05/31/2024. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	50535-710.305
	Application Number	
Title of Invention	METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS	

The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.

Secrecy Order 37 CFR 5.2:

☐ Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)

Inventor Information:

Inventor 1 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Alexis		HOWERTON	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	San Francisco	State/Province	CA	Country of Residence	US

Mailing Address of Inventor:

Address 1	611 Gateway Boulevard, Suite #740		
Address 2			
City	South San Francisco	State/Province	CA
Postal Code	94080	Country	US

Inventor 2 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Hal		GERBER	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	San Francisco	State/Province	CA	Country of Residence	US

Mailing Address of Inventor:

Address 1	611 Gateway Boulevard, Suite #740		
Address 2			
City	South San Francisco	State/Province	CA
Postal Code	94080	Country	US

All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the **Add** button. Add

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below.
For further information see 37 CFR 1.33(a).

PTO/AIA/14 (01-22)
Approved for use through 05/31/2024. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	50535-710.305
	Application Number	
Title of Invention	METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS	

☐ An Address is being provided for the correspondence Information of this application.			
Customer Number	21971		
Email Address	patentdocket@wsgr.com	Add Email	Remove Email

Application Information:

Title of the Invention	METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS		
Attorney Docket Number	50535-710.305	**Small Entity Status Claimed**	☐
Application Type	Nonprovisional		
Subject Matter	Utility		
Total Number of Drawing Sheets (if any)	14	**Suggested Figure for Publication (if any)**	

Filing By Reference:

Only complete this section when filing an application by reference under 35 U.S.C. 111(c) and 37 CFR 1.57(a). Do not complete this section if application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").

For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).

Application number of the previously filed application	Filing date (YYYY-MM-DD)	Intellectual Property Authority or Country

Publication Information:

☐ Request Early Publication (Fee required at time of Request 37 CFR 1.219)

☐ **Request Not to Publish.** I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application **has not and will not** be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer Number will be used for the Representative Information during processing.

Please Select One:	◉ Customer Number	○ US Patent Practitioner	○ Limited Recognition (37 CFR 11.9)
Customer Number	21971		

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	50535-710.305
	Application Number	
Title of Invention	METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS	

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) or indicate National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
When referring to the current application, please leave the "Application Number" field blank.

Prior Application Status	Pending		Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)
	Continuation of	18941832	2024-11-08
Prior Application Status	Abandoned		Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)
18941832	Continuation of	17667285	2022-02-08
Prior Application Status	Patented		Remove

Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	Patent Number	Issue Date (YYYY-MM-DD)
17/667285	Continuation of	17/081694	2020-10-27	11304950	2022-04-19

Prior Application Status	Expired		Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)
17/081694	Continuation of	PCT/US2019/029486	2019-04-26
Prior Application Status	Expired		Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)
PCT/US2019/029486	Claims benefit of provisional	62/822815	2019-03-23
Prior Application Status	Expired		Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)
PCT/US2019/029486	Claims benefit of provisional	62/663951	2018-04-27

Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the **Add** button. Add

Foreign Priority Information:

PTO/AIA/14 (01-22)
Approved for use through 05/31/2024. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	50535-710.305
	Application Number	
Title of Invention	METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS	

This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55. When priority is claimed to a foreign application that is eligible for retrieval under the priority document exchange program (PDX)[i] the information will be used by the Office to automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the PDX program, applicant bears the ultimate responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).

Remove

Application Number	Country[i]	Filing Date (YYYY-MM-DD)	Access Code[i] (if applicable)

Additional Foreign Priority Data may be generated within this form by selecting the **Add** button. Add

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications

☐ This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March 16, 2013.
NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March 16, 2013, will be examined under the first inventor to file provisions of the AIA.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	50535-710.305
	Application Number	
Title of Invention	METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS	

Authorization or Opt-Out of Authorization to Permit Access:

When this Application Data Sheet is properly signed and filed with the application, applicant has provided written authority to permit a participating foreign intellectual property (IP) office access to the instant application-as-filed (see paragraph A in subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant application (see paragraph B in subsection 1 below).

Should applicant choose not to provide an authorization identified in subsection 1 below, applicant **must opt-out** of the authorization by checking the corresponding box A or B or both in subsection 2 below.

NOTE: This section of the Application Data Sheet is **ONLY** reviewed and processed with the **INITIAL** filing of an application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind authorization for access by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.

1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)

A. Priority Document Exchange (PDX) - Unless box A in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the State Intellectual Property Office of the People's Republic of China (SIPO), the World Intellectual Property Organization (WIPO), and any other foreign intellectual property office participating with the USPTO in a bilateral or multilateral priority document exchange agreement in which a foreign application claiming priority to the instant patent application is filed, access to: (1) the instant patent application-as-filed and its related bibliographic data, (2) any foreign or domestic application to which priority or benefit is claimed by the instant application and its related bibliographic data, and (3) the date of filing of this Authorization. See 37 CFR 1.14(h)(1).

B. Search Results from U.S. Application to EPO - Unless box B in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the EPO access to the bibliographic data and search results from the instant patent application when a European patent application claiming priority to the instant patent application is filed. See 37 CFR 1.14(h)(2).

The applicant is reminded that the EPO's Rule 141(1) EPC (European Patent Convention) requires applicants to submit a copy of search results from the instant application without delay in a European patent application that claims priority to the instant application.

2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s)

☐ A. Applicant **DOES NOT** authorize the USPTO to permit a participating foreign IP office access to the instant application-as-filed. If this box is checked, the USPTO will not be providing a participating foreign IP office with any documents and information identified in subsection 1A above.

☐ B. Applicant **DOES NOT** authorize the USPTO to transmit to the EPO any search results from the instant patent application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant application.

NOTE: Once the application has published or is otherwise publicly available, the USPTO may provide access to the application in accordance with 37 CFR 1.14.

PTO/AIA/14 (01-22)
Approved for use through 05/31/2024. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	50535-710.305
	Application Number	
Title of Invention	METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS	

Applicant Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Applicant 1 Remove

If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed. The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR 1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be identified in this section.

Clear

(•) Assignee	( ) Legal Representative under 35 U.S.C. 117	( ) Joint Inventor
( ) Person to whom the inventor is obligated to assign.	( ) Person who shows sufficient proprietary interest	

If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:

Name of the Deceased or Legally Incapacitated Inventor:

If the Applicant is an Organization check here. [X]

Organization Name	Spruce Biosciences, Inc.		
Mailing Address Information For Applicant:			
Address 1	611 Gateway Boulevard, Suite #740		
Address 2			
City	South San Francisco	**State/Province**	CA
Country	US	Postal Code	94080
Phone Number		Fax Number	
Email Address			

Additional Applicant Data may be generated within this form by selecting the Add button. Add

Assignee Information including Non-Applicant Assignee Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

PTO/AIA/14 (01-22)
Approved for use through 05/31/2024. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	50535-710.305
	Application Number	
Title of Invention	METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS	

Assignee 1

Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent application publication. An assignee-applicant identified in the "Applicant Information" section will appear on the patent application publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the patent application publication.

Remove

If the Assignee or Non-Applicant Assignee is an Organization check here. ☐

Prefix	**Given Name**	Middle Name	**Family Name**	Suffix

Mailing Address Information For Assignee including Non-Applicant Assignee:

Address 1			
Address 2			
City		**State/Province**	
Country i		Postal Code	
Phone Number		Fax Number	
Email Address			

Additional Assignee or Non-Applicant Assignee Data may be generated within this form by selecting the Add button. Add

Signature:

Remove

NOTE: This Application Data Sheet must be signed in accordance with 37 CFR 1.33(b). **However, if this Application Data Sheet is submitted with the INITIAL filing of the application and either box A or B is not checked in subsection 2 of the "Authorization or Opt-Out of Authorization to Permit Access" section, then this form must also be signed in accordance with 37 CFR 1.14(c).**

This Application Data Sheet **must** be signed by a patent practitioner if one or more of the applicants is a **juristic entity** (e.g., corporation or association). If the applicant is two or more joint inventors, this form must be signed by a patent practitioner, **all** joint inventors who are the applicant, or one or more joint inventor-applicants who have been given power of attorney (e.g., see USPTO Form PTO/AIA/81) on behalf of **all** joint inventor-applicants.

See 37 CFR 1.4(d) for the manner of making signatures and certifications.

Signature	/Victoria Cheng/			Date (YYYY-MM-DD)	2025-01-31
First Name	Victoria	Last Name	Cheng	Registration Number	79641

Additional Signature may be generated within this form by selecting the Add button. Add

PTO/AIA/14 (01-22)
Approved for use through 05/31/2024. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	50535-710.305
	Application Number	
Title of Invention	METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS	

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1 The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3 A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent CooperationTreaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.



Baseline (AM) & PK/PD (Overnight)
PK/PD (Overnight)
PK/PD (Overnight)
PK/PD (Overnight)
Washout / Follow-Up (AM)
Cohort A: Open Label
Strength 1
Strength 2
Strength 3
14 Days
14 Days
14 Days
30 days

FIG. 1A



SPR001
Inhibits CRF1 receptor to reduce ACTH
ACTH
17 OHP
21 Hydroxylase Deficiency
Aldosterone
Cortisol
Androgens

FIG. 1B



Treatment
200 mg single-dose, Day 1
200 mg Q24h Day 14
600 mg Q24h Day 28
1000 mg Q24h Day 42
Mean SPR001 Concentration (ng/mL)
0
Time from Dose (hr)

FIG. 2



Concentration (ng/mL)
300
200
100
0
0
2
4
6
8
10
12
14
Time after first dose (days)
100 mg bid
200 mg bid
300 mg bid
200 mg qd
600 mg qd

FIG. 3



ACTH
% Change from Baseline
100
50
0
-50
-100
004-001
006-003
005-003
005-002
007-001
005-001
004-004
007-002
006-004
003-001

FIG. 4




FIG. 5A




FIG. 5B




FIG. 6




FIG. 7A




FIG. 7B




FIG. 8




FIG. 9A




FIG. 9B




FIG. 10A




FIG. 10B

In Vitro Binding Assay




FIG. 11A




FIG. 11B




FIG. 12A




FIG. 12B




FIG. 13

ACTH: 7.2-63.3 pg/mL 17-OHP: <1200 ng/dL A4: 41-262 ng/dL (M) 27-152 ng/dL (F)




FIG. 13 (Cont.)

ACTH: 7.2-63.3 pg/mL 17-OHP: <1200 ng/dL A4: 41-262 ng/dL (M) 27-152 ng/dL (F)



Cohort A: Proof of concept, escalating QD dosing at 10 PM
(n=10 enrolled)
Baseline PD (Overnight);
Day 1 PK/PD (Overnight)
Week 2 PK/PD
(Overnight)
Week 4 PK/PD
(Overnight)
Week 6 PK/PD
(Overnight)
Follow-up
(Outpatient)
200 mg QD
600 mg QD
1000 mg QD
14 days
14 days
14 days
30 days
Cohort B: Single dose level, BID dosing at 10 AM and 10 PM
(n=9 enrolled)
Baseline PD
(Overnight)
Outpatient
Week 2 PK/PD
(Overnight)
Follow-up
(Outpatient)
200 mg BID
14 days
30 days

FIG. 14




FIG. 15A




FIG. 15B




FIG. 15C




FIG. 15D




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D




FIG. 17A




FIG. 17B




FIG. 17C




FIG. 17D

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
19/043,303	**01/31/2025 07:48:28 PM Z ET**	**50535-710.305**

Title of Invention

METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	1040	FILED BY	Colleen Mensching
PATENT CENTER #	69010424	FILING DATE	-
CUSTOMER #	21971	FIRST NAMED INVENTOR	Alexis HOWERTON
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	Victoria Cheng

Documents

TOTAL DOCUMENTS: 6

DOCUMENT		PAGES	DESCRIPTION	SIZE (KB)
Spruce Biosciences Inc. 50535-710.305 - ADS.pdf		9	Application Data Sheet	2180 KB
Spruce Biosciences Inc. 50535-710.305 - Figures.pdf		14	Drawings-other than black and white line drawings	1089 KB
Spruce Biosciences Inc. 50535-710.305 - Specification.pdf		116	-	1638 KB
Spruce Biosciences Inc. 50535-710.305 - Specification-SPEC.pdf	(1-112)	112	Specification	1663 KB
Spruce Biosciences Inc. 50535-710.305 - Specification-CLM.pdf	(113-115)	3	Claims	141 KB

Spruce Biosciences Inc. 50535-710.305 - Specification-ABST.pdf	(116-116)	1	Abstract	87 KB
Spruce Biosciences Inc. 50535-710.305 - Track 1 Request.pdf		2	Track One Request	174 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
Spruce Biosciences Inc. 50535-710.305 - ADS.pdf	B2BE4859B1AAEA9C5D836D581D1DF49E23A0AC033BC231D61886484B2C36F5A56DB97ECC8BB7A11587175005F989C4E8E39F71E8FF02A3105A741E4CC44E1B49
Spruce Biosciences Inc. 50535-710.305 - Figures.pdf	7037A1FF19D8EB20A63B100B88165C9505B47B42AAAD9BFEBEF3F5C07BD33F054652182B37ED1DF5BFB495E110C70289B66B01374FEB0059FC480C4439501C77
Spruce Biosciences Inc. 50535-710.305 - Specification.pdf	AAF723E73ED80B9635161266C6C048946C3297AFEA5C443D8A1AB2D34DB98AD4CABF486C9BE790292EC5801F7646072415A4E55446C1F5108B929EF8CF71224D
Spruce Biosciences Inc. 50535-710.305 - Specification-SPEC.pdf	B61E671CFDC0DA25C101FC707BBB3CB2BF1453C236E951A001A570A5260CB47EEE9A559F8C514997F110AF2FECB66A9A7FD9C6CAF98319A6B3203AF095A043C6
Spruce Biosciences Inc. 50535-710.305 - Specification-CLM.pdf	16095AB472EDB7174FCD81CA10963C83259D9E2800558CB45D9B659475DD3F9B547CF15F35C8A066641AEBD40547AE25A8E74FAB64C59D5937E4BADEBF2A3702
Spruce Biosciences Inc. 50535-710.305 - Specification-ABST.pdf	32940171FB905DFAA8FF5E54859F5AF7D8D9D21006540FEA39E990C1988F66C71E4560D5068BF9892EA8AF31DA955BB9631FD3859D942E2B1A45BCF666F3F2C4
Spruce Biosciences Inc. 50535-710.305 - Track 1 Request.pdf	C0724F8EAE43E7BA415629A8ECA0691F153AFA733CA751DB0AA168C15A33FE776CBBECC0F4E965B8A190BB50B1DE3BCFC0B8DEA56914325C59919D4A53397571

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage

submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Doc Code: TRACK1.REQ
Document Description: TrackOne Request

PTO/AIA/424 (11-23)

CERTIFICATION AND REQUEST FOR PRIORITIZED EXAMINATION UNDER 37 CFR 1.102(e) (Page 1 of 1)

First Named Inventor:	Alexis HOWERTON	Nonprovisional Application Number (if known):	
Title of Invention:	METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS		

APPLICANT HEREBY CERTIFIES THE FOLLOWING AND REQUESTS PRIORITIZED EXAMINATION FOR THE ABOVE-IDENTIFIED APPLICATION.

1. The processing fee set forth in 37 CFR 1.17(i)(1) and the prioritized examination fee set forth in 37 CFR 1.17(c) have been filed with the request. The publication fee requirement is met because that fee, set forth in 37 CFR 1.18(d), is currently $0. The basic filing fee, search fee, and examination fee are filed with the request or have been already been paid. I understand that any required excess claims fees or application size fee must be paid for the application.

2. I understand that the application may not contain, or be amended to contain, more than four independent claims, more than thirty total claims, or any multiple dependent claims, and that any request for an extension of time will cause an outstanding Track I request to be dismissed.

3. The applicable box is checked below:

I. ☑ Original Application (Track One) - Prioritized Examination under § 1.102(e)(1)

i. (a) The application is an original nonprovisional utility application filed under 35 U.S.C. 111(a). This certification and request is being filed with the utility application via USPTO patent electronic filing system.

---OR---

(b) The application is an original nonprovisional plant application filed under 35 U.S.C. 111(a). This certification and request is being filed with the plant application in paper.

ii. An executed inventor's oath or declaration under 37 CFR 1.63 or 37 CFR 1.64 for each inventor, **or** the application data sheet meeting the conditions specified in 37 CFR 1.53(f)(3)(i) is filed with the application.

II. ☐ Request for Continued Examination - Prioritized Examination under § 1.102(e)(2)

i. A request for continued examination has been filed with, or prior to, this form.
ii. If the application is a utility application, this certification and request is being filed via USPTO patent electronic filing system.
iii. The application is an original nonprovisional utility application filed under 35 U.S.C. 111(a), or is a national stage entry under 35 U.S.C. 371.
iv. This certification and request is being filed prior to the mailing of a first Office action responsive to the request for continued examination.
v. No prior request for continued examination has been granted prioritized examination status under 37 CFR 1.102(e)(2).

Signature /Victoria Cheng/	Date 1/31/2025
Name (Print/Typed) Victoria Cheng	Practitioner Registration Number 79641

Note: *This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications. Submit multiple forms if more than one signature is required.**

☑ *Total of 1 forms are submitted.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. The United States Patent and Trademark Office (USPTO) collects the information in this record under authority of 35 U.S.C. 2. The USPTO's system of records is used to manage all applicant and owner information including name, citizenship, residence, post office address, and other information with respect to inventors and their legal representatives pertaining to the applicant's/owner's activities in connection with the invention for which a patent is sought or has been granted. The applicable Privacy Act System of Records Notice for the information collected in this form is COMMERCE/PAT-TM-7 Patent Application Files, available in the Federal Register at 78 FR 19243 (March 29, 2013). https://www.govinfo.gov/content/pkg/FR-2013-03-29/pdf/2013-07341.pdf

Routine uses of the information in this record may include disclosure to:

1) law enforcement, in the event that the system of records indicates a violation or potential violation of law;

2) a federal, state, local, or international agency, in response to its request;

3) a contractor of the USPTO having need for the information in order to perform a contract;

4) the Department of Justice for determination of whether the Freedom of Information Act (FOIA) requires disclosure of the record;

5) a Member of Congress submitting a request involving an individual to whom the record pertains, when the individual has requested the Member's assistance with respect to the subject matter of the record;

6) a court, magistrate, or administrative tribunal, in the course of presenting evidence, including disclosures to opposing counsel in the course of settlement negotiations;

7) the Administrator, General Services Administration (GSA), or their designee, during an inspection of records conducted by GSA under authority of 44 U.S.C. 2904 and 2906, in accordance with the GSA regulations and any other relevant (i.e., GSA or Commerce) directive, where such disclosure shall not be used to make determinations about individuals;

8) another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c));

9) the Office of Personnel Management (OPM) for personnel research purposes; and

10) the Office of Management and Budget (OMB) for legislative coordination and clearance.

If you do not furnish the information requested on this form, the USPTO may not be able to process and/or examine your submission, which may result in termination of proceedings, abandonment of the application, and/or expiration of the patent.

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC PAYMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
19/043,303	**01/31/2025 07:48:28 PM Z ET**	**50535-710.305**

Title of Invention

METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	1040	FILED BY	Colleen Mensching
PATENT CENTER #	69010424	AUTHORIZED BY	Victoria Cheng
CUSTOMER #	21971	FILING DATE	-
CORRESPONDENCE ADDRESS	-	FIRST NAMED INVENTOR	Alexis HOWERTON

Payment Information

PAYMENT METHOD	PAYMENT TRANSACTION ID	PAYMENT AUTHORIZED BY
DA / 232415	**E20251UJ49259105**	**Colleen Mensching**

FEE CODE	DESCRIPTION	ITEM PRICE($)	QUANTITY	ITEM TOTAL($)
1011	BASIC FILING FEE - UTILITY (PAPER FILING ALSO REQUIRES NON-ELECTRONIC FILING FEE UNDER 1.16(T))	350.00	1	350.00
1111	UTILITY PATENT APPL. SEARCH FEE	770.00	1	770.00
1311	PATENT APPL. EXAMINATION FEE	880.00	1	880.00
1817	REQUEST FOR PRIORITIZED EXAMINATION	4515.00	1	4515.00
1051	SURCHARGE- LATE FILING FEE, SEARCH FEE, EXAMINATION FEE, INVENTOR'S OATH OR DECLARATION, OR APPLICATION FILED WITHOUT AT LEAST ONE	170.00	1	170.00

	CLAIM OR BY REFERENCE			
1054	Non-DOC-X Filing Surcharge	430.00	1	430.00
1830	PROCESSING FEE, EXCEPT IN PROVISIONAL APPLICATIONS	150.00	1	150.00
			TOTAL AMOUNT:	**$7,265.00**

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS

CROSS-REFERENCE

[0001] This application is a continuation of U.S. Application No. 18/941,832, filed November 8, 2024, which is a continuation of U.S. Application No. 17/667,285, filed on February 8, 2022, which is a continuation of U.S. Application No. 17/081,694 filed on October 27, 2020, which issued as U.S. Pat. No. 11,304,950 on April 19, 2022, and which is a continuation of International Application No. PCT/US2019/029486 filed on April 26, 2019, which claims the benefit of U.S. Provisional Patent Application No. 62/663,951, filed April 27, 2018, and U.S. Provisional Patent Application No. 62/822,815, filed March 23, 2019, each of which is entirely incorporated herein by reference.

BACKGROUND

[0002] Corticotropes are basophilic cells in the anterior pituitary that produce melanocyte-stimulating hormone, adrenocorticotropic hormone (ACTH) and lipotropin. The cells produce pro-opiomelanocortin (POMC) which undergoes cleavage to ACTH and β-lipotropin (β-LPH). These cells respond to corticotropin-releasing factor (CRF) and make up about 20% of the cells in the anterior pituitary. CRF is a releasing hormone that belongs to the corticotropin-releasing factor family and is the primary physiological regulator of proopiomelanocortin (POMC).

[0003] CRF is produced by parvocellular neuroendocrine cells within the paraventricular nucleus of the hypothalamus and is released at the median eminence from neurosecretory terminals of these neurons into the primary capillary plexus of the hypothalamo-hypophyseal portal system. The portal system carries the CRF to the anterior lobe of the pituitary, where it stimulates corticotropes to secrete ACTH and other biologically-active substances. ACTH, in turn, stimulates the synthesis of cortisol, glucocorticoids, mineralocorticoids and DHEA.

[0004] Testicular adrenal rest tumors (TART) and ovarian adrenal rest tumors (OART) are ACTH-responsive lesions of the testes and ovaries derived from adrenal tissue interchelated within these organs during embryogenesis. In response to high ACTH, hyperplasia of this tissue occurs, resulting in single or multiple lesions that may cause pain and infertility. The identification of compounds that modulate CRF function and downstream processes is an ongoing challenge. Currently, there are no non-steroidal, non-surgical solutions to control, shrink, or reduce TART. Disclosed herein, *inter alia*, are solutions to these and other problems in the art.

SUMMARY


[0005] Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a serious genetic disorder characterized by impaired adrenal synthesis of cortisol and consequent overproduction of adrenocorticotropic hormone (ACTH), 17-hydroxyprogesterone (17OHP), and adrenal androgens such as androstenedione (A4). CAH is an orphan condition with no FDA-approved therapy. To suppress androgen production, patients are often prescribed long-term supraphysiologic doses of glucocorticoid (GC), which has adverse effects and fail to suppress 17OHP and A4 in the majority of patients.

[0006] Compound 1 may be a potent, selective, nonsteroidal, oral corticotropin-releasing factor type-1 (CRF1) receptor antagonist that reduces excess ACTH, 17OHP, and A4 to improve clinical and biochemical sequelae of CAH. This may obviate the need for high dose steroids.

[0007] One aspect provided herein is a method of treating or preventing testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a corticotropin-releasing factor type-1 (CRF_1) antagonist or a pharmaceutically acceptable salt thereof.

[0008] In some embodiments, the subject has congenital adrenal hyperplasia (CAH). In some embodiments, the size and/or number of the tumors is decreased or reduced.





[0009] One aspect provided herein is a method of treating or preventing testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a compound of structural Formula (I):


(I), or a pharmaceutically acceptable salt thereof,



wherein:

R^1 and R^2 are independently ethyl or n-propyl;


R^3 is hydrogen, Cl, Br, methyl, trifluoromethyl, or methoxy; and

R^4 is hydrogen, Br, R^aR^bN–, methoxymethyl, n-butyl, acetamido, pyridin-4-yl, morpholin-4-yl,  ,  ,  , or  ;

R^a and R^b are independently hydrogen, C_1-C_3alkyl, $H_2NCH_2CH_2$–, $(CH_3)_3COC(O)NHCH_2CH_2$–, or $CH_3CH_2CH_2NHCH_2CH_2$–.


[0010] In some embodiments, R^3 is Cl, Br, methyl, or trifluoromethyl. In some embodiments, R^3 is Cl, Br, or methyl. In some embodiments, R^4 is Br, R^aR^bN–, pyridin-4-yl, morpholin-4-yl, or  . In some embodiments, R^4 is morpholin-4-yl or  .

[0011] In some embodiments, R^4 is hydrogen, Br, R^aR^bN– and R^a and R^b are independently C_1-C_3alkyl. In some embodiments, the compound is




, or a pharmaceutically acceptable salt thereof.

[0012] In some embodiments, the compound is



, or a pharmaceutically acceptable salt thereof.

[0013] In some embodiments, the compound is



, or a pharmaceutically acceptable salt thereof.

[0014] In some embodiments, the subject has congenital adrenal hyperplasia (CAH). In some embodiments, the size and/or number of the tumors is decreased or reduced.

[0015] In some embodiments, from about 5 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In some embodiments, from about 5 mg to about 25 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In some embodiments, from about 10 mg to about 400 mg of a compound of Formula (I), or a pharmaceutically


acceptable salt thereof, is administered to the subject. In some embodiments, from about 100 mg to about 600 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject.

[0016] In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 5 mg/day to about 1000 mg/day is administered to the subject. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose from about 5 mg/day to about 25 mg/day is administered to the subject. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose from about 10 mg/day to about 400 mg/day is administered to the subject. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 100 mg/day to about 600 mg/day is administered to the subject.

[0017] In some embodiments, the compound is administered orally. In some embodiments, the compound is formulated as a capsule or tablet. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in the fed state. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in the fasted state.

[0018] In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at least once per day. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at bedtime. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 4 hours before sleep. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 2 hours before sleep. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 30 minutes before sleep. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in the evening. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at about 10 pm at night.





[0019] One aspect described herein is a method of treating or preventing testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a pharmaceutical composition, comprising a compound of structural Formula (I) and a pharmaceutically acceptable excipient:


(I), or a pharmaceutically acceptable salt thereof,

wherein:


R^1 and R^2 are independently ethyl or n-propyl;

R^3 is hydrogen, Cl, Br, methyl, trifluoromethyl, or methoxy; and

R^4 is hydrogen, Br, R^aR^bN–, methoxymethyl, n-butyl, acetamido, pyridin-4-yl, morpholin-4-yl,  ,  ,  , or  ;

R^a and R^b are independently hydrogen, C_1-C_3alkyl, $H_2NCH_2CH_2$–, $(CH_3)_3COC(O)NHCH_2CH_2$–, or $CH_3CH_2CH_2NHCH_2CH_2$–.

[0020] In some embodiments, the compound of Formula (I) has the structure:


, or a pharmaceutically acceptable salt thereof.

[0021] In some embodiments, the pharmaceutical composition comprises from about 5 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises from about 5 mg to about 25 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises from about 10 mg to about 400 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises from about 100 mg to about 600 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0022] In some embodiments, the pharmaceutical composition comprises about 5 mg, about 10 mg, about 15 mg, about 20 mg, 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265

mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg about 500 mg, or about 600 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.


[0023] In some embodiments, the pharmaceutical composition is administered at a dose of from about 5 mg/day to about 1000 mg/day. In some embodiments, the pharmaceutical composition is administered at a dose of from about 5 mg/day to about 25 mg/day. In some embodiments, the pharmaceutical composition is administered at a dose of from about 10 mg/day to about 400 mg/day. In some embodiments, the pharmaceutical composition is administered at a dose of from about 100 mg/day to about 600 mg/day.


[0024] In some embodiments, the pharmaceutical composition is administered orally. In some embodiments, the pharmaceutical composition is formulated as capsule or a tablet. In some embodiments, the pharmaceutical composition is administered in the fed state. In some embodiments, the pharmaceutical composition is administered in the fasted state. In some embodiments, the pharmaceutical composition is administered at least once per day.

[0025] In some embodiments, the pharmaceutical composition is administered at bedtime. In some embodiments, the pharmaceutical composition is administered less than about 4 hours before sleep. In some embodiments, the pharmaceutical composition is administered less than about 2 hours before sleep. In some embodiments, the pharmaceutical composition is administered less than about 30 minutes before sleep. In some embodiments, the pharmaceutical composition is administered in the evening. In some embodiments, the pharmaceutical composition is administered at about 10 pm at night.


[0026] In some embodiments, the method further comprises administering to the subject an additional chemotherapeutic agent. In some embodiments, the additional chemotherapeutic agent is a glucocorticoid, a mineralocorticoid, an ACAT1 inhibitor, or an anti-androgen. In some embodiments, the glucocorticoid is beclomethasone, betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, or triamcinolone. In some embodiments, the mineralocorticoid is fludrocortisone.

[0027] In some embodiments, the additional chemotherapeutic agent is another CRF_1 antagonist. In some embodiments, the CRF_1 antagonist is


, SSR-126374,


, or a pharmaceutically acceptable salt thereof.

[0028] In some embodiments, the CRF_1 antagonist is


, or a pharmaceutically acceptable salt thereof.

[0029] In some embodiments, the method further comprises an additional treatment selected from surgical resection of the tumors and radiation therapy, or a combination thereof.

[0030] In some embodiments, the additional therapy is surgical resection and the surgical resection is prior to, after, and/or concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition, or any combination thereof.

[0031] In some embodiments, the surgical resection is prior to administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In some embodiments, the surgical resection is after administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In some embodiments, the surgical resection is concurrent with

administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition.

[0032] In some embodiments, the additional treatment is radiation therapy and the radiation therapy is prior to, after, and/or concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition, or any combination thereof. In some embodiments, the radiation therapy is prior to administration of the CRF_1 antagonist of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition.

[0033] In some embodiments, the radiation therapy is after administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In some embodiments, the radiation therapy is concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition.

[0034] Additional aspects and advantages of the present disclosure will become readily apparent to those skilled in this art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be realized, the present disclosure is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.

INCORPORATION BY REFERENCE

[0035] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.

BRIEF DESCRIPTION OF THE DRAWINGS

[0036] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also "Figure" and "FIG." herein), of which:

[0037] FIG. 1A-1B. A schematic representation of intra-patient dose escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics **(A).** A schematic representation of inhibition of CRF_1 with a CRF_1 antagonist (Compound 1) **(B)**.

[0038] FIG. 2. Graphic representation of pharmacokinetics (dose-proportional, adequate exposure at safe doses) in patients with CAH following 14-days of once daily dosing at each dose level with a CRF_1 antagonist (Compound 1).

[0039] FIG. 3. Graphic representation of pharmacokinetics (dose-proportional, adequate exposure at safe doses) in patients with CAH following 14-days of once daily dosing at each dose level with a CRF_1 antagonist (Compound 1).

[0040] FIG. 4. Graphic representation of patient-level response (measuring ACTH levels) to a CRF_1 antagonist (Compound 1).

[0041] FIG. 5A-5B. Graphic representation of patient-level response of sample responders (measuring ACTH levels) to a CRF_1 antagonist [Subject 003001 **(A)**; Subject 007002 **(B)**].

[0042] FIG. 6. Graphic representation of patient-level response (measuring 17-OHP levels) to a CRF_1 antagonist (Compound 1).

[0043] FIG. 7A-7B. Graphic representation of patient-level response of sample responders (measuring 17-OHP levels) to a CRF_1 antagonist [Subject 003001 **(A)**; Subject 007002 **(B)**].

[0044] FIG. 8. Graphic representation of patient-level response (measuring androstenedione levels) to a CRF_1 antagonist (Compound 1).

[0045] FIG. 9A-9B. Graphic representation of patient-level response of sample responders (measuring androstenedione levels) to a CRF_1 antagonist (Compound 1) [Subject 003001 **(A)**; Subject 007002 **(B)**].

[0046] FIG. 10A-10B. Images of a patient with TART pre-treatment with a CRF_1 antagonist (Compound 1) **(A)** and 6-weeks post-treatment with a CRF_1 antagonist (Compound 1) **(B)**.

[0047] FIG. 11A-11B. Graphic representation of an *in vitro* binding assay of a CRF_1 antagonist (Compound 1); ^{125}I-sauvagine binding to rat cerebellar membranes one hour after oral administration of increasing Compound 1 doses **(A)** and *in vivo* inhibition of CRF-induced activity after treatment with a CRF_1 antagonist; Compound 1 (oral, 10 mg/kg) **(B)**.

[0048] FIG. 12A-12B. Graphic representation of ACTH levels **(A)** and 17-OHP levels **(B)** after treatment with a CRF_1 antagonist (Compound 1).

[0049] FIG. 13. Graphic representation of hormone responses after treatment with a CRF_1 antagonist (Compound 1).

[0050] FIG. 14 depicts the proof of concept and escalating QD dosing at 10 pm.

[0051] FIG. 15A-15D are graphic representations of changes in androstenedione seen in participants in Cohort A and Cohort B.

[0052] **FIG. 16A-16D** are graphic representations of changes in 17-hydroxyprogesterone seen in participants in Cohort A and Cohort B.

[0053] **FIG. 17A-17D** are graphic representations of changes in adrenocorticotropic hormone seen in participants in Cohort A and Cohort B.

DETAILED DESCRIPTION

[0054] While various embodiments of the invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions may occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed.

I. Definitions

[0055] The abbreviations used herein have their conventional meaning within the chemical and biological arts. The chemical structures and formulae set forth herein are constructed according to the standard rules of chemical valency known in the chemical arts.

[0056] Where substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., $-CH_2O-$ is equivalent to $-OCH_2-$.

[0057] The term "alkyl," by itself or as part of another substituent, means, unless otherwise stated, a straight (i.e., unbranched) or branched carbon chain (or carbon), or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include mono-, di- and multivalent radicals, having the number of carbon atoms designated (i.e., C_1-C_{10} means one to ten carbons). Alkyl is an uncyclized chain. Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, (cyclohexyl)methyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers. An alkoxy is an alkyl attached to the remainder of the molecule via an oxygen linker (-O-).

[0058] The term "alkylene," by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited by, $-CH_2CH_2CH_2CH_2-$. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred herein. A "lower alkyl" or "lower alkylene" is a shorter chain alkyl or alkylene group, generally having eight or fewer

carbon atoms. The term "alkenylene," by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkene.

[0059] The term "heteroalkyl," by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or combinations thereof, including at least one carbon atom and at least one heteroatom (e.g., O, N, P, Si, and S), and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) (e.g., N, S, Si, or P) may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Heteroalkyl is an uncyclized chain. Examples include, but are not limited to: $-CH_2-CH_2-O-CH_3$, $-CH_2-CH_2-NH-CH_3$, $-CH_2-CH_2-N(CH_3)-CH_3$, $-CH_2-S-CH_2-CH_3$, $-CH_2-CH_2$, $-S(O)-CH_3$, $-CH_2-CH_2-S(O)_2-CH_3$, $-CH=CH-O-CH_3$, $-Si(CH_3)_3$, $-CH_2-CH=N-OCH_3$, $-CH=CH-N(CH_3)-CH_3$, $-O-CH_3$, $-O-CH_2-CH_3$, and -CN. Up to two or three heteroatoms may be consecutive, such as, for example, $-CH_2-NH-OCH_3$ and $-CH_2-O-Si(CH_3)_3$. A heteroalkyl moiety may include one heteroatom (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include two optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include three optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include four optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include five optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include up to 8 optionally different heteroatoms (e.g., O, N, S, Si, or P).

[0060] Similarly, the term "heteroalkylene," by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not limited by, $-CH_2-CH_2-S-CH_2-CH_2-$ and $-CH_2-S-CH_2-CH_2-NH-CH_2-$. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula $-C(O)_2R'-$ represents both $-C(O)_2R'-$ and $-R'C(O)_2-$. As described above, heteroalkyl groups, as used herein, include those groups that are attached to the remainder of the molecule through a heteroatom, such as -C(O)R', -C(O)NR', -NR'R", -OR', -SR', and/or $-SO_2R'$. Where "heteroalkyl" is recited, followed by recitations of specific heteroalkyl groups, such as -NR'R" or the like, it will be understood that the terms heteroalkyl and -NR'R" are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term "heteroalkyl" should not be interpreted herein as excluding specific heteroalkyl groups, such as -NR'R" or the like.

[0061] The terms "cycloalkyl" and "heterocycloalkyl," by themselves or in combination with other terms, mean, unless otherwise stated, cyclic versions of "alkyl" and "heteroalkyl,"

respectively. Cycloalkyl and heterocycloalkyl are not aromatic. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like. A "cycloalkylene" and a "heterocycloalkylene," alone or as part of another substituent, means a divalent radical derived from a cycloalkyl and heterocycloalkyl, respectively. "Cycloalkyl" is also meant to refer to bicyclic and polycyclic hydrocarbon rings such as, for example, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, etc.

[0062] The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as "haloalkyl" are meant to include monohaloalkyl and polyhaloalkyl. For example, the term "halo(C_1-C_4)alkyl" includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.

[0063] The term "acyl" means, unless otherwise stated, -C(O)R where R is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0064] The term "aryl" means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently. A fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring. The term "heteroaryl" refers to aryl groups (or rings) that contain at least one heteroatom such as N, O, or S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. Thus, the term "heteroaryl" includes fused ring heteroaryl groups (i.e., multiple rings fused together wherein at least one of the fused rings is a heteroaromatic ring). A 5,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. Likewise, a 6,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. And a 6,5-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 5 members, and wherein at least one ring is a heteroaryl ring. A heteroaryl group can be attached to the remainder of the molecule through a carbon or heteroatom. Non-


limiting examples of aryl and heteroaryl groups include phenyl, naphthyl, pyrrolyl, pyrazolyl, pyridazinyl, triazinyl, pyrimidinyl, imidazolyl, pyrazinyl, purinyl, oxazolyl, isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidyl, benzothiazolyl, benzoxazoyl benzimidazolyl, benzofuran, isobenzofuranyl, indolyl, isoindolyl, benzothiophenyl, isoquinolyl, quinoxalinyl, quinolyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below. An "arylene" and a "heteroarylene," alone or as part of another substituent, mean a divalent radical derived from an aryl and heteroaryl, respectively. A heteroaryl group substituent may be -O- bonded to a ring heteroatom nitrogen.

[0065] Spirocyclic rings are two or more rings wherein adjacent rings are attached through a single atom. The individual rings within spirocyclic rings may be identical or different. Individual rings in spirocyclic rings may be substituted or unsubstituted and may have different substituents from other individual rings within a set of spirocyclic rings. Possible substituents for individual rings within spirocyclic rings are the possible substituents for the same ring when not part of spirocyclic rings (e.g. substituents for cycloalkyl or heterocycloalkyl rings). Spirocylic rings may be substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heterocycloalkylene and individual rings within a spirocyclic ring group may be any of the immediately previous list, including having all rings of one type (e.g. all rings being substituted heterocycloalkylene wherein each ring may be the same or different substituted heterocycloalkylene). When referring to a spirocyclic ring system, heterocyclic spirocyclic rings means a spirocyclic rings wherein at least one ring is a heterocyclic ring and wherein each ring may be a different ring. When referring to a spirocyclic ring system, substituted spirocyclic rings means that at least one ring is substituted and each substituent may optionally be different.

[0066] The symbol "" denotes the point of attachment of a chemical moiety to the remainder of a molecule or chemical formula.

[0067] The term "oxo," as used herein, means an oxygen that is double bonded to a carbon atom.

[0068] The term "alkylarylene" as an arylene moiety covalently bonded to an alkylene moiety (also referred to herein as an alkylene linker). In embodiments, the alkylarylene group has the formula:



[0069] An alkylarylene moiety may be substituted (e.g. with a substituent group) on the alkylene moiety or the arylene linker (e.g. at carbons 2, 3, 4, or 6) with halogen, oxo, $-N_3$, $-CF_3$, $-CCl_3$, $-CBr_3$, $-CI_3$, -CN, -CHO, -OH, $-NH_2$, -COOH, $-CONH_2$, $-NO_2$, -SH, $-SO_2CH_3$ $-SO_3H$, $-OSO_3H$, $-SO_2NH_2$, $-NHNH_2$, $-ONH_2$, $-NHC(O)NHNH_2$, substituted or unsubstituted C_1-C_5 alkyl or substituted or unsubstituted 2 to 5 membered heteroalkyl). In embodiments, the alkylarylene is unsubstituted.

[0070] Each of the above terms (e.g., "alkyl," "heteroalkyl," "cycloalkyl," "heterocycloalkyl," "aryl," and "heteroaryl") includes both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.

[0071] Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one or more of a variety of groups selected from, but not limited to, -OR', =O, =NR', =N-OR', -NR'R", -SR', -halogen, -SiR'R"R"', -OC(O)R', -C(O)R', $-CO_2R'$, -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR'-C(O)NR"R"', $-NR"C(O)_2R'$, -NR-C(NR'R"R"')=NR"", -NR-C(NR'R")=NR"', $-S(O)R'$, $-S(O)_2R'$, $-S(O)_2NR'R"$, $-NRSO_2R'$, $-NR'NR"R"'$, $-ONR'R"$, $-NR'C(O)NR"NR"'R""$, -CN, $-NO_2$, $-NR'SO_2R"$, -NR'C(O)R", -NR'C(O)-OR", -NR'OR", in a number ranging from zero to (2m'+1), where m' is the total number of carbon atoms in such radical. R, R', R", R"', and R"" each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, alkoxy, or thioalkoxy groups, or arylalkyl groups. When a compound described herein includes more than one R group, for example, each of the R groups is independently selected as are each R', R", R"', and R"" group when more than one of these groups is present. When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example, -NR'R" includes, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term "alkyl" is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., $-CF_3$ and $-CH_2CF_3$) and acyl (e.g., $-C(O)CH_3$, $-C(O)CF_3$, $-C(O)CH_2OCH_3$, and the like).

[0072] Similar to the substituents described for the alkyl radical, substituents for the aryl and heteroaryl groups are varied and are selected from, for example: -OR', -NR'R", -SR', -halogen, -

SiR'R"R'", -OC(O)R', -C(O)R', -CO_2R', -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR'-C(O)NR"R'", -NR"C(O)$_2$R', -NR-C(NR'R"R'")=NR"", -NR-C(NR'R")=NR'", -S(O)R', -S(O)$_2$R', -S(O)$_2$NR'R", -NRSO$_2$R', –NR'NR"R'", –ONR'R", –NR'C(O)NR"NR'"R"", -CN, -NO_2, -R', -N_3, -CH(Ph)$_2$, fluoro(C_1-C_4)alkoxy, and fluoro(C_1-C_4)alkyl, -NR'SO$_2$R", -NR'C(O)R", -NR'C(O)-OR", -NR'OR", in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R', R", R'", and R"" are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. When a compound described herein includes more than one R group, for example, each of the R groups is independently selected as are each R', R", R'", and R"" groups when more than one of these groups is present.

[0073] Substituents for rings (e.g. cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene) may be depicted as substituents on the ring rather than on a specific atom of a ring (commonly referred to as a floating substituent). In such a case, the substituent may be attached to any of the ring atoms (obeying the rules of chemical valency) and in the case of fused rings or spirocyclic rings, a substituent depicted as associated with one member of the fused rings or spirocyclic rings (a floating substituent on a single ring), may be a substituent on any of the fused rings or spirocyclic rings (a floating substituent on multiple rings). When a substituent is attached to a ring, but not a specific atom (a floating substituent), and a subscript for the substituent is an integer greater than one, the multiple substituents may be on the same atom, same ring, different atoms, different fused rings, different spirocyclic rings, and each substituent may optionally be different. Where a point of attachment of a ring to the remainder of a molecule is not limited to a single atom (a floating substituent), the attachment point may be any atom of the ring and in the case of a fused ring or spirocyclic ring, any atom of any of the fused rings or spirocyclic rings while obeying the rules of chemical valency. Where a ring, fused rings, or spirocyclic rings contain one or more ring heteroatoms and the ring, fused rings, or spirocyclic rings are shown with one more floating substituents (including, but not limited to, points of attachment to the remainder of the molecule), the floating substituents may be bonded to the heteroatoms. Where the ring heteroatoms are shown bound to one or more hydrogens (e.g. a ring nitrogen with two bonds to ring atoms and a third bond to a hydrogen) in the structure or formula with the floating substituent, when the heteroatom is bonded to the floating substituent, the substituent will be understood to replace the hydrogen, while obeying the rules of chemical valency.

[0074] Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups. Such so-called ring-forming substituents are typically, though not

necessarily, found attached to a cyclic base structure. In one embodiment, the ring-forming substituents are attached to adjacent members of the base structure. For example, two ring-forming substituents attached to adjacent members of a cyclic base structure create a fused ring structure. In another embodiment, the ring-forming substituents are attached to a single member of the base structure. For example, two ring-forming substituents attached to a single member of a cyclic base structure create a spirocyclic structure. In yet another embodiment, the ring-forming substituents are attached to non-adjacent members of the base structure.

[0075] Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally form a ring of the formula -T-C(O)-$(CRR')_q$-U-, wherein T and U are independently -NR-, -O-, -CRR'-, or a single bond, and q is an integer of from 0 to 3. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-$(CH_2)_r$-B-, wherein A and B are independently -CRR'-, -O-, -NR-, -S-, -S(O) -, -$S(O)_2$-, -$S(O)_2$NR'-, or a single bond, and r is an integer of from 1 to 4. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -$(CRR')_s$-X'- $(C"R"R"')_d$-, where s and d are independently integers of from 0 to 3, and X' is -O-, -NR'-, -S-, -S(O)-, -$S(O)_2$-, or -$S(O)_2$NR'-. The substituents R, R', R", and R"' are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.

[0076] As used herein, the terms "heteroatom" or "ring heteroatom" are meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).

[0077] A "substituent group," as used herein, means a group selected from the following moieties:

(A) oxo, halogen, -CF_3, -CN, -OH, -NH_2, -COOH, -$CONH_2$, -NO_2, -SH, -SO_3H, -SO_4H, -SO_2NH_2, –$NHNH_2$, –ONH_2, –NHC=(O)$NHNH_2$, –NHC=(O) NH_2, -$NHSO_2H$, -NHC= (O)H, -NHC(O)-OH, -NHOH, -OCF_3, -$OCHF_2$, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and

(B) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, substituted with at least one substituent selected from:

(i) oxo, halogen, -CF_3, -CN, -OH, -NH_2, -COOH, -$CONH_2$, -NO_2, -SH, -SO_3H, -SO_4H, -SO_2NH_2, –$NHNH_2$, –ONH_2, –NHC=(O)$NHNH_2$, –NHC=(O) NH_2, -$NHSO_2H$, -NHC= (O)H, -NHC(O)-OH, -NHOH, -OCF_3, -$OCHF_2$, unsubstituted alkyl, unsubstituted heteroalkyl,

unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and

(ii) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, substituted with at least one substituent selected from:

(a) oxo, halogen, -CF_3, -CN, -OH, -NH_2, -COOH, -$CONH_2$, -NO_2, -SH, -SO_3H, -SO_4H, -SO_2NH_2, –$NHNH_2$, –ONH_2, –NHC=(O)$NHNH_2$, –NHC=(O) NH_2, -$NHSO_2H$, -NHC=(O)H, -NHC(O)-OH, -NHOH, -OCF_3, -$OCHF_2$, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and

(b) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, substituted with at least one substituent selected from: oxo, halogen, -CF_3, -CN, -OH, -NH_2, -COOH, -$CONH_2$, -NO_2, -SH, -SO_3H, -SO_4H, -SO_2NH_2, –$NHNH_2$, –ONH_2, –NHC=(O)$NHNH_2$, –NHC=(O) NH_2, -$NHSO_2H$, -NHC=(O)H, -NHC(O)-OH, -NHOH, -OCF_3, -$OCHF_2$, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl.

[0078] A "size-limited substituent" or " size-limited substituent group," as used herein, means a group selected from all of the substituents described above for a "substituent group," wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C_1-C_{20} alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C_3-C_8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C_6-C_{10} aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl.

[0079] A "lower substituent" or " lower substituent group," as used herein, means a group selected from all of the substituents described above for a "substituent group," wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C_1-C_8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C_3-C_7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C_6-C_{10} aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl.

[0080] In some embodiments, each substituted group described in the compounds herein is substituted with at least one substituent group. More specifically, in some embodiments, each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene described in the compounds herein are substituted with at least one substituent group. In other embodiments, at least one or all of these groups are substituted with at least one size-limited substituent group. In other embodiments, at least one or all of these groups are substituted with at least one lower substituent group.

[0081] In other embodiments of the compounds herein, each substituted or unsubstituted alkyl may be a substituted or unsubstituted C_1-C_{20} alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C_3-C_8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C_6-C_{10} aryl, and/or each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl. In some embodiments of the compounds herein, each substituted or unsubstituted alkylene is a substituted or unsubstituted C_1-C_{20} alkylene, each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 20 membered heteroalkylene, each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C_3-C_8 cycloalkylene, each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene, each substituted or unsubstituted arylene is a substituted or unsubstituted C_6-C_{10} arylene, and/or each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 10 membered heteroarylene.

[0082] In some embodiments, each substituted or unsubstituted alkyl is a substituted or unsubstituted C_1-C_8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C_3-C_7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C_6-C_{10} aryl, and/or each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl. In some embodiments, each substituted or unsubstituted alkylene is a substituted or unsubstituted C_1-C_8 alkylene, each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 8 membered heteroalkylene, each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C_3-C_7 cycloalkylene, each substituted or unsubstituted heterocycloalkylene is a

substituted or unsubstituted 3 to 7 membered heterocycloalkylene, each substituted or unsubstituted arylene is a substituted or unsubstituted C_6-C_{10} arylene, and/or each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 9 membered heteroarylene. In some embodiments, the compound is a chemical species set forth in the Examples section, figures, or tables below.

[0083] Certain compounds of the present invention possess asymmetric carbon atoms (optical or chiral centers) or double bonds; the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisometric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids, and individual isomers are encompassed within the scope of the present invention. The compounds of the present invention do not include those that are known in art to be too unstable to synthesize and/or isolate. The present invention is meant to include compounds in racemic and optically pure forms. Optically active (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.

[0084] As used herein, the term "isomers" refers to compounds having the same number and kind of atoms, and hence the same molecular weight, but differing in respect to the structural arrangement or configuration of the atoms.

[0085] The term "tautomer," as used herein, refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one isomeric form to another.

[0086] It will be apparent to one skilled in the art that certain compounds of this invention may exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the invention.

[0087] Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention.

[0088] Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by ^{13}C- or ^{14}C-enriched carbon are within the scope of this invention.

[0089] The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the

compounds may be radiolabeled with radioactive isotopes, such as for example tritium (^{3}H), iodine-125 (^{125}I), or carbon-14 (^{14}C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.

[0090] It should be noted that throughout the application that alternatives are written in Markush groups, for example, each amino acid position that contains more than one possible amino acid. It is specifically contemplated that each member of the Markush group should be considered separately, thereby comprising another embodiment, and the Markush group is not to be read as a single unit.

[0091] "Analog" or "analogue" is used in accordance with its plain ordinary meaning within Chemistry and Biology and refers to a chemical compound that is structurally similar to another compound (i.e., a so-called "reference" compound) but differs in composition, e.g., in the replacement of one atom by an atom of a different element, or in the presence of a particular functional group, or the replacement of one functional group by another functional group, or the absolute stereochemistry of one or more chiral centers of the reference compound. Accordingly, an analog is a compound that is similar or comparable in function and appearance but not in structure or origin to a reference compound.

[0092] The terms "a" or "an," as used in herein means one or more. In addition, the phrase "substituted with a[n]," as used herein, means the specified group may be substituted with one or more of any or all of the named substituents. For example, where a group, such as an alkyl or heteroaryl group, is "substituted with an unsubstituted C_1-C_{20} alkyl, or unsubstituted 2 to 20 membered heteroalkyl," the group may contain one or more unsubstituted C_1-C_{20} alkyls, and/or one or more unsubstituted 2 to 20 membered heteroalkyls.

[0093] Moreover, where a moiety is substituted with an R substituent, the group may be referred to as "R-substituted." Where a moiety is R-substituted, the moiety is substituted with at least one R substituent and each R substituent is optionally different. Where a particular R group is present in the description of a chemical genus (such as Formula (I)), a Roman alphabetic symbol may be used to distinguish each appearance of that particular R group. For example, where multiple R^{13} substituents are present, each R^{13} substituent may be distinguished as R^{13A}, R^{13B}, R^{13C}, R^{13D}, etc., wherein each of R^{13A}, R^{13B}, R^{13C}, R^{13D}, etc. is defined within the scope of the definition of R^{13} and optionally differently.

[0094] A "detectable moiety" as used herein refers to a moiety that can be covalently or noncovalently attached to a compound or biomolecule that can be detected for instance, using techniques known in the art. In embodiments, the detectable moiety is covalently attached. The detectable moiety may provide for imaging of the attached compound or biomolecule. The detectable moiety may indicate the contacting between two compounds. Exemplary detectable

moieties are fluorophores, antibodies, reactive dies, radio-labeled moieties, magnetic contrast agents, and quantum dots. Exemplary fluorophores include fluorescein, rhodamine, GFP, coumarin, FITC, Alexa fluor, Cy3, Cy5, BODIPY, and cyanine dyes. Exemplary radionuclides include Fluorine-18, Gallium-68, and Copper-64. Exemplary magnetic contrast agents include gadolinium, iron oxide and iron platinum, and manganese.

[0095] Descriptions of compounds of the present invention are limited by principles of chemical bonding known to those skilled in the art. Accordingly, where a group may be substituted by one or more of a number of substituents, such substitutions are selected so as to comply with principles of chemical bonding and to give compounds which are not inherently unstable and/or would be known to one of ordinary skill in the art as likely to be unstable under ambient conditions, such as aqueous, neutral, and several known physiological conditions. For example, a heterocycloalkyl or heteroaryl is attached to the remainder of the molecule via a ring heteroatom in compliance with principles of chemical bonding known to those skilled in the art thereby avoiding inherently unstable compounds.

[0096] The term "pharmaceutically acceptable salts" is meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, oxalic, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (*see*, for example, Berge *et al.*, "Pharmaceutical Salts", *Journal of Pharmaceutical Science*, **1977**, *66*, 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

[0097] Thus, the compounds of the present invention may exist as salts, such as with pharmaceutically acceptable acids. The present invention includes such salts. Non-limiting examples of such salts include hydrochlorides, hydrobromides, phosphates, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, proprionates, tartrates (e.g., (+)-tartrates, (-)-tartrates, or mixtures thereof including racemic mixtures), succinates, benzoates, and salts with amino acids such as glutamic acid, and quaternary ammonium salts (e.g. methyl iodide, ethyl iodide, and the like). These salts may be prepared by methods known to those skilled in the art.

[0098] The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound may differ from the various salt forms in certain physical properties, such as solubility in polar solvents. In embodiments, compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts. The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in a conventional manner. The parent form of the compounds differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but, unless specifically indicated, the salts disclosed herein are equivalent to the parent form of the compound for the purposes of the present invention.

[0099] In addition to salt forms, the present invention provides compounds, which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Prodrugs of the compounds described herein may be converted *in vivo* after administration. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an *ex vivo* environment, such as, for example, when contacted with a suitable enzyme or chemical reagent.

[0100] Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.

[0101] "Pharmaceutically acceptable excipient" and "pharmaceutically acceptable carrier" refer to a substance that aids the administration of a compound to and absorption by a subject and can be included in the compositions of the present invention without causing a significant adverse toxicological effect on the patient. Non-limiting examples of pharmaceutically acceptable

excipients include water, NaCl, normal saline solutions, lactated Ringer's, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, and the like. Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present invention.

[0102] The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

[0103] A "CRF1 inhibitor" refers to a compound (e.g., compounds described herein) that reduces the activity of CRF1 when compared to a control, such as absence of the compound or a compound with known inactivity.

[0104] The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues, wherein the polymer may optionally be conjugated to a moiety that does not consist of amino acids. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer. In embodiments, the terms "polypeptide," "peptide," and "protein", used interchangeably herein, refer to a polymeric form of amino acids of any length, which can include genetically coded and non-genetically coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified polypeptide backbones. The terms include fusion proteins, including, but not limited to, fusion proteins with a heterologous amino acid sequence; fusion proteins with heterologous and homologous leader sequences, with or without N-terminus methionine residues; immunologically tagged proteins; and the like.

[0105] A polypeptide, or a cell is "recombinant" when it is artificial or engineered, or derived from or contains an artificial or engineered protein or nucleic acid (*e.g.* non-natural or not wild type). For example, a polynucleotide that is inserted into a vector or any other heterologous location, *e.g.*, in a genome of a recombinant organism, such that it is not associated with nucleotide sequences that normally flank the polynucleotide as it is found in nature is a

recombinant polynucleotide. A protein expressed *in vitro* or *in vivo* from a recombinant polynucleotide is an example of a recombinant polypeptide. Likewise, a polynucleotide sequence that does not appear in nature, for example a variant of a naturally occurring gene, is recombinant.

[0106] "Contacting" is used in accordance with its plain ordinary meaning and refers to the process of allowing at least two distinct species (e.g. chemical compounds including biomolecules or cells) to become sufficiently proximal to react, interact or physically touch. It should be appreciated; however, the resulting reaction product can be produced directly from a reaction between the added reagents or from an intermediate from one or more of the added reagents that can be produced in the reaction mixture.

[0107] The term "contacting" may include allowing two species to react, interact, or physically touch, wherein the two species may be a compound as described herein and a protein or enzyme. In some embodiments contacting includes allowing a compound described herein to interact with a protein or enzyme that is involved in a signaling pathway (e.g., MAP kinase pathway).

[0108] As defined herein, the term "activation", "activate", "activating" and the like in reference to a protein refers to conversion of a protein into a biologically active derivative from an initial inactive or deactivated state. The terms reference activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein decreased in a disease.

[0109] The terms "agonist," "activator," "upregulator," etc. refer to a substance capable of detectably increasing the expression or activity of a given gene or protein. The agonist can increase expression or activity 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more in comparison to a control in the absence of the agonist. In certain instances, expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or higher than the expression or activity in the absence of the agonist. In embodiments, an agonist is a molecule that interacts with a target to cause or promote an increase in the activation of the target. In embodiments, activators are molecules that increase, activate, facilitate, enhance activation, sensitize, or up-regulate, e.g., a gene, protein, ligand, receptor, or cell.

[0110] As defined herein, the term "inhibition", "inhibit", "inhibiting" and the like in reference to a protein-inhibitor interaction means negatively affecting (e.g. decreasing) the activity or function of the protein relative to the activity or function of the protein in the absence of the inhibitor. In embodiments inhibition means negatively affecting (e.g. decreasing) the concentration or levels of the protein relative to the concentration or level of the protein in the absence of the inhibitor. In embodiments inhibition refers to reduction of a disease or symptoms of disease. In embodiments, inhibition refers to a reduction in the activity of a particular protein

target. Thus, inhibition includes, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating signal transduction or enzymatic activity or the amount of a protein. In embodiments, inhibition refers to a reduction of activity of a target protein resulting from a direct interaction (e.g. an inhibitor binds to the target protein). In embodiments, inhibition refers to a reduction of activity of a target protein from an indirect interaction (e.g. an inhibitor binds to a protein that activates the target protein, thereby preventing target protein activation).

[0111] The terms "inhibitor," "repressor" or "antagonist" or "downregulator" interchangeably refer to a substance capable of detectably decreasing the expression or activity of a given gene or protein. The antagonist can decrease expression or activity 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more in comparison to a control in the absence of the antagonist. In certain instances, expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or lower than the expression or activity in the absence of the antagonist. An antagonist prevents, reduces, inhibits, or neutralizes the activity of an agonist, and an antagonist can also prevent, inhibit, or reduce constitutive activity of a target, e.g., a target receptor, even where there is no identified agonist. In embodiments, inhibitors are molecules that decrease, block, prevent, delay activation, inactivate, desensitize, or down-regulate, e.g., a gene, protein, ligand, receptor, or cell. An inhibitor may also be defined as a molecule that reduces, blocks, or inactivates a constitutive activity. An "antagonist" is a molecule that opposes the action(s) of an agonist.

[0112] The terms "corticotropin-releasing factor type-1," "CRF_1," "corticotropin-releasing hormone receptor 1," and "CHHR1" refer to a protein (including homologs, isoforms, and functional fragments thereof) and is a receptor for corticotropin releasing-hormone. The terms include any recombinant or naturally-occurring form of CRF_1 variants thereof that maintain CRF_1 activity (e.g. within at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% activity compared to wildtype CRF1). The terms include any mutant form of CRF_1 variants (e.g., frameshift mutations) thereof that maintain CRF_1 activity (e.g. within at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% activity compared to wildtype CRF_1). In embodiments, the CRF_1 protein encoded by the *CRHR1* gene has the amino acid sequence set forth in or corresponding to Entrez 1233, UniProt P34998.

[0113] The term "expression" includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion. Expression can be detected using conventional techniques for detecting protein (*e.g.*, ELISA, Western blotting, flow cytometry, immunofluorescence, immunohistochemistry, *etc.*).

[0114] The terms "disease" or "condition" refer to a state of being or health status of a patient or subject capable of being treated with the compounds or methods provided herein. The disease may be a malignant or benign tumor (e.g., testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART)). The disease may be cancer. In some further instances, "cancer" refers to human cancers and carcinomas, sarcomas, adenocarcinomas, lymphomas, leukemias, etc., including solid and lymphoid cancers, kidney, breast, lung, bladder, colon, ovarian, prostate, pancreas, adrenal, stomach, brain, head and neck, skin, uterine, testicular, glioma, esophagus, and liver cancer, including hepatocarcinoma, lymphoma, including B-acute lymphoblastic lymphoma, non-Hodgkin's lymphomas (*e.g.*, Burkitt's, Small Cell, and Large Cell lymphomas), Hodgkin's lymphoma, leukemia (including MDS, AML, ALL, ATLL and CML), or multiple myeloma.

[0115] As used herein, the term "cancer" refers to all types of cancer, neoplasm or malignant tumors found in mammals (e.g. humans), including leukemia, carcinomas and sarcomas. Exemplary cancers that may be treated with a compound or method provided herein include adrenal cancer and tumors (e.g., testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART)) brain cancer, glioma, glioblastoma, neuroblastoma, prostate cancer, colorectal cancer, pancreatic cancer, cervical cancer, gastric cancer, ovarian cancer, lung cancer, and cancer of the head. Exemplary cancers that may be treated with a compound or method provided herein include cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head & neck, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus, Medulloblastoma, colorectal cancer, pancreatic cancer. Additional examples include, thyroid carcinoma, cholangiocarcinoma, pancreatic adenocarcinoma, skin cutaneous melanoma, colon adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, breast invasive carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, or prostate cancer.

[0116] The term "congenital adrenal hyperplasia" or "CAH" are any of several autosomal recessive diseases resulting from mutations of genes for enzymes mediating the biochemical

steps of production of mineralocorticoids, glucocorticoids or sex steroids from cholesterol by the adrenal glands (steroidogenesis). These conditions involve excessive or deficient production of sex steroids and can alter development of primary or secondary sex characteristics in some affected infants, children, or adults.

[0117] "Adrenal rest tumor" refers to a neoplasm of the testis (or ovaries) consisting of adrenal tissue. It may be secondary to hyperplasia of an adrenal gland.

[0118] "Testicular adrenal rest tumor(s)" or "TART" and/or ovarian adrenal rest tumor(s) are a complication of congenital adrenal hyperplasia (CAH), which may develop from ectopic remnants of intra-testicular adrenal tissue stimulated by adrenocorticotropic hormone (ACTH) hypersecretion. TART lesions are typically located within the rete testis and are bilateral, synchronous, nodular and multiple. TART can lead to testicular structural damage, spermatogenesis disorders, infertility and mass-forming lesions.

[0119] The term "leukemia" refers broadly to progressive, malignant diseases of the blood-forming organs and is generally characterized by a distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemia is generally clinically classified on the basis of (1) the duration and character of the disease-acute or chronic; (2) the type of cell involved; myeloid (myelogenous), lymphoid (lymphogenous), or monocytic; and (3) the increase or non-increase in the number abnormal cells in the blood-leukemic or aleukemic (subleukemic). Exemplary leukemias that may be treated with a compound or method provided herein include, for example, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, a leukocythemic leukemia, basophylic leukemia, blast cell leukemia, bovine leukemia, chronic myelocytic leukemia, leukemia cutis, embryonal leukemia, eosinophilic leukemia, Gross' leukemia, hairy-cell leukemia, hemoblastic leukemia, hemocytoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenous leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblastic leukemia, myelocytic leukemia, myeloid granulocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, multiple myeloma, plasmacytic leukemia, promyelocytic leukemia, Rieder cell leukemia, Schilling's leukemia, stem cell leukemia, subleukemic leukemia, or undifferentiated cell leukemia.

[0120] The term "sarcoma" generally refers to a tumor which is made up of a substance like the embryonic connective tissue and is generally composed of closely packed cells embedded in a fibrillar or homogeneous substance. Sarcomas that may be treated with a compound or method

provided herein include a chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, chorio carcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic multiple pigmented hemorrhagic sarcoma, immunoblastic sarcoma of B cells, lymphoma, immunoblastic sarcoma of T-cells, Jensen's sarcoma, Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma, leukosarcoma, malignant mesenchymoma sarcoma, parosteal sarcoma, reticulocytic sarcoma, Rous sarcoma, serocystic sarcoma, synovial sarcoma, or telangiectaltic sarcoma.

[0121] The term "melanoma" is taken to mean a tumor arising from the melanocytic system of the skin and other organs. Melanomas that may be treated with a compound or method provided herein include, for example, acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungal melanoma, or superficial spreading melanoma.

[0122] The term "carcinoma" refers to a malignant new growth made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. Exemplary carcinomas that may be treated with a compound or method provided herein include, for example, thyroid carcinoma, cholangiocarcinoma, pancreatic adenocarcinoma, skin cutaneous melanoma, colon adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, breast invasive carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocellulare, basaloid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, carcinoma durum, embryonal carcinoma, encephaloid carcinoma, epiermoid carcinoma, carcinoma epitheliale adenoides, exophytic carcinoma, carcinoma ex ulcere, carcinoma fibrosum, gelatiniforni carcinoma, gelatinous carcinoma, giant cell carcinoma, carcinoma gigantocellulare, glandular carcinoma, granulosa cell carcinoma, hair-matrix carcinoma, hematoid carcinoma, hepatocellular carcinoma, Hurthle cell carcinoma, hyaline carcinoma, hypernephroid carcinoma,

infantile embryonal carcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma, Krompecher's carcinoma, Kulchitzky-cell carcinoma, large-cell carcinoma, lenticular carcinoma, carcinoma lenticulare, lipomatous carcinoma, lymphoepithelial carcinoma, carcinoma medullare, medullary carcinoma, melanotic carcinoma, carcinoma molle, mucinous carcinoma, carcinoma muciparum, carcinoma mucocellulare, mucoepidermoid carcinoma, carcinoma mucosum, mucous carcinoma, carcinoma myxomatodes, nasopharyngeal carcinoma, oat cell carcinoma, carcinoma ossificans, osteoid carcinoma, papillary carcinoma, periportal carcinoma, preinvasive carcinoma, prickle cell carcinoma, pultaceous carcinoma, renal cell carcinoma of kidney, reserve cell carcinoma, carcinoma sarcomatodes, schneiderian carcinoma, scirrhous carcinoma, carcinoma scroti, signet-ring cell carcinoma, carcinoma simplex, small-cell carcinoma, solanoid carcinoma, spheroidal cell carcinoma, spindle cell carcinoma, carcinoma spongiosum, squamous carcinoma, squamous cell carcinoma, string carcinoma, carcinoma telangiectaticum, carcinoma telangiectodes, transitional cell carcinoma, carcinoma tuberosum, tuberous carcinoma, verrucous carcinoma, or carcinoma villosum.

[0123] The terms "treating" or "treatment" refer to any indicia of success in the therapy or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient's physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation. The term "treating" and conjugations thereof, may include prevention of an injury, pathology, condition, or disease. In embodiments, treating is preventing. In embodiments, treating does not include preventing.

[0124] "Treating" or "treatment" as used herein (and as well-understood in the art) also broadly includes any approach for obtaining beneficial or desired results in a subject's condition, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of the extent of a disease, stabilizing (*i.e.*, not worsening) the state of disease, prevention of a disease's transmission or spread, delay or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission, whether partial or total and whether detectable or undetectable. In other words, "treatment" as used herein includes any cure, amelioration, or prevention of a disease. Treatment may prevent the disease from occurring; inhibit the disease's spread; relieve the disease's symptoms (*e.g.*, ocular pain, seeing

halos around lights, red eye, very high intraocular pressure), fully or partially remove the disease's underlying cause, shorten a disease's duration, or do a combination of these things.

[0125] "Treating" and "treatment" as used herein include prophylactic treatment. Treatment methods include administering to a subject a therapeutically effective amount of a compound described herein. The administering step may consist of a single administration or may include a series of administrations. The length of the treatment period depends on a variety of factors, such as the severity of the condition, the age of the patient, the concentration of the compound, the activity of the compositions used in the treatment, or a combination thereof. It will also be appreciated that the effective dosage of an agent used for the treatment or prophylaxis may increase or decrease over the course of a particular treatment or prophylaxis regime. Changes in dosage may result and become apparent by standard diagnostic assays known in the art. In some instances, chronic administration may be required. For example, the compositions are administered to the subject in an amount and for a duration sufficient to treat the patient.

[0126] The term "prevent" refers to a decrease in the occurrence of disease symptoms in a patient. As indicated above, the prevention may be complete (no detectable symptoms) or partial, such that fewer symptoms are observed than would likely occur absent treatment. In embodiments, prevent refers to slowing the progression of the disease, disorder or condition or inhibiting progression thereof to a harmful or otherwise undesired state.

[0127] "Patient" or "subject in need thereof" refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a pharmaceutical composition as provided herein. Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals. In some embodiments, a patient is human.

[0128] An "effective amount" is an amount sufficient for a compound to accomplish a stated purpose relative to the absence of the compound (e.g., achieve the effect for which it is administered, treat a disease, reduce enzyme activity, increase enzyme activity, reduce a signaling pathway, or reduce one or more symptoms of a disease or condition). An example of an "effective amount" is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which could also be referred to as a "therapeutically effective amount." A "reduction" of a symptom or symptoms (and grammatical equivalents of this phrase) means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s). A "prophylactically effective amount" of a drug is an amount of a drug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology or condition, or reducing the likelihood of the onset (or reoccurrence) of an injury, disease, pathology, or

condition, or their symptoms. The full prophylactic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a prophylactically effective amount may be administered in one or more administrations. An "activity decreasing amount," as used herein, refers to an amount of antagonist required to decrease the activity of an enzyme relative to the absence of the antagonist. A "function disrupting amount," as used herein, refers to the amount of antagonist required to disrupt the function of an enzyme or protein relative to the absence of the antagonist. The exact amounts will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (*see, e.g.*, Lieberman, *Pharmaceutical Dosage Forms* (vols. 1-3, 1992); Lloyd, *The Art, Science and Technology of Pharmaceutical Compounding* (1999); Pickar, *Dosage Calculations* (1999); and *Remington: The Science and Practice of Pharmacy*, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins). The therapeutically effective amount can be ascertained by measuring relevant physiological effects, and it can be adjusted in connection with the dosing regimen and diagnostic analysis of the subject's condition, and the like. By way of example, measurement of the serum level of a CRF1 inhibitor (or, e.g., a metabolite thereof) at a particular time post-administration may be indicative of whether a therapeutically effective amount has been administered.

[0129] For any compound described herein, the therapeutically effective amount can be initially determined from cell culture assays. Target concentrations will be those concentrations of active compound(s) that are capable of achieving the methods described herein, as measured using the methods described herein or known in the art.

[0130] Therapeutically effective amounts for use in humans can also be determined from animal models. For example, a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals. The dosage in humans can be adjusted by monitoring compounds effectiveness and adjusting the dosage upwards or downwards, as described above. Adjusting the dose to achieve maximal efficacy in humans based on the methods described above and other methods is well within the capabilities of the ordinarily skilled artisan. Adjusting the dose to achieve maximal therapeutic window efficacy or toxicity in humans based on the methods described above and other methods is well within the capabilities of the ordinarily skilled artisan.

[0131] The term "therapeutically effective amount," as used herein, refers to that amount of the therapeutic agent sufficient to ameliorate the disorder, as described above. For example, for the given parameter, a therapeutically effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Therapeutic efficacy can also be expressed as "-fold" increase or decrease. For example, a therapeutically

effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control.

[0132] The terms "QD," "qd," and "q.d." refer to once a day, i.e., a drug or therapeutic agent is administered once a day for the duration of the therapeutic regimen.

[0133] The terms "BD," "bd," and "b.i.d." refer to twice a day, i.e., a drug or therapeutic agent is administered two times a day for the duration of the therapeutic regimen.

[0134] The terms "QID," "qid," and "q.i.d." refer to three times a day, i.e., a drug or therapeutic agent is administered three times a day for the duration of the therapeutic regimen.

[0135] Dosages may be varied depending upon the requirements of the patient and the compound being employed. The dose administered to a patient, in the context of the present invention should be sufficient to effect a beneficial therapeutic response in the patient over time. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. Dosage amounts and intervals can be adjusted individually to provide levels of the administered compound effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.

[0136] As used herein, the term "administering" means oral administration, administration as a suppository, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intracranial, intranasal or subcutaneous administration, or the implantation of a slow-release device, *e.g.,* a mini-osmotic pump, to a subject. Administration is by any route, including parenteral and transmucosal (*e.g.,* buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, *e.g.,* intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, *etc.* By "co-administer" it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies (e.g. anti-cancer agent, chemotherapeutic, or treatment for a neurodegenerative disease). The compound of the invention can be administered alone or can be coadministered to the patient. Coadministration is meant to include simultaneous or sequential administration of the compound individually or in combination (more than one compound or agent). Thus, the preparations can also be combined, when desired, with other active substances (e.g. to reduce metabolic degradation). The compositions of the present invention can be

delivered by transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols. Oral preparations include tablets, pills, powder, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions. The compositions of the present invention may additionally include components to provide sustained release and/or comfort. Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Pat. Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes. The compositions of the present invention can also be delivered as microspheres for slow release in the body. For example, microspheres can be administered via intradermal injection of drug-containing microspheres, which slowly release subcutaneously (see Rao, *J. Biomater Sci. Polym. Ed.* 7:623-645, 1995; as biodegradable and injectable gel formulations (see, e.g., Gao *Pharm. Res.* 12:857-863, 1995); or, as microspheres for oral administration (see, e.g., Eyles, *J. Pharm. Pharmacol.* 49:669-674, 1997). In another embodiment, the formulations of the compositions of the present invention can be delivered by the use of liposomes which fuse with the cellular membrane or are endocytosed, *i.e.*, by employing receptor ligands attached to the liposome, that bind to surface membrane protein receptors of the cell resulting in endocytosis. By using liposomes, particularly where the liposome surface carries receptor ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the compositions of the present invention into the target cells in vivo. (See, *e.g.*, Al-Muhammed, *J. Microencapsul.* 13:293-306, 1996; Chonn, *Curr. Opin. Biotechnol.* 6:698-708, 1995; Ostro, *Am. J. Hosp. Pharm.* 46:1576-1587, 1989). The compositions of the present invention can also be delivered as nanoparticles.

[0137] By "co-administer" it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies. The compounds of the invention can be administered alone or can be coadministered to the patient. Coadministration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound). The compositions of the present invention can be delivered transdermally, by a topical route, or formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.

[0138] For any compound described herein, the therapeutically effective amount can be initially determined from cell culture assays. Target concentrations will be those concentrations of active compound(s) that are capable of achieving the methods described herein, as measured using the methods described herein or known in the art.

[0139] Utilizing the teachings provided herein, an effective prophylactic or therapeutic treatment regimen can be planned that does not cause substantial toxicity and yet is effective to treat the clinical symptoms demonstrated by the particular patient. This planning should involve the careful choice of active compound by considering factors such as compound potency, relative bioavailability, patient body weight, presence and severity of adverse side effects, preferred mode of administration and the toxicity profile of the selected agent.

[0140] The compounds described herein can be used in combination with one another, with other active agents known to be useful in treating cancer (e.g. colon cancer), cardiovascular disease, metabolic disease, immune or inflammatory disease or disorder.

[0141] In some embodiments, co-administration includes administering one active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, 24 hours, 2 days, 4 days, 1 week or 1 month of a second active agent. Co-administration includes administering two active agents simultaneously, approximately simultaneously (e.g., within about 1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order. In some embodiments, co-administration can be accomplished by co-formulation, i.e., preparing a single pharmaceutical composition including both active agents. In other embodiments, the active agents can be formulated separately. In another embodiment, the active and/or adjunctive agents may be linked or conjugated to one another. In some embodiments, the compounds described herein may be combined with treatments for cancer (e.g. colon cancer), cardiovascular disease, metabolic disease, immune or inflammatory disease or disorder.

[0142] The compounds described herein can be administered to treat a fertility disease or disorder and/or cancer. In this regard, the compounds disclosed herein may be administered either alone to treat such diseases or disorders or may be co-administered with another therapeutic agent to treat such diseases or disorders.

[0143] The compounds disclosed herein may be co-administered with an agonist or antagonist of CRF_1 function. The compounds described herein can be co-administered with conventional anti-cancer/chemotherapeutic.

[0144] "Anti-cancer agent" is used in accordance with its plain ordinary meaning and refers to a composition (e.g. compound, drug, antagonist, inhibitor, modulator) having antineoplastic properties or the ability to inhibit the growth or proliferation of cells. In some embodiments, an anti-cancer agent is a chemotherapeutic. In some embodiments, an anti-cancer agent is an agent

identified herein having utility in methods of treating cancer. In some embodiments, an anti-cancer agent is an agent approved by the FDA or similar regulatory agency of a country other than the USA, for treating cancer. Examples of anti-cancer agents include, but are not limited to, MEK (e.g. MEK1, MEK2, or MEK1 and MEK2) inhibitors (e.g. XL518, CI-1040, PD035901, selumetinib/ AZD6244, GSK1120212/ trametinib, GDC-0973, ARRY-162, ARRY-300, AZD8330, PD0325901, U0126, PD98059, TAK-733, PD318088, AS703026, BAY 869766), alkylating agents (*e.g.,* cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, meiphalan), ethylenimine and methylmelamines (e.g., hexamethlymelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin), triazenes (decarbazine)), anti-metabolites (*e.g.,* 5-azathioprine, leucovorin, capecitabine, fludarabine, gemcitabine, pemetrexed, raltitrexed, folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., fluorouracil, floxouridine, Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin), *etc.*), plant alkaloids (*e.g.,* vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel, docetaxel, *etc.*), topoisomerase inhibitors (*e.g.,* irinotecan, topotecan, amsacrine, etoposide (VP16), etoposide phosphate, teniposide, *etc.*), antitumor antibiotics (*e.g.,* doxorubicin, adriamycin, daunorubicin, epirubicin, actinomycin, bleomycin, mitomycin, mitoxantrone, plicamycin, *etc.*), platinum-based compounds (*e.g.* cisplatin, oxaloplatin, carboplatin), anthracenedione (e.g., mitoxantrone), substituted urea (e.g., hydroxyurea), methyl hydrazine derivative (e.g., procarbazine), adrenocortical suppressant (e.g., mitotane, aminoglutethimide), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), inhibitors of mitogen-activated protein kinase signaling (e.g. U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002, Syk inhibitors, mTOR inhibitors, antibodies (e.g., rituxan), gossyphol, genasense, polyphenol E, Chlorofusin, all trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2'-deoxycytidine, all trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (Gleevec.RTM.), geldanamycin, 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 11-7082, PKC412, PD184352, 20-epi-1, 25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense

oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9-dioxamycin; diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone;

miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylerie conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen-binding protein; sizofuran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem

cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; zinostatin stimalamer, Adriamycin, Dactinomycin, Bleomycin, Vinblastine, Cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; fluorocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; iimofosine; interleukin I1 (including recombinant interleukin II, or rlL.sub.2), interferon alfa-2a; interferon alfa-2b; interferon alfa-n1; interferon alfa-n3; interferon beta-1a; interferon gamma-1b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazoie; nogalamycin; ormaplatin; oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone

hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride, agents that arrest cells in the G2-M phases and/or modulate the formation or stability of microtubules, (e.g. Taxol.TM (i.e. paclitaxel), Taxotere.TM, compounds comprising the taxane skeleton, Erbulozole (i.e. R-55104), Dolastatin 10 (i.e. DLS-10 and NSC-376128), Mivobulin isethionate (i.e. as CI-980), Vincristine, NSC-639829, Discodermolide (i.e. as NVP-XX-A-296), ABT-751 (Abbott, i.e. E-7010), Altorhyrtins (e.g. Altorhyrtin A and Altorhyrtin C), Spongistatins (e.g. Spongistatin 1, Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and Spongistatin 9), Cemadotin hydrochloride (i.e. LU-103793 and NSC-D-669356), Epothilones (e.g. Epothilone A, Epothilone B, Epothilone C (i.e. desoxyepothilone A or dEpoA), Epothilone D (i.e. KOS-862, dEpoB, and desoxyepothilone B), Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone A N-oxide, 16-aza-epothilone B, 21-aminoepothilone B (i.e. BMS-310705), 21-hydroxyepothilone D (i.e. Desoxyepothilone F and dEpoF), 26-fluoroepothilone, Auristatin PE (i.e. NSC-654663), Soblidotin (i.e. TZT-1027), LS-4559-P (Pharmacia, i.e. LS-4577), LS-4578 (Pharmacia, i.e. LS-477-P), LS-4477 (Pharmacia), LS-4559 (Pharmacia), RPR-112378 (Aventis), Vincristine sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, i.e. WS-9885B), GS-164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy of Sciences), BSF-223651 (BASF, i.e. ILX-651 and LU-223651), SAH-49960 (Lilly/Novartis), SDZ-268970 (Lilly/Novartis), AM-97 (Armad/Kyowa Hakko), AM-132 (Armad), AM-138 (Armad/Kyowa Hakko), IDN-5005 (Indena), Cryptophycin 52 (i.e. LY-355703), AC-7739 (Ajinomoto, i.e. AVE-8063A and CS-39.HCl), AC-7700 (Ajinomoto, i.e. AVE-8062, AVE-8062A, CS-39-L-Ser.HCl, and RPR-258062A), Vitilevuamide, Tubulysin A, Canadensol, Centaureidin (i.e. NSC-106969), T-138067 (Tularik, i.e. T-67, TL-138067 and TI-138067), COBRA-1 (Parker Hughes Institute, i.e. DDE-261 and WHI-261), H10 (Kansas State University), H16 (Kansas State University), Oncocidin A1 (i.e. BTO-956 and DIME), DDE-313 (Parker Hughes Institute), Fijianolide B, Laulimalide, SPA-2 (Parker Hughes Institute), SPA-1 (Parker Hughes Institute, i.e. SPIKET-P), 3-IAABU (Cytoskeleton/Mt. Sinai School of Medicine, i.e. MF-569), Narcosine (also known as NSC-5366), Nascapine, D-24851 (Asta Medica), A-105972 (Abbott), Hemiasterlin, 3-BAABU (Cytoskeleton/Mt. Sinai School of Medicine, i.e. MF-191), TMPN (Arizona State University), Vanadocene acetylacetonate, T-138026 (Tularik), Monsatrol, Inanocine (i.e. NSC-698666), 3-IAABE (Cytoskeleton/Mt. Sinai

School of Medicine), A-204197 (Abbott), T-607 (Tuiarik, i.e. T-900607), RPR-115781 (Aventis), Eleutherobins (such as Desmethyleleutherobin, Desaetyleleutherobin, Isoeleutherobin A, and Z-Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, D-64131 (Asta Medica), D-68144 (Asta Medica), Diazonamide A, A-293620 (Abbott), NPI-2350 (Nereus), Taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott), Diozostatin, (-)-Phenylahistin (i.e. NSCL-96F037), D-68838 (Asta Medica), D-68836 (Asta Medica), Myoseverin B, D-43411 (Zentaris, i.e. D-81862), A-289099 (Abbott), A-318315 (Abbott), HTI-286 (i.e. SPA-110, trifluoroacetate salt) (Wyeth), D-82317 (Zentaris), D-82318 (Zentaris), SC-12983 (NCI), Resverastatin phosphate sodium, BPR-OY-007 (National Health Research Institutes), and SSR-250411 (Sanofi)), steroids (*e.g.,* dexamethasone), finasteride, aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRH) such as goserelin or leuprolide, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethlystilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogen (e.g., flutamide), immunostimulants (*e.g.,* Bacillus Calmette-Guérin (BCG), levamisole, interleukin-2, alpha-interferon, *etc.*), monoclonal antibodies (*e.g.,* anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR, and anti-VEGF monoclonal antibodies), immunotoxins (*e.g.,* anti-CD33 monoclonal antibody-calicheamicin conjugate, anti-CD22 monoclonal antibody-pseudomonas exotoxin conjugate, *etc.*), radioimmunotherapy (*e.g.,* anti-CD20 monoclonal antibody conjugated to ^{111}In, ^{90}Y, or ^{131}I, *etc.*), triptolide, homoharringtonine, dactinomycin, doxorubicin, epirubicin, topotecan, itraconazole, vindesine, cerivastatin, vincristine, deoxyadenosine, sertraline, pitavastatin, irinotecan, clofazimine, 5-nonyloxytryptamine, vemurafenib, dabrafenib, erlotinib, gefitinib, EGFR inhibitors, epidermal growth factor receptor (EGFR)-targeted therapy or therapeutic (e.g. gefitinib (Iressa ™), erlotinib (Tarceva ™), cetuximab (Erbitux™), lapatinib (Tykerb™), panitumumab (Vectibix™), vandetanib (Caprelsa™), afatinib/BIBW2992, CI-1033/canertinib, neratinib/HKI-272, CP-724714, TAK-285, AST-1306, ARRY334543, ARRY-380, AG-1478, dacomitinib/PF299804, OSI-420/desmethyl erlotinib, AZD8931, AEE788, pelitinib/EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626), sorafenib, imatinib, sunitinib, dasatinib, or the like.

[0145] "Chemotherapeutic" or "chemotherapeutic agent" is used in accordance with its plain ordinary meaning and refers to a chemical composition or compound having antineoplastic properties or the ability to inhibit the growth or proliferation of cells.

[0146] The compounds disclosed herein may be co-administered with an antiproliferative/antineoplastic drug or a combination thereof, as used in medical oncology, such as an alkylating agent (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard,

melphalan, chlorambucil, busulphan or a nitrosourea); an antimetabolite (for example an antifolate such as a fluoropyrimidine like 5-fluorouracil or tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, gemcitabine or paclitaxel); an antitumour antibiotic (for example an anthracycline such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin or mithramycin); an antimitotic agent (for example a vinca alkaloid such as vincristine, vinblastine, vindesine or vinorelbine, or a taxoid such as taxol or taxotere); or a topoisomerase inhibitor (for example an epipodophyllotoxin such as etoposide, teniposide, amsacrine, topotecan or a camptothecin); (ii) a cytostatic agent such as an antioestrogen (for example tamoxifen, toremifene, raloxifene, droloxifene or iodoxyfene), an oestrogen receptor down regulator (for example fulvestrant), an antiandrogen (for example bicalutamide, flutamide, nilutamide or cyproterone acetate), a LHRH antagonist or LHRH agonist (for example goserelin, leuprorelin or buserelin), a progestogen (for example megestrol acetate), an aromatase inhibitor (for example as anastrozole, letrozole, vorazole or exemestane) or an inhibitor of 5.alpha.-reductase such as finasteride; (iii) an agent which inhibits cancer cell invasion (for example a metalloproteinase inhibitor like marimastat or an inhibitor of urokinase plasminogen activator receptor function); (iv) an inhibitor of growth factor function, for example: a growth factor antibody (for example the anti-erbb2 antibody trastuzumab, or the anti-erbb1 antibody cetuximab [C225]), a farnesyl transferase inhibitor, a tyrosine kinase inhibitor or a serine/threonine kinase inhibitor, an inhibitor of the epidermal growth factor family (for example an EGFR family tyrosine kinase inhibitor such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazoli- n-4-amine (gefitinib, AZD 1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) or 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazoli- n-4-amine (CI 1033)), an inhibitor of the platelet-derived growth factor family, or an inhibitor of the hepatocyte growth factor family; (v) an antiangiogenic agent such as one which inhibits the effects of vascular endothelial growth factor (for example the anti-vascular endothelial cell growth factor antibody bevacizumab, a compound disclosed in WO 97/22596, WO 97/30035, WO 97/32856 or WO 98/13354), or a compound that works by another mechanism (for example linomide, an inhibitor of integrin .alpha.v.beta.3 function or an angiostatin); (vi) a vascular damaging agent such as combretastatin A4, or a compound disclosed in WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 or WO 02/08213; (vii) an agent used in antisense therapy, for example one directed to one of the targets listed above, such as ISIS 2503, an anti-ras antisense; (viii) an agent used in a gene therapy approach, for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a

bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; or (ix) an agent used in an immunotherapeutic approach, for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.

[0147] In embodiments, the compounds disclosed herein can be co-administered with an antibody, such as a monoclonal antibody targeting B-Lymphocytes (such as CD20 (rituximab), MRA-alL16R and T-Lymphocytes, CTLA4-Ig, HuMax I1-15) or antibody modulating Ig function such as anti-IgE (for example omalizumab).

[0148] In embodiments, treatment of cancer includes administration of an effective amount of at least two of the following: a CRF1 inhibitor, an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4, an agonistic antibody of CD137 (4-1BB). In some embodiments, the method may comprise the use of two or more combinations.

[0149] In a further embodiment, the compounds described herein can be co-administered with conventional radiotherapeutic agents including, but not limited to, radionuclides such as ^{47}Sc, ^{64}Cu, ^{67}Cu, ^{89}Sr, ^{86}Y, ^{87}Y, ^{90}Y, ^{105}Rh, ^{111}Ag, ^{111}In, ^{117m}Sn, ^{149}Pm, ^{153}Sm, ^{166}Ho, ^{177}Lu, ^{186}Re, ^{188}Re, ^{211}At, and ^{212}Bi, optionally conjugated to antibodies directed against tumor antigens.

[0150] In addition, a CRF_1 inhibitor may be combined with the therapeutic administration of immune cells, sometimes referred to as adoptive cell transfer. These cells may be cells from the patient, a genetically related or unrelated donor, they may be genetically modified (e.g. CAR-T cells, NK cells, etc), cell lines, genetically modified cell lines and live or dead versions of the above. CRF1 inhibitors may also be combined with vaccines of any kind (e.g. protein/peptide, viral, bacterial, cellular) to stimulate immune responses to cancer.

[0151] The CRF_1 inhibitors/CRF_1 antagonists disclosed herein can be administered by any acceptable route, such oral, intraadiposal, intraarterial, intraarticular, intracranial, intradermal, intralesional, intramusculay, intranasal, intraocularal, intrapericardial, intraperitoneal, intrapleural, intraprostatical, intrarectal, intrathecal, intratracheal, intratumoral, intraumbilical, intravaginal, intravenousl, intravesicullar, intravitreal, liposomal, local, mucosal, parenteral, rectal, subconjunctival, subcutaneous, sublingual, topical, transbuccal, transdermal, vaginal, in cremes, in lipid compositions, via a catheter, via a lavage, via continuous infusion, via infusion, via inhalation, via injection, via local delivery, via localized perfusion, bathing target cells directly, or any combination thereof.

[0152] The CRF_1 inhibitors/CRF_1 antagonists disclosed herein can be administered by any acceptable route, such oral, intraadiposal, intraarterial, intraarticular, intracranial, intradermal, intralesional, intramusculay, intranasal, intraocularal, intrapericardial, intraperitoneal, intrapleural, intraprostatical, intrarectal, intrathecal, intratracheal, intratumoral, intraumbilical, intravaginal, intravenousl, intravesicullar, intravitreal, liposomal, local, mucosal, parenteral, rectal, subconjunctival, subcutaneous, sublingual, topical, transbuccal, transdermal, vaginal, in cremes, in lipid compositions, via a catheter, via a lavage, via continuous infusion, via infusion, via inhalation, via injection, via local delivery, via localized perfusion, bathing target cells directly, or any combination thereof.

[0153] The CRF_1 inhibitors/CRF_1 antagonists disclosed herein may be administered once daily until study reached endpoint. The CRF_1 inhibitors/CRF_1 antagonists disclosed herein may be administered at least three times but in some studies four or more times depending on the length of the study and/or the design of the study.

[0154] The methods disclosed herein may be used in combination with additional cancer therapy. In some embodiments, the distinct cancer therapy comprises surgery, radiotherapy, chemotherapy, toxin therapy, immunotherapy, cryotherapy or gene therapy. In some embodiments, the cancer is a chemotherapy-resistant or radio-resistant cancer.

[0155] A "cell" as used herein, refers to a cell carrying out metabolic or other function sufficient to preserve or replicate its genomic DNA. A cell can be identified by well-known methods in the art including, for example, presence of an intact membrane, staining by a particular dye, ability to produce progeny or, in the case of a gamete, ability to combine with a second gamete to produce a viable offspring. Cells may include prokaryotic and eukaroytic cells. Prokaryotic cells include but are not limited to bacteria. Eukaryotic cells include but are not limited to yeast cells and cells derived from plants and animals, for example mammalian, insect (*e.g.*, spodoptera) and human cells. Cells may be useful when they are naturally nonadherent or have been treated not to adhere to surfaces, for example by trypsinization.

[0156] "Control" or "control experiment" is used in accordance with its plain ordinary meaning and refers to an experiment in which the subjects or reagents of the experiment are treated as in a parallel experiment except for omission of a procedure, reagent, or variable of the experiment. In some instances, the control is used as a standard of comparison in evaluating experimental effects. In some embodiments, a control is the measurement of the activity of a protein in the absence of a compound as described herein (including embodiments and examples).

[0157] The term "modulator" refers to a composition that increases or decreases the level of a target molecule or the function of a target molecule or the physical state of the target of the molecule. In some embodiments, a CRF1 associated disease modulator is a compound that

reduces the severity of one or more symptoms of a disease associated with CRF_1 (e.g. an endocrine disorder, a cancer including but not limited to TART or OART). A CRF_1 modulator is a compound that increases or decreases the activity or function or level of activity or level of function of CRF_1. A modulator may act alone, or it may use a cofactor, e.g., a protein, metal ion, or small molecule. Examples of modulators include small molecule compounds and other bioorganic molecules. Numerous libraries of small molecule compounds (e.g., combinatorial libraries) are commercially available and can serve as a starting point for identifying a modulator. The skilled artisan is able to develop one or more assays (e.g., biochemical or cell-based assays) in which such compound libraries can be screened in order to identify one or more compounds having the desired properties; thereafter, the skilled medicinal chemist is able to optimize such one or more compounds by, for example, synthesizing and evaluating analogs and derivatives thereof. Synthetic and/or molecular modeling studies can also be utilized in the identification of an activator.

[0158] The term "modulate" is used in accordance with its plain ordinary meaning and refers to the act of changing or varying one or more properties. "Modulation" refers to the process of changing or varying one or more properties. For example, as applied to the effects of a modulator on a target protein, to modulate means to change by increasing or decreasing a property or function of the target molecule or the amount of the target molecule. In embodiments, the terms "modulate", "modulation" and the like refer to the ability of a molecule (e.g., an activator or an inhibitor) to increase or decrease the function or activity of CRF_1, either directly or indirectly, relative to the absence of the molecule.

[0159] The term "associated" or "associated with" in the context of a substance or substance activity or function associated with a disease (e.g. a protein associated disease, an endocrine disorder, a disease associated with CRF_1 activity, a CRF_1 associated disease (e.g., testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART)) means that the disease (e.g., testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART)) is caused by (in whole or in part), or a symptom of the disease is caused by (in whole or in part) the substance or substance activity or function. For example, an endocrine disorder associated with CRF_1 activity or function may be an endocrine disorder that results (entirely or partially) from aberrant CRF_1 function (e.g. enzyme activity, protein-protein interaction, signaling pathway) or an endocrine disorder wherein a particular symptom of the disease is caused (entirely or partially) by aberrant CRF_1 activity or function. As used herein, what is described as being associated with a disease, if a causative agent, could be a target for treatment of the disease. For example, an endocrine disorder associated with CRF_1 activity or function or a CRF_1 associated disease (e.g., an endocrine disorder including but not limited to TART or OART), may be treated with a

compound described herein (e.g., CRF_1 modulator, CRF_1 inhibitor, or CRF_1 antagonist), in the instance where increased CRF_1 activity or function (e.g. signaling pathway activity) causes the disease (e.g., an endocrine disorder such as TART or OART). For example, an endocrine disorder associated with CRF_1 activity or function or a CRF_1 associated endocrine disorder, may be treated with an CRF_1 modulator or CRF_1 inhibitor, in the instance where increased CRF_1 activity or function (e.g. signaling pathway activity) causes the disease.

[0160] The term "aberrant" as used herein refers to different from normal. When used to describe enzymatic activity or protein function, aberrant refers to activity or function that is greater or less than a normal control or the average of normal non-diseased control samples. Aberrant activity may refer to an amount of activity that results in a disease, wherein returning the aberrant activity to a normal or non-disease-associated amount (e.g. by administering a compound or using a method as described herein), results in reduction of the disease or one or more disease symptoms.

[0161] The term "signaling pathway" as used herein refers to a series of interactions between cellular and optionally extra-cellular components (e.g. proteins, nucleic acids, small molecules, ions, lipids) that conveys a change in one component to one or more other components, which in turn may convey a change to additional components, which is optionally propogated to other signaling pathway components. For example, binding of a CRF_1 with a compound as described herein may reduce the level of a product of the CRF_1 catalyzed reaction or the level of a downstream derivative of the product or binding may reduce the interactions between the CRF_1 or a reaction product and downstream effectors or signaling pathway components (e.g., MAP kinase pathway), resulting in changes in cell growth, proliferation, or survival.

[0162] As used herein, the terms "corticotropin-releasing factor type-1," "CRF_1," "corticotropin-releasing hormone receptor 1," and "CHHR1" and all other related art-accepted terms, many of which are set forth below, refer to a compound capable of modulating, either directly or indirectly, the CRF_1 receptor in an *in vitro* assay, an *in vivo* model, and/or other means indicative of therapeutic efficacy. The terms also refer to a compound that exhibits at least some therapeutic benefit in a human subject.

[0163] The phrase "in a sufficient amount to effect a change" means that there is a detectable difference between a level of an indicator measured before (e.g., a baseline level) and after administration of a particular therapy. Indicators include any objective parameter (e.g., serum concentration) or subjective parameter (e.g., a subject's feeling of well-being).

[0164] The "activity" of a molecule may describe or refer to the binding of the molecule to a ligand or to a receptor; to catalytic activity; to the ability to stimulate gene expression or cell signaling, differentiation, or maturation; to antigenic activity; to the modulation of activities of

other molecules; and the like. The term "proliferative activity" encompasses an activity that promotes, that is necessary for, or that is specifically associated with, for example, normal cell division, as well as cancer, tumors, dysplasia, cell transformation, metastasis, and angiogenesis.

[0165] "Substantially pure" indicates that a component makes up greater than about 50% of the total content of the composition, and typically greater than about 60% of the total polypeptide content. More typically, "substantially pure" refers to compositions in which at least 75%, at least 85%, at least 90% or more of the total composition is the component of interest. In some cases, the polypeptide will make up greater than about 90%, or greater than about 95% of the total content of the composition (percentage in a weight per weight basis).

[0166] The terms "specifically binds" and "selectively binds," when referring to a ligand/receptor, antibody/antigen, or other binding pair, indicates a binding reaction which is determinative of the presence of the protein in a heterogeneous population of proteins and other biologics. Thus, under designated conditions, a specified ligand binds to a particular receptor and does not bind in a significant amount to other proteins present in the sample. The antibody, or binding composition derived from the antigen-binding site of an antibody, of the contemplated method binds to its antigen, or a variant or mutein thereof, with an affinity that is at least two-fold greater, at least 10-times greater, at least 20-times greater, or at least 100-times greater than the affinity with any other antibody, or binding composition derived therefrom. In embodiments, the antibody will have an affinity that is greater than about 10^9 liters/mol, as determined by, e.g., Scatchard analysis (Munsen, et al. (1980) Analyt. Biochem. 107:220-239).

[0167] The terms "DNA," "nucleic acid," "nucleic acid molecule," "polynucleotide" and the like are used interchangeably herein to refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Non-limiting examples of polynucleotides include linear and circular nucleic acids, messenger RNA (mRNA), complementary DNA (cDNA), recombinant polynucleotides, vectors, probes, primers and the like.


[0168] As used herein, the terms "variants" and "homologs" are used interchangeably to refer to amino acid or nucleic acid sequences that are similar to reference amino acid or nucleic acid sequences, respectively. The term encompasses naturally-occurring variants and non-naturally-occurring variants. Naturally-occurring variants include homologs (polypeptides and nucleic acids that differ in amino acid or nucleotide sequence, respectively, from one species to another), and allelic variants (polypeptides and nucleic acids that differ in amino acid or nucleotide sequence, respectively, from one individual to another within a species). Thus, variants and homologs encompass naturally occurring amino acid and nucleic acid sequences encoded thereby and their isoforms, as well as splice variants of a protein or gene. The terms also





encompass nucleic acid sequences that vary in one or more bases from a naturally-occurring nucleic acid sequence but still translate into an amino acid sequence that corresponds to the naturally-occurring protein due to degeneracy of the genetic code. Non-naturally-occurring variants and homologs include polypeptides and nucleic acids that comprise a change in amino acid or nucleotide sequence, respectively, where the change in sequence is artificially introduced (e.g., muteins); for example, the change is generated in the laboratory by human intervention ("hand of man"). Therefore, non-naturally occurring variants and homologs may also refer to those that differ from the naturally-occurring sequences by one or more conservative substitutions and/or tags and/or conjugates.

[0169] The term "muteins" as used herein refers broadly to mutated recombinant proteins. These proteins usually carry single or multiple amino acid substitutions and are frequently derived from cloned genes that have been subjected to site-directed or random mutagenesis, or from completely synthetic genes.

II. Compounds


[0170] In an aspect provided herein, is a compound of Formula (I):




, or a pharmaceutically acceptable salt thereof. R^1 and R^2 are independently ethyl or n-propyl. R^3 is hydrogen, Cl, Br, methyl, trifluoromethyl, or methoxy. R^4 is hydrogen, Br, R^aR^bN–, methoxymethyl, n-butyl, acetamido, pyridin-4-yl, morpholin-4-yl,  ,  ,  , or  . R^a and R^b are independently hydrogen, C_1-C_3alkyl, $H_2NCH_2CH_2$–, $(CH_3)_3COC(O)NHCH_2CH_2$–, or $CH_3CH_2CH_2NHCH_2CH_2$–In embodiments, the inhibitor forms an irreversible bond with the amino acid residue. In embodiments, the bond is a covalent bond.


[0171] In certain embodiments, R^3 is Cl, Br, methyl, or trifluoromethyl.

[0172] In certain embodiments, R^3 is Cl, Br, or methyl.


[0173] In certain embodiments, R^4 is Br, R^aR^bN–, pyridin-4-yl, morpholin-4-yl, or  .

[0174] In certain embodiments, R^4 is morpholin-4-yl or  .


[0175] In certain embodiments, R^4 is hydrogen, Br, R^aR^bN– and R^a and R^b are independently C_1-C_3alkyl.

[0176] In certain embodiments, the compound is  , or a pharmaceutically acceptable salt thereof.

[0177] In certain embodiments, the compound is

 , or a pharmaceutically acceptable salt thereof.

[0178] In certain embodiments, the compound is

 , or a pharmaceutically acceptable salt thereof.

[0179] In one aspect described herein, there is a method of treating a subject in need thereof comprising administering an astressin or a pharmaceutically acceptable salt or solvate thereof. An astressin generally refers to a nonselective corticotropin releasing hormone antagonist that reduces the synthesis of ACTH and cortisol.

[0180] In one aspect described herein, there is a method of treating congenital adrenal hyperplasia (CAH) in a subject in need thereof, comprising administering an astressin or a variant having at least about 70% identity thereto or a pharmaceutically acceptable salt or solvate thereof. In one aspect described herein, there is a method of treating congenital adrenal hyperplasia (CAH) in a subject in need thereof, the method comprising: (i) measuring a hormone

level in the subject in need thereof; (ii) administering an astressin or a variant having at least about 70% identity thereto, or a pharmaceutically acceptable salt or solvate thereof; and repeating steps (i) and (ii) until the hormone level reaches a pre-determined range followed by a maintenance therapy of a daily dosing of said astressin.

[0181] In one aspect described herein, there is a method of improving hyperandrogenic symptoms in a subject in need thereof, comprising administering an astressin or a variant having at least about 70% identity thereto, or a pharmaceutically acceptable salt or solvate thereof. In one aspect described herein, there is a method of treating menstrual irregularity, ovulatory dysfunction or infertility, in a subject in need thereof, comprising administering an astressin or a variant having at least about 70% identity thereto, or a pharmaceutically acceptable salt or solvate thereof. In one aspect described herein, there is a method of improving metabolic symptoms in a subject in need thereof, comprising administering an astressin or a variant having at least about 70% identity thereto; or a pharmaceutically acceptable salt or solvate thereof.

[0182] In one aspect described herein, there is a method of improving quality of life in a subject in need thereof, comprising administering an astressin or a variant having at least about 70% identity thereto, or a pharmaceutically acceptable salt or solvate thereof.

III. Pharmaceutical Compositions

[0183] In an aspect, there is provided a pharmaceutical composition, including a compound as described herein, including embodiments, or the structural Formula (I), and a pharmaceutically acceptable excipient.

[0184] The compounds (e.g., CRF_1 inhibitors/antagonists) of the present disclosure may be in the form of compositions suitable for administration to a subject. In general, such compositions are "pharmaceutical compositions" comprising a compound (e.g., CRF_1 inhibitor(s)/ antagonist(s)) and one or more pharmaceutically acceptable or physiologically acceptable diluents, carriers or excipients. In certain embodiments, the compound (e.g., CRF_1 inhibitor/antagonist) are present in a therapeutically acceptable amount. The pharmaceutical compositions may be used in the methods of the present disclosure; thus, for example, the pharmaceutical compositions can be administered *ex vivo* or *in vivo* to a subject in order to practice the therapeutic and prophylactic methods and uses described herein.

[0185] In one aspect described herein, there is a pharmaceutical composition in the form of a capsule comprising an astressin or a variant having at least about 70% identity thereto, or a pharmaceutically acceptable salt or solvate thereof. In one aspect described herein, there is a pharmaceutical composition in the form of a tablet comprising an astressin or a variant having at least about 70% identity thereto, or a pharmaceutically acceptable salt or solvate thereof.

[0186] The pharmaceutical compositions of the present disclosure can be formulated to be compatible with the intended method or route of administration; exemplary routes of administration are set forth herein.

[0187] The pharmaceutical compositions containing the active ingredient (e.g., an inhibitor of CRF_1 function) may be in a form suitable for oral use, for example, as tablets, capsules, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups, solutions, microbeads or elixirs. Pharmaceutical compositions intended for oral use may be prepared for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents such as, for example, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets, capsules and the like contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture thereof. These excipients may be, for example, diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.

[0188] The tablets, capsules and the like suitable for oral administration may be uncoated or coated to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action. For example, a time-delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated to form osmotic therapeutic tablets for controlled release. Additional agents include biodegradable or biocompatible particles or a polymeric substance such as polyesters, polyamine acids, hydrogel, polyvinyl pyrrolidone, polyanhydrides, polyglycolic acid, ethylene-vinylacetate, methylcellulose, carboxymethylcellulose, protamine sulfate, or lactide/glycolide copolymers, polylactide/glycolide copolymers, or ethylenevinylacetate copolymers in order to control delivery of an administered composition. For example, the oral agent can be entrapped in microcapsules prepared by coacervation techniques or by interfacial polymerization, by the use of hydroxymethylcellulose or gelatin-microcapsules or poly(methylmethacrolate) microcapsules, respectively, or in a colloid drug delivery system. Colloidal dispersion systems include macromolecule complexes, nano-capsules, microspheres, microbeads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes. Methods for the preparation of the above-mentioned formulations will be apparent to those skilled in the art.

[0189] Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium

phosphate, kaolin or microcrystalline cellulose, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

[0190] Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture thereof. Such excipients can be suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents, for example a naturally-occurring phosphatide (e.g., lecithin), or condensation products of an alkylene oxide with fatty acids (e.g., polyoxy-ethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols (e.g., for heptadecaethyleneoxycetanol), or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol (e.g., polyoxyethylene sorbitol monooleate), or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides (e.g., polyethylene sorbitan monooleate). The aqueous suspensions may also contain one or more preservatives.

[0191] Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.

[0192] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, and optionally one or more suspending agents and/or preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified herein.

[0193] The pharmaceutical compositions of the present disclosure may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example, liquid paraffin, or mixtures of these. Suitable emulsifying agents may be naturally occurring gums, for example, gum acacia or gum tragacanth; naturally occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids; hexitol anhydrides, for example, sorbitan monooleate; and condensation products of partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate.

[0194] The pharmaceutical compositions typically comprise a therapeutically effective amount of a CRF_1 inhibitor/antagonist contemplated by the present disclosure and one or more pharmaceutically and physiologically acceptable formulation agents. Suitable pharmaceutically acceptable or physiologically acceptable diluents, carriers or excipients include, but are not limited to, antioxidants (e.g., ascorbic acid and sodium bisulfate), preservatives (e.g., benzyl

alcohol, methyl parabens, ethyl or n-propyl, p-hydroxybenzoate), emulsifying agents, suspending agents, dispersing agents, solvents, fillers, bulking agents, detergents, buffers, vehicles, diluents, and/or adjuvants. For example, a suitable vehicle may be physiological saline solution or citrate-buffered saline, possibly supplemented with other materials common in pharmaceutical compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. Those skilled in the art will readily recognize a variety of buffers that can be used in the pharmaceutical compositions and dosage forms contemplated herein. Typical buffers include, but are not limited to, pharmaceutically acceptable weak acids, weak bases, or mixtures thereof. As an example, the buffer components can be water soluble materials such as phosphoric acid, tartaric acids, lactic acid, succinic acid, citric acid, acetic acid, ascorbic acid, aspartic acid, glutamic acid, and salts thereof. Acceptable buffering agents include, for example, a Tris buffer; N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES); 2-(N-Morpholino)ethanesulfonic acid (MES); 2-(N-Morpholino)ethanesulfonic acid sodium salt (MES); 3-(N-Morpholino)propanesulfonic acid (MOPS); and N-tris[Hydroxymethyl]methyl-3-aminopropanesulfonic acid (TAPS).

[0195] After a pharmaceutical composition has been formulated, it may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder. Such formulations may be stored either in a ready-to-use form, a lyophilized form requiring reconstitution prior to use, a liquid form requiring dilution prior to use, or other acceptable form. In some embodiments, the pharmaceutical composition is provided in a single-use container (e.g., a single-use vial, ampule, syringe, or autoinjector (similar to, e.g., an EpiPen®)), whereas a multi-use container (e.g., a multi-use vial) is provided in other embodiments.

[0196] Formulations can also include carriers to protect the composition against rapid degradation or elimination from the body, such as a controlled release formulation, including liposomes, hydrogels, prodrugs and microencapsulated delivery systems. For example, a time-delay material such as glyceryl monostearate or glyceryl stearate alone, or in combination with a wax, may be employed. Any drug delivery apparatus may be used to deliver a CRF_1 inhibitor/antagonist, including implants (e.g., implantable pumps) and catheter systems, slow injection pumps and devices, all of which are well known to the skilled artisan.

[0197] Depot injections, which are generally administered subcutaneously or intramuscularly, may also be utilized to release the compound (e.g., CRF_1 inhibitor/antagonist) disclosed herein over a defined period of time. Depot injections are usually either solid- or oil-based and generally comprise at least one of the formulation components set forth herein. One of ordinary skill in the art is familiar with possible formulations and uses of depot injections.

[0198] The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents mentioned herein. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Acceptable diluents, solvents and dispersion media that may be employed include water, Ringer's solution, isotonic sodium chloride solution, Cremophor® EL (BASF, Parsippany, NJ) or phosphate buffered saline (PBS), ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. In addition, sterile fixed oils are conventionally employed as a solvent or suspending medium; for this purpose, any bland fixed oil may be employed, including synthetic mono- or diglycerides. Moreover, fatty acids, such as oleic acid, find use in the preparation of injectables. Prolonged absorption of particular injectable formulations can be achieved by including an agent that delays absorption (e.g., aluminum monostearate or gelatin).

[0199] The present disclosure contemplates the administration of the compound (e.g., CRF_1 inhibitor/antagonist) in the form of suppositories for rectal administration. The suppositories can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include, but are not limited to, cocoa butter and polyethylene glycols.

[0200] The compound (e.g., CRF_1 inhibitor/antagonist) contemplated by the present disclosure may be in the form of any other suitable pharmaceutical composition (e.g., sprays for nasal or inhalation use) currently known or developed in the future.

IV. Methods

[0201] In certain embodiments, provided herein are methods for treating or preventing a disease comprising administering an effective amount of a compound of Formula (I), or an isotopic variant thereof or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[0202] In one embodiment, provided herein are methods for treating or preventing a tumor, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for treating or preventing a benign tumor, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for treating or preventing a malignant tumor, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for treating or preventing an adrenal

tumor, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for treating or preventing an adrenal rest tumor, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[0203] In one embodiment, provided herein are methods for treating or preventing infertility, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for treating or preventing male infertility, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for improving or increasing sperm count, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for improving or increasing sperm motility, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for improving or increasing sperm morphology, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, provided herein are methods for treating or preventing female infertility, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

[0204] In one embodiment, provided herein are methods for treating or preventing a proliferative or hyperproliferative disease or disorder, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, the proliferative disease is cancer. In certain embodiments, the proliferative disease is a cancer of the breast, skin, prostate, cervix, uterus, ovary, testes, bladder, lung, liver, larynx, oral cavity, colon and gastrointestinal tract (e.g., esophagus, stomach, pancreas), brain, thyroid, blood, and lymphatic system.

[0205] In certain embodiments, the cancer treatable with the methods provided herein includes, but is not limited to, (1) leukemias, including, but not limited to, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemias such as myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia leukemias and myelodysplastic syndrome or a symptom thereof (such as anemia, thrombocytopenia, neutropenia, bicytopenia or pancytopenia), refractory anemia (RA), RA with ringed sideroblasts (RARS), RA with excess blasts (RAEB),

RAEB in transformation (RAEB-T), preleukemia, and chronic myelomonocytic leukemia (CMML), (2) chronic leukemias, including, but not limited to, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, and hairy cell leukemia; (3) polycythemia vera; (4) lymphomas, including, but not limited to, Hodgkin's disease and non-Hodgkin's disease; (5) multiple myelomas, including, but not limited to, smoldering multiple myeloma, nonsecretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma, and extramedullary plasmacytoma; (6) Waldenstrom's macroglobulinemia; (7) monoclonal gammopathy of undetermined significance; (8) benign monoclonal gammopathy; (9) heavy chain disease; (10) bone and connective tissue sarcomas, including, but not limited to, bone sarcoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma, soft-tissue sarcomas, angiosarcoma (hemangiosarcoma), fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, metastatic cancers, neurilemmoma, rhabdomyosarcoma, and synovial sarcoma; (11) brain tumors, including, but not limited to, glioma, astrocytoma, brain stem glioma, ependymoma, aligodendrogliorna, nonglial tumor, acoustic neurinoma, craniopharyngioma, medulloblastoma, meningioma, pineocytoma, pineoblastoma, and primary brain lymphoma; (12) breast cancer, including, but not limited to, adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast cancer, mutinous breast cancer, tubular breast cancer, papillary breast cancer, primary cancers, Paget's disease, and inflammatory breast cancer; (13) adrenal cancer, including, but not limited to, pheochromocytom and adrenocortical carcinoma; (14) thyroid cancer, including, but not limited to, papillary or follicular thyroid cancer, medullary thyroid cancer, and anaplastic thyroid cancer; (15) pancreatic cancer, including, but not limited to, insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumor, and carcinoid or islet cell tumor; (16) pituitary cancer, including, but limited to, Cushing's disease, prol actin-secreting tumor, acromegaly, and diabetes insipius; (17) eye cancer, including, but not limited, to ocular melanoma such as iris melanoma, choroidal melanoma, and cilliary body melanoma, and retinoblastoma; (18) vaginal cancer, including, but not limited to, squamous cell carcinoma, adenocarcinoma, and melanoma; (19) vulvar cancer, including, but not limited to, squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease; (20) cervical cancers, including, but not limited to, squamous cell carcinoma, and adenocarcinoma; (21) uterine cancer, including, but not limited to, endometrial carcinoma and uterine sarcoma; (22) ovarian cancer, including, but not limited to, ovarian epithelial carcinoma, borderline tumor, germ cell tumor, and stromal tumor; (23) esophageal cancer, including, but not limited to, squamous cancer, adenocarcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, adenosquamous

carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma; (24) stomach cancer, including, but not limited to, adenocarcinoma, fungating (polypoid), ulcerating, superficial spreading, diffusely spreading, malignant lymphoma, liposarcoma, fibrosarcoma, and carcinosarcoma; (25) colon cancer; (26) rectal cancer; (27) liver cancer, including, but not limited to, hepatocellular carcinoma and hepatoblastoma; (28) gallbladder cancer, including, but not limited to, adenocarcinoma; (29) cholangiocarcinomas, including, but not limited to, pappillary, nodular, and diffuse; (30) lung cancer, including, but not limited to, non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large-cell carcinoma, and small-cell lung cancer; (31) testicular cancer, including, but not limited to, germinal tumor, seminoma, anaplastic, classic (typical), spermatocytic, nonseminoma, embryonal carcinoma, teratoma carcinoma, and choriocarcinoma (yolk-sac tumor); (32) prostate cancer, including, but not limited to, adenocarcinoma, leiomyosarcoma, and rhabdomyosarcorna; (33) penal cancer; (34) oral cancer, including, but not limited to, squamous cell carcinoma; (35) basal cancer; (36) salivary gland cancer, including, but not limited to, adenocarcinoma, mucoepidermoid carcinoma, and adenoidcystic carcinoma; (37) pharynx cancer, including, but not limited to, squamous cell cancer and verrucous; (38) skin cancer, including, but not limited to, basal cell carcinoma, squamous cell carcinoma and melanoma, superficial spreading melanoma, nodular melanoma, lentigo malignant melanoma, and acral lentiginous melanoma; (39) kidney cancer, including, but not limited to, renal cell cancer, adenocarcinoma, hypernephroma, fibrosarcoma, and transitional cell cancer (renal pelvis and/or uterer); (40) Wilms' tumor; (41) bladder cancer, including, but not limited to, transitional cell carcinoma, squamous cell cancer, adenocarcinoma, and carcinosarcoma; and other cancer, including, not limited to, myxosarcoma, osteogenic sarcoma, endotheliosarcoma, lymphangio-endotheliosarcoma, mesothelioma, synovioma, hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, and papillary adenocarcinomas (*See* Fishman *et al.*, 1985, *Medicine*, 2d Ed., J.B. Lippincott Co., Philadelphia and Murphy *et al.*, 1997, *Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery*, Viking Penguin, Penguin Books U.S.A., Inc., United States of America).

[0206] Depending on the disorder, disease, or condition to be treated, and the subject's condition, the compounds or pharmaceutical compositions provided herein can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracistemal injection or infusion, subcutaneous injection, or implant), inhalation, nasal, vaginal, rectal, sublingual, or topical (e.g., transdermal or local) routes of administration and can be formulated, alone or

together, in suitable dosage unit with pharmaceutically acceptable excipients, carriers, adjuvants, and vehicles appropriate for each route of administration as described elsewhere herein.

[0207] The suitability of a particular route of administration employed for a particular active agent will depend on the active agent itself (e.g., whether it can be administered orally without decomposing prior to entering the blood stream) and the disease being treated. Recommended routes of administration for the second active agents are known to those of ordinary skill in the art. See, e.g., Physicians' Desk Reference, 1755-1760 (56th ed., 2002).


[0208] In one embodiment, provided herein are methods for treating or preventing testicular adrenal rest tumors (TART) in a subject, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein the subject has congenital adrenal hyperplasia (CAH).


[0209] In one embodiment, provided herein are methods for treating or preventing ovarian adrenal rest tumors (OART) in a subject, comprising administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein the subject has congenital adrenal hyperplasia (CAH).




[0210] In an aspect provided herein, is a method of treating or preventing testicular adrenal rest tumors (TART), comprising administering to a subject in need thereof a corticotropin-releasing factor type-1 (CRF_1) antagonist or a pharmaceutically acceptable salt thereof.

[0211] In an aspect provided herein, is a method of treating or preventing ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a corticotropin-releasing factor type-1 (CRF_1) antagonist or a pharmaceutically acceptable salt thereof.


[0212] In an aspect provided herein, is a method of treating or preventing testicular adrenal rest tumors (TART), comprising administering to a subject in need thereof a compound of structural Formula (I):




, or a pharmaceutically acceptable salt thereof. R^1 and R^2 are independently ethyl or n-propyl. R^3 is hydrogen, Cl, Br, methyl, trifluoromethyl, or methoxy. R^4 is hydrogen, Br, R^aR^bN–, methoxymethyl, n-butyl, acetamido, pyridin-4-yl, morpholin-4-yl,  ,

 ,  , or  . R^a and R^b are independently hydrogen, C_1-C_3alkyl, $H_2NCH_2CH_2$–, $(CH_3)_3COC(O)NHCH_2CH_2$–, or $CH_3CH_2CH_2NHCH_2CH_2$–.

[0213] In an aspect provided herein, is a method of treating or preventing ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a compound of structural Formula (I):

 , or a pharmaceutically acceptable salt thereof. R^1, R^2, R^3 and R^4 are as described herein, including embodiments.


[0214] In an aspect provided herein, is a method of decreasing or reducing adrenocorticotropic hormone (ACTH) levels in a subject in need thereof, comprising administering to the subject contacting the ACTH with a compound of structural Formula (I):

 , or a pharmaceutically acceptable salt thereof. R^1, R^2, R^3 and R^4 are as described herein, including embodiments. R^1, R^2, R^3 and R^4 are as described herein, including embodiments. In certain embodiments, at least about 50% of the subjects demonstrate reduction in ACTH.In certain embodiments, at least about 60% of the subjects demonstrate reduction in ACTH.In certain embodiments, at least about 70% of the subjects demonstrate reduction in ACTH. In certain embodiments, at least about 80% of the subjects demonstrate reduction in ACTH. In embodiments, at least about 10% of subjects were in the standard or normal range for ACTH after treatment.

[0215] In embodiments, at least about 20% of subjects were in the standard or normal range for ACTH after treatment. In embodiments, at least about 30% of subjects were in the standard or normal range for ACTH after treatment. In certain embodiments, ACTH levels are decreased or reduced within about 30 minutes post dosing. In certain embodiments, ACTH levels are decreased or reduced within about 1 hour post dosing. In certain embodiments, ACTH levels are


decreased or reduced within about 90 minutes post dosing. In certain embodiments, ACTH levels are decreased or reduced within about 2 hours post dosing.

[0216] In an aspect provided herein, is a method of decreasing or reducing 17α-hydroxyprogesterone (17-OHP) levels in a subject in need thereof, comprising administering to the subject a compound of structural Formula (I):




, or a pharmaceutically acceptable salt thereof. R^1, R^2, R^3 and R^4 are as described herein, including embodiments. R^1, R^2, R^3 and R^4 are as described herein, including embodiments. In certain embodiments, at least about 50% of the subjects demonstrate reduction in 17-OHP. In certain embodiments, at least about 60% of the subjects demonstrate reduction in 17-OHP. In certain embodiments, at least about 70% of the subjects demonstrate reduction in 17-OHP. In certain embodiments, at least about 80% of the subjects demonstrate reduction in 17-OHP. In embodiments, at least about 30% of subjects were in the standard or normal range of 1200 ng/dL after treatment. In embodiments, at least about 40% of subjects were in the standard or normal range of 1200 ng/dL after treatment. In embodiments, at least about 50% of subjects were in the standard or normal range of 1200 ng/dL after treatment. In embodiments, at least about 60% of subjects were in the standard or normal range of 1200 ng/dL after treatment. In embodiments, at least about 30% of subjects demonstrated an at least about 25% reduction in 17-OHP after treatment. In embodiments, at least about 40% of subjects demonstrated an at least about 25% reduction in 17-OHP after treatment. In embodiments, at least about 50% of subjects demonstrated an at least about 25% reduction in 17-OHP after treatment. In embodiments, at least about 60% of subjects demonstrated an at least about 25% reduction in 17-OHP after treatment.


[0217] In an aspect provided herein, is a method of decreasing or reducing androstenedione levels in a subject in need thereof, comprising administering to the subject a compound of structural Formula (I):

 , or a pharmaceutically acceptable salt thereof. R^1, R^2, R^3 and R^4 are as described herein, including embodiments. R^1, R^2, R^3 and R^4 are as described herein, including embodiments. In certain embodiments, at least about 50% of the subjects demonstrate reduction in androstenedione.In certain embodiments, at least about 60% of the subjects demonstrate reduction in androstenedione.In certain embodiments, at least about 70% of the subjects demonstrate reduction in androstenedione. In certain embodiments, at least about 80% of the subjects demonstrate reduction in androstenedione. In certain embodiments, at least about 90% of the subjects demonstrate reduction in androstenedione. In certain embodiments, at least 100% of the subjects demonstrate reduction in androstenedione. In embodiments, at least about 30% of subjects demonstrated an at least about 25% reduction in androstenedione after treatment. In embodiments, at least about 40% of subjects demonstrated an at least about 25% reduction in androstenedione after treatment. In embodiments, at least about 50% of subjects demonstrated an at least about 25% reduction in androstenedione after treatment. In embodiments, at least 60% of subjects demonstrated an at least about 25% reduction in androstenedione after treatment. In embodiments, at least about 30% of subjects were in the standard or normal range for androstenedione after treatment. In embodiments, at least about 40% of subjects were in the standard or normal range for androstenedione after treatment. In embodiments, at least about 50% of subjects were in the standard or normal range for androstenedione after treatment.


[0218] In certain embodiments, R^3 is Cl, Br, methyl, or trifluoromethyl.

[0219] In certain embodiments, R^3 is Cl, Br, or methyl.

[0220] In certain embodiments, R^4 is Br, R^aR^bN–, pyridin-4-yl, morpholin-4-yl, or  .


[0221] In certain embodiments, R^4 is morpholin-4-yl or  .

[0222] In certain embodiments, R^4 is hydrogen, Br, R^aR^bN– and R^a and R^b are independently C_1-C_3alkyl.




[0223] In certain embodiments, the compound is , or a pharmaceutically acceptable salt thereof.

[0224] In certain embodiments, the compound is



, or a pharmaceutically acceptable salt thereof.

[0225] In certain embodiments, the compound is



, or a pharmaceutically acceptable salt thereof.

[0226] In certain embodiments, a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is cyclically administered to a patient. Cycling therapy involves the administration of an active agent or a combination of active agents for a period of time, followed by a rest for a period of time, and repeating this sequential administration. Cycling therapy can reduce the development of resistance to one or more of the therapies, avoid or reduce the side effects of one of the therapies, and/or improves the efficacy of the treatment.

[0227] In certain embodiments, in the treatment, prevention, or amelioration of one or more symptoms of the disorders, diseases, or conditions described herein (e.g., treatment or prevention of testicular adrenal rest tumors (TART) or treatment or prevention of ovarian adrenal rest tumors (OART)), an appropriate dosage level of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof generally is ranging from about 1 mg to 3000 mg, from about 1 mg to 2000 mg, from about 1 mg to 1000 mg, from about 1 mg to about 500 mg, from about 5 mg to about 500 mg,

from about 5 mg to about 400 mg, from about 5 mg to about 300 mg, from about 5 mg to about 250 mg, from about 5 mg to about 200 mg, from about 50 mg to about 200 mg, from about 10 mg to about 400 mg, from about 5 mg to about 25 mg, from about 10 mg to about 25 mg, or from about 25 to about 200 mg, which can be administered in single or multiple doses. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1 mg, about 5 mg, about 10 mg mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 800 mg, or about 1000 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1 mg, about 5 mg, about 10 mg mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 800 mg, or about 1000 mg/day.

[0228] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 5 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 10 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 15 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 20 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 25 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 220 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 260 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an

amount of about 270 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 280 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 370 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is

administered in an amount of about 600 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg.

[0229] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, about 200 mg, or about 1000 mg.

[0230] For oral administration, the pharmaceutical compositions provided herein can be formulated in the form of tablets or capsules containing from about 1.0 mg to about 1,000 mg of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, for oral administration, the pharmaceutical compositions provided herein can be formulated in the form of tablets or capsules containing about 1 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about

350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 405 mg, about 410 mg, about 415 mg, about 420 mg, about 425 mg, about 430 mg, about 435 mg, about 440 mg, about 445 mg, about 450 mg, about 455 mg, about 460 mg, about 465 mg, about 470 mg, about 475 mg, about 480 mg, about 485 mg, about 490 mg, about 495 mg, about 500 mg, about 505 mg, about 510 mg, about 515 mg, about 520 mg, about 525 mg, about 530 mg, about 535 mg, about 540 mg, about 545 mg, about 550 mg, about 555 mg, about 560 mg, about 565 mg, about 570 mg, about 575 mg, about 580 mg, about 585 mg, about 590 mg, about 595 mg, about 600 mg, about 605 mg, about 610 mg, about 615 mg, about 620 mg, about 625 mg, about 630 mg, about 635 mg, about 640 mg, about 645 mg, about 650 mg, about 655 mg, about 660 mg, about 665 mg, about 670 mg, about 675 mg, about 680 mg, about 685 mg, about 690 mg, about 695 mg, about 700 mg, about 705 mg, about 710 mg, about 715 mg, about 720 mg, about 725 mg, about 730 mg, about 735 mg, about 740 mg, about 745 mg, about 750 mg, about 755 mg, about 760 mg, about 765 mg, about 770 mg, about 775 mg, about 780 mg, about 785 mg, about 790 mg, about 795 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 990 mg, about 990 mg, or about 1000 mg of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof for the symptomatic adjustment of the dosage to the patient to be treated. In certain embodiments, for oral administration, the pharmaceutical compositions provided herein can be formulated in the form of tablets or capsules containing about 50 mg of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In certain embodiments, for oral administration, the pharmaceutical compositions provided herein can be formulated in the form of tablets or capsules containing about 200 mg of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.The pharmaceutical compositions can be administered on a regimen of one (1) to four (4) times per day, including once, twice, three times, and four times per day. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered once per day. In some embodiments, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about

310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 405 mg, about 410 mg, about 415 mg, about 420 mg, about 425 mg, about 430 mg, about 435 mg, about 440 mg, about 445 mg, about 450 mg, about 455 mg, about 460 mg, about 465 mg, about 470 mg, about 475 mg, about 480 mg, about 485 mg, about 490 mg, about 495 mg, about 500 mg, about 505 mg, about 510 mg, about 515 mg, about 520 mg, about 525 mg, about 530 mg, about 535 mg, about 540 mg, about 545 mg, about 550 mg, about 555 mg, about 560 mg, about 565 mg, about 570 mg, about 575 mg, about 580 mg, about 585 mg, about 590 mg, about 595 mg, about 600 mg, about 605 mg, about 610 mg, about 615 mg, about 620 mg, about 625 mg, about 630 mg, about 635 mg, about 640 mg, about 645 mg, about 650 mg, about 655 mg, about 660 mg, about 665 mg, about 670 mg, about 675 mg, about 680 mg, about 685 mg, about 690 mg, about 695 mg, about 700 mg, about 705 mg, about 710 mg, about 715 mg, about 720 mg, about 725 mg, about 730 mg, about 735 mg, about 740 mg, about 745 mg, about 750 mg, about 755 mg, about 760 mg, about 765 mg, about 770 mg, about 775 mg, about 780 mg, about 785 mg, about 790 mg, about 795 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 990 mg, about 990 mg, or about 1000 mg of the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered once per day. In some embodiments, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 405 mg, about 410 mg, about 415 mg, about 420 mg, about 425 mg, about 430 mg, about 435 mg, about 440 mg, about 445 mg, about 450 mg, about 455 mg, about 460 mg, about 465 mg, about 470 mg, about 475 mg, about 480 mg, about 485 mg, about 490 mg, about 495 mg, about 500 mg, about 505 mg, about 510 mg, about 515 mg, about 520 mg, about 525 mg, about 530 mg, about 535 mg, about 540 mg, about 545 mg, about 550 mg, about 555 mg, about 560 mg, about 565 mg, about 570 mg, about 575 mg, about 580 mg, about 585 mg, about 590 mg, about 595 mg, about 600 mg, about 605 mg,

about 610 mg, about 615 mg, about 620 mg, about 625 mg, about 630 mg, about 635 mg, about 640 mg, about 645 mg, about 650 mg, about 655 mg, about 660 mg, about 665 mg, about 670 mg, about 675 mg, about 680 mg, about 685 mg, about 690 mg, about 695 mg, about 700 mg, about 705 mg, about 710 mg, about 715 mg, about 720 mg, about 725 mg, about 730 mg, about 735 mg, about 740 mg, about 745 mg, about 750 mg, about 755 mg, about 760 mg, about 765 mg, about 770 mg, about 775 mg, about 780 mg, about 785 mg, about 790 mg, about 795 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, or about 1000 mg of the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered twice per day. In some embodiments, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 405 mg, about 410 mg, about 415 mg, about 420 mg, about 425 mg, about 430 mg, about 435 mg, about 440 mg, about 445 mg, about 450 mg, about 455 mg, about 460 mg, about 465 mg, about 470 mg, about 475 mg, about 480 mg, about 485 mg, about 490 mg, about 495 mg, about 500 mg, about 505 mg, about 510 mg, about 515 mg, about 520 mg, about 525 mg, about 530 mg, about 535 mg, about 540 mg, about 545 mg, about 550 mg, about 555 mg, about 560 mg, about 565 mg, about 570 mg, about 575 mg, about 580 mg, about 585 mg, about 590 mg, about 595 mg, about 600 mg, about 605 mg, about 610 mg, about 615 mg, about 620 mg, about 625 mg, about 630 mg, about 635 mg, about 640 mg, about 645 mg, about 650 mg, about 655 mg, about 660 mg, about 665 mg, about 670 mg, about 675 mg, about 680 mg, about 685 mg, about 690 mg, about 695 mg, about 700 mg, about 705 mg, about 710 mg, about 715 mg, about 720 mg, about 725 mg, about 730 mg, about 735 mg, about 740 mg, about 745 mg, about 750 mg, about 755 mg, about 760 mg, about 765 mg, about 770 mg, about 775 mg, about 780 mg, about 785 mg, about 790 mg, about 795 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, or about 1000 mg of the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered three times per day.

[0231] In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered for a period of one day. In some embodiments, the compound of Formula (I), or an isotopic variant

thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of two days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of three days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of four days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of five days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of six days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of seven days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of eight days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of nine days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of ten days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 11 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 12 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 13 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 14 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered for a period of 15 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 16 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 17 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically

acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 18 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 19 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 20 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 21 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 22 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 23 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 24 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 25 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 26 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 27 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 28 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 29 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered for a period of 30 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 31 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 32 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 33 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate,

hydrate, or prodrug thereof is administered over a period of 34 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 35 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 36 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 37 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 38 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 39 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 40 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 41 days. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered over a period of 42 days or more.

[0232] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 25 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg once daily for a period of up to at least about 14 days.

[0233] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically

acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 220 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 260 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 270 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 140 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg once daily for a period of up to at least

about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 370 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically

acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 600 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg once daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg once daily for a period of up to at least about 14 days.

[0234] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 5 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 10 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 15 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 20 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 25 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg twice daily

for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 220 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 260 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 270 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 140 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a

pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 370 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 600 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg twice daily

for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg twice daily for a period of up to at least about 14 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg twice daily for a period of up to at least about 14 days.

[0235] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 5 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 10 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 15 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 20 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 25 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant

thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 220 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 260 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 270 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 280 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330

mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 370 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 600 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant

thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg once daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg once daily for a period of up to at least about 28 days.

[0236] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 5 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 10 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 15 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 20 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 25 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an

amount of about 220 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 260 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 270 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 280 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula

(I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 370 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 600 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg twice daily for a period of up to at least about 28 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a

pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg twice daily for a period of up to at least about 28 days.

[0237] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 255 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 10 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 15 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 20 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 25 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 220 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230

mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 260 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 270 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 420 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant

thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 370 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 600 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg once daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg once daily for a period of up to at least about 42 days.

[0238] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an

amount of about 5 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 10 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 15 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 20 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 25 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 50 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 100 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 200 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 210 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 220 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 230 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 240 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula

(I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 250 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 260 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 270 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 420 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 290 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 300 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 310 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 320 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 330 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 340 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 350 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 360 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an

amount of about 370 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 380 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 390 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 400 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 450 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 500 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 600 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 700 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 800 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 900 mg twice daily for a period of up to at least about 42 days. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1000 mg twice daily for a period of up to at least about 42 days.

[0239] In some embodiments, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, or about 400 mg of the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered twice per day. In some embodiments, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 150 mg, about 200

mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, or about 800 mg of the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered at least once per day.

[0240] In certain embodiments, from about 5 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In certain embodiments, from about 25 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In certain embodiments, from about 5 mg to about 25 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In certain embodiments, from about 10 mg to about 400 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In certain embodiments, from about 100 mg to about 600 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject.

[0241] In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered orally.

[0242] In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is formulated as a capsule or tablet.

[0243] In certain embodiments, from about 25 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject.


[0244] In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 5 mg/day to about 1000 mg/day is administered to the subject. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 25 mg/day to about 1000 mg/day is administered to the subject. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 5 mg/day to about 25 mg/day is administered to the subject. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 10 mg/day to about 400 mg/day is administered to the subject.In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose of from about 100 mg/day to about 600 mg/day.

[0245] In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in the fed state. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in the fasted state. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at least once per day.

[0246] In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at bedtime. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 6 hours before sleep. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 5 hours before sleep. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 4 hours before sleep. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 3 hours before sleep. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 2 hours before sleep. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 1 hour before sleep. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered less than about 30 minutes before sleep.

[0247] In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in the evening. In certain embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at about 10 pm at night.

[0248] In another aspect is provided a method of treating or preventing testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a pharmaceutical composition, comprising a compound of structural Formula (I): and a pharmaceutically acceptable excipientcomprising with a compound as described herein, including embodiments, or the structural Formulae (I) and a pharmaceutically acceptable excipient:



, or a pharmaceutically acceptable salt thereof. R^1, R^2, R^3, and R^4 are as described herein, including embodiments.

[0249] In certain embodiments, the pharmaceutical composition comprises from about 25 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In certain embodiments, the pharmaceutical composition comprises from about 25 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In certain embodiments, the pharmaceutical composition comprises from about 5 mg to about 25 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In certain embodiments,

the pharmaceutical composition comprises from about 10 mg to about 400 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In certain embodiments, the pharmaceutical composition comprises from about 100 mg to about 600 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0250] In certain embodiments, the pharmaceutical composition comprises about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg about 500 mg, or about 600 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0251] In certain embodiments, the pharmaceutical composition is administered orally.

[0252] In certain embodiments, the pharmaceutical composition is formulated as a capsule or tablet. In certain embodiments, the capsule or tablet comprises about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, or about 400 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In certain embodiments, the capsule or tablet comprises about 50 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In certain embodiments, the capsule or tablet comprises about 200 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0253] In certain embodiments, the pharmaceutical composition is administered at a dose of from about 5 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 25 mg to about 1000 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 5 mg to about 25 mg of a compound of Formula (I), or a pharmaceutically

acceptable salt thereof, is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 10 mg to about 400 mg of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject.

[0254] In certain embodiments, the pharmaceutical composition is administered at a dose of from about 5 mg/day to about 1000 mg/day is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 25 mg/day to about 1000 mg/day is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 5 mg/day to about 25 mg/day is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 10 mg/day to about 400 mg/day is administered to the subject. In certain embodiments, the pharmaceutical composition is administered at a dose of from about 100 mg/day to about 600 mg/day.

[0255] In certain embodiments, the pharmaceutical composition is administered in the fed state. In certain embodiments, the pharmaceutical composition is administered in the fasted state. In certain embodiments, the pharmaceutical composition is administered at least once per day.

[0256] In certain embodiments, the pharmaceutical composition is administered at bedtime. In certain embodiments, the pharmaceutical composition is administered less than about 6 hours before sleep. In certain embodiments, the pharmaceutical composition is administered less than about 5 hours before sleep. In certain embodiments, the pharmaceutical composition is administered less than about 4 hours before sleep. In certain embodiments, the pharmaceutical composition is administered less than about 3 hours before sleep. In certain embodiments, the pharmaceutical composition is administered less than about 2 hours before sleep. In certain embodiments, the pharmaceutical composition is administered less than about 1 hour before sleep. In certain embodiments, the pharmaceutical composition is administered less than about 30 minutes before sleep.







[0257] In certain embodiments, the pharmaceutical composition is administered in the evening. In certain embodiments, the pharmaceutical composition is administered at about 10 pm at night.


[0258] In certain embodiments, the subject has congenital adrenal hyperplasia (CAH).

[0259] In certain embodiments, the size and/or number of the tumors is decreased or reduced. In certain embodiments, the size of the tumors is decreased or reduced. In certain embodiments, the size of the tumors is decreased or reduced.

[0260] In certain embodiments of the methods disclosed herein, the method further comprises administering to the subject an additional chemotherapeutic agent.

[0261] In certain embodiments, the the additional chemotherapeutic agent is a glucocorticoid, a mineralocorticoid, an ACAT1 inhibitor, or an anti-androgen. In certain embodiments, the glucocorticoid is beclomethasone, betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, or triamcinolone. In certain embodiments, the mineralocorticoid is fludrocortisone. In certain embodiments, the additional chemotherapeutic agent is another CRF_1 antagonist. In certain embodiments, the CRF_1 antagonist is:


,

,

, SSR-126374,

,

, or

, or a pharmaceutically acceptable salt thereof. In certain embodiments, the CRF_1 antagonist is


, or a pharmaceutically acceptable salt thereof.

[0262] In certain embodiments of the methods disclosed herein, the method further comprises an additional treatment selected from surgical resection of the tumors and radiation therapy, or a combination thereof. In certain embodiments, the additional therapy is surgical resection and the surgical resection is prior to, after, and/or concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition, or any combination thereof. In certain embodiments, the surgical resection is prior

to administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In certain embodiments, the surgical resection is after administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In certain embodiments, the surgical resection is concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition.

[0263] In certain embodiments, the additional treatment is radiation therapy and the radiation therapy is prior to, after, and/or concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition, or any combination thereof. In certain embodiments, the radiation therapy is prior to administration of the CRF_1 antagonist of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In certain embodiments, the radiation therapy is after administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition. In certain embodiments, the radiation therapy is concurrent with administration of the compound of structural Formula (I), or a pharmaceutically acceptable salt thereof or the pharmaceutical composition.

[0264] In one embodiment, the pharmaceutical compositions are provided in a dosage form for oral administration, which comprise a compound provided herein, and one or more pharmaceutically acceptable excipients or carriers. The pharmaceutical compositions provided herein that are formulated for oral administration may be in tablet, capsule, powder, or liquid form. In some embodiments, a tablet comprises a solid carrier or an adjuvant. Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil, or synthetic oil. Physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol, or polyethylene glycol may be included. In some embodiments, a capsule comprises a solid carrier such as gelatin.

[0265] In another embodiment, the pharmaceutical compositions are provided in a dosage form for parenteral administration, which comprise a compound provided herein, and one or more pharmaceutically acceptable excipients or carriers. Where pharmaceutical compositions may be formulated for intravenous, cutaneous or subcutaneous injection, the active ingredient will be in the form of a parenterally acceptable aqueous solution, which is pyrogen-free and has a suitable pH, isotonicity, and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles, such as Sodium Chloride injection, Ringer's injection, or Lactated Ringer's injection. In some embodiments, preservatives, stabilisers, buffers, antioxidants, and/or other additives are included as required.

[0266] In yet another embodiment, the pharmaceutical compositions are provided in a dosage form for topical administration, which comprise a compound provided herein, and one or more pharmaceutically acceptable excipients or carriers.

[0267] The pharmaceutical compositions can also be formulated as modified release dosage forms, including delayed-, extended-, prolonged-, sustained-, pulsatile-, controlled-, accelerated-, fast-, targeted-, and programmed-release, and gastric retention dosage forms. These dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art (*see, Remington: The Science and Practice of Pharmacy*, supra; *Modified-Release Drug Delivery Technology*, 2nd Edition, Rathbone *et al.*, Eds., Marcel Dekker, Inc.: New York, NY, 2008).

[0268] The pharmaceutical compositions provided herein can be provided in a unit-dosage form or multiple-dosage form. A unit-dosage form, as used herein, refers to physically discrete a unit suitable for administration to a human and animal subject, and packaged individually as is known in the art. Each unit-dose contains a predetermined quantity of an active ingredient(s) sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carriers or excipients. Examples of a unit-dosage form include an ampoule, syringe, and individually packaged tablet and capsule. A unit-dosage form may be administered in fractions or multiples thereof. A multiple-dosage form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dosage form. Examples of a multiple-dosage form include a vial, bottle of tablets or capsules, or bottle of pints or gallons.

[0269] The pharmaceutical compositions provided herein can be administered at once, or multiple times at intervals of time. It is understood that the precise dosage and duration of treatment may vary with the age, weight, and condition of the patient being treated, and may be determined empirically using known testing protocols or by extrapolation from *in vivo* or *in vitro* test or diagnostic data. It is further understood that for any particular individual, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations.

[0270] In certain embodiments, the pharmaceutical compositions provided herein further comprise one or more chemotherapeutic agents as defined herein.

A. Oral Administration

[0271] The pharmaceutical compositions provided herein for oral administration can be provided in solid, semisolid, or liquid dosage forms for oral administration. As used herein, oral administration also includes buccal, lingual, and sublingual administration. Suitable oral dosage

forms include, but are not limited to, tablets, fastmelts, chewable tablets, capsules, pills, strips, troches, lozenges, pastilles, cachets, pellets, medicated chewing gum, bulk powders, effervescent or non-effervescent powders or granules, oral mists, solutions, emulsions, suspensions, wafers, sprinkles, elixirs, and syrups. In addition to the active ingredient(s), the pharmaceutical compositions can contain one or more pharmaceutically acceptable carriers or excipients, including, but not limited to, binders, fillers, diluents, disintegrants, wetting agents, lubricants, glidants, coloring agents, dye-migration inhibitors, sweetening agents, flavoring agents, emulsifying agents, suspending and dispersing agents, preservatives, solvents, non-aqueous liquids, organic acids, and sources of carbon dioxide.

[0272] Binders or granulators impart cohesiveness to a tablet to ensure the tablet remaining intact after compression. Suitable binders or granulators include, but are not limited to, starches, such as corn starch, potato starch, and pre-gelatinized starch (e.g., STARCH 1500); gelatin; sugars, such as sucrose, glucose, dextrose, molasses, and lactose; natural and synthetic gums, such as acacia, alginic acid, alginates, extract of Irish moss, panwar gum, ghatti gum, mucilage of isabgol husks, carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone (PVP), Veegum, larch arabogalactan, powdered tragacanth, and guar gum; celluloses, such as ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), hydroxypropyl methyl cellulose (HPMC); microcrystalline celluloses, such as AVICEL-PH-101, AVICEL-PH-103, AVICEL RC-581, AVICEL-PH-105 (FMC Corp., Marcus Hook, PA); and mixtures thereof. Suitable fillers include, but are not limited to, talc, calcium carbonate, microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof. The amount of a binder or filler in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The binder or filler may be present from about 50 to about 99% by weight in the pharmaceutical compositions provided herein.

[0273] Suitable diluents include, but are not limited to, dicalcium phosphate, calcium sulfate, lactose, sorbitol, sucrose, inositol, cellulose, kaolin, mannitol, sodium chloride, dry starch, and powdered sugar. Certain diluents, such as mannitol, lactose, sorbitol, sucrose, and inositol, when present in sufficient quantity, can impart properties to some compressed tablets that permit disintegration in the mouth by chewing. Such compressed tablets can be used as chewable tablets. The amount of a diluent in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art.

[0274] Suitable disintegrants include, but are not limited to, agar; bentonite; celluloses, such as methylcellulose and carboxymethylcellulose; wood products; natural sponge; cation-exchange

resins; alginic acid; gums, such as guar gum and Veegum HV; citrus pulp; cross-linked celluloses, such as croscarmellose; cross-linked polymers, such as crospovidone; cross-linked starches; calcium carbonate; microcrystalline cellulose, such as sodium starch glycolate; polacrilin potassium; starches, such as corn starch, potato starch, tapioca starch, and pre-gelatinized starch; clays; aligns; and mixtures thereof. The amount of a disintegrant in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The amount of a disintegrant in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The pharmaceutical compositions provided herein may contain from about 0.5 to about 15% or from about 1 to about 5% by weight of a disintegrant.

[0275] Suitable lubricants include, but are not limited to, calcium stearate; magnesium stearate; mineral oil; light mineral oil; glycerin; sorbitol; mannitol; glycols, such as glycerol behenate and polyethylene glycol (PEG); stearic acid; sodium lauryl sulfate; talc; hydrogenated vegetable oil, including peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil; zinc stearate; ethyl oleate; ethyl laureate; agar; starch; lycopodium; silica or silica gels, such as AEROSIL® 200 (W.R. Grace Co., Baltimore, MD) and CAB-O-SIL® (Cabot Co. of Boston, MA); and mixtures thereof. The pharmaceutical compositions provided herein may contain about 0.1 to about 5% by weight of a lubricant.

[0276] Suitable glidants include, but are not limited to, colloidal silicon dioxide, CAB-O-SIL® (Cabot Co. of Boston, MA), and asbestos-free talc. Suitable coloring agents include, but are not limited to, any of the approved, certified, water soluble FD&C dyes, and water insoluble FD&C dyes suspended on alumina hydrate, and color lakes and mixtures thereof. A color lake is the combination by adsorption of a water-soluble dye to a hydrous oxide of a heavy metal, resulting in an insoluble form of the dye. Suitable flavoring agents include, but are not limited to, natural flavors extracted from plants, such as fruits, and synthetic blends of compounds which produce a pleasant taste sensation, such as peppermint and methyl salicylate. Suitable sweetening agents include, but are not limited to, sucrose, lactose, mannitol, syrups, glycerin, and artificial sweeteners, such as saccharin and aspartame. Suitable emulsifying agents include, but are not limited to, gelatin, acacia, tragacanth, bentonite, and surfactants, such as polyoxyethylene sorbitan monooleate (TWEEN® 20), polyoxyethylene sorbitan monooleate 80 (TWEEN® 80), and triethanolamine oleate. Suitable suspending and dispersing agents include, but are not limited to, sodium carboxymethylcellulose, pectin, tragacanth, Veegum, acacia, sodium carbomethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Suitable preservatives include, but are not limited to, glycerin, methyl and propylparaben, benzoic add,

sodium benzoate and alcohol. Suitable wetting agents include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether. Suitable solvents include, but are not limited to, glycerin, sorbitol, ethyl alcohol, and syrup. Suitable non-aqueous liquids utilized in emulsions include, but are not limited to, mineral oil and cottonseed oil. Suitable organic acids include, but are not limited to, citric and tartaric acid. Suitable sources of carbon dioxide include, but are not limited to, sodium bicarbonate and sodium carbonate.

[0277] It should be understood that many carriers and excipients may serve several functions, even within the same formulation.

[0278] The pharmaceutical compositions provided herein for oral administration can be provided as compressed tablets, tablet triturates, chewable lozenges, rapidly dissolving tablets, multiple compressed tablets, or enteric-coating tablets, sugar-coated, or film-coated tablets. Enteric-coated tablets are compressed tablets coated with substances that resist the action of stomach acid but dissolve or disintegrate in the intestine, thus protecting the active ingredients from the acidic environment of the stomach. Enteric-coatings include, but are not limited to, fatty acids, fats, phenyl salicylate, waxes, shellac, ammoniated shellac, and cellulose acetate phthalates. Sugar-coated tablets are compressed tablets surrounded by a sugar coating, which may be beneficial in covering up objectionable tastes or odors and in protecting the tablets from oxidation. Film-coated tablets are compressed tablets that are covered with a thin layer or film of a water-soluble material. Film coatings include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000, and cellulose acetate phthalate. Film coating imparts the same general characteristics as sugar coating. Multiple compressed tablets are compressed tablets made by more than one compression cycle, including layered tablets, and press-coated or dry-coated tablets.

[0279] The tablet dosage forms can be prepared from the active ingredient in powdered, crystalline, or granular forms, alone or in combination with one or more carriers or excipients described herein, including binders, disintegrants, controlled-release polymers, lubricants, diluents, and/or colorants. Flavoring and sweetening agents are especially useful in the formation of chewable tablets and lozenges.

[0280] The pharmaceutical compositions provided herein for oral administration can be provided as soft or hard capsules, which can be made from gelatin, methylcellulose, starch, or calcium alginate. The hard gelatin capsule, also known as the dry-filled capsule (DFC), consists of two sections, one slipping over the other, thus completely enclosing the active ingredient. The soft elastic capsule (SEC) is a soft, globular shell, such as a gelatin shell, which is plasticized by the addition of glycerin, sorbitol, or a similar polyol. The soft gelatin shells may contain a

preservative to prevent the growth of microorganisms. Suitable preservatives are those as described herein, including methyl- and propyl-parabens, and sorbic acid. The liquid, semisolid, and solid dosage forms provided herein may be encapsulated in a capsule. Suitable liquid and semisolid dosage forms include solutions and suspensions in propylene carbonate, vegetable oils, or triglycerides. Capsules containing such solutions can be prepared as described in U.S. Pat. Nos. 4,328,245; 4,409,239; and 4,410,545. The capsules may also be coated as known by those of skill in the art in order to modify or sustain dissolution of the active ingredient.

[0281] Coloring and flavoring agents can be used in all of the above dosage forms.

[0282] The pharmaceutical compositions provided herein for oral administration can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed-release forms.

B. Parenteral Administration

[0283] The pharmaceutical compositions provided herein can be administered parenterally by injection, infusion, or implantation, for local or systemic administration. Parenteral administration, as used herein, include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial, intravesical, and subcutaneous administration.

[0284] The pharmaceutical compositions provided herein for parenteral administration can be formulated in any dosage forms that are suitable for parenteral administration, including solutions, suspensions, emulsions, micelles, liposomes, microspheres, nanosystems, and solid forms suitable for solutions or suspensions in liquid prior to injection. Such dosage forms can be prepared according to conventional methods known to those skilled in the art of pharmaceutical science (*see, Remington: The Science and Practice of Pharmacy*, supra).

[0285] The pharmaceutical compositions intended for parenteral administration can include one or more pharmaceutically acceptable carriers and excipients, including, but not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, cryoprotectants, lyoprotectants, thickening agents, pH adjusting agents, and inert gases.

[0286] Suitable aqueous vehicles include, but are not limited to, water, saline, physiological saline or phosphate buffered saline (PBS), sodium chloride injection, Ringers injection, isotonic dextrose injection, sterile water injection, dextrose and lactated Ringers injection. Suitable non-aqueous vehicles include, but are not limited to, fixed oils of vegetable origin, castor oil, corn oil, cottonseed oil, olive oil, peanut oil, peppermint oil, safflower oil, sesame oil, soybean oil,

hydrogenated vegetable oils, hydrogenated soybean oil, and medium-chain triglycerides of coconut oil, and palm seed oil. Suitable water-miscible vehicles include, but are not limited to, ethanol, 1,3-butanediol, liquid polyethylene glycol (e.g., polyethylene glycol 300 and polyethylene glycol 400), propylene glycol, glycerin, *N*-methyl-2-pyrrolidone, *N,N*-dimethylacetamide, and dimethyl sulfoxide.

[0287] Suitable antimicrobial agents or preservatives include, but are not limited to, phenols, cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoates, thimerosal, benzalkonium chloride (e.g., benzethonium chloride), methyl-and propyl-parabens, and sorbic acid. Suitable isotonic agents include, but are not limited to, sodium chloride, glycerin, and dextrose. Suitable buffering agents include, but are not limited to, phosphate and citrate. Suitable antioxidants are those as described herein, including bisulfite and sodium metabisulfite. Suitable local anesthetics include, but are not limited to, procaine hydrochloride. Suitable suspending and dispersing agents are those as described herein, including sodium carboxymethylcelluose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Suitable emulsifying agents are those described herein, including polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate 80, and triethanolamine oleate. Suitable sequestering or chelating agents include, but are not limited to EDTA. Suitable pH adjusting agents include, but are not limited to, sodium hydroxide, hydrochloric acid, citric acid, and lactic acid. Suitable complexing agents include, but are not limited to, cyclodextrins, including α-cyclodextrin, β-cyclodextrin, hydroxypropyl-β-cyclodextrin, sulfobutylether-β-cyclodextrin, and sulfobutylether 7-β-cyclodextrin (CAPTISOL®, CyDex, Lenexa, KS).

[0288] When the pharmaceutical compositions provided herein are formulated for multiple dosage administration, the multiple dosage parenteral formulations must contain an antimicrobial agent at bacteriostatic or fungi static concentrations. All parenteral formulations must be sterile, as known and practiced in the art.

[0289] In one embodiment, the pharmaceutical compositions for parenteral administration are provided as ready-to-use sterile solutions. In another embodiment, the pharmaceutical compositions are provided as sterile dry soluble products, including lyophilized powders and hypodermic tablets, to be reconstituted with a vehicle prior to use. In yet another embodiment, the pharmaceutical compositions are provided as ready-to-use sterile suspensions. In yet another embodiment, the pharmaceutical compositions are provided as sterile dry insoluble products to be reconstituted with a vehicle prior to use. In still another embodiment, the pharmaceutical compositions are provided as ready-to-use sterile emulsions.

[0290] The pharmaceutical compositions provided herein for parenteral administration can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed-release forms.

[0291] The pharmaceutical compositions provided herein for parenteral administration can be formulated as a suspension, solid, semi-solid, or thixotropic liquid, for administration as an implanted depot. In one embodiment, the pharmaceutical compositions provided herein are dispersed in a solid inner matrix, which is surrounded by an outer polymeric membrane that is insoluble in body fluids but allows the active ingredient in the pharmaceutical compositions diffuse through.

[0292] Suitable inner matrixes include, but are not limited to, polymethylmethacrylate, polybutyl-methacrylate, plasticized or unplasticized polyvinylchloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinyl acetate copolymers, silicone rubbers, polydimethylsiloxanes, silicone carbonate copolymers, hydrophilic polymers, such as hydrogels of esters of acrylic and metliacrylic acid, collagen, cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate.

[0293] Suitable outer polymeric membranes include but are not limited to, polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, ethylene/vinyl acetate copolymers, silicone rubbers, polydimethyl siloxanes, neoprene rubber, chlorinated polyethylene, polyvinylchloride, vinyl chloride copolymers with vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, and ethylene/vinyloxyethanol copolymer.

V. Examples

[0294] While preferred embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.


Example 1. A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Compound 1 in Subjects with Testicular Adrenal Rest Tumors

[0295] Testicular adrenal rest tumors (TART) is a common complication in congenital adrenal hyperplasia (CAH) that is caused by adrenocorticotropin hormone (ACTH)–driven

overstimulation of aberrant adrenal cells within the testes and results in impaired spermatogenesis and infertility. TARTS can be found anywhere on the testes, though a typical (very common) location is within the mediastinum. This is a particularly problematic location. Because of the central location of TARTs being in the mediastinum, compression of the nearby seminiferous tubules is common and can lead to obstructive azoospermia, irreversible damage to surrounding tissue, and permanent infertility in males.

[0296] Current treatment for TART consists of chronic high-dose glucocorticoids, a problematic therapy with significant side effects and a narrow therapeutic window. Given the serious nature of TART and the limitations and risks of chronic steroid therapy, new treatment modalities are needed for patients with TART. Compound 1, a high-affinity and selective small-molecule antagonist of the corticotropin-releasing factor type-1 (CRF_1) receptor, may be effective in blocking ACTH synthesis, thereby reducing the size of testicular lesions in TART and reducing the need for chronic supraphysiologic doses of glucocorticoids. This mechanism of action has been validated in a previous proof-of-concept study using a similar small-molecule CRF_1 receptor antagonist, which produced dose-dependent reductions in ACTH and 17-hydroxyprogesterone (17-OHP) in subjects with CAH. Compound 1 has been shown to have an acceptable safety and tolerability profile in nonclinical toxicology studies and in 2 completed Phase 1 clinical studies in healthy volunteers. These promising results provide a rationale for investigating the use of Compound 1 in the treatment of TART, in combination with replacement glucocorticoids and mineralocorticoids.

[0297] The structure of Compound 1 is:



[0298] Building upon the 2 completed Phase 1 studies of Compound 1 in healthy volunteers and the ongoing Phase 2 proof-of-concept study of Compound 1 in subjects with CAH, this Phase 2 will study Compound 1 specifically in male CAH subjects with TART for the first time. A sample size of approximately 12 subjects was selected to provide sufficient data for an initial evaluation of efficacy and safety in subjects with TART while maintaining feasible subject recruitment goals for this rare condition. Given the rarity of the disease and thus the small sample size that can be recruited, this study will be open label, and all enrolled subjects will

receive active study drug. Subjects will serve as their own controls in that their outcome measures after 12 weeks of study drug dosing will be compared to their baseline measures.

[0299] The schedule of study visits (every 2 weeks through Week 4, then every 4 weeks for the remainder of the study) provides an appropriate balance between minimizing subject burden and closely monitoring subject safety and response to therapy. The 4-week post-treatment washout period will allow for adequate safety follow-up and analysis of any HPA axis rebound after the last dose of study drug.

[0300] The specification of study drug dosing at 10pm and after consumption of a snack is based on information from the Phase 1 studies in healthy volunteers. The plasma C_{max} (maximum concentration) for Compound 1 in the Phase 1 studies occurred approximately 5 hours after dosing. Therefore, Compound 1 will be dosed daily at 10pm in this study in order to achieve peak plasma study drug concentration at the time of day when most adrenal androgens are produced. Subjects will consume a standardized snack before taking study drug because the Phase 1 studies showed minimal study drug absorption when subjects were dosed in a fasted state. Specific dose reduction criteria, strict individual treatment stopping criteria, and appropriate laboratory and medical assessments have been established to ensure subject safety. (**FIGS. 1A-1B**).

Objectives	**Endpoints**
Primary	
• To assess the efficacy of Compound 1 in subjects with TART	• Reduction in the size/volume of TART on testicular ultrasound from screening to Week 12
Secondary	
• To evaluate the safety of Compound 1 in subjects with TART	• Adverse events (AEs), serious adverse events (SAEs), AEs leading to withdrawal, AEs of special interest (AESIs) • Physical examination findings • Vital signs • Changes in electrocardiogram (ECG) • Changes in clinical laboratory values
• To assess the pharmacodynamic (PD) biomarker effects of Compound 1	• Changes in plasma concentrations of key PD biomarkers, including ACTH, 17-OHP, testosterone, androstenedione, luteinizing hormone (LH),

	follicle-stimulating hormone (FSH), inhibin B, sex hormone–binding globulin (SHBG), renin, and aldosterone from baseline to Week 12
• To assess changes on semen analysis	• Changes in sperm count, morphology, and motility from baseline to Week 12
• To assess changes in metabolism	• Changes in metabolic parameters, including fasting glucose, HbA1c, insulin sensitivity, and lipid profile (including LDL cholesterol, HDL cholesterol, and triglycerides), from baseline to Week 12 • Changes in body weight, body mass index (BMI), waist circumference, and blood pressure
• To evaluate changes in quality of life (QoL) and mood	• Changes in QoL measured using the Short Form 36 (SF-36) • Changes in mood measured using the Hospital Anxiety and Depression Scale (HADS)

Study Population

[0301] Approximately 12 male subjects with TART will be enrolled at approximately 6 investigative sites in the United States, United Kingdom, and possibly other countries. Up to 12 additional subjects may be added to further evaluate specific safety, PD, or efficacy findings.

Eligibility Criteria

Inclusion Criteria

- Adult male subjects aged 18 to 30, inclusive
- Documented historical diagnosis of CAH based on documented genetic mutation or historical documentation of elevated 17-OHP
- Diagnosis of TART via testicular ultrasound and/or magnetic resonance imaging (MRI) at screening with ≥1 lesion(s) measuring ≥2 cm in diameter
- On a stable regimen of GC replacement for ≥30 days before baseline
- Agree to follow contraception guidelines and refrain from donating sperm throughout the treatment period and for 90 days after the last dose of study drug
- Subject is able to understand all study procedures and risks involved and provides written informed consent indicating willingness to comply with all aspects of the protocol

Exclusion Criteria

- Any clinically significant unstable medical condition, medically significant illness, or chronic disease within 30 days of screening, including but not limited to:

  - A malignancy or <3 years of remission history from any malignancy, other than successfully treated localized skin cancer
  - Presence of clinically significant renal disease, as evidenced by an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73m^2
  - Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  - Confirmed positive test at screening for active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
- Any clinically significant psychiatric disorders, including any current major depressive episode, bipolar disorder, schizophrenia, schizoaffective disorder, major depressive disorder with psychotic features, or any other psychotic disorder within the preceding 6 months
- HADS score >12 for either depression or anxiety
- At increased risk of suicide on the basis of the Investigator's judgment or the results of the Columbia-Suicide Severity Rating Scale (C-SSRS) conducted at screening and baseline (eg, C-SSRS Type 3, 4, or 5 ideation during the preceding 6 months or any suicidal behavior within the past 12 months)
- Clinically significant and abnormal clinical or laboratory assessments must be discussed with the Medical Monitor to determine eligibility for this study. Abnormal assessments that must be reviewed to determine eligibility include but are not limited to:
  - Clinically meaningful abnormal ECG results, in the opinion of the Investigator
  - Fridericia-corrected QT interval (QTcF) >450 msec
  - Alanine aminotransferase (ALT) >2x upper limit of normal (ULN)
  - Bilirubin >1.5x ULN (isolated bilirubin >1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%)
- A history that includes bilateral adrenalectomy or hypopituitarism
- Use of any other investigational drug within 30 days or 5 half-lives, whichever is longer, before initial screening
- Require use of prohibited concomitant medications, including strong inhibitors and/or inducers of CYP3A4 (with the exception of glucocorticoids, hydrocortisone, and dexamethasone) within 30 days or 5 half-lives (whichever is longer) of first dose of study drug. Medications that are sensitive substrates or substrates with narrow therapeutic ranges (metabolized by CYP3A4, 2C8, 2C9, or 2C19) should be discussed on a case-by-case basis with the Medical Monitor to determine whether the medication should be discontinued or may be continued with caution. If washout is feasible, then the medication should be

withdrawn at least 30 days or 5 half-lives (whichever is longer) before the first dose of study drug.

- Donation of blood within 60 days before first dose of study drug, or donation of platelets, white blood cells, or plasma within 15 days before first dose of study drug.

Study Duration

[0302] The expected duration of study participation for each subject is up to approximately 20 weeks. This includes a screening period of ≤4 weeks, a treatment period of 12 weeks, and a safety follow-up period of 4 weeks.

Study Design

[0303] This is a Phase 2, open-label efficacy and safety study of Compound 1 for the treatment of TART. All subjects will receive a daily oral dose of Compound 1 for 12 weeks.In-clinic study visits will occur for screening and at Day 1 (baseline) and Weeks 2, 4, 8, 12 (end of treatment), and 16 (follow-up).

Dose, Route, Regimen

[0304] All subjects will receive a daily oral dose of Compound 1 for 12 weeks. Subjects will receive 600 mg/day during the first 2 weeks and 1000 mg/day during the remaining 10 weeks of the treatment period. Study drug will be taken daily at 10pm (or bedtime, if earlier), 5 to 15 minutes after consumption of a standardized snack.

[0305] On mornings of study visits with 8am blood draws for laboratory assessments, subjects should take their morning glucocorticoid replacement after the blood draws. For all other days during the study, subjects may take their morning glucocorticoid replacement at their usual time (generally between 6am and 8am).

[0306] If a subject experiences a Grade 3 or higher TEAE considered at least possibly related to study drug, the Investigator may reduce the subject's daily dose of Compound 1 down in increments of 200 mg. Study drug will be discontinued in subjects who experience clinically significant liver chemistry, QTcF, or other individual treatment stopping criteria.

Investigational Drug

[0307] Compound 1 is a small-molecule CRF_1 receptor antagonist and will be supplied as 200-mg, size 1, white, hard gelatin capsules.

Example 2.

[0308] Since elevated ACTH is the primary driver for TART growth, blocking ACTH synthesis using Compound 1, a small-molecule antagonist of the CRF_1 receptor, may be effective in reducing ACTH levels, thereby reducing the size of testicular lesions in TART and reducing the need for chronic supraphysiologic doses of GCs. In CAH, this mechanism of action has been

validated in a previous proof-of-concept study using a similar small-molecule CRF_1 receptor antagonist, which produced dose-dependent reductions in ACTH and 17-OHP in subjects with CAH. The safety profile of Compound 1 has been established in nonclinical toxicology studies and in 2 completed Phase 1 clinical studies in healthy volunteers. A Phase 2 study in subjects with CAH is currently ongoing.

Nonclinical Toxicology of Compound 1

[0309] The nonclinical safety profile of Compound 1 has been evaluated in repeat-dose range-finding and definitive toxicology studies of up to 91 days in duration in rats and dogs using the clinically relevant route (oral) and schedule of administration (once daily). In rats and beagle dogs administered oral Compound 1 once daily for 91 consecutive days at doses up to 2000 mg/kg/day, toxicologic findings were all mild and limited to the male reproductive tract, and all Compound 1-related findings were reversible following a 6-week treatment-free recovery period.

[0310] Additionally, a fertility toxicology study was conducted in rats. In this study, male rats were administered oral Compound 1 once daily at 0, 5, 20, or 1000 mg/kg for 85 to 87 days (70 days before mating, during mating, and ≤4 days between mating and necropsy). Male reproductive performance (mean day of mating, mating and fertility indices, and conception rates) was unaffected by Compound 1 treatment. Untreated females mated with the Compound 1-treated males had no ovarian and uterine effects.

[0311] In addition, a complete battery of standard genotoxicity tests consisting of in vitro bacterial reverse mutation and chromosome aberration assays and an in vivo (rat) bone marrow micronucleus assay has been conducted. Exploratory and definitive embryo-fetal development studies in rabbits and a bovine corneal opacity and permeability assay have also been conducted.

Clinical Experience with Compound 1

[0312] To date, a total of 53 subjects, all healthy adults aged 21 to 65 years, have been treated with at least 1 dose of Compound 1 in 2 Phase 1 studies. The first-in-human study of Compound 1 (Study I3C-FW-BLAA) evaluated single ascending doses of 2 mg to 800 mg. In this study, a small number of subjects experienced diarrhea and headache of mild or moderate severity. A subsequent study (Study I3C-FW-BLAB) evaluated repeat doses of 50 mg, 100 mg, or 200 mg Compound 1 once daily for 14 consecutive days. A small number of subjects in the repeat-dose study experienced dyspnea, rhinorrhea, palpitations, and headache. The Phase 1 studies showed no clinically significant alterations in safety laboratory values, vital signs, or electrocardiograms (ECGs). Compound 1 has been well tolerated in healthy human subjects, with no SAEs, AEs leading to discontinuation, or dose-limiting toxicities (DLTs). A maximum tolerated dose has not been reached in humans.

[0313] An ongoing Phase 2 open-label study (Study Compound 2) is currently evaluating the safety and efficacy of Compound 1 dosed once daily for 6 weeks in adults with classic CAH. In the initial Cohort A of this study, all subjects are dosed starting at 200 mg/day for 14 days, escalating for each subject to 600 mg/day for 14 days, then 1000 mg/day for 14 days if the subject experiences no DLTs at the previous dose level. **(FIGS. 2-3)**.

Known Potential Risks

[0314] Because the reversible testicular effects (degeneration/atrophy) observed in rats and dogs treated with high-dose Compound 1 (2,000 mg/kg/day) are likely associated with on-target (mechanism-driven) effects, these effects are likely to be relevant to human risk. However, male reproductive studies in rodents showed no impairment in fertility at the highest dose tested (1,000 mg/kg/day). Additionally, there were no effects on clinical laboratory markers of testicular function (LH and FSH) when Compound 1 was administered to healthy male volunteers at doses up to 200 mg per day for 14 consecutive days. Clinical laboratory measures of testicular function (LH, FSH, inhibin B, and SHBG) will be assessed throughout this study to monitor the risk of testicular injury. Testicular ultrasounds and semen analysis will also be performed at screening/baseline and the end of the treatment period.

[0315] Laboratory abnormalities in liver function tests (LFTs) have been observed at significantly higher doses in nonclinical studies. However, these events were not observed in the Phase 1 clinical studies. Clinical laboratory measures of liver chemistry will be assessed throughout this study, and strict individual treatment stopping criteria for liver chemistry findings are in place.

[0316] Compound 1-induced effects on the thyroid gland were noted in dogs after 91 days of high-dose (2,000 mg/kg/day) treatment but not in any other nonclinical studies. Clinical pathology parameters of thyroid function (eg, T4, T3, thyroid-stimulating hormone [TSH]) were not evaluated in the Phase 1 studies but will be monitored throughout this study.

Known Potential Benefits

[0317] Early clinical studies suggests that Compound 1 is effective as a CRF_1 receptor antagonist, a mechanism of action that supports the clinical investigation of Compound 1 for treatment of TART. In CAH, this mechanism of action has been validated in a previous proof-of-concept study using a similar small-molecule CRF_1 receptor antagonist, which produced dose-dependent reductions in ACTH and 17-OHP in subjects with CAH.

Assessment of Potential Risks and Benefits

[0318] The mild and reversible toxicologic effects of Compound 1 on the male reproductive tract in nonclinical studies occurred in the context of animals with normal, rather than elevated, baseline hormone function. As a CRF_1 receptor antagonist, Compound 1 is intended to reduce

abnormally elevated ACTH levels, which in TART drives overstimulation of aberrant adrenal cells within the testes. In nonclinical models where baseline hormone levels are within normal ranges, clinical benefits are not expected, and indeed, toxicities may be expected as a result of androgen reduction outside of the normal range. In TART, where baseline ACTH and androgen levels are pathologically elevated, androgen reduction would be considered a positive, therapeutic effect.

[0319] Given the serious nature of TART and the limitations (and risks) of chronic steroid therapy, new treatment modalities are needed for patients with TART. Given the acceptable safety and tolerability profile of Compound 1 in healthy volunteers from the Phase 1 program, the low probability of demonstrating meaningful PD marker changes in healthy subjects, and the lack of any clear benefit to exposing more healthy subjects to study drug, the Sponsor believes the benefit-to-risk profile favors the entry of Compound 1 into Phase 2 in subjects with TART.

Example 3. Congenital Andrenal Hyperplasia (CAH)

[0320] CAH results from a genetic defect in the 21-hydroxylase enzyme. CAH patients are thus unable to produce cortisol. Without cortisol to provide negative feedback, patients over-produce ACTH. High ACTH promotes the overproduction of potent androgens (male sex hormones). Without wishing to be bound by theory, Compound 1 blocks CRF_1 receptor to prevent ACTH release by the pituitary and associated drive on the hypothalamic-pituitary-adrenal axis. Replacement of cortisol to physiological levels will correct cortisol deficiency, however, will not lower ACTH, resulting in hyperplasia of adrenal gland and associated overproduction of adrenal androgens.

[0321] As shown in **FIGS. 4** and **5A-5B**, the attenuation of ACTH demonstrates target engagement and functional CRF_1 receptor antagonism. 80% of subjects demonstrated reduction in ACTH. 70% of subjects demonstrated > 25% reduction in ACTH. 30% of subjects were in the normal range (*) after treatment with a CRF_1 receptor antagonist.

[0322] **FIGS. 6** and **7A-7B** demonstrate "control" of disease based on standard guidelines, which would then allow steroid taper. 80% of subjects demonstrated reduction in 17-OHP. 50% of subjects demonstrated > 25% reduction in ACTH. 50% of subjects were in the guideline range (*; 1200 ng/dL) after treatment with a CRF_1 receptor antagonist.

[0323] **FIGS. 8** and **9A-9B** demonstrate attenuation of morning rise in A4 upon treatment with a CRF1 antagonist, indicative of its ability to control excess andreogen production and associated symptoms. 100% of subjects demonstrated reduction in androstenedione (at various doses). 60% of subjects demonstrated > 25% reduction in androstenedione. 50% of subjects were within the normal reference range after treatment with a CRF_1 receptor antagonist.

[0324] FIGS. 10A-10B show approximately 25% shrinkage in TART in a 25 year old male with classic congenital adrenal hyperplasia following 6 weeks treatment with a CRF_1 receptor antagonist.

[0325] FIGS. 11A-11B demonstrate Compound 1 is a potent, selective, and functional CRF_1 receptor antagonist. In in vitro and ex vivo studies, Compound 1 was determined to be a potent and selective CRF_1 receptor antagonist with high affinity and selective for the $hCRF_1$ receptor. Compound 1 was found to have functional potency to inhibit adenylate cyclase activity (CRF_1 receptor-mediated downstream cascade), demonstrating in vitro efficacy as a CRF_1 receptor antagonist. Compound 1 was found to significantly inhibit CRF-induced locomotor behavior in response to i.c.v. administration of CRF **(FIG. 11B)**.

[0326] FIGS. 12A-12B demonstrate single pill of CRF_1 receptor antagonist improves ACTH and 17-OHP in CAH patients.

[0327] FIG. 13 shows the subject level hormone changes (ACTH, 17-OHP, and androstenedione) by dose of a CRF_1 receptor antagonist.

Example 4. Assess reduction in excess ACTH and adrenal steroid production

[0328] The objectives of the study are: to assess the ability of Compound 1 to reduce excess ACTH and adrenal steroid production in participants with classic CAH on a stable gluococorticoid regimen; to evaluate the safety and tolerability of tildacerfont in participants with classic CAH; and to evaluate the pharmacokinetics (PK) of tildacerfont.

ELIGIBILITY CRITERIA

[0329] Inclusion Criteria:

- Adult males and females 18 years or older
- Diagnosis of classic CAH due to 21-hydroxylase deficiency
- Morning 17OHP ≥800 ng/dL, before taking any morning GC dose
- On a stable regimen of gluococorticoid replacement for ≥30 days before enrollment

[0330] Exclusion Criteria:

- Clinically significant unstable medical condition, illness, or chronic disease within 30 days of screening
- Clinically significant psychiatric disorder
- History of bilateral adrenalectomy or hypopituitarism

STUDY DESIGN

[0331] FIG. 14 depicts the proof of concept and escalating QD dosing at 10 PM for Cohort A and the single dose level and BID dosing at 10 AM and 10 pm for Cohort B.

BASELINE CHARACTERISTICS

[0332] Table 1 provides a description of the baseline characteristics displayed by Cohort A and Cohort B. In Cohort A, 10 partcipants were enrolled and received at least 1 dose of Compound 1. One participant withdrew early because of an occupation-related scheduling conflict. In Cohort B, 9 participants were enrolled and received at least one dose of Compound 1. One participant was withdrawn upon discovery of a major protocol violation at Baseline and did not have postbaseline efficacy/PK data. Thus, baseline characteristics are calculated for n=8 in Cohort B. One participant in Cohort B was taking both HC and prednisone.

Table 1 – Baseline characteristics of each cohort

Parameter	Cohort A (n=10)	Cohort B (n=8)
Demographics		
Age (years), mean (range)	39.3 (24-66)	36.8 (19-66)
Sex	5M, 5F	1M, 7F
Bmi (kg/m^2), mean ± SD	31.5 ± 12.0	31.1 ± 6.7
Daily GC dose (mg HC equivalents), mean range	28 (13-40)	35 (20-50)
Types of GCs	4 JC, 3 pred, 3 dex	2HC, 4 pred, 3 dex
17OHP at screening[a] (ng/dl), mean ± SD	5,985 ± 6,347	4,592 ±4,624

Abbreviations: 17OHP: 17-hydroxyprogesterone; BMI: body mass index; dex: dexamethasone; F: female; GC: glucocorticoid; HC: hydrocortisone; M: male; pred: prednisone; SD: standard deviation.
a 17OHP reference ranges: 27-199 ng/dL males, 15-290 ng/dL females.

SAFETY

[0333] Across both cohorts, Compound 1 was generally well tolerated. The most common type of adverse event (AE) was gastrointestinal disorders There were no serious AEs and no AEs leading to withdrawal.

PHARMACOKINETICS

[0334] Over a wide range of doses (200 to 1000 mg QD), Compound 1exhibited a predictable, dose-dependent PK profile.

EFFICACY

[0335] FIG. 15A-15D show the changes in levels of Androstenedione (A4) across both cohorts. Levels of A4 improved at ≥1 dose level for 10 out of 10 participants in Cohort A and 6 out of 8 participants in Cohort B. Excess A4 is associated with clinical sequelae in CAH. Attenuation of A4 demonstrates control of adrenal androgen.

[0336] FIG. 16A-16D show the changes in levels of 17-hydroxyprogesterone (17-OHP) across both cohorts. Levels of 17OHP improved at ≥1 dose level for 8 out of 10 participants in Cohort A and 6 out of 7 participants in Cohort B. 17OHP is a critical hormone in CAH diagnosis and management. Attenuation of 17OHP demonstrates control of adrenal steroid production.

[0337] FIG. 17A-17D show the changes in levels of adrenocorticotropic hormone (ACTH) across both cohorts. Levels of ACTH improved at ≥1 dose level for 8 out of 10 participants in

Cohort A and 5 out of 7 participants in Cohort B. Attenuation of ACTH demonstrates target engagement and fucntional CRF_1 receptor antagonism.

Table 2 – Percentage change from baseline in ACTH, 17OHP and A4.

	Cohort A			Cohort B
	200 mg QD (Week 2)	600 mg QD (Week 4)	1000 mg QD (Week 6)	200 mg BID (Weed 2)
ACTH	-25.7 (±51.6)	-60.1 (±37.5)	-32.7 (±47.0)	-36.5 (±58.0)
17OHP	+22.2 (±172.3)	-23.7 (±64.2)	-13.8 (±74.7)	-47.8 (±63.3)
A4	-12.1 (±47.4)	-33.2 (±36.5)	-28.6 (±44.6)	-16.0 (±81.4)

CONCLUSIONS










[0338] Compound 1, a potent and selective CRF_1 receptor antagonist, offers a novel nonsteroidal oral treatment approach for CAH. Compound 1 was well tolerated and efficacious in reducing excess ACTH, 17OHP, and androstenedione in patients with classic CAH. Compound 1 exhibited a predictable, dose-dependent PK profile suitable for the target population.

[0339] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. It is not intended that the invention be limited by the specific examples provided within the specification. While the invention has been described with reference to the aforementioned specification, the descriptions and illustrations of the embodiments herein are not meant to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. Furthermore, it shall be understood that all aspects of the invention are not limited to the specific depictions, configurations or relative proportions set forth herein which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is therefore contemplated that the invention shall also cover any such alternatives, modifications, variations or equivalents. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby

CLAIMS


WHAT IS CLAIMED IS:

1. A method of changing a metabolic parameter of a subject having a testicular adrenal rest tumor (TART) or an ovarian adrenal rest tumor (OART), comprising administering to the subject in need thereof a small molecule corticotropin-releasing factor type-1 (CRF_1) antagonist, or a pharmaceutically acceptable salt thereof, wherein the small molecule CRF_1 antagonist is:


,

,

,

,

,

, SSR-126374,

,

, or

, or a pharmaceutically acceptable salt thereof, and


wherein the metabolic parameter comprises fasting glucose, HbA1c level, insulin sensitivity, or a lipid profile, or a combination thereof.

2. The method of claim 1, wherein the small molecule CRF_1 antagonist is:



, or a pharmaceutically acceptable salt thereof.

3. The method of claim 1, wherein the small molecule CRF_1 antagonist is:



, or a pharmaceutically acceptable salt thereof.

4. The method of claim 1, wherein the metabolic parameter is insulin sensitivity.
5. The method of claim 1, wherein the subject has congenital adrenal hyperplasia (CAH).
6. The method of claim 1, wherein the administering reduces a size of the TART or the OART.
7. The method of claim 1, wherein the administering reduces a number of the TART or the OART.
8. The method of claim 1, wherein the small molecule CRF_1 antagonist is administered at a dose of about 10 mg/day to about 400 mg/day to the subject.
9. The method of claim 8, wherein the small molecule CRF_1 antagonist is administered at a dose of about 50 mg.
10. The method of claim 8, wherein the small molecule CRF_1 antagonist is administered at a dose of about 100 mg.
11. The method of claim 8, wherein the small molecule CRF_1 antagonist is administered at a dose of about 200 mg.
12. The method of claim 8, wherein the small molecule CRF_1 antagonist is administered at a dose of about 400 mg.
13. The method of claim 1, wherein the small molecule CRF_1 antagonist is administered to the subject once per day.
14. The method of claim 1, wherein the small molecule CRF_1 antagonist is administered to the subject twice per day.
15. The method of claim 1, wherein the small molecule CRF_1 antagonist is administered orally.
16. The method of claim 1, wherein the small molecule CRF_1 antagonist is formulated as a capsule or tablet.

17. The method of claim 1, wherein the administering reduces a plasma concentration of a biomarker comprising 17α-hydroxyprogesterone (17-OHP), adrenocorticotropic hormone (ACTH), testosterone, androstenedione (A4), luteinizing hormone (LH), follicle-stimulating hormone (FSH), inhibin B, sex hormone-binding globulin (SHBG), renin, or aldosterone, or a combination thereof.
18. The method of claim 1, wherein the biomarker is selected from the group consisting of 17-OHP, ACTH, and A4.
19. The method of claim 1, wherein the plasma concentration of the biomarker is at least 10% from baseline.

ABSTRACT OF THE DISCLOSURE

Provided herein are compounds and pharmaceutical compositions for the prevention and treatment of testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART).

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor:	HOWERTON; Alexis et al.	Group Art Unit:	
Serial Number:	19/043,303	Examiner:	Not Yet Assigned
Filing or 371 (c) Date:	2025-01-31	**CONFIRMATION NO:**	**1040**
Title:	METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS		

FILED ELECTRONICALLY ON: February 5, 2025

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Commissioner for Patents:

An Information Disclosure Statement along with attached PTO/SB/08 is hereby submitted. A copy of each listed publication is submitted, if required, pursuant to 37 CFR §§1.97-1.98, as indicated below.

The Examiner is requested to review the information provided and to make the information of record in the above-identified application. The Examiner is further requested to initial and return the attached PTO/SB/08 in accordance with MPEP § 609.

The right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered, is hereby reserved.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in § 1.56.

A. ☒ *37 CFR § 1.97 (b).* This Information Disclosure Statement should be considered by the Office because:

☐ (1) It is being filed within 3 months of the filing date of a national application and is other than a continued prosecution application under § 1.53 (d);

-- OR --

☐ (2) It is being filed within 3 months of entry of the national stage as set forth in § 1.491 in an international application;

-- OR --

☒ (3) It is being filed before the mailing of a first Office action on the merits;

-- OR --

☐ (4) It is being filed before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.

B. ☐ *37 CFR § 1.97(c).* Although this Information Disclosure Statement is being filed after the period specified in *37 CFR § 1.97(b),* above, it is filed before the mailing date of the earlier of (1) a final office action under § 1.113, (2) a notice of allowance under § 1.311, or (3) an action that otherwise closes prosecution in the application, this Information Disclosure Statement should be considered because it is accompanied by one of:

☐ a statement as specified in §1.97 (e) provided concurrently herewith;

-- OR --

☐ a fee of [$280.00/112.00/56.00] as set forth in § 1.17 (p) authorized below, enclosed, or included with the payment of other papers filed together with this statement.

C. ☐ *37 CFR § 1.97 (d).* Although this Information Disclosure Statement is being filed after the mailing date of the earlier of (1) a final office action under § 1.113, (2) a notice of allowance under § 1.311, or (3) an action that otherwise closes prosecution in the application, it is being filed before payment of the issue fee and should be considered because it is accompanied by:

i. a statement as specified in § 1.97 (e);

-- AND --

ii. a fee of [$280.00/112.00/56.00] as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this Statement.

D. ☐ *37 CFR §1.97 (e).* Statement.

☐ A statement is provided herewith to satisfy the requirement under 37 CFR §§ 1.97 (c);

-- AND/OR --

☐ A statement is provided herewith to satisfy the requirement under 37 CFR §§ 1.97 (d);

-- AND/OR --

☐ A copy of a dated communication from a foreign patent office clearly showing that the information disclosure statement is being submitted within 3 months of the filing date on the communication is provided in lieu of a statement under 37 C.F.R. § 1.97(e) (1) as provided for under MPEP 609.04(b) V.

E. ☐ *Statement Under 37 C.F.R. §1.704(d).* Each item of information contained in the information disclosure statement was first cited in any communication from a patent office in a counterpart foreign or international application or from the Office or is a communication that was issued by a

patent office in a counterpart foreign or international application or by the Office that was received by an individual designated in § 1.56(c) not more than thirty (30) days prior to the filing of this information disclosure statement. This statement is made pursuant to the requirements of 37 C.F.R. §1.704(d) to avoid reduction of the period of adjustment of the patent term for Applicant(s) delay. The Patent Term Adjustment Statement Under 37 CFR 1.704(d) on Form PTO/SB/133 is filed herewith.

F. ☒ *37 CFR §1.98 (a) (2).* The content of the Information Disclosure Statement is as follows:

☐ Copies of each of the references listed on the attached Form PTO/SB/08 are enclosed herewith.

-- OR --

☒ Copies of U.S. Patent Documents (issued patents and patent publications) listed on the attached Form PTO/SB/08 are not enclosed.

-- AND/OR --

☒ Copies of Foreign Patent Documents and/or Non Patent Literature Documents listed on the attached Form PTO/SB/08 are enclosed in accordance with 37 CFR §1.98 (a)(2).

-- AND/OR --

☒ Copies of pending unpublished U.S. patent applications are enclosed in accordance with 37 CFR §1.98 (a) (2) (iii).

G. ☒ *37 CFR §1.98(a)(3).* The Information Disclosure Statement includes non-English patents and/or references.

☐ Pursuant to 37 CFR §1.98(a)(3)(i), a concise explanation of the relevance of each patent, publication or other information provided that is not in English is provided herewith.

☐ Pursuant to MPEP 609(B), an English language copy of a foreign search report is submitted herewith to satisfy the requirement for a concise explanation where non-English language information is cited in the search report.

-- OR --

☐ A concise explanation of the relevance of each patent, publication or other information provided that is not in English is as follows: _____

☒ Pursuant to 37 CFR §1.98(a) (3) (ii), a copy of a translation, or a portion thereof, of the non-English language reference(s) is provided herewith.

H. ☐ *37 CFR §1.98(d).* Copies of patents, publications and pending U.S. patent applications, or other information specified in 37 C.F.R. § 1.98(a) are not provided herewith because:

☐ Pursuant to 37 CFR §1.98(d)(1) the information was previously submitted in an Information Disclosure Statement, or cited by examiner for another application under which this application claims priority for an earlier effective filing date under 35 U.S.C. 120.

Application in which the information was submitted: _____

Information Disclosure Statement(s) filed on: _____

AND

☐ The information disclosure statement submitted in the earlier application complied with paragraphs (a) through (c) of 37 CFR §1.98.

I. ☒ *Fee Authorization*. The Commissioner is hereby authorized to charge the above-referenced fees of $200.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 23-2415 (50535-710.305).

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Dated: February 5, 2025

By: /Victoria Cheng/
Victoria Cheng, Reg. No. 79641

650 Page Mill Road
Palo Alto, CA 94304-1050
(650) 493-9300
Customer No. 21971

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				***Complete if Known***	
				Application Number	19/043,303
				Filing Date	01-31-2025
				First Named Inventor	HOWERTON; Alexis
				Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	1	of	9	Attorney Docket Number	50535-710.305

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	001	US-4328245	05-04-1982	YU; Cheng-Der et al.	
	002	US-4409239	10-11-1983	YU; Cheng-Der	
	003	US-4410545	10-18-1983	YU; Cheng-Der et al.	
	004	US-4861760	08-29-1989	MAZUEL; Claude et al.	
	005	US-4911920	03-27-1990	JANI; Rajni et al.	
	006	US-5212162	05-18-1993	MISSEL; Paul J. T. et al.	
	007	US-5403841	04-04-1995	LANG; John C. et al.	
	008	US-10849908	12-01-2020	HOWERTON; Alexis et al.	
	009	US-11007201	05-18-2021	HOWERTON; Alexis et al.	
	010	US-11304950	04-19-2022	HOWERTON et al.	
	011	US-11311549	04-26-2022	HOWERTON; Alexis et al.	
	012	US-11344557	05-31-2022	HOWERTON; Alexis et al.	
	013	US-11351177	06-07-2022	HOWERTON; Alexis et al.	
	014	US-12115166	10-15-2024	HOWERTON; Alexis et al.	
	015	US-20100196389	08-05-2010	EVANS-FREKE; Stephen	
	016	US-20100222339	09-02-2010	CHEN; Zhaogen et al.	
	017	US-20170020877	01-26-2017	GRIGORIADIS; Dimitri E.	
	018	US-20220143037	05-12-2022	HOWERTON; Alexis et al.	
	019	US-20220211711	07-07-2022	HOWERTON; Alexis et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				***Complete if Known***	
				Application Number	19/043,303
				Filing Date	01-31-2025
				First Named Inventor	HOWERTON; Alexis
				Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	2	of	9	Attorney Docket Number	50535-710.305

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	001	CN-101516887-A	08-26-2009	LILLY CO ELI [US]	Abstract:	☒
	002	CN-106102740-A	11-09-2016	NEUROCRINE BIOSCIENCES INC.	Abstract:	☒
	003	JP-2010504344-A	02-12-2010	ELI LILLY AND CO.	Machine Translation:	☒
	004	JP-2017503030-A	01-26-2017	NEUROCRINE BIOSCIENCES, INC.	Machine Translation:	☒
	005	JP-H0971528-A	03-18-1997	HAYASHIBARA BIOCHEM LAB [JP]	Abstract:	☒
	006	WO-0040529-A1	07-13-2000	ANGIOGENE PHARM LTD [GB], et al.		☐
	007	WO-0041669-A2	07-20-2000	ANGIOGENE PHARM LTD [GB], et al.		☐
	008	WO-0192224-A1	12-06-2001	ASTRAZENECA AB [SE], et al.		☐
	009	WO-0204434-A1	01-17-2002	ANGIOGENE PHARM LTD [GB], et al.		☐
	010	WO-0208213-A1	01-31-2002	ANGIOGENE PHARM LTD [GB], et al.		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				***Complete if Known***	
				Application Number	19/043,303
				Filing Date	01-31-2025
				First Named Inventor	HOWERTON; Alexis
				Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	3	of	9	Attorney Docket Number	50535-710.305

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	011	WO-2007109853-A1	10-04-2007	VELACOR THERAPEUTICS PTY LTD [AU], et al.		☐
	012	WO-2008036579-A1	03-27-2008	LILLY CO ELI [US], et al.		☐
	013	WO-2015112642-A1	07-30-2015	NEUROCRINE BIOSCIENCES INC [US]		☐
	014	WO-2019036472-A1	02-21-2019	SPRUCE BIOSCIENCES INC [US]		☐
	015	WO-2019036503-A1	02-21-2019	SPRUCE BIOSCIENCES INC [US]		☐
	016	WO-2019210266-A1	10-31-2019	SPRUCE BIOSCIENCES INC [US]		☐
	017	WO-9722596-A1	06-26-1997	ZENECA LTD [GB], et al.		☐
	018	WO-9730035-A1	08-21-1997	ZENECA LTD [GB], et al.		☐
	019	WO-9732856-A1	09-12-1997	ZENECA LTD [GB], et al.		☐
	020	WO-9813354-A1	04-02-1998	ZENECA LTD [GB], et al.		☐
	021	WO-9902166-A1	01-21-1999	ANGIOGENE PHARM LTD [GB], et al.		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				***Complete if Known***	
				Application Number	19/043,303
				Filing Date	01-31-2025
				First Named Inventor	HOWERTON; Alexis
				Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	4	of	9	Attorney Docket Number	50535-710.305

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	001	AL-MUHAMMED, J. et al. In-vivo studies on dexamethasone sodium phosphate liposomes. Journal of microencapsulation 13(3):293-306 (1996).	☐
	002	BERGE, Stephen M. et al. Pharmaceutical Salts. Journal of Pharmaceutical Sciences 66(1):1-19 (1977).	☐
	003	CHEN, Hua-dong. et al. Ovarian adrenal rest tumors undetected by imaging studies and identified at surgery in three females with congenital adrenal hyperplasia unresponsive to increased hormone therapy dosage. Endocrine pathology 28(2):146-151 (2017).	☐
	004	CHONN, Archadio et al. Recent Advances in Liposomal Drug-delivery Systems. Current Opinion in Biotechnology 6(6):698-708 (1995).	☐
	005	Co-pending U.S. Application No. 18/941,832, inventors HOWERTON; Alexis et al., filed on November 08, 2024.	☐
	006	Co-pending U.S. Application No. 19/043,264, inventors HOWERTON; Alexis et al., filed on January 31, 2025.	☐
	007	Co-pending U.S. Application No. 19/043,275, inventors HOWERTON; Alexis et al., filed on January 31, 2025.	☐
	008	EYLES et al. Oral delivery and fate of poly(lactic acid) microsphere-encapsulated interferon in rats. J Pharm Pharmacol. 49(7):669-74 (1997).	☐
	009	GAO, Zhi-Hui. et al. Controlled Release of a Contraceptive Steroid From Biodegradable and Injectable Gel Formulations: in Vitro Evaluation. Pharmaceutical research 12(6):857-863 (1995).	☐
	010	JIN et al. Testicular adrenal rest tumors in a patient with untreated congenital adrenal hyperplasia. Korean J Pediatr 2011;54(3):137-140.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				***Complete if Known***	
				Application Number	19/043,303
				Filing Date	01-31-2025
				First Named Inventor	HOWERTON; Alexis
				Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	5	of	9	Attorney Docket Number	50535-710.305

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	011	KAPRARA, et al. The corticotropin releasing factor system in cancer: expression and pathophysiological implications. Cellular and molecular life sciences 67(8):1293-1306 (2010).	☐
	012	MENDES-DOS-SANTOS et al. Prevalence of Testicular Adrenal Rest Tumor and Factors Associated with Its Development in Congenital Adrenal Hyperplasia. Hormone Res. In Paed. 90:161-168 (2018).	☐
	013	MUNSON, Peter et al. Ligand: a Versatile Computerized Approach for Characterization of Ligand-binding Systems. Analytical Biochemistry 107(1):220-239 (1980).	☐
	014	Neurocrine Biosciences, Inc. (Petitioner) v. Spruce Biosciences, Inc. (Patent Owner). Decision Granting Institution of Post-Grant Review of U.S. Patent No. 11,007,201 dated December 1, 2023 (pp. 1-38) (PGR2022-00025).	☐
	015	Neurocrine Biosciences, Inc. (Petitioner) v. Spruce Biosciences, Inc. (Patent Owner). Final Written Decision of Post-Grant Review of U.S. Patent No. 10,849,908 dated November 26, 2024 (pp. 1-62) (PGR2021-00088).	☐
	016	Neurocrine Biosciences, Inc. (Petitioner) v. Spruce Biosciences, Inc. (Patent Owner). Final Written Decision of Post-Grant Review of U.S. Patent No. 11,007,201 dated November 27, 2024 (pp. 1-60) (PGR2022-00025).	☐
	017	Neurocrine Biosciences, Inc. (Petitioner) v. Spruce Biosciences, Inc. (Patent Owner). Petition for Post Grant Review of U.S. Patent No. 10,849,908 dated May 28, 2021 (pp. 1-90) (PGR2021-00088).	☐
	018	Neurocrine Biosciences, Inc. (Petitioner) v. Spruce Biosciences, Inc. (Patent Owner). Petition for Post Grant Review of U.S. Patent No. 11,007,201 dated February 18, 2022 (pp 1-92) (PGR2022-00025).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				***Complete if Known***	
				Application Number	19/043,303
				Filing Date	01-31-2025
				First Named Inventor	HOWERTON; Alexis
				Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	6	of	9	Attorney Docket Number	50535-710.305

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	019	OSTRO, Mark J. et al. Use of Liposomes as Injectable-drug Delivery Systems. American Journal of Hospital Pharmacy 46(8):1576-1587 (1989).	☐
	020	PCT/US2019/029486 International Invitation to Pay Additional Fees dated June 4, 2019.	☐
	021	PCT/US2019/029486 International Search Report and Written Opinion dated August 12, 2019.	☐
	022	RAO. Recent developments of collagen-based materials for medical applications and drug delivery systems. J Biomater Sci Polym Ed. 7(7):623-45 (1995).	☐
	023	REICHMAN et al. Fertility in Patients with Congenital Adrenal Hyperplasia. Fertility and Sterility, Vol. 101, No. 2, 2014. 301-309.	☐
	024	REISCH et al. Testicular adrenal rest tumors develop independently of long-term disease control: a longitudinal analysis of 50 adult men with congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 98(11):E1820-E1826 (2013).	☐
	025	SMEETS et. al. Molecular characterization of testicular adrenal rest tumors in congenital adrenal hyperplasia: lesions with both adrenocortical and Leydig cell features. JCEM 100(3):E524-E530 (2015).	☐
	026	TIOSANO et al. Ovarian adrenal rest tumor in a congenital adrenal hyperplasia patient with adrenocorticotropin hypersecretion following adrenalectomy. Hormone Res. in Paediatrics 74:223-228 (2010).	☐
	027	U.S. Serial No. 17/081,694 Office Action dated February 26, 2021.	☐
	028	U.S. Serial No. 17/081,694 Office Action dated June 11, 2021.	☐
	029	U.S. Serial No. 17/667,285 Office Action dated December 29, 2023.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				***Complete if Known***	
				Application Number	19/043,303
				Filing Date	01-31-2025
				First Named Inventor	HOWERTON; Alexis
				Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	7	of	9	Attorney Docket Number	50535-710.305

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	030	U.S. Serial No. 17/667,285 Office Action dated June 10, 2024.	☐
	031	ZAAROUR et al. Bilateral Ovary Adrenal Rest Tumor in a Congenital Adrenal Hyperplasia Following Adrenalectomy. Endocrinol. Pract. 20(4):e69-e74 (2014).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				***Complete if Known***	
				Application Number	19/043,303
				Filing Date	01-31-2025
				First Named Inventor	HOWERTON; Alexis
				Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	8	of	9	Attorney Docket Number	50535-710.305

TIMING STATEMENT

Please see 37 CFR 1.97(e) to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached timing statement under 37 CFR 1.97(e).

☒ A timing statement under 37 CFR 1.97(e) is not submitted herewith.

TIMING FEE

☐ The fee set forth in 37 CFR 1.17(p) has been submitted herewith.

COPIES

☐ An identification of an earlier application pursuant to 37 CFR 1.98(d)(1) is attached.

SIZE FEE ASSERTION

Please see 37CFR 1.17(v) and attached instructions for completing this form to make the appropriate selection of an assertion under 37 CFR 1.98. For the information disclosure statement (IDS) submitted herewith, the applicant or patent owner certifies the following with respect to the cumulative number of applicant-provided or patent-owner provided items of information submitted to date including those in the accompanying IDS (select only one):

☐ No IDS size fee is required under 37 CFR 1.17 (v) at this time.

☒ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(1).

☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(2).

☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(3).

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 11.18. Please see CFR 1.4(d) for the form of the signature.

Signature:	**/Victoria Cheng/**	Date (YYYY-MM-DD)	**2025-02-05**
Name/Print	Victoria Cheng	Registration Number	79641

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				***Complete if Known***	
				Application Number	19/043,303
				Filing Date	01-31-2025
				First Named Inventor	HOWERTON; Alexis
				Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	9	of	9	Attorney Docket Number	50535-710.305

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor:	HOWERTON; Alexis et al.	Group Art Unit:	
Serial Number:	19/043,303	Examiner:	Not Yet Assigned
Filing or 371 (c) Date:	2025-01-31	**CONFIRMATION NO:**	**1040**
Title:	METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS		

FILED ELECTRONICALLY ON: February 5, 2025

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Commissioner for Patents:

An Information Disclosure Statement along with attached PTO/SB/08 is hereby submitted. A copy of each listed publication is submitted, if required, pursuant to 37 CFR §§1.97-1.98, as indicated below.

The Examiner is requested to review the information provided and to make the information of record in the above-identified application. The Examiner is further requested to initial and return the attached PTO/SB/08 in accordance with MPEP § 609.

The right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered, is hereby reserved.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in § 1.56.

A. ☒ *37 CFR § 1.97 (b).* This Information Disclosure Statement should be considered by the Office because:

☐ (1) It is being filed within 3 months of the filing date of a national application and is other than a continued prosecution application under § 1.53 (d);

-- OR --

☐ (2) It is being filed within 3 months of entry of the national stage as set forth in § 1.491 in an international application;

-- OR --

☒ (3) It is being filed before the mailing of a first Office action on the merits;

-- OR --

☐ (4) It is being filed before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.

B. ☐ *37 CFR § 1.97(c).* Although this Information Disclosure Statement is being filed after the period specified in *37 CFR § 1.97(b),* above, it is filed before the mailing date of the earlier of (1) a final office action under § 1.113, (2) a notice of allowance under § 1.311, or (3) an action that otherwise closes prosecution in the application, this Information Disclosure Statement should be considered because it is accompanied by one of:

☐ a statement as specified in §1.97 (e) provided concurrently herewith;

-- OR --

☐ a fee of [$280.00/112.00/56.00] as set forth in § 1.17 (p) authorized below, enclosed, or included with the payment of other papers filed together with this statement.

C. ☐ *37 CFR § 1.97 (d).* Although this Information Disclosure Statement is being filed after the mailing date of the earlier of (1) a final office action under § 1.113, (2) a notice of allowance under § 1.311, or (3) an action that otherwise closes prosecution in the application, it is being filed before payment of the issue fee and should be considered because it is accompanied by:

i. a statement as specified in § 1.97 (e);

-- AND --

ii. a fee of [$280.00/112.00/56.00] as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this Statement.

D. ☐ *37 CFR §1.97 (e).* Statement.

☐ A statement is provided herewith to satisfy the requirement under 37 CFR §§ 1.97 (c);

-- AND/OR --

☐ A statement is provided herewith to satisfy the requirement under 37 CFR §§ 1.97 (d);

-- AND/OR --

☐ A copy of a dated communication from a foreign patent office clearly showing that the information disclosure statement is being submitted within 3 months of the filing date on the communication is provided in lieu of a statement under 37 C.F.R. § 1.97(e) (1) as provided for under MPEP 609.04(b) V.

E. ☐ *Statement Under 37 C.F.R. §1.704(d).* Each item of information contained in the information disclosure statement was first cited in any communication from a patent office in a counterpart foreign or international application or from the Office or is a communication that was issued by a

patent office in a counterpart foreign or international application or by the Office that was received by an individual designated in § 1.56(c) not more than thirty (30) days prior to the filing of this information disclosure statement. This statement is made pursuant to the requirements of 37 C.F.R. §1.704(d) to avoid reduction of the period of adjustment of the patent term for Applicant(s) delay. The Patent Term Adjustment Statement Under 37 CFR 1.704(d) on Form PTO/SB/133 is filed herewith.

F. ☒ *37 CFR §1.98 (a) (2).* The content of the Information Disclosure Statement is as follows:

☐ Copies of each of the references listed on the attached Form PTO/SB/08 are enclosed herewith.

-- OR --

☒ Copies of U.S. Patent Documents (issued patents and patent publications) listed on the attached Form PTO/SB/08 are not enclosed.

-- AND/OR --

☒ Copies of Foreign Patent Documents and/or Non Patent Literature Documents listed on the attached Form PTO/SB/08 are enclosed in accordance with 37 CFR §1.98 (a)(2).

-- AND/OR --

☒ Copies of pending unpublished U.S. patent applications are enclosed in accordance with 37 CFR §1.98 (a) (2) (iii).

G. ☒ *37 CFR §1.98(a)(3).* The Information Disclosure Statement includes non-English patents and/or references.

☐ Pursuant to 37 CFR §1.98(a)(3)(i), a concise explanation of the relevance of each patent, publication or other information provided that is not in English is provided herewith.

☐ Pursuant to MPEP 609(B), an English language copy of a foreign search report is submitted herewith to satisfy the requirement for a concise explanation where non-English language information is cited in the search report.

-- OR --

☐ A concise explanation of the relevance of each patent, publication or other information provided that is not in English is as follows: _____

☒ Pursuant to 37 CFR §1.98(a) (3) (ii), a copy of a translation, or a portion thereof, of the non-English language reference(s) is provided herewith.

H. ☐ *37 CFR §1.98(d).* Copies of patents, publications and pending U.S. patent applications, or other information specified in 37 C.F.R. § 1.98(a) are not provided herewith because:

☐ Pursuant to 37 CFR §1.98(d)(1) the information was previously submitted in an Information Disclosure Statement, or cited by examiner for another application under which this application claims priority for an earlier effective filing date under 35 U.S.C. 120.

Application in which the information was submitted: _____

Information Disclosure Statement(s) filed on: _____

AND

☐ The information disclosure statement submitted in the earlier application complied with paragraphs (a) through (c) of 37 CFR §1.98.

I. ☒ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of $200.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 23-2415 (50535-710.305).

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Dated: February 5, 2025

By: /Victoria Cheng/
Victoria Cheng, Reg. No. 79641

650 Page Mill Road
Palo Alto, CA 94304-1050
(650) 493-9300
Customer No. 21971

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				*Complete if Known*	
				Application Number	19/043,303
				Filing Date	01-31-2025
				First Named Inventor	HOWERTON; Alexis
				Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	1	of	9	Attorney Docket Number	50535-710.305

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	001	US-4328245	05-04-1982	YU; Cheng-Der et al.	
	002	US-4409239	10-11-1983	YU; Cheng-Der	
	003	US-4410545	10-18-1983	YU; Cheng-Der et al.	
	004	US-4861760	08-29-1989	MAZUEL; Claude et al.	
	005	US-4911920	03-27-1990	JANI; Rajni et al.	
	006	US-5212162	05-18-1993	MISSEL; Paul J. T. et al.	
	007	US-5403841	04-04-1995	LANG; John C. et al.	
	008	US-10849908	12-01-2020	HOWERTON; Alexis et al.	
	009	US-11007201	05-18-2021	HOWERTON; Alexis et al.	
	010	US-11304950	04-19-2022	HOWERTON et al.	
	011	US-11311549	04-26-2022	HOWERTON; Alexis et al.	
	012	US-11344557	05-31-2022	HOWERTON; Alexis et al.	
	013	US-11351177	06-07-2022	HOWERTON; Alexis et al.	
	014	US-12115166	10-15-2024	HOWERTON; Alexis et al.	
	015	US-20100196389	08-05-2010	EVANS-FREKE; Stephen	
	016	US-20100222339	09-02-2010	CHEN; Zhaogen et al.	
	017	US-20170020877	01-26-2017	GRIGORIADIS; Dimitri E.	
	018	US-20220143037	05-12-2022	HOWERTON; Alexis et al.	
	019	US-20220211711	07-07-2022	HOWERTON; Alexis et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				*Complete if Known*	
				Application Number	19/043,303
				Filing Date	01-31-2025
				First Named Inventor	HOWERTON; Alexis
				Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	2	of	9	Attorney Docket Number	50535-710.305

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	001	CN-101516887-A	08-26-2009	LILLY CO ELI [US]	Abstract:	☒
	002	CN-106102740-A	11-09-2016	NEUROCRINE BIOSCIENCES INC.	Abstract:	☒
	003	JP-2010504344-A	02-12-2010	ELI LILLY AND CO.	Machine Translation:	☒
	004	JP-2017503030-A	01-26-2017	NEUROCRINE BIOSCIENCES, INC.	Machine Translation:	☒
	005	JP-H0971528-A	03-18-1997	HAYASHIBARA BIOCHEM LAB [JP]	Abstract:	☒
	006	WO-0040529-A1	07-13-2000	ANGIOGENE PHARM LTD [GB], et al.		☐
	007	WO-0041669-A2	07-20-2000	ANGIOGENE PHARM LTD [GB], et al.		☐
	008	WO-0192224-A1	12-06-2001	ASTRAZENECA AB [SE], et al.		☐
	009	WO-0204434-A1	01-17-2002	ANGIOGENE PHARM LTD [GB], et al.		☐
	010	WO-0208213-A1	01-31-2002	ANGIOGENE PHARM LTD [GB], et al.		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				*Complete if Known*	
				Application Number	19/043,303
				Filing Date	01-31-2025
				First Named Inventor	HOWERTON; Alexis
				Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	3	of	9	Attorney Docket Number	50535-710.305

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	011	WO-2007109853-A1	10-04-2007	VELACOR THERAPEUTICS PTY LTD [AU], et al.		☐
	012	WO-2008036579-A1	03-27-2008	LILLY CO ELI [US], et al.		☐
	013	WO-2015112642-A1	07-30-2015	NEUROCRINE BIOSCIENCES INC [US]		☐
	014	WO-2019036472-A1	02-21-2019	SPRUCE BIOSCIENCES INC [US]		☐
	015	WO-2019036503-A1	02-21-2019	SPRUCE BIOSCIENCES INC [US]		☐
	016	WO-2019210266-A1	10-31-2019	SPRUCE BIOSCIENCES INC [US]		☐
	017	WO-9722596-A1	06-26-1997	ZENECA LTD [GB], et al.		☐
	018	WO-9730035-A1	08-21-1997	ZENECA LTD [GB], et al.		☐
	019	WO-9732856-A1	09-12-1997	ZENECA LTD [GB], et al.		☐
	020	WO-9813354-A1	04-02-1998	ZENECA LTD [GB], et al.		☐
	021	WO-9902166-A1	01-21-1999	ANGIOGENE PHARM LTD [GB], et al.		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				***Complete if Known***	
				Application Number	19/043,303
				Filing Date	01-31-2025
				First Named Inventor	HOWERTON; Alexis
				Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	4	of	9	Attorney Docket Number	50535-710.305

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	001	AL-MUHAMMED, J. et al. In-vivo studies on dexamethasone sodium phosphate liposomes. Journal of microencapsulation 13(3):293-306 (1996).	☐
	002	BERGE, Stephen M. et al. Pharmaceutical Salts. Journal of Pharmaceutical Sciences 66(1):1-19 (1977).	☐
	003	CHEN, Hua-dong. et al. Ovarian adrenal rest tumors undetected by imaging studies and identified at surgery in three females with congenital adrenal hyperplasia unresponsive to increased hormone therapy dosage. Endocrine pathology 28(2):146-151 (2017).	☐
	004	CHONN, Archadio et al. Recent Advances in Liposomal Drug-delivery Systems. Current Opinion in Biotechnology 6(6):698-708 (1995).	☐
	005	Co-pending U.S. Application No. 18/941,832, inventors HOWERTON; Alexis et al., filed on November 08, 2024.	☐
	006	Co-pending U.S. Application No. 19/043,264, inventors HOWERTON; Alexis et al., filed on January 31, 2025.	☐
	007	Co-pending U.S. Application No. 19/043,275, inventors HOWERTON; Alexis et al., filed on January 31, 2025.	☐
	008	EYLES et al. Oral delivery and fate of poly(lactic acid) microsphere-encapsulated interferon in rats. J Pharm Pharmacol. 49(7):669-74 (1997).	☐
	009	GAO, Zhi-Hui. et al. Controlled Release of a Contraceptive Steroid From Biodegradable and Injectable Gel Formulations: in Vitro Evaluation. Pharmaceutical research 12(6):857-863 (1995).	☐
	010	JIN et al. Testicular adrenal rest tumors in a patient with untreated congenital adrenal hyperplasia. Korean J Pediatr 2011;54(3):137-140.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				***Complete if Known***	
				Application Number	19/043,303
				Filing Date	01-31-2025
				First Named Inventor	HOWERTON; Alexis
				Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	5	of	9	Attorney Docket Number	50535-710.305

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	011	KAPRARA, et al. The corticotropin releasing factor system in cancer: expression and pathophysiological implications. Cellular and molecular life sciences 67(8):1293-1306 (2010).	☐
	012	MENDES-DOS-SANTOS et al. Prevalence of Testicular Adrenal Rest Tumor and Factors Associated with Its Development in Congenital Adrenal Hyperplasia. Hormone Res. In Paed. 90:161-168 (2018).	☐
	013	MUNSON, Peter et al. Ligand: a Versatile Computerized Approach for Characterization of Ligand-binding Systems. Analytical Biochemistry 107(1):220-239 (1980).	☐
	014	Neurocrine Biosciences, Inc. (Petitioner) v. Spruce Biosciences, Inc. (Patent Owner). Decision Granting Institution of Post-Grant Review of U.S. Patent No. 11,007,201 dated December 1, 2023 (pp. 1-38) (PGR2022-00025).	☐
	015	Neurocrine Biosciences, Inc. (Petitioner) v. Spruce Biosciences, Inc. (Patent Owner). Final Written Decision of Post-Grant Review of U.S. Patent No. 10,849,908 dated November 26, 2024 (pp. 1-62) (PGR2021-00088).	☐
	016	Neurocrine Biosciences, Inc. (Petitioner) v. Spruce Biosciences, Inc. (Patent Owner). Final Written Decision of Post-Grant Review of U.S. Patent No. 11,007,201 dated November 27, 2024 (pp. 1-60) (PGR2022-00025).	☐
	017	Neurocrine Biosciences, Inc. (Petitioner) v. Spruce Biosciences, Inc. (Patent Owner). Petition for Post Grant Review of U.S. Patent No. 10,849,908 dated May 28, 2021 (pp. 1-90) (PGR2021-00088).	☐
	018	Neurocrine Biosciences, Inc. (Petitioner) v. Spruce Biosciences, Inc. (Patent Owner). Petition for Post Grant Review of U.S. Patent No. 11,007,201 dated February 18, 2022 (pp 1-92) (PGR2022-00025).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				*Complete if Known*	
				Application Number	19/043,303
				Filing Date	01-31-2025
				First Named Inventor	HOWERTON; Alexis
				Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	6	of	9	Attorney Docket Number	50535-710.305

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	019	OSTRO, Mark J. et al. Use of Liposomes as Injectable-drug Delivery Systems. American Journal of Hospital Pharmacy 46(8):1576-1587 (1989).	☐
	020	PCT/US2019/029486 International Invitation to Pay Additional Fees dated June 4, 2019.	☐
	021	PCT/US2019/029486 International Search Report and Written Opinion dated August 12, 2019.	☐
	022	RAO. Recent developments of collagen-based materials for medical applications and drug delivery systems. J Biomater Sci Polym Ed. 7(7):623-45 (1995).	☐
	023	REICHMAN et al. Fertility in Patients with Congenital Adrenal Hyperplasia. Fertility and Sterility, Vol. 101, No. 2, 2014. 301-309.	☐
	024	REISCH et al. Testicular adrenal rest tumors develop independently of long-term disease control: a longitudinal analysis of 50 adult men with congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 98(11):E1820-E1826 (2013).	☐
	025	SMEETS et. al. Molecular characterization of testicular adrenal rest tumors in congenital adrenal hyperplasia: lesions with both adrenocortical and Leydig cell features. JCEM 100(3):E524-E530 (2015).	☐
	026	TIOSANO et al. Ovarian adrenal rest tumor in a congenital adrenal hyperplasia patient with adrenocorticotropin hypersecretion following adrenalectomy. Hormone Res. in Paediatrics 74:223-228 (2010).	☐
	027	U.S. Serial No. 17/081,694 Office Action dated February 26, 2021.	☐
	028	U.S. Serial No. 17/081,694 Office Action dated June 11, 2021.	☐
	029	U.S. Serial No. 17/667,285 Office Action dated December 29, 2023.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				***Complete if Known***	
				Application Number	19/043,303
				Filing Date	01-31-2025
				First Named Inventor	HOWERTON; Alexis
				Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	7	of	9	Attorney Docket Number	50535-710.305

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	030	U.S. Serial No. 17/667,285 Office Action dated June 10, 2024.	☐
	031	ZAAROUR et al. Bilateral Ovary Adrenal Rest Tumor in a Congenital Adrenal Hyperplasia Following Adrenalectomy. Endocrinol. Pract. 20(4):e69-e74 (2014).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				***Complete if Known***	
				Application Number	19/043,303
				Filing Date	01-31-2025
				First Named Inventor	HOWERTON; Alexis
				Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	8	of	9	Attorney Docket Number	50535-710.305

TIMING STATEMENT

Please see 37 CFR 1.97(e) to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached timing statement under 37 CFR 1.97(e).

☒ A timing statement under 37 CFR 1.97(e) is not submitted herewith.

TIMING FEE

☐ The fee set forth in 37 CFR 1.17(p) has been submitted herewith.

COPIES

☐ An identification of an earlier application pursuant to 37 CFR 1.98(d)(1) is attached.

SIZE FEE ASSERTION

Please see 37CFR 1.17(v) and attached instructions for completing this form to make the appropriate selection of an assertion under 37 CFR 1.98. For the information disclosure statement (IDS) submitted herewith, the applicant or patent owner certifies the following with respect to the cumulative number of applicant-provided or patent-owner provided items of information submitted to date including those in the accompanying IDS (select only one):

☐ No IDS size fee is required under 37 CFR 1.17 (v) at this time.

☒ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(1).

☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(2).

☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(3).

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 11.18. Please see CFR 1.4(d) for the form of the signature.

Signature:	**/Victoria Cheng/**	Date (YYYY-MM-DD)	**2025-02-05**
Name/Print	Victoria Cheng	Registration Number	79641

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				***Complete if Known***	
				Application Number	19/043,303
				Filing Date	01-31-2025
				First Named Inventor	HOWERTON; Alexis
				Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	9	of	9	Attorney Docket Number	50535-710.305

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/66, 31/165, 31/27, C07C 13/547 — A1

(11) International Publication Number: **WO 99/02166**

(43) International Publication Date: 21 January 1999 (21.01.99)

(21) International Application Number: PCT/GB98/01977

(22) International Filing Date: 6 July 1998 (06.07.98)

(30) Priority Data:
9714249.1 8 July 1997 (08.07.97) GB

(71) Applicant *(for all designated States except US)*: ANGIOGENE PHARMACEUTICALS LTD. [GB/GB]; 14 Plowden Park, Aston Rowant, Watlington, Oxfordshire OX9 5SX (GB).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: DOUGHERTY, Graeme [GB/GB]; 4 Bonaly Grove, Edindurgh EH13 0QD (GB).

(74) Agent: BAILLIE, Iain, C.; Langner Parry, 52–54 High Holborn, London WC1V 6RR (GB).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: USE OF COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS

(57) Abstract

Colchinol derivatives of formula (I) wherein R_1, R_2, R_3 and R_6 are each independently H, optionally substituted alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, alkanoyl, PO_3H_2; X is carbonyl (CO), thiocarbonyl (CS), methylene (CH_2) or a group CHR_4; R_4 is OH, O–alkyl or NR_8R_9; R_5 and R_7 are each independently H, alkyl, halogen, hydroxy, alkoxy, nitro or amino; R_8 is H, optionally substituted alkyl, cycloalkyl, alkanoyl, thioalkanoyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, arylaminocarbonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl or arylaminosulfonyl; and R_9 is H, alkyl or cycloalkyl and the pharmaceutically acceptable salts, solvates, and hydrates thereof have been found to be useful for treatment of diseases involving angiogenesis. Some of these compounds are novel. Particularly preferred are those compounds in which R_6 is PO_3H_2.



(I)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		


USE OF COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS

This invention relates to vascular damaging agents and particularly to use in the preparation of agents for treatment of neovascularisation of a group of colchinol derivatives some of which are new compounds.

Formation of new vasculature by angiogenesis is a key pathological feature of several diseases (J Folkman, New England Journal of Medicine 333, 1757 (1995)). For example, for a solid tumour to grow it must develop its own blood supply upon which it depends critically for the provision of oxygen and nutrients; if this blood supply is mechanically shut off the tumour undergoes necrotic death. Neovascularisation is also a clinical feature of skin lesions in psoriasis, of the invasive pannus in the joints of rheumatoid arthritis patients and of atherosclerotic plaques. Retinal neovascularisation is pathological in macular degeneration and in diabetic retinopathy. In all these diseases reversal of neovascularisation by damaging the newly-formed vascular endothelium is expected to have a beneficial therapeutic effect.

Colchinol derivatives for example N-acetyl-colchinol are known. Anti-tumour effects have been noted on animal models (see for example - JNCI (Journal National Cancer Institute) Page 379-392 1952, Vol 13). However, the effect studied was that of gross damage (haemorrhage, softening and necrosis) and there is no suggestion of treatment of inappropriate angiogenesis by destruction of neovasculature.

A search of Chemical Abstracts (post 1955) based on the substructure




revealed a number of colchinol related structures.

To the extent that any of these compounds have been studied for anti-cancer activity it is because tubulin binding agents might be expected to be anti-mitotic and therefore to have a direct effect on tumour cells.

In the course of the work on the present invention, the issue of the relevance of tubulin-binding properties to possible effectiveness as anti-vascular agent was studied but no predictability was found. Thus docetaxel (Lancet, 344, 1267-1271, 1994), which is a tubulin-binding agent, had no vascular-damaging effects even when administered at its Maximum Tolerated Dose. Even when the present inventors tested some compounds structurally related to the present invention, the therapeutic window (ratio of MTD (Maximum tolerated dose) to MED (Minimum effective dose)) was found to be too small for potential clinical effectiveness.

According to the present invention there is provided the use of colchinol derivatives for the preparation of compositions for the treatment of diseases involving angiogenesis in which the colchinol derivative has the formula



I

wherein

R_1, R_2, R_3 and R_6 are each independently H, optionally substituted alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, alkanoyl, PO_3H_2;

X is carbonyl (CO), thiocarbonyl (CS), methylene (CH_2) or a group CHR_4

R_4 is OH, O-alkyl or NR_8R_9;

R_5 and R_7 are each independently H, alkyl, halogen, hydroxy, alkoxy, nitro or amino;


R_8 is H, optionally substituted alkyl, cycloalkyl, alkanoyl, thioalkanoyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, arylaminocarbonyl, alkylsulphonyl, arylsulphonyl, aminosulphonyl, alkylaminosulphonyl, dialkylaminosulphonyl or arylaminosulphonyl;

and R_9 is H, alkyl or cycloalkyl

and the pharmaceutically acceptable salts, solvates, and hydrates thereof.

It is believed, though this is not limiting on the invention, that the use of compounds of the invention damages newly-formed vasculature, for example the vasculature of tumours, thus effectively reversing the process of angiogenesis as compared to known anti-angiogenic agents which tend to be less effective once the vasculature has formed.


Certain of these compounds are novel. In one embodiment the novel compounds are those of formula I in which at least one of R_1, R_2, R_3, R_6 is PO_3H_2. In a particular preferred embodiment R_6 is PO_3H_2. Particularly preferred are compounds defined by the formula



II

wherein
R_1, R_2 and R_3 are each independently H, optionally substituted alkyl, cycloalkyl, alkenyl, alkynyl, alkanoyl, or PO_3H_2;
R_6 is PO_3H_2;
R_4 is H or NR_8R_9;
R_5 and R_7 are each independently H, alkyl, halogen, alkoxy, nitro or amino;
R_8 is H, optionally substituted alkyl, cycloalkyl, alkanoyl, thioalkanoyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, arylaminocarbonyl, alkylsulphonyl, arylsulphonyl, aminosulphonyl, alkylaminosulphonyl, dialkylaminosulphonyl or arylaminosulphonyl;
and R_9 is H, alkyl or cycloalkyl,
and the pharmaceutically acceptable salts, solvates and hydrates thereof.

In another aspect of the invention the novel compounds are of formula



IIA

wherein

R_1, R_2 and R_3 are each independently H, optionally substituted alkyl, cycloalkyl, alkenyl, alkynyl, alkanoyl or PO_3H_2;

R_6 is H, optionally substituted alkyl, cycloalkyl, alkenyl, akynyl or PO_3H_2;

R_4 is H or NR_8R_9;

R_5 and R_7 are each independently H, alkyl, halogen, nitro or amino;

R_8 is H, optionally substituted alkyl, cycloalkyl, alkanoyl, thioalkanoyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, arylaminocarbonyl, alkylsulphonyl, arylsulphonyl, aminosulphonyl, alkylaminosulphonyl, dialkylaminosulphonyl or arylaminosulphonyl;

and R_9 is H, alkyl or cycloalkyl, with the proviso that, when R_1, R_2 and R_3 are all methyl groups and R_4 is hydrogen, acetylamino, acetylmethylamino, amino, methylamino or dimethylamino then R_6 is not hydrogen, methyl or hydroxyethyl, or acetoxyethyl,

and the pharmaceutically acceptable salts, solvates and hydrates thereof.

Preferred compounds used in the invention and of the invention are those in which R_1, R_2 and R_3 are alkyl and

those in which R_4 is acylamino.

As used herein the term "alkyl", (including any aliphatic structure chain related to alkyl) means a straight or branched-chain group containing from one to seven, preferably a maximum of four, carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl and pentyl. Optional substituents which may be present on the alkyl groups include one or more substituents selected from halogen, amino, monoalkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, alkylsulphonyl, acylamino, alkoxycarbonylamino, alkanoyl, acyloxy, carboxyl, sulphate or phosphate groups. Examples of alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy and t-butoxy. The term "halogen" means fluorine, chlorine, bromine or iodine.

An alkenyl group is an olefinic group containing from two to seven carbon atoms for example methylene, ethylene, n-propylene, i-propylene, n-butylene, i-butylene, s-butylene and t-butylene. An alkynyl group is of a group of 2-7 carbon atoms for example ethynyl, propynyl or butynyl group.

The term aryl alone or in combination means an unsubstituted phenyl group or a phenyl group carrying one or more, preferably one to three, substituents examples of which are halogen, alkyl, haloalkyl, hydroxy, nitro, cyano, amino and alkoxy. A haloalkyl group can carry one or more halogen atoms with the examples of such groups being trifluoromethyl and dichloromethyl.

The term heteroaryl is defined herein as a mono- or bi-cyclic aromatic group containing one to four heteroatoms selected in any combination from N, S or O atoms and a maximum of 9 carbon atoms. Examples of heteroaryl groups include pyridyl, pyrimidyl, furyl, thienyl, pyrrolyl,

pyrazolyl, indolyl, benzofuryl, benzothienyl, benzothiazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, triazolyl, quinolyl and isoquinolyl groups.

The term aralkyl is defined herein as an alkyl group, as previously defined, in which one of the hydrogen atoms is replaced by an aryl or heteroaryl group as defined herein.

Where one or more functional groups in compounds of formulae I, II, IIA are sufficiently basic or acidic the formation of salts is possible. Suitable salts include pharmaceutically acceptable salts for example acid addition salts including hydrochlorides, hrdrobromides, phosphates, sulphates, hydrogen sulphates, alkylsulphonates, arylsulphonates, acetates, benzoates, citrates, maleates, fumarates, succinates, lactates and tartrates, salts derived from inorganic bases including alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as magnesium or calcium salts, and salts derived from organic amines such as morpholine, piperidine or dimethylamine salts.

Those skilled in the art will recognise that compounds of formulae I, II, IIA may exist as stereoisomers and/or geometrical isomers and accordingly the present invention includes all such isomers and mixtures thereof.

One useful group of compounds includes those in which R_1, R_2 and R_3 are each alkyl.


Another useful group of compounds includes those in which R_1, R_2 and R_3 are each alkyl and R_5 and R_7 are each hydrogen. A particularly useful subset of this group includes compounds in which R_1, R_2 and R_3 are each methyl and R_6 is hydrogen, alkyl or PO_3H_2.

Particularly useful compounds according to the invention include:

N-Acetylcolchinol-O-phosphate and its salts, solvates and hydrates.


Compounds of formulae I, II or IIA may be prepared by a number of processes as generally described below and more specifically in the Examples hereinafter. In the following process description the symbols R_1, R_2, R_3, R_4, R_5, R_6 and R_7 when used in the formulae depicted are to be understood to represent those groups described above in relation to formulae I, II or IIA unless otherwise indicated. In the schemes described below it may be necessary to employ protecting groups which are then removed during the final stages of the synthesis. The appropriate use of such protecting groups and processes for their removal will be readily apparent to those skilled in the art.

Thus according to a further aspect of the invention compounds of formulae II or IIA in which R_5, R_6 and R_7 are each hydrogen may be prepared by treatment of a compound of formula (2) with alkaline hydrogen peroxide. The reaction may be conveniently performed in aqueous sodium hydroxide solution in the absence or presence of a cosolvent such as an alcohol, for example ethanol, at a temperature in the range for example 0- 100°C preferably at or near to 60°C.



(2) II or IIA

Intermediates of formulae (2) may be prepared by acid hydrolysis of compounds of formulae (3); The reaction is conveniently carried out in an aqueous acid such as hydrochloric acid at an elevated temperature, for example at or near 100°C.



(3) (2)

Compounds of formula (3) are either known or can be prepared from colchicine by conventional procedures.

Compounds of formulae I, II or IIA may also be prepared from other compounds of formulae I, II or IIA, by chemical modification. Examples of such chemical modifications that may be applied are standard alkylation, arylation, heteroarylation, acylation, thioacylation, sulphonylation, sulphation, phosphorylation, aromatic halogenation and coupling reactions. These reactions may be used to add new substituents or to modify existing substituents. Alternatively, existing substituents in compounds of formulae I, II or IIA may be modified by, for example oxidation, reduction, elimination, hydrolysis or other cleavage reaction to yield other compounds of formulae I, II or IIA.

Thus for example a compound of formulae II or IIA containing an amino group may be acylated on the amino group by treatment with, for example, an acyl halide or anhydride in the presence of a base, for example a

tertiary amine base such as triethylamine, in for example, a solvent such as a hydrocarbon solvent e.g. dichloromethane at a temperature in the range for example -30°C to 120°C, conveniently at or near ambient temperature.

In another general example of an interconversion process an amino group in a compound of formulae II or IIA may be sulphonylated by treatment with, for example, an alkyl or aryl sulphonyl chloride or an alkyl or aryl sulphonic anhydride in the presence of a base, for example a tertiary amine base such as triethylamine, in for example a solvent such as a hydrocarbon solvent e.g. dichloromethane at a temperature in the range for example -30°C to 120°C, conveniently at or near ambient temperature.

In a further general example a compound of formulae II or IIA containing a hydroxy group can be converted into the corresponding dihydrogenphosphate ester by treatment with for example di-tert-butyl diethylphosphoramidite in the presence of a suitable catalyst for example tetrazole. In a solvent such as an ether solvent for example tetrahydrofuran at a temperature in the range -40 to 40°C, conveniently at or near room temperature, followed by treatment with an oxidising agent for example 3-chloroperoxy benzoic acid at a temperature in the range -78°C to 40°C preferably -40 to -10°C. The resulting intermediate phosphate triester is treated with an acid for example trifluoroacetic acid in a solvent such as a chlorinated solvent e.g. dichloromethane at a temperature in the range -30 to 40°C conveniently at or near 0°C to give the compound of formula (2) containing a dihydrogenphosphate ester.

In a further general example a compound of formula (2) containing an amide can be hydrolysed by treatment with

for example an acid such as hydrochloric acid in a solvent such as an alcohol, for example methanol at an elevated temperature conveniently at the reflux temperature.

In another general example an O-alkyl group may be cleaved to the corresponding alcohol (OH) by reaction with boron tribromide in a solvent such as a chlorinated solvent e.g. dichloromethane at a low temperature e.g. around -78°C.

In a further general example compounds of formulae II or IIA may be alkylated by reaction with a suitable alkylating agent such as an alkyl halide, an alkyl toluenesulphonate, an alkyl methanesulphonate or an alkyl triflate. The alkylation reaction can be carried out in the presence of a base for example an inorganic base such as a carbonate e.g. caesium or potassium carbonate, a hydride such as sodium hydride or an alkoxide such as potassium t-butoxide in a suitable solvent such as an aprotic solvent e.g. dimethylformamide or an ether solvent such as tetrahydrofuran at a temperature of around -10 to 80°C.

Preparation of a compound of formulae II or IIA as a single enantiomer or, where appropriate, diastereomer may be effected by synthesis from an enantiomerically pure starting material or intermediate or by resolution of the final product in a conventional manner.

Acid addition salts of the compounds of formulae II or IIA are prepared in a conventional manner by treating a solution or suspension of the free base II or IIA with about one equivalent of a pharmaceutically acceptable acid. Salts of compounds of formulae I, II or IIA derived from inorganic or organic bases are prepared in a conventional manner by treating a solution or suspension

of the free acid I, II or IIA with about one equivalent of a pharmaceutically acceptable organic or inorganic base. Alternatively both acid addition salts and salts derived from bases may be prepared by treatment of the parent compound with the appropriate ion-exchange resin in a standard fashion. Conventional concentration and recrystallisation techniques are employed in isolating the salts.

Compounds according to the invention are able to destroy tumour vasculature and vasculature that has been newly formed while leaving unaffected normal, mature vasculature. The ability of the compounds to act in this way may be determined by the tests described in the Examples hereinafter.

The compounds according to the invention are thus of particular use in the prophylaxis and treatment of cancers involving solid tumours and in the prophylaxis and treatment of diseases where inappropriate angiogenesis occurs such as diabetic retinopathy, psoriasis, rheumatoid arthritis, atherosclerosis and macular degeneration.

The compounds of the invention may be administered as a sole therapy or in combination with other treatments. For the treatment of solid tumours compounds of the invention may be administered in combination with radiotherapy or in combination with other anti-tumour substances for example those selected from mitotic inhibitors, for example vinblastine, paclitaxel and docetaxel; alkylating agents, for example cisplatin, carboplatin and cyclophosphamide, antimetabolites, for example 5-fluorouracil, cytosine arabinoside and hydroxyurea; intercalating agents for example adriamycin and bleomycin; enzymes, for example aspariginase; topoisomerase inhibitors for example etoposide, topotecan

and irinotecan; thymidylate synthase inhibitors for example raltitrexed; biological response modifiers for example interferon; antibodies for example edrecolomab; and anti-hormones for example tamoxifen. Such combination treatment may involve simultaneous or sequential application of the individual components of the treatment.

For the prophylaxis and treatment of disease the compounds according to the invention may be administered as pharmaceutical compositions selected with regard to the intended route of administration and standard pharmaceutical practice. Such pharmaceutical compositions may take a form suitable for oral, buccal, nasal, topical, rectal or parenteral administration and may be prepared in a conventional manner using conventional excipients. For example for oral administration the pharmaceutical compositions may take the form of tablets or capsules. For nasal administration or administration by inhalation the compounds may be conveniently delivered as a powder or in solution. Topical administration may be as an ointment or cream and rectal administration may be as a suppository. For parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) the composition may take the form of, for example, a sterile solution, suspension or emulsion.

The dose of a compound of the invention required for the prophylaxis or treatment of a particular condition will vary depending on the compound chosen, the route of administration, the form and severity of the condition and whether the compound is to be administered alone or in combination with another drug. Thus the precise dose will be determined by the administering physician but in general daily dosages may be in the range 0.001 to 100mg/kg preferably 0.1 to 50mg/kg.

BIOLOGICAL ACTIVITY

The following tests were used to demonstrate the activity and selectivity of compounds according to the invention.

Activity against tumour vasculature measured by radioactive tracer.

The following experiment demonstrates the ability of the compounds to damage selectively tumour vasculature.

Subcutaneous CaNT tumours were initiated by injecting 0.05ml of a crude tumour cell suspension, approximately 10^6 cells, under the skin overlying the rear dorsum of 12-16 week-old mice. The animals were selected for treatment after approximately 3-4 weeks, when their tumours reached a geometric mean diameter of 5.5-6.5mm. Compounds were dissolved in sterile saline and injected intraperitoneally in a volume of 0.1 ml per 10 g body weight. Tumour perfusion was measured 6 hours after intraperitoneal administration in tumour, kidney, liver, skin muscle, gut and brain by the ^{86}RbCI extraction technique (Sapirstein, Amer J Physiol, 193, 161-168, 1958). Tissue radioactivity measured 1 minute after an intravenous injection of ^{86}RbCI was used to calculate relative blood flow as a proportion of cardiac output (Hill and Denekamp, Brit J Radiol, 55, 905-913, 1982). Five animals were used in control and treated groups. Results were expressed as a percentage of the blood flow in the corresponding tissues in vehicle treated animals.

Activity against tumour vasculature measured by fluorescent dye.

The following experiment further demonstrates the ability of the compounds to damage tumour vasculature.

Tumour functional vascular volume in CaNT tumour-bearing mice was measured using the florescent dye Hoechst 33342

according to the method of Smith *et al* (Brit J Cancer 57, 247-253, 1988). Five animals were used in control and treated groups. The fluorescent dye was dissolved in saline at 6.25 mg/ml and injected intravenously at 10 mg/kg 6 hours after intraperitoneal drug treatment. One minute later, animals were killed and tumours excised and frozen; 10μm sections were cut at 3 different levels and observed under UV illumination using an Olympus microscope equipped with epifluorescence. Blood vessels were identified by their fluorescent outlines and vascular volume was quantified using a point scoring system based on that described by Chalkley, (J Natl Cancer Inst, 4, 47-53, 1943). All estimates were based on counting a minimum of 100 fields from sections cut at the 3 different levels. Compounds of the invention reduced tumour functional vascular volume by greater than 20% at doses of 50mg/kg or below.

The following non-limiting Examples illustrate the invention. In the Examples all ^{1}Hnmr were run at 300MHz unless otherwise specified. Column chromatography was performed on silica gel. All temperatures are in °C. The following abbreviations are used: THF - tetrahydrofuran; DMSO - dimethylsulphoxide; MCPBA - 3-chloroperoxybenzoic acid.

EXAMPLE 1

N-Acetylcolchinol-O-phosphate

A solution of N-acetylcolchinol (260mg, 0.76 mmol) in anhydrous THF (2ml) under an atmosphere of nitrogen was treated with di-t-butyl diethylphosphoramidite (189mg, 0.75mmol) and 1(H)-tetrazole (0.14g, 1.99mmol) and the solution stirred at 20° for 0.5h. The solution was cooled to -40° and a solution of 85% MCPBA (202mg, 0.99mmol) in anhydrous dichloromethane (2ml) at such a rate that the temperature remained below -10°. The solution was allowed to warm to room temperature, diethyl

ether (30ml) was added and the resulting solution washed successively with 10% aqueous sodium metabisulphite (two 25ml portions), 5% aqueous sodium bicarbonate (two 25ml portions), 5% aqueous citric acid (30ml), 5% aqueous sodium bicarbonate, and brine. The organic solution was concentrated under reduced pressure and the residue subjected to column chromatography to afford a white foam (170mg) containing N-acetylcolchinol-O-di-*t*-butylphosphate which was redissolved in dichloromethane (5ml), cooled to 0° and treated with trifluoroacetic acid (0.5ml).

The solution was allowed to warm to room temperature and stir 1 hr before being concentrated under reduced pressure and triturated with ether to give the title compound (110mg) as a white solid m.p. 233-235°. δH (d6-DMSO) 8.38(d,1H, J=8Hz), 7.27(d, 1H,J=7Hz), 7.12(d, 1H, J=8Hz), 7.10(s,1H), 6.77 (s, 1H), 4.48 (m, 1H), 3.81 (s, 3H), 3.76 (s, 3H), 3.49 (s, 3H), 2.5 (signal partially obscured by DMSO peak), 1.9-2.2 (m, 2H), 1.86 (s, 3H).

The activity of the phosphate compound was measured by the radioactive tracer assay described above: the compound of this Example gave a 65% decrease in tumour blood flow at a dose of 125mg/kg with no significant reduction in blood flow in skin, muscle, liver, kidney, gut or heart.

The phosphate compound was compared with the parent N-acetylcolchinol for the maximum tolerated dose (MTD) (no deaths in three animals), minimum effective dose (MED) measured by the fluorescent dye technique already described and the therapeutic window (MTD/MED).

	MTD mg/Kg body weight	MED mg/Kg body weight	Therapeutic Window (MTD/MED)
N-acetyl colchinol	125	30	4
N-acetyl colchinol-O-phosphate	750	50	15

Though the phosphate had a slightly higher MED the "window" was significantly greater. This was unexpected. The phosphate also gave greater solubility.

For comparison the "therapeutic windows" for colchicine (the closest structure to the present compounds and docetaxel (a tubulin-binding drug, marketed as "Taxotere", which has no vascular-damaging activity) and these data are presented in the following table:

Table 1 - Therapeutic windows of other tubulin-binding agents (by fluorescent dye technique)

Compound	MED (mg/kg body weight)	MTD (mg/kg body weight)	MTD/MED
Docetaxel	>30(No effect at 30)	30	<1
Colchicine	2.5	5	2

EXAMPLE 2

N-Ethylcolchinol

A solution of N-acetylcolchinol (500mg, 1.4mmol) in THF (15ml) was added dropwise over 15 minutes to a suspension of lithium aluminum hydride (106mg, 2.74mmol) in THF (10ml) with ice-bath cooling. The mixture was heated at reflux for 15h, allowed to cool and treated with further lithium aluminium hydride (53mg, 1.4mmol) before heating at reflux for a further 3h. The mixture was cooled (ice bath) and water (10ml) added dropwise before extraction with three portions of ethyl acetate. The combined,

dried (MgSO4) extracts were concentrated under reduced pressure to a green gum which, on trituration with ether, gave the title compound as a light-green solid. m.p. 185°C (dec.), m/e 343 (M+). Anal. Calculated for $C_{20}H_{25}NO_4$ H_2O: C, 66.46; H, 7.53; N, 3.88. Found: C,66.50; H, 7.17; N, 3.79.

EXAMPLE 3

N-Benzyloxycarbonylcolchinol

A solution of colchinol (625mg, 1.98mmol) in dry pyridine (10ml) was treated dropwise with benzylchloroformate (0.566ml, 3.97 mmol) and the mixture stirred 16h. Solvent was removed under reduced pressure, water added and the resulting mixture extracted with three portions of chloroform. The combined, dried ($MgSO_4$) extracts were concentrated under reduced pressure to a dark brown gum which was subjected to column chromatography on silica gel eluting with 50% ethyl acetate/petroleum ether. The resultant orange gum was crystallised from ether/petroleum ether to give the title compound (346mg) as a pale yellow solid. m.p. 79-81°C, m/e 449 (M+). Anal. Calculated for $C_{26}H_{27}NO_6$ $0.33H_20$; C, 68.57; H, 6.07; N, 3.08. Found: C,68.71; H, 6.18; N, 2.91.

EXAMPLE 4

N-(Phenylcarbamoyl) colchinol

A solution of colchinol (400mg, 1.27mmol) in dry pyridine (10ml) was treated dropwise with phenyl isocyanate (0.151ml, 1.39mmol) and the mixture stirred for 18h before heating at reflux for 2h. Solvent was removed under reduced pressure, water added and the resulting mixture extracted with three portions of chloroform. The combined, dried ($MgSO_4$) extracts were concentrated under reduced pressure to a dark brown gum which was subjected to column chromatography on silica gel eluting with 35% ethyl acetate/petroleum ether. The resultant gum was crystallised from ether/petroleum ether to give the title

compound (261mg) as a pale orange solid. m.p. 145-146°C, m/e 434 (M+).

EXAMPLE 5

N-Mesylcolchinol

A solution of N,O-dimesylcolchinol (234mg, 0.5mmol) in methanol (8ml) was treated with sodium hydroxide (40mg, 1mmol) and the mixture heated at reflux for 3h. Solvent was removed under reduced pressure and water (5ml) added. The solution was rendered neutral by the addition of 1M hydrochloric acid and extracted with three portions of dichloromethane. The combined, dried ($MgSO_4$) extracts were concentrated under reduced pressure to give the title compound (123mg) as a pink solid. m.p. 234-236°C, m/e 393 (M+).

The N,O-dimesylcolchinol used as starting material was prepared as follows: A solution of colchinol (500mg, 1.6mmol) in dry pyridine (15ml) was treated with mesyl chloride (0.135ml, 1.7mmol) and the mixture stirred at room temperature 36h. A further portion of mesyl chloride (0.135ml, 1.7mmol) was added and stirring continued 16h. Solvent was removed under reduced pressure and water (5ml) added. The solution was extracted with three portions of chloroform and the combined, dried ($MgSO_4$) extracts were concentrated under reduced pressure to give a brown gum which was subjected to column chromatography on silica gel eluting with ethyl acetate to give N,O-dimesylcolchinol (292mg) as a light orange solid.

EXAMPLE 6

N-Dimethylsulphamoylcolchinol

A solution of colchinol (50mg, 0.16mmol) in dry acetonitrile (3ml) and triethylamine (0.022ml, 0.16mmol) was treated with dimethylsulphamoyl chloride and the mixture stirred for 30 minutes before heating at reflux

for 15h. Solvent was removed under reduced pressure, water added and the resulting mixture extracted with three portions of chloroform. The combined, dried (Na_2SO_4) extracts were concentrated under reduced pressure to a dark brown gum which was subjected to column chromatography on silica gel eluting with ethyl acetate to give the title compound (46mg) as a pale orange gum which solidified. m.p. 82-85°C m/e 422 (M+).

EXAMPLE 7

N-Acetyl-O-methoxycarbonylmethylcolchinol

A solution of N-acetylcolchinol (500mg, 1.4mmol) in dry DMF (5ml) at 0°C was treated with methylbromoacetate (322mg, 2.1mmol) and sodium hydride (84mg of a 60% suspension in oil, 2.1mmol) and the mixture stirred for 30 minutes. Water (50ml) was added and the mixture extracted with four portions of ethyl acetate. The combined extracts were washed successively with four portions of water and two portions of saturated aqueous sodium chloride solution, dried ($MgSO_4$) and solvent removed under reduced pressure to give the title compound (280mg) as a white solid m.p. 82-83°C. m/e 429 2 (M+). Anal. Calculated for $C_{23}H_{27}NO_7$ $0.33H_2O$; C, 63.45; H, 6.40; N, 3.22. Found: C, 63.53; H, 6.29; N, 3.17.

EXAMPLE 8

N-Acetyl-O-carboxymethylcolchinol

A solution of N-acetyl-O-methoxycarbonylmethylcolchinol (140mg, 0.33mmol) in acetonitrile (5ml) was treated with aqueous potassium hydroxide solution (1.0M, 5ml) and the mixture heated at 80°C for 30 minutes. The cooled mixture was adjusted to pH3 by addition of 2M hydrochloric acid and extracted with four portions of ethyl acetate. The combined extracts were washed with two portions of saturated aqueous sodium chloride solution, dried ($MgSO_4$) and concentrated under reduced

pressure. Addition of acetone (2ml) and hexane (1ml) produced the title compound (58mg) as a white solid m.p. 220-221°C. m/e 415.3 (M+). Anal. Calculated for $C_{22}H_{25}NO_7$ $0.33H_2O$; C,62.71; H, 6.14; N, 3.32. Found: C, 62.63; H, 6.02; N, 3.26.

EXAMPLE 9

N-Acetyl-O-cyclopentylcolchinol

A solution of N-acetylcolchinol (200mg, 0.56mmol) in dry DMF (2ml) at 0°C was treated with sodium hydride (33mg of a 60% suspension in oil, 0.84mmol) followed by cyclopentyl bromide (125mg, 0.84mmol) and the mixture stirred 1h. A further portion of sodium hydride (17mg of a 60% suspension in oil, 0.42mmol) and of cyclopentyl bromide (63mg, 0.42mmol) and the mixture stirred overnight at room temperature. Water (10ml) was added and the mixture extracted with four portions of ethyl acetate. The combined extracts were washed with two portions of saturated aqueous sodium chloride solution, dried ($MgSO_4$) and concentrated under reduced pressure. The title compound (160mg) was obtained as a white solid m.p. 89-94°C. m/e 425.3 (M+). Anal. Calculated for $C_{25}H_{31}NO_5$: C,70.54; H, 7.35; N, 3.29. Found: C, 70.55; H, 7.35; N, 3.25.

EXAMPLE 10

N-Acetyl-10-nitrocolchinol

A solution of N-acetylcolchinol (100mg, 0.27mmol) in glacial acetic acid (20ml) was treated slowly with 20ml of a solution of concentrated nitric acid (0.34ml) in acetic acid (100ml) keeping the temperature at about 12°C. The mixture was stirred at room temperature for 18h, a further 1ml of the nitric acid/acetic acid solution added and stirring continued for 2h. The mixture was poured onto ice and extracted with three portions of ethyl acetate. The combined extracts were washed with two portions of saturated aqueous sodium

cloride solution, dried ($MgSO_4$) and concentrated under reduced pressure. Purification on silica gel eluting with ethyl acetate gave the title compound (50mg) as a pale yellow solid m.p. 117-8°C. m/e 401.9 (M+) Anal. Calculated for $C_{20}H_{22}N_2O_7$ $0.33H_2O$; C, 58.82; H, 5.56; N, 6.86. Found: C, 58.87; H, 5.66; N, 6.55.


EXAMPLE 11

The activity against tumour vasculature was measured by the fluorescent dye technique described above for the compounds of Examples 1-10 administered at 50mg/kg and N-acetylcolchinol

Compound of Example	% decrease in vascular volume
1	89
2	38
3	43
4	37
5	38
6	30
7	12
8	49
9	59
10	28
N-acetylcolchinol	78

CLAIMS:

1. The use of colchinol derivatives for the preparation of compositions for the treatment of diseases involving angiogenesis in which the colchinol derivative has the formula



I

wherein

R_1, R_2, R_3 and R_6 are each independently H, optionally substituted alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, alkanoyl, PO_3H_2;
X is carbonyl (CO), thiocarbonyl (CS), methylene (CH_2) or a group CHR_4
R_4 is OH, O-alkyl or NR_8R_9;
R_5 and R_7 are each independently H, alkyl, halogen, hydroxy, alkoxy, nitro or amino;
R_8 is H, optionally substituted alkyl, cycloalkyl, alkanoyl, thioalkanoyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, arylaminocarbonyl, alkylsulphonyl, arylsulphonyl, aminosulphonyl, alkylaminosulphonyl, dialkylaminosulphonyl or arylaminosulphonyl;
and R_9 is H, alkyl or cycloalkyl
and the pharmaceutically acceptable salts, solvates, and hydrates thereof.

2. A use according to claim 1 wherein at least one of R_1, R_2, R_3 and R_6 is PO_3H_2.

3. A use according to claim 2 wherein R_6 is PO_3H_2.

4. A use according to any one of claims 1 to 3 in which R_1, R_2 and R_3 are alkyl.

5. A use according to any one of claims 1 to 4 in which R_4 is acylamino.


6. A use according to claim 1 in which R_6 is PO_3H, R_1, R_2 and R_3 are alkyl and R_4 is acylamino.

7. Compounds of formula I in which at least one of R_1, R_2, R_3 and R_6 is PO_3H_2.

8. A compound according to claim 7 in which R_6 is PO_3H_2.

9. A compound according to claim 8 in which R_1, R_2 and R_3 are alkyl and R_4 is acylamino.

10. A compound according to claim 7 of formula




II

wherein

R_1, R_2 and R_3 are each independently H, optionally substituted alkyl, cycloalkyl, alkenyl, alkynyl, alkanoyl, or PO_3H_2;

R_6 is PO_3H_2;
R_4 is H or NR_8R_9;
R_5 and R_7 are each independently H, alkyl, halogen, alkoxy, nitro or amino;
R_8 is H, optionally substituted alkyl, cycloalkyl, alkanoyl, thioalkanoyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, arylaminocarbonyl, alkylsulphonyl, arylsulphonyl, aminosulphonyl, alkylaminosulphonyl, dialkylaminosulphonyl or arylaminosulphonyl;
and R_9 is H, alkyl or cycloalkyl,
and the pharmaceutically acceptable salts, solvates and hydrates thereof.

11. A compound of the formula



IIA

wherein
R_1, R_2 and R_3 are each independently H, optionally substituted alkyl, cycloalkyl, alkenyl, alkynyl, alkanoyl or PO_3H_2;
R_6 is H, optionally substituted alkyl, cycloalkyl, alkenyl, akynyl or PO_3H_2;
R_4 is H or NR_8R_9;
R_5 and R_7 are each independently H, alkyl, halogen, nitro or amino;
R_8 is H, optionally substituted alkyl, cycloalkyl, alkanoyl, thioalkanoyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl,

aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, arylaminocarbonyl, alkylsulphonyl, arylsulphonyl, aminosulphonyl, alkylamnosulphonyl, dialkylaminosulphonyl or arylaminosulphonyl;

and R_9 is H, alkyl or cycloalkyl, with the proviso that, when R_1, R_2 and R_3 are all methyl groups and R_4 is hydrogen, acetylamino, acetylmethylamino, amino, methylamino or dimethylamino then R_6 is not hydrogen, methyl, hydroxyethyl, or acetoxyethyl,

and the pharmaceutically acceptable salts, solvates and hydrates thereof.

12. A compound according to claim 11 in which R_1, R_2 and R_3 are alkyl and R_4 is acylamino.

INTERNATIONAL SEARCH REPORT

In ational Application No
PCT/GB 98/01977

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/66 A61K31/165 A61K31/27 C07C13/547

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	O. BOYE ET AL.: "Synthesis of carbon-14 labeled electrophilic ligands of the colchicine binding site of tubulin: chloroacetates of demethylthiocolchicines and of N-acetylcolchinol, isothiocyanates of 9-deoxy-N-acetylcolchinol." J. LABELLED COMPD. RADIOPHARM., vol. 33, no. 4, 1993, pages 293-299, XP002081866 ---	
A	R. BRECHT ET AL.: "Dihydrocolchicine 8,12-endoperoxide. a novel starting material for convenient syntheses of the allocolchicinoids N-acetylcolchinol O-methyl ether and androbiphenyline." LIEBIGS ANN., no. 11, 1997, pages 2275-2279, XP002081867 --- -/--	

[X] Further documents are listed in the continuation of box C. [ ] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
23 October 1998	11/11/1998

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Klaver, T

1

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

In tional Application No
PCT/GB 98/01977

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
A	GIL-JONG KANG ET AL: "n-acetylcolchinol O-methyl ether and thiocolchicine, potent nalogs of colchicine modified in the C-ring" J. BIOL. CHEM., vol. 265, no. 18, 1990, pages 10255-10259, XP002081868 ---	
A	DATABASE WPI Week 6800 Derwent Publications Ltd., London, GB; AN 66-13831f XP002081869 & JP 39 019635 B (SANKYO CO.) see abstract ---	
A	DATABASE WPI Week 6800 Derwent Publications Ltd., London, GB; AN 66-13830f XP002081870 & JP 39 019634 B (SANKYO CO.) see abstract -----	

1

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
19/043,303	**02/05/2025 07:18:13 PM Z ET**	**50535-710.305**

Title of Invention

METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	1040	FILED BY	Jennifer Vail
PATENT CENTER #	69068550	FILING DATE	-
CUSTOMER #	21971	FIRST NAMED INVENTOR	Alexis HOWERTON
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	Victoria Cheng

Documents

TOTAL DOCUMENTS: 54

DOCUMENT		PAGES	DESCRIPTION	SIZE (KB)
Spruce 50535-710_305_IDS.pdf		14	-	459 KB
Spruce 50535-710_305_IDS-TRAN.LET.pdf	(1-4)	4	Transmittal Letter	155 KB
Spruce 50535-710_305_IDS-IDS.pdf	(5-14)	10	Information Disclosure Statement (IDS) Form (SB08)	439 KB
FOR_JPH0971528A_EFS.pdf		8	Foreign Reference	301 KB
FOR_WO0041669A2_EFS.pdf		26	Foreign Reference	1059 KB
FOR_CN106102740A_EFS.pdf		32	Foreign Reference	2285 KB

FOR_CN101516887A_EFS.pdf	54	Foreign Reference	2716 KB
FOR_JP2010504344A_EFS.pdf	32	Foreign Reference	5381 KB
FOR_WO0208213A1_EFS.pdf	57	Foreign Reference	2298 KB
FOR_WO0204434A1_EFS.pdf	82	Foreign Reference	3543 KB
FOR_WO0192224A1_EFS.pdf	89	Foreign Reference	3856 KB
FOR_WO0040529A1_EFS.pdf	136	Foreign Reference	5907 KB
FOR_WO9902166A1_EFS.pdf	30	Foreign Reference	1093 KB
FOR_WO9732856A1_EFS.pdf	73	Foreign Reference	3041 KB
FOR_WO9730035A1_EFS.pdf	103	Foreign Reference	4474 KB
FOR_WO9722596A1_EFS.pdf	163	Foreign Reference	6589 KB
FOR_WO2007109853A1_EFS.pdf	28	Foreign Reference	1552 KB
FOR_WO2015112642A1_EFS.pdf	50	Foreign Reference	1718 KB
FOR_WO9813354A1_EFS.pdf	137	Foreign Reference	6116 KB
FOR_WO2008036579A1_EFS.pdf	60	Foreign Reference	2467 KB
FOR_JP2017503030A_EFS.pdf	52	Foreign Reference	20122 KB
FOR_WO2019036472A1_EFS.pdf	64	Foreign Reference	3373 KB
FOR_WO2019036503A1_EFS.pdf	78	Foreign Reference	4057 KB
FOR_WO2019210266A1_EFS.pdf	138	Foreign Reference	8451 KB
NPL_CHEN_Ovarian_adrena	6	Non Patent Literature	824 KB

l_146_151_2017.pdf			
NPL_CHONN_Recent_Advances_698_708_1995.pdf	11	Non Patent Literature	1529 KB
NPL_BERGE_Pharmaceutical_Salts_1_19_1977.pdf	19	Non Patent Literature	2263 KB
NPL_ALMUHAMMED_In_vivo_studies_293_306_1996.pdf	13	Non Patent Literature	2081 KB
NPL_EYLES_Oraldeliveryandfate_669-74.pdf	6	Non Patent Literature	528 KB
NPL_JIN-Testicular-adrenal-rest-tumors-2011.pdf	4	Non Patent Literature	422 KB
NPL_GAO_Controlled_Release_857_863_1995.pdf	7	Non Patent Literature	1079 KB
NPL_MENDES-DOS-SANTOS_PrevalenceofTesticular_161-168.pdf	8	Non Patent Literature	1084 KB
NPL_KAPRARA_Corticotropin_Releasing_1293_1306_2010.pdf	14	Non Patent Literature	2177 KB
NPL_CO-PENDING_US19043264.pdf	147	Non Patent Literature	8253 KB
NPL_CO-PENDING_US18941832.pdf	152	Non Patent Literature	8586 KB
NPL_MUNSON_Ligand_Versatile_220_239_1980.pdf	20	Non Patent Literature	2581 KB
NPL_CO-PENDING_US19043275.pdf	147	Non Patent Literature	8253 KB
NPL_NEUROCRINE_v_SPRUCE_DecisionGrantingPGR_USPN11007201_01Dec2023.pdf	38	Non Patent Literature	3364 KB
NPL_PCTUS2019-029486-IPAF-4June2019.pdf	2	Non Patent Literature	152 KB
NPL_PCTUS2019-029486-ISR-12Aug2019.pdf	12	Non Patent Literature	679 KB
NPL_OSTRO_Use_Liposomes_1576_1587_1989.pdf	13	Non Patent Literature	4491 KB

NPL_RAO_Recentdevelopmentsofcollagen-based_623-45.pdf	24	Non Patent Literature	1549 KB
NPL_NEUROCRINE_v_SPRUCE_PetitionForPostGrantReview_USPN10849908_28May2021.pdf	90	Non Patent Literature	5422 KB
NPL_REISCH_Testicularadrenalrest_E820-E1826.pdf	7	Non Patent Literature	992 KB
NPL_NEUROCRINE_v_SPRUCE_PetitionForPostGrantReview_USPN11007201_18Feb2022.pdf	92	Non Patent Literature	6033 KB
NPL_SMEETS_Molecularcharacterizationoftesticular_E524-E530.pdf	7	Non Patent Literature	736 KB
NPL_TIOSANO_Ovarianadrenalrest_223-228.pdf	7	Non Patent Literature	821 KB
NPL_US17081694_OA_11JUNE2021.pdf	22	Non Patent Literature	711 KB
NPL_US17081694_OA_26FEB2021.pdf	17	Non Patent Literature	551 KB
NPL_ZAAROUR-_BilateralOvaryAdrenal_e69-e74.pdf	6	Non Patent Literature	549 KB
NPL_US17667285_OA_2024_06_10.pdf	27	Non Patent Literature	1976 KB
NPL_NEUROCRINE_v_SPRUCE_FinalWrittenDecision_USPN10849908_26NOV2024.pdf	62	Non Patent Literature	18775 KB
NPL_NEUROCRINE_v_SPRUCE_FinalWrittenDecision_USPN11007201_26NOV2024.pdf	60	Non Patent Literature	19340 KB
NPL_REICHMAN-Fertility-in-patients-301-309.pdf	9	Non Patent Literature	19609 KB
NPL_US17667285_OA_29Dec2023.pdf	28	Non Patent Literature	22774 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
Spruce 50535-710_305_IDS.pdf	E214F0455067284261EA32CC50454C2AF57CAF83809F159224AA2514206279EBF4360854800309E918889D13D44E519E2420A289210C75C0140DDD82E7DB29D9
Spruce 50535-710_305_IDS-TRAN.LET.pdf	E3ED97417C16A10A895590A058F9509D1FD3EF2699A6748ADAE6126B4C83B6362452D86CF73EC35A99716D8C95E2EBA670FC9DA7F22B3B415539D6A24795CFE2
Spruce 50535-710_305_IDS-IDS.pdf	8C4A30A7C9192363C486514001984E7406E5172F2717F2D742BC25DC982CC675F46F89994B3FFDF425EE628BA65A217C06B75758468B4A5836D2BB5B67576E17
FOR_JPH0971528A_EFS.pdf	99DB9593EE16038D27DF78D6D5FE613B841CEFAB36284B74A7B719B36CC9876829468DCAAA6E638733C3A0A4EA4D18EDCAD97AE197B428157FA764ED1DB1F925
FOR_WO0041669A2_EFS.pdf	70F2BB6009A3E74F2AA039E3B185942CB9BA81B4D7F4B2B7EED839779B81A8E951F5E92F0C5AE3ECC05CFF0EAC4C3D26EDC589F7EAC83EEE7EEE3D30C15FF0FF
FOR_CN106102740A_EFS.pdf	6356026BBA9AA3F7CC5F63586F15086DF27355D4AB380A0E913F34FAFCF12854328F36061999F58B8A583C64ABA6DD338F8ADCA4B952D234778AE78D09DA7822
FOR_CN101516887A_EFS.pdf	6D0952E9E4FE229ECF2FD2E2E163513BAC476DFC98C5AF37A8BEB58B0F4632DF98D4912886E3B0A2F723BF3A5482124BAD90F347FE03517E5014607317F5735D
FOR_JP2010504344A_EFS.pdf	DC0666839B2BB8C39A298273CCC01593AEB32B377FDCB5C949F6B5DDBEB2561B5A30BC74552A1F540AC926276D43234DBEE940ECA5BE5A89244936582F7000EA
FOR_WO0208213A1_EFS.pdf	9DCC2B8CC6623288D1D911D289841106823E7FB468409E8E51A0F821CA141E04E6F8B85624E87CDD453451C6FBD3AD1B3F10A752739C138E5210BBEF5CC037F5
FOR_WO0204434A1_EFS.pdf	A2FA2EA82717D1F524F3D64E893A3B4285B02CD1D0BCA77E7B7519ABE8309B2518FD079F06E541BB3FD03F948BCFEEA642AFC2308FD55D0D631A1694B4CB8A26
FOR_WO0192224A1_EFS.pdf	780F2389A1C593581D6B1CD135495BDC1FDE0D0312EEDA149C01C98F01BFCD27222119C26F8BA4215FD9EAECA2A1F0193A4551613D2D262367DFD00DBF0EE97C
FOR_WO0040529A1_EFS.pdf	BE1EDCEB4BB7C41B12018F48FC68AEF1F499597A8F4FD161647E9A2E1F20F8F7C6C56659FC3B841AFA25D7ADDB05143F954780E7DD1C79F8DAF312DAAF7F1870

FOR_WO9902166A1_EFS.pdf	099B2258AB4D346C26970F56E23F3F4C11AFF4276207EB9DF4762D4491C7F372B113AFDC9FAB46301ED18845358D853A8AE2A7ECF6B7889690CDE54CC051415A
FOR_WO9732856A1_EFS.pdf	43082FC01B6B942A954D3C23FE392D4E40D7FD551B6A5F1E82F14A44DE8661165E89C28423B7240B5525DDD8ABAE8C3C0A8F5E0D0C93B663B9A11BC659754AA3
FOR_WO9730035A1_EFS.pdf	384CDC7099106CFDF03FAE4C3A7FD194B91F610B2C57F8D7D3E7DA8687ECA7F9C53FF3A38414757BA589C07088BF3EE21B271B6331C087CD6A6B385C14A0C951
FOR_WO9722596A1_EFS.pdf	B8415404FA2F2BF4A288EDF944D957267AF2CDC1AC9C802E2D0CBF17FD852C855B117B8A55A2874FD9FCDBE7E2B60DB81CC3C8A9E6E35765DD6592D4FD67176A
FOR_WO2007109853A1_EFS.pdf	33AA536C196699DF6720CE346555B89A88F18DEF95B03928FD58E51B025158E0451021EB6F9F462782E824B4EE9626E64FFDACE8E7A1C5BFD9F57CB8F340208E
FOR_WO2015112642A1_EFS.pdf	A55EFF1D161A2ADEA8BB1DA46AE9CEE32474E7E2C4871D9C46394219E78E04A5F9D96BBAA45A5E4465B92A07B3F13CD9C1BDEF8096E0A9173A539385ED8BE4FC
FOR_WO9813354A1_EFS.pdf	60791BC25983416104A752825A9265788FF617F4F68076E8F8871751E69E04F9A45DE02EE160F630A46830BC9C3B1B66DDB3169CCA8D9EAE345EDBEC792D4440
FOR_WO2008036579A1_EFS.pdf	4FF01A21135811282E9F25F5D8FAC7BB1E77FEA8783F9C364EE8A788EAAD3A07B735E0C0AEF06E517B28A370F9469A14D03A044E66610E076E3CA1A2208D107B
FOR_JP2017503030A_EFS.pdf	0AA3814BAFDD9492B58E9614A949FF9F0FD6EF907437FEA43049B2D484846571FF8EDC3B82D3F30D981ED548F214D182AE38E74A84821B14EB5AA50F1E02B5F1
FOR_WO2019036472A1_EFS.pdf	5710AF7DA13BB41769F63E18C559470BC69D13E48BB52EA12546306530D8BBF951179202C01AF5641C2700A8B3F8FBDF32BD019F651311133BB93A0076E8FF19
FOR_WO2019036503A1_EFS.pdf	7AAE80F99D43322954550F25CBC3E4C9110161D3779CBEBC683DED4BD81A679C4349027C00C9738EB7A949176277DA2BDE001085E9EE8C83E883755C8CF85829
FOR_WO2019210266A1_EFS.pdf	4C73ABFA2CAC334F7999760CE098E9A7C2A1F204EF53D1AB87B13CA2DFC61FF6F4CBCE9CC8F0C343AF85DA036D1E1DD5315D0B61AFADD7E0EBE2CC8C5EE3BDEA
NPL_CHEN_Ovarian_adrenal_146_151_2017.pdf	15F788A6CFB803DB39997F10FDCD52C4CB48DADBBF002889F3D8B31851EBE2C71EF078F9502EF33640071A820068FFBBE6DF55D4ECD41224446109379BD83574
NPL_CHONN_Recent_Advances_698_708_1995.pdf	D0E9730F13869E60BA488C00C0860DFB627A03E1EB4E18C3B9740BBB63A2408DED73A2F0FB82C901C4BA0919406459A42E

	D5A7BF0167B4CB071466E30191D8FE
NPL_BERGE_Pharmaceutical_Salts_1_19_1977.pdf	FB162B3CF4079F35E3BC039E0E0B5BAC1F11BCD3815DC01B6C5DF8BE4B0599251C8A11F2287BA9ABB0DF0C13A9472C28AFA908F6CC7EA96C4D7DD5405462BE4C
NPL_ALMUHAMMED_In_vivo_studies_293_306_1996.pdf	B3639FC7AF994F747166B3BE0AE1041353337FC89ED1CD67C842842217588C288DD68F28AF1DEE5F5353908F659461B3BE00B29DBE121E932B7E970B380295F3
NPL_EYLES_Oraldeliveryandfate_669-74.pdf	0D400DD1F3239F83736A264BFB631FF9C35643DB0E058FE1B418E414CB3DC031565323D7CB7D23CF8F1BDBBF310BDE08C24C35090555EDD7C727719328ED2795
NPL_JIN-Testicular-adrenal-rest-tumors-2011.pdf	F98E3D8CE205EBCD83569B551AFE51032412D4A25A54F3870AD19716D053D2945A97DFD0C16EC07C930B0FC3DAF04E72C571FB721A46454A98F57C5AE3C7D775
NPL_GAO_Controlled_Release_857_863_1995.pdf	821B84DD44EF3AD3605B93E3B52FFE30B06F59BE4505FBF4C60CB83C22F5FE4B10C3E5A87061B5727ED431557EC70E9A5632FB27CADAB0B7573D67CE70A9F774
NPL_MENDES-DOS-SANTOS_PrevalenceofTesticular_161-168.pdf	9E31167C70521476943F4CC8EF57292F7B1076351B7F53AFD3FDF4D524D43BF755B13133F6C28CC739B76A48CC752F839FC852D5D9F456F8D6C8C7047A8B7B1C
NPL_KAPRARA_Corticotropin_Releasing_1293_1306_2010.pdf	C0577D053A0A44F94B7511FD61543936B4955C3B04417249F4F1C110F4E15D56A6E9FEFE5F97BB371323BCE4A16C830E3593085A0BDB926526E1D455A36AB51F
NPL_CO-PENDING_US19043264.pdf	E1027A539BC63A3680E4DD29CDC5B9B5CF972AB54331E84F5889AE59A974F632AC76B146DB68DF6396009480FF0E9A8932C1EF56413AD50EA6292B2C09F902D4
NPL_CO-PENDING_US18941832.pdf	DF1182FBB91A7CA3B2DEF528C710672D432B57AE21F615CDA7CC6777CF9EACC77EE4DC74A2E391F1D2230826F597165ED3D74A350319B3119BF1FCCC68A72C36
NPL_MUNSON_Ligand_Versatile_220_239_1980.pdf	AB009CCCE7A27CE52564205B188FCFF1EEF2E87413BA66A5747A349982CF7E9D05AF67AD278C821F466A5E57AB98E0016A5618EE04CF78E1879392EE3F365AED
NPL_CO-PENDING_US19043275.pdf	F74C7F39ECB7524CD849C90AFF5DDF9DC09771ADC5BAA781B40B61B08BC861872E6A75C9E99DE6BB5CABB95EE7D3013E6B148EDBF6F52004B0CB6865AEF5F1CB
NPL_NEUROCRINE_v_SPRUCE_DecisionGrantingPGR_USPN11007201_01Dec2023.pdf	FEE958B8E9ADCA3BA20556070284E8726B9018C741CD882B74FAD2D04B138C4556EF9215C63898B8316325A9D532A98971008B44440B64E26055CFD0010298B9
NPL_PCTUS2019-029486-IPAF-4June2019.pdf	EF5B4CA0AA9671CE15BC4CAC52E5DE4363E1C9AFC1BDBA71144AF1A8254D1461DCAE029C31A742BC680D0E4B8A88693702A6634F4533768A2137C005DBFD2268

NPL_PCTUS2019-029486-ISR-12Aug2019.pdf	F6965D9591D63B0A7A395C11B6A9F698DD425E2ECC78740942B29A50914F2F4461FE084A05B6568F3E196D0F62D3981195CAEEF77910DAC50B4A02ED2825D46C
NPL_OSTRO_Use_Liposomes_1576_1587_1989.pdf	D04C2F08CEB669DF1FC6CE4B1D67B09C7F66C9B05DC08EB01B97B78D64F948234C23568E2F66315BC307EE6B1FEE82EBE814BC069E871431049DADDA033B6F14
NPL_RAO_Recentdevelopmentsofcollagen-based_623-45.pdf	9BF438E9783F34A0BF429F2B2615F038FABB569A2210D916F5EF90C494BD0B3FC48FFFA0BD51FCD2DB15493B60034EE179E9A3285C5BBC6B9738878E5E9C6F54
NPL_NEUROCRINE_v_SPRUCE_PetitionForPostGrantReview_USPN10849908_28May2021.pdf	3619452D8081A5337814178A75D7A38DF1640100C1B1234C82C065E2FCADEFF6977BA7B50EB46A446AB76CC11E96A5CCE27681B45B532508F97D59A38433A056
NPL_REISCH_Testicularadrenalrest_E820-E1826.pdf	E9F051D9E51FA32EA85B703DAE1FB171C00D604B29882E45A9C83009B027DEABCDE030A5BF9E1E4DAABF8AA9ADD3ADBF692C777AB0F5E31F2F1A063ABC6DA5D8
NPL_NEUROCRINE_v_SPRUCE_PetitionForPostGrantReview_USPN11007201_18Feb2022.pdf	7F585C92FE36BE5D2A92E2889BA548C11CAF1641F91832CF2B6194ABC1DB55A5064D1CEA3F57207D5A697E43F4BEA5F7EBC4C503C571C5A0EA9275485FA6A36A
NPL_SMEETS_Molecularcharacterizationoftesticular_E524-E530.pdf	6202F851C8E6BDA97AAE48888C0D3A14DF6A1E2CEBADFC51FABC3539D32DE2C49222500742F7D60BFAB41DD7625F2B07D2E3D25FEE5E057D31B46460E4B7878B
NPL_TIOSANO_Ovarianadrenalrest_223-228.pdf	FAD2CC0F2EB7BD685296E9823B398A8223F6A23DB674635999D41F2C8FB2F52732FBEF5709D53FA93D294F96EDD7A00AC0AF09F346B7B1FE39D100D6725C4DD3
NPL_US17081694_OA_11JUNE2021.pdf	844C8D2D78D1A958A02B37B9B875F0ACF76F28A04C7B6CD63F8EB63E7DD581C50EACD041EF4082C7BA78D494E421605A059179544F3E928E600ECE4C637DBD3A
NPL_US17081694_OA_26FEB2021.pdf	4A6AB07F16A208E61B351D5EBA2B825C30555DC570AA953259DBCFF5B29A5CF12E12B32BC7D14B78D310C174BDC7C9D208A810AC15EA289625AC8C57DAA988F1
NPL_ZAAROUR-_BilateralOvaryAdrenal_e69-e74.pdf	F34F08AF63FDA07520F1FD2F506B3ECF24AA9046CF38FA9FEDCCD1E3202C0546871748F4F36C18E6196BF92711A28AE95CF28660057FD0C70BA0D74B30F154B7
NPL_US17667285_OA_2024_06_10.pdf	36455BE2255515F1592EF7F1F82A2172AD53863BB8725AE0A384EEE3B6929487CF3D7FE06305B041AB3DC730135D7FA6997077F5A7A8AD454ED0A7AD2E4557C2
NPL_NEUROCRINE_v_SPRUCE_FinalWrittenDecision_USPN10849908_26NOV2024.pdf	F415F39E7130AB67C3369E83D0766646F790CF1587EF26174DDAD1A28E5B1BCBDA50CF62BFEABA76318FCAE10BB8EE5448C93216F46D4E8EDCC50EBC3D472649

NPL_NEUROCRINE_v_SPRUCE_FinalWrittenDecision_USPN11007201_26NOV2024.pdf	8153881F5B1C3BC39CD39018BB9416774B7D6DE7C822DD5383749A1A33B3A4BD414502EC28369F94A0448B214DEB4A61D4DC8379A135D05BD06342820F62F7C2
NPL_REICHMAN-Fertility-in-patients-301-309.pdf	08ABB8462F7209FAB5EC7BFDD3B748DEF9DF20777CF8F926D22B2564B58894AF63DA1C184DCC4229E596B33EDF868E3D4299FA28D7474C7F8D254A2060929B15
NPL_US17667285_OA_29Dec2023.pdf	BD832940ADD40D41F91F71CC20853A1DDE5A3B495301CB348B412D80EC51180E021A615A803A3BDB50C34C660BABA556323DE50BD991C4B78B6987A65AD387F4

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 239/94, A61K 31/505 — A1

(11) International Publication Number: **WO 97/32856**

(43) International Publication Date: 12 September 1997 (12.09.97)

(21) International Application Number: PCT/GB97/00550

(22) International Filing Date: 28 February 1997 (28.02.97)

(30) Priority Data:
96400468.3 5 March 1996 (05.03.96) EP
(34) Countries for which the regional or international application was filed: AT et al.
96401499.7 8 July 1996 (08.07.96) EP
(34) Countries for which the regional or international application was filed: AT et al.

(71) Applicants *(for all designated States except US)*: ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB). ZENECA PHARMA S.A. [FR/FR]; "Le Galien", 1, rue des Chauffours, Boîte postale 127, F-95022 Cergy Cédex (FR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: THOMAS, Andrew, Peter [GB/GB]; Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). HENNEQUIN, Laurent, François, André [FR/FR]; Zeneca Pharma S.A., Centre de Recherches Z.I. La Pompelle, Chemin de Vrilly, Boîte postale 1050, F-51689 Reims Cédex (FR). JOHNSTONE, Craig [GB/GB]; Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: MACK, John, Richard; Zeneca Pharmaceuticals, Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: 4-ANILINOQUINAZOLINE DERIVATIVES

(57) Abstract

The invention relates to quinazoline derivatives of formula (I) (wherein: R^1 represents hydrogen or methoxy; R^2 represents methoxy, ethoxy, 2-methoxyethoxy, 3-methoxypropoxy, 2-ethoxyethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, 2-hydroxyethoxy, 3-hydroxypropoxy, 2-(N,N-dimethylamino)ethoxy, 3-(N,N-dimethylamino)propoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 4-morpholinobutoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 4-piperidinobutoxy, 2-(piperazin-1-yl)ethoxy, 3-(piperazin-1-yl)propoxy, 4-(piperazin-1-yl)butoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy or 4-(4-methylpiperazin-1-yl)butoxy; the phenyl group bearing $(R^3)_2$ is selected from: 2-fluoro-5-hydroxyphenyl, 4-bromo-2-fluorophenyl, 2,4-difluorophenyl, 4-chloro-2-fluorophenyl, 2-fluoro-4-methylphenyl, 2-fluoro-4-methoxyphenyl, 4-bromo-3-hydroxyphenyl, 4-fluoro-3-hydroxyphenyl, 4-chloro-3-hydroxyphenyl, 3-hydroxy-4-methylphenyl, 3-hydroxy-4-methoxyphenyl and 4-cyano-2-fluorophenyl); and salts thereof, processes for their preparation and pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.



(I)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	**GB**	United Kingdom	**MW**	Malawi
AT	Austria	**GE**	Georgia	**MX**	Mexico
AU	Australia	**GN**	Guinea	**NE**	Niger
BB	Barbados	**GR**	Greece	**NL**	Netherlands
BE	Belgium	**HU**	Hungary	**NO**	Norway
BF	Burkina Faso	**IE**	Ireland	**NZ**	New Zealand
BG	Bulgaria	**IT**	Italy	**PL**	Poland
BJ	Benin	**JP**	Japan	**PT**	Portugal
BR	Brazil	**KE**	Kenya	**RO**	Romania
BY	Belarus	**KG**	Kyrgystan	**RU**	Russian Federation
CA	Canada	**KP**	Democratic People's Republic of Korea	**SD**	Sudan
CF	Central African Republic			**SE**	Sweden
CG	Congo	**KR**	Republic of Korea	**SG**	Singapore
CH	Switzerland	**KZ**	Kazakhstan	**SI**	Slovenia
CI	Côte d'Ivoire	**LI**	Liechtenstein	**SK**	Slovakia
CM	Cameroon	**LK**	Sri Lanka	**SN**	Senegal
CN	China	**LR**	Liberia	**SZ**	Swaziland
CS	Czechoslovakia	**LT**	Lithuania	**TD**	Chad
CZ	Czech Republic	**LU**	Luxembourg	**TG**	Togo
DE	Germany	**LV**	Latvia	**TJ**	Tajikistan
DK	Denmark	**MC**	Monaco	**TT**	Trinidad and Tobago
EE	Estonia	**MD**	Republic of Moldova	**UA**	Ukraine
ES	Spain	**MG**	Madagascar	**UG**	Uganda
FI	Finland	**ML**	Mali	**US**	United States of America
FR	France	**MN**	Mongolia	**UZ**	Uzbekistan
GA	Gabon	**MR**	Mauritania	**VN**	Viet Nam

4-ANILINOQUINAZOLINE DERIVATIVES

The present invention relates to quinazoline derivatives, processes for their preparation, pharmaceutical compositions conta ining them as active ingredient, methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability, to their use as medicaments and to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans.

Normal angiogenesis plays an important role in a variety of processes including embryonic development, wound healing and several components of female reproductive function. Undesirable or pathological angiogenesis has been associated with disease states including diabetic retinopathy, psoriasis, cancer, rheumatoid arthritis, atheroma, Kaposi's sarcoma and haemangioma (Fan et al, 1995, Trends Pharmacol. Sci. 16: 57-66; Folkman, 1995, Nature Medicine 1: 27-31). Alteration of vascular permeability is thought to play a role in both normal and pathological physiological processes (Cullinan-Bove et al, 1993, Endocrinology 133: 829-837; Senger et al, 1993, Cancer and Metastasis Reviews, 12: 303-324). Several polypeptides with in vitro endothelial cell growth promoting activity have been identified including, acidic and basic fibroblast growth factors (aFGF & bFGF) and vascular endothelial growth factor (VEGF). By virtue of the restricted expression of its receptors, the growth factor activity of VEGF, in contrast to that of the FGFs, is relatively specific towards endothelial cells. Recent evidence indicates that VEGF is an important stimulator of both normal and pathological angiogenesis (Jakeman et al, 1993, Endocrinology, 133: 848-859; Kolch et al, 1995, Breast Cancer Research and Treatment, 36:139-155) and vascular permeability (Connolly et al, 1989, J. Biol. Chem. 264: 20017-20024). Antagonism of VEGF action by sequestration of VEGF with antibody can result in inhibition of tumour growth (Kim et al, 1993, Nature 362: 841-844).

Receptor tyrosine kinases (RTKs) are important in the transmission of biochemical signals across the plasma membrane of cells. These transmembrane molecules characteristically consist of an extracellular ligand-binding domain connected through a segment in the plasma membrane to an intracellular tyrosine kinase domain. Binding of ligand to the receptor results in stimulation of the receptor-associated tyrosine kinase activity which

leads to phosphorylation of tyrosine residues on both the receptor and other intracellular molecules. These changes in tyrosine phosphorylation initiate a signalling cascade leading to a variety of cellular responses. To date, at least nineteen distinct RTK subfamilies, defined by amino acid sequence homology, have been identified. One of these subfamilies is presently comprised by the fms-like tyrosine kinase receptor, Flt or Flt1, the kinase insert domain-containing receptor, KDR (also referred to as Flk-1), and another fms-like tyrosine kinase receptor, Flt4. Two of these related RTKs, Flt and KDR, have been shown to bind VEGF with high affinity (De Vries et al, 1992, Science 255: 989-991; Terman et al, 1992, Biochem. Biophys. Res. Comm. 1992, 187: 1579-1586). Binding of VEGF to these receptors expressed in heterologous cells has been associated with changes in the tyrosine phosphorylation status of cellular proteins and calcium fluxes.


European Patent Publication No. 0326330 discloses certain quinoline, quinazoline and cinnoline plant fungicides. Certain of these plant fungicides are also stated to possess insecticidal and miticidal activity. There is however no disclosure or any suggestion that any of the compounds disclosed may be used for any purpose in animals such as humans. In particular, the European Patent Publication contains no teaching whatsoever concerning angiogenesis and/or increased vascular permeability mediated by growth factors such as VEGF.

European Patent Publication No. 0566226 describes compounds having activity against epidermal growth factor (EGF) receptor tyrosine kinase. Whilst the compounds of the present invention fall within the broad general disclosure of EP 0566226, we have found, surprisingly, that the compounds of the present invention possess very good inhibitory activity against VEGF, a property nowhere disclosed in EP 0566226. Moreover compounds of EP 0566226, outside the scope of the present invention, which have been tested, do not show significant inhibtory activity against VEGF receptor tyrosine kinase.

The present invention is thus based on the discovery of compounds that surprisingly inhibit the effects of VEGF, a property of value in the treatment of disease states associated with angiogenesis and/or increased vascular permeability such as cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation and ocular diseases with retinal vessel proliferation. Compounds of the present invention possess higher potency

against VEGF receptor tyrosine kinase whilst possessing some activity against EGF receptor tyrosine kinase. Furthermore, compounds of the present invention, possess substantially higher potency against VEGF receptor tyrosine kinase than against EGF receptor tyrosine kinase or FGF R1 receptor tyrosine kinase.

According to one aspect of the present invention there is provided a quinazoline derivative of the formula I:



(I)

(wherein:

R^1 represents hydrogen or methoxy;

R^2 represents methoxy, ethoxy, 2-methoxyethoxy, 3-methoxypropoxy, 2-ethoxyethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, 2-hydroxyethoxy, 3-hydroxypropoxy, 2-(N,N-dimethylamino)ethoxy, 3-(N,N-dimethylamino)propoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 4-morpholinobutoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 4-piperidinobutoxy, 2-(piperazin-1-yl)ethoxy, 3-(piperazin-1-yl)propoxy, 4-(piperazin-1-yl)butoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy or 4-(4-methylpiperazin-1-yl)butoxy;

the phenyl group bearing $(R^3)_2$ is selected from: 2-fluoro-5-hydroxyphenyl, 4-bromo-2-fluorophenyl, 2,4-difluorophenyl, 4-chloro-2-fluorophenyl, 2-fluoro-4-methylphenyl, 2-fluoro-4-methoxyphenyl, 4-bromo-3-hydroxyphenyl, 4-fluoro-3-hydroxyphenyl, 4-chloro-3-hydroxyphenyl, 3-hydroxy-4-methylphenyl, 3-hydroxy-4-methoxyphenyl and 4-cyano-2-fluorophenyl);

and salts thereof.

R^1 is preferably methoxy.

Advantageously R^2 represents methoxy, ethoxy, 2-methoxyethoxy, 3-methoxypropoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, 2-hydroxyethoxy, 3-hydroxypropoxy, 2-(N,N-dimethylamino)ethoxy, 3-(N,N-dimethylamino)propoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 2-(piperazin-1-yl)ethoxy or 3-(piperazin-1-yl)propoxy. Further advantageous values of R^2 are 2-(4-methylpiperazin-1-yl)ethoxy and 3-(4-methylpiperazin-1-yl)propoxy.

Preferably R^2 is methoxy, ethoxy, 2-methoxyethoxy, 3-methoxypropoxy, 2,2,2-trifluoroethoxy, 2-hydroxyethoxy, 3-hydroxypropoxy, 2-(N,N-dimethylamino)ethoxy, 3-(N,N-dimethylamino)propoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 2-(piperazin-1-yl)ethoxy or 3-(piperazin-1-yl)propoxy. Additional preferred values of R^2 are 2-(4-methylpiperazin-1-yl)ethoxy and 3-(4-methylpiperazin-1-yl)propoxy.

More preferably R^2 is 2-methoxyethoxy, 2-hydroxyethoxy, 3-(N,N-dimethylamino)propoxy, 2-morpholinoethoxy, 3-morpholinopropoxy or 3-(piperazin-1-yl)propoxy, and additional more preferred values of R^2 are 2-(4-methylpiperazin-1-yl)ethoxy and 3-(4-methylpiperazin-1-yl)propoxy.

Particularly preferred values of R^2 are 2-methoxyethoxy, 2-morpholinoethoxy, 3-morpholinopropoxy and 2-(4-methylpiperazin-1-yl)ethoxy.

Especially preferred values of R^2 are 2-methoxyethoxy and 3-morpholinopropoxy.

In a particular aspect of the invention the phenyl group bearing $(R^3)_2$ is selected from: 2-fluoro-5-hydroxyphenyl, 4-bromo-2-fluorophenyl, 2,4-difluorophenyl, 4-chloro-2-fluorophenyl, 2-fluoro-4-methylphenyl, 2-fluoro-4-methoxyphenyl, 4-bromo-3-hydroxyphenyl, 4-fluoro-3-hydroxyphenyl, 4-chloro-3-hydroxyphenyl, 3-hydroxy-4-methylphenyl and 3-hydroxy-4-methoxyphenyl.

The phenyl group bearing $(R^3)_2$ is preferably 3-hydroxy-4-methylphenyl or 4-chloro-2-fluorophenyl especially 4-chloro-2-fluorophenyl. A further especially preferred value for the phenyl group bearing $(R^3)_2$ is 4-bromo-2-fluorophenyl.

Preferred compounds are

4-(4-chloro-2-fluoroanilino)-7-(2-methoxyethoxy)quinazoline,

6,7-dimethoxy-4-(2-fluoro-5-hydroxyanilino)quinazoline,

4-(4-chloro-3-hydroxyanilino)-6,7-dimethoxyquinazoline,

4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6,7-dimethoxyquinazoline,
4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-7-(3-hydroxypropoxy)-6-methoxyquinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-morpholinoethoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline
and salts thereof especially hydrochloride salts thereof,
and other preferred compounds are
4-(4-bromo-2-fluoroanilino)-6,7-dimethoxyquinazoline,
4-(2-fluoro-4-methylanilino)-6,7-dimethoxyquinazoline,
6,7-dimethoxy-4-(3-hydroxy-4-methylanilino)quinazoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,
4-(2-fluoro-4-methylanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,
4-(3-hydroxy-4-methylanilino)-7-(2-methoxyethoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-7-(3-morpholinopropoxy)quinazoline,
4-(4-cyano-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-methoxypropoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-ethoxyethoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-7-(2-hydroxyethoxy)-6-methoxyquinazoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-morpholinoethoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(4-morpholinobutoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(4-methylpiperazin-1yl)propoxy)quinazoline
and salts thereof especially hydrochloride salts thereof.
More preferred compounds are
4-(4-chloro-2-fluoroanilino)-7-(2-methoxyethoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6,7-dimethoxyquinazoline,

4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-7-(3-hydroxypropoxy)-6-methoxyquinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-morpholinoethoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,
4-(2-fluoro-4-methylanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,
4-(3-hydroxy-4-methylanilino)-7-(2-methoxyethoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-7-(3-morpholinopropoxy)quinazoline,
4-(4-cyano-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-methoxypropoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-ethoxyethoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-7-(2-hydroxyethoxy)-6-methoxyquinazoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-morpholinoethoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(4-morpholinobutoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(4-methylpiperazin-1yl)propoxy)quinazoline
and salts thereof especially hydrochloride salts thereof.

Particularly preferred compounds are

4-(4-chloro-2-fluoroanilino)-7-(2-methoxyethoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6,7-dimethoxyquinazoline,
4-(4-chloro-2-fluoroanilino)-7-(3-hydroxypropoxy)-6-methoxyquinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-morpholinoethoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline
and salts thereof especially hydrochloride salts thereof, other particularly preferred compounds are

4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline,

4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline,

4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-morpholinoethoxy)quinazoline

and salts thereof especially hydrochloride salts thereof.

More particularly preferred compounds are

4-(4-chloro-2-fluoroanilino)-7-(2-methoxyethoxy)quinazoline,

4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,

4-(4-chloro-2-fluoroanilino)-7-(3-hydroxypropoxy)-6-methoxyquinazoline,

4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-morpholinoethoxy)quinazoline,

4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,

4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline,

4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline,

4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-morpholinoethoxy)quinazoline

and salts thereof especially hydrochloride salts thereof.

Especially preferred compounds are

4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,

4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-morpholinoethoxy)quinazoline,

4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,

4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline,

4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline,

4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-morpholinoethoxy)quinazoline

and salts thereof especially hydrochloride salts thereof.

More especially preferred compounds are

4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,

4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-morpholinoethoxy)quinazoline,

4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline,

4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline and salts thereof especially hydrochloride salts thereof, of which 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline, 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline and salts thereof especially hydrochloride salts thereof are preferred.

For the avoidance of doubt it is to be understood that where in this specification a group is qualified by 'hereinbefore defined' or 'defined hereinbefore' the said group encompasses the first occurring and broadest definition as well as each and all of the preferred definitions for that group.

In this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. An analogous convention applies to other generic terms. Unless otherwise stated the term "alkyl" advantageously refers to chains with 1-6 carbon atoms, preferably 1-4 carbon atoms.

In this specification the term "alkoxy" means an alkyl group as defined hereinbefore linked to an oxygen atom.

In this specification the term "aryl" includes C_{6-10}aromatic groups which may, if desired, carry one or more substituents selected from halogeno, alkyl, alkoxy, cyano, nitro or trifluoromethyl (wherein alkyl and alkoxy are as hereinbefore defined). The term "aryloxy" means an aryl group as defined hereinbefore linked to an oxygen atom.

In this specification the term "sulphonyloxy" includes alkylsulphonyloxy and arylsulphonyloxy wherein "alkyl" and "aryl" are as defined hereinbefore.

In formula I, as hereinbefore defined, hydrogen will be present at positions 2, 5 and 8 of the quinazoline group.

Within the present invention it is to be understood that a quinazoline of the formula I or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which inhibits VEGF receptor tyrosine kinase activity and is not to be limited merely to any one tautomeric form utilised within the formulae drawings.

It is also to be understood that certain quinazolines of the formula I and salts thereof can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which inhibit VEGF receptor tyrosine kinase activity.


The present invention relates to the compounds of formula I as hereinbefore defined as well as to the salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula I and their pharmaceutically acceptable salts. Pharmaceutically acceptable salts of the invention may, for example, include acid addition salts of the compounds of formula I as hereinbefore defined which are sufficiently basic to form such salts. Such acid addition salts include for example salts with inorganic or organic acids affording pharmaceutically acceptable anions such as with hydrogen halides (especially hydrochloric or hydrobromic acid of which hydrochloric acid is particularly preferred) or with sulphuric or phosphoric acid, or with trifluoroacetic, citric or maleic acid. In addition where the compounds of formula I are sufficiently acidic, pharmaceutically acceptable salts may be formed with an inorganic or organic base which affords a pharmaceutically acceptable cation. Such salts with inorganic or organic bases include for example an alkali metal salt, such as a sodium or potassium salt, an alkaline earth metal salt such as a calcium or magnesium salt, an ammonium salt or for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

A compound of the formula I, or salt thereof, and other compounds of the invention (as hereinafter defined) may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Such processes include, for example, those illustrated in European Patent Applications, Publication Nos. 0520722, 0566226, 0602851 and 0635498. Such processes, are provided as a further feature of the invention and are as described hereinafter. Necessary starting materials may be obtained by standard procedures of organic chemistry. The preparation of such starting materials is described within the accompanying non-limiting Examples. Alternatively necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist.

Thus the following processes (a) to (e) and (i) to (v) constitute further features of the present invention.


Synthesis of Compounds of Formula I

(a) Compounds of the formula I and salts thereof may be prepared by the reaction of a compound of the formula III:



(III)

(wherein R^1 and R^2 are as defined hereinbefore and L^1 is a displaceable moiety), with a compound of the formula IV:




(IV)

(wherein R^3 is as defined hereinbefore) whereby to obtain compounds of the formula I and salts thereof. A convenient displaceable moiety L^1 is, for example, a halogeno, alkoxy (preferably C_{1-4}alkoxy), aryloxy or sulphonyloxy group, for example a chloro, bromo, methoxy, phenoxy, methanesulphonyloxy or toluene-4-sulphonyloxy group.

The reaction is advantageously effected in the presence of either an acid or a base. Such an acid is, for example, an anhydrous inorganic acid such as hydrogen chloride. Such a base is, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene, or for example, an alkali metal or alkaline earth metal carbonate or hydroxide, for example sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide. Alternatively such a base is, for example, an alkali metal hydride, for example sodium hydride, or an alkali metal or alkaline earth metal amide, for example sodium amide or sodium bis(trimethylsilyl)amide. The reaction is preferably effected in the presence of an inert solvent or diluent, for example an alkanol or ester such as methanol, ethanol, isopropanol or ethyl acetate, a halogenated solvent such as methylene chloride, trichloromethane or carbon tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxan, an aromatic hydrocarbon solvent such as toluene, or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide. The reaction is conveniently effected at a temperature in the range, for example, 10 to 150°C, preferably in the range 20 to 80°C.


The compound of the invention may be obtained from this process in the form of the free base or alternatively it may be obtained in the form of a salt with the acid of the formula H-L^1 wherein L^1 has the meaning defined hereinbefore. When it is desired to obtain the free base from the salt, the salt may be treated with a base as defined hereinbefore using a conventional procedure.

(b) Where the group of formula II:



(II)


(wherein R^3 is as hereinbefore defined) represents a phenyl group carrying a hydroxy group, a compound of the formula I and salts thereof can be prepared by the deprotection of a compound of formula V:



(V)

(wherein R^1, R^2 and R^3 are as hereinbefore defined and P represents a phenolic hydroxy protecting group). The choice of phenolic hydroxy protecting group P is within the standard knowledge of an organic chemist, for example those included in standard texts such as "Protective Groups in Organic Synthesis" T.W. Greene and R.G.M.Wuts, 2nd Ed. Wiley 1991, including ethers (for example, methyl, methoxymethyl, allyl and benzyl), silyl ethers (for example, t-butyldiphenylsilyl and t-butyldimethylsilyl), esters (for example, acetate and benzoate) and carbonates (for example, methyl and benzyl). The removal of such a phenolic hydroxy protecting group may be effected by any of the procedures known for such a transformation, including those reaction conditions indicated in standard texts such as that indicated hereinbefore, or by a related procedure. The reaction conditions preferably being such that the hydroxy derivative is produced without unwanted reactions at other sites within the starting or product compounds. For example, where the protecting group P is acetate, the transformation may conveniently be effected by treatment of the quinazoline derivative with a base as defined hereinbefore and including ammonia, and its mono and di-alkylated derivatives, preferably in the presence of a protic solvent or co-solvent such as water or an alcohol, for example methanol or ethanol. Such a reaction can be effected in the presence of an additional inert solvent or diluent as defined hereinbefore and at a temperature in the range 0 to 50°C, conveniently at about 20°C.

(c) Production of compounds of formula I and salts thereof can be achieved by the reaction, conveniently in the presence of a base as defined hereinbefore, of a compound of the formula VI:




(VI)

(wherein R^1 and R^3 are as hereinbefore defined) with a compound of formula VII:

$$R^4\text{-}L^1 \qquad \text{(VII)}$$

(wherein L^1 is as hereinbefore defined and R^4 is methyl, ethyl, 2-methoxyethyl, 3-methoxypropyl, 2-ethoxyethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-(N,N-dimethylamino)ethyl, 3-(N,N-dimethylamino)propyl, 2-morpholinoethyl, 3-morpholinopropyl, 4-morpholinobutyl, 2-piperidinoethyl, 3-piperidinopropyl, 4-piperidinobutyl, 2-(piperazin-1-yl)ethyl, 3-(piperazin-1-yl)propyl, 4-(piperazin-1-yl)butyl, 2-(4-methylpiperazin-1-yl)ethyl, 3-(4-methylpiperazin-1-yl)propyl or 4-(4-methylpiperazin-1-yl)butyl); L^1 is a displaceable moiety for example a halogeno or sulphonyloxy group such as a bromo or methanesulphonyloxy group. The reaction is preferably effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously in the presence of an inert solvent or diluent (as defined hereinbefore in process (a)), advantageously at a temperature in the range, for example 10 to 150°C, conveniently at about 50°C.

(d) Compounds of the formula I and salts thereof may be prepared by the reaction of a compound of the formula VIII:




(VIII)

with a compound of the formula IX:

$$R^2\text{-}H \qquad \text{(IX)}$$

(wherein L^1, R^1, R^2 and R^3 are all as hereinbefore defined). The reaction may conveniently be effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously in the presence of an inert solvent or diluent (as defined hereinbefore in process (a)), advantageously at a temperature in the range, for example 10 to 150°C, conveniently at about 100°C.

(e) Compounds of the formula I and salts thereof wherein R^2 is R^5C_{1-4}alkoxy, in particular R^5C_{1-3}alkoxy, (wherein R^5 is selected from methoxy, ethoxy, hydroxy, N,N-dimethylamino, morpholino, piperidino, piperazin-1-yl or 4-methylpiperazin-1-yl) may be prepared by reacting a compound of the formula X:



(X)


(wherein L^1, R^1 and R^3 are as hereinbefore defined and R^6 is C_{1-4}alkoxy, in particular C_{1-3}alkoxy) with a compound of the formula XI:

R^5-H (XI)

(wherein R^5 is as defined hereinbefore) to give a compound of the formula I. The reaction may conveniently be effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously in the presence of an inert solvent or diluent (as defined hereinbefore in process (a)), and at a temperature in the range, for example 0 to 150°C, conveniently at about 50°C.

Synthesis of Intermediates

(i) Compounds of formula III and salts thereof constitute a further feature of the present invention. Such compounds in which L^1 is halogeno may for example be prepared by halogenating a compound of the formula XII:




(XII)

(wherein R^1 and R^2 are as hereinbefore defined).

Convenient halogenating agents include inorganic acid halides, for example thionyl chloride, phosphorus(III)chloride, phosphorus(V)oxychloride and phosphorus(V)chloride. The halogenation reaction is conveniently effected in the presence of an inert solvent or diluent such as for example a halogenated solvent such as methylene chloride, trichloromethane or carbon tetrachloride, or an aromatic hydrocarbon solvent such as benzene or toluene. The reaction is conveniently effected at a temperature in the range, for example 10 to 150°C, preferably in the range 40 to 100°C.


The compounds of formula XII and salts thereof which constitute a further feature of the present invention may for example be prepared by reacting a compound of the formula XIII:



(XIII)

(wherein R^1 and L^1 are as hereinbefore defined) with a compound of the formula IX as hereinbefore defined. The reaction may conveniently be effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously in the presence of an inert solvent or diluent (as defined hereinbefore in process (a)), advantageously at a temperature in the range, for example 10 to 150°C, conveniently at about 100°C.

The compounds of formula XII and salts thereof may also be prepared by cyclising a compound of the formula XIV:




(XIV)

(wherein R^1 and R^2 are as hereinbefore defined, and A^1 is an hydroxy, alkoxy (preferably C_{1-4}alkoxy) or amino group) whereby to form a compound of formula XII or salt thereof. The cyclisation may be effected by reacting a compound of the formula XIV, where A^1 is an hydroxy or alkoxy group, with formamide or an equivalent thereof effective to cause cyclisation whereby a compound of formula XII or salt thereof is obtained, such as [3-(dimethylamino)-2-azaprop-2-enylidene]dimethylammonium chloride. The cyclisation is conveniently effected in the presence of formamide as solvent or in the presence of an inert solvent or diluent such as an ether for example 1,4-dioxan. The cyclisation is conveniently effected at an elevated temperature, preferably in the range 80 to 200°C. The compounds of formula XII may also be prepared by cyclising a compound of the formula XIV, where A^1 is an amino group, with formic acid or an equivalent thereof effective to cause cyclisation whereby a

compound of formula XII or salt thereof is obtained. Equivalents of formic acid effective to cause cyclisation include for example a tri-C_{1-4}alkoxymethane, for example triethoxymethane and trimethoxymethane. The cyclisation is conveniently effected in the presence of a catalytic amount of an anhydrous acid, such as a sulphonic acid for example p-toluenesulphonic acid, and in the presence of an inert solvent or diluent such as for example a halogenated solvent such as methylene chloride, trichloromethane or carbon tetrachloride, an ether such as diethylether or tetrahydrofuran, or an aromatic hydrocarbon solvent such as toluene. The cyclisation is conveniently effected at a temperature in the range, for example 10 to 100°C, preferably in the range 20 to 50°C.


Compounds of formula XIV and salts thereof, which constitute a further feature of the present invention, may for example be prepared by the reduction of the nitro group in a compound of the formula XV:



(XV)

(wherein R^1, R^2 and A^1 are as hereinbefore defined) to yield a compound of formula XIV as hereinbefore defined. The reduction of the nitro group may conveniently be effected by any of the procedures known for such a transformation. The reduction may be carried out, for example, by the hydrogenation of a solution of the nitro compound in the presence of an inert solvent or diluent as defined hereinbefore in the presence of a metal effective to catalyse hydrogenation reactions such as palladium or platinum. A further reducing agent is, for example, an activated metal such as activated iron (produced for example by washing iron powder with a dilute solution of an acid such as hydrochloric acid). Thus, for example, the reduction may be effected by heating the nitro compound and the activated metal in the presence of a solvent or diluent such as a mixture of water and alcohol, for example methanol or ethanol, to a temperature in the range, for example 50 to 150°C, conveniently at about 70°C.


Compounds of the formula XV and salts thereof which constitute a further feature of the present invention, may for example be prepared by the reaction of a compound of the formula XVI:



(XVI)

(wherein R^1, L^1 and A^1 are as hereinbefore defined) with a compound of the formula IX as hereinbefore defined to give a compound of the formual XV. The reaction of the compounds of formulae XVI and IX is conveniently effected under conditions as described for process (d) hereinbefore.


Compounds of formula XV and salts thereof, may for example also be prepared by the reaction of a compound of the formula XVII:



(XVII)

(wherein R^1 and A^1 are as hereinbefore defined) with a compound of the formula VII as hereinbefore defined to yield a compound of formula XV as hereinbefore defined. The reaction of the compounds of formulae XVII and VII is conveniently effected under conditions as described for process (c) hereinbefore.

The compounds of formula III and salts thereof may also be prepared for example by reacting a compound of the formula XVIII:




(XVIII)

(wherein R^1 is as hereinbefore defined and L^2 represents a displaceable protecting moiety) with a compound of the formula VII as hereinbefore defined, whereby to obtain a compound of formula III in which L^1 is represented by L^2.

A compound of formula XVIII is conveniently used in which L^2 represents a phenoxy group which may if desired carry up to 5 substituents, preferably up to 2 substituents, selected from halogeno, nitro and cyano. The reaction may be conveniently effected under conditions as described for process (c) hereinbefore.

The compounds of formula XVIII and salts thereof as hereinbefore defined may for example be prepared by deprotecting a compound of the formula XIX:




(XIX)

(wherein R^1, P and L^2 are as hereinbefore defined). Deprotection may be effected by techniques well known in the literature, for example where P represents a benzyl group deprotection may be effected by hydrogenolysis or by treatment with trifluoroacetic acid.

One compound of formula III may if desired be converted into another compound of formula III in which the moiety L^1 is different. Thus for example a compound of formula III in which L^1 is other than halogeno, for example optionally substituted phenoxy, may be converted to a compound of formula III in which L^1 is halogeno by hydrolysis of a compound of formula III (in which L^1 is other than halogeno) to yield a compound of formula XII as hereinbefore

defined, followed by introduction of halide to the compound of formula XII, thus obtained as hereinbefore defined, to yield a compound of formula III in which L^1 represents halogen.


(ii) The compounds of formula V and salts thereof, constitute a further feature of the present invention, and may for example be prepared by the reaction of a compound of formula III as hereinbefore defined with a compound of the formula XX:



(XX)

(wherein R^3 and P are as hereinbefore defined). The reaction may for example be effected as described for process (a) hereinbefore.


The compounds of formula V and salts thereof may also be prepared by reacting a compound of formula XXI:



(XXI)

(wherein R^1, L^1, R^3 and P are as hereinbefore defined) with a compound of formula IX as hereinbefore defined. The reaction may for example be effected as described for process (d) above.


The compounds of formula V and salts thereof may also be prepared by reacting a compound of formula XXII:



(XXII)

(wherein R^1, R^3 and P are as hereinbefore defined) with a compound of the formula VII as hereinbefore defined. The reaction may for example be effected as described for process (c) hereinbefore.


The compounds of formula XXI and salts thereof may for example be prepared by reaction of a compound of formula XXIII:



(XXIII)

(wherein R^1 and L^1 are as hereinbefore defined, and L^1 in the 4- and 7- positions may be the same or different) with a compound of the formula XX as hereinbefore defined. The reaction may be effected for example by a process as described in (a) above.


Compounds of the formula XXII and salts thereof may be made by reacting compounds of the formulae XIX and XX as hereinbefore defined, under conditions described in (a) hereinbefore, to give a compound of formula XXIV:



(XXIV)

(wherein R^1, R^3 and P are as hereinbefore defined) and then deprotecting the compound of formula XXIV for example as described in (i) above.

(iii) Compounds of the formula VI as hereinbefore defined and salts thereof may be made by deprotecting the compound of formula XXV:



(XXV)

(wherein R^1, R^3 and P are as hereinbefore defined) by a process for example as described in (i) above.

Compounds of the formula XXV and salts thereof may be made by reacting compounds of the formulae XIX and IV as hereinbefore defined, under the conditions described in (a) hereinbefore, to give a compound of the formula XXV or salt thereof.

(iv) Compounds of the formula VIII and salts thereof as hereinbefore defined may be made by reacting compounds of the formulae XXIII and IV as hereinbefore defined, the reaction for example being effected by a process as described in (a) above.


(v) Compounds of the formula X as defined hereinbefore and salts thereof may for example be made by the reaction of a compound of formula VI as defined hereinbefore with a compound of the formula XXVI:

L^1-R^6-L^1

(XXVI)

(wherein L^1 and R^6 are as hereinbefore defined) to give a compound of the formula X. The reaction may be effected for example by a process as described in (c) above.

Compounds of the formula X and salts thereof may also be made for example by deprotecting a compound of the formula XXVII:



(XXVII)

(wherein L^1, R^6, R^1, R^3 and P are as defined hereinbefore) by a process for example as described in (b) above.

Compounds of the formula XXVII and salts thereof may be made for example by reacting compounds of the formulae XXII and XXVI as defined hereinbefore, under the conditions described in (c) above.

When a pharmaceutically acceptable salt of a compound of the formula I is required, it may be obtained, for example, by reaction of said compound with, for example, an acid using a conventional procedure, the acid having a pharmaceutically acceptable anion.

Many of the intermediates defined herein are novel, for example, those of the formulae III, V, XII, XIV and XV, and these are provided as a further feature of the invention.

Intermediates of the formulae VI, VIII, X, XXI, XXII, XXIV, XXV and XXVII are also provided as a further feature of the invention.

The identification of compounds which potently inhibit the tyrosine kinase activity associated with the VEGF receptors such as Flt and/or KDR and which inhibit angiogenesis and/or increased vascular permeability is desirable and is the subject of the present invention.

These properties may be assessed, for example, using one or more of the procedures set out below:

(a) In Vitro Receptor Tyrosine Kinase Inhibition Test

This assay determines the ability of a test compound to inhibit tyrosine kinase activity. DNA encoding VEGF or epidermal growth factor (EGF) receptor cytoplasmic domains may be obtained by total gene synthesis (Edwards M, International Biotechnology Lab 5(3), 19-25, 1987) or by cloning. These may then be expressed in a suitable expression system to obtain polypeptide with tyrosine kinase activity. For example VEGF and EGF receptor cytoplasmic domains, which were obtained by expression of recombinant protein in insect cells, were found to display intrinsic tyrosine kinase activity. In the case of the VEGF receptor Flt (Genbank accession number X51602), a 1.7kb DNA fragment encoding most of the cytoplasmic domain, commencing with methionine 783 and including the termination codon, described by Shibuya et al (Oncogene, 1990, 5: 519-524), was isolated from cDNA and cloned into a baculovirus transplacement vector (for example pAcYM1 (see The Baculovirus Expression System: A Laboratory Guide, L.A. King and R. D. Possee, Chapman and Hall, 1992) or pAc360 or pBlueBacHis (available from Invitrogen Corporation)). This recombinant construct was co-transfected into insect cells (for example Spodoptera frugiperda 21(Sf21)) with viral DNA (eg Pharmingen BaculoGold) to prepare recombinant baculovirus. (Details of the methods for the assembly of recombinant DNA molecules and the preparation and use of recombinant baculovirus can be found in standard texts for example Sambrook et al, 1989, Molecular cloning - A Laboratory Manual, 2nd edition, Cold Spring Harbour Laboratory Press and O'Reilly et al, 1992, Baculovirus Expression Vectors - A Laboratory Manual, W. H. Freeman and Co, New York). For other tyrosine kinases for use in assays, cytoplasmic fragments starting from methionine 806 (KDR, Genbank accession number L04947) and methionine 668 (EGF receptor, Genbank accession number X00588) may be cloned and expressed in a similar manner.

For expression of cFlt tyrosine kinase activity, Sf21 cells were infected with plaque-pure cFlt recombinant virus at a multiplicity of infection of 3 and harvested 48 hours later. Harvested cells were washed with ice cold phosphate buffered saline solution (PBS) (10mM sodium phosphate pH7.4, 138mM NaCl, 2.7mM KCl) then resuspended in ice cold

HNTG/PMSF (20mM Hepes pH7.5, 150mM NaCl, 10% v/v glycerol, 1% v/v Triton X100, 1.5mM $MgCl_2$, 1mM ethylene glycol-bis(βaminoethyl ether) N,N,N',N'-tetraacetic acid (EGTA), 1mM PMSF (phenylmethylsulphonyl fluoride); the PMSF is added just before use from a freshly-prepared 100mM solution in methanol) using 1ml HNTG/PMSF per 10 million cells. The suspension was centrifuged for 10 minutes at 13,000 rpm at 4°C, the supernatant (enzyme stock) was removed and stored in aliquots at -70°C. Each new batch of stock enzyme was titrated in the assay by dilution with enzyme diluent (100mM Hepes pH 7.4, 0.2mM Na_3VO_4, 0.1% v/v Triton X100, 0.2mM dithiothreitol). For a typical batch, stock enzyme is diluted 1 in 2000 with enzyme diluent and 50µl of dilute enzyme is used for each assay well.

A stock of substrate solution was prepared from a random copolymer containing tyrosine, for example Poly (Glu, Ala, Tyr) 6:3:1 (Sigma P3899), stored as 1 mg/ml stock in PBS at -20°C and diluted 1 in 500 with PBS for plate coating.

On the day before the assay 100µl of diluted substrate solution was dispensed into all wells of assay plates (Nunc maxisorp 96-well immunoplates) which were sealed and left overnight at 4°C.

On the day of the assay the substrate solution was discarded and the assay plate wells were washed once with PBST (PBS containing 0.05% v/v Tween 20) and once with 50mM Hepes pH7.4.

Test compounds were diluted with 10% dimethylsulphoxide (DMSO) and 25µl of diluted compound was transferred to wells in the washed assay plates. "Total" control wells contained 10% DMSO instead of compound. Twenty five microlitres of 40mM $MnCl_2$ containing 8µM adenosine-5'-triphosphate (ATP) was added to all test wells except "blank" control wells which contained $MnCl_2$ without ATP. To start the reactions 50µl of freshly diluted enzyme was added to each well and the plates were incubated at room temperature for 20 minutes. The liquid was then discarded and the wells were washed twice with PBST. One hundred microlitres of mouse IgG anti-phosphotyrosine antibody (Upstate Biotechnology Inc. product 05-321), diluted 1 in 6000 with PBST containing 0.5% w/v bovine serum albumin (BSA), was added to each well and the plates were incubated for 1 hour at room temperature before discarding the liquid and washing the wells twice with PBST. One hundred microlitres of horse radish peroxidase (HRP)-linked sheep anti-mouse Ig antibody (Amersham product NXA 931), diluted 1 in 500 with PBST containing 0.5% w/v BSA, was added and the plates

were incubated for 1 hour at room temperature before discarding the liquid and washing the wells twice with PBST. One hundred microlitres of 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) solution, freshly prepared using one 50mg ABTS tablet (Boehringer 1204 521) in 50ml freshly prepared 50mM phosphate-citrate buffer pH5.0 + 0.03% sodium perborate (made with 1 phosphate citrate buffer with sodium perborate (PCSB) capsule (Sigma P4922) per 100ml distilled water), was added to each well. Plates were then incubated for 20-60 minutes at room temperature until the optical density value of the "total" control wells, measured at 405nm using a plate reading spectrophotometer, was approximately 1.0. "Blank" (no ATP) and "total" (no compound) control values were used to determine the dilution range of test compound which gave 50% inhibtion of enzyme activity.

(b) In Vitro HUVEC Proliferation Assay

This assay determines the ability of a test compound to inhibit the growth factor-stimulated proliferation of human umbilical vein endothelial cells (HUVEC).

HUVEC cells were isolated in MCDB 131 (Gibco BRL) + 7.5% v/v foetal calf serum (FCS) and were plated out (at passage 2 to 8), in MCDB 131 + 2% v/v FCS + 3μg/ml heparin + 1μg/ml hydrocortisone, at a concentration of 1000 cells/well in 96 well plates. After a minimum of 4 hours they were dosed with the appropriate growth factor (i.e. VEGF 3ng/ml, EGF 3ng/ml or b-FGF 0.3ng/ml) and compound. The cultures were then incubated for 4 days at 37°C with 7.5% CO_2. On day 4 the cultures were pulsed with 1μCi/well of tritiated-thymidine (Amersham product TRA 61) and incubated for 4 hours. The cells were harvested using a 96-well plate harvester (Tomtek) and then assayed for incorporation of tritium with a Beta plate counter. Incorporation of radioactivity into cells, expressed as cpm, was used to measure inhibition of growth factor-stimulated cell proliferation by compounds.

(c) In Vivo Rat Uterine Oedema Assay

This test measures the capacity of compounds to reduce the acute increase in uterine weight in rats which occurs in the first 4-6 hours following oestrogen stimulation. This early increase in uterine weight has long been known to be due to oedema caused by increased permeability of the uterine vasculature and recently Cullinan-Bove and Koos (Endocrinology, 1993,133:829-837) demonstrated a close temporal relationship with increased expression of

VEGF mRNA in the uterus. We have found that prior treatment of the rats with a neutralising monoclonal antibody to VEGF significantly reduces the acute increase in uterine weight, confirming that the increase in weight is substantially mediated by VEGF.

Groups of 20 to 22-day old rats were treated with a single subcutaneous dose of oestradiol benzoate (2.5μg/rat) in a solvent, or solvent only. The latter served as unstimulated controls. Test compounds were orally administered at various times prior to the administration of oestradiol benzoate. Five hours after the administration of oestradiol benzoate the rats were humanely sacrificed and their uteri were dissected, blotted and weighed. The increase in uterine weight in groups treated with test compound and oestradiol benzoate and with oestradiol benzoate alone was compared using a Student T test. Inhibition of the effect of oestradiol benzoate was considered significant when $p<0.05$.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula I as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier.

The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) for example as a sterile solution, suspension or emulsion, for topical administration for example as an ointment or cream or for rectal administration for example as a suppository. In general the above compositions may be prepared in a conventional manner using conventional excipients.

The compositions of the present invention are advantageously presented in unit dosage form. The compound will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000mg per square metre body area of the animal, i.e. approximately 0.1-100mg/kg. A unit dose in the range, for example, 1-100mg/kg, preferably 1-50mg/kg is envisaged and this normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-250mg of active ingredient.

According to a further aspect of the present invention there is provided a compound of the formula I or a pharmaceutically acceptable salt thereof as defined hereinbefore for use in a method of treatment of the human or animal body by therapy.

We have found that compounds of the present invention inhibit VEGF receptor tyrosine kinase activity and are therefore of interest for their antiangiogenic effects and/or their ability to cause a reduction in vascular permeability.

A further feature of the present invention is a compound of formula I, or a pharmaceutically acceptable salt thereof, for use as a medicament, conveniently a compound of formula I, or a pharmaceutically acceptable salt thereof, for use as a medicament for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human being.

Thus according to a further aspect of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human being.

According to a further feature of the invention there is provided a method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof as defined hereinbefore.

As stated above the size of the dose required for the therapeutic or prophylactic treatment of a particular disease state will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. Preferably a daily dose in the range of 1-50mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.

The antiangiogenic and/or vascular permeability reducing treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. In the field of medical oncology it is normal practice to use a combination of different forms of treatment to treat each patient with cancer. In medical oncology the other component(s) of such conjoint treatment in addition to the

antiangiogenic and/or vascular permeability reducing treatment defined hereinbefore may be: surgery, radiotherapy or chemotherapy. Such chemotherapy may cover three main categories of therapeutic agent:

(i) other antiangiogenic agents that work by different mechanisms from those defined hereinbefore (for example linomide, inhibitors of integrin $\alpha v\beta 3$ function, angiostatin, razoxin, thalidomide);

(ii) cytostatic agents such as antioestrogens (for example tamoxifen,toremifene, raloxifene, droloxifene, iodoxyfene), progestogens (for example megestrol acetate), aromatase inhibitors (for example anastrozole, letrazole, vorazole, exemestane), antiprogestogens, antiandrogens (for example flutamide, nilutamide, bicalutamide, cyproterone acetate), LHRH agonists and antagonists (for example goserelin acetate, luprolide), inhibitors of testosterone 5α-dihydroreductase (for example finasteride), anti-invasion agents (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function) and inhibitors of growth factor function, (such growth factors include for example platelet derived growth factor and hepatocyte growth factor such inhibitors include growth factor antibodies, growth factor receptor antibodies, tyrosine kinase inhibitors and serine/threonine kinase inhibitors); and

(iii) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as antimetabolites (for example antifolates like methotrexate, fluoropyrimidines like 5-fluorouracil, purine and adenosine analogues, cytosine arabinoside); antitumour antibiotics (for example anthracyclines like doxorubicin, daunomycin, epirubicin and idarubicin, mitomycin-C, dactinomycin, mithramycin); platinum derivatives (for example cisplatin, carboplatin); alkylating agents (for example nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotepa); antimitotic agents (for example vinca alkaloids like vincrisitine and taxoids like taxol, taxotere); topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan).

As stated above the compounds defined in the present invention are of interest for their antiangiogenic and/or vascular permeability reducing effects. Such compounds of the invention may therefore be useful in a wide range of disease states including cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic

nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation and ocular diseases with retinal vessel proliferation. In particular such compounds of the invention are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the colon, breast, prostate, lungs and skin. More particularly such compounds of the invention are expected to inhibit the growth of those primary and recurrent solid tumours which are associated with VEGF, especially those tumours which are significantly dependent on VEGF for their growth and spread, including for example, certain tumours of the colon, breast, prostate, lung, vulva and skin.

Furthermore compounds of the present invention may be particularly useful in any of the disease states listed above such as cancer in which VEGF is a significant contributing factor to angiogenesis and in which EGF is contributing less than VEGF to angiogenesis.

In addition to their use in therapeutic medicine, the compounds of formula I and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of VEGF receptor tyrosine kinase activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.

It is to be understood that where the term "ether" is used anywhere in this specification it refers to diethyl ether.

The invention will now be illustrated in the following non-limiting Examples in which, unless otherwise stated:-

[(i) evaporations were carried out by rotary evaporation in vacuo and work-up procedures were carried out after removal of residual solids such as drying agents by filtration;

(ii) operations were carried out at ambient temperature, that is in the range 18-25°C and under an atmosphere of an inert gas such as argon;

(iii) column chromatography (by the flash procedure) and medium pressure liquid chromatography (MPLC) were performed on Merck Kieselgel silica (Art. 9385) or Merck Lichroprep RP-18 (Art. 9303) reversed-phase silica obtained from E. Merck, Darmstadt, Germany;

(iv) yields are given for illustration only and are not necessarily the maximum attainable;

(v) melting points are uncorrected and were determined using a Mettler SP62 automatic melting point apparatus, an oil-bath apparatus or a Koffler hot plate apparatus.

(vi) the structures of the end-products of the formula I were confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectral techniques; proton magnetic resonance chemical shift values were measured on the delta scale and peak multiplicities are shown as follows: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad; q, quartet;

(vii) intermediates were not generally fully characterised and purity was assessed by thin layer chromatography (TLC), high-performance liquid chromatography (HPLC), infra-red (IR) or NMR analysis;

(viii) the following abbreviations have been used:-

DMF N,N-dimethylformamide

DMSO dimethylsulphoxide

THF tetrahydrofuran

NMP 1-methyl-2-pyrrolidinone

TFA trifluoroacetic acid.]

Example 1

A solution of 4-chloro-7-(2-methoxyethoxy)quinazoline hydrochloride (624mg, 2.27mmol) and 4-chloro-2-fluoroaniline (305µl, 2.6mmol) in isopropanol (20ml) was heated at reflux for 30 minutes. The solvent was removed by evaporation and the residue partitioned between ethyl acetate and water. The organic layer was separated, washed with aqueous sodium hydrogen carbonate solution, then with water, dried ($MgSO_4$) and the solvent removed by evaporation. The residue was triturated with ether to give **4-(4-chloro-2-fluoroanilino)-7-(2-methoxyethoxy)quinazoline** (662mg, 84%) as a white solid.

m.p. 140-141°C

^{1}H NMR Spectrum: ($DMSOd_6$) 3.35(s, 3H); 3.74(t, 2H); 4.29(t, 2H); 7.21(s, 1H); 7.28(d, 1H); 7.35(d, 1H); 7.6(m, 2H); 8.36(d, 1H); 8.43(s, 1H); 9.75(s, 1H)

MS - ESI: 347 $[MH]^+$

Elemental analysis:	Found	C 58.49	H 4.41	N 12.08
$C_{17}H_{15}N_3O_2FCl$	Requires	C 58.70	H 4.31	N 12.08%

The starting material was prepared as follows:

A solution of 2-amino-4-fluorobenzoic acid (3g, 19.3mmol) in formamide (30ml) was heated at 150°C for 6 hours. The reaction mixture was poured onto ice/water (1/1) (250ml). The precipitated solid was collected by filtration, washed with water and dried to give 7-fluoro-3,4-dihydroquinazolin-4-one (2.6g, 82%).

Sodium (400mg, 17mmol) was added carefully to 2-methoxyethanol (10ml) and the mixture heated at reflux for 30 minutes. 7-Fluoro-3,4-dihydroquinazolin-4-one (750mg, 4.57mmol) was added to the resulting solution and the mixture heated at reflux for 15 hours. The mixture was cooled and poured into water (250ml). The mixture was acidified to pH4 with concentrated hydrochloric acid. The resulting solid product was collected by filtration, washed with water and then with ether, and dried under vacuum to give 7-(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one (580mg, 58%).

A solution of 7-(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one (500mg, 2.2mmol) in thionyl chloride (15ml) and DMF (0.1ml) was heated at reflux for 3 hours. The volatiles were removed by evaporation to give 4-chloro-7-(2-methoxyethoxy)quinazoline hydrochloride as a cream solid (520mg, 83%).

Example 2

4-Chloro-6,7-dimethoxyquinazoline hydrochloride (342mg, 1.3mmol), and 2-fluoro-5-hydroxyaniline (183mg, 1.4mmol) in isopropanol (10ml) were heated at reflux for 2 hours. The reaction mixture was allowed to cool, the precipitated product collected by filtration, washed with isopropanol and dried to give **6,7-dimethoxy-4-(2-fluoro-5-hydroxyanilino)quinazoline** hydrochloride (66mg, 15%) as a solid.

m.p. 219-220°C

^{1}H NMR Spectrum: ($DMSOd_6$) 3.99(s, 3H); 4.01(s, 3H); 6.81(dd, 1H); 6.90(dd, 1H); 7.20(t, 1H); 7.31(s, 1H); 8.15(s, 1H); 8.81(s, 1H); 9.72(s, 1H); 11.28(s, 1H)

MS - ESI: 316 $[MH]^+$

Elemental analysis:	Found	C 53.5	H 5.3	N 9.9
$C_{16}H_{14}N_3O_3F$ HCl $0.5H_2O$ $0.5C_3H_8O$	Requires	C 53.8	H 5.1	N 10.7%

The starting material was prepared as follows:

A mixture of 4,5-dimethoxyanthranilic acid (19.7g) and formamide (10ml) was stirred and heated at 190°C for 5 hours. The mixture was allowed to cool to approximately 80°C and water (50ml) was added. The mixture was stored at ambient temperature for 3 hours. The precipitate was isolated, washed with water and dried to give 6,7-dimethoxy-3,4-dihydroquinazolin-4-one (3.65g).

A mixture of a portion (2.06g) of the material so obtained, thionyl chloride (20ml) and DMF (1 drop) was stirred and heated at reflux for 2 hours. The volatiles were removed by evaporation to give 4-chloro-6,7-dimethoxyquinazoline hydrochloride.

4-Chloro-5-methoxycarbonyloxy-2-fluoronitrobenzene (1.2g, 4.8mmol), (as described in EP 61741 A2), and 10% palladium-on-charcoal catalyst (500mg) in ethanol (100ml) was stirred under hydrogen at 1 atmosphere pressure for 18 hours. A further batch of 10% palladium-on-charcoal catalyst (500mg) was added and the mixture stirred under hydrogen for a further 3 hours. The catalyst was removed by filtration through diatomaceous earth and the solvent removed from the filtrate by evaporation. The residue was purified by flash chromatography eluting with methylene chloride/hexane (1/4) to give 2-fluoro-5-methoxycarbonyloxyaniline (0.42g, 47%) as an oil.

^{1}H NMR Spectrum: ($DMSOd_6$) 3.82(s, 3H); 5.33(s, 2H); 6.32(dt, 1H); 6.57(dd, 1H); 6.98(dd, 1H)

MS - ESI: 186 $[MH]^+$

Concentrated aqueous ammonia (15ml) was added to a solution of 2-fluoro-5-methoxycarbonyloxyaniline (400mg, 2.16mmol) in methanol (10ml). The mixture was stirred for 2 hours and most of the solvent was removed by evaporation. The resulting suspension was diluted with water, acidified to pH7 and extracted with ethyl acetate. The organic extracts were washed with water, dried ($MgSO_4$) and solvent removed by evaporation to give 2-fluoro-5-hydroxyaniline (200mg, 73%).

^{1}H NMR Spectrum: ($DMSOd_6$) 4.90(s, 2H); 5.84(dd, 1H); 6.17(dd, 1H); 6.65(ddd, 1H); 8.80(s, 1H)

Example 3

A mixture of 4-chloro-6,7-dimethoxyquinazoline hydrochloride (500mg, 1.916mmol), (prepared as described for the starting material in Example 2), and 4-chloro-3-

hydroxyaniline (300mg, 2.09mmol), (as described in UK patent 1427658), in isopropanol (10ml) was heated at reflux for 2 hours. The mixture was allowed to cool, the solid product collected by filtration, washed with isopropanol and dried to give **4-(4-chloro-3-hydroxyanilino)-6,7-dimethoxyquinazoline** hydrochloride (605mg, 86%).

m.p. >250°C

^{1}H NMR Spectrum: ($DMSOd_6$) 4.02(s, 3H); 4.04(s, 3H); 7.15(dd, 1H); 7.34-7.44(m, 3H); 8.28(s, 1H); 8.82(s, 1H); 10.52(s, 1H); 11.24(s, 1H)

MS: 332 $[MH]^+$

Elemental analysis:	Found	C 52.4	H 4.2	N 11.3
$C_{16}H_{14}N_3O_3Cl$ 1HCl	Requires	C 52.2	H 4.1	N 11.4%

Example 4

2-Bromoethyl methyl ether (712µl, 7.56mmol) was added dropwise to a solution of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (2.2g, 6.88mmol) and potassium carbonate (2.84g, 20.6mmol) in DMF (110ml). The mixture was stirred for 10 hours at 60°C then for 2 days at ambient temperature, the solvent was removed by evaporation and the crude product purified by flash chromatography eluting with ethyl acetate/petroleum ether (4/1). The resulting solid was dissolved in hot ethanol and ethanolic hydrogen chloride was added. After cooling, the resulting solid was collected by filtration, washed with ethanol and dried under vacuum to give **4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline** hydrochloride (1.74g, 62%).

m.p. 255-257°C

^{1}H NMR Spectrum: ($DMSOd_6$; CD_3COOD) 3.36(s, 3H); 3.79(t, 2H); 4.02(s, 3H); 4.34(t, 2H); 7.33(s, 1H); 7.46(dd, 1H); 7.60-7.68(m, 2H); 8.15(s, 1H); 8.79(s, 1H)

MS - ESI: 378-380 $[MH]^+$

Elemental analysis:	Found	C 52.1	H 4.6	N 10.1
$C_{18}H_{17}N_3O_3ClF$ 1HCl	Requires	C 52.19	H 4.38	N 10.14%

The starting material was prepared as follows:

A mixture of 2-amino-4-benzyloxy-5-methoxybenzamide (J. Med. Chem. 1977, vol 20, 146-149, 10g, 0.04mol) and Gold's reagent (7.4g, 0.05mol) in dioxane (100ml) was stirred

and heated at reflux for 24 hours. Sodium acetate (3.02g, 0.037mol) and acetic acid (1.65ml, 0.029mol) were added to the reaction mixture and it was heated for a further 3 hours. The volatiles were removed by evaporation, water was added to the residue, the solid was collected by filtration, washed with water and dried. Recrystallisation from acetic acid gave 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (8.7g, 84%).

A mixture of 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (2.82g, 0.01mol), thionyl chloride (40ml) and DMF (0.28ml) was stirred and heated at reflux for 1 hour. The volatiles were removed by evaporation, the residue was azeotroped with toluene to give 7-benzyloxy-4-chloro-6-methoxyquinazoline hydrochloride (3.45g).

A solution of 7-benzyloxy-4-chloro-6-methoxyquinazoline hydrochloride (1.2g, 3.5mmol) and 4-chloro-2-fluoroaniline (444µl, 4mmol) in isopropanol (40ml) was refluxed for 1.5 hours. After cooling, the precipitate was collected by filtration, washed with isopropanol then ether and dried under vacuum to give 7-benzyloxy-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline hydrochloride (1.13g, 71%).

m.p. 239-242°C

^{1}H NMR Spectrum: ($DMSOd_6$) 4.0(s, 3H); 5.36(s, 2H); 7.39-7.52(m, 9H); 8.1(s, 1H); 8.75(s, 1H)

MS - ESI: 410 $[MH]^+$

Elemental analysis:	Found	C 59.2	H 4.3	N 9.4
$C_{22}H_{17}N_3O_2ClF$ 1HCl	Requires	C 59.21	H 4.07	N 9.41%

A solution of 7-benzyloxy-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline hydrochloride (892mg, 2mmol) in TFA (10ml) was refluxed for 50 minutes. After cooling, the mixture was poured onto ice. The precipitate was collected by filtration, dissolved in methanol (10ml) and basified to pH11 with aqueous ammonia. After concentration by evaporation, the solid product was collected by filtration, washed with water then ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline as a yellow solid (460mg, 72%).

m.p. 141-143°C

^{1}H NMR Spectrum: ($DMSOd_6$) 3.95(s, 3H); 7.05(s, 1H); 7.35(d, 1H); 7.54-7.59(m, 2H); 7.78(s, 1H); 8.29(s, 1H)

MS - ESI: 320-322 $[MH]^+$

Example 5

A mixture of 4-chloro-6,7-dimethoxyquinazoline hydrochloride (147mg, 0.56mmol), (prepared as described for the starting material in Example 2), and 4-chloro-2-fluoroaniline (82mg, 0.56mmol) in isopropanol (7ml) was heated at reflux for 2 hours. The mixture was allowed to cool, the solid product collected by filtration, washed with isopropanol and dried to give **4-(4-chloro-2-fluoroanilino)-6,7-dimethoxyquinazoline** hydrochloride (102mg, 49%).

^{1}H NMR Spectrum: (DMSOd_6) 4.00(s, 6H); 7.37(s, 1H); 7.42(d, 1H); 7.60(t, 1H); 7.67(dd, 1H); 8.27(s, 1H); 8.80 (s, 1H)

MS - ESI: 334 $[MH]^+$

Example 6

4-(3-Chloropropyl)morpholine (J. Am. Chem. Soc. 1945, 67, 736, 174mg, 1.06mmol) in DMF (0.5ml) was added to a stirred suspension of 4-(3-*t*-butyldiphenylsilyloxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline (471 mg, 0.88mmol) and potassium carbonate (200mg, 1.45mmol) in DMF (5ml). The mixture was then heated at 100°C for 2.5 hours. The solvent was removed by evaporation, and the residues partitioned between methylene chloride and water. The product was extracted with methylene chloride and the combined extracts passed through phase separating paper. The solvent was removed by evaporation to give a yellow oil. This oil was dissolved in THF (4ml) and tetra-*n*-butylammonium fluoride (2ml of a 1M solution in THF, 2mmol) added. The mixture was stirred at ambient temperature for 72 hours, the solvent was removed by evaporation and the residue partitioned between methylene chloride and saturated aqueous sodium hydrogen carbonate solution. The aqueous phase was extracted with methylene chloride (3x20ml), the combined extracts passed through phase separating paper and the solvent removed by evaporation. The residue was purified by flash chromatography eluting with methanol/methylene chloride (1/9) to give **4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline** as a pale yellow solid (225mg, 60% over two steps).

^{1}H NMR Spectrum : (DMSOd_6) 2.0(m, 2H); 2.15(s, 3H); 2.4(m, 4H); 3.6(t, 4H); 3.95(s, 3H); 4.20(t, 2H); 7.05(s, 2H); 7.15(s, 1H); 7.35(s, 1H); 7.85(s, 1H); 8.40(s, 1H); 9.25(s, 2H)

MS - ESI: 425 $[MH]^+$

The starting material was prepared as follows:

A mixture of 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (5.18g, 18.4mmol), (prepared as described for the starting material in Example 4), DMF (1ml) and thionyl chloride (70ml) was heated at reflux under argon for 2 hours. The mixture was allowed to cool, excess thionyl chloride was removed by evaporation and the residue azeotroped to dryness with toluene. The resulting crude 7-benzyloxy-4-chloro-6-methoxyquinazoline hydrochloride was suspended in isopropanol (50ml) and 3-hydroxy-4-methylaniline (2.60g, 21.1mmol) added. The mixture was heated at reflux for 3 hours and then allowed to cool. The precipitated product was collected by filtration, washed with isopropanol and dried to give 7-benzyloxy-4-(3-hydroxy-4-methylanilino)-6-methoxyquinazoline (4.7g, 60%).

^1H NMR Spectrum : ($DMSOd_6$) 2.15 (s, 3H); 4.0(s, 3H); 5.35(s, 2H); 6.95(dd, 1H); 7.15(m, 2H); 7.35-7.55(m, 5H); 8.25(s, 1H); 8.75(s, 1H); 9.6(s, 1H); 11.2(s, 1H)

Imidazole (1.45g, 21.6mmol) was added to 7-benzyloxy-4-(3-hydroxy-4-methylanilino)-6-methoxyquinazoline (4.11g, 9.69mmol) in DMF (50ml) and the mixture was stirred at ambient temperature until complete dissolution was achieved. *t*-Butyldiphenylsilyl chloride (2.5ml, 9.6mmol) was added dropwise and the reaction mixture stirred at ambient temperature for 72 hours. Saturated aqueous sodium hydrogen carbonate solution was added, and the product was extracted with methylene chloride. The solvent was removed by evaporation to give a damp solid which was dissolved in a mixture of DMF (40ml), methanol (40ml), and ethyl acetate (40ml). 10% Palladium-on-charcoal catalyst (500mg) was added and the mixture stirred under hydrogen at 1 atmosphere pressure for 36 hours. The catalyst was removed by filtration through diatomaceous earth, and the solvent removed from the filtrate by evaporation. The crude product was purified by flash chromatography eluting with methanol/methylene chloride (1/9) to give 4-(3-*t*-butyldiphenylsilyloxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline (2.2g, 42% over two steps) as a yellow solid.

^1H NMR Spectrum : ($DMSOd_6$) 1.1 (s, 9H); 2.35(s, 3H); 3.90(s, 3H); 6.9(m, 2H); 7.1(d, 1H); 7.4(m, 6H); 7.5(d, 1H); 7.7(m, 5H); 7.85(s, 1H); 9.05(s, 1H); 10.2(s, 1H)

MS - ESI : 536 $[MH]^+$

Example 7

A mixture of 7-(3-benzyloxypropoxy)-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline hydrochloride (180mg, 0.4mmol) and 5% palladium-on-charcoal catalyst (50mg) in methanol (5ml), trichloromethane (5ml) and DMF (1ml) was stirred under hydrogen at 1 atmosphere pressure for 2 hours. The catalyst was removed by filtration through diatomaceous earth and the solvent removed by evaporation. The residue was partitioned between ethyl acetate and aqueous sodium hydrogen carbonate solution, the organic layer separated and dried ($MgSO_4$) and the solvent removed by evaporation. The residue was recrystallised from ethyl acetate/hexane to give **4-(4-chloro-2-fluoroanilino)-7-(3-hydroxypropoxy)-6-methoxyquinazoline** (48mg, 33%).

m.p. 199-201 °C

^{1}H NMR Spectrum: ($DMSOd_6$) 1.92(t, 2H); 3.60(t, 2H); 3.95(s, 3H); 4.20(t, 2H); 4.55(t, 1H); 7.18(s, 1H); 7.33(dd, 1H); 7.51(dd, 1H); 7.55(td, 1H); 7.78(s, 1H); 8.38(s, 1H); 8.32(s, 1H); 9.50(s, 1H)

MS - ESI: 378 $[MH]^+$

Elemental analysis:	Found	C 57.2	H 4.6	N 11.0
$C_{18}H_{17}N_3O_3FCl$	Requires	C 57.2	H 4.5	N 11.1%

The starting material was prepared as follows:

A solution of 3-benzyloxy-1-propanol (150µl, 0.9mmol) was added to tributylphosphine (376mg, 1.9mmol) and 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (200mg, 0.63mmol), (prepared as described for the starting material in Example 4), in methylene chloride (20ml) at 5°C. To the resulting mixture 1,1'-azodicarbonyldipiperidine (480mg, 1.9mmol) was added, the mixture stirred at 5°C for 1 hour, allowed to warm to ambient temperature and stirred overnight. Ether (10ml) was added, the mixture stirred for 15 minutes and the precipitated solids removed by filtration. The volatiles were removed from the filtrate by evaporation, and the residue was partitioned between ethyl acetate and water. The organic layer was separated, dried ($MgSO_4$) and the solvent removed by evaporation.The residue was dissolved in acetone, and hydrogen chloride in ether (0.6ml of a 1M solution, 0.6mmol) added. The resulting precipitated product was collected by filtration

and dried to give 7-(3-benzyloxypropoxy)-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline hydrochloride (90mg, 31%).

^{1}H NMR Spectrum: (DMSOd_6) 2.22(t, 2H); 3.74(t, 2H); 4.10(s, 3H); 4.37(t, 2H); 4.60(s, 2H); 7.34-7.56(m, 7H); 7.68(t, 1H); 7.76(dd, 1H); 8.38(s, 1H); 8.90(s, 1H); 11.73(s, 1H)

Example 8

4-(2-Chloroethyl)morpholine hydrochloride (40mg, 2.1mmol) was added to 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (63mg, 0.2mmol), (prepared as described for the starting material in Example 4), and potassium carbonate (95mg, 0.69mmol) in DMF (3ml) and the mixture heated at 100°C for 3 hours. The mixture was allowed to cool, the volatiles were removed by evaporation and the residues partitioned between water and methylene chloride. The organic phase was separated, passed through phase separating paper and the solvent was removed by evaporation. The residue was dissolved in acetone, and hydrogen chloride in ether (0.2ml of a 1M solution, 0.2mmol) was added. The precipitated product was collected by filtration and dried to give **4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-morpholinoethoxy)quinazoline** hydrochloride (50mg, 50%).

^{1}H NMR Spectrum: (DMSOd_6) 3.6(m, 2H); 3.85(m, 4H); 3.95(s, 3H); 4.6(m, 2H); 7.35(m, 2H); 7.6(m, 2H); 8.05(s, 1H); 8.55(s, 1H)

MS - ESI: 433 $[MH]^+$

Elemental analysis:	Found	C 50.5	H 4.9	N 10.9
$C_{21}H_{22}N_4O_3FCl$ 2HCl	Requires	C 49.9	H 4.8	N 11.1%

Example 9

4-(3-Chloropropyl)morpholine (J. Am. Chem. Soc. 1945, 67, 736, 2.26g, 13.8mmol) was added to 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (2.21g, 6.9mmol), (prepared as described for the starting material in Example 4), and potassium carbonate (6.5g, 47mmol) in DMF (100ml). The mixture was heated at 110°C for 4 hours and then allowed to cool. The volatiles were removed by evaporation and the residue was partitioned between water and methylene chloride. The organic phase was separated, washed with brine, passed through phase separating paper and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene

chloride/methanol/ammonia (aq.) (100/8/1). The product was dissolved in acetone and isopropanol and hydrogen chloride in ether (4.8ml of a 1M solution, 4.8mmol) was added. The precipitated product was collected by filtration and washed with acetone and ether to give **4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline** hydrochloride (2.16g, 65%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.25(m, 2H); 3.7-3.9(br s, 4H); 3.95(s, 3H); 4.25 (t, 2H); 7.2(s, 1H); 7.3(dt, 1H); 7.55(m, 2H); 7.95(s, 1H); 8.40(s, 1H); 9.85(br s, 1H); 11.0(br s, 1H)

MS - ESI: 447 $[MH]^+$

Elemental analysis:	Found	C 54.7	H 5.6	N 10.8
$C_{22}H_{24}N_4O_3FCl$ 1HCl $0.5C_3H_6O$	Requires	C 55.1	H 5.5	N 10.9%

Example 10

Concentrated aqueous ammonia (8ml) was added to a solution of 4-(3-acetoxy-4-methylanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline (2.38g , 6mmol) in a mixture of trichloromethane (24ml) and methanol (24ml). The mixture was heated at reflux for 8 hours and the volatiles removed by evaporation. The residue was triturated with water, the resulting solid was collected by filtration and recrystallised from methylene chloride/ethanol. The product was redissolved in a mixture of methylene chloride/ethanol and a saturated solution of hydrogen chloride in ethanol was added. The solvent was partially removed by evaporation and the mixture cooled. The resulting precipitate was collected by filtration washed with ether and dried under vacuum to give **4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline** hydrochloride (1.68g, 80%).

m.p. 270°C (decomposition)

^{1}H NMR Spectrum: ($DMSOd_6$; CF_3COOD) 2.17(s, 3H); 3.35(s, 3H); 3.78(t, 2H); 4.00(s, 3H); 4.33(t, 2H); 6.96(d, 1H); 7.08(s, 1H); 7.16(d, 1H); 7.3(s, 1H); 8.09(s, 1H); 8.81(s, 1H)

MS - ESI: 378 $[MNa]^+$

Elemental analysis:	Found	C 58.0	H 5.9	N 10.7
$C_{19}H_{21}N_3O_4$ 1HCl	Requires	C 58.2	H 5.7	N 10.7%

The starting material was prepared as follows:

Acetic anhydride (1.9ml, 20.3mmol) was added to a mixture of 2-methyl-5-nitrophenol (2.5g, 16.3mmol) and 1M aqueous sodium hydroxide (24.5ml) at ambient temperature. The mixture was stirred for 40 minutes, the solid was removed by filtration and the filtrate extracted with ethyl acetate. The combined organic extracts were washed with brine, dried ($MgSO_4$) and the solvent removed by evaporation to give 2-acetoxy-4-nitrotoluene (3.1g, 100%). A mixture of this material (3.1g, 15.9mmol) and 10% palladium-on-charcoal catalyst (0.12g) in ethyl acetate (50ml) was stirred at ambient temperature under hydrogen at 1 atmosphere pressure for 2 hours. The catalyst was removed by filtration through diatomaceous earth and the solvent removed from filtrate by evaporation to give 3-acetoxy-4-methylaniline (2.45g, 94%).

A mixture of 7-benzyloxy-4-chloro-6-methoxyquinazoline (2.18g, 7.25mmol), (prepared as described for the starting material in Example 4), 3-acetoxy-4-methylaniline (1.32g, 8mmol) and isopropanol (50ml) was stirred and heated at reflux for 1 hour. The mixture was cooled to ambient temperature. The precipitate was collected by filtration, washed with isopropanol and ether to give 4-(3-acetoxy-4-methylanilino)-7-benzyloxy-6-methoxyquinazoline.

A mixture of 4-(3-acetoxy-4-methylanilino)-7-benzyloxy-6-methoxyquinazoline (2.68g, 5.75mmol) and 10% palladium-on-charcoal catalyst (0.27g) in methanol (50ml), DMF (12ml) and trichloromethane (50ml) was stirred at ambient temperature under hydrogen at 1.5 atmospheres pressure for 30 minutes. The catalyst was removed by filtration through diatomaceous earth and the solvent removed from filtrate by evaporation. The residue was triturated with ether, collected by filtration and dried under vacuum at 50°C to give 4-(3-acetoxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline (2.1g, 100%).

Potassium carbonate (2.2g, 16mmol) was added to a solution of 4-(3-acetoxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline (1.51g, 4mmol) in DMF (30ml) and the mixture stirred for 15 minutes. 2-Bromoethyl methyl ether (667mg, 4.8mmol) was then added dropwise. The mixture was stirred for 1 hour at ambient temperature, then heated at 60°C for 17 hours and finally allowed to cool. The insoluble material was removed by filtration and the filter pad washed with DMF. The filtrate was partitioned between ethyl acetate and water, the organic layer was separated, washed with brine, dried ($MgSO_4$) and the solvent removed by evaporation. The residue was purified by column chromatography eluting

with methylene chloride/methanol (95/5 followed by 93/7). The purified product was triturated with ether to give 4-(3-acetoxy-4-methylanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline (1.34g, 84%) as a white powder.

m.p. 180-183°C

^{1}H NMR Spectrum: ($CDCl_3$) 2.16(s, 3H); 2.34(s, 3H); 3.47(s, 3H); 3.87(t, 2H); 3.99(s, 3H); 4.31(t, 2H); 6.98(s, 1H); 7.21(d, 1H); 7.24(d, 1H); 7.42(d, 1H); 7.50(s, 1H); 8.64(s, 1H)

MS - ESI: 420 $[MNa]^+$

Elemental analysis :	Found	C 63.1	H 6.1	N 10.4
$C_{21}H_{23}N_3O_5$	Requires	C 63.5	H 5.8	N 10.6%

Example 11

A mixture of 4-chloro-6,7-dimethoxyquinazoline hydrochloride (130mg, 0.5mmol), (prepared as described for the starting material in Example 2), and 4-bromo-2-fluoroaniline (95mg, 0.5mmol) in isopropanol (7ml) was heated at reflux for 2 hours. The mixture was allowed to cool to ambient temperature, the precipitated solid was collected by filtration, washed with isopropanol and ether and dried to give **4-(4-bromo-2-fluoroanilino)-6,7-dimethoxyquinazoline** hydrochloride (124mg, 60%) as an off-white solid.

HPLC characteristics:

Column:- 200 x 4.6 mm C18 ODS Hypersil (trade mark of Shandon) reversed phase 5μm

Solvent:- flow 1.5 ml/min.

0-3 minutes:- H_2O/CH_3CN (95/5) 0.03M triethylamine

3-17 minutes:- gradient H_2O/CH_3CN (95/5 to 5/95); constant 0.03M triethylamine

Retention time:- 13.01 minutes

Example 12

A mixture of 4-chloro-6,7-dimethoxyquinazoline hydrochloride (130mg, 0.5mmol), (prepared as described for the starting material in Example 2), and 2-fluoro-4-methylaniline (63mg, 0.5mmol) in isopropanol (7ml) was heated at reflux for 2 hours. The mixture was allowed to cool to ambient temperature, the precipitated solid was collected by filtration, washed with isopropanol and ether and dried to give 4-**(2-fluoro-4-methylanilino)-6,7-dimethoxyquinazoline** hydrochloride (87mg, 50%) as an off-white solid.

HPLC characteristics:

Column - 200 x 4.6 mm C18 ODS Hypersil (trade mark of Shandon) reversed phase 5μm

Solvent - flow 1.5 ml/min.

0-3 minutes:- H_2O/CH_3CN (95/5) 0.03M triethylamine

3-17 minutes:- gradient H_2O/CH_3CN (95/5 to 5/95); constant 0.03M triethylamine

Retention time - 12.32 minutes

Example 13

A mixture of 4-chloro-6,7-dimethoxyquinazoline hydrochloride (130mg, 0.5mmol), (prepared as described for the starting material in Example 2), and 3-hydroxy-4-methylaniline (62mg, 0.5mmol) in isopropanol (7ml) was heated at reflux for 2 hours. The mixture was allowed to cool to ambient temperature, the precipitated solid was collected by filtration, washed with isopropanol and ether and dried to give **6,7-dimethoxy-4-(3-hydroxy-4-methylanilino)quinazoline** hydrochloride (98mg, 56%) as an off-white solid.

^1H NMR Spectrum: ($DMSOd_6$) 2.14(s, 3H); 3.98(s, 3H); 4.00(s, 3H); 6.97(d, 1H); 7.12(s, 1H); 7.14(d, 1H); 7.38(s, 1H); 8.27(s, 1H); 8.77(s, 1H); 9.65(br s, 1H)

MS - ESI: 312 $[MH]^+$

Elemental analysis:	Found	C 59.1	H 5.4	N 11.8
$C_{1,}H_{17}N_3O_3$ 1HCl	Requires	C 58.6	H 5.2	N 12.1%

Example 14

A mixture of 4-chloro-6-methoxy-7-(2-methoxyethoxy)quinazoline (107mg, 0.4mmol) and 4-bromo-2-fluoroaniline (76mg, 0.4mmol) in isopropanol (7ml) was heated at reflux for 2 hours. The mixture was allowed to cool to ambient temperature, the precipitated solid was collected by filtration, washed with isopropanol and ether and dried to give **4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline** hydrochloride (151mg, 82%) as an off-white solid.

m.p. 200-204°C

^1H NMR Spectrum: ($DMSOd_6$; TFA) 3.36(s, 3H); 3.79(t, 2H); 4.02(s, 3H); 4.39(t, 2H); 7.37(s, 1H); 7.54-7.61(m, 2H); 7.81(dd, 1H); 8.16(s, 1H); 8.86(s, 1H)

MS - ESI: 422 $[MH]^-$

Elemental analysis:	Found	C 47.56	H 4.01	N 9.29
$C_{20}H_{21}N_3O_4BrF$ 0.95HCl	Requires	C 47.32	H 3.96	N 9.20%

The starting material was prepared as follows:

A mixture of ethyl 4-hydroxy-3-methoxybenzoate (9.8g, 50mmol), 2-bromoethyl methyl ether (8.46ml, 90mmol) and potassium carbonate (12.42g, 90mmol) in acetone (60ml) was heated at reflux for 30 hours. The mixture was allowed to cool and the solids removed by filtration. The volatiles were removed from the filtrate by evaporation and the residue triturated with hexane to give ethyl 3-methoxy-4-(2-methoxyethoxy)benzoate (11.3g, 89%) as a white solid.

m.p. 57-60°C

^{1}H NMR Spectrum: ($DMSOd_6$) 1.31(t, 3H); 3.29(s, 3H); 3.32(s, 3H); 3.68(m, 2H); 4.16(m, 2H); 4.28(q, 2H); 7.06(d, 1H); 7.45(d, 1H); 7.56(dd, 1H)

MS - FAB: 255 $[MH]^+$

Ethyl 3-methoxy-4-(2-methoxyethoxy)benzoate (9.5g, 37mmol) was added portionwise to stirred concentrated nitric acid (75ml) at 0°C. The mixture was allowed to warm to ambient temperature and stirred for a further 90 minutes. The mixture was diluted with water and extracted with methylene chloride, dried ($MgSO_4$) and the solvent removed by evaporation. The residue was triturated with hexane to give ethyl 5-methoxy-4-(2-methoxyethoxy)-2-nitrobenzoate (10.6g, 95%) as an orange solid.

m.p. 68-69°C

^{1}H NMR Spectrum: ($DMSOd_6$) 1.27(t, 3H); 3.30(s, 3H); 3.69(m, 2H); 3.92(s, 3H); 4.25(m, 2H); 4.29(q, 2H); 7.30(s, 1H); 7.65(s, 1H)

MS - CI: 300 $[MH]^-$

A mixture of ethyl 5-methoxy-4-(2-methoxyethoxy)-2-nitrobenzoate (10.24g, 34mmol), cyclohexene (30ml) and 10% palladium-on-charcoal catalyst (2.0g) in methanol (150ml) was heated at reflux for 5 hours. The reaction mixture was allowed to cool and diluted with methylene chloride. The catalyst was removed by filtration and the volatiles removed from the filtrate by evaporation. The residue was recrystallised from ethyl acetate/hexane to give ethyl 2-amino-5-methoxy-4-(2-methoxyethoxy) benzoate (8.0g) as a buff solid. Formamide (80ml) was added to this product and the mixture heated at 170°C for

18 hours. About half the solvent was removed by evaporation under high vacuum and the residue was left to stand overnight. The solid product was collected by filtration, washed with ether and dried to give 6-methoxy-7-(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one (5.3g, 62% over two steps) as a grey solid.

^{1}H NMR Spectrum: ($DMSOd_6$) 3.35(s, 3H); 3.74(m, 2H); 3.89(s, 3H); 4.26(m, 2H); 7.15(s, 1H); 7.47(s, 1H); 7.98(s, 1H); 12.03(br s, 1H)

MS - CI: 251 $[MH]^+$

DMF (0.5ml) was added to a mixture of 6-methoxy-7-(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one (5.1g, 20mmol) in thionyl chloride (50ml). The mixture was stirred and heated at reflux for 3 hours, allowed to cool and the excess thionyl chloride removed by evaporation. The residue was suspended in methylene chloride and washed with aqueous sodium hydrogen carbonate solution. The aqueous phase was extracted with methylene chloride and the combined extracts dried ($MgSO_4$). The crude product was recrystallised from methylene chloride/hexane to give 4-chloro-6-methoxy-7-(2-methoxyethoxy)quinazoline (2.8g, 51%) as a fine white solid.

^{1}H NMR Spectrum: ($DMSOd_6$) 3.37(s, 3H); 3.77(m, 2H); 4.01(s, 3H); 4.37(m, 2H); 7.40(s, 1H); 7.49(s, 1H); 8.88(s, 1H)

MS - CI: 269 $[MH]^+$

Example 15

A mixture of 4-chloro-6-methoxy-7-(2-methoxyethoxy)quinazoline (107mg, 0.4mmol), (prepared as described for the starting material in Example 14), and 2-fluoro-4-methylaniline (50mg, 0.4mmol) in isopropanol (7ml) was heated at reflux for 2 hours. The mixture was allowed to cool to ambient temperature, the precipitated solid was collected by filtration, washed with isopropanol and ether and dried to give **4-(2-fluoro-4-methylanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline** hydrochloride (95mg, 60%) as an off-white solid.

HPLC characteristics:

Column - 200 x 4.6 mm C18 ODS Hypersil (trade mark of Shandon) reversed phase 5μm

Solvent - flow 1.5 ml/min.

0-3 minutes:- H_2O/CH_3CN (95/5) 0.001M triethylamine

3-17 minutes:- gradient H_2O/CH_3CN (95/5 to 5/95); constant 0.001M triethylamine
Retention time:- 10.46 minutes

Example 16

A mixture of 4-chloro-7-(2-methoxyethoxy)quinazoline hydrochloride (450mg, 1.6mmol), (prepared as described for the starting material in Example 1), and 3-hydroxy-4-methylaniline (280mg, 2.27mmol) in isopropanol (20ml) was heated at reflux for 30 minutes. The solvent was removed by evaporation and the residue was triturated with isopropanol. The resulting solid was collected by filtration, washed with isopropanol and dried under vacuum to give **4-(3-hydroxy-4-methylanilino)-7-(2-methoxyethoxy)quinazoline** hydrochloride (428mg, 74%).

^{1}H NMR Spectrum : ($DMSOd_6$) 2.18 (s, 3H); 3.38 (s, 3H); 3.8 (t, 2H); 4.35 (t, 2H); 7.05 (d, 1H); 7.15 (m, 2H); 7.35 (s, 1H); 7.52 (d, 1H); 8.75 (d, 1H); 8.85 (s, 1H); 9.7 (br s, 1H)
MS - ESI : 326 $[MH]^+$

Elemental analysis:	Found	C 59.6	H 5.8	N 11.7
$C_{18}H_{19}N_3O_3$ 1HCl	Requires	C 59.7	H 5.5	N 11.6%

Example 17

A solution of 1-(2-hydroxyethyl)-4-methylpiperazine (112mg, 0.78mmol) in methylene chloride (1ml) was added to a stirred suspension of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxy-quinazoline (225mg, 0.7mmol), (prepared as described for the starting material in Example 4), and tributylphosphine (420mg, 2.1mmol) in methylene chloride (10ml). 1,1'-(Azodicarbonyl)dipiperidine (525mg, 2.1mmol) was then added in portions to the mixture. The resulting clear, pale yellow solution was stirred for 3.5 hours, then allowed to stand overnight. The reaction mixture was quenched with ether (8ml) and the precipitate was removed by filtration. The solvent was removed from the filtrate by evaporation and the residue dissolved in acetone and treated with 1M ethereal hydrogen chloride until the hydrochloride salt precipitated. The precipitate was collected by filtration, dissolved in methanol and then basified with excess triethylamine. The volatiles were removed by evaporation and the residue purified by column chromatography eluting with methylene chloride/methanol/0.88 aqueous ammonia (100/8/1). The resulting purified oil was triturated

with ether, collected by filtration and dried to give **4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline** (79mg, 25%) as a white solid.

m.p. 173-175°C

^{1}H NMR Spectrum: ($DMSOd_6$) 2.10(s, 3H); 2.3(m, 4H); 2.5(m, 4H); 2.75(t, 2H); 3.95(s, 3H); 4.25(t, 2H); 7.21(s, 1H); 7.30(dd, 1H); 7.50(d, 1H); 7.55(dd, 1H); 7.75(s, 1H); 8.30(s, 1H); 9.50(s, 1H)

MS - ESI: 446 $[MH]^+$

Elemental analysis:	Found	C 59.1	H 5.8	N 15.5
$C_{22}H_{25}N_5O_2FCl$	Requires	C 59.3	H 5.7	N 15.7%

The starting material was prepared as follows:-

2-Bromoethanol (2.36g, 19mmol) was added dropwise to a mixture of 1-methylpiperazine (1.26g, 13mmol) and potassium carbonate (5.0g, 36mmol) in absolute ethanol (150ml) and the mixture heated at reflux for 18 hours. The mixture was allowed to cool and the precipitates were removed by filtration and the solvent volatiles were removed by evaporation. The residue was treated with acetone/methylene chloride, the insolubles were removed by filtration and the solvent was removed from the filtrate by evaporation to give 1-(2-hydroxyethyl)-4-methylpiperazine (870mg, 48%) as a light brown oil.

^{1}H NMR Spectrum: ($CDCl_3$) 2.18(s, 3H); 2.3-2.7(br m, 8H); 2.56(t, 2H); 3.61(t, 2H)

MS - ESI: 145 $[MH]^+$

Example 18

A solution of 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (2.5g, 7.41mmol) and 4-bromo-2-fluoroaniline (1.55g, 8.15mmol) in DMF (20ml) was heated at 150°C for 4 hours. The mixture was diluted with ether (200ml) and the resulting precipitate collected by filtration. The solid was partitioned between methylene chloride and water and the aqueous phase was adjusted to pH8.5 with 1M aqueous sodium hydroxide solution. The organic layer was separated, washed with brine, dried ($MgSO_4$) and the solvent removed by evaporation. The residue was purified by flash chromatography eluting with methylene chloride/methanol (9/1). The purified solid was dissolved in methanol and methylene chloride and 2.2M ethereal hydrogen chloride (3ml) was added. The volatiles were removed

by evaporation, the residue was resuspended in ether, collected by filtration and dried under vacuum to give **4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline** hydrochloride (1.61g, 26%).

^{1}H NMR Spectrum: ($DMSOd_6$; CF_3COOD) 2.3-2.4 (m, 2H); 3.15 (t, 2H); 3.34 (t, 2H); 3.54 (d, 2H); 3.76 (t, 2H); 4.02 (s, 3H); 4.04 (m, 2H); 4.33 (t, 2H); 7.41 (s, 1H); 7.5-7.65 (m, 2H); 7.80 (dd, 1H); 8.20 (s, 1H); 8.9 (s, 1H)

Elemental analysis:	Found	C 46.5	H 5.0	N 9.9
$C_{22}H_{24}N_4O_3BrF\ 0.4H_2O\ 1.9HCl$	Requires	C 46.5	H 4.7	N 9.9%

The starting material was prepared as follows:-

A mixture of 4-hydroxy-3-methoxybenzoic acid (4.5g, 26.8mmol), 3-morpholinopropyl chloride (9.5g, 58.0mmol), (prepared according to J. Am. Chem. Soc. 1945, 67, 736), potassium carbonate (8.0g, 58mmol), potassium iodide (1.0g, 0.22mmol) and DMF (80ml) was stirred and heated at 100°C for 3 hours. The solid was removed by filtration and the filtrate evaporated. The residue was dissolved in ethanol (50ml), 2M sodium hydroxide (50ml) was added and the mixture heated at 90°C for 2 hours. After partial evaporation, the mixture was acidified with concentrated hydrochloric acid, washed with ether and then subjected to purification on a Diaion (trade mark of Mitsubishi) HP20SS resin column, eluting with water and then with a gradient of methanol (0 to 25%) in hydrochloric acid (pH2). Partial evaporation of the solvents and lyophilisation gave 3-methoxy-4-(3-morpholinopropoxy)benzoic acid (8.65g, 97%).

^{1}H NMR Spectrum: ($DMSOd_6$; TFA) 2.17-2.24(m, 2H); 3.10-3.16(m, 2H); 3.30(t, 2H); 3.52(d, 2H); 3.71(t, 2H); 3.82(s, 3H); 4.01(br d, 2H); 4.14(t, 2H); 7.08(d, 1H); 7.48(d, 1H); 7.59(dd, 1H)

MS - ESI: 296 $[MH]^+$

Fuming nitric acid (1.5ml, 36.2mmol) was added slowly at 0°C to a solution of 3-methoxy-4-(3-morpholinopropoxy)benzoic acid (7.78g, 23.5mmol) in TFA (25ml). The cooling bath was removed and the reaction mixture stirred at ambient temperature for 1 hour. The TFA was removed by evaporation and ice was added to the residue. The precipitate was collected by filtration, washed with a minimum of water followed by toluene and ether. The

solid was dried under vacuum over phosphorus pentoxide to give 5-methoxy-4-(3-morpholinopropoxy)-2-nitrobenzoic acid (7.54g) which was used without further purification.
^{1}H NMR Spectrum: ($DMSOd_6$; TFA) 2.16-2.23(m, 2H); 3.10-3.17(m, 2H); 3.30(t, 2H); 3.52(d, 2H); 3.66(t, 2H); 3.93(s, 3H); 4.02(br d, 2H); 4.23(t, 2H); 7.34(s, 1H); 7.61(s, 1H)
MS - EI: 340 $[M]^+$

Thionyl chloride (15ml) and DMF (0.05ml) were added to 5-methoxy-4-(3-morpholinopropoxy)-2-nitrobenzoic acid (7.54g). The mixture was heated at 50°C for 1 hour, the excess thionyl chloride was removed by evaporation and by azeotroping with toluene (x2). The resulting solid was suspended in THF (200ml) and ammonia was bubbled through the mixture for 30 minutes. The precipitate was removed by filtration and washed with THF. After concentration of the filtrate by evaporation, the product crystallised and was collected by filtration to give 5-methoxy-4-(3-morpholinopropoxy)-2-nitrobenzamide (5.25g) as light yellow crystals which were used without further purification.
^{1}H NMR Spectrum: ($DMSOd_6$; TFA) 2.17-2.24(m, 2H); 3.11-3.18(m, 2H); 3.31(t, 2H); 3.53(d, 2H); 3.67(t, 2H); 3.93(s, 3H); 4.03(br d, 2H); 4.21(t, 2H); 7.17(s, 1H); 7.62(s, 1H)
MS - EI: 339 $[M]^+$

Concentrated hydrochloric acid (30ml) was added to a suspension of 5-methoxy-4-(3-morpholinopropoxy)-2-nitrobenzamide (5.67g) in methanol (150ml) and the mixture was heated to 60°C. When the 5-methoxy-4-(3-morpholinopropoxy)-2-nitrobenzamide had dissolved, iron powder (5.6g, 100mmol) was added in portions to the reaction mixture which was then heated for 90 minutes. After cooling, the insolubles were removed by filtration through diatomaceous earth, the volatiles were removed from the filtrate by evaporation and the residue was purified on a Diaion (trade mark of Mitsubishi) HP20SS resin column, eluting with water and then with hydrochloric acid (pH2). Concentration of the fractions by evaporation gave a precipitate which was collected by filtration and dried under vacuum over phosphorus pentoxide to give 2-amino-5-methoxy-4-(3-morpholinopropoxy)benzamide as a hydrochloride salt (4.67g, 75%) as beige crystals.
^{1}H NMR Spectrum: ($DMSOd_6$; TFA) 2.22-2.28(m, 2H); 3.12(br t, 2H); 3.29(t, 2H); 3.51(d, 2H); 3.75(t, 2H); 3.87(s, 3H); 4.00(br d, 2H); 4.12(t, 2H); 7.06(s, 1H); 7.53(s, 1H)
MS - EI: 309 $[M]^+$

A mixture of 2-amino-5-methoxy-4-(3-morpholinopropoxy)benzamide (4.57g, 12.25mmol) and Gold's reagent (2.6g, 15.89mmol) in dioxane (35ml) was heated at reflux for 5 hours. Acetic acid (0.55ml) and sodium acetate (1.0g) were added to the reaction mixture which was heated for a further 3 hours. The mixture was cooled to ambient temperature and the volatiles removed by evaporation. The residue was adjusted to pH7 with 2M sodium hydroxide and then purified on a Diaion (trade mark of Mitsubishi) HP20SS resin column, eluting with methanol (gradient of 0 to 60%) in water. Concentration of the fractions by evaporation gave a precipitate which was collected by filtration and dried under vacuum over phosphorus pentoxide to give 6-methoxy-7-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one (3.04g, 78%) as a white solid.

^{1}H NMR Spectrum: ($CDCl_3$) 2.10(q, 2H); 2.48(m, 4H); 2.56(t, 2H); 3.72(t, 4H); 4.00(s, 3H); 4.24(t, 2H); 7.18(s, 1H); 7.60(s, 1H); 8.00(s, 1H); 10.86(br s, 1H)

MS - EI: 319 $[M]^+$

A mixture of 6-methoxy-7-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one (638mg, 2mmol) and thionyl chloride (8ml) was heated at reflux for 30 minutes. Excess thionyl chloride was removed by evaporation and by azeotroping with toluene (x2). The residue was suspended in methylene chloride and 10% aqueous solution of sodium hydrogen carbonate was added to the mixture. The organic layer was separated, dried ($MgSO_4$) and the solvent removed by evaporation. The residue was triturated with ether, the solid was collected by filtration, washed with ether and dried under vacuum to give 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (590mg, 87%).

^{1}H NMR Spectrum: ($CDCl_3$) 2.10-2.16(m, 2H); 2.48(br s, 4H); 2.57(t, 2H); 3.73(t, 4H); 4.05(s, 3H); 4.29(t, 2H); 7.36(s, 1H); 7.39(s, 1H); 8.86(s, 1H)

MS - ESI: 337 $[MH]^+$

Example 19

A mixture of 4-chloro-7-(3-morpholinopropoxy)quinazoline hydrochloride (238mg, 0.69 mmol) and 4-chloro-2-fluoroaniline (145mg, 1mmol) in isopropanol (5ml) was heated at reflux for 1 hour. The solvent was removed by evaporation and the residue partitioned between water and ethyl acetate and the aqueous layer adjusted to pH8 with sodium hydrogen carbonate. The organic layer was separated, washed with brine, dried ($MgSO_4$) and the

solvent removed by evaporation. The residue was purified by flash chromatography eluting with methylene chloride/acetonitrile/methanol (60/30/10 followed by 60/20/20). The resulting semi-purified solid was repurified by chromatography on neutral alumina eluting with methylene chloride/methanol (95/5). The resulting white solid was dissolved in methylene chloride and 4M ethereal hydrogen chloride (0.5ml) was added. The volatiles were removed by evaporation, and the residue triturated by the addition of methylene chloride followed by methanol and ether. The precipitated solid was collected by filtration and dried under vacuum to give **4-(4-chloro-2-fluoroanilino)-7-(3-morpholinopropoxy)quinazoline** hydrochloride (35mg, 10%).

^{1}H NMR Spectrum: (DMSOd_6; CF_3COOD) 2.3(m, 2H); 3.13(t, 2H); 3.34(t, 2H); 3.52(d, 2H); 3.68(t, 2H); 4.01(d, 2H); 4.34(t, 2H); 7.37(s, 1H); 7.46(d, 1H); 7.54(dd, 1H); 7.61(t, 1H); 7.71(d, 1H); 8.71(d, 1H); 8.93(s, 1H)

MS - ESI : 417 $[MH]^+$

Elemental analysis:	Found	C 50.9	H 5.2	N 11.5
$C_{21}H_{22}N_4O_2ClF$ 0.8H_2O 1.75HCl	Requires	C 50.9	H 5.2	N 11.3%

The starting material was prepared as follows:

Sodium metal (2.2g, 95mmol) was added carefully to benzyl alcohol (50ml) at ambient temperature. The mixture was stirred for 30 minutes at ambient temperature and then heated at 80°C for 1 hour. The mixture was allowed to cool to 40°C and 7-fluoro-3,4-dihydroquinazolin-4-one (3.9g, 24mmol), (prepared as described for the starting material in Example 1), was added. The reaction mixture was then stirred and heated at 130°C for 4 hours and left to cool to ambient temperature overnight. The mixture was quenched with water, the resulting precipitate was triturated by the addition of ether (150ml), collected by filtration and dried for 4 hours at 60°C under high vacuum to give 7-benzyloxy-3,4-dihydroquinazolin-4-one (5.33g, 89%).

7-Benzyloxy-3,4-dihydroquinazolin-4-one (5.3g, 21mmol) was suspended in dry DMF (50ml) and sodium hydride (1g of a 60% suspension in mineral oil, 25mmol) was added. After hydrogen evolution had ceased, the reaction was allowed to cool to ambient temperature and then chloromethyl pivalate (4.1g, 27mmol) was added dropwise over 10 minutes. The mixture was stirred for 30 minutes then poured into aqueous citric acid solution

(pH5) (250ml) and extracted with ether (3x300ml). The combined extracts were washed with brine, dried ($MgSO_4$) and the solvent removed by evaporation. The resulting solid was triturated with isohexane, collected by filtration and dried under vacuum to give 7-benzyloxy-3-methylpivaloyl-3,4-dihydroquinazolin-4-one (6.9g, 90%).

5% Palladium-on-charcoal catalyst (0.7g, 50% in water) was added to a solution of 7-benzyloxy-3-methylpivaloyl-3,4-dihydroquinazolin-4-one (6.85g, 18.7mmol) in ethyl acetate (300ml), methanol (40ml), DMF (40ml), and acetic acid (0.7ml). The mixture was vigorously stirred under hydrogen at atmospheric pressure for 4.5 hours. The catalyst was removed by filtration through diatomaceous earth, the filtrate concentrated by evaporation to about 60ml, diluted with water (300ml) and extracted with ether (3x300ml). The combined extracts were washed with brine, dried ($MgSO_4$), and the volatiles removed by evaporation. The resulting crude solid was dissolved in acetone (200ml) and acetic acid (0.2ml) and cooled to 0°C. Potassium permanganate (1.8g) was added and the mixture stirred for 10 minutes. The reaction mixture was poured into water (250ml) and ethyl acetate (250ml) was added. The precipitate was removed by filtration, the organic phase separated and the aqueous phase re-extracted with ethyl acetate (2x100ml). The combined extracts were washed with water and brine, dried ($MgSO_4$) and the volatiles removed by evaporation to give 7-hydroxy-3-methylpivaloyl-3,4-dihydroquinazolin-4-one (4.05g, 78%) as a cream solid.

7-hydroxy-3-methylpivaloyl-3,4-dihydroquinazolin-4-one (750mg, 2.7mmol) was suspended in methylene chloride (40ml) and 1-(3-hydroxypropyl)morpholine (490mg, 3.4mmol) and triphenylphosphine (890mg, 3.4mmol) were added at 5 °C. The mixture was stirred for 5 minutes at 5°C and diethyl azodicarboxylate (590mg, 3.4mmol) was added over 5 minutes. The reaction mixture was stirred at 5°C for 30 minutes then at ambient temperature for 1 hour. The reaction mixture was purified directly by column chromatography eluting with methylene chloride, then ethyl acetate, then acetonitrile/ethyl acetate (1/5), and finally acetonitrile/ethyl acetate/aqueous ammonia (50/50/0.5). The purified product was triturated with ether/isohexane and collected by filtration to give 3-methylpivaloyl-7-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one (745mg, 68%).

A solution of 3-methylpivaloyl-7-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one (680mg, 1.6mmol) in saturated methanolic ammonia (20ml) was stirred at 40°C for 6 hours then for 18 hours at ambient temperature. The solvent was removed by evaporation and

the residue was triturated with ether/isohexane. The resulting solid was collected by filtration to give 7-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one (450mg, 92%) as a white solid.

^{1}H NMR Spectrum: ($DMSOd_6$) 1.9(m, 2H); 2.35(t, 4H); 2.4(t, 2H); 3.55(t, 4H); 4.15(t, 2H); 7.05(m, 2H); 7.97(d, 1H); 8.02(s, 1H)

MS - ESI: 290 $[MH]^+$

A mixture of 7-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one (200mg, 0.69mmol) in thionyl chloride (5ml) and DMF (0.1ml) was heated at reflux for 1 hour. The solution was diluted with toluene and the volatiles removed by evaporation. The residue was dissolved in methylene chloride and ether was added. The resulting precipitate was collected by filtration, washed with ether and dried under vacuum to give 4-chloro-7-(3-morpholinopropoxy)quinazoline hydrochloride (238mg, 100%).

The 1-(3-hydroxypropyl)morpholine was prepared as follows:

Morpholine (94g, 1.08mol) was added dropwise to a solution of 3-bromo-1-propanol (75g, 0.54mol) in toluene (750ml) and the reaction then heated at 80°C for 4 hours. The mixture was allowed to cool to ambient temperature and the precipitated solid was removed by filtration. The volatiles were removed from the filtrate and the resulting yellow oil was purified by distillation at 0.4-0.7 mmHg to give 1-(3-hydroxypropyl)morpholine (40g, 50%) as a colourless oil.

b.p. 68-70°C (~0.5mmHg)

^{1}H NMR Spectrum: ($DMSOd_6$) 1.65-1.78(m, 2H); 2.50(t, 4H); 2.60(t, 2H); 3.68(t, 4H); 3.78(t, 2H); 4.90(br d, 1H)

Example 20

5M Isopropanolic hydrogen chloride (1.5ml) was added to a solution of 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (202mg, 0.6mmol), (prepared as described for the starting material in Example 18), and 4-cyano-2-fluoroaniline (100mg, 0.72mmol), (US patent 4,120,693), in isopropanol (5ml) heated at 50°C. The mixture was then heated at 80°C for 2 hours, allowed to cool to ambient temperature and left standing overnight. The resulting precipitate was collected by filtration and the solid was then partitioned between methylene

chloride and water and 1M aqueous sodium hydroxide solution (0.8ml) was added. The organic layer was separated, washed with brine, dried ($MgSO_4$) and the solvent removed by evaporation. The residue was purified by flash chromatography eluting with methylene chloride/methanol (94/6). The purified solid was dissolved in methylene chloride and 2.2M ethereal hydrogen chloride was added. The precipitated product was collected by filtration, washed with ether and dried under vacuum to give **4-(4-cyano-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline** hydrochloride (125mg, 39%).

^{1}H NMR Spectrum: ($DMSOd_6$; CF_3COOD) 2.3-2.4(m, 2H); 3.15(t, 2H); 3.36(t, 2H); 3.54(d, 2H); 3.75(t, 2H); 4.02(d, 2H); 4.04(s, 3H); 4.34(t, 2H); 7.44(s, 1H); 7.8-7.9(m, 2H); 8.11(d, 1H); 8.25(s, 1H); 8.94(s, 1H)

Elemental analysis:	Found	C 52.7	H 5.4	N 12.9
$C_{23}H_{24}N_5O_3F$ 0.5H_2O 1.9HCl	Requires	C 52.7	H 5.3	N 13.1%
0.07 ether 0.15 methylene chloride				

Example 21

Diethyl azodicarboxylate (123µl, 0.88mmol) was added portionwise to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (250mg, 0.8mmol), (prepared as described for the starting material in Example 4), triphenylphosphine (228mg, 0.96mmol) and 3-methoxy-1-propanol (71mg, 0.8mmol) in methylene chloride (20ml) cooled at 0°C. The mixture was then allowed to warm to ambient temperature and stirred for 18 hours. The resulting precipitate was removed by filtration and the solvent removed from the filtrate by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol/concentrated aqueous ammonia (100/8/1). The purified oil was treated with ethereal hydrogen chloride and the volatiles were then removed by evaporation. The residue was triturated with ether and the solid collected by filtration to give **4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-methoxypropoxy)quinazoline** hydrochloride (100mg, 32%) as a yellow solid.

^{1}H NMR Spectrum: ($DMSOd_6$) 2.10(m, 2H); 3.25(s, 3H); 3.5(t, 2H); 4.00(s, 3H); 4.25(t, 2H); 7.4(s, 1H); 7.45(dd, 1H); 7.60(m, 2H); 8.25(s, 1H); 8.8(s, 1H); 11.5(s, 1H)

MS - ESI: 392 $[MH]^+$

Elemental analysis:	Found	C 52.7	H 4.4	N 10.1
$C_{19}H_{19}N_3O_3FCl$ 0.1H_2O 1HCl	Requires	C 53.1	H 4.7	N 9.8%

Example 22

Diethyl azodicarboxylate (123µl, 0.88mmol) was added portionwise to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (250mg, 0.8mmol), (prepared as described for the starting material in Example 4), triphenylphosphine (228mg, 0.96mmol) and 2-ethoxyethanol (71µl, 0.8mmol) in methylene chloride (20ml) cooled at 0°C. The mixture was then allowed to warm to ambient temperature and stirred for 18 hours. The resulting precipitate was removed by filtration and the solvent removed from the filtrate by evaporation. The residue was purified by chromatography eluting with methylene chloride/methanol (96/4). The resulting purified oil was dissolved in acetone and treated with water (80µl) then ethereal hydrogen chloride. The resulting granular solid was collected by filtration to give **4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-ethoxyethoxy)quinazoline** hydrochloride (96mg, 31%).

^{1}H NMR Spectrum: ($DMSOd_6$) 1.15(t, 3H); 3.50(q, 2H); 3.8(t, 2H); 4.00(s, 3H); 4.30(t, 2H); 7.35(s, 1H); 7.40(dd, 1H); 7.60(dd, 1H); 7.65(dd 1H); 8.25(s, 1H); 8.8(s, 1H); 11.53(s, 1H)

MS - ESI: 392 $[MH]^+$

Elemental analysis:	Found	C 53.2	H 4.6	N 10.1	
$C_{19}H_{19}N_3O_3FCl$ 1HCl	Requires	C 53.28	H 4.71	N 9.81%	

Example 23

Lithium borohydride (150µl of a 2M solution in THF, 0.15mmol) was added to a solution of 4-(4-chloro-2-fluoroanilino)-7-(ethoxycarbonylmethoxy)-6-methoxyquinazoline (150mg, 0.3mmol) in THF (1ml) and the mixture stirred for 1.5 hours. The reaction mixture was quenched with aqueous ammonium chloride solution and extracted with ethyl acetate. The combined extracts were washed with water, dried ($MgSO_4$) and concentrated by evaporation. Hexane was added, the mixture was cooled and the precipitated solid was collected by filtration to give **4-(4-chloro-2-fluoroanilino)-7-(2-hydroxyethoxy)-6-methoxyquinazoline** (30mg, 23%).

^{1}H NMR Spectrum: ($DMSOd_6$) 3.82(t, 2H); 3.98(s, 3H); 4.18(t, 2H); 4.92(t, 1H); 7.20(dd, 1H); 7.54-7.63(m, 2H); 7.72(s, 1H); 7.92(s, 1H); 8.60(s, 1H)

MS - ESI: 364 $[MH]^+$

The starting material was prepared as follows:

A mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (3.0g, 9mmol), (prepared as described for the starting material in Example 4), ethyl bromoacetate (1.11ml, 10mmol) and potassium carbonate (2.84g, 20.6mmol) in NMP (60ml) was heated at 90°C for 3 hours. The mixture was allowed to cool, diluted with water and extracted with ethyl acetate. The combined extracts were washed with water, dried ($MgSO_4$) and concentrated by evaporation. Hexane was added, the mixture was cooled and the precipitated solid was collected by filtration to give 4-(4-chloro-2-fluoroanilino)-7-(ethoxycarbonylmethoxy)-6-methoxyquinazoline (1.75g, 48%).

^{1}H NMR Spectrum: ($DMSOd_6$) 1.20(t, 3H); 3.95(s, 3H); 4.18(q, 2H); 4.98(s, 2H); 7.08(s, 1H); 7.30(dd, 1H); 7.48-7.58(m, 2H); 7.82(s, 1H); 8.34(s, 1H); 9.57(s, 1H)

Example 24

Diethyl azodicarboxylate (209mg, 1.2mmol) was added dropwise to a suspension of 4-(4-bromo-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (146mg, 0.4mmol), triphenylphosphine (314mg, 1.2mmol) and 1-(2-hydroxyethyl)-4-methylpiperazine (86mg, 0.6mmol), (prepared as described for the starting material in Example 17), in methylene chloride (5ml). The mixture was stirred for 1 hour at ambient temperature and the mixture was purified by column chromatography eluting with methylene chloride/methanol (90/10 followed by 80/20). The purified product was triturated with ether, collected by filtration and dried under vacuum. The solid was dissolved in methylene chloride and 3M ethereal hydrogen chloride (0.5ml) was added. The volatiles were removed by evaporation and the resulting oil was triturated with ether. The solid was collected by filtration, washed with ether and dried under vacuum to give **4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline** hydrochloride (100mg, 41%).

^{1}H NMR Spectrum: ($DMSOd_6$; CF_3COOD; 60°C) 2.89(s, 3H); 3.55-3.7(m, 8H); 3.74(t, 2H); 4.04(s, 3H); 4.68(t, 2H); 7.49(s, 1H); 7.55(m, 1H); 7.56(s, 1H); 7.75(d, 1H); 8.29(s, 1H); 8.84(s, 1H)

MS - EI: 490 $[M^{\cdot}]^+$

Elemental analysis:	Found	C 43.9 H 5.1 N 11.0
$C_{22}H_{25}N_5O_2BrF$ $1H_2O$ 2.7HCl 0.2ether	Requires	C 44.0 H 5.1 N 11.3%

The starting material was prepared as follows:

A solution of 7-benzyloxy-4-chloro-6-methoxyquinazoline hydrochloride (8.35g, 24.8mmol), (prepared as described for the starting material in Example 4), and 4-bromo-2-fluoroaniline (5.65g, 29.7mmol) in isopropanol (200ml) was heated at reflux for 4 hours. The resulting precipitated solid was collected by filtration, washed with isopropanol and then ether and dried under vacuum to give 7-benzyloxy-4-(4-bromo-2-fluoroanilino)-6-methoxyquinazoline hydrochloride (9.46g, 78%).

^{1}H NMR Spectrum: (DMSOd_6; CD_3COOD) 4.0(s, 3H); 5.37(s, 2H); 7.35-7.5(m, 4H); 7.52-7.62(m, 4H); 7.8(d, 1H); 8.14(9s, 1H); 8.79(s, 1H)

MS - ESI: 456 $[MH]^+$

Elemental analysis:	Found	C 54.0	H 3.7	N 8.7
$C_{22}H_{17}O_2N_3BrF$ 0.9HCl	Requires	C 54.2	H 3.7	N 8.6%

A solution of 7-benzyloxy-4-(4-bromo-2-fluoroanilino)-6-methoxyquinazoline hydrochloride (9.4g, 19.1mmol) in TFA (90ml) was heated at reflux for 50 minutes. The mixture was allowed to cool and was poured on to ice. The resulting precipitate was collected by filtration and dissolved in methanol (70ml). The solution was adjusted to pH9-10 with concentrated aqueous ammonia solution. The mixture was concentrated to half initial volume by evaporation. The resulting precipitate was collected by filtration, washed with water and then ether, and dried under vacuum to give 4-(4-bromo-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (5.66g, 82%).

^{1}H NMR Spectrum: (DMSOd_6; CD_3COOD) 3.95(s, 3H); 7.09(s, 1H); 7.48(s, 1H); 7.54(t, 1H); 7.64(d, 1H); 7.79(s, 1H); 8.31(s, 1H)

MS - ESI: 366 $[MH]^+$

Elemental analysis:	Found	C 49.5	H 3.1	N 11.3
$C_{15}H_{11}O_2N_3BrF$	Requires	C 49.5	H 3.0	N 11.5%

Example 25

Diethyl azodicarboxylate (209mg, 1.2mmol) was added dropwise to a suspension of 4-(4-bromo-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (146mg, 0.4mmol), (prepared as described for the starting material in Example 24), triphenylphosphine (314mg, 1.2mmol)

and 4-(2-hydroxyethyl)morpholine (79mg, 0.6mmol) in methylene chloride (5ml). The mixture was stirred for 1 hour at ambient temperature and purified by column flash chromatography eluting with methylene chloride/methanol (95/5 followed by 90/10) to give a white solid. The solid was dissolved in methylene chloride/methanol and 2M ethereal hydrogen chloride (0.5ml) was added. The mixture was concentrated by evaporation and the resulting precipitate was collected by filtration, washed with ether and dried under vacuum to give **4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-morpholinoethoxy)quinazoline** hydrochloride (155mg, 70%).

^{1}H NMR Spectrum: ($DMSOd_6$; CF_3COOD) 3.3(t, 2H); 3.6(d, 2H); 3.75(m, 2H); 3.8(m, 2H); 4.0(m, 2H); 4.03(s, 3H); 4.7(t, 2H); 7.5(s, 1H); 7.55-7.65(m, 2H); 7.8(d, 1H); 8.26(s, 1H); 8.9(s, 1H)

MS - EI: 477 $[M.]^+$

Elemental analysis:	Found	C 45.3	H 4.5	N 9.8	
$C_{21}H_{22}N_4O_3BrF$ $0.4H_2O$ 2.0HCl	Requires	C 45.2	H 4.5	N 10.0%	

Example 26

A solution of 7-(4-chlorobutoxy)-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline (3.64g, 8.87mmol) in morpholine (70ml) was heated at 110°C for 2 hours. The mixture was allowed to cool and was partitioned between ethyl acetate and water. The organic layer was separated, washed with brine, dried ($MgSO_4$) and the volatiles removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride and methanol (92/8). The purified solid product was dissolved in methylene chloride and 3M ethereal hydrogen chloride was added. The volatiles were removed by evaporation, and the residue triturated with ether. The solid was collected by filtration, washed with ether and dried under vacuum at 60°C to give **4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(4-morpholinobutoxy)quinazoline** hydrochloride (3.8g, 78%).

^{1}H NMR Spectrum: ($DMSOd_6$; CF_3COOD) 1.85-2.0(m, 4H); 3.09(t, 2H); 3.2-3.3(t, 2H); 3.46(d, 2H); 3.74(t, 2H); 4.0(d, 2H); 4.03(s, 3H); 4.27(s, 2H); 7.42(s, 1H); 7.46(d, 1H); 7.63(t, 1H); 7.68(d, 1H); 8.21(s, 1H); 8.88(s, 1H)

MS - ESI: 461 $[MH]^+$

Elemental analysis:	Found	C 50.8	H 5.3	N 10.0

$C_{23}H_{26}N_4O_3ClF$ 1.95HCl 0.6H_2O 0.08ether	Requires	C 51.0	H 5.5	N 10.2%

The starting material was prepared as follows:

A mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (3.6g, 11.3mmol), (prepared as described for the starting material in Example 4), 1-bromo-4-chlorobutane (1.95ml, 16.9mmol) and potassium carbonate (4.66g, 33.8mmol) in DMF (75ml) was heated at 40°C for 4 hours. The mixture was allowed to cool and was partitioned between methylene chloride and water. The aqueous layer was adjusted to pH7 with 2M hydrochloric acid. The organic layer was separated, washed with brine, dried ($MgSO_4$) and the volatiles removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/ethyl acetate (1/1). The purified solid product was triturated with pentane, collected by filtration and dried under vacuum to give 7-(4-chlorobutoxy)-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline (3.64g, 79%).

^{1}H NMR Spectrum: ($DMSOd_6$; CF_3COOD) 1.9-2.1(m, 4H); 3.76(t, 2H); 4.01(s, 3H); 4.28(t, 2H); 7.33(s, 1H); 7.46(d, 1H); 7.63(t, 1H); 7.70(d, 1H); 8.08(s, 1H); 8.88(s, 1H)

Example 27

A suspension of 4-(4-chloro-2-fluoroanilino)-7-(3-chloropropoxy)-6-methoxyquinazoline (150mg, 0.38mmol) in 1-methylpiperazine (2ml) was heated at 100°C for 3 hours. The mixture was allowed to cool and was partitioned between aqueous sodium carbonate solution (pH11.5) and ethyl acetate. The organic layer was separated, washed with brine, dried ($MgSO_4$) and the volatiles removed by evaporation. The residue was dissolved in methylene chloride and ether was added. The resulting precipitate was collected by filtration, washed with ether and dried. The solid was dissolved in methylene chloride and 2.2M ethereal hydrogen chloride (1ml) was added. After concentrating to half of initial volume, the resulting precipitate was collected by filtration, washed with ether and dried under vacuum to give **4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazoline** hydrochloride (158mg, 75%).

^{1}HNMR Spectrum: ($DMSOd_6$; CF_3COOD; 60°C) 2.35(m, 2H); 2.95(s, 3H); 3.43(t, 2H); 3.52-3.7(m, 8H); 4.03(s, 3H); 4.34(t, 2H); 7.41(s, 1H); 7.45(d, 1H); 7.6-7.7(m, 2H); 8.11(s, 1H); 8.8(s, 1H)

MS - EI: 460 $[MH]^+$

Elemental analysis:	Found	C 48.6	H 5.6 N 11.9
$C_{23}H_{27}N_5O_2FCl$ 0.7H_2O 2.75HCl	Requires	C 48.2	H 5.5 N 12.2%

The starting material was prepared as follows:

A mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (957mg, 3mmol), (prepared as described for the starting material in Example 4), 1-bromo-3-chloropropane (2.36g, 15mmol) and potassium carbonate (2.1g, 15mmol) in DMF (20ml) was heated at 40°C for 1.5 hours. The mixture was allowed to cool, was diluted with water and extracted with ethyl acetate (3x50ml). The organic extracts were combined, washed with water and brine, dried ($MgSO_4$) and the volatiles were removed by evaporation. The residue was triturated with hexane/ethyl acetate, collected by filtration and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-7-(3-chloropropoxy)-6-methoxyquinazoline (650mg, 55%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.26(m, 2H); 3.82(t, 2H); 3.95(s, 3H); 4.26(t, 2H); 7.20(s, 1H); 7.32(dd, 1H); 7.48-7.60(m, 2H); 7.80(s, 1H); 8.35(s, 1H); 9.52(s, 1H)

MS - EI: 396 $[MH]^+$

Example 28

The following illustrate representative pharmaceutical dosage forms containing the compound of formula I, or a pharmaceutically acceptable salt thereof (hereafter compound X), for therapeutic or prophylactic use in humans:

(a) Tablet I

	mg/tablet
Compound X	100
Lactose Ph.Eur	182.75
Croscarmellose sodium	12.0
Maize starch paste (5% w/v paste)	2.25
Magnesium stearate	3.0

(b) Tablet II

mg/tablet

Compound X	50
Lactose Ph.Eur	223.75
Croscarmellose sodium	6.0
Maize starch	15.0
Polyvinylpyrrolidone (5% w/v paste)	2.25
Magnesium stearate	3.0

(c) Tablet III

	mg/tablet
Compound X	1.0
Lactose Ph.Eur	93.25
Croscarmellose sodium	4.0
Maize starch paste (5% w/v paste)	0.75
Magnesium stearate	1.0

(d) Capsule

	mg/capsule
Compound X	10
Lactose Ph.Eur	488.5
Magnesium stearate	1.5

(e) Injection I

	(50 mg/ml)
Compound X	5.0% w/v
1N Sodium hydroxide solution	15.0% v/v
0.1N Hydrochloric acid (to adjust pH to 7.6)	
Polyethylene glycol 400	4.5% w/v
Water for injection to 100%	

(f) Injection II

	10 mg/ml)
Compound X	1.0% w/v
Sodium phosphate BP	3.6% w/v
0.1N Sodium hydroxide solution	15.0% v/v

Water for injection to 100%

(g) Injection III (1mg/ml,buffered to pH6)


Compound X	0.1% w/v
Sodium phosphate BP	2.26% w/v
Citric acid	0.38% w/v
Polyethylene glycol 400	3.5% w/v
Water for injection to 100%	

Note

The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

CLAIMS

1. A quinazoline derivative of the formula I:



(I)

(wherein:

R^1 represents hydrogen or methoxy;

R^2 represents methoxy, ethoxy, 2-methoxyethoxy, 3-methoxypropoxy, 2-ethoxyethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, 2-hydroxyethoxy, 3-hydroxypropoxy, 2-(N,N-dimethylamino)ethoxy, 3-(N,N-dimethylamino)propoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 4-morpholinobutoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 4-piperidinobutoxy, 2-(piperazin-1-yl)ethoxy, 3-(piperazin-1-yl)propoxy, 4-(piperazin-1-yl)butoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy or 4-(4-methylpiperazin-1-yl)butoxy;

the phenyl group bearing $(R^3)_2$ is selected from: 2-fluoro-5-hydroxyphenyl, 4-bromo-2-fluorophenyl, 2,4-difluorophenyl, 4-chloro-2-fluorophenyl, 2-fluoro-4-methylphenyl, 2-fluoro-4-methoxyphenyl, 4-bromo-3-hydroxyphenyl, 4-fluoro-3-hydroxyphenyl, 4-chloro-3-hydroxyphenyl, 3-hydroxy-4-methylphenyl, 3-hydroxy-4-methoxyphenyl and 4-cyano-2-fluorophenyl);

and salts thereof.

2. A quinazoline derivative as claimed in claim 1 wherein R^1 is methoxy.

3. A quinazoline derivative as claimed in claim 1 or claim 2 wherein the phenyl group bearing $(R^3)_2$ is 4-chloro-2-fluorophenyl or 4-bromo-2-fluorophenyl.

4. A quinazoline derivative as claimed in any one of the preceding claims wherein R^2 is methoxy, ethoxy, 2-methoxyethoxy, 3-methoxypropoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, 2-hydroxyethoxy, 3-hydroxypropoxy, 2-(N,N-dimethylamino)ethoxy, 3-(N,N-dimethylamino)propoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 2-(piperazin-1-yl)ethoxy, 3-(piperazin-1-yl)propoxy, 2-(4-methylpiperazin-1-yl)ethoxy, or 3-(4-methylpiperazin-1-yl)propoxy.

5. A quinazoline derivative as claimed in claim 4 wherein R^2 is 2-methoxyethoxy, 2-morpholinoethoxy, 3-morpholinopropoxy or 2-(4-methylpiperazin-1-yl)ethoxy.

6. A quinazoline derivative as claimed in claim 5 wherein R^2 is 2-methoxyethoxy or 3-morpholinopropoxy.


7. A quinazoline derivative as claimed in claim 1 selected from:
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-morpholinoethoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline
and salts thereof.

8. A quinazoline derivative as claimed in claim 1 selected from:
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-morpholinoethoxy)quinazoline
and salts thereof.

9. A quinazoline derivative as claimed in any one of the preceding claims in the form of a pharmaceutically acceptable salt.


10. A process for the preparation of a quinazoline derivative of formula I or salt thereof (as defined in claim 1) which comprises:

(a) the reaction of a compound of the formula III:



(III)


(wherein R^1 and R^2 are as defined in claim 1 and L^1 is a displaceable moiety), with a compound of the formula IV:



(IV)


(wherein R^3 is as defined in claim 1) whereby to obtain compounds of the formula I and salts thereof;

(b) for the preparation of compounds of formula I and salts thereof in which the group of formula II:



(II)


(wherein R^3 is as defined in claim 1) represents a phenyl group carrying a hydroxy group, the deprotection of a compound of formula V:



(V)

(wherein R^1, R^2 and R^3 are as defined in claim 1 and P represents a phenolic hydroxy protecting group);

(c) the reaction of a compound of the formula VI:



(VI)


(wherein R^1 and R^3 are as defined in claim 1) with a compound of formula VII:

$$R^4\text{-}L^1 \qquad \text{(VII)}$$

(wherein L^1 is as defined herein and R^4 is methyl, ethyl, 2-methoxyethyl, 3-methoxypropyl, 2-ethoxyethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-(N,N-dimethylamino)ethyl, 3-(N,N-dimethylamino)propyl, 2-morpholinoethyl, 3-morpholinopropyl, 4-morpholinobutyl, 2-piperidinoethyl, 3-piperidinopropyl, 4-piperidinobutyl, 2-(piperazin-1-yl)ethyl, 3-(piperazin-1-yl)propyl, 4-(piperazin-1-yl)butyl, 2-

(4-methylpiperazin-1-yl)ethyl, 3-(4-methylpiperazin-1-yl)propyl or 4-(4-methylpiperazin-1-yl)butyl);

(d) the reaction of a compound of the formula VIII:




(VIII)

with a compound of the formula IX:

$$R^2\text{-}H \qquad \text{(IX)}$$

(wherein L^1 is as defined herein and R^1, R^2 and R^3 are as defined in claim 1):

(e) for the preparation of compounds of formula I and salts thereof wherein R^2 is R^5C_{1-4}alkoxy, (wherein R^5 is selected from methoxy, ethoxy, hydroxy, N,N-dimethylamino, morpholino, piperidino, piperazin-1-yl or 4-methylpiperazin-1-yl) reacting a compound of the formula X:



(X)

(wherein L^1 is as defined herein, R^1 and R^3 are as defined in claim 1 and R^6 is C_{1-4}alkoxy) with a compound of the formula XI:

R^5-H (XI)

(wherein R^5 is as defined herein);

and when a salt of a quinazoline derivative of formula I is required, reaction of the compound obtained with an acid or base whereby to obtain the desired salt.

11. A pharmaceutical composition which comprises as active ingredient a quinazoline derivative of formula I or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 9 in association with a pharmaceutically acceptable excipient or carrier.

12. A method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 9.

13. A quinazoline derivative as claimed in any one of claims 1 to 9 for use as a medicament.

INTERNATIONAL SEARCH REPORT

Intern al Application No
PCT/GB 97/00550

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D239/94 A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 566 226 A (ZENECA LTD) 20 October 1993 cited in the application see the whole document	1,11
Y	WO 95 15758 A (RHONE POULENC RORER PHARMA ;MYERS MICHAEL R (US); SPADA ALFRED P () 15 June 1995 see the whole document	1,11
Y	FR 2 435 248 A (SANKYO CO) 4 April 1980 see examples 11,22,28,30	1,11
A,P	WO 96 33977 A (ZENECA LTD ;BARKER ANDREW JOHN (GB)) 31 October 1996 see the whole document	1,11

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

1

Date of the actual completion of the international search	Date of mailing of the international search report
29 May 1997	11. 06. 97

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016	Frelon, D

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Ir .iational application No.
PCT/GB 97/ 00550

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claim(s) 12 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

...formation on patent family members

Intern al Application No
PCT/GB 97/00550

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0566226 A	20-10-93	AT 130000 T	15-11-95
		AU 661533 B	27-07-95
		AU 3101093 A	22-07-93
		CA 2086968 A	21-07-93
		DE 69300754 D	14-12-95
		DE 69300754 T	28-03-96
		ES 2078798 T	16-12-95
		HK 36497 A	04-04-97
		HU 9500185 A	28-07-95
		NZ 245662 A	26-09-95
		SK 1693 A	09-09-93
		US 5457105 A	10-10-95
		US 5616582 A	01-04-97
		ZA 9300015 A	20-07-93
		JP 6073025 A	15-03-94
WO 9515758 A	15-06-95	US 5480883 A	02-01-96
		AU 1305095 A	27-06-95
FR 2435248 A	04-04-80	JP 1400162 C	28-09-87
		JP 55038325 A	17-03-80
		JP 62006546 B	12-02-87
		BE 878723 A	11-03-80
		CA 1151168 A	02-08-83
		CH 642361 A	13-04-84
		DE 2936705 A	20-03-80
		GB 2033894 A,B	29-05-80
		NL 7906761 A	13-03-80
		SE 446337 B	01-09-86
		SE 7907493 A	12-03-80
		US 4322420 A	30-03-82
		US 4464375 A	07-08-84
WO 9633977 A	31-10-96	AU 5343096 A	18-11-96

Bibliographic data

Title:	CRFL receptor antagonists for the treatment of congenital adrenal hyperplasia
Pub/Pat no:	CN106102740A
Pub/Issue Date:	2016-11-09
Inventor(s):	GRIGORIADIS DIMITRI E|·E·
Applicant(s):	NEUROCRINE BIOSCIENCES INC
Classification:	A61K31/427AI; A61K31/4985AI; A61K31/519AI
Application number:	CN20158005270 2015-01-21
Priority number:	US201461929941P 20140121; US201461981033P 20140417; US201462069155P 20141027; WO2015US12315 20150121;

Abstract of CN106102740A

CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.

(19)中华人民共和国国家知识产权局

(12)发明专利申请

(10)申请公布号 CN 106102740 A
(43)申请公布日 2016.11.09

(21)申请号 201580005270.4

(22)申请日 2015.01.21

(30)优先权数据
61/929,941 2014.01.21 US
61/981,033 2014.04.17 US
62/069,155 2014.10.27 US

(85)PCT国际申请进入国家阶段日
2016.07.21

(86)PCT国际申请的申请数据
PCT/US2015/012315 2015.01.21

(87)PCT国际申请的公布数据
WO2015/112642 EN 2015.07.30

(71)申请人 纽罗克里生物科学有限公司
地址 美国加利福尼亚州

(72)发明人 季米特·E·格里戈里尔蒂斯

(74)专利代理机构 北京英赛嘉华知识产权代理有限责任公司 11204
代理人 王达佐 洪欣

(51)Int.Cl.
A61K 31/427(2006.01)
A61K 31/4985(2006.01)
A61K 31/519(2006.01)


权利要求书2页 说明书22页 附图6页

(54)发明名称

治疗先天性肾上腺增生的CRF_1受体拮抗剂

(57)摘要

CRF_1受体拮抗剂可能直接抑制患有CAH的患者的ACTH释放，从而在使用多个较低生理剂量的氢化可的松时，使雄激素的产生正常化，并且因此减少治疗相关的副作用。



CN 106102740 A

1.治疗先天性肾上腺增生(CAH)的方法,其通过向有需要的对象施用具有超过30分钟的解离半衰期的CRF_1受体拮抗剂来进行。

2.如权利要求1所述的方法,其中所述CRF_1受体拮抗剂具有超过40分钟的解离半衰期。

3.如权利要求1所述的方法,其中所述CRF_1受体拮抗剂具有超过50分钟的解离半衰期。

4.如权利要求1所述的方法,其中所述CRF_1受体拮抗剂为化合物I(NBI-77860;2,5-二甲基-3-[2-甲基-4-(甲氧基)苯基]-N-[(1S)-1-(3-甲基-1,2,4-噁二唑-5-基)丙基]吡唑并[1,5-a]嘧啶-7-胺)。

5.如权利要求1所述的方法,其中所述CRF_1受体拮抗剂为NBI-30775、NBI-34041、SSR-126374、SSR-125543、安他拉明(N-丁基-N-乙基-2,5,6-三甲基-7-(2,4,6-三甲基苯基)吡咯并[3,2-e]嘧啶-4-胺)、或者DMP904。

6.如权利要求1-5中任一项所述的方法,其中所述CRF_1受体拮抗剂在临睡前施用。

7.如权利要求1-5中任一项所述的方法,其中所述CRF_1受体拮抗剂在预期的生理节律释放ACTH之时或者之前施用。

8.如权利要求7所述的方法,其中所述CRF_1受体拮抗剂在预期的生理节律释放ACTH之前3-4小时施用。

9.降低患有先天性肾上腺增生(CAH)的对象中的17-OHP水平和ACTH水平的方法,所述方法包括在临睡前向所述对象施用CRF_1受体拮抗剂。

10.如权利要求9所述的方法,其中所述CRF_1受体拮抗剂在预期的生理节律释放ACTH之时或者之前施用。

11.如权利要求9所述的方法,其中所述CRF_1受体拮抗剂在预期的生理节律释放ACTH之前3-4小时施用。

12.如权利要求9-11中任一项所述的方法,其中所述CRF_1受体拮抗剂为化合物I(NBI-77860;2,5-二甲基-3-[2-甲基-4-(甲氧基)苯基]-N-[(1S)-1-(3-甲基-1,2,4-噁二唑-5-基)丙基]吡唑并[1,5-a]嘧啶-7-胺)。

13.如权利要求9-11中任一项所述的方法,其中所述CRF_1受体拮抗剂为NBI-30775、NBI-34041、SSR-126374、SSR-125543、安他拉明(N-丁基-N-乙基-2,5,6-三甲基-7-(2,4,6-三甲基苯基)吡咯并[3,2-e]嘧啶-4-胺)、或者DMP904。

14.用于治疗先天性肾上腺增生(CAH)的CRF_1受体拮抗剂,其中所述CRF_1受体拮抗剂具有超过30分钟的解离半衰期。

15.如权利要求14所述的CRF_1受体拮抗剂,其中所述CRF_1受体拮抗剂具有超过40分钟的解离半衰期。

16.如权利要求14所述的CRF_1受体拮抗剂,其中所述CRF_1受体拮抗剂具有超过50分钟的解离半衰期。

17.如权利要求14所述的CRF_1受体拮抗剂,其中所述CRF_1受体拮抗剂为化合物I(NBI-77860;2,5-二甲基-3-[2-甲基-4-(甲氧基)苯基]-N-[(1S)-1-(3-甲基-1,2,4-噁二唑-5-基)丙基]吡唑并[1,5-a]嘧啶-7-胺)。

18.如权利要求14所述的CRF_1受体拮抗剂,其中所述CRF_1受体拮抗剂为NBI-30775、NBI-34041、SSR-126374、SSR-125543、安他拉明(N-丁基-N-乙基-2,5,6-三甲基-7-(2,4,6-三甲基苯基)吡咯并[3,2-e]嘧啶-4-胺)、或者DMP904。

0420

19.如权利要求14-18中任一项所述的CRF_1受体拮抗剂，其中所述CRF_1受体拮抗剂适于临睡前施用。

20.如权利要求14-18中任一项所述的CRF_1受体拮抗剂，其中所述CRF_1受体拮抗剂适于在预期的生理节律释放ACTH之时或者之前施用。

21.如权利要求14-18中任一项所述的CRF_1受体拮抗剂，其中所述CRF_1受体拮抗剂适于在预期的生理节律释放ACTH之前3-4小时施用。

0421

治疗先天性肾上腺增生的CRF$_1$受体拮抗剂

[0001] 发明背景

技术领域

[0002] 本文描述了治疗先天性肾上腺增生的组合物和方法。

[0003] 相关技术描述

[0004] 先天性肾上腺增生(CAH)是一组常染色体隐性基因病症，其导致很少或者没有皮质醇生物合成。最常见的疾病形式为山位于染色体6p21上的CYP21A2基因的突变引起的21-羟化酶缺乏症，这约占CAH病例的95％(对于综述，参见，例如，Speiser等人，Int.J.Pediatr.Endocrinol.2010:494173(2010))。这些突变的范围可以从合成肾上腺皮质中的皮质醇所需的酶活性的完全丧失至一系列部分丧失，这导致疾病严重度，所述疾病严重度是特异性突变的直接结果。这种连续的21-羟化酶缺乏症已经被广泛分为：被分组为典型CAH的失盐型和单纯雄性化型，以及被称为非典型CAH(NCCAH)或者“晚发型”CAH的轻微形式，所述轻微形式通常在儿童晚期或者成人早期被诊断出。非典型CAH患者是纯合或者混合的杂合子，通常具有典型CAH等位基因。这些患者具有足够的酶活性(>正常的20％-50％)，使得他们在出生时不会患有失盐型缺乏症或者皮质醇缺乏症，具有正常的生殖器，并且许多人在整个一生都保持无症状(Trapp等人，Steroids 77(4):342-46(2012))。在较少见的疾病形式中，11β-羟化酶基因CYP11B1的突变导致CAH(11β-OH CAH)，这占病例的5％。

[0005] 两种基因突变都导致先天性肾上腺增生、皮质醇缺乏症和过度的促肾上腺皮质激素(ACTH)产生以及雄激素的过度产生。这些患者需要终身管理糖皮质激素以及与该治疗相关的附带问题。因此，对于改善患有CAH的患者的健康、提升其幸福、改善其生命质量以及管理其相关病症的治疗方案存在重大需求。

[0006] 发明概述

[0007] 促肾上腺皮质激素释放因子(CRF)激活CRF$_1$受体(一类B G蛋白偶联受体(GPCR))。CRF$_1$拮抗剂可能直接抑制患有CAH的患者的ACTH释放，从而在使用多个较低生理剂量的氢化可的松时，使雄性激素的产生正常化并且减少治疗相关的副作用。

[0008] 在一个实施方案中，提供了通过向有需要的对象施用有效量的CRF$_1$拮抗剂治疗CAH的方法，其包括(但不限于)临睡前施用。

[0009] 在更具体的实施方案中，CRF$_1$拮抗剂具有超过30分钟的解离半衰期($t_{1/2}$)，并且在另一实施方案中，CRF$_1$拮抗剂具有超过40分钟的解离半衰期($t_{1/2}$)，以及在另一实施方案中，CRF$_1$拮抗剂具有超过50分钟的解离半衰期($t_{1/2}$)。

[0010] 实施方案1.治疗先天性肾上腺增生(CAH)的方法，其通过向有需要的对象施用具有超过30分钟的解离半衰期的CRF$_1$受体拮抗剂来进行。

[0011] 实施方案2.如实施方案1所述的方法，其中所述CRF$_1$受体拮抗剂具有超过40分钟的解离半衰期。

[0012] 实施方案3.如实施方案1所述的方法，其中所述CRF$_1$受体拮抗剂具有超过50分钟

0422

的解离半衰期。

[0013] 实施方案4.如实施方案1-3中任一项所述的方法，其中所述CRF_1受体拮抗剂为化合物I(NBI-77860;2,5-二甲基-3-[2-甲基-4-(甲氧基)苯基]-N-[(1S)-1-(3-甲基-1,2,4-噁二唑-5-基)丙基]吡唑并[1,5-a]嘧啶-7-胺)。

[0014] 实施方案5.如实施方案1-3中任一项所述的方法，其中所述CRF_1受体拮抗剂为NBI-30775、NBI-34041、SSR-126374、SSR-125543、安他拉明(antalarmin)(N-丁基-N-乙基-2,5,6-三甲基-7-(2,4,6-三甲基苯基)吡咯并[3,2-e]嘧啶-4-胺)或者DMP904。

[0015] 实施方案6.如实施方案1-5中任一项所述的方法，其中所述CRF_1受体拮抗剂在临睡前施用。

[0016] 实施方案7.如实施方案1-6中任一项所述的方法，其中所述CRF_1受体拮抗剂在预期的生理节律释放ACTH之时或者之前施用。

[0017] 实施方案8.如实施方案7所述的方法，其中所述CRF_1受体拮抗剂在预期的生理节律释放ACTH之前3-4小时施用。

[0018] 实施方案9.降低患有先天性肾上腺增生(CAH)的对象中的17-OHP水平和ACTH水平的方法，所述方法包括在临睡前向所述对象施用CRF_1受体拮抗剂。

[0019] 实施方案10.如实施方案9所述的方法，其中所述CRF_1受体拮抗剂在预期的生理节律释放ACTH之时或者之前施用。

[0020] 实施方案11.如实施方案9或者实施方案10所述的方法，其中所述CRF_1受体拮抗剂在预期的生理节律释放ACTH之前3-4小时施用。

[0021] 实施方案12.如实施方案9-11中任一项所述的方法，其中所述CRF_1受体拮抗剂为化合物I(NBI-77860;2,5-二甲基-3-[2-甲基-4-(甲氧基)苯基]-N-[(1S)-1-(3-甲基-1,2,4-噁二唑-5-基)丙基]吡唑并[1,5-a]嘧啶-7-胺)。

[0022] 实施方案13.如实施方案9-11中任一项所述的方法，其中所述CRF_1受体拮抗剂为NBI-30775、NBI-34041、SSR-126374、SSR-125543、安他拉明(N-丁基-N-乙基-2,5,6-三甲基-7-(2,4,6-三甲基苯基)吡咯并[3,2-e]嘧啶-4-胺)或者DMP904。

[0023] 实施方案14.用于治疗先天性肾上腺增生(CAH)的CRF_1受体拮抗剂，其中所述CRF_1受体拮抗剂具有超过30分钟的解离半衰期。

[0024] 实施方案15.如实施方案14所述的CRF_1受体拮抗剂，其中所述CRF_1受体拮抗剂具有超过40分钟的解离半衰期。

[0025] 实施方案16.如实施方案14所述的CRF_1受体拮抗剂，其中所述CRF1受体拮抗剂具有超过50分钟的解离半衰期。

[0026] 实施方案17.如实施方案14-16中任一项所述的CRF_1受体拮抗剂，其中所述CRF_1受体拮抗剂为化合物1(NBI-77860;2,5-二甲基-3-[2-甲基-4-(甲氧基)苯基]-N-[(1S)-1-(3-甲基-1,2,4-噁二唑-5-基)丙基]吡唑并[1,5-a]嘧啶-7-胺)。

[0027] 实施方案18.如实施方案14-16中任一项所述的CRF_1受体拮抗剂，其中所述CRF_1受体拮抗剂为NBI-30775、NBI-34041、SSR-126374、SSR-125543、安他拉明(N-丁基-N-乙基-2,5,6-三甲基-7-(2,4,6-三甲基苯基)吡咯并[3,2-e]嘧啶-4-胺)或者DMP904。

[0028] 实施方案19.如实施方案14-18中任一项所述的CRF_1受体拮抗剂，其中所述CRF_1受体拮抗剂适于临睡前施用。

0423

[0029] 实施方案20.如实施方案14-19中任一项所述的CRF_1受体拮抗剂，其中所述CRF_1受体拮抗剂适于在预期的生理节律释放ACTH之时或者之前施用。

[0030] 实施方案21.如实施方案14-20中任一项所述的CRF_1受体拮抗剂，其中所述CRF_1受体拮抗剂适于在预期的生理节律释放ACTH之前3-4小时施用。

[0031] 在其它实施方案中，以上以及本文所述的方法和用途还包括将糖皮质激素或者盐皮质激素的量从施用于患有CAH的发育完全的对象(例如，人对象)的GC(例如氢化可的松(HC)、强的松、泼尼松龙、地塞米松或者氟氢可的松)的推荐日剂量降低至少10％、15％、20％、30％、40％、50％、60％。在其它实施方案中，以上以及本文所述的方法和用途还包括将糖皮质激素或者盐皮质激素的量从施用于患有CAH的正在发育的对象(例如，人对象)的GC(例如氢化可的松)或者盐皮质激素(例如氟氢可的松)的推荐日剂量降低至少10％、15％、20％、30％、40％、50％、60％。

[0032] 参照以下详细说明，这些以及其它实施方案是显而易见的。为此，本文列出了各种参考文献，其更详细地描述某些背景信息、程序、化合物和组合物，并且将每一篇参考文献据此通过引用整体并入。

[0033] 本文未明确定义的术语应具有由本领域技术人员根据本公开内容和上下文所给出的含义。然而，除非作出相反说明，如说明书中所用，术语具有所指定的含义。在整个说明书中提及的“一个实施方案”或者“实施方案”，意指结合实施方案所述的具体的特征、结构或者特点被包括在至少一个实施方案中。因此，在整个说明书的不同地方出现的短语“在一个实施方案中”或者“在实施方案中”不必全部指同一实施方案。而且，具体的特征、结构或特点可以任何适合的方式组合在一个或多个实施方案中。

[0034] 此外，如在本说明书和所附权利要求中所用，单数形式“一个/一种(a)”、“一个/一种(a)”和“所述”包括复数指示物，除非上下文另外明确规定。因此，例如，关于“非人动物”可以指一种或者多种非人动物或者多个此类动物，并且关于“细胞”或者“所述细胞”包括提及的一个或者多个细胞以及本领域技术人员已知的其等同物(例如，多个细胞)等。当描述或者要求保护方法的步骤，并且所述步骤被描述为以特定顺序发生时，第一步骤“优先于”(即，先于)第二步骤发生(或者进行)的描述如果被改写为第二步骤“随后于”第一步骤发生(或者进行)的陈述，那么它们具有相同的含义。当提及数字或者数值范围时，术语“约”意指提及的数字或者数值范围为实验变异内的近似值(或者在统计实验误差内)，因此，数字或者数值范围可以在所述数字或者数值范围的1％至15％变化。还应当注意的是，术语“或者”通常采用包括“和/或”的含义，除非上下文另外明确规定。例如，当提及至少一种化合物或者至少一种组合物时，术语“至少一种”具有与术语“一种或者多种”相同的含义和理解。

[0035] 附图简述

[0036] 图1表示肾上腺的类固醇合成途径的示意图。最常见的CAH形式由导致皮质醇减少以及雄激素(例如睾酮)和雌激素增加的21-羟化酶(又称为21-α羟化酶)缺乏症所引起。更稀有的典型CAH类型为11β-羟化酶缺乏症。

[0037] 图2表示示例化合物I(NBI-77860)对切除肾上腺的大鼠中的ACTH浓度的影响的图。大鼠口服接受30mg/kg的化合物I(NBI-77860)。数据表示为ACTH的平均血浆浓度(±SEM)。

[0038] 图3A-C表示示例CRF_1受体拮抗剂(以它们的解离半衰期加以区分)对切除肾上腺

0424

的大鼠中的ACTH浓度的影响的图。

[0039] 图4表示实施例6中所述的临床试验的研究设计示意图，其被设计为评估NBI-77860的安全性、耐受性和血浆暴露，以及该化合物对HPA(下丘脑-垂体-肾上腺的)轴激素的内源水平的影响。

[0040] 图5表示实施例6中所述的临床试验的17-OHP水平(上图)和ACTH水平(下图)在给药后整个24小时期间的平均数据。

[0041] 图6表示在施用300mg和600mg NBI-77860和安慰剂后，具体单个对象的17-OHP水平(上图)和ACTH水平(下图)随时间的反应。

[0042] 发明详述

[0043] 如本文所述，已经发现CRF_1受体拮抗剂直接抑制患有CAH的患者中的ACTH释放，从而使雄激素的产生正常化。CRF_1受体拮抗剂的施用允许在患有CAH的患者中使用多个较低生理剂量的氢化可的松，因此减少治疗相关的副作用。

[0044] 通过免疫分析对CAH进行新生儿筛查，以对生命的最初72小时内获得的脚跟毛细血管血液样本中的17-OHP水平进行测量。通过可商购获得的解离增强镧系荧光免疫分析(DELFIA;PerkinElmer,Waltham Massachusetts)(White等人，J.Pediatr.163:10-12(2013))来分析血液样品的17-OHP。

[0045] 使用生物化学测试方法和分子基因测试方法的第二级筛选试验(在生命的第8天至第14天进行)被美国的九个州所采用，并且被额外的5个州强烈推荐。生物化学方法包括用有机溶剂萃取或者液相色谱随后串联质谱的免疫分析，以测量17-OHP、雄烯二酮和21-脱氧皮质醇与皮质醇的类固醇比值(参见，例如，Speiser等人，Int.J.Pediatr.Endocrinol.2010:494173,2010)。基因筛选寻找与CAH有关的CYP21A2突变。尽管未在美国得到广泛采用，但是增加第二筛选可能提高整个筛选过程的灵敏度，其中单独的第一筛选的灵敏度为约72%。

[0046] 在没有新生儿筛选的结果时，患有典型CAH的女婴通常由于存在模糊不清的生殖器而被鉴定。男性在出生时具有正常的生殖器，因此不进行诊断，除非进行新生儿筛选或者其它医学并发症引起注意。最初未被诊断患有CAH并且患有失盐型疾病的婴儿随后在生命的最初几周内在体重增加困难、呕吐、高钾血症以及低钠血症的情况下被诊断。

[0047] CAH的治疗基于在婴儿期至成人期使用来自诊断的各种药物使激素水平和类固醇水平正常化。糖皮质激素是CAH的目前标准治疗，并且被用于校正内源性皮质醇缺乏症以及降低来自脑垂体的升高的ACTH水平。与艾迪生氏病(肾上腺机能不全)的治疗不同，在所述治疗中，皮质醇替代是充分的，但CAH的治疗还必须降低ACTH的产生，以控制后续雄激素过量。因此，糖皮质激素治疗的目标包括皮质醇替代和ACTH的抑制，以防止女性的男性化和月经紊乱并且抑制男性的睾丸肾上腺残余瘤。需要盐皮质激素替代用于实现正常的血浆肾素活性以维持那些患有失盐型的CAH的患者中的正常血压、电解质平衡和容量状态。

[0048] 糖皮质激素治疗的方案必须支持正常的生理机能并且还应确保在可以引起强的应激反应的事件(例如，并发疾病、运动、低血压)期间可获得足够的皮质醇。仔细监测对于避免由于试图充分抑制雄激素产生而进行的糖皮质激素过度治疗引起的医源性库欣综合征(iatrogenic Cushing's syndrome)或者由于治疗不足引起的艾迪生综合征的形成也是必要的。盐皮质激素的过度治疗可以引起高血压，然而治疗不足可以导致低血压、盐缺失、

0425

疲劳和对糖皮质激素的需求增加。监测治疗功效的典型实验室试验包括测量17-OHP、雄烯二酮、睾酮、肾素活性和电解质的血浆浓度。

[0049] 患有CAH的成年患者具有增加的包括肥胖、高血压和胰岛素抗性在内的心血管疾病的风险因素的发生率(参见,例如,Kim等人,Semin.Reprod.Med.27(4):316-21(2009))。一大组CAH儿科患者和成年患者(n=244)的研究表明患者被开出各种糖皮质激素治疗方案,然而却频繁地遭受较差的激素控制和前述的不良后果(参见,例如,Finkielstain等人,J.Clin.Endocrinol Metab.97(12):4429-38(2012))。

[0050] CAH的治疗包括使用糖皮质激素(对于儿童通常为氢化可的松,但是对于成人通常为具有狭窄的治疗指数的更有效试剂,例如地塞米松)努力使皮质醇缺乏正常化,并且如果失盐需要,使用盐皮质激素(通常为氟氢可的松)。然而,实现充分抑制过量雄激素所需的糖皮质激素剂量通常远高于如在患有艾迪生氏病的患者中单独用于皮质醇替代的正常生理剂量。这种对糖皮质激素暴露的增加可以导致CAH患者的医源性库欣综合征、心血管风险因素增加、葡萄糖耐受不良和骨矿物质密度降低(参见,例如,Elnecave等人,J.Pediatr.Endocrinol.Metab.21:1155-62(2008);King等人,J.Clin.Endocrinol.Metab.91(3):8656-59(2006);Migeon等人,Endocrinol.Metab.Clin.North Am.30:193-206(2001))。

[0051] 促肾上腺皮质激素释放因子(CRF)从羊下丘脑分离并且被鉴定为41个氨基酸的肽。已经发现CRF引起内分泌、神经和免疫系统功能产生显著变化。据信CRF是来自垂体前叶的促肾上腺皮质激素("ACTH")、β-内啡肽和其它前阿黑皮素原(POMC)衍生肽的基础性和应激诱导的释放的主要生理调节剂(参见,例如,Vale等人,Science 213:1394-1397,1981)。CRF的分泌物经由与CRF_1受体(G蛋白偶联受体的B类家族的成员)结合引起ACTH从垂体前叶的促肾上腺皮质激素细胞释放。


[0052] 由于CRF的生理学重要性,开发具有显著的CRF_1受体结合活性并且能够拮抗CRF_1受体的生物活性的小分子仍然是期望的目标,并且是用于治疗焦虑、抑郁、肠易激综合征、创伤后应激障碍和药物滥用的正在进行的研究和开发的主题。

[0053] 在下丘脑促肾上腺皮质激素释放因子(CRF)的控制下,脑垂体激素ACTH刺激胆固醇的吸收并且驱动孕烯醇酮的合成,从而启动肾上腺中的类固醇生成(参见图1)。肾上腺皮质由三个区组成,所述三个区产生不同类型的激素,许多激素通过这种途径被ACTH动员的胆固醇驱动。由于突变或者缺失导致的这些酶的缺乏引起底物浓度增加。在21-羟化酶基因(CYP21A2)中的突变或者缺失产生的最常见的CAH形式中,由于类固醇前体、孕酮和17-羟孕酮(17-OHP)的积累,有效的雄激素通过肾上腺来产生。在这些情况中,17-OHP的血浆水平可以达到正常浓度的10-1000倍。这些增长导致引起女性男性化的雄激素的过度产生,所述雄激素特别是雄烯二酮、睾酮和二羟基睾酮。此外,在CAH中的21-羟化酶缺乏引起糖皮质激素和盐皮质激素,特别是皮质醇和醛固酮的生物合成不足。皮质醇是下丘脑的CRF分泌和脑垂体的ACTH释放的关键性负反馈调节剂。糖皮质激素合成和释放的不足消除了对下丘脑和脑垂体的抑制,这引起ACTH水平增加。过度的ACTH刺激引起束状带和网状带的肥大,从而导致肾上腺增生。

[0054] 在实施方案中,可用于治疗CAH的CRF_1受体拮抗剂为NBI-77860(2,5-二甲基-3-[2-甲基-4-(甲氧基)苯基]-N-[(1S)-1-(3-甲基-1,2,4-噁二唑-5-基)丙基]吡唑并[1,5-

0426

a]嘧啶-7-胺(在本文又称为“化合物I”)),并且其具有以下结构。

[0055] 

化合物I

[0056] 化合物I是拥有结合pKi＝8.2的有效CRF_1拮抗剂(参见,例如,Tellew等人,Bioorg.Med.Chem.Lett.20:7259,2010和Int'l.Patent Appl.Publ.No.WO 2006/044958,以上两篇参考文献通过引用整体并入本文)。如本文所述,化合物I具有有效的降低ACTH的效果,如在切除肾上腺的大鼠中所示。

[0057] 在另一实施方案中,可用于治疗CAH的CRF_1受体拮抗剂为以下中所述的小分子拮抗剂:U.S.6,586,456、US 6,806,282、US 6,531,475、US 6,664,261、US 6,610,678、WO 98/08846、WO 98/11075、WO 99/10350、WO 2000/059888、WO 2006/044821、WO 2006/102194、WO 2006/107784、WO 2006/116412、WO 2006/126718、WO 2007/069565、WO 2007/069671、WO 2008/036541、WO 2008/036579、WO 2008/051533、WO 2008/082003、WO 2008/083070、WO2008/136377、WO 2009/008552、WO 2009/144632、WO 2010/014280、WO 2010/014687、WO 2010/015628、WO 2010/015655、WO 2010/062718、WO 2010/096426、WO 2011/043387、WO 2011/092293、WO 2011/095450、WO 2011/092290以及WO 2011/043381。



[0058] 在另一实施方案中,CRF_1受体拮抗剂为NBI-30775、CP-316,311、培沙舍封(pexacerfont)、emicerfont、SSR-125543[4-(2-氯-4-甲氧基-5-甲基苯基)-N-[(1S)-2-环丙基-1-(3-氟-4-甲基苯基)乙基]-5-甲基-N-(2-丙炔-1-基)-2-噻唑胺]、SSR-126374、ONO-2333、NBI-34041、JNJ-19567470、GSK586529、PF-00572778、CP-376395、安他拉明(N-丁基-N-乙基-2,5,6-三甲基-7-(2,4,6-三甲基苯基)吡咯并[3,2-e]嘧啶-4-胺)和DMP904。

[0059] 在另一实施方案中,CRF_1受体拮抗剂具有超过30分钟的解离半衰期($t_{1/2}$),在另一实施方案中,CRF_1受体拮抗剂具有超过40分钟的解离半衰期($t_{1/2}$),并且在另一实施方案中,CRF_1受体拮抗剂具有超过50分钟的解离半衰期($t_{1/2}$)。具体的CRF_1受体拮抗剂的解离半衰期由实施例3所公开的技术来测定。这些实施方案的代表性CRF_1受体拮抗剂包括化合物I、NBI-30775、NBI-34041、SSR-125543A、安他拉明(N-丁基-N-乙基-2,5,6-三甲基-7-(2,4,6-三甲基苯基)吡咯并[3,2-e]嘧啶-4-胺)和DMP904。





[0060] 关于本文所述的化合物,还应当理解,当特定位置被指定为氢时,该氢(H)可以用氘(D)替代。已知掺入代替氢的氘对所取代的化合物的生理和药理活性产生显著影响。为此,应当理解,氘替代氢意指氘在该位置的丰度基本上大于氘的天然丰度。因此,在一个实施方案中,代表性化合物包括以下化合物。

0427




[0061]

化合物	结构	化学名称
NBI-77860		2,5-二甲基-3-[2-甲基-4-(甲氧基)苯基]-N-[(1S)-1-(3-甲基-1,2,4-噁二唑-5-基)丙基]吡唑并[1,5-a]嘧啶-7-胺
氘化NBI-77860		2,5-二甲基-3-[2-甲基-4-(d_3-甲氧基)苯基]-N-[(1S)-1-(3-甲基-1,2,4-噁二唑-5-基)丙基]吡唑并[1,5-a]嘧啶-7-胺




[0062]

化合物	结构	化学名称
氘化 NBI-77860		2,5-二甲基-3-[2-甲基-4-(甲氧基)苯基]-N-[(1S)-1-(3-d_3-甲基-1,2,4-噁二唑-5-基)丙基]吡唑并[1,5-a]嘧啶-7-胺
氘化 NBI-77860		2,5-二甲基-3-[2-甲基-4-(d_3-甲氧基)苯基]-N-[(1S)-1-(3-d_3-甲基-1,2,4-噁二唑-5-基)丙基]吡唑并[1,5-a]嘧啶-7-胺
氘化 NBI-77860	 R_1-R_{26} 独立地为 H 或者 D	
SSR-125543		4-(2-氯-4-甲氧基-5-甲基苯基)-*N*-[(1*S*)-2-环丙基-1-(3-氟-4-甲基苯基)乙基]-5-甲基-*N*-(2-丙炔-1-基)-2-噻唑胺




[0063]

化合物	结构	化学名称
氘化 SSR-125543	 R_1-R_{37} 独立地为 H 或者 D	
NBI-30775		5-[7-(二丙基氨基)-2,5-二甲基吡唑并[1,5-a]嘧啶-3-基]-N,N,4-三甲基吡啶-2-胺
氘化 NBI-30775	 R_1-R_{32} 独立地为 H 或者 D	




[0064]

化合物	結构	化学名称
NBI-34041		3-(2,4- 二 氯 苯 基)-9-(庚 -4- 基)-6- 甲 基 -1,2,5,9- 四 氮 杂 三 环 [6.3.1.$0^{4,12}$] 十 二 -2,4(12),5,7- 四 烯
氘 化 NBI-34041	 R_1-R_{36} 独立地为 H 或者 D	
培沙舍封		N-[(2R)- 丁 -2- 基]-8-(6- 甲氧基 -2- 甲基吡啶 -3- 基)-2,7- 二甲基吡唑并 [1,5-a][1,3,5] 三 嗪 -4- 胺




[0065]



化合物	結构	化学名称
氘化培沙舍封	 R_1-R_{24} 独立地为 H 或者 D	
CP-316,311		3,6-二甲基-4-(戊-3-基氧基)-2-(2,4,6-三甲基苯氧基)吡啶
氘化 CP-316,311	 R_1-R_{29} 独立地为 H 或者 D	

[0066]

化合物	結构	化学名称
GSK876008		
氘化 GSK876008	 R_1-R_{22} 独立地为 H 或者 D	
CRA5626/R317573		

[0067]

化合物	结构	化学名称
氘化 CRA5626/R317573	 R_1-R_{34} 独立地为 H 或者 D	
ONO2333Ms		10-(2-氯-4-甲氧基苯基)-11-甲基-N-(戊-3-基)-1,8,12-三氮杂三环[7.3.0.$0^{3,7}$]十二-2,7,9,11-四烯-2-胺
氘化 ONO2333	 R_1-R_{27} 独立地为 H 或者 D	

化合物	结构	化学名称
NBI76169		
氘化 NBI76169	 R_1-R_{23}独立地为H或者D	

[0068]

[0069] 在另一实施方案中，任一前述化合物可以掺入稳定的或者放射性同位素。因此，还考虑使用与本文所述的那些相同的同位素标记的化合物，其中用具有与自然界中通常存在的原子质量或者质量数不同的原子质量或者质量数的原子替代一个或者多个原子。可以掺入这些化合物的同位素的实例包括氢、碳、氮、氧、磷、氟和氯的同位素，例如但不限于以上所述的氘(2H)，以及3H、13C、14C、15N、18O、17O、31P、32P、35S、18F和36Cl。某些同位素标记的化合物，例如掺入放射性同位素(例如3H和14C)的那些化合物也可用于药物或者底物组织分布测定。由于容易制备和可检测性，氚化氢(3H)和碳-14(14C)同位素为特别优选的。较重同位素(例如氘(2H))的取代可以由于较高的代谢稳定性而提供某些治疗优势，例如体内半衰期增加或者剂量需求降低，并且因此，在一些情况下，可以是优选的。同位素标记的化合物通常可以通过进行本领域中常规实践的程序来制备。

[0070] 对切除肾上腺的大鼠的血浆ACTH的作用

[0071] 肾上腺切除术消除大鼠中的循环皮质酮(主要的糖皮质激素)，并且去除下丘脑和脑垂体(促肾上腺皮质激素细胞)水平的HPA轴的负反馈控制，因此慢性升高血浆ACTH(参见，例如，Mims等人，J.Natl.Med.Assoc.69:145-47(1977))。已经证明静脉注射肽CRF_1受体拮抗剂将降低切除肾上腺(ADX)的大鼠中的高的血浆ACTH水平(参见，例如，Rivier等人，J.Med.Chem.12:42:3175-82(1999))。小分子NBI-77860(化合物I)重现了这些发现。在切除

肾上腺的大鼠中，化合物I能够有效降低ACTH。ACTH的最大降低与NBI-77860的最大血浆浓度有关；然而，降低ACTH的作用的持续时间超过药物血浆暴露。因此，在切除肾上腺的大鼠中，在口服施用后，NBI-77860的完整血浆暴露量与体内功效之间存在可预测的关系。

[0072] 化合物作为CRF受体拮抗剂的效果可以通过各种测定方法来确定。本文所述的CRF拮抗剂可以能够抑制CRF与其受体的特异性结合，因此拮抗活性与CRF有关。可以通过一种或者多种普遍接受的测定对化合物作为CRF拮抗剂的活性进行评估，所述测定包括实施例中所述的测定。可用于本文所述方法的CRF拮抗剂包括对CRF受体显示亲和性的化合物。

[0073] 不希望受理论束缚，在CAH的治疗中，CRF受体拮抗剂将可能阻止脑垂体促肾上腺皮质激素细胞释放ACTH，从而降低雄激素的产生，并且使皮质醇的替代为更精细的治疗范式。动物和人类研究已经显示化合物I(NBI-77860)对ACTH释放的药理学效应。监测治疗功效时内分泌学家所用的标准生物标志物评估可以用于监测该CRF_1受体拮抗剂的作用。17-OHP、雄烯二酮、睾酮、皮质醇和ACTH的血浆水平以及这些类固醇的尿液代谢物可以在儿童和成人中容易地测量，从而给出关于治疗影响的快速且有意义的数据。

[0074] 治疗的药物组合物和方法

[0075] 本公开内容还提供了用于治疗CAH的方法中的药物组合物，其包含本文所述的任一CRF拮抗剂化合物和药物可接受的赋形剂。药物可接受的赋形剂是生理学上和药学上适宜的无毒且非活性材料或者成分，所述材料或者成分不会干扰活性成分的活性；赋形剂还可以被称为载体。CRF拮抗剂化合物可以配制为药物组合物用于治疗或者防止性(或者预防性)治疗(例如，减少CAH疾病的恶化，或者疾病的一种或者多种症状的发生或者复发)。本文所述的方法和赋形剂是示例性的而非限制。药物可接受的赋形剂在药物领域是众所周知的并且在以下文献中进行了描述，例如，Rowe等人，Handbook of Pharmaceutical Excipients:A Comprehensive Guide to Uses,Properties,and Safety,第5版，2006，以及Remington:The Science and Practice of Pharmacy(Gennaro,第21版，Mack Pub.Co.,Easton,PA(2005))。药物可接受的赋形剂的实例包括无菌盐水以及处于生理学pH的磷酸盐缓冲盐水。可以将防腐剂、稳定剂、染料、缓冲液等提供在药物组合物中。此外，还可以使用抗氧化剂和悬浮剂。

[0076] 治疗和/或预防益处包括，例如改善的临床结果，治疗性治疗和预防性(prophylactic)或防止性(preventative)措施，其中目标是预防或减缓或延迟(减少)不期望的生理变化或病症，或者预防或减缓或延迟(减少)这类病症的扩展或严重性。如本文所讨论的，来自治疗对象的有益的或期望的临床结果包括但不限于减轻、减少或缓解由待治疗的疾病、病况或病症导致的症状或者与待治疗的疾病、病况或病症有关的症状；降低症状的发生率；改善生命质量；较长的无病状态(即，根据症状，进行疾病诊断，降低对象呈现所述症状的可能性或倾向性)；疾病范围的减小；稳定的(即，不恶化)疾病状态；疾病进展的延迟或减缓；疾病状态的改善或减轻；以及缓解(无论是部分还是全部)，无论是可检测的或不可检测的；和/或总存活期。“治疗”还可以意指相比于如果对象不接受治疗的预期生存，延长生存。需要治疗的对象包括已经患有病况或病症的那些，以及易患疾病、病况或病症或处于患有疾病、病况或病症的风险中的对象，以及将预防疾病、病况或病症(即，降低疾病、病症或病况发生的可能性)的那些。对象可以是人或者非人哺乳动物(例如，大鼠、小鼠、狗、猫、家畜、动物园动物)。

0436

[0077] 通常可以使用实验模型和/或临床试验确定最佳剂量。最佳剂量可以取决于对象的身体质量、体重或血容量。通常，本文所述的存在于一个剂量中的化合物的量为约0.1mg至约30mg/kg对象体重。在某些实施方案中，单剂量为约50-1000mg。通常优选使用足以提供有效治疗的最小剂量。通常可以由临床评估以及使用适于治疗或预防病况的测定来监测对象的治疗效果，所述测定是本领域普通技术人员所熟悉的，并且在本文中进行了描述。可以通过测定来自对象的生物流体，例如血液、血液部分(例如血清)和/或尿液和/或其它生物样品中的化合物水平来监测施用于对象的化合物水平。可以使用本领域实践的测定化合物的任何方法来测量治疗方案期间的化合物水平。

[0078] 包括至少一种用于治疗CAH或者相关疾病或者病症的本文所述的化合物的组合物的剂量可以取决于对象的状况，即，疾病的阶段、由疾病引起的症状的严重度、总体健康状态以及年龄、性别和体重以及对医学领域中的技术人员显而易见的其它因素。类似地，化合物的剂量可以根据医学领域的技术人员所理解的参数来确定。

[0079] 可以通过有效递送有效量的化合物的若干途径中的任一种，将包含至少一种本文所述的CRF_1拮抗剂化合物的本文所述的药物组合物施用于需要的对象。此类施用途径包括，例如，口服、肠胃外、肠内、直肠、鼻内、颊部、舌下、肌肉内和经皮。本文更详细地描述了通过这些施用途径和其它施用途径施用的组合物。

[0080] 所公开的化合物或者组合物的施用包括夜间施用或者睡前施用(即，临睡前施用)。如本文所用，临睡前施用是指旨在预期的生理节律释放ACTH之时或者之前(例如2-5小时前)递送临床相关浓度的CRF_1拮抗剂的给药。由于该ACTH释放通常在凌晨1-2点进行，并且因为大多数口服施用的药物具有数个小时的Tmax，所以期望例如在晚上10点给药，这比预期的生理节律释放ACTH提前3-4小时。这种相同的预脉冲临睡前给药可以适于轮班工人(例如，夜晚工作白天睡觉的那些工人)，在这种情况下，不一定在夜间进行施用。因此，施用取决于预期的生理节律释放ACTH并且可以根据个体(即，对象、患者)的具体工作和睡眠类型来变化。在某些实施方案中，将本文所述的CRF_1受体拮抗剂(例如，NBI-77860，或者NBI-30775、NBI-34041、SSR-126374、SSR-125543、安他拉明(N-丁基-N-乙基-2,5,6-三甲基-7-(2,4,6-三甲基苯基)吡咯并[3,2-c]嘧啶-4-胺)或者DMP904中的任一种)在预期的生理节律释放ACTH前(即，之前、提前)约2-5小时进行施用。在其它实施方案中，将CRF_1受体拮抗剂在预期的生理节律释放ACTH前约2-4小时或者3-5小时施用于对象。在更具体的实施方案中，将CRF_1受体拮抗剂在预期的生理节律释放ACTH前约3-4小时施用于对象。

[0081] 本文还提供通过施用CRF_1受体拮抗剂降低患有CAH的对象(即，患者、个体)的17-OHP和/或ACTH水平的方法。在某些实施方案中，在预期的生理节律释放ACTH之时或者之前施用拮抗剂。在其它某些实施方案中，在预期的生理节律释放ACTH之前约2-4小时或者约3-5小时施用CRF_1受体拮抗剂。在更具体的实施方案中，将CRF_1受体拮抗剂在预期的生理节律释放ACTH之前约3-4小时施用于对象。

[0082] 本文所述的方法可以导致雄激素(例如睾酮和雄烯二酮)的释放减少，所述方法包括将CRF_1受体拮抗剂以本文所述的方式施用于有需要的女性对象，所述方式引起对象的ACTH和17-OHP水平降低。糖皮质激素的剂量可以通过临床上显著的量伴随降低，这继而导致副作用减少。

[0083] 用于维持患有CAH且年青和正发育的患者的治疗以及用于维持发育完全的患者的

0437

治疗的糖皮质激素(GC)和盐皮质激素(MC)的量对于本领域技术人员是已知的。例如,指南描述于Speiser等人(J.Clin.Endocrinol.Metab.95:4133-60(2010)中,通过引用整体并入)中,并且显示在其中的表1和表2中。特别地,对于年青、正发育的CAH患者,本领域技术人员应理解,太高的GC给药可以阻止患者的身高生长。因此,本文所述的用CRF_1受体拮抗剂治疗患者的方法可以包括以临床上显著的方式降低GC的剂量。

[0084] 在某些实施方案中,通过施用CRF_1受体拮抗剂治疗CAH的方法还可以包括以低于治疗患有CAH的对象的目前推荐的GC剂量的剂量施用GC。当对象为发育完全的患者时,GC剂量(例如为了维持治疗发育完全的对象所推荐的氢化可的松(HC)、强的松、泼尼松龙、地塞米松或者氟氢可的松的剂量)可以从以下推荐剂量降低约10%、15%、20%、30%、40%、50%、60%或者更多:15-25mg/天HC;5-7.5mg/天强的松,4-6mg/天泼尼松龙;0.25-0.5mg/天地塞米松或者0.05-0.2mg/天氟氢可的松。在正在发育的CAH患者的对象中,GC(例如HC)的推荐剂量可以在接受如本文所述的CRF_1受体拮抗剂的对象中从10-15mg/m^2/天的总推荐剂量降低和/或0.05-0.2mg/天的氟氢可的松的总剂量可以在接受如本文所述的CRF_1受体拮抗剂的对象中各自降低约10%、15%、20%、30%、40%、50%、60%或者更多。在实施方案中,相对于安慰剂,本文所述的方法导致ACTH水平在临床上显著降低,所述方法包括向有需要的对象施用有效量的CRF_1拮抗剂。在具体的实施方案中,相对于安慰剂,向有需要的对象施用有效量的CRF_1拮抗剂导致ACTH水平在临床上显著降低,其中所述降低为至少25%。在另一实施方案中,相对于安慰剂,向有需要的对象施用有效量的CRF_1拮抗剂导致ACTH水平在临床上显著降低,其中所述降低为至少50%。关于施用糖皮质激素和盐皮质激素的指南,参见Speiser等人,同上。

[0085] 在另一实施方案中,相对于安慰剂,本文所述的方法导致17-OHP水平在临床上显著降低,所述方法包括向有需要的对象施用有效量的CRF_1拮抗剂。在另一具体实施方案中,相对于安慰剂,向有需要的对象施用有效量的CRF_1拮抗剂导致17-OHP水平在临床上显著降低,其中所述降低为至少25%。在另一实施方案中,相对于安慰剂,向有需要的对象施用有效量的CRF_1拮抗剂导致17-OHP水平在临床上显著降低,其中所述降低为至少50%。

[0086] 在实施方案中,相对于安慰剂,本文所述的方法导致ACTH和17-OHP水平在临床上都显著降低,所述方法包括向有需要的对象施用有效量的CRF_1拮抗剂。在某些实施方案中,相对于安慰剂,向有需要的对象施用有效量的CRF_1拮抗剂导致ACTH和17-OHP水平在临床上都显著降低,其中所述降低为至少25%。在另一具体实施方案中,相对于安慰剂,向有需要的对象施用有效量的CRF_1拮抗剂导致ACTH和17-OHP水平在临床上都显著降低,其中所述降低为至少50%。

[0087] 药物组合物可以是溶液的形式。可选地,它们可以是固体的形式,例如粉末、片剂等。包含本文所述的任一化合物的组合物可以配制用于持续释放或者缓慢释放。此类组合物通常可以使用众所周知的技术来制备以及通过例如口服、直肠或者皮下植入或者通过在所期望的靶位点植入来施用。持续释放制剂可以包含分散在载体基质中和/或包含在由速率控制膜包围的储器内的化合物。用于此类制剂中的赋形剂是生物相容的,并且还可以是生物可降解的;优选地,制剂提供相对恒定水平的活性组分释放。包含在持续释放制剂中的活性化合物的量取决于植入位点、释放速率和预期持续时间、以及待治疗或者预防的病况的性质。

0438

[0088] 对于口服制剂，至少一种本文所述的化合物可以单独使用或者与适当的添加剂组合使用以制备片剂、粉末、粒剂或者胶囊，所述适当的添加剂例如常规添加剂，例如乳糖、甘露醇、玉米淀粉或者马铃薯淀粉；粘合剂；崩解剂；润滑剂；并且如果需要，稀释剂、缓冲剂、湿润剂、防腐剂、着色剂和调味剂。化合物可以与缓冲剂配制来为化合物提供免受胃部环境和/或肠溶衣的低pH的保护。包含在组合物中的化合物可以与调味剂(例如在液体、固体或者半固体制剂中)和/或肠溶衣配制用于口服递送。口服制剂可以以明胶胶囊提供，所述明胶胶囊可以包含活性化合物以及粉末状载体，例如乳糖、淀粉、纤维素衍生物、硬脂酸镁、硬脂酸等。类似的载体和稀释剂可以用于制备压缩片剂。

实施例

[0089] 实施例1

[0090] CRF受体结合活性

[0091] 可以通过如Grigoriadis等人(参见，例如，Mol.Pharmacol第50卷，第679-686页，1996)和Hoare等人(参见，例如，Mol.Pharmacol 63:751-765,2003)中通常所述的标准放射性配体结合测定，评价本文所述的方法中使用的CRF拮抗剂对于CRF受体的结合活性。通过使用放射性标记的CRF配体，可以将测定用于评价本文所述的化合物与任何CRF受体亚型的结合活性。

[0092] 简而言之，结合测定涉及从CRF受体置换放射性标记的CRF配体。更具体地，使用来自人CRF受体稳定转染的细胞的1-10μg细胞膜在96孔测定板中进行结合测定。各孔接收包含目标化合物或者参考配体(例如，蛙皮降压肽、尿皮素I或者CRF)的约0.05mL测定缓冲液(例如，Dulbecco磷酸盐缓冲盐水、10mM氯化镁、2mM EGTA)、0.05mL[^{125}I]酪氨酸-蛙皮降压肽(最终浓度～150pM或者K_D大约如通过斯卡查德分析测定)以及包含CRF受体的0.1mL细胞膜悬浮液。将混合物在22℃孵育2小时，然后通过经玻璃纤维过滤器快速过滤以使结合的放射性配体与游离的放射性配体分离。在三次洗涤后，干燥过滤器并且使用闪烁计数器计算放射性(来自^{125}I的俄歇电子)。可以使用非线性最小二乘曲线拟合程序Prism(GraphPad Software Inc)或者XLfit(ID Business Solutions Ltd)分析所有的放射性配体结合数据。

[0093] 实施例2

[0094] CRF_1受体激动剂活性

[0095] 如Fleck等人(J.Pharmacology and Experimental Therapeutics,341(2):518-531,2012)(以下为"Fleck等人"并且通过引用整体并入)所报道，呈现了先前所鉴定的CRF_1受体拮抗剂的活性。此类活性被报道为由缔合速率常数(k_1)和解离速率常数(k_{-1})通过以下等式计算的动力学推导的亲和力(K_i)：

[0096] $K_i = k_{-1}/k_1$

[0097] 此外，如Fleck等人所报道，已经报道列于下表1中的CRF_1受体拮抗剂的动力学K_i。

[0098] 表1

[0099] 代表性CRF_1受体拮抗剂

0439

[0100]

配体	k_1 ($10^6M^{-1}min^{-1}$)	动力学 K_i (nM)
NBI-27914	9.4 ± 3	25
CP-316,311	13 ± 2	12
NBI-46200	6.2 ± 2	22

[0101]

配体	k_1 ($10^6M^{-1}min^{-1}$)	动力学 K_i (nM)
DMP696	7.7 ± 2	9.5
培沙舍封	2.6 ± 0.1	19
NBI-35965	20 ± 2	2.3
ONO-2333Ms	4.4 ± 2.2	15
安他拉明	3.4 ± 0.6	3.9
NBI-34041	8.3 ± 2.0	1.7
DMP904	18 ± 1	0.38
NBI-30775	14 ± 2.0	0.36
SSR125543A	33 ± 5	0.049

[0102] 通过这种相同的技术，发现化合物I(NBI-77860)的动力学Ki如下：

[0103] 表1(续)

[0104]

配体	k_1 ($10^6M^{-1}min^{-1}$)	动力学 Ki (nM)
NBI-77860	0.24 ± 0.05	48 ± 9

[0105] 实施例3

[0106] CRF_1受体拮抗剂的解离半衰期($T_{1/2}$)

[0107] 如用于本文所述的方法中的CRF_1受体拮抗剂的解离半衰期($t_{1/2}$)通过Flock等人所述的技术来评价。如于其中所述的，将标记和未标记配体的解离速率常数表示为k_1，而来自受体的药物解离半衰期($t_{1/2}$)(其与中值停留时间相等)由解离速率常数(k_{-1})通过以下等式来计算：

[0108] $t_{1/2}=0.693/k_{-1}$

[0109] 如Fleck等人所报道，已经报道列于下表2中的CRF_1受体拮抗剂的解离半衰期

($t_{1/2}$)。

[0110] 表2

[0111] 代表性化合物的解离半衰期

[0112]

配体	k_{-1} (min^{-1})	解离 $t_{1/2}$ (min)
NBI 27914	0.27 ± 0.07	2.6
CP-316,311	0.17 ± 0.04	4.1
NBI-46200	0.13 ± 0.002	5.3
DMP696	0.095 ± 0.02	7.3
培沙舍封	0.049 ± 0.001	14
NBI-35965	0.048 ± 0.005	16
ONO-2333Ms	0.063 ± 0.029	17
安他拉明	0.013 ± 0.002	53
NBI-34041	0.013 ± 0.002	53
DMP904	0.0072 ± 0.002	96
NBI-30775	0.0054± 0.0006	130
SSR125543A	0.0016± 0.0003	430

[0113] 通过这种相同的技术，发现化合物1(NBI-77860)的解离半衰期如下。

[0114] 表2(续)

[0115]

配体	k_{-1}, min^{-1}	解离 $t_{1/2}$, min
NBI-77860	0.012 ± 0.0003	58

[0116] 因此，具有超过30分钟的解离半衰期($t_{1/2}$)的CRF_1受体拮抗剂包括(但不限于)安他拉明、NBI-34041、DMP904、NBI-30775、SSR125543A和NBI-77860(化合物I)。这些相同的化合物也代表具有超过40分钟的解离半衰期($t_{1/2}$)以及超过50分钟的解离半衰期($t_{1/2}$)的CRF_1受体拮抗剂。

[0117] 实施例4

[0118] 切除肾上腺的大鼠的ACTH的降低

[0119] 化合物I(NBI-77860)(参见，例如，Tellew等人，Bioorg.Med.Chem.Lett.2010,20:7259;WO2006044958)是有效的CRF_1拮抗剂，其拥有的结合pKi为8.2、动力学Ki为49nM(以上

表1)以及解离$t_{1/2}$为58分钟(以上表2)。

[0120] 已经证明静脉注射肽CRF_1受体拮抗剂将降低切除肾上腺(ADX)的大鼠的高的血浆ACTH水平(参见,例如,Rivier等人,J.Med.Chem.12:42:3175-82(1999))。小分子NBI-77860重现了这些发现。当口服施用于ADX大鼠(n=6只/组)时,30mg/kg单剂量的NBI-77860显著降低血浆ACTH水平保持长达5小时(参见图2)。功效的持续时间与最大血浆浓度相关,时间进程超过药物血浆暴露。在切除肾上腺的大鼠中,在口服施用后,NBI-77860的完整血浆暴露量与体内功效之间存在可预测的关系。

[0121] Fleck等人还报道了解离半衰期不同的CRF_1受体拮抗剂对切除肾上腺的大鼠的血浆ACTH水平的影响;即,NBI 30775、NBI 34041和NBI 35965。在最大剂量(10mg/kg)时,全部三种配体剧烈降低ACTH(注射1小时后,图3A-图3C)。在较长的持续时间后,在NBI 35965与其它两种配体之间出现了明显的差别。对于NBI 35965而言,ACTH水平经2小时恢复至媒介物水平(图3C),然而对于NBI 30775和NBI 34041而言,反应持续4-6小时。

[0122] 实施例5

[0123] 化合物I在人中的药效动力学作用

[0124] 在本研究中,通过观察相对于安慰剂以及单剂量的阿普唑仑(0.75mg),单次口服剂量的NBI-77860(化合物I)对由甲吡酮(0.04g/kg)产生的HPA轴反应的作用来评价NBI-77860(化合物I)对人类对象的药效动力学作用。甲吡酮阻断肾上腺中皮质醇的合成,由此模拟CAH的皮质醇缺乏,并且与急剧折转升高的ACTH水平有关。

[0125] 通过在给药后30min至4h测定ACTH值(AUC(30min至4h))进行主要分析。在该分析中,当与安慰剂比较时,进行了以下观察。使用400mg阿普唑仑和400mg NBI-77860治疗,观察到ACTH AUC(30min至4h)显著降低。使用50mg NBI-77860治疗,观察到ACTH AUC(30min至4h)的非显著降低。使用10mg NBI-77860治疗,观察到AUC(30min至4h)增加。

[0126] 在给药后2h至4h(暴露达到C_{max}值时的时间)对ACTH值(AUC(2h至4h))进行的分析中,相对于安慰剂治疗期间,ACTH水平在400mg和50mg NBI-77860治疗期间存在显著降低;然而,在使用10mg剂量NBI-77860的情况下,未观察到降低。

[0127] 实施例6

[0128] 临床研究

[0129] 在本研究中,在标题为"评价NBI-77860在患有先天性肾上腺增生的成年女性中的安全性和耐受性的1期、单盲、安慰剂对照的、固定顺序、单剂量研究(A Phase 1,Single-Blind,Placebo-Controlled,Fixed-Sequence,Single-Dose Study to Evaluate the Safety and To Tolerability of NBI-77860 in Adult Females with Congenital Adrenal Hyperplasia)"(IND 117,388)的临床研究中评价NBI-77860(化合物I)。该研究在典型的成年女性CAH患者中为单盲、安慰剂对照的、单中心、固定顺序的单剂量临床试验。其被设计为评估NBI-77860的安全性、耐受性和血浆暴露,以及该化合物对HPA轴激素的内源性水平的影响。

[0130] 总共8名女性对象(年龄为19至58岁,医学诊断为患有典型的21-羟化酶缺乏CAH)在三个单独治疗期间被施用单次临睡前剂量(hs)为300mg、600mg的NBI-77860以及安慰剂(参见图4中的研究设计示意图)。对象的同时留体治疗的常规早晨给药被延迟,直至给药后16小时之后,收集血液样品(即,直到约1400h)。

0442

[0131] 本研究的PD端点包括该患者人群中的目标HPA轴生物标志物；即，17-羟孕酮(17-OHP；作为主要的PD端点)、促肾上腺皮质激素(ACTH)、雄烯二酮、睾酮和血清皮质醇水平。PD变量的初始分析为检查各生物标志物的分组对象数据，所述数据被表示为相对于安慰剂条件，来自两种活性给药条件的给药前水平的平均变化百分比。图5提供了在给药后整个24小时期间的17-OHP和ACTH的平均水平的数据。

[0132] 相对于安慰剂，在这些CAH患者中施用NBI-77860后，在给药后的整个时期观察来自17-OHP和ACTH的给药前水平的一致性和临床上有意义的降低。除了群组平均数据之外，评价了个体反应并且治疗“应答者”被保守地定义为在早晨峰值期间活性NBI-77860相对于安慰剂的情况下，17-OHP和ACTH至少降低50％的那些对象。在研究中，该应答者分析产生相当大的50％的应答者比率(在初始的安慰剂治疗期间，这些对象中没有应答者)。此外，300mg剂量对17-OHP和ACTH产生与600mg剂量几乎相同的作用。图6提供了单个对象对这些生物标志物反应的实例。

[0133] 可以组合以上所述的各种实施方案以提供其它实施方案。本说明书中提及的和/或应用数据表中列出的所有美国专利、美国专利申请公开、美国专利申请、外国专利、外国专利申请和非专利公开，包括2014年1月21日提交的美国临时申请序列号61,929,941、2014年4月17日提交的美国临时申请序列号61,981,033、2014年10月27日提交的美国临时申请序列号62/069,155，通过引用整体并入本文。如果需要采用各种专利、申请和公开的理念以提供其它实施方案，可以修改实施方案的方面。

[0134] 可以根据以上详细描述对实施方案进行这些和其它变化。通常，在以下权利要求中，使用的术语不应解释为将权利要求限制于本说明书和权利要求公开的具体实施方案中，而是应解释为包括所有可能的实施方案以及该权利要求书所享有的等同物的全部范围。因此，权利要求不受公开内容的限制。



下丘脑
CRF
脑垂体
ACTH
肾上腺
胆固醇
刺激胆固醇进
送至线粒体
增加胆固醇的
生物利用度
95%的
CAH
孕烯醇酮
孕酮
17-OH
孕烯醇酮
17-OH孕酮
DHEA
雄烯二酮
21-a-羟化酶
脱氧皮质酮
脱氧皮质醇
11-b-羟化酶
皮质酮
皮质醇
睾酮
雌激素

图1



ACTH (pg / ml)
2000
1800
1600
1400
1200
1000
800
600
400
200
0
媒介物
NBI 77860 (30 mg/kg)
0
1
2
3
4
5
口服给药后的小时数

图2



给药NBI 30775
0
1 mg/kg
10 mg/kg
ACTH/0小时的ACTH (%)
200
175
150
125
100
75
50
25
0
0
1
2
3
4
5
6
时间(hr)

图3A



ACTH/0小时的ACTH (%)
200
175
150
125
100
75
50
25
0
0
1
2
3
4
5
6
时间(hr)
给药NBI 34041
0
1 mg/kg
10 mg/kg

图3B



ACTH/0小时的ACTH (%)
200
175
150
125
100
75
50
25
0
0
1
2
3
4
5
6
时间(hr)
给药NBI 35965
0
1 mg/kg
10 mg/kg

图3C




筛选期
随访期
单盲期
治疗期1
治疗期2
治疗期3
第-21天至第-1天
第1夜至第2天
第1夜至第2天
第1夜至第2天
安慰剂
NBI-77860 300mg
NBI-77860 600mg
21-天
(+3天窗口期)
无药物间隔
21-天
(+3天窗口期)
无药物间隔
5周
(+7天窗口期)
最终
研究访问

图4


17-OHP:所有对象(N=8)
2000
1500
1000
500
0
-500
从基线的变化%
安慰剂
300 mg
600 mg
给药前
1hr
2hr
3hr
4hr
6hr
8hr
10hr
12hr
14hr
16hr
20hr
24hr



ACTH:所有对象(N=8)
3500
3000
2500
2000
1500
1000
500
0
-500
从基线的变化%
安慰剂
300 mg
600 mg
给药前
1hr
2hr
3hr
4hr
6hr
8hr
10hr
12hr
14hr
16hr
20hr
24hr

图5



17-OHP-对象1003
浓度(ng/dL)
9000
8000
7000
6000
5000
4000
3000
2000
1000
0
安慰剂
300 mg
600 mg
给药前
1hr
2hr
3hr
4hr
6hr
8hr
10hr
12hr
14hr
16hr
20hr
24hr
ACTH-对象1003
浓度(ng/dL)
600
500
400
300
200
100
0
安慰剂
300 mg
600 mg
给药前
1hr
2hr
3hr
4hr
6hr
8hr
10hr
12hr
14hr
16hr
20hr
24hr

图6

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 February 2019 (21.02.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/036472 A1

(51) International Patent Classification:
C07D 471/04 (2006.01)

(21) International Application Number:
PCT/US2018/046707

(22) International Filing Date:
14 August 2018 (14.08.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/545,393 14 August 2017 (14.08.2017) US

(71) Applicant: **SPRUCE BIOSCIENCES, INC.** [US/US]; 548 Market Street, Suite 74589, San Francisco, CA 94105 (US).

(72) Inventors: **HOWERTON, Alexis**; 548 Market Street, Suite 74589, San Francisco, CA 94105 (US). **GERBER, Hal**; 548 Market Street, Suite 74589, San Francisco, CA 94105 (US). **KARABORNI, Sami**; 548 Market Street, Suite 74589, San Francisco, CA 94105 (US).

(74) Agent: **DELANEY, Simren**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS




FIG. 2

(57) Abstract: The present invention provides novel pharmaceutical compositions comprising 3-(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5- a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).

[Continued on next page]

WO 2019/036472 A1

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS

CROSS-REFERENCE

[0001] This patent application claims the benefit of U.S. Provisional Patent Application No. 62/545,393, filed August 14, 2017, which is incorporated herein by reference in its entirety.


BACKGROUND OF THE INVENTION

[0002] Corticotropin releasing factor (CRF) is a 41 amino acid peptide that is the primary physiological regulator of proopiomelanocortin (POMC) derived peptide secretion from the anterior pituitary gland. In addition to its endocrine role at the pituitary gland, immunohistochemical localization of CRF has demonstrated that the hormone has a broad extrahypothalamic distribution in the central nervous system and produces a wide spectrum of autonomic, electrophysiological and behavioral effects consistent with a neurotransmitter or neuromodulator role in the brain. There is also evidence that CRF plays a significant role in integrating the response in the immune system to physiological, psychological, and immunological stressors.

SUMMARY OF THE INVENTION

[0003] The present invention provides novel pharmaceutical compositions comprising 3-(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods using such pharmaceutical compositions for treating congenital adrenal hyperplasia (CAH).

[0004] In one aspect, the present disclosure provides a pharmaceutical composition in the form of a capsule comprising Compound 1:



or a pharmaceutically acceptable salt or solvate thereof.

[0005] In one embodiment, the pharmaceutical composition comprises between about 1 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises between about 5 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment the pharmaceutical composition comprises between about 10 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical

composition comprises between about 10 mg and about 300 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises between about 10 mg and about 100 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

[0006] In one embodiment, the pharmaceutical composition comprises between about 50 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises between about 100 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises between about 100 mg and about 400 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises between about 100 mg and about 300 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises between about 150 mg and about 250 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

[0007] In one embodiment, the pharmaceutical composition comprises about 400 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises about 300 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises about 250 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises about 200 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises about 150 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises about 100 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises about 80 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises about 60 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises about 50 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises about 30 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.


[0008] In one embodiment, Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is in the form of microparticles. In one embodiment, the average size of the microparticles is between about 1 μm and about 20 μm. In one embodiment, the average size of

the microparticles is between about 5 μm and about 15 μm. In one embodiment, the average size of the microparticles is less than about 10 μm.

[0009] In one embodiment, the capsule is a hard gelatin capsule. In one embodiment, the capsule is a soft gelatin capsule. In one embodiment, the capsule is formed using materials selected from the group consisting of natural gelatin, synthetic gelatin, pectin, casein, collagen, protein, modified starch, polyvinylpyrrolidone, acrylic polymers, cellulose derivatives, and any combinations thereof.

[0010] In one embodiment, the pharmaceutical composition is free of additional excipients. In one embodiment, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.

[0011] In one aspect, the present disclosure provides a pharmaceutical composition in the form of a tablet comprising Compound 1:



or a pharmaceutically acceptable salt or solvate thereof.

[0012] In one embodiment, the pharmaceutical composition comprises between about 1 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises between about 5 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises between about 10 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises between about 10 mg and about 300 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises between about 10 mg and about 100 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

[0013] In one embodiment, the pharmaceutical composition comprises between about 50 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises between about 100 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises between about 100 mg and about 400 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises between about 100 mg and about 300

mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises between about 150 mg and about 250 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

[0014] In one embodiment, the pharmaceutical composition comprises about 400 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises about 300 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises about 250 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises about 200 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises about 150 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises about 100 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises about 80 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises about 60 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises about 50 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical composition comprises about 30 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

[0015] In one embodiment, Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is in the form of microparticles. In one embodiment, the average size of the microparticles is between about 1 μm and about 20 μm. In one embodiment, the average size of the microparticles is between about 5 μm and about 15 μm. In one embodiment, the average size of the microparticles is less than about 10 μm.

[0016] In one embodiment, the tablet is made by compression, molding, or extrusion. In one embodiment, he tablet is made by hot-melt extrusion. In one embodiment, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.

[0017] In one embodiment, the pharmaceutical composition is stable for at least 1 month at 25 °C. In one embodiment, the pharmaceutical composition is stable for at least 3 months at 25 °C. In one embodiment, the pharmaceutical composition is stable for at least 6 months at 25 °C. In one embodiment, the pharmaceutical composition is stable for at least 9 months at 25 °C. In one embodiment, the pharmaceutical composition is stable for at least 12 months at 25 °C.

INCORPORATION BY REFERENCE

[0018] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

[0019] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

[0020] FIG. 1 shows Compound 1 in patients with CAH following 14-days of once daily dosing at each level;

[0021] FIG. 2 demonstrates the attenuation of ACTH across different subjects due to the administration of Compound 1;

[0022] FIG. 3 demonstrates the reduction in 17-OHP due to the administration of Compound 1;

[0023] FIG. 4 demonstrates the reduction of Androstenedione due to the administration of Compound 1;

[0024] FIG. 5 demonstrates the percentage release of Manufacturing Formulae A-1, A-2 and A-3 in 0.1N HCL + 1.0% SDS, media at 50 rpm and 900 mL using USP-II (Paddle);

[0025] FIG. 6 demonstrates the percentage release of Manufacturing Formulae B-1, B-2 and B-3 in 0.1N HCL + 1.0% SDS, media at 50 rpm and 900 mL using USP-II (Paddle); and

[0026] FIG. 7 demonstrates the percentage release of Manufacturing Formulae C-1, C-2 and C-3 in 0.1N HCL + 1.0% SDS, media at 50 rpm and 900 mL using USP-II (Paddle).

DETAILED DESCRIPTION OF THE INVENTION

[0027] CRF has been implicated in psychiatric disorders and neurological diseases including depression and anxiety, as well as the following: Alzheimer's disease, Huntington's disease, progressive supranuclear palsy, amyotrophic lateral sclerosis, Parkinson's disease, epilepsy, migraine, alcohol and substance abuse and associated withdrawal symptoms, obesity, metabolic syndrome, congenital adrenal hyperplasia (CAH), Cushing's disease, hypertension, stroke, irritable bowel syndrome, stress-induced gastric ulceration, premenstrual syndrome, sexual dysfunction, premature labor, inflammatory disorders, allergies, multiple sclerosis, visceral pain, sleep disorders, pituitary tumors or ectopic pituitary derived tumors, chronic fatigue syndrome, and fibromyalgia.

[0028] CRF receptor subtypes, CRF1 and CRF2, have been identified and are distributed heterogeneously within the brain thereby suggesting potential functional diversity. For example, widely distributed brain CRF1 receptors are strongly implicated in emotionality accompanying exposure to environmental stressors. Significantly, CRF1, not CRF2, receptors appear to mediate select anxiogenic like behaviors. A more discrete septallhypothalmic distribution and the availability of alternative endogenous ligands suggest a different functional role for the CRF2 receptor. For example, a novel CRF-family neuropeptide with preferential affinity for CRF2 relative to CRF 1 receptors is reported to suppress appetite without producing the profile of behavioral activation observed with selective CRF1 agonism. In other cases, CRF2 agonism produces similar effects to those reported for CRF 1 antagonists or CRF 1 gene deletion. For example, while CRF2 agonists have been proposed as antiobesity agents, CRF1 antagonists may be an important treatment for obesity as well.

[0029] Treatment of CAH is based on normalization of hormone and steroid levels using a variety of medications from diagnosis in infancy through adulthood. Glucocorticoids are the current standard treatment in CAH and are used both to correct the endogenous Cortisol deficiency and for reducing the elevated ACTH levels from the pituitary, which drives increased androgen production. Unlike the treatment of Addison's disease (adrenal insufficiency), in which Cortisol replacement is sufficient, the treatment of CAH must also reduce ACTH production, to control the subsequent androgen excess as well. Thus, the goals of glucocorticoid treatment include Cortisol replacement and suppression of ACTH to prevent virilization and menstrual disturbances in women. Mineralocorticoid replacement is needed to achieve normal plasma renin activity for maintenance of regular blood pressure, electrolyte balance, and volume status in those patients with the salt-wasting form of CAH.

[0030] The regimen of glucocorticoid treatment must support normal physiology and also ensure that sufficient Cortisol is available during events that may elicit a strong stress response (e.g., intercurrent illness, exercise, hypotension). Careful monitoring is also necessary to avoid the development of Addisonian syndrome due to under-treatment. Overtreatment with mineralocorticoids may cause hypertension while under-treatment may lead to low blood pressure, salt loss, fatigue and increased requirements for glucocorticoids. Typical laboratory tests for monitoring treatment efficacy include measurement of plasma concentrations of 17-OHP, androstenedione, testosterone, renin activity, and electrolytes.

[0031] Adult patients with CAH have an increased prevalence of risk factors for cardiovascular disease including obesity, hypertension, and insulin resistance. A study of a large cohort of pediatric and adult CAH patients (n=244) demonstrated that patients are prescribed a variety of glucocorticoid treatment regimens yet frequently suffer from poor hormonal control and the

aforementioned adverse outcomes. Treatment of CAH includes efforts to normalize the Cortisol deficiency with glucocorticoids (usually hydrocortisone in children but often more potent agents with narrow therapeutic indices, such as dexamethasone, in adults) and, if necessary for salt-wasting, mineralocorticoids (usually fludrocortisone). The glucocorticoid doses required to achieve sufficient suppression of excess androgens, however, are usually well above the normal physiologic dose used for Cortisol replacement alone as in patients with Addison's disease. This increased exposure to glucocorticoids can lead to increased cardiovascular risk factors, glucose intolerance, and decreased bone mineral density in CAH patients.

[0032] CRF is believed to be the major physiological regulator of the basal and stress-induced release of adrenocorticotropic hormone ("ACTH"), β-endorphin, and other proopiomelanocortin ("POMC")-derived peptides from the anterior pituitary. Secretion of CRF causes release of ACTH from corticotrophs in the anterior pituitary via binding to the CRF_1 receptor, a member of the class B family of G-protein coupled receptors.

[0033] Due to the physiological significance of CRF_1, the development of biologically-active small molecules having significant CRF receptor binding activity and which are capable of antagonizing the CRF_1 receptor remains a desirable goal and has been the subject of ongoing research and development for the treatment of anxiety, depression, irritable bowel syndrome, post-traumatic stress disorder, and substance abuse.

[0034] The pituitary hormone ACTH, under the control of hypothalamic corticotropin-releasing factor (CRF), stimulates uptake of cholesterol and drives the synthesis of pregnenolone initiating steroidogenesis in the adrenal gland. The adrenal cortex is comprised of three zones, which produce distinct classes of hormones many of which are driven by ACTH mobilizing cholesterol through this pathway. Deficiencies in these enzymes as a result of mutation or deletion cause the substrate concentrations to increase. In the most common form of CAH resulting from mutations or deletions in the 21 -hydroxylase gene (CYP21A2), potent androgens are produced by the adrenal because of the accumulation of the steroid precursors, progesterone and 17-hydroxyprogesterone (17-OHP). Plasma levels of 17-OHP can reach 10-1000 times the normal concentration in these cases. These increases result in the overproduction of androgens, specifically androstenedione, testosterone, and dihydroxytestosterone causing virilization in females. In addition, 21 -hydroxylase deficiency in CAH causes insufficient biosynthesis of glucocorticoids and mineralocorticoids, specifically Cortisol and aldosterone. Cortisol is a critical negative feedback regulator of hypothalamic CRF secretion and pituitary ACTH release. The lack of glucocorticoid synthesis and release eliminates the restraint on the hypothalamus and pituitary, which causes ACTH levels to increase. The excessive ACTH stimulation causes hypertrophy of the zona fasciculata and zona reticularis resulting in adrenal hyperplasia.

[0035] In one embodiment, the CRF receptor antagonist useful for the treatment of CAH is 3-(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine.

Certain Definitions

[0036] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments described herein, certain preferred methods, devices, and materials are now described.

[0037] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "an excipient" is a reference to one or more excipients and equivalents thereof known to those skilled in the art, and so forth.

[0038] The term "about" is used to indicate that a value includes the standard level of error for the device or method being employed to determine the value.

[0039] The use of the term "or" in the claims is used to mean "and/or" unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and to "and/or."

[0040] The terms "comprise," "have" and "include" are open-ended linking verbs. Any forms or tenses of one or more of these verbs, such as "comprises," "comprising," "has," "having," "includes" and "including," are also open-ended. For example, any method that "comprises," "has" or "includes" one or more steps is not limited to possessing only those one or more steps and also covers other unlisted steps.

[0041] "Administering" when used in conjunction with a therapeutic means to administer a therapeutic systemically or locally, as directly into or onto a target tissue, or to administer a therapeutic to a patient whereby the therapeutic positively impacts the tissue to which it is targeted. "Administering" a pharmaceutical composition may be accomplished by injection, topical administration, and oral administration or by other methods alone or in combination with other known techniques.

[0042] By "pharmaceutically acceptable", it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the composition and not deleterious to the recipient thereof.

[0043] The term "pharmaceutical composition" means a composition comprising at least one active ingredient, such as Compound 1, whereby the composition is amenable to investigation for a specified, efficacious outcome in a mammal (for example, without limitation, a human). Those of ordinary skill in the art will understand and appreciate the techniques appropriate for

determining whether an active ingredient has a desired efficacious outcome based upon the needs of the artisan.

[0044] The term "supraphysiologic" amount" describes hormones levels that are elevated compared to average levels found in healthy individuals.

[0045] The term "physiologic amount" describes average hormone levels found in healthy individuals.


[0046] A "therapeutically effective amount" or "effective amount" as used herein refers to the amount of active compound or pharmaceutical agent that elicits a biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes one or more of the following: (1) preventing the disease; for example, preventing a disease, condition or disorder in an individual that may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease, (2) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology), and (3) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology).

[0047] The terms "treat," "treated," "treatment," or "treating" as used herein refers to both therapeutic treatment in some embodiments and prophylactic or preventative measures in other embodiments, wherein the object is to prevent or slow (lessen) an undesired physiological condition, disorder or disease, or to obtain beneficial or desired clinical results. For the purposes described herein, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of the extent of the condition, disorder or disease; stabilization (i.e., not worsening) of the state of the condition, disorder or disease; delay in onset or slowing of the progression of the condition, disorder or disease; amelioration of the condition, disorder or disease state; and remission (whether partial or total), whether detectable or undetectable, or enhancement or improvement of the condition, disorder or disease. Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment. A prophylactic benefit of treatment includes prevention of a condition, retarding the progress of a condition, stabilization of a condition, or decreasing the likelihood of occurrence of a condition. As used herein, "treat," "treated," "treatment," or "treating" includes prophylaxis in some embodiments.

[0048] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Compound

[0049] Disclosed herein is 3-(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine (or alternatively 4-(4-chloro-5-(2,5-dimethyl-7-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-3-yl)thiazol-2-yl)morpholine), a pharmaceutically acceptable salt, and/or a solvate thereof:



. In some embodiments, 4-(4-chloro-5-(2,5-dimethyl-7-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-3-yl)thiazol-2-yl)morpholine is referred to as Compound 1. In some embodiments, 3-(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine is referred to as Compound 1.

Pharmaceutical Compositions

[0050] Poorly soluble drugs may be difficult to formulate using technologies such as high shear wet granulation. Optimum delivery of poorly soluble drugs may require complex technologies such as solid solutions or amorphous dispersions (for example hot melt extrusion or spray drying), nano-formulations or lipid-based formulations. Hydrophobic drug substances which may be considered poorly soluble according to USP criteria may also be difficult to granulate with water and other excipients as most excipients for immediate-release formulations may be water soluble or water-swellable.

[0051] Making a small tablet of a high dose drug substance that is poorly soluble may require a high concentration of the drug substance. However, as the drug concentration is increased above a certain level, formation of granules may become more difficult, and at a certain drug load, it may become impossible.

[0052] In one embodiment, the pharmaceutical compositions described herein may be for a pediatric population. Hence, it may be necessary to maintain the pharmaceutical composition as small as possible to facilitate swallowing of pills and therefore increase patient compliance. In some embodiments, tablet weights are less than 400 mg. In some embodiments, tablet weights are less than 300 mg. In some embodiments, where dose strength is 200 mg, the drug load in the tablet is higher than 50%. In some embodiments, where dose strength is 200 mg, the drug load in the tablet is higher than 66%. In some embodiments, where dose strength is 200 mg, the drug load is as high as possible.

[0053] Disclosed herein is a pharmaceutical composition comprising Compound 1, a pharmaceutically acceptable salt, and/or a solvate thereof.

Dosage Form

[0054] In some embodiments, the pharmaceutical compositions described herein are provided in unit dosage form. As used herein, a "unit dosage form" is a composition containing an amount of Compound 1 that is suitable for administration to an animal, preferably mammal, subject in a single dose, according to good medical practice. The preparation of a single or unit dosage form however, does not imply that the dosage form is administered once per day or once per course of therapy. Such dosage forms are contemplated to be administered once, twice, thrice or more per day and may be administered as infusion over a period of time (e.g., from about 30 minutes to about 2-6 hours), or administered as a continuous infusion, and may be given more than once during a course of therapy, though a single administration is not specifically excluded.

[0055] Pharmaceutical compositions are administered in a manner appropriate to the disease to be treated (or prevented). An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient's disease, the particular form of the active ingredient, and the method of administration. In general, an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (e.g., an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity. Optimal doses are generally determined using experimental models and/or clinical trials. The optimal dose depends upon the body mass, weight, or blood volume of the patient.

[0056] In some embodiments, the pharmaceutical compositions described herein are formulated as oral dosage forms. Suitable oral dosage forms include, for example, tablets, pills, sachets, or capsules. In some embodiments, the pharmaceutical composition comprises one or more additional pharmaceutically acceptable excipients. *See, e.g., Remington: The Science and*

Practice of Pharmacy (Gennaro, 21st Ed. Mack Pub. Co., Easton, PA (2005) for a list of pharmaceutically acceptable excipients.

Capsule

[0057] In some embodiments, the pharmaceutical composition is formulated as a capsule. In some embodiments, the pharmaceutical composition is formulated as a hard gel capsule. In some embodiments, the pharmaceutical composition is formulated as a soft gel capsule.

[0058] In some embodiments, the capsule is formed using materials which include, but are not limited to, natural or synthetic gelatin, pectin, casein, collagen, protein, modified starch, polyvinylpyrrolidone, acrylic polymers, cellulose derivatives, or any combinations thereof. In some embodiments, the capsule is formed using preservatives, coloring and opacifying agents, flavorings and sweeteners, sugars, gastroresistant substances, or any combinations thereof. In some embodiments, the capsule is coated. In some embodiments, the coating covering the capsule includes, but is not limited to, immediate release coatings, protective coatings, enteric or delayed release coatings, sustained release coatings, barrier coatings, seal coatings, or combinations thereof. In some embodiments, a capsule herein is hard or soft. In some embodiments, the capsule is seamless. In some embodiments, the capsule is broken such that the particulates are sprinkled on soft foods and swallowed without chewing. In some embodiments, the shape and size of the capsule also vary. Examples of capsule shapes include, but are not limited to, round, oval, tubular, oblong, twist off, or a non-standard shape. The size of the capsule may vary according to the volume of the particulates. In some embodiments, the size of the capsule is adjusted based on the volume of the particulates and powders. Hard or soft gelatin capsules may be manufactured in accordance with conventional methods as a single body unit comprising the standard capsule shape. A single-body soft gelatin capsule typically may be provided, for example, in sizes from 3 to 22 minims (1 minims being equal to 0.0616 ml) and in shapes of oval, oblong or others. The gelatin capsule may also be manufactured in accordance with conventional methods, for example, as a two-piece hard gelatin capsule, sealed or unsealed, typically in standard shape and various standard sizes, conventionally designated as (000), (00), (0), (1), (2), (3), (4), and (5). The largest number corresponds to the smallest size. In some embodiments, the pharmaceutical composition described herein (e.g., capsule) is swallowed as a whole.

[0059] In some embodiments, the capsule comprises one or more pharmaceutically acceptable excipients. In some embodiments, the capsule is free of additional excipients.

[0060] In some embodiments, a capsule is developed, manufactured and commercialized for a drug substance that is insoluble. In some embodiments, a drug substance is insoluble if solubility is less than 0.002 mg/mL in water. In some embodiments, the capsule has a dose

strength of up to 200 mg. In some embodiments, drug substance in the capsule is immediately released in a dissolution medium using USP apparatus I. In some embodiments, drug substance in the capsule is immediately released in a dissolution medium using USP apparatus II.

Tablet

[0061] Insoluble drugs may be difficult to formulate using standard technologies such as high shear wet granulation. Optimum delivery of insoluble drugs may require complex technologies such as solid solutions amorphous dispersions (hot melt extrusion or spray drying), nano-formulations or lipid-based formulations. Hydrophobic drug substances may be considered insoluble according to USP criteria and may be known to be difficult to granulate with water and other excipients. This is likely due to most known excipients for immediate release formulations being water soluble or water-swellable. Making a tablet of a high dose drug substance that is insoluble may require a high concentration of the drug substance. However, as the drug concentration is increased above a certain level, formation of granules may become more and more difficult. Furthermore, at a certain drug load, it may become impossible.

[0062] In some embodiments, the pharmaceutical composition is formulated as a tablet.

[0063] In some embodiments, the tablet is made by compression, molding, or extrusion, optionally with one or more pharmaceutically acceptable excipient. In some embodiments, compressed tablets are prepared by compressing Compound 1 in a free-flowing form, optionally mixed with pharmaceutically acceptable excipients. In some embodiments, molded tablets are made by molding a mixture of the powdered Compound 1 moistened with an inert liquid diluent. In some embodiments, the tablet is prepared by hot-melt extrusion. In some embodiments, extruded tablets are made by forcing a mixture comprising Compound 1 through an orifice or die under controlled conditions. In some embodiments, the tablet is coated or scored. In some embodiments, the tablet is formulated so as to provide slow or controlled release of Compound 1. In some embodiments, a tablet is developed, manufactured and commercialized for a drug substance that is insoluble. In some embodiments, a drug substance is insoluble if solubility is less than 0.002 mg/mL in water. In some embodiments, the tablet has a dose strength of up to 200 mg. In some embodiments, drug substance in the tablet is immediately released in a dissolution medium using USP apparatus I. In some embodiments, drug substance in the tablet is immediately released in a dissolution medium using USP apparatus II.

[0064] In some embodiments, the tablet size is less than about 1000 mg, less than about 800 mg, less than about 600 mg, less than about 400 mg or less than about 200 mg. In some embodiments, the tablet has a dose strength of more than about 50 mg, more than about 100 mg, more than about 150 mg, more than about 200 mg, or more than about 250 mg. In some embodiments, the tablet size is less than about 1000 mg for a dose strength of more than about

50 mg. In some embodiments, the tablet size is less than 800 mg for a dose strength of more than about 100 mg. In some embodiments, the tablet size is less than 600 mg for a dose strength of more than about 150 mg. In some embodiment, the tablet size is less than 400 mg for a dose strength of more than about 200 mg. In some embodiments, the tablet size is less than 400 mg for a dose strength of 200 mg.

In some embodiments, more than about 20% of the tablet is dissolved in conventional dissolution media. In some embodiments, more than about 40% of the tablet is dissolved in conventional dissolution media. In some embodiments, more than about 50% of the tablet is dissolved in conventional dissolution media. In some embodiments, more than about 60% of the tablet is dissolved in conventional dissolution media. In some embodiments, more than about 70% of the tablet is dissolved in conventional dissolution media. In some embodiments, more than about 80% of the tablet is dissolved in conventional dissolution media. In some embodiments, more than about 20% of the tablet is dissolved in less than 24 hours in conventional dissolution media. In some embodiments, more than about 20% of the tablet is dissolved in less than 12 hours in conventional dissolution media. In some embodiments, more than about 20% of the tablet is dissolved in less than 6 hours in conventional dissolution media. In some embodiments, more than about 20% of the tablet is dissolved in less than 3 hours in conventional dissolution media. In some embodiments, more than about 20% of the tablet is dissolved in less than 2 hours in conventional dissolution media. In some embodiments, more than about 20% of the tablet is dissolved in less than 60 minutes in conventional dissolution media. In some embodiments, more than about 40% of the tablet is dissolved in less than 60 minutes in conventional dissolution media. In some embodiments, more than about 50% of the tablet is dissolved in less than 60 minutes in conventional dissolution media. In some embodiments, more than about 60% of the tablet is dissolved in less than 60 minutes in conventional dissolution media. In some embodiments, more than about 70% of the tablet is dissolved in less than 60 minutes in conventional dissolution media. In some embodiments, more than about 80% of the tablet is dissolved in less than 60 minutes in conventional dissolution media. In some embodiments, more than 70% of the tablet is dissolved in 60 minutes in conventional dissolution media.

[0065] In some embodiments, the tablet is produced at a commercial scale.

[0066] In some embodiments, the tablet comprises one or more pharmaceutically acceptable excipients.

[0067] In some embodiments, the tablet is coated with a coating material, e.g., a sealant. In some embodiments, the coating material is water soluble. In some embodiments, the coating material comprises a polymer, plasticizer, a pigment, or any combination thereof. In some

embodiments, the coating material is in the form of a film coating, e.g., a glossy film, a pH independent film coating, an aqueous film coating, a dry powder film coating (e.g., complete dry powder film coating), or any combination thereof. In some embodiments, the coating material is highly adhesive. In some embodiments, the coating material provides low level of water permeation. In some embodiments, the coating material provides oxygen barrier protection. In some embodiments, the coating material allows immediate disintegration for fast release of Compound 1. In some embodiments, the coating material is pigmented, clear, or white. In some embodiments, the coating is an enteric coating. Exemplary coating materials include, without limitation, polyvinylpyrrolidone, polyvinyl alcohol, an acrylate-methacrylic acid copolymer, a methacrylate-methacrylic acid copolymer, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, shellac, cellulose acetate trimellitate, sodium alginate, zein, and any combinations thereof.

Pharmaceutically Acceptable Excipients

[0068] In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable excipient. In some embodiments, the composition is free of pharmaceutically acceptable excipients. The term "pharmaceutically acceptable excipient", as used herein, means one or more compatible solid or encapsulating substances, which are suitable for administration to a mammal. The term "compatible", as used herein, means that the components of the composition are capable of being commingled with the subject compound, and with each other, in a manner such that there is no interaction, which would substantially reduce the pharmaceutical efficacy of the composition under ordinary use situations. In some embodiments, the pharmaceutically acceptable excipient is of sufficiently high purity and sufficiently low toxicity to render them suitable for administration preferably to an animal, preferably mammal, being treated.

[0069] Some examples of substances, which can serve as pharmaceutically acceptable excipients include:

- Amino acids such as alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine. In some embodiments, the amino acid is arginine. In some embodiments, the amino acid is L-arginine.
- Monosaccharides such as glucose (dextrose), arabinose, mannitol, fructose (levulose), and galactose.
- Cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose.

- Solid lubricants such as talc, stearic acid, magnesium stearate and sodium stearyl fumarate.
- Polyols such as propylene glycol, glycerin, sorbitol, mannitol, and polyethylene glycol.
- Emulsifiers such as the polysorbates.
- Wetting agents such as sodium lauryl sulfate, Tween®, Span , alkyl sulphates, and alkyl ethoxylate sulphates.
- Cationic surfactants such as cetrimide, benzalkonium chloride, and cetylpyridinium chloride.
- Diluents such as calcium carbonate, microcrystalline cellulose, calcium phosphate, starch, pregelatinized starch, sodium carbonate, mannitol, and lactose.
- Binders such as starches (corn starch and potato starch), gelatin, sucrose hydroxypropyl cellulose (HPC), polyvinylpyrrolidone (PVP), and hydroxypropyl methyl cellulose (HPMC).
- Disintegrants such as starch, and alginic acid.
- Super-disintegrants such as ac-di-sol, croscarmellose sodium, sodium starch glycolate and crospovidone.
- Glidants such as silicon dioxide.
- Coloring agents such as the FD&C dyes.
- Sweeteners and flavoring agents, such as aspartame, saccharin, menthol, peppermint, and fruit flavors.
- Preservatives such as benzalkonium chloride, PHMB, chlorobutanol, thimerosal, phenylmercuric, acetate, phenylmercuric nitrate, parabens, and sodium benzoate.
- Tonicity adjustors such as sodium chloride, potassium chloride, mannitol, and glycerin.
- Antioxidants such as sodium bisulfite, acetone sodium bisulfite, sodium formaldehyde, sulfoxylate, thiourea, and EDTA.
- pH adjuster such as NaOH, sodium carbonate, sodium acetate, HCl, and citric acid.
- Cryoprotectants such as sodium or potassium phosphates, citric acid, tartaric acid, gelatin, and carbohydrates such as dextrose, mannitol, and dextran.
- Surfactants such as sodium lauryl sulfate. For example, cationic surfactants such as cetrimide (including tetradecyl trimethyl ammonium bromide with dodecyl and hexadecyl compounds), benzalkonium chloride, and cetylpyridinium chloride. Some examples of anionic surfactants are alkylsulphates, alkylethoxylate sulphates, soaps, carxylate ions, sulfate ions, and sulfonate ions. Some examples of non-ionic surfactants are polyoxyethylene derivatives, polyoxypropylene derivatives, polyol derivatives,

polyol esters, polyoxyethylene esters, poloxamers, glocol, glycerol esters, sorbitan derivatives, polyethylene glycol (such as PEG-40, PEG-50, or PEG-55) and esters of fatty alcohols.

- Organic materials such as carbohydrates, modified carbohydrates, lactose (including a-lactose, monohydrate spray dried lactose or anhydrous lactose), starch, pregelatinized starch, sucrose, mannitol, sorbital, cellulose (including powdered cellulose and microcrystalline cellulose).
- Inorganic materials such as calcium phosphates (including anhydrous dibasic calcium hosphate, dibasic calcium phosphate or tribasic calcium phosphate).
- Co-processed diluents.
- Compression aids .
- Anti-tacking agents such as silicon dioxide and talc.

Amounts

[0070] In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 1 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 1 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 1 mg and about 400 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 1 mg and about 300 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 1 mg and about 200 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 1 mg and about 100 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 1 mg and about 90 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 1 mg and about 80 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 1 mg and about 70 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 1 mg and about 60 mg

of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 1 mg and about 50 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 1 mg and about 40 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 1 mg and about 30 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 1 mg and about 20 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 1 mg and about 10 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 1 mg and about 5 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule comprises about 1 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule comprises about 5 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

[0071] In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 1 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 5 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 10 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 10 mg and about 400 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 10 mg and about 300 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 10 mg and about 200 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 10 mg and about 100 mg of Compound 1, or a pharmaceutically

acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 10 mg and about 90 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 10 mg and about 80 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 10 mg and about 70 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 10 mg and about 60 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

[0072] In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 20 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 20 mg and about 400 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 20 mg and about 300 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 20 mg and about 200 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 20 mg and about 100 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 20 mg and about 90 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 20 mg and about 80 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 20 mg and about 70 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 20 mg and about 60 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

[0073] In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 30 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 30 mg and about 400

mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 30 mg and about 300 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 30 mg and about 200 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 30 mg and about 100 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 30 mg and about 90 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 30 mg and about 80 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 30 mg and about 70 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 30 mg and about 60 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

[0074] In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 40 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 40 mg and about 400 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 40 mg and about 300 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 40 mg and about 200 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 40 mg and about 100 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 40 mg and about 90 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 40 mg and about 80 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 40 mg and about 70 mg

of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 40 mg and about 60 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. . In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises about 50 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

[0075] In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 50 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 50 mg and about 400 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 50 mg and about 300 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 50 mg and about 200 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 50 mg and about 100 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 50 mg and about 90 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 50 mg and about 80 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition, in the form of a tablet or capsule, comprises between about 50 mg and about 70 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

[0076] In some embodiments, the pharmaceutical composition comprises between about 100 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises between about 100 mg and about 400 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises between about 100 mg and about 300 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises between about 150 mg and about 250 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises between about 100 mg and about 200 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

[0077] In some embodiments, the pharmaceutical composition comprises about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises about 400 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises about 300 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises about 250 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises about 200 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises about 150 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises about 100 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises about 90 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises about 80 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises about 70 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises about 60 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises about 50 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises about 40 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises about 30 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises about 20 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises about 10 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

Particle size

[0078] In some embodiments, the pharmaceutical composition, in the form of a tablet or a capsule, comprises Compound 1, or a pharmaceutically acceptable salt or solvate thereof, in the form of microparticles. In some embodiments, microparticles of Compound 1 have an average size from about 1 μm to about 100 μm. In some embodiments, microparticles of Compound 1 have an average size from about 1 μm to about 50 μm. In some embodiments, microparticles of Compound 1 have an average size from about 1 μm to about 30 μm. In some embodiments, microparticles of Compound 1 have an average size from about 1 μm to about 20 μm. In some

embodiments, microparticles of Compound 1 have an average size from about 5 μm to about 15 μm. In some embodiments, microparticles of Compound 1 have an average size from about 1 μm to about 10 μm. In some embodiments, microparticles of Compound 1 have an average size from about 3 μm to about 10 μm. In some embodiments, microparticles of Compound 1 have an average size from about 4 μm to about 9 μm.

[0079] In some embodiments, microparticles of Compound 1 have an average size less than about 100 μm. In some embodiments, microparticles of Compound 1 have an average size less than about 80 μm. In some embodiments, microparticles of Compound 1 have an average size less than about 60 μm. In some embodiments, microparticles of Compound 1 have an average size less than about 50 μm. In some embodiments, microparticles of Compound 1 have an average size less than about 40 μm. In some embodiments, microparticles of Compound 1 have an average size less than about 30 μm. In some embodiments, microparticles of Compound 1 have an average size less than about 20 μm. In some embodiments, microparticles of Compound 1 have an average size less than about 10 μm.

Pharmacokinetics

[0080] In some embodiments, Compound 1 is formulated as a capsule or a tablet as to provide a Tmax of about 1 to about 8 hours in a subject. In some embodiments, Compound 1 is formulated as a capsule or a tablet as to provide a Tmax of about 2 to about 7 hours in a subject. In some embodiments, Compound 1 is formulated as a capsule or a tablet as to provide a Tmax of about 2 to about 6 hours in a subject. In some embodiments, Compound 1 is formulated as a capsule or a tablet as to provide a Tmax of about 3 to about 5 hours in a subject.

[0081] In some embodiments, Compound 1 is formulated as a capsule or a tablet as to provide a Tmax of about 8 hours in a subject. In some embodiments, Compound 1 is formulated as a capsule or a tablet as to provide a Tmax of about 7 hours in a subject. In some embodiments, Compound 1 is formulated as a capsule or a tablet as to provide a Tmax of about 6 hours in a subject. In some embodiments, Compound 1 is formulated as a capsule or a tablet as to provide a Tmax of about 5 hours in a subject. In some embodiments, Compound 1 is formulated as a capsule or a tablet as to provide a Tmax of about 4 hours in a subject. In some embodiments, Compound 1 is formulated as a capsule or a tablet as to provide a Tmax of about 3 hours in a subject. In some embodiments, Compound 1 is formulated as a capsule or a tablet as to provide a Tmax of about 2 hours in a subject. In some embodiments, Compound 1 is formulated as a capsule or a tablet as to provide a Tmax of about 1 hour in a subject.

Stability

[0082] The pharmaceutical compositions described herein are stable in various storage conditions including refrigerated, ambient and accelerated conditions. Stable as used herein

refers to pharmaceutical compositions having about 95% or greater of the initial Compound 1 amount and about 5% w/w or less total impurities or related substances at the end of a given storage period. The percentage of impurities is calculated from the amount of impurities relative to the amount of Compound 1. Stability is assessed by HPLC or any other known testing method. In some embodiments, the stable pharmaceutical compositions have about 5% w/w, about 4% w/w, about 3% w/w, about 2.5% w/w, about 2% w/w, about 1.5% w/w, about 1% w/w, or about 0.5% w/w total impurities or related substances. In other embodiments, the stable pharmaceutical compositions have about 5% w/w total impurities or related substances. In yet other embodiments, the stable pharmaceutical compositions have about 4% w/w total impurities or related substances. In yet other embodiments, the stable pharmaceutical compositions have about 3% w/w total impurities or related substances. In yet other embodiments, the stable pharmaceutical compositions have about 2% w/w total impurities or related substances. In yet other embodiments, the stable pharmaceutical compositions have about 1% w/w total impurities or related substances.

[0083] At refrigerated condition, the pharmaceutical compositions described herein are stable for at least 1 month, at least 2 months, at least 3 months, at least 6 months, at least 9 months, at least 12 months, at least 15 months, at least 18 months, at least 24 months, at least 30 months and at least 36 months. In some embodiments, refrigerated condition is 5±5 °C. In some embodiments, refrigerated condition is about 0 °C, about 0.1 °C, about 0.2 °C, about 0.3 °C, about 0.4 °C, about 0.5 °C, about 0.6 °C, about 0.7 °C, about 0.8 °C, about 0.9 °C, about 1 °C, about 1.1 °C, about 1.2 °C, about 1.3 °C, about 1.4 °C, about 1.5 °C, about 1.6 °C, about 1.7 °C, about 1.8 °C, about 1.9 °C, about 2 °C, about 2.1 °C, about 2.2 °C, about 2.3 °C, about 2.4 °C, about 2.5 °C, about 2.6 °C, about 2.7 °C, about 2.8 °C, about 2.9 °C, about 3 °C, about 3.1 °C, about 3.2 °C, about 3.3 °C, about 3.4 °C, about 3.5 °C, about 3.6 °C, about 3.7 °C, about 3.8 °C, about 3.9 °C, about 4 °C, about 4.1 °C, about 4.2 °C, about 4.3 °C, about 4.4 °C, about 4.5 °C, about 4.6 °C, about 4.7 °C, about 4.8 °C, about 4.9 °C, about 5 °C, about 5.1 °C, about 5.2 °C, about 5.3 °C, about 5.4 °C, about 5.5 °C, about 5.6 °C, about 5.7 °C, about 5.8 °C, about 5.9 °C, about 6 °C, about 6.1 °C, about 6.2 °C, about 6.3 °C, about 6.4 °C, about 6.5 °C, about 6.6 °C, about 6.7 °C, about 6.8 °C, about 6.9 °C, about 7 °C, about 7.1 °C, about 7.2 °C, about 7.3 °C, about 7.4 °C, about 7.5 °C, about 7.6 °C, about 7.7 °C, about 7.8 °C, about 7.9 °C, about 8 °C, about 8.1 °C, about 8.2 °C, about 8.3 °C, about 8.4 °C, about 8.5 °C, about 8.6 °C, about 8.7 °C, about 8.8 °C, about 8.9 °C, about 9 °C, about 9.1 °C, about 9.2 °C, about 9.3 °C, about 9.4 °C, about 9.5 °C, about 9.6 °C, about 9.7 °C, about 9.8 °C, about 9.9 °C, or about 10 °C. At accelerated conditions, the pharmaceutical compositions described herein are stable for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6

months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 18 months, or at least 24 month. Accelerated conditions for the pharmaceutical compositions described herein include temperatures that are at or above ambient levels (e.g. 25±5 °C). In some instances, an accelerated condition is at about 40±2 °C. In some instances, an accelerated condition is at about 35 °C, about 40 °C, about 45 °C, about 50 °C, about 55 °C, or about 60 °C. Accelerated conditions for the pharmaceutical compositions described herein also include relative humidity (RH) that are at or above ambient levels (55±10% RH). In other instances, an accelerated condition is above about 65% RH, about 70% RH, about 75% RH, or about 80% RH. In further instances, an accelerated condition is about 40 °C or 60 °C at ambient humidity. In yet further instances, an accelerated condition is about 40±2 °C at 75±5% RH humidity.

[0084] In some embodiments, the pharmaceutical compositions are stable at about 5±5 °C to about 25±5 °C for at least 12 months. In one embodiment, the pharmaceutical compositions are stable at about 5±5 °C for at least 12 months. In one embodiment, the pharmaceutical compositions are stable at about 25±5 °C for at least 12 months. In one embodiment, the pharmaceutical compositions are stable at about 5±5 °C for at least 24 months. In one embodiment, the pharmaceutical compositions are stable at about 25±5 °C for at least 24 months.


Methods of Use

[0085] Disclosed herein is a method of treating congenital adrenal hyperplasia (CAH) in a subject in need thereof, comprising administering a pharmaceutical composition comprising Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, CAH is classic CAH. In some embodiments, CAH is non-classic CAH. In some embodiments, the methods described herein result in the reduction of a hormone level. Such hormones include deoxycorticosterone, 11-deoxycortisol, cortisol, corticosterone, aldosterone, pregnenolone, 17α-hydroxy pregnenolone, progesterone, 17α-hydroxy progesterone (17-OHP), dehydroepiandrosterone, androstenediol, androstenedione, testosterone, dihydrotestosterone, estrone, estradiol, estriol, and adrenocorticotropic hormone (ACTH). In some embodiments, the methods described herein result in the reduction of 17α-hydroxy progesterone (17-OHP). In some embodiments, the methods described herein result in the reduction of adrenocorticotropic hormone (ACTH), also known as corticotropin.

[0086] Also disclosed herein is a method of treating congenital adrenal hyperplasia (CAH) in a subject in need thereof, the method comprising:

(i) measuring a hormone level in the subject in need thereof;

(ii) administering Compound 1:



or a pharmaceutically acceptable salt or solvate thereof;

(iii) repeating steps (i) and (ii) until the hormone level reaches a pre-determined range followed by a maintenance therapy of a daily dosing of compound 1.

[0087] In some embodiment, the hormone is 17α-Hydroxyprogesterone (17-OHP), adrenocorticotropic hormone (ACTH), testosterone, or androstenedione.

[0088] In some embodiment, the hormone is 17-OHP, and the pre-determined range is from about 200 ng/dL to about 400 ng/dL. In some embodiment, the hormone is 17-OHP, and the pre-determined range is less than about 400 ng/dL, less than about 350 ng/dL, less than about 300 ng/dL, less than about 250 ng/dL, or less than about 200 ng/dL.

[0089] In some embodiment, the hormone is ACTH, and the pre-determined range is below about 100 pg/mL. In some embodiment, the hormone is ACTH, and the pre-determined range is below about 100 pg/mL, below about 90 pg/mL, or below about 80 pg/mL.

[0090] In some embodiment, the hormone is testosterone and the pre-determined range is from about 14 ng/dL to about 76 ng/dL. In some embodiment, the hormone is testosterone and the pre-determined range is less than about 76 ng/dL, less than about 70 ng/dL, less than about 65 ng/dL, less than about 60 ng/dL, less than about 55 ng/dL, less than about 50 ng/dL, less than about 45 ng/dL, less than about 40 ng/dL, less than about 35 ng/dL, less than about 30 ng/dL, less than about 25 ng/dL, less than about 20 ng/dL, or less than about 15 ng/dL.

[0091] In some embodiment, the hormone is androstenedione and the pre-determined range is from about 30 ng/dL to about 200 ng/dL in males. In some embodiment, the hormone is androstenedione and the pre-determined range is less than about 200 ng/dL, less than about 150 ng/dL, less than about 100 ng/dL, less than about 50 ng/dL, or less than about 30 ng/dL in males

[0092] In some embodiment, the hormone is androstenedione and the pre-determined range is from about 40 ng/dL to about 150 ng/dL in females. In some embodiment, the hormone is androstenedione and the pre-determined range is less about 150 ng/dL, less about 100 ng/dL, less about 50 ng/dL, or less about 40 ng/dL in females.

[0093] In some embodiments, the methods described herein include administration of the pharmaceutical composition comprising Compound 1, or a pharmaceutically acceptable salt or solvate thereof once a month, twice a month, three times a month, once a week, twice a week, three times a week, once every two days, once a day, twice a day, three times a day, or four

times a day. In some embodiments, the methods described herein administer Compound 1, or a pharmaceutically acceptable salt or solvate thereof once a day. In some embodiments, the methods described herein administer Compound 1, or a pharmaceutically acceptable salt or solvate thereof twice a day.

[0094] In some embodiments, the methods described herein include administration of about 1 mg to about 2000 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof, per day. In some embodiments, about 100 mg to about 1600 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, about 200 mg to about 1600 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, about 200 mg to about 1200 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, about 200 mg to about 1000 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, about 200 mg to about 800 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, about 100 mg to about 800 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, about 200 mg to about 800 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, about 100 mg to about 600 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, about 200 mg to about 600 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, about 300 mg to about 600 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, about 100 mg to about 400 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, about 200 mg to about 400 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, about 300 mg to about 400 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered each day.

[0095] In some embodiments, less than about 2000 mg Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, less than about 1800 mg Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, less than about 1600 mg Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, less than about 1400 mg Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, less than about 1200 mg Compound 1, or a pharmaceutically

acceptable salt or solvate thereof, is administered per day. In some embodiments, less than about 1000 mg Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, less than about 800 mg Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, less than about 600 mg Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, less than about 500 mg Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, less than about 400 mg Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, less than about 300 mg Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day. In some embodiments, less than about 200 mg Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is administered per day.

[0096] In some embodiments, the methods described herein include administration of the pharmaceutical compositions described herein wherein the subject is in the fed state. In some embodiments, the methods described herein include administration of the pharmaceutical compositions described herein wherein the subject is in the fasted state.

[0097] In some embodiments, the methods described herein include administration of the pharmaceutical compositions described herein at bedtime.

[0098] In some embodiments, the methods described herein include administration of the pharmaceutical compositions described herein less than about 4 hours before sleep. In some embodiments, the methods described herein include administration of the pharmaceutical compositions described herein less than about 3 hours before sleep. In some embodiments, the methods described herein include administration of the pharmaceutical compositions described herein less than about 2 hours before sleep. In some embodiments, the methods described herein include administration of the pharmaceutical compositions described herein less than about 1 hour before sleep. In some embodiments, the methods described herein include administration of the pharmaceutical compositions described herein less than about 30 mins before sleep.

[0099] In some embodiments, the methods described herein include administration of the pharmaceutical compositions described herein in the evening.

[0100] In some embodiments, the methods described herein include administration of the pharmaceutical compositions described herein at about 11 pm at night. In some embodiments, the methods described herein include administration of the pharmaceutical compositions described herein at about 10 pm at night. In some embodiments, the methods described herein include administration of the pharmaceutical compositions described herein at about 9 pm at

night. In some embodiments, the methods described herein include administration of the pharmaceutical compositions described herein at about 8 pm at night.

[0101] In some embodiments, the methods described herein include administration of the pharmaceutical compositions described herein at or before the expected circadian release of adrenocorticotropic hormone (ACTH). In some embodiments, the methods described herein include administration of the pharmaceutical compositions described herein about 3-4 hours before the expected circadian release of adrenocorticotropic hormone (ACTH).

Combination Therapy

[0102] Disclosed herein is a method of treating congenital adrenal hyperplasia (CAH) in a subject in need thereof, comprising administering a combination of Compound 1, or a pharmaceutically acceptable salt or solvate thereof; and a glucocorticoid. In some embodiments, the amount of glucocorticoid administered is reduced as compared to a method not comprising administering Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

[0103] In some embodiments, the methods described herein reduce the amount of a glucocorticoid administered from a supraphysiologic amount to a physiologic amount.

[0104] In some embodiments, the methods described herein reduce the symptoms associated with high-dose glucocorticoid therapy. In some embodiments, the symptoms associated with high-dose glucocorticoid therapy are obesity, insulin resistance, metabolic abnormalities, hypertension, cardiovascular diseases, or osteoporosis.

[0105] In some embodiments, the amount of glucocorticoid administered is reduced by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 80, or about 90% as compared to a method not comprising administering Compound 1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the amount of glucocorticoid administered is reduced by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, or about 60% as compared to a method not comprising administering Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

[0106] In some embodiments, the amount of glucocorticoid administered is reduced by about 1% to about 90%, about 1% to about 60%, about 1% to about 30%, about 1% to about 10%, about 10% to about 50%, about 10% to about 40%, about 10% to about 30%, about 15% to about 25%, about 20% to about 30%, about 5% to about 25%, about 20% to about 50%, about 30% to about 60%, or about 40% to about 70% as compared to a method not comprising administering Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

[0107] In some embodiments, the glucocorticoid is administered at a dose between about 0.1 mg/day and about 25 mg/day. In some embodiments, the glucocorticoid is administered at a dose between about 1 mg/day and about 20 mg/day. In some embodiments, the glucocorticoid is administered at a dose between about 1 mg/day and about 15 mg/day. In some embodiments, the glucocorticoid is administered at a dose between about 1 mg/day and about 12 mg/day. In some embodiments, the glucocorticoid is administered at a dose between about 1 mg/day and about 11 mg/day. In some embodiments, the glucocorticoid is administered at a dose between about 1 mg/day and about 10 mg/day. In some embodiments, the glucocorticoid is administered at a dose between about 1 mg/day and about 9 mg/day. In some embodiments, the glucocorticoid is administered at a dose between about 1 mg/day and about 8 mg/day. In some embodiments, the glucocorticoid is administered at a dose between about 1 mg/day and about 7 mg/day. In some embodiments, the glucocorticoid is administered at a dose between about 1 mg/day and about 6 mg/day. In some embodiments, the glucocorticoid is administered at a dose between about 1 mg/day and about 5 mg/day. In some embodiments, the glucocorticoid is administered at a dose between about 1 mg/day and about 4 mg/day. In some embodiments, the glucocorticoid is administered at a dose between about 1 mg/day and about 3 mg/day. In some embodiments, the glucocorticoid is administered at a dose between about 1 mg/day and about 2 mg/day. In some embodiments, the glucocorticoid is administered at a dose between about 3 mg/day and about 13 mg/day. In some embodiments, the glucocorticoid is administered at a dose between about 5 mg/day and about 11 mg/day. In some embodiments, the glucocorticoid is administered at a dose between about 8 mg/day and about 11 mg/day. In some embodiments, the glucocorticoid is administered at a dose between about 9 mg/day and about 12 mg/day. In some embodiments, the glucocorticoid is administered at a dose between about 9 mg/day and about 10 mg/day. In some embodiments, the glucocorticoid is administered at a dose between about 5 mg/day and about 10 mg/day.

[0108] In some embodiments, Compound 1, or a pharmaceutically acceptable salt or solvate thereof, and the glucocorticoid are administered concurrently. In some embodiments, Compound 1, or a pharmaceutically acceptable salt or solvate thereof, and the glucocorticoid are administered in one pharmaceutical composition. In some embodiments, Compound 1, or a pharmaceutically acceptable salt or solvate thereof, and the glucocorticoid are administered concurrently in separate pharmaceutical compositions.

[0109] In some embodiments, Compound 1, or a pharmaceutically acceptable salt or solvate thereof, and the glucocorticoid are administered sequentially. In some embodiments, Compound 1, or a pharmaceutically acceptable salt or solvate thereof, and the glucocorticoid are administered within 24 hours. In some embodiments, Compound 1, or a pharmaceutically

acceptable salt or solvate thereof, and the glucocorticoid are administered within 12 hours. In some embodiments, Compound 1, or a pharmaceutically acceptable salt or solvate thereof, and the glucocorticoid are administered within 8 hours. In some embodiments, Compound 1, or a pharmaceutically acceptable salt or solvate thereof, and the glucocorticoid are administered within 6 hours. In some embodiments, Compound 1, or a pharmaceutically acceptable salt or solvate thereof, and the glucocorticoid are administered within 4 hours. In some embodiments, Compound 1, or a pharmaceutically acceptable salt or solvate thereof, and the glucocorticoid are administered within 2 hours. In some embodiments, Compound 1, or a pharmaceutically acceptable salt or solvate thereof, and the glucocorticoid are administered within 1 hour. In some embodiments, Compound 1, or a pharmaceutically acceptable salt or solvate thereof, and the glucocorticoid are administered within 30 minutes. In some embodiments, Compound 1, or a pharmaceutically acceptable salt or solvate thereof, and the glucocorticoid are administered within 10 minutes.

[0110] In some embodiments, the glucocorticoid is beclomethasone, betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, or triamcinolone. In some embodiments, the glucocorticoid is hydrocortisone.

[0111] In some embodiments, the glucocorticoid is hydrocortisone and the dose administered is less than the recommended dose of 15-25 mg/day.

[0112] In some embodiments, the glucocorticoid is prednisone and the dose administered is less than the recommended dose of 5-7.5 mg/day.

[0113] In some embodiments, the glucocorticoid is prednisolone and the dose administered is less than the recommended dose of 4-6 mg/day.

[0114] In some embodiments, the glucocorticoid is dexamethasone and the dose administered is less than the recommended dose of 0.25-0.5 mg/day.

[0115] Disclosed herein is a method of treating congenital adrenal hyperplasia (CAH) in a subject in need thereof, comprising administering a combination of Compound 1, or a pharmaceutically acceptable salt or solvate thereof; a glucocorticoid; and optionally a mineralcorticoid. In some embodiments, the mineralocorticoid is fludrocortisone and the dose is less than the recommended dose of 0.05-0.2 mg/day.

EXAMPLES

[0116] The following examples further illustrate the invention but should not be construed as in any way limiting its scope. In particular, the processing conditions are merely exemplary and can be readily varied by one of ordinary skill in the art.

[0117] All methods described herein can be performed in a suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples,

or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. Unless defined otherwise, technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs.

Example 1: Pharmaceutical Composition

[0118] The pharmaceutical composition is manufactured as size 1 white hard gelatin capsules containing 200 mg of Compound 1 micronized to and average size of 10 microns or less. The pharmaceutical composition contains no additional excipients.

Example 2: Stability of the Pharmaceutical Composition

Stability Data Summary

[0119] A summary of the pharmaceutical composition stability studies is provided in Table 1. The pharmaceutical composition is a Compound 1 neat-filled into size 0 capsules with no added excipients, in 3 strength configurations: 1-mg, 5-mg, and 50-mg. The capsules were blister packaged in a polyvinyl chloride (PVC)-based film.

[0120] Under long term and accelerated conditions, no significant trend was observed in the three lots for any of the attributes evaluated throughout the course of the stability study.

Table 1. Summary of Stability

Lot Number	Strength	CCS	Stability Conditions	Available Data
#1	1-mg	PVC-based blister pack	25 °C/60% RH	6 months
			40 °C/75% RH	6 months
#2	5-mg	PVC-based blister pack	25 °C/60% RH	6 months
			40 °C/75% RH	6 months
#3	50-mg	PVC-based blister pack	25 °C/60% RH	6 months
			40 °C/75% RH	6 months
#4	200-mg	75 mL HDPE bottle	25 °C/60% RH	1 month
			40 °C/75% RH	9 months
#5	200-mg	30 mL HDPE bottle	25 °C/60% RH	6 months
			40 °C/75% RH	6 months
#6	200-mg	30 mL HDPE bottle	25 °C/60% RH	6 months
			40 °C/75% RH	6 months

CCS = container closure system; CRC = child-resistant closure; DoM = date of manufacture; HDPE = high density polyethylene; PVC = polyvinyl chloride

Stability Protocols

[0121] The stability protocol for various pharmaceutical compositions is provided in Table 2, 3, and 4.

Table 2. Stability Protocol

Test	Acceptance Criteria	Time (months)			
		T_0	1	3	6
Appearance	Size 0 blue capsule containing yellow powder, blister pack and foil backing intact	X	A,B	A,B	A,B
Assay	Report (% Label Claim)	X	A,B	A,B	A,B
Related Substances	Report RRT and % each individual species and total	X	A,B	A,B	A,B
Disintegration	Report	X	A,B	A,B	A,B

RRT = relative retention time
X-testing performed at the time study was initiated
A-samples stored under long term conditions of 25 ± 2 °C/60 ± 5 % RH
B-samples stored under accelerated conditions of 40 ± 2 °C/75 ± 5 % RH

Table 3. Stability Protocol (200-mg capsules in 30 mL HDPE bottles)

Test	Acceptance Criteria	Time (months)			
		T_0	1	3	6
Appearance	Size 1 white capsule containing an off-white to yellow powder	X	A,B	A,B	A,B
Assay (%LC)	90.0 – 110.0	X	A,B	A,B	A,B
Related Substances Any Unspecified Impurity (%) Total Impurities (%)	 ≤1.0 ≤2.0	X	A,B	A,B	A,B
Disintegration (min)	NMT 15	X	A,B	A,B	A,B
Water Activity	Report result	X	A,B	A,B	A,B

LC = label claim; NMT = not more than
X-testing performed at the time study was initiated
A-samples stored under long term conditions of 25 ± 2 °C/60 ± 5 % RH
B-samples stored under accelerated conditions of 40 ± 2 °C/75 ± 5 % RH

Table 4. Stability Protocol (200-mg capsules in 30 mL HDPE bottles) for Lots to be Used in Phase 2 Clinical Study

Test	Acceptance Criteria	Time (months)					
		T_0	1	3	6	9	12
Appearance	Size 1 white capsule containing an off-white to yellow powder	X	B	A,B	A,B	A	A
Assay (%LC)	90.0 – 110.0	X	B	A,B	A,B	A	A
Related Substances Any Unspecified Impurity (%) Total Impurities (%)	 ≤1.0 ≤2.0	X	B	A,B	A,B	A	A
Disintegration (min)	NMT 15	X	B	A,B	A,B	A	A
Water Activity	Report result	X	n/a	n/a	n/a	A	A
Microbial Enumeration Total Aerobic Microbial Count (CFU/g) Total Combined Yeast and Mold (CFU/g) Count	NMT 2000 CFU/g NMT 200 CFU/g	X	n/a	n/a	n/a	A	A
Test for Specified Microorganisms *E. coli* (/g)	Absent	X	n/a	n/a	n/a	A	A

CFU = colony forming units; LC = label claim; n/a = not applicable; NMT = not more than
X-testing performed at the time study was initiated
A-samples stored under long term conditions of 25 ± 2 °C/60 ± 5 % RH
B-samples stored under accelerated conditions of 40 ± 2 °C/75 ± 5 % RH

[0122] The supportive data demonstrate that the pharmaceutical composition is stable for a minimum of 6 months (end of study). No adverse trends were observed under long term and accelerated conditions. The assay results were consistent through the entire study and no new related substances species were observed during the stability study. The reported stability results for lots stored in a blister packaging configuration are considered supportive for the updated packaging configuration of a 30-mL HDPE bottle, induction seal, and a child resistant cap. There are no excipients in either configuration and both configurations provide protection from light.

Example 3: Phase 1 Clinical Studies

[0123] Compound 1 has been investigated in 2 Phase 1 studies in healthy adult volunteers.

[0124] Study 1 was the first-in-human study that investigated the safety, tolerability, and PK of single-escalating doses of Compound 1, given orally, to healthy adult subjects. Safety and tolerability assessments were made over a wide range of single oral doses, and dose escalation did not proceed until safety data from the preceding doses had been reviewed. The data from this study were used for the selection of doses for Study 2.

[0125] The 2-part multiple-dose study, Study 2, determined the safety and tolerability of repeated daily doses of Compound 1 and investigated the effects on biomarkers of relevance for the treatment of alcohol dependence. Part B investigated the interaction of Compound 1 with midazolam (a cytochrome P450 3A4 [CYP3A4] substrate), determining whether Compound 1 significantly inhibited the metabolism of drugs that are metabolized by CYP3A4.

[0126] In Study 1, Compound 1 was administered to healthy adult subjects as a single PO dose of 2, 10, 50, 150, 400, or 800 mg in the fed state and 150 mg in the fasted state. Absorption occurred moderately late, achieving peak C_{max} between 4 to 6 hours following dosing in the fed state.

[0127] Table 5 provides a summary of the PK parameters at each dose level. When Compound 1 was given in the fed state, median time to reach maximum plasma concentration (T_{max}) occurred between 4 and 6 hours. The median T_{max} was 10.05 hours when Compound 1 was given in the fasted state at 150 mg and ranged between 6 and 12 hours, suggesting possible delayed absorption in the fasted state. Mean half-life ($t_{1/2}$) after a single PO dose (fed and fasted state) was between 31 and 44 hours, ranging from 11 to 101 hours. Apparent volume of distribution (V_z/F) was large and appeared highly variable with greatest variability observed at the 2 highest dose levels of 400 mg and 800 mg.

Table 5. Summary of Pharmacokinetic Parameters of Compound 1 Following Single Oral Dose Administration in Healthy Volunteers (all Fed)

PK Parameters	Geometric Mean (CV%) Analyte = Plasma Compound 1					
	2 mg	**10 mg**	**50 mg**	**150 mg**	**400 mg**	**800 mg**
N	6	6	6	6	6	6
C_{max} (ng/mL)	0.867 (53)	3.01 (87)	19.5 (39)	93.4 (22)	207 (92)	382 (110)
T_{max}[a] (h)	6.00 (4.00-6.00)	4.00 (2.00 -6.00)	4.00 (3.00 - 6.00)	4.00 (3.00 - 6.00)	4.00 (3.00 - 6.00)	6.00 (4.00 - 6.00)
$t_{1/2}$b (h)	NC (NC)	NC (NC)	31 (10.8-53.4)	29.2 (20.0 - 41.5)	44.2 (20.2 - 101)	41.9 (24.1 - 67.8)
$AUC_{0\text{-tlast}}$ (ng•h/mL)	NC (NC)	NC (NC)	152 (60)	891 (26)	2300 (103)	4390 (100)

$AUC_{0-\infty}$ (ng•h/mL)	NC (NC)	NC (NC)	165 (64)	956 (25)	2580 (93)	4850 (95)
CL/F (L/h)	NC (NC)	NC (NC)	302 (64)	157 (25)	155 (93)	165 (95)
V_z/F (L)	NC (NC)	NC (NC)	13500 (45)	6620 (38)	9890 (212)	9970 (144)
V_{ss}/F (L)	NC (NC)	NC (NC)	8080 (36)	4600 (33)	6580 (152)	6820 (120)

AUC = area under the plasma concentration-time curve; CL/F = oral clearance; C_{max} = maximum plasma concentration; CV = coefficient of variation; NC = not calculable; $t_{1/2}$ = elimination half-life; T_{max} = time to reach maximum plasma concentration; V_{ss}/F = volume of distribution at steady state; V_z/F = volume of distribution at terminal phase

a Median (range)

b Geometric mean (range)

[0128] As part of this single-dose escalation study, a food effect PK investigation was performed to examine Compound 1 exposures in both the fed and fasted states at the 150-mg dose level. A total of 6 subjects were administered 150 mg Compound 1 in each of these 2 dosing groups. Of these 6 subjects, 4 subjects received Compound 1 at the same dose in both fed and fasted states. The administration of Compound 1 in the fasted state resulted in a much flatter mean concentration-time (i.e., with significantly lower absorption) profile when compared against the mean profile at the same dose, given within 5 minutes after a standardized breakfast meal. The mean $AUC_{0-\infty}$, and C_{max} values for a 150-mg dose in the fed state was approximately 3- and 11-fold greater than that of the fasted state, respectively. Table 6 provides a summary of the PK parameters at the 150-mg dose level under both fed and fasted state conditions.

Table 6. Summary of Pharmacokinetic Parameters of Compound 1 Following Single Oral Dose Administration in Healthy Volunteers – Fed vs. Fasted State

Pharmacokinetic Parameters	**Geometric Mean (CV %)**	
	Analyte = Plasma Compound 1	
	150 mg Fed	**150 mg Fasted**
N	6	6
C_{max} (ng/mL)	93.4 (22)	8.22 (83)
T_{max}[a] (h)	4.00 (3.00 – 6.00)	10.05 (6.00 – 12.00)
$t_{1/2}$[b] (h)	29.2 (20.0 – 41.5)	38.4 (24.2 – 88.5)
$AUC_{0-tlast}$ (ng•h/mL)	891 (26)	288 (48)
$AUC_{0-\infty}$ (ng•h/mL)	956	331

	(25)	(44)
CL/F (L/h)	157 (25)	454 (44)
V_Z/F (L)	6620 (38)	25100 (81)
V_{SS}/F (L)	4600 (33)	25200 (68)

AUC = area under the plasma concentration-time curve; CL/F = apparent total body clearance; C_{max} = maximum plasma concentration; CV = coefficient of variation; N = number of subjects; NC = not calculable; PK = pharmacokinetic; T_{max} = time to reach maximum plasma concentration; t1/2 = elimination half-life; $V_{ss}F$ = apparent volume of distribution at steady state during the terminal phase after extravascular administration; V_z/F = apparent volume of distribution during the terminal phase after extravascular administration.

a Median (range)

b Geometric mean (range)

[0129] PK parameters $AUC_{0-\infty}$ and C_{max} were analyzed separately for dose proportionality for Compound 1 from 50 to 800 mg when administered in the fed state. The analysis results suggested that for every doubling of dose, $AUC_{0-\infty}$ can be expected to increase 1.74 times more than what would be expected under dose proportionality. C_{max} appeared more than dose proportional but the formal test was inconclusive as the 90% confidence interval were partially within the 0.8 – 1.25 interval. Dose proportionality across administered doses in the fed state could not be concluded on the basis of $AUC_{0-\infty}$ or C_{max}.

[0130] PK were also evaluated in the multiple-dose, dose-escalation study, Study 2. In Part A of the study, subjects were divided into 3 cohorts and received 50, 150, or 200 mg Compound 1 or placebo for 14 consecutive days (at least 6 subjects received Compound 1 and 2 subjects received placebo in each cohort). Blood concentrations of Compound 1 were close to steady-state levels after 2 weeks of dosing and the accumulation ratio was between 2.51 to 3.65. Part B investigated the interaction of Compound 1 with midazolam (a CYP3A4 substrate), thereby determining whether this compound significantly inhibited the metabolism of drugs that are metabolized by CYP3A4 serial blood samples were collected to determine plasma concentrations of study drug after a single dose of Compound 1 had been administered and at steady state. All dosing occurred in the fed state. An assessment of diurnal cortisol levels, plus when under conditions of glucose clamp, were also carried out both prior to and during the dosing period.

[0131] Overall concentration time profiles of Compound 1 showed that absorption was moderately delayed with C_{max} achieved at a median of 5 hours following oral dosing. Consistent with the single-dose study (Study 1), concentrations appeared to decline in a bi-exponential

manner, characterized by a rapid decrease within the first 24 hours. Following multiple daily dosing for 2 weeks, the $t_{1/2}$ of Compound 1 exceeded 100 hours; therefore, an accumulation ratio of Compound 1 was between 2.51 to 3.65 (see Table 7). The T_{max} appeared to be consistent across doses. Overall half-lives, weight normalized CL/F and V/F were consistent for 150 and 200 mg. However, the values for these latter 2 parameters were almost doubled at the 50-mg dose level. Variability (CV%) for apparent clearance and volume of distribution were large and not reduced with weight-normalization.

Table 7. Summary of Noncompartmental Pharmacokinetic Parameters of Compound 1 After Single (Day 1) and Multiple (Day 14) Oral Doses of 50 mg, 150 mg, and 200 mg of Compound 1 in Part A of the Study

	Geometric Mean (CV%)					
	50 mg Day 1	**150 mg Day 1**	**200 mg Day 1**	**50 mg Day 14**	**150 mg Day 14**	**200 mg Day 14**
N	**8**	**9**	**7**	**8**	**9**	**6**
C_{max} (ng/mL)	22.7 (59)	127 (52)	143 (62)	50.3 (56)	222 (58)	314 (93)
T_{max} [a] (hr)	4.52 (3.00 – 10.00)	5.00 (5.00 - 6.00)	5.00 (2.00 - 5.00)	5.00 (3.00 - 5.00)	5.00 (3.00 - 5.03)	5.00 (3.00 - 5.00)
Effective $t_{1/2}$ [b] (hr)	NC NC	NC NC	NC NC	37.7 (27.4)	32.7 (29.7)	52.0
$AUC_{0-\infty}$ (ng•hr/mL)	NC NC	NC NC	NC NC	980 (53.8)	4680 (104)	5660 (122)
AUC_{0-24h} (ng•hr/mL)	97.6 (58)	590 (56)	559 (55[c])	273 (56)	1480 (66)	2040 (98)
C_{avg} (ng/mL)	NC NC	NC NC	NC NC	11.4 (56)	61.7 (66)	85.0 (98)
CL_{aa}/F (L/hr)	NC NC	NC NC	NC NC	183 (56)	101 (66)	98 (98)
WT-norm						
Cl_{aa}/F (L/hr/kg)	NC NC	NC NC	NC NC	2.88 (46.9)	1.42 (72.9)	1.50 (89.9)
Vz/F (L)	NC NC	NC NC	NC NC	33500 (90)	17600 (59)	16300 (76)
Vss/F (L)	NC NC	NC NC	NC NC	12900 (91)	6170 (40)	5080 (78)
WT-norm						
Vss/F (L/kg)	NC NC NC	NC NC NC	NC NC NC	204 (71.3) 2.80	86.5 (41.0) 2.51	77.4 (68.6) 3.65
R_A	NC	NC	NC	(27.4)	(29.7)	(34.4)

AUC = area under the plasma concentration-time curve; CL/F = apparent clearance; C_{max} = maximum plasma concentration; RA = accumulation ratio calculated as Day 14 AUC_{0-24}/Day 1 AUC_{0-24}; t1/2 = terminal half-life; effective t1/2 = half-life calculated by accumulation ratio; Tmax = time to maximum plasma concentration; Vss/F = volume of distribution at steady state; Vz/F = volume of distribution at terminal phase; WT-norm = weight normalized

[a] Median (range).

[b] Geometric mean (range).

[c] n = 6, Dropout Subject 306 not included in the calculation of summary statistics.

[0132] Table 8 presents the results of the dose proportionality assessment for the AUC_{0-24} and C_{max} over the tested dose range. For AUC_{0-24} and C_{max}, the adjusted mean slope at Day 1 and Day 14 were all above the value of 1, suggesting a slightly more than proportional increase of AUC_{0-24} and C_{max} values with increasing doses.

Table 8. Summary of Assessment of Dose Proportionality as Assessed by the Power Model for Plasma Compound 1

Parameter	Day	Mean Slope	Standard Error	90% CI for Slope	CV%
AUC_{0-24} (ng hr/mL)	1	1.40	0.194	(1.069, 1.737)	59.3
	14	1.48	0.221	(1.104, 1.864)	69.1
C_{max} (ng/mL)	1	1.41	0.185	(1.092, 1.728)	57.5
	14	1.33	0.210	(0.972, 1.693)	64.8

AUC = area under the plasma concentration-time curve; C_{max} = maximum plasma concentration

Safety

[0133] The safety of Compound 1 was evaluated in 2 Phase 1 studies in healthy adult volunteers (Study 1 and Study 2). In both studies, adverse events (AEs), clinical laboratory tests, vital signs (supine blood pressure and pulse rate), and electrocardiograms (ECGs) were evaluated. Overall, in Study 1, Compound 1 was well-tolerated. Compound 1, when administered as multiple doses up to 200 mg, was generally well tolerated in the healthy subject population studied.

[0134] In Study 1, the effects upon biomarkers of relevance for the treatment of alcohol dependence were investigated. Five clusters of an Addiction Research Center Inventory Questionnaire (ARCI-49) were used to compare the effect of Compound 1 vs. placebo: Morphine-Benzedrine Group Scale measuring euphoria; Lysergic-Acid-Diethylamide Group Scale estimating dysphoric and somatic changes; Pentobarbital-Chlorpromazine-Alcohol Group Scale measuring sedation; Benzedrine Group (BG) Scale measuring intellectual efficiency and energy; Amphetamine Group Scale measuring effects of d-amphetamine, respectively. No

systematic pattern or dose-response for the change from baseline or for the difference over placebo in each cluster was observed.

[0135] In summary, single, oral doses up to 800 mg and multiple doses up to 200 mg of Compound 1 were well-tolerated by healthy male and female subjects.

Example 4: Phase 2 Multiple-Dose, Dose-Escalation Clinical Studies

[0136] Cohort A of the Phase 2 Study includes a 6-week, multiple-dose, dose escalation study of Compound 1 for the treatment of adults with classic CAH. After screening, eligible patients will be enrolled into a 6-week treatment period followed by a 4-week washout/safety follow-up period.

[0137] This cohort will be conducted in approximately 9 patients, who will receive Compound 1 daily for up to 6 weeks. Compound 1 will be administered as an oral daily dose. Patients will undergo titration of Compound 1 through three escalating dosage strengths at 2-week intervals. Patients will have overnight PK/PD assessments performed at baseline, which include an pre-dose overnight assessment and a post-dose overnight assessment for PK/PD following administration of the first dose. At the end of each 2-week dosing period, patients will return for single overnight visits for steady-state PK/PD assessments. A follow-up outpatient visit will occur 30 days after their last dose. Upon completion of the initial cohort (Cohort A), the study will proceed to a multiple ascending dose (MAD) design with up to 3 sequential cohorts (Cohorts B, C, and D) to further evaluate the safety, PK, and PD of various SPR001 dosing regimens and to identify an optimal dose regimen. Each cohort will undergo a 2-week run-in period, a 2-week treatment period, and a 30-day washout and safety follow-up period. During the run-in period, which will occur during screening, subjects will document in a paper diary each dose of glucocorticoid medication taken, the time of each meal, and the time they went to bed and woke up each day, to ensure compliance with background glucocorticoid regimens and the stability of their daily routine.

[0138] Patients in Cohort B will receive study drug at 200 mg BID, with a dose in the morning and a dose in the evening, either with a meal or consumption of a standardized snack. For Cohorts C and D, the dose level and the frequency and timing of dosing will be determined based on interim data from the previous cohorts. However, the dose level of each successive cohort will be capped at twice the daily dose level of the previous cohort.

Study Design

- Study Type: Interventional
- Primary Purpose: Treatment
- Study Phase: Phase 2
- Interventional Study Model: Sequential Assignment

- Number of Cohorts: Up to 4
- Masking: No masking
- Allocation: Non-Randomized
- Enrollment: Up to approximately 27 [Anticipated]

Arms and Interventions

Arms	Assigned Interventions
Experimental: Cohort A The first cohort of 9 patients will be administered Compound 1 at dose strength of 200 mg daily for 2 weeks, and escalating through 600 mg per day for 2 weeks and 1,000 mg per day for 2 weeks.	Drug: Compound 1 200-mg capsules
Experimental: Cohort B Cohort B patients will be administered Compound 1 at a dose strength of 200 mg twice daily (BID) for 2 weeks.	Drug: Compound 1 200-mg capsules
Experimental: Cohort C The dose/dose regimen for Cohort C will be determined based on an interim review of safety and PK/PD data from the previous Cohorts	Drug: Compound 1 50-mg or 200 mg capsules
Experimental: Cohort D The dose/dose regimen for Cohort C will be determined based on an interim review of safety and PK/PD data from the previous Cohorts	Drug: Compound 1 50-mg or 200 mg capsules

Outcome Measures

Primary Outcome Measure:

1. To evaluate the safety of Compound 1 in subjects with CAH.

2. To assess the efficacy of Compound 1 in subjects with classic CAH as measured by percent and absolute change in 17-OHP compared to baseline.

Secondary Outcome Measure:

3. To explore the dose(s) of Compound 1 that cause pharmacodynamics changes in plasma concentrations of ACTH, androstenedione, and testosterone, as measured by the absolute and percent change from baseline by dose.

4. To determine pharmacokinetics of Compound 1 in subjects with CAH.

5. To explore potential relationships between pharmacodynamics and pharmacokinetics.

Exploratory

7. To explore the dose(s) of Compound 1 that cause changes in pharmacodynamics biomarkers in urine, as measured by the absolute and percent change from baseline by dose.

Eligibility

- Minimum Age: 18 Years
- Maximum Age:
- Sex: All

- Gender Based: No
- Accepts Healthy Volunteers: No
- Criteria: Inclusion

Criteria:

Inclusion Criteria:

- Male and female patients age 18 or older.
- Documented diagnosis of classic CAH due to 21-hydroxylase deficiency
- Elevated 17-OHP at screening
- On a stable glucocorticoid replacement regimen for a minimum of 30 days

Exclusion Criteria:

- Clinically significant unstable medical condition, illness, or chronic disease
- Clinically significant psychiatric disorder.
- Clinically significant abnormal laboratory finding or assessment
- History of bilateral adrenalectomy or hypopituitarism
- Pregnant or nursing females
- Use of any other investigational drug within 30 days
- Unable to understand and comply with the study procedures, understand the risks, and/or unwilling to provide written informed consent.

Results:

The phase 2 study showed that Compound 1 was generally well-tolerated. The study established a range of safe doses after exploring a wide range of doses (5-fold range) (see FIG. 1).

[0139] With respect to patient-level response to Compound 1, 80% showed reduced ACTH (see FIG. 2). Generally, attenuation of ACTH demonstrates target engagement and functional CRF_1 receptor antagonism. 80% of patient subjects demonstrated reduction in ACTH. 70% of subject demonstrated more than 25% reduction in ACTH. 40% of subjects were in the normal range after treatment.

[0140] A reduction of 17-OHP demonstrates "control" of the disease based on Standard guidelines. This allows for steroid taper. 80% of subjects demonstrated reduction in 17-OHP (see FIG. 3). 50% of subjects demonstrated more than 25% reduction in 17-OHP. 50% of subjects were within the guideline range (1200 ng/dL) after treatment.

Compound 1 attenuates morning rise in A4 which indicates an ability to control excess androgen production and associated symptoms (see FIG. 4). 100% of subjects demonstrated reduction in Androstenedione (at various doses). 60% of subjects demonstrated more than 25% reduction in Androstenedione. 50% of subjects were within normal reference range after treatment.

Example 5: Formulation Development

[0141] The objectives of this experiment was to (1) evaluate different formulations to obtain a Compound 1 200 mg immediate release core tablet; (2) evaluate dissolution profiles of

Compound 1 tablets in wet granulation process and in granulation with Gelucire 48/16 and/or Vitamin E TPGS; and (3) evaluate dissolution of the tablets/capsules in various bio-relevant media and sink conditions to compare dissolution of API in capsule.

Experimental Outcomes

[0142] The formulation of Compound 1 tablets were performed in two phases.

[0143] In the first phase of manufacturing, two immediate release trial formulations were manufactured. The first trial involved granulation of Compound 1 using Gelucire (10%) and included fillers and disintegrants. No surfactant was used in his formulation. The granules were final belnded and compressed at a tablet weight of 500 mg. No issues were observed in granulation and compression. The second trial involved wet granulation with HPC as the binder with fillers and disintegrants. Sodium lauryl sulphate was used as a surfactant at a concentration of 1%. The granules were softer when compared to the first trial and the final blend had poor flow. The filler in the extra granular portion was increased to improve flow and weight variation during compression. The tablets were compressed at 600 mg tablet weight. The first and second trial batches were tested for dissolution in different bio-relevant media – SGF (simulated gastric fluid), SIF (simulated intestinal fluid), FaSSIF (fasted state simulated intestinal fluid) and FeSSIF (fed state simulated intestinal fluid).

[0144] In the second phase of manufacturing, two additional formulations with Gelucire and Vitamin E TPGS at a percentage of 8% and with high concentration of sodium lauryl sulphate were manufactured. The percentage of the surfactant was increased to 7%. The tablets were compressed at 570 mg tablet weight. No issues were observed in the manufacturing process. Further development included manufacturing with high concentration of Gelucire (25%). Due to the high concentration of the Gelucire in the formulation, the granules could not be compressed and were manually filed into size 0 capsules.

[0145] Further development of wet granulation process was recommended as the flow was poor and particle size of granules was not optimum. The granules from the wet granulation formulation also showed weight variation during compression.

[0146] The release in SIF and FaSSIF was very low, ranging from between 0.5% to 3% at 60 minutes for the Gelucire and HPC formulations. The release in SGF and FeSSIF was higher and ranged from 11-16% in 60 minutes. The higher release in SGF and FeSSIF may have been due to the presence of surfactants in the media. However, the dissolution in the bio-relevant media did not show improvement with the lipid excipients or high concentration of surfactants. The release in SIF and FeSSIF was below 2%, in SGF approximately 15% and 10% in FeSSIR at 60 minutes. Dissolution showed no improvement with high concentration of Gelucire in the capsule formulation. A comparison of the dissolution of API in capsule and the different

formulations did not show any improvement in dissolution. An animal pK study was also prformed with the wet granulation formulation and the Gelucire formulation. The dissolution and pK studies indicate that the current formulation approach may not be suitable to improve bioavailability of Compound 1 or minimize the food effect. A different formulation approach was recommended for Compound 1 in Phase 2/3 studies.

Example 6: Preliminary Tablet formulation

[0147] The objective of the general experiments were to develop, manufacture and commercialize a small tablet or capsule for a drug substance that is insoluble (solubility less than 0.002 mg/ml in water and at all physiological pHs ranging from 1.2 to 7.5) and a dose strength up to 200 mg. Tablet should be immediately released in a dissolution medium using USP apparatus I or II.

Success criteria

1. A tablet size less than 400 mg for a dose strength of 200 mg
2. More than 70% dissolved in 60 minutes in conventional dissolution media.

General Manufacturing Procedure

[0148] The relevant excipients were manually sieved and then dry mixed. A binder solution was added and the mixture subjected to wet granulation. The granules were then wet milled and dried. The resulting granules were dry milled and added to other relevant common granules and excipients. The mixture was then compressed into tablets to a target tablet weight.

[0149] A granulation was developed with a minimum amount and number of excipients. The granulation consisted of at least 90% Compound 1 with a surfactant and a binder and in some cases, a super-disintegrant. After granulation was successful, other excipients were added to enable compression. These excipients included a compression aid, a lubricant, an anti-tacking agent and a super-disintegrant.

[0150] Two blends were granulated. One blend had 95% Compound 1, 1% sodium lauryl sulfate, and 4% HPC-EXF. The second blend had 91% Compound 1, 1% sodium lauryl sulfate (surfactant and wetting agent), 6% PVP (water soluble binder) and 2% Ac-di-sol (water-swellable super-disintegrant).

[0151] The granulation consisting of HPC-EXF (binder) was further blended with SiO_2 (flow aid and anti-tacking agent), ac-di-sol (water swellable disintegrant) and magnesium stearate (lubricant). Different levels of MCC were added to the tablets (0, 10 and 20% levels). All three formulations (90%, 81% and 71% DL) dissolved quickly, and there were no significant changes during accelerated stability in open dish conditions. The granulation with PVP as a binder was repeated three times. The first granulation consisted of 93% Compound 1, 6% PVP and 1%

SLS. This formulation demonstrated inferior manufacturing features (granular flow) however the tablets had acceptable dissolution. No further stability was conducted.

[0152] The second granulation (identical to first) had acceptable manufacturing features (good flow and compression) however dissolution was somewhat slower and there were significant changes during on stability in very stressful conditions.

[0153] The third granulation consisted of 91% Compound 1, 6% PVP, 1% SLS and 2% Ac-di-sol as intra-granular super-disintegrant. The granulation was further blended with SiO_2 (flow aid and anti-tacking agent), ac-di-sol (water swellable disintegrant) and magnesium stearate (lubricant). Different levels of MCC were added to the tablets (0, 10 and 20% levels). All three formulations (86%, 77% AND 68% DL) all dissolved quickly.

[0154] This demonstrated a successful tablet of Compound 1 with water solubility less than 0.002 mg/ml, while maintaining a drug load above 50% and resulting in acceptable dissolution in a conventional dissolution media (1% SLS and USP apparatus II). The tablet was manufactured using a conventional high shear wet granulation method.

Table 10. Summary of Compound 1 solubility in different aqueous media (n=2, 24 hours at room temperature)

Aqueous media	Equilibrium pH	Solubility mg/mL	Standard Deviation (n=2)	Description
Water	7.78	0.0003	0.0000	insoluble
0.1N HCl	1.06	0.0018	0.0000	insoluble
0.01N HCl	2.06	0.0004	0.0000	Insoluble
0.001N HCl	3.36	0.0003	0.0000	Insoluble
pH 4.5 Acetate (USP)	4.65	0.0005	0.0000	Insoluble
pH 6.0 Phosphate (USP)	6.08	0.0002	0.0000	Insoluble
pH 7.5 Phosphate (USP)	7.57	0.0006	0.0000	Insoluble
0.1N NaOH	11.65	0.0002	0.0000	Insoluble
SGF	2.25	0.0204	0.0001	Insoluble
FaSSIF	6.73	0.0036	0.0000	Insoluble
FaSSIF	5.16	0.0104	0.0000	insoluble

Example 7: Tablet Formulation A

[0155] Three formulations were prepared using wet granulations with common granules and PVP K30 as a binder (see Table 11). The granules were diluent with MCC PH102 with 95%, 85% and 75% drug loads respectively.

Table 11. Manufacturing Formulae A

Material	A-1		A-2		A-3	
	%w/w	mg/tablet	%w/w	mg/tablet	%w/w	mg/tablet
Common Granular						
Compound 1	93	200.00	93	200.00	93	200.00
Povidone Compendial [plasdoneK-29/32]	6	12.90	6	12.90	6	12.90
Kolliphor® SLS fine	1	2.15	1	2.15	1	2.15
Extra Granular						
Common granules	95	215.05	85	215.05	75	215.05
Microcrystalline Cellulose PH102	-	0.00	10	25.30	20	57.35
Croscarmellose Sodium, Compendial	3	6.79	3	7.59	3	8.60
Silica Dioxide (Aerosil200Pharma)	1	2.26	1	2.53	1	2.87
LIGAMEDMF-2-V Magnesium Stearate	1	2.26	1	2.53	1	2.87
Target Tablet Weight (mg)		226.37		253.00		286.73

[0156] Compound 1, Povidone and sodium lauryl sulfate were mixed to produce a dry mixture. Water was added to the dry mixture and subjected to a wet granulation at an impeller speed of about 550 – 560 rpm. The wet granules were then sifted and dried. The dry granules were dry-sieved after which the granules were compressed into tablets.

[0157] In process control tests, each tablet was satisfactory. Dissolution results of A-1 and A-3 showed similar curves whereas A-2 was slightly slower than the other two in the first few points (see table 12 and FIG. 5).

Table 12. Dissolution for Manufacturing Formulae A

Dissolution in 0.1N HCl + 1.0% SDS, media at 50 rpm and 900 ml using USP-II (Paddle)			
Time points (Minutes)	A-1	A-2	A-3
5 minutes	48.4	35.0	46.7
10 minutes	58.3	48.2	56.4
15 minutes	65.2	55.9	62.2
20 minutes	70.4	61.3	65.9
30 minutes	78.1	68.3	71.9
45 minutes	85.6	77.4	79.3
60 minutes	91.5	84.1	85.1

90 minutes	98.5	92.6	91.9
120 minutes	100.5	97.2	95.6

Example 8: Tablet Formulation B

[0158] Three formulations were prepared using wet granulation with common granules and PVP K30 as a binder (see Table 13). The granules were diluent with MCC PH102 with 95%, 85% and 75% drug loads respectively.

Table 13. Manufacturing Formulae B

Material	B-1		B-2		B-3	
	%w/w	mg/tablet	%w/w	mg/tablet	%w/w	mg/tablet
Common Granular						
Compound 1	93	200.00	93	200.00	93	200.00
Povidone Compendial [plasdoneK-29/32]	6	12.90	6	12.90	6	12.90
Kolliphor® SLS fine	1	2.15	1	2.15	1	2.15
Extra Granular						
Common granules	95	215.05	85	215.05	75	215.05
Microcrystalline Cellulose PH102	-	0.00	10	25.30	20	57.35
Croscarmellose Sodium, Compendial	3	6.79	3	7.59	3	8.60
Silica Dioxide (Aerosil200Pharma)	1	2.26	1	2.53	1	2.87
LIGAMEDMF-2-V Magnesium Stearate	1	2.26	1	2.53	1	2.87
Target Tablet Weight (mg)		226.37		253.00		286.73

[0159] Compound 1, Povidone and sodium lauryl sulfate were mixed to produce a dry mixture. Water was added to the dry mixture and subjected to a wet granulation at an impeller speed of about 600 – 610 rpm. The wet granules were then sifted and dried. The dry granules were dry-sieved after which the granules were compressed into tablets.

[0160] Dissolution results showed slower dissolution than previous tablets which may be caused by more granules and more hardness (see table 14 and FIG. 6).

Table 14. Dissolution for Manufacturing Formulae B

Dissolution in 0.1N HCl + 1.0% SDS, media at 50 rpm and 900 ml using USP-II (Paddle)			
Time points (Minutes)	B-1	B-2	B-3
5 minutes	9.4	13.7	20.4
10 minutes	21.2	33.3	47.0
15 minutes	28.6	47.8	56.4
20 minutes	34.7	54.3	61.9
30 minutes	41.8	62.0	68.2
45 minutes	49.5	70.1	74.4
60 minutes	56.3	75.8	78.8

90 minutes	66.9	84.0	84.3
120 minutes	74.8	89.5	87.4

Example 9: Tablet Formulation C

[0161] Three formulations were prepared using wet granulation with common granules, PVP K30 as a binder, and 2% Croscarmellose Sodium Intragranular (see Table 15).

Table 15. Manufacturing Formulae C

Material Name	C-1		C-2		C-3	
	%w/w	Mg/tablet	%w/w	Mg/tablet	%w/w	Mg/tablet
Common Granular						
C07102401-F	91	200	91	200	91	200
Povidone Compendial [plasdoncK-29/32]	6	13.2	6	13.2	6	13.2
Kolliphor® SLS Fine	1	2.2	1	2.2	1	2.2
Croscarmellose Sodium, Compendial	2	4.4	2	4.4	2	4.4
Extra Granular						
Common granules	95	219.78	85	219.78	75	219.78
Microcrystalline Cellulose PH102	-	-	10	25.86	20	58.61
Croscarmellose Sodium, Compendial	3	6.94	3	7.76	3	8.79
Silica Dioxide(Aerosil200Pharma)	1	2.31	1	2.59	1	2.93
LIGAMEDMF-2-V Magnesium Stearate	1	2.31	1	2.59	1	2.93
Target Tablet Weight (mg)		231.36		258.60		293.06

[0162] Compound 1, Povidone, croscarmellose sodium and sodium lauryl sulfate were mixed to produce a dry mixture. Water was added to the dry mixture and subjected to a wet granulation at an impeller speed of about 600 – 610 rpm. The wet granules were then sifted and dried. The dry granules were dry-sieved after which the granules were compressed into tablets.

[0163] Dissolution results showed faster dissolution than other tablets which may be caused by the additional quantity of croscarmellose sodium (see Table 16 and FIG. 7).

Table 16. Dissolution for Manufacturing Formulae C

Dissolution in 0.1N HCl + 1.0% SDS, media at 50 rpm and 900 ml using USP-II (Paddle)			
Time points (Minutes)	1806DFP2555-02A	1806DFP2555-02B	1806DFP2555-02C
5 minutes	26.3	25.1	26.2
10 minutes	66.3	62.7	65.8
15 minutes	79.9	81.7	77.8
20 minutes	85.4	89.3	83.6
30 minutes	90.6	94.9	88.5
45 minutes	94.2	98.3	92.4
60 minutes	95.4	99.6	94.1

90 minutes	95.3	100.2	95.0
120 minutes	95.5	100.4	95.7
250RPM/5min	95.6	100.5	98.0

Example 10: Tablet Formulation D

[0164] Two formulations were prepared using wet granulation (see Table 17).

Table 17. Manufacturing Formulae D

Material Name	D-1			D-2		
	%w/w	mg/tablet	Batch formula	%w/w	Mg/tablet	Batch formula
C07102401-F	71.25	200.000	570.00	77.35	200.000	546.00
Kluccl(TM)EXF PHARM Hydroxypropyl cellulose	3.00	8.421	24.00	-	-	-
Povidone Compendial |plasdoneK-29/32|	-	-	-	5.10	13.187	36.00
Kolliphor® SLS Fine	0.75	2.105	6.00	0.85	2.198	6.00
Croscarmellose Sodium, Compendial	-	-	-	1.70	4.396	12.00
Extra granular material						
Microcrystalline Cellulose PH102	20.00	56.140	160.00	10.00	25.856	70.59
Croscarmellose Sodium, Compendial	3.00	8.421	24.00	3.00	7.757	21.18
Silica Dioxide (Aerosil200 Pharma)	1.00	2.807	8.00	1.00	2.586	7.06
LIGAMEDMF-2-V Magnesium Stearate	1.00	2.807	8.00	1.00	2.586	7.06
Target Tablet Weight (mg)		280.701	800.00		258.566	705.89

[0165] Compound 1, Povidone, croscarmellose sodium and sodium lauryl sulfate were mixed to produce a dry mixture. Water was added to the dry mixture and subject to a wet granulation at an impeller speed of about 600 – 610 rpm. The wet granules were then sifted and dried. The dry granules were dry-sieved after which the granules were compressed into tablets.

[0166] The release profile of Formulation D-1 and D2 were similar to previous formulations with no significant changes (see Table 18).

Table 18. Dissolution for Manufacturing Formulae C

Dissolution in 0.1N HCl + 1.0% SDS, media at 50 rpm and 900 ml using USP-II (Paddle)		
Time points (Minutes)	D-1	D-2
5 minutes	18.7	30.6
10 minutes	43.8	72.1
15 minutes	56.9	85.1
20 minutes	65.2	91.5
30 minutes	73.9	96.4
45 minutes	81.9	99.9
60 minutes	87.1	101.3

90 minutes	92.4	102.3
120 minutes	95.6	-
250RPM/5min	99.4	100.9

[0167] Both formulations had a faster relief profile in SGF media (see Table 19).

Table 19. Dissolution for Manufacturing Formulae C in SGF media


Dissolution in SGF, media at 60 rpm and 900 ml using USP-II (Paddle)			
Time points (Minutes)	D-1	D-2	Capsule with Compound 1
5 minutes	10.8	7.0	0.3
10 minutes	18.4	11.0	1.9
15 minutes	21.3	11.8	4.2
20 minutes	23.4	12.2	6.5
30 minutes	24.4	12.4	9.4
45 minutes	26.1	12.8	13.6
60 minutes	25.7	13.0	15.1
90 minutes	27.9	13.1	15.5
120 minutes	28.2	13.2	15.2
250RPM/5min	28.0	13.2	15.8

[0168] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

CLAIMS

WHAT IS CLAIMED IS:

1. A pharmaceutical composition in the form of a capsule comprising Compound 1:




or a pharmaceutically acceptable salt or solvate thereof.

2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises between about 1 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.
3. The pharmaceutical composition of claim 1 or 2, wherein the pharmaceutical composition comprises between about 5 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.
4. The pharmaceutical composition of any one of claims 1 to 3, wherein the pharmaceutical composition comprises between about 10 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.
5. The pharmaceutical composition of any one of claims 1 to 4, wherein the pharmaceutical composition comprises between about 10 mg and about 300 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.
6. The pharmaceutical composition of any one of claims 1 to 5, wherein the pharmaceutical composition comprises between about 10 mg and about 100 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.
7. The pharmaceutical composition of any one of claims 1 to 4, wherein the pharmaceutical composition comprises between about 50 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.
8. The pharmaceutical composition of any one of claims 1 to 4, wherein the pharmaceutical composition comprises between about 100 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.
9. The pharmaceutical composition of any one of claims 1 to 4, wherein the pharmaceutical composition comprises between about 100 mg and about 400 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

10. The pharmaceutical composition of any one of claims 1 to 5, wherein the pharmaceutical composition comprises between about 100 mg and about 300 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.
11. The pharmaceutical composition of any one of claims 1 to 5, wherein the pharmaceutical composition comprises between about 150 mg and about 250 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.
12. The pharmaceutical composition of any one of claims 1 to 4, wherein the pharmaceutical composition comprises about 400 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.
13. The pharmaceutical composition of any one of claims 1 to 5, wherein the pharmaceutical composition comprises about 300 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.
14. The pharmaceutical composition of any one of claims 1 to 5, wherein the pharmaceutical composition comprises about 250 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.
15. The pharmaceutical composition of any one of claims 1 to 5, wherein the pharmaceutical composition comprises about 200 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.
16. The pharmaceutical composition of any one of claims 1 to 5, wherein the pharmaceutical composition comprises about 150 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.
17. The pharmaceutical composition of any one of claims 1 to 6, wherein the pharmaceutical composition comprises about 100 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.
18. The pharmaceutical composition of any one of claims 1 to 6, wherein the pharmaceutical composition comprises about 80 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.
19. The pharmaceutical composition of any one of claims 1 to 6, wherein the pharmaceutical composition comprises about 60 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.
20. The pharmaceutical composition of any one of claims 1 to 6, wherein the pharmaceutical composition comprises about 50 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

21. The pharmaceutical composition of any one of claims 1 to 6, wherein the pharmaceutical composition comprises about 30 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.
22. The pharmaceutical composition of any one of claims 1-21, wherein Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is in the form of microparticles.
23. The pharmaceutical composition of claim 22, wherein the average size of the microparticles is between about 1 μm and about 20 μm.
24. The pharmaceutical composition of claim 22 or 23, wherein the average size of the microparticles is between about 5 μm and about 15 μm.
25. The pharmaceutical composition of any one of claims 22 to 24, wherein the average size of the microparticles is less than about 10 μm.
26. The pharmaceutical composition of any one of claims 1 to 25, wherein the capsule is a hard gelatin capsule.
27. The pharmaceutical composition of any one of claims 1 to 25, wherein the capsule is a soft gelatin capsule.
28. The pharmaceutical composition of any one of claims 1 to 27, wherein the capsule is formed using materials selected from the group consisting of natural gelatin, synthetic gelatin, pectin, casein, collagen, protein, modified starch, polyvinylpyrrolidone, acrylic polymers, cellulose derivatives, and any combinations thereof.
29. The pharmaceutical composition of any one of claims 1 to 28, wherein the pharmaceutical composition is free of additional excipients.
30. The pharmaceutical composition of any one of claims 1 to 28, wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.
31. A pharmaceutical composition in the form of a tablet comprising Compound 1:



or a pharmaceutically acceptable salt or solvate thereof.
32. The pharmaceutical composition of claim 31, wherein the pharmaceutical composition comprises between about 1 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

33. The pharmaceutical composition of claim 31 or 32, wherein the pharmaceutical composition comprises between about 5 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

34. The pharmaceutical composition of any one of claims 31 to 33, wherein the pharmaceutical composition comprises between about 10 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

35. The pharmaceutical composition of any one of claims 31 to 34, wherein the pharmaceutical composition comprises between about 10 mg and about 300 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

36. The pharmaceutical composition of any one of claims 31 to 35, wherein the pharmaceutical composition comprises between about 10 mg and about 100 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

37. The pharmaceutical composition of any one of claims 31 to 34, wherein the pharmaceutical composition comprises between about 50 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

38. The pharmaceutical composition of any one of claims 31 to 34, wherein the pharmaceutical composition comprises between about 100 mg and about 500 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

39. The pharmaceutical composition of any one of claims 31 to 34, wherein the pharmaceutical composition comprises between about 100 mg and about 400 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

40. The pharmaceutical composition of any one of claims 31 to 35, wherein the pharmaceutical composition comprises between about 100 mg and about 300 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

41. The pharmaceutical composition of any one of claims 31 to 35, wherein the pharmaceutical composition comprises between about 150 mg and about 250 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

42. The pharmaceutical composition of any one of claims 31 to 34, wherein the pharmaceutical composition comprises about 400 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

43. The pharmaceutical composition of any one of claims 31 to 35, wherein the pharmaceutical composition comprises about 300 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

44. The pharmaceutical composition of any one of claims 31 to 35, wherein the pharmaceutical composition comprises about 250 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

45. The pharmaceutical composition of any one of claims 31 to 35, wherein the pharmaceutical composition comprises about 200 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

46. The pharmaceutical composition of any one of claims 31 to 35, wherein the pharmaceutical composition comprises about 150 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

47. The pharmaceutical composition of any one of claims 31 to 36, wherein the pharmaceutical composition comprises about 100 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

48. The pharmaceutical composition of any one of claims 31 to 36, wherein the pharmaceutical composition comprises about 80 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

49. The pharmaceutical composition of any one of claims 31 to 36, wherein the pharmaceutical composition comprises about 60 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

50. The pharmaceutical composition of any one of claims 31 to 36, wherein the pharmaceutical composition comprises about 50 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof.

51. The pharmaceutical composition of any one of claims 31 to 36, wherein the pharmaceutical composition comprises about 30 mg of Compound 1, or a pharmaceutically acceptable salt or solvate thereof. The pharmaceutical composition of any one of claims 31 to 50, wherein Compound 1, or a pharmaceutically acceptable salt or solvate thereof, is in the form of microparticles.

52. The pharmaceutical composition of claim 51, wherein the average size of the microparticles is between about 1 μm and about 20 μm.

53. The pharmaceutical composition of claim 51 or 52, wherein the average size of the microparticles is between about 5 μm and about 15 μm.

54. The pharmaceutical composition of any one of claims 51 to 53, wherein the average size of the microparticles is less than about 10 μm.

55. The pharmaceutical composition of any one of claims 31 to 54, wherein the tablet is made by compression, molding, or extrusion.

56. The pharmaceutical composition of claim 55, wherein the tablet is made by hot-melt extrusion.

57. The pharmaceutical composition of any one of claims 31 to 56, wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.

58. The pharmaceutical composition of any one of claims 1 to 57, wherein the pharmaceutical composition is stable for at least 1 month at 25 °C.

59. The pharmaceutical composition of any one of claims 1 to 58, wherein the pharmaceutical composition is stable for at least 3 months at 25 °C.

60. The pharmaceutical composition of any one of claims 1 to 59, wherein the pharmaceutical composition is stable for at least 6 months at 25 °C.

61. The pharmaceutical composition of any one of claims 1 to 60, wherein the pharmaceutical composition is stable for at least 9 months at 25 °C.

62. The pharmaceutical composition of any one of claims 1 to 61, wherein the pharmaceutical composition is stable for at least 12 months at 25 °C.



Mean SPR001 Concentration (ng/mL)
Time from Dose (hr)
1000 mg Q24h Day 42
800 mg Q24h Day 56
200 mg Q24h Day 14
100 mg single dose, Day 1

FIG. 1



ACTH
% Change from Baseline
100
50
0
-50
-100

FIG. 2



17-OHP
% Change from Baseline
50
25
0
-25
-50
-75
-100
-125

FIG. 3



Androstenedione
% Change from Baseline
25
0
-25
-50
-75
-100

FIG. 4



120.0
100.0
80.0
60.0
40.0
20.0
0.0
Release%
A-1
A-2
A-3
0
20
40
60
80
100
120
140
T/min

FIG. 5



100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
Dissolution%
B-1
B-2
B-3
0
20
40
60
80
100
120
140
T/min

FIG. 6



120.0
100.0
80.0
60.0
40.0
20.0
0.0
Dissolution/%
0
20
40
60
80
100
120
140
T/min
C-1
C-2
C-3

FIG. 7

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 18/46707

A. CLASSIFICATION OF SUBJECT MATTER
IPC(8) - C07D 471/04 (2018.01)
CPC - A61P 35/00, C07D 471/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
See Search History Document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
See Search History Document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
See Search History Document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2010/0222339 A1 (Chen et al.) 02 September 2010 (02.09.2010); Abstract, para[0055], para[0056], para[0144]	1-3, 31-33
A	US 2011/0166345 A1 (Rizzo et al.) 07 July 2011 (07.07.2011); entire document	1-3, 31-33
A	US 2010/0022560 A1 (Chen et al.) 28 January 2010 (28.01.2010); entire document	1-3, 31-33
A	Hodgetts et al. 'Discovery of N-(1-Ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): An Orally Active Corticotropin Releasing Factor-1 (CRF-1) Receptor Antagonist', Journal of Medicinal Chemistry, 07 May 2011 (07.05.2011), Vol.54, pages4187-4206; entire document	1-3, 31-33

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
08 October 2018	24 OCT 2018
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-8300	Authorized officer: Lee W. Young PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774

Form PCT/ISA/210 (second sheet) (January 2015)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 18/46707

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 4-30, 34-62
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

Bibliographic data

Title:	Thiazole pyrazolopyrimidines as crf1 receptor antagonists
Pub/Pat no:	CN101516887A
Pub/Issue Date:	2009-08-26
Inventor(s):	ZHAOGEN CHEN[US]| HAMDOUCHI HAMDOUCHI CHAFIQ [US]| JAMES HEMBRE ERIK[US]| ARTHUR HIPSKIND PHILIP[US]| KENNETH MYERS JASON[US]| TAKAKO TAKAKUWA[US]| LEE TOTH JAMES[US] |CHEN ZHAOGEN |HAMDOUCHI CHAFIQ HAMDOUCHI |HEMBRE ERIK JAMES |HIPSKIND PHILIP ARTHUR |MYERS JASON KENNETH |TAKAKUWA TAKAKO |TOTH JAMES LEE
Applicant(s):	LILLY CO ELI[US]
Classification:	A61K31/505AI; A61P25/22AI; A61P25/24AI; A61P25/30AI; A61P29/00AI; C07D487/04AI
Application number:	CN20078035145 2007-09-17
Priority number:	WO2007US78605 20070917; US20060826264P 20060920;

Abstract of CN101516887A

The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.

[19] 中华人民共和国国家知识产权局

[12] 发明专利申请公布说明书

[21] 申请号 200780035145.3

[51] Int. Cl.
C07D 487/04 (2006.01)
A61P 25/22 (2006.01)
A61K 31/505 (2006.01)
A61P 25/24 (2006.01)
A61P 29/00 (2006.01)
A61P 25/30 (2006.01)

[43] 公开日 2009 年 8 月 26 日

[11] 公开号 CN 101516887A

[22] 申请日 2007.9.17
[21] 申请号 200780035145.3
[30] 优先权
[32] 2006. 9.20 [33] US [31] 60/826,264
[86] 国际申请 PCT/US2007/078605 2007.9.17
[87] 国际公布 WO2008/036579 英 2008.3.27
[85] 进入国家阶段日期 2009.3.20
[71] 申请人 伊莱利利公司
地址 美国印第安纳州
[72] 发明人 Z·陈 C·H·哈姆杜迟
E·J·亨布雷
P·A·希普斯金德
J·K·迈尔斯 高赤贵子
J·L·托特

[74] 专利代理机构 北京市中咨律师事务所
代理人 黄革生 贾士聪


权利要求书 3 页 说明书 49 页

[54] 发明名称

作为 CRF1 受体拮抗剂的噻唑吡唑并嘧啶类


[57] 摘要

本发明涉及式(I)化合物、其药学上可接受的盐以及其作为促肾上腺皮质激素释放因子 1(CRF1)受体拮抗剂在治疗精神病学和神经内分泌障碍、神经病学疾病和代谢综合征中的用途。



I

1. 式 I 化合物或其药学上可接受的盐:







式 I

其中:

R^1 和 R^2 独立地是乙基或正丙基;


R^3 是氢、Cl、Br、甲基、三氟甲基或甲氧基;


R^4 是氢、Br、R^aR^bN-、甲氧基甲基、正丁基、乙酰氨基、吡啶-4-基、吗啉-4-基、  、  、  或  ;

R^a 和 R^b 独立地是氢、C_1-C_3 烷基、$H_2NCH_2CH_2$-、$(CH_3)_3COC(O)NHCH_2CH_2$-或 $CH_3CH_2CH_2NHCH_2CH_2$-。

2. 根据权利要求 1 所述的化合物或其药学上可接受的盐,其中 R^3 是 Cl、Br、甲基或三氟甲基。

3. 根据权利要求 1 或 2 所述的化合物或其药学上可接受的盐,其中 R^3 是 Cl 或 Br。

4. 根据权利要求 1 至 3 中任意一项所述的化合物或其药学上可接受的盐,其中 R^4 是 R^aR^bN-、吡啶-4-基、吗啉-4-基或  。

5. 根据权利要求 1 至 4 中任意一项所述的化合物或其药学上可接受的盐,其中 R^4 是吗啉-4-基或  。

6. 根据权利要求 1 至 4 中任意一项所述的化合物或其药学上可接受的盐，其中 R^4 是 R^aR^bN-，R^a 和 R^b 独立地是 C_1-C_3 烷基。

7. 根据权利要求 1 所述的化合物或其药学上可接受的盐，其是 3-[4-溴-2-(2-甲基-2*H*-[1,2,4]三唑-3-基)-噻唑-5-基]-2,5-二甲基-7-(1-丙基-丁基)-吡唑并[1,5-*a*]嘧啶。

8. 根据权利要求 1 所述的化合物或其药学上可接受的盐，其是 3-(4-溴-2-(2-甲基-2H-[1,2,4]三唑-3-基)-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶。

9. 根据权利要求 1 所述的化合物或其药学上可接受的盐，其是 3-(4-氯-2-吗啉-4-基-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶。

10. 一种药物组合物，其包含：权利要求 1 至 9 中任意一项所述的化合物或其药学上可接受的盐和药学上可接受的赋形剂。

11. 一种治疗患者的抑郁、焦虑、酒精或物质滥用、肥胖、高血压、代谢综合征、肠易激惹综合征、癫痫、中风、睡眠障碍、变态反应、偏头痛、经前期综合征、不孕、性功能障碍、先天性肾上腺增生、库欣病、早产、应激诱导的胃溃疡、炎性障碍、垂体肿瘤或异位垂体源肿瘤、慢性疲劳综合征、纤维肌痛、内脏痛或多发性硬化的方法，其包括：给需要其的患者施用治疗有效量的权利要求 1 至 9 中任意一项所述的化合物或其药学上可接受的盐。

12. 一种治疗患者的焦虑或抑郁的方法，其包括：给需要其的患者施用治疗有效量的权利要求 1 至 9 中任意一项所述的化合物或其药学上可接受的盐。

13. 一种治疗患者的酒精或物质滥用的方法，其包括：给需要其的患者施用治疗有效量的权利要求 1 至 9 中任意一项所述的化合物或其药学上可接受的盐。

14. 根据权利要求 1 至 9 中任意一项所述的化合物或其药学上可接受的盐，其用在治疗中。

15. 根据权利要求 1 至 9 中任意一项所述的化合物或其药学上可接受

的盐，其用于治疗抑郁、焦虑、酒精或物质滥用、肥胖、高血压、代谢综合征、肠易激惹综合征、癫痫、中风、睡眠障碍、变态反应、偏头痛、经前期综合征、不孕、性功能障碍、先天性肾上腺增生、库欣病、早产、应激诱导的胃溃疡、炎性障碍、垂体肿瘤或异位垂体源肿瘤、慢性疲劳综合征、纤维肌痛、内脏痛或多发性硬化。

16. 根据权利要求 1 至 9 中任意一项所述的化合物或其药学上可接受的盐，其用于治疗焦虑或抑郁。

17. 根据权利要求 1 至 9 中任意一项所述的化合物或其药学上可接受的盐，其用于治疗酒精或物质滥用。

作为 CRF1 受体拮抗剂的噻唑吡唑并嘧啶类

技术领域

本发明涉及新的噻唑吡唑并嘧啶化合物、其药物组合物以及其作为 CRF1 受体拮抗剂在治疗精神病学和神经内分泌障碍、神经病学疾病和代谢综合征中的用途。

背景技术

促肾上腺皮质激素释放因子(CRF)是一种 41 个氨基酸的肽，其是垂体前叶分泌阿黑皮素原(POMC)衍生肽的主要生理调节物。除其对垂体的内分泌作用外，CRF 的免疫组织化学定位还证明，该激素在中枢神经组织中具有广泛的下丘脑外(extrahypothalamic)分布并且产生与其在脑中的神经递质或神经调节物作用相一致的广谱自律、电生理和行为作用。还有迹象表明，CRF 在整合免疫系统对生理学、心理学和免疫学应激物的响应方面具有重要作用。

已经表明在精神病学障碍和包括抑郁和焦虑在内的神经病学疾病以及下面的疾病中涉及 CRF：阿尔茨海默病、亨廷顿舞蹈病、进行性核上性麻痹、肌萎缩性侧索硬化、帕金森病、癫痫、偏头痛、酒精和物质滥用以及相关的戒断症状、肥胖、代谢综合征、先天性肾上腺增生、库欣病、高血压、中风、肠易激惹综合征、应激诱导的胃溃疡、经前期综合征、性功能障碍、早产、炎性障碍、变态反应、多发性硬化、内脏痛、睡眠障碍、垂体肿瘤或异位垂体源肿瘤(ectopic pituitary-derived tumors)、慢性疲劳综合征和纤维肌痛。

已经鉴定了 CRF 受体亚型 CRF1 和 CRF2，其在脑中的分布不均，从而表明可能的功能多样性。例如，广泛分布的脑 CRF1 受体强烈参与与环境应激物接触时伴随的情绪性。显然是 CRF1 而不是 CRF2 受体介导选择


致焦虑样(select anxiogenic like)行为。更离散的间隔/下丘脑(hypothalmic)分布和供替代选择的内源性配体的可用性表明 CRF2 受体具有不同的功能。例如，据报道，一种相对于 CRF1 受体而言对 CRF2 具有优先亲合性的新 CRF-族神经肽在不产生用选择性 CRF1 激动作用所观察到的行为活化特性的情况下抑制食欲。在另一些情况中，CRF2 激动作用产生与 CRF1 拮抗剂或 CRF1 基因缺失所报道的那些作用相似的作用。例如，虽然已经提出用 CRF2 激动剂作为抗肥胖药，但是 CRF1 拮抗剂对肥胖而言也可能是一种重要的治疗。

在 WO 94/13676、WO 97/29109、WO 98/08847 和 WO 98/03510 中描述了可用作 CRF 拮抗剂的某些吡咯并[2,3-*d*]嘧啶类、吡咯并[3,2-*d*]嘧啶类、吡唑并[1,5-*a*]嘧啶类、1,2,3-三唑并[4,5-*b*]吡啶类和吡唑并[1,5-*a*]-1,3,5-三嗪类。

本发明提供了可用作 CRF1 受体拮抗剂的新的噻唑吡唑并嘧啶类。由于上述原因，希望发现对于精神病学和神经内分泌障碍、神经病学疾病和代谢综合征的治疗而言为可能有价值的治疗剂的新的有效的选择性 CRF1 拮抗剂。此外，由于大多数可商购获得的 CNS 和心血管药物表现出不良的生物利用度和药动学性质，还希望发现相对于已知 CRF 拮抗剂如 CP154526 和 NBI30775 而言具有良好生物利用度和药动学性质的新化合物。

发明概述

在一个实施方案中，本发明提供了式 I 化合物或其药学上可接受的盐，







式 I

其中：

0520

R^1和R^2独立地是乙基或正丙基;

R^3是氢、Cl、Br、甲基、三氟甲基或甲氧基;

R^4是氢、Br、R^aR^bN-、甲氧基甲基、正丁基、乙酰氨基、吡啶-4-基、吗啉-4-基、  、  、  或  ;

R^a和R^b独立地是氢、C_1-C_3烷基、$H_2NCH_2CH_2$-、$(CH_3)_3COC(O)NHCH_2CH_2$-或$CH_3CH_2CH_2NHCH_2CH_2$-。

在另一个实施方案中，本发明提供了一种药物组合物，其包含：式I化合物或其药学上可接受的盐和药学上可接受的赋形剂。

在另一个实施方案中，本发明涉及一种治疗患者的抑郁、焦虑、酒精或物质滥用、肥胖、高血压、代谢综合征、肠易激惹综合征、癫癎、中风、睡眠障碍、变态反应、偏头痛、经前期综合征、不孕、性功能障碍、先天性肾上腺增生、库欣病、早产、应激诱导的胃溃疡、炎性障碍、垂体肿瘤或异位垂体源肿瘤、慢性疲劳综合征、纤维肌痛、内脏痛或多发性硬化的方法，其包括：给需要其的患者施用治疗有效量的式I化合物或其药学上可接受的盐。

在另一个实施方案中，本发明涉及式I化合物或其药学上可接受的盐在制备药物中的用途，所述药物用于治疗抑郁、焦虑、酒精或物质滥用、肥胖、高血压、代谢综合征、肠易激惹综合征、癫癎、中风、睡眠障碍、变态反应、偏头痛、经前期综合征、不孕、性功能障碍、先天性肾上腺增生、库欣病、早产、应激诱导的胃溃疡、炎性障碍、垂体肿瘤或异位垂体源肿瘤、慢性疲劳综合征、纤维肌痛、内脏痛或多发性硬化。

在另一个实施方案中，本发明涉及用于治疗抑郁、焦虑、酒精或物质滥用、肥胖、高血压、代谢综合征、肠易激惹综合征、癫癎、中风、睡眠障碍、变态反应、偏头痛、经前期综合征、不孕、性功能障碍、先天性肾上腺增生、库欣病、早产、应激诱导的胃溃疡、炎性障碍、垂体肿瘤或异位垂体源肿瘤、慢性疲劳综合征、纤维肌痛、内脏痛或多发性硬化的式I

化合物或其药学上可接受的盐。

在另一个实施方案中，本发明涉及用于治疗的式 I 化合物或其药学上可接受的盐。

发明详述

如上文和整个本申请的说明书中所用的那样，除非另有说明，否则下面的术语应被理解为具有下列含义：

“烷基”是指在链中具有 1 至 5 个碳原子的饱和脂族烃基，其可以是直链的或支链的。

“药学上可接受的赋形剂”是指用于增进制剂特性的药学上可接受的配制载体、溶液或添加剂。该类赋形剂必需与制剂中的其它成分相容并且对其接受者无害，它们是本领域技术人员所众所周知的(参见例如 ***Remingtons Pharmaceutical Sciences***, 第 19 版, **Mack Publishing Company, 1995**)。

“药学上可接受的盐”是指本发明的化合物相对无毒的无机和有机酸加成盐和碱加成盐。这些盐可以在化合物的最后分离和纯化中原位制备。具体而言，酸加成盐可通过分别将纯化的游离碱形式的化合物与适宜的有机酸或无机酸反应并分离由此形成的盐来制备(参见例如 ***Remingtons Pharmaceutical Sciences***, 第 19 版, **Mack Publishing Company, 1995**)。

“治疗有效量”或“有效量”是指将在组织、系统、动物或人中引起研究者、兽医、医生或其它临床医师所寻求的生物学或医学响应或者所需的治疗作用的本发明式 I 化合物或包含本发明式 I 化合物的药物组合物的量。

术语“治疗”等包括减缓和逆转障碍的进展。这些术语还包括即使障碍或病症实际上未被消除和即使障碍或病症的进展本身未被减缓或逆转但是缓解、改善、减弱、消除或减轻了障碍或病症的一种或多种症状。术语“治疗”以及类似术语还包括防止性(例如，预防性)治疗和姑息性治疗。疾病的预防表现为疾病的发作被拖延或延迟。

分子结构中的符号“——”表示该特定取代基的连接位置。

当任何变量在任何组分或在式 I 中出现一次以上时，其定义在每次出

现时都是彼此独立的。而且，只有当取代基和/或变量的组合产生稳定的化合物时，该类组合才是允许的。在选择本发明的化合物时，本领域普通技术人员将意识到各种取代基、即 R^1、R^2 等是根据化学结构连接性的众所周知的原则来进行选择的。

按照本公开物中所用的标准命名法，首先描述指定侧链的末端部分，然后描述朝向连接点的毗邻官能团。例如，芳基羰基氨基烷基取代基与芳基-C(O)-NH-烷基-等同。

本发明包括下列实施方案，它们可以被进一步组合:


(a) 式 I 化合物，其中 R^1 和 R^2 是乙基;

(b) 式 I 化合物，其中 R^1 和 R^2 是正丙基;


(c) 式 I 化合物，其中 R^3 是 Cl、Br、甲基或三氟甲基;

(d) 式 I 化合物，其中 R^3 是 Cl;

(e) 式 I 化合物，其中 R^3 是 Br;

(f) 式 I 化合物，其中 R^4 是 R^aR^bN-、吡啶-4-基、吗啉-4-基或  ;

(g) 式 I 化合物，其中 R^4 是吗啉-4-基;

(h) 式 I 化合物，其中 R^4 是  ;


(i) 式 I 化合物，其中 R^a 和 R^b 独立地是 C_1-C_3 烷基;


(j) 式 I 化合物，其中 R^1 和 R^2 是乙基，R^3 是 Cl，R^4 是吗啉-4-基;


(k) 式 I 化合物，其中 R^1 和 R^2 是正丙基，R^3 是 Cl，R^4 是吗啉-4-基;


(l) 式 I 化合物，其中 R^1 和 R^2 是乙基，R^3 是 Br，R^4 是吗啉-4-基;

(m) 式 I 化合物，其中 R^1 和 R^2 是正丙基，R^3 是 Br，R^4 是吗啉-4-基;

(n) 式 I 化合物，其中 R^1 和 R^2 是乙基，R^3 是 Cl，R^4 是  ;

(o) 式 I 化合物，其中 R^1 和 R^2 是正丙基，R^3 是 Cl，R^4 是  ；

(p) 式 I 化合物，其中 R^1 和 R^2 是乙基，R^3 是 Br，R^4 是  ；

(q) 式 I 化合物，其中 R^1 和 R^2 是正丙基，R^3 是 Br，R^4 是  ；

(r) 式 I 化合物或其药学上可接受的盐用于治疗抑郁或焦虑的用途;

(s) 式 I 化合物或其药学上可接受的盐用于治疗酒精或物质滥用的用途;

(t) 式 I 化合物或其药学上可接受的盐用于治疗酒精或物质滥用以及相关的戒断症状的用途;

(u) 式 I 化合物或其药学上可接受的盐，对于 CRF1 结合而言，其表现出≤ 500 nM 的 Ki 值;

(v) 式 I 化合物或其药学上可接受的盐，对于 CRF1 结合而言，其表现出≤ 50 nM 的 Ki 值;

(w) 式 I 化合物或其药学上可接受的盐，对于 CRF1 结合而言，其表现出≤ 5 nM 的 Ki 值;

(x) 式 I 化合物或其药学上可接受的盐，对于 CRF1 结合而言，其表现出≤ 500 nM 的 Ki 值，并且相对于 CRF2 而言选择性与 CRF1 结合(即，更低的 Ki);

(y) 式 I 化合物或其药学上可接受的盐，对于 CRF1 结合而言，其表现出≤ 50 nM 的 Ki 值，并且相对于 CRF2 而言选择性与 CRF1 结合(即，更低的 Ki);

(z) 式 I 化合物或其药学上可接受的盐，对于 CRF1 结合而言，其表现出≤ 5 nM 的 Ki 值，并且相对于 CRF2 而言选择性与 CRF1 结合(即，更低的 Ki); 和/或

(aa) 相对于一些已知的 CRF 拮抗剂(例如，CP154526 和 NBI30775)

而言，具有优良的生物利用度和药动学性质的具体例举的化合物，如实施例 15。

本发明的化合物优选被配制为通过各种途径施用的药物组合物的形式。该类组合物优选用于口服施用。该类药物组合物和制备该类药物组合物的方法在本领域中是众所周知的(参见例如 ***Remington: The Science and Practice of Pharmacy***, A. Gennaro 等人编辑，第 19 版, Mack Publishing Co., 1995)。

式 I 化合物一般在宽的剂量范围内都有效。例如，每天的剂量通常落在约 0.0001 至约 30 mg/kg 体重范围内。在一些情况中，低于上述范围下限的剂量水平可能就远远足够了，而在另一些情况中，可以使用更大的剂量而不会导致任何有害的副作用，因此，上述剂量范围并非旨在以任何方式对本发明的范围进行限制。应当清楚的是，实际施用的化合物的量将由医师根据相关的情况来确定，所述情况包括所治疗的病症、所选择的施用途径、被施用的实际化合物或化合物组合、各患者的年龄、体重和响应情况以及患者的症状的严重程度。

式 I 化合物是 CRF-1 拮抗剂并且因此可用于治疗能通过降低 CRF1 受体的品质(tone)或兴奋性(stimulation)来治疗的病症。已经表明促肾上腺皮质激素释放因子(CRF)(一种 41 个氨基酸的肽，其是垂体前叶分泌阿黑皮素原(POMC)衍生肽的主要生理调节物)[J. Rivier 等人, ***Proc. Natl. Acad. Sci (USA)*** 80:4851 (1983); W. Vale 等人, ***Science*** 213:1394 (1981)]与许多医学病症有关。例如，除其对垂体的内分泌作用外，CRF 的免疫组织化学定位还证明，该激素在中枢神经组织中具有广泛的下丘脑外分布并且产生与其在脑中的神经递质或神经调节物作用相一致的广谱自律、电生理和行为作用[W. Vale 等人, ***Rec. Prog. Horm. Res.*** 39:245 (1983); G. F. Koob, ***Persp. Behav. Med.*** 2:39 (1985); E. B. De Souza 等人, ***J. Neurosci.*** 5:3189 (1985)]。还有迹象表明，CRF 在整合免疫系统对生理学、心理学和免疫学应激物的响应方面具有重要作用[参见例如 J. E. Blalock, ***Physiological Reviews*** 69:1 (1989); J. E. Morley, ***Life Sci.*** 41:527 (1987)]。

已经表明在精神病学障碍和包括抑郁和焦虑在内的神经病学疾病中涉及CRF[D. M. Nielsen, *Life Sci.* 78:909-919; H. E. Kunzel 等人, *J. Psychiatr. Res.* 37:525-533; D. R. Gehlert 等人, *Eur. J. Pharmacol.* 509:145-153]。认为CRF还参与下列疾病的病因学和病理生理学：阿尔茨海默病、亨廷顿舞蹈病、进行性核上性麻痹和肌萎缩性侧索硬化，因为这些疾病涉及中枢神经系统中 CRF 神经元功能障碍[关于综述，参见：E. B. De Souze, *Hosp. Practice* 23:59 (1988)]。已经表明长期施用CRF产生多巴胺系统损害，这表明其在帕金森病中起作用[E. Izzo 等人, *Pharmacol. Biochem. Behav.* 81:701-708 (2005)]。其中有CRF参与的其它神经病学障碍包括癫痫[T. Z. Baram 等人, *Brain Res.* 770:89-95 (1997)]和偏头痛[T. C. Theoharides 等人, *Endocrinology* 136:5745-5750(1995)]。已经表明CRF参与酒精和物质滥用以及相关的戒断症状[D. H. Overstreet 等人, *Pharmacol. Biochem. Behav.* 77:405-413; Y. Shaham 等人, *Psychopharmacology (Berl)* 137: 184-190]。此外，有迹象表明CRF在各种内分泌障碍和心血管疾病如肥胖[E. Timofeeva 和 D. Richard, *Neuroendocrinology* 66:327-340 (1997)]、代谢综合征[A. M. Ward 等人, *Metabolism* 53:720-726(2004)]、先天性肾上腺增生[D. P. Merke 和 G. B. Cutler Jr., *Endocrinol. Metab. Clin. North Am.* 30:121-135(2001)]、库欣病[M. Labeur 等人, *Curr. Drug Targets Immune Endocr. Metabol. Disord.* 4:335-342(2004)]，高血压[R. J. Briscoe 等人，*Brain Res.* 881:204-207(2000)]和中风[S. L. Stevens 等人, *J. Cereb. Blood Flow Metab.* 23:1151-1159(2003)]中起作用。已经表明胃紊乱如肠易激惹综合征[Y. Tache 等人, *Eur J. Surg.* Suppl:16-22(2002)]和应激诱导的胃溃疡[K. E. Gabry 等人, *Mol. Psychiatry* 7:474-483, 433(2002)]与CRF有关。此外，还表明CRF在女性健康的各个领域例如经前期综合征[F. Facchinetti 等人, *Psychosom. Med.* 56:418-422(1994)]、不孕[L. Ghizzoni 等人，*Endocrinology* 138:4806-4811(1997)]、性功能障碍[J. E. Jones 等人, *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 283:R591-597(2002)]和早产[P. D. Wadhwa 等人, *Am. J. Obstet. Gynecol.* 191:1063-1069(2004)]中起作用。还有迹象表明CRF在


免疫系统中具有重要作用，表明其有治疗炎性障碍[A. Gravanis 和 A. N. Margioris, *Curr. Med. Chem.* 12:1503-1512(2005)]、变态反应[L. K. Singh 等人, *Brain Behav. Immun.* 13:225-239(1999)]、多发性硬化和其它自身免疫性障碍[C. Benou 等人, *J. Immunol.* 174:5407-5413(2005)]的潜能。除前述疾病外，还表明在内脏痛[M. Nijsen 等人，*Neurogastroenterol. Motil.* 17:423-432(2005)]、睡眠障碍[T. M. Buckley 和 A. F. Schatzberg, *J. Clin. Endocrinol. Metab.* 90:3106-3114(2005)]、垂体肿瘤或异位垂体源肿瘤[K. D. Dieterich 等人, *J. Clin. Endocrinol. Metab.* 83: 3327-3331 (1998)]、慢性疲劳综合征和纤维肌痛[G. Neeck 和 L. J. Crofford, *Rheum. Dis. Clin. North Am.* 26:989-1002(2000)]中也涉及 CRF。

已经鉴定了 CRF 受体亚型 CRF1 和 CRF2，其在脑中的分布不均[D. T. Chalmers 等人, *TIPS* 17:166-72(1996)]，从而表明其可能的功能多样性[S. C. Heinrichs 等人, *Regul. Peptides* 71:15(1997)]。例如，广泛分布的脑 CRF1 受体强烈参与与环境应激物接触时伴随的情绪性[G. Liebsch 等人, *Regul. Peptides* 59: 229-39(1995); D. W. Schulz, *PNAS* 93: 10477-82(1996)]。显然，是 CRF1 而不是 CRF2 受体介导选择致焦虑样行为[Heinrichs 等人, 1997]。更离散的间隔/下丘脑分布[D. T. Chalmers 等人, *J. Neurosci.* 15(10): 6340-50 (1995)]和供替代选择的内源性配体的可用性[J. Vaughan 等人, *Nature* 378: 287-92(1995)]表明 CRF2 受体具有不同的功能角色[Heinrichs 等人, 1997]。例如，据报道，一种相对于 CRF1 受体而言对 CRF2 具有优先亲合性的新 CRF-族神经肽在不产生用选择性 CRF1 激动作用所观察到的行为活化特性的情况下抑制食欲(H. Tezval 等人, *PNAS* 101(25): 9468-9473 (2004)]。在一些情况中，CRF2 激动作用产生与 CRF1 拮抗剂或 CRF1 基因缺失所报道的那些作用相似的作用[S. C. Heinrichs, *Trends in Pharmacological Sciences* 20(8):311-5(1999)]。例如，虽然已经提出用 CRF2 激动剂作为抗肥胖药，但是 CRF1 拮抗剂对肥胖而言也可能是一种重要的治疗[C. Contoreggi 等人, *Neuroendocrinology* 80(2):111-23(2004)]。

制备本发明的化合物

本发明的所有化合物都可以化学制备，例如，通过按照下面所述的合成途径来制备。但是，下面的讨论并非旨在以任何方式对本发明的范围进行限制。例如，所述各途径的特定合成步骤可以以不同方式组合，或者与来自不同流程图的步骤联合，从而制备另外的式 I 化合物。各步骤的产物可以用常规方法来回收，所述方法包括萃取、蒸发、沉淀、色谱法、过滤、研磨、结晶等。在下面的流程图中，除非另有说明，否则所有取代基均如前面所定义，适宜的试剂在本领域中是众所周知和可理解的。

流程图 1



可以按照流程图 1 中所述的反应来形成式(6a,b)、(7)或 8(a-c)的化合物。一种适宜的式(6a,b)、(7)或(8a-c)的化合物是其中基团定义如下的化合物：R^1 和 R^2 如式 I 中所定义，R^{3a} = H 或 CH_3，R^{3b} = Br 或 CH_3，R^{3c} = H、CH_3 或 Br。

在流程图 1 的步骤 1 中，用氯氧化磷(phosphorous oxychloride)和二甲基苯胺在惰性溶剂如甲苯中在溶剂的回流温度下将式(1)的吡唑并[1,5-a]嘧啶-7-酮转化成 7-氯-2,5-二甲基-吡唑并[1,5-a]嘧啶。

在步骤 2 中，使式(3)的格氏试剂(X = Cl 或 Br)与式(2)的氯化物在惰性溶剂如甲苯中在回流温度下反应，得到式(4)的 7-烷基吡唑并嘧啶。

或者，可以如步骤 3、4 和 5 中所示的那样获得式(4)的 7-烷基吡唑并嘧啶。在步骤 3 中，将乙酰乙酸乙酯用式(4a)的酰卤在存在氯化镁的情况下进行酰化，得到式(4b)的二酮基-酯。将式(4b)的二酮基-酯在 Krapcho 条件下脱羧，得到式(4c)的二酮。例如，将(4b)在二甲基亚砜中在约 130 至 170℃的温度下加热以进行脱羧。在步骤 5 中，将式(4c)的二酮与 3-氨基-5-甲基吡唑在质子溶剂如甲醇、乙醇或乙酸中环化，得到式(4)的 7-烷基吡唑并嘧啶。优选的条件在约 0 至 60℃的温度下使用乙酸。

在步骤 6 中，用过量的 N-碘琥珀酰亚胺在乙腈中将式(4)的吡唑并嘧啶官能化成式(5)的碘代吡唑并嘧啶。

在流程图 1 的步骤 7 或 8 中，使式(5)的碘代吡唑并嘧啶与噻唑卤化锌在 Negishi 交叉偶联反应中反应，得到式(6a)或(6b)的噻唑基吡唑并嘧啶(Jensen, J.; Skjaerbaek, N.; Vedso, P. *Synthesis* 2001, 128)。所述噻唑卤化锌是用本领域技术人员众所周知的方法产生的。例如，在步骤 7 中，将 2-三甲基硅烷基噻唑用正丁基锂、仲丁基锂或叔丁基锂处理，然后用 $ZnCl_2$ 进行锂-锌交换。将有机锌试剂与式(5)的碘代吡唑并嘧啶在存在钯催化剂例如二氯[1,1'-双(二苯基-膦基)二茂铁]钯(II)二氯甲烷的情况下在惰性溶剂如 THF 中在回流温度下偶联约 12 至 36 小时，得到式(6a)的噻唑吡唑并嘧啶。

或者，在步骤 8 中，用 5-溴-4-甲基噻唑和锌金属产生噻唑溴化锌并基本如步骤 7 中所述的那样将其用于 Negishi 交叉偶联中，得到式(6b)的噻唑


吡唑并嘧啶。

在流程图 1 的步骤 9 中，将式(6a,b)的噻唑溴化，得到式(7)的溴代或二溴代噻唑，其中 R^{3b} = Br 或 CH_3。根据 R^{3a} 是 CH_3 还是 H，将噻唑分别用 1 或 2 eq N-溴琥珀酰亚胺溴化。

式(8a-c)的烷基噻唑是在步骤 11 中由式(6a,b)的噻唑获得的或者在步骤 10 中由式(7)的溴代噻唑获得的。在步骤 10 中，用正丁基锂、仲丁基锂或叔丁基锂进行卤素-锂交换，得到噻唑锂试剂，随后使其与亲电子试剂如烷基卤如碘甲基甲基醚或碘丁烷反应。在步骤 11 中，通过用正丁基锂、仲丁基锂或叔丁基锂去质子化和随后与亲电子试剂如碘甲基甲基醚或碘丁烷反应来形成噻唑锂试剂。

本领域技术人员应当意识到，可以容易地对噻唑环系进行官能化，可以容易地制备噻唑中间体如 2-三甲基硅烷基-噻唑(Dondoni, A.等人 *J. Org. Chem.* 1988, *53*, 1748)。5-溴-4-甲基噻唑是通过用溴在乙酸中对 4-甲基噻唑进行溴化来获得的(Collins, I. J.等人, WO2003093252, 2003 年 11 月 13 日)。通过使乙酰乙酸乙酯与 5-甲基-2*H*-吡唑-3-基胺在回流的乙酸中进行缩合可容易地制得 2,5-二甲基-4*H*-吡唑并[1,5-a]嘧啶-7-酮(1)。

流程图 2



可以按照流程图 2 中所述的反应来形成式(9)、(10)或(11)的化合物。一


种适宜的式(9)、(10)或(11)的化合物是其中基团定义如下的化合物：R^1、R^2、R^a和R^b如式I中所定义，R^{3b} = Br或CH_3，R^{4a} = $-NR^aR^b$或-N-吗啉基，"het"具有所述的定义。

在步骤1中，使式(7)的溴代噻唑与杂环锌试剂在Negishi交叉偶联反应中偶联，得到式(9)的噻唑杂环。例如，将1-甲基-1,2,4-三唑在约-80至-65℃下用正丁基锂、仲丁基锂或叔丁基锂处理、然后用氯化锌处理，并且在原位与式(7)的溴代噻唑反应。该反应优先在惰性溶剂如THF中在存在钯催化剂如二氯[1,1'-双(二苯基-膦基)二茂铁]钯(II)二氯甲烷或四(三苯基膦)钯(0)的情况下进行。将反应温热至回流温度。或者，杂环锌试剂由卤代杂环如4-碘吡啶和锌金属形成。

在流程图2的步骤2中，中间体2-甲酰基噻唑是通过用正丁基锂、仲丁基锂或叔丁基锂进行卤素-锂交换、然后与N-甲酰基吗啉反应来形成的。使甲酰基噻唑在存在有机胺如吗啉的情况下进行还原胺化，得到式(10)的吗啉基甲基噻唑。还原胺化在本领域中是众所周知的，通常使用无机硼氢化物试剂如硼氢化钠或氰基硼氢化钠。优选的条件在惰性溶剂如二氯甲烷或THF中使用三乙酰氧基硼氢化钠。

在步骤3中，用式$-NR^aR^b$的胺或用吗啉使式(7)的溴代噻唑进行置换反应，得到式(11)的氨基噻唑。该反应在惰性溶剂如THF或二噁烷中用无机碱如碳酸铯在70至110℃下进行。

流程图3




可以按照流程图 3 中所述的反应来形成式(13)、(14)或(15)的化合物。一种适宜的式(13)、(14)或(15)的化合物是其中 R^1、R^2 和 R^4 如式 I 中所定义的化合物。

本领域技术人员应当意识到，可以容易地将 4-溴噻唑如式(12)的 4-溴噻唑处理成具有其它官能团。例如，在步骤 1 中，可以用氯化亚铜将该溴化物脱卤素化，得到式(13)的噻唑，随后用 N-氯琥珀酰亚胺将其氯化，得到式(14)的 4-氯噻唑。

在流程图 3 的步骤 3 中，在存在处于甲醇中的碘化亚铜(I)的情况下在约 100 至 120℃下在惰性溶剂如二甲基甲酰胺中用甲醇钠对式(12)的 4-溴噻唑进行置换，得到式(15)的 4-甲氧基噻唑。

流程图 4



可以按照流程图 4 中所述的反应来形成式(17)、(18)、(19)、(20)、(20a)或(21)的化合物。一种适宜的式(17)、(18)、(19)、(20)、(20a)或(21)的化合物是其中基团定义如下的化合物：R^1、R^2、R^a和R^b如式 I 中所定义，R^{4a}是-NR^aR^b或-N-吗啉基，“het”具有所述的定义。

在流程图 4 的步骤 1 中，使式(5)的碘代吡唑并嘧啶和式(6)的 5-溴噻唑进行 Negishi 交叉偶联，形成式(17)的二甲基吡咯基噻唑。例如，将式(16)的 5-溴噻唑在约-80 至-65℃下用正丁基锂、仲丁基锂或叔丁基锂处理、然后用氯化锌处理。将有机锌试剂在原位与式(5)的碘代吡唑并嘧啶反应。该偶联反应优先在惰性溶剂如 THF 中在回流温度下在存在钯催化剂如双(三-叔丁基膦)钯(0)的情况下进行。

在步骤 2 中，将式(17)的二甲基吡咯基噻唑去保护，得到式(19)的氨基噻唑。将二甲基吡咯用羟胺在乙酸中在约 60 至 100℃的温度下处理约 4 至

8 小时，优选约 6 小时。在步骤 3 中，为了形成式(18)的噻唑乙酰胺，使用与步骤 2 中所用条件相同的条件，不同的是反应持续约 72 小时。


在流程图 4 的步骤 4 中，用改进的 Sandmeyer 反应将式(19)的 2-氨基噻唑转化成式(20)的 2-溴噻唑。优选的条件在约 60 至 80℃的温度下在乙腈中使用亚硝酸烷基酯如亚硝酸叔丁酯和溴化铜(II)。

在步骤 5 中，用式-NR^aR^b 的胺或用吗啉使式(20)的 2-溴噻唑进行置换反应，得到式(21)的氨基噻唑。该反应在惰性溶剂如甲醇、THF 或二噁烷中进行，或者在不使用溶剂的情况下进行，使用过量的胺，反应温度为约 70 至 110℃。或者，用反应胺和过量的三乙胺或无机碱如碳酸铯进行该反应。在式(21)的氨基噻唑的合成中，也考虑各种去保护步骤，如除去氨基甲酸叔丁酯(BOC)，因为在-NR^aR^b 携带式 I 中所定义的其它胺官能团的情况下，为了进行上述反应，这样的步骤可能是需要的或有益的。适宜的保护基团的选择和使用在本领域中是众所周知的和可理解的(参见例如 ***Protecting Groups in Organic Synthesis***, Theodora Greene (Wiley-Interscience))。

在流程图 4 的步骤 6 中，以与流程图 2 的步骤 1 中所述方式相似的方式使式(20)的 2-溴噻唑与杂环锌试剂在 Negishi 交叉偶联反应中偶联，得到式(20a)的噻唑杂环。

本领域技术人员应当意识到，式(16)的官能化的噻唑可用本领域中已知的方式来制备。例如，将硫脲与溴代酮如 3-溴-1,1,1-三氟丙-2-酮环化，得到 4-三氟甲基-噻唑-2-基胺。随后用己烷-2,5-二酮对该胺进行溴化和保护，得到(16)。

流程图 5




可以按照流程图 5 中所述的反应来形成式(23)的化合物。一种适宜的式(23)的化合物是其中基团定义如下的化合物：R^1 和 R^2 如式 I 中所定义，R^{4b} 具有所述定义。

使式(5)的碘代吡唑并嘧啶与例如式(22)的 4-氯-2-吗啉代-噻唑进行交叉偶联，形成式(23)的吡唑并嘧啶噻唑。例如，将所述反应物在存在碘化铜、醋酸钯和三苯基膦的情况下用碱如碳酸铯偶联。该偶联反应优先在惰性溶剂如 DMF 中在约 100 - 150℃下进行 4-24 小时。

本领域技术人员应当意识到，式(22)的官能化的噻唑可用本领域中已知的方式来制备。例如，可以使 2,4-二氯噻唑与吗啉反应，得到式(22)的 2-吗啉代-噻唑。也可以将 2,4-二氯噻唑耗竭性溴化，得到 2,5-二溴-4-氯噻唑。随后用正丁基锂在 THF 中在-90℃下进行溴-锂交换并用水淬灭，得到 2-溴-4-氯噻唑[*J. Chem. Soc. Perkin Trans I: Org Bioorg. Chem.* (1972-1999), (2):215-219(1992)]。可以用杂环锌试剂使 2-溴-4-氯噻唑进行 Negishi 交叉偶联反应，得到噻唑-2-基三唑或吡啶。

流程图 6



可以按照流程图 6 中所述的反应来形成式(27)的化合物。一种适宜的式(27)的化合物是其中基团定义如下的化合物：R^1 和 R^2 如式 I 中所定义，"het"分别具有步骤 1 或步骤 3 中所述的定义。

在流程图 6 的步骤 1 中，通过使式(5)的碘代吡唑并嘧啶与式(24)的溴代噻唑反应获得杂环噻唑，例如式(25)的杂环噻唑。该反应在存在溴化 N-丁基铵和碱如醋酸钾的情况下用钯催化剂如具有三(2,4-二-叔丁基-苯基)-磷烷(phosphane)的醋酸钯在惰性溶剂如 N-甲基吡咯烷酮中在约 100-150℃的温度下进行。

或者，在步骤 2 中，将式(6a)的噻唑基吡唑并嘧啶碘化，得到式(26)的 2-碘噻唑。将该噻唑用二异丙基氨基锂在-70 至-80℃的温度下处理约 1 小时，然后用 N-碘琥珀酰亚胺在大约相同的温度下在惰性溶剂如 THF 中处理。然后进行步骤 3，在该步骤中，用与流程图 2 的步骤 1 中所述条件相似的 Negishi 交叉偶联条件形成式(25)的三唑基或 4-吡啶基噻唑。

在流程图 6 的步骤 4 中，将式(25)的噻唑基吡唑并嘧啶溴化，得到式(27)的溴代噻唑。该溴化是用 N-溴琥珀酰亚胺在存在少量乙酸的情况下在惰性溶剂如乙腈中进行的。

可以如流程图 4 的步骤 2、3、4 和 5 中所述的那样进一步对其中 het = 2,5-二甲基-吡咯-1-基的式(27)的化合物进行修饰，从而获得本发明的化合物。

本领域技术人员应当意识到，可以用本领域中已知的方法容易地制备式(24)的杂环噻唑类。例如，可以用 1,1-二甲氧基-N,N-二甲基-甲胺将噻唑-2-甲酰胺环化成三唑，然后用 N-甲基-肼处理，获得三唑基噻唑，随后可以用 N-溴琥珀酰亚胺将其溴化。根据文献操作可得到 4-噻唑-2-基-吡啶，可将其溴化，得到 4-(5-溴-噻唑-2-基)-吡啶。5-溴-2-(2,5-二甲基-吡咯-1-基)-噻唑可以通过使 2-氨基-5-溴噻唑与己烷-2,5-二酮反应来容易地获得。

本文所用的“TLC”是指薄层色谱；“HPLC”是指高效液相色谱；“LC/MS”是指液相色谱/质谱；“GC/MS”是指气相色谱/质谱”；“HR-ToF’是指高分辨率的飞行时间(high resolution time-of-flight)；“APCI”是指大气压化学电离；“δ”是指从四甲基硅烷向低磁场的百万分数；“THF”是指四氢呋喃；“EtOAc”是指乙酸乙酯；“MeOH”是指甲醇；“EtOH”是指乙醇；“DMF”是指二甲基甲酰胺。

实施例

无需进一步加工，认为本领域技术人员可以用前面的描述来充分实施本发明。用下面的制备例和实施例来对本发明进行进一步详细说明。它们旨在进行举例说明，而不是要以任何方式对本发明进行限制。其中的试剂和起始材料可容易地获得或者可被本领域普通技术人员容易地合成。实施例 1-35 提供了代表性的化合物并说明了其制备。实施例 A-D 说明了可用于测定本发明化合物的生物学性质的各种生物学测定法。本领域技术人员将迅速意识到实施例中所述的操作的适宜变型。本发明的化合物的名称是用 ChemDraw Ultra® 7.0.1 版提供的。盐是以游离碱加共轭酸的形式来进行命名的。

制备例 1

2,5-二甲基-4H-吡唑并[1,5-*a*]嘧啶-7-酮

将乙酰乙酸乙酯(128 g, 0.98 mol)滴加到 5-甲基-2*H*-吡唑-3-基胺(100 g, 0.95 mol 的乙酸溶液(500 mL)中，同时保持其温度为 25-28℃。将混合物在回流下加热 10 小时，然后将其冷却至室温。将反应加入到被冷却至 5℃的叔-丁基甲基醚(5 L)中，同时保持其温度低于 10℃。将其在 5℃下搅拌 1 小时，过滤。将所得物质真空干燥过夜，得到白色固体(158 g, 96%)。

制备例 2

7-氯-2,5-二甲基-吡唑并[1,5-*a*]嘧啶

向 2,5-二甲基-4*H*-吡唑并[1,5-*a*]嘧啶-7-酮(10.0 g, 61.3 mmol)在甲苯(150 mL)中的混悬液中加入 *N*,*N*-二甲基苯胺(9.7 mL, 76.7 mmol)。向这种白色混悬液中滴加三氯氧化磷(phosphorus oxychloride)(11.2 mL, 122.6 mmol)。将其在惰性气氛下回流 3 小时，冷却至室温并将反应减压浓缩成棕色油状物。将该油状物溶解于乙酸乙酯(250 mL)中并用 1.0 N NaOH 碱化。分离出有机相，用乙酸乙酯对碱性水相进行萃取(2 × 100 mL)。将有机相合并，用无水硫酸镁干燥，过滤，减压浓缩，得到棕色固体。将该物质


用快速色谱进行纯化，用 80%己烷/20%(30% THF/己烷)至 0%己烷/100%(30% THF/己烷)以 20%的增量逐步梯度洗脱，得到浅绿色固体(6.65 g, 59%)。ES/MS m/z (^{35}Cl) 182.3 $(M+1)^+$。

另一种操作:

将 2,5-二甲基吡唑并[1,5-*a*]嘧啶-7-酮(20 g, 122 mmol)加入到 1,4-二噁烷(60 mL)中。将混合物在 22℃下搅拌 10 分钟，然后加入 N,N-二乙基苯胺(20.8 mL, 128 mmol)。将其再搅拌 5 分钟，然后历经 15 分钟加入三氯氧化磷(11.7 mL, 126 mmol)。将混合物在 22℃下搅拌 15 分钟，然后历经 35 分钟加热至 80-85℃并将反应在这一温度下保持 1.5 小时。将被冷却的反应混合物缓慢加入到被冷却至 0-5℃的磷酸氢二钾(106.7 g, 612.82 mmol)在水(325 mL)中的溶液中，在加入期间保持温度低于 5℃。将混合物在 22℃下进行搅拌，然后加入甲基-叔-丁基醚(150 mL)。分离有机层，用甲基-叔-丁基醚对水层进行萃取(2 × 100 mL)。将有机部分合并，用硫酸钠干燥，过滤，蒸发掉溶剂。用硅胶色谱进行纯化，用己烷/乙酸乙酯(2/1)进行洗脱，得到黄色固体形式的标题化合物(20.7 g, 88%)。ES/MS m/z (^{35}Cl) 182 $(M+1)^+$。

制备例 3

7-(1-丙基-丁基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶



向一个配有回流冷凝器的烘箱干燥的烧瓶中加入无水 THF(40 mL)、碘(催化量)、镁条(1.92 g, 78.9 mmol)和 4-溴庚烷(9.4 mL, 52 mmol)。将反应在油浴中加热至回流。当格氏反应开始时，反应温度迅速升高。将反应在 90℃下再搅拌 4 小时，冷却至室温。使镁金属沉降(也可以进行离心)，在正氩气压下通过套管将格氏试剂加入到装有 7-氯-2,5-二甲基吡唑并[1,5-*a*]嘧啶(4.80 g, 26.3 mmol)(位于无水甲苯(20 mL)中)的烧瓶中。将反应

在惰性气氛下回流过夜。将反应冷却至室温并用水淬灭。用乙酸乙酯(150 mL)稀释，然后加入水(100 mL)和饱和氯化铵(50 mL)。将水相分离出来并用二氯甲烷(75 mL)萃取。将有机相合并，用无水硫酸镁干燥，过滤，减压浓缩。将所得残余物用快速色谱进行纯化，用 80%己烷/20%(20%乙酸乙酯/己烷)至 0%己烷/100%(20%乙酸乙酯/己烷)以 20%的增量逐步梯度洗脱，得到黄色晶体(3.08 g, 48%)。ES/MS m/z 246.3 $(M+1)^+$。

另一种操作：

将镁屑(3.5 g, 144 mmol)和催化量的碘(100 mg)在 THF(100 mL)中的混合物在氮气气氛下加热至 65℃。加入几滴纯 4-溴庚烷并将混合物加热至反应开始。然后，历经在 2 小时加入 4-溴庚烷(17.6 mL, 94.9 mmol)在 THF(42 mL)中的溶液，同时保持温度为 65-70℃。将混合物再回流 1 小时，然后将反应冷却至 22℃。在氮气气氛下，将制得的格氏试剂加入到被冷却至 0℃的 7-氯-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(10.2 g; 53.3 mmol)在 THF(60 mL)中的溶液中。历经 45 分钟，通过套管加入镁试剂溶剂，同时保持温度低于 10℃。然后将混合物在 5℃下再搅拌 30 分钟。向这种混合物中加入 10%氯化铵水溶液(wt/wt)(125 mL)并将其在 22℃下搅拌 30 分钟。分离有机层并用乙酸乙酯对水层进行萃取(2 × 25 mL)。将有机层合并并用硫酸钠干燥。对混合物进行过滤并蒸发掉溶剂。用硅胶快速色谱对该粗品物质进行纯化，用己烷/乙酸乙酯(5/1)进行洗脱，得到标题化合物(8 g, 62%)。ES/MS m/z 246 $(M+1)^+$。

制备例 3a

7-(1-丙基-丁基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶

另一种路径

步骤 1：3-乙酰基-3-氧代-4-丙基-庚酸乙酯

将氯化镁(14.63 g, 153.70 mmol)加入到二氯甲烷(500 mL)中，然后一次性加入乙酰乙酸乙酯(19.55 mL, 20.00 g, 153.79 mmol)并将其在室温下搅拌 1 小时。将混合物在冰水浴中冷却并滴加吡啶(24.86 mL, 24.32 g, 307.39 mmol)。在 0℃下在氮气下向该白色浆液中滴加二-正丙基乙酰氯(25.00 g,

153.70 mmoles)。在完全加入后，除去冷却浴，温热至环境温度并将其搅拌 16 小时。将反应用 1 N HCl(400 mL)淬灭并分离出底层。将有机部分用硫酸镁干燥，过滤，真空浓缩，得到黄色油状物(34 g, 86%)。将该物质不进行进一步纯化地直接用于下一步。

步骤 2: 5-丙基-辛烷-2,4-二酮

将 3-乙酰基-3-氧代-4-丙基-庚酸乙酯(32.4 g, 126.39 mmol)溶解于二甲基亚砜(100 mL)和水(5 mL)中。将该溶液在 150℃下加热 6 至 8 小时或者用 GC/MS 对反应进行追踪。将反应冷却，用庚烷萃取(3 × 100 mL)。将合并的有机部分用水(100 mL)和盐水(100 mL)洗涤。在 50℃下真空浓缩以除去大部分庚烷。得到 23.29g 油状物并将其直接用于下一步。

步骤 3: 7-(1-丙基-丁基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶

将 5-丙基-辛烷-2,4-二酮(15 g, 81.40 mmol)混合到乙酸(15 mL)中并将其在冰浴上进行冷却。分批加入 5-氨基-3-甲基吡唑(7.91 g, 81.40 mmol)并在环境温度下进行搅拌。在 3 小时后，用 GC/MS 检查是否反应完全。GC 表明与真实样品相比存在正确的区域异构体。蒸馏掉过量的乙酸。加入水(50 mL)并用庚烷(50 mL)萃取。用盐水(50 mL)对庚烷部分进行洗涤。将有机层用 $MgSO_4$ 干燥，过滤，真空浓缩，得到粗品油状物(15.8 g, 79%)。^1H NMR ($CDCl_3$): 6.39(s, 1H); 6.31(s, 1H); 3.75(m, 1H); 2.55(s, 3H); 2.45(s, 3H); 1.71(q, 4H); 1.23(m, 4H); 0.85(t, 6H)。

基本如制备例 3 中所述的那样用任何一种操作制备下面的化合物。用 3-溴戊烷来制备格氏试剂。

制备例号	化学名	物理数据
4	7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶	ES/MS m/z 218.1 $(M+1)^+$

制备例 5

7-(1-丙基-丁基)-3-碘-2,5-二甲基-吡唑并[1,5-*a*]嘧啶

将 7-(1-丙基-丁基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(3.08 g, 12.5 mmol)溶

解于无水乙腈(25 mL)中并以 10 分钟的时间间隔加入 6 份(每份 0.70 g) N-碘琥珀酰亚胺(4.2 g, 18.7 mmol)。在室温下搅拌过周末。除去乙腈，用二氯甲烷(100 mL)对剩下的油状物进行稀释。用饱和氯化铵溶液(2 × 50 mL)洗涤。收集有机相，用无水硫酸镁干燥，过滤，减压浓缩，得到深红色的油状物。用快速色谱对该油状物进行纯化，用 100%己烷/0%(20%乙酸乙酯/己烷)至 0%己烷/100%(20%乙酸乙酯/己烷)以 50%的增量逐步进行梯度洗脱，得到橙色油状物(10.97 g, 87%)。^{1}H NMR (400 MHz, $CDCl_3$): 6.42(s, 1H), 3.74-3.70(m, 1H), 2.58(s, 3H), 2.46(s, 3H), 1.74-1.68(m, 4H), 1.28-1.14 (m, 4H), 0.84(t, J = 7.0 Hz, 6H)。

基本如制备例 5 所述的那样制备下面的化合物。

制备例号	化学名	物理数据
6	7-(1-乙基-丙基)-3-碘-2,5-二甲基-吡唑并[1,5-*a*]嘧啶	1H NMR(400 MHz, $CDCl_3$): 6.44(s, 1H), 3.59(m, 1H), 2.61(s, 3H), 2.49(s, 3H), 1.86-1.76(m, 4H), 0.85(t, J = 7.5 Hz, 6H)。

制备例 6 的另一种操作:

将乙酸(1 mL)和 N-碘琥珀酰亚胺(6.7 g, 29.9 mmol)一次性加入到 7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(6 g, 27.5 mmol)在乙腈(60 mL)中的溶液中。将混合物在 22℃下搅拌 2 小时。蒸发掉溶剂，将残余物吸收于水(50 mL)和甲基-叔丁基醚(100 mL)中。将有机部分分离出来，用硫酸钠干燥，过滤，蒸发掉溶剂，得到标题化合物(9.2 g, 96%)。ES/MS m/z 344 $(M+1)^+$。

制备例 7

2-三甲基硅烷基-噻唑

将正丁基锂(20.4 mL, 51.0 mmol, 2.5 M 的己烷溶液)与乙醚(50 mL)在一个配有滴液漏斗和温度计的三颈烧瓶中混合到一起。冷却至-78℃，滴加

噻唑(4.25 g, 50.0 mmol)在乙醚(50 mL)中的溶液。在完全加入后，将反应混合物在-78℃下搅拌 30 分钟，然后加入三甲基氯硅烷(5.4 g, 50 .0 mmol)。在-78℃下搅拌 1 小时，然后温热至室温。通过加入饱和碳酸氢钠来将反应淬灭。用乙醚萃取水层。用盐水洗涤合并的有机部分，用硫酸钠干燥。过滤并减压浓缩，得到残余物。通过蒸馏进行纯化，得到 8.33 g (52-56℃/ 15 mm Hg)标题化合物。^{1}H NMR (400 MHz, $CDCl_3$) 8.13(d, 1H, J=2.6 Hz), 7.54(d, 1H, J = 2.6 Hz), 0.43(s, 9H)。

制备例 8

5-溴-4-甲基噻唑

在 0℃下，向 4-甲基噻唑(15.0 g, 152 mmol)在乙酸(30 mL)中的溶液中加入溴(9.27 mL, 182 mmol)。将反应混合物缓慢温热至室温并搅拌过夜。用二氯甲烷稀释并用 1 N NaOH 和盐水洗涤。将有机层用硫酸钠干燥，过滤，真空浓缩。用硅胶柱色谱对粗产物进行纯化，用己烷/乙酸乙酯(5/1)进行洗脱，得到标题化合物(9.94 g, 37%)。^{1}H NMR (400 MHz, $CDCl_3$): δ 8.69(s, 1H), 2.43(s, 3H)。

制备例 9

噻唑-2-甲酸乙酯

历经 15 分钟，向 2-三甲基硅烷基噻唑(135 g, 858.1 mmol)在甲苯(1350 mL)中的混合物中加入氯甲酸乙酯(98.4 mL, 1.03 mol)在甲苯(1350 mL)中的溶液。将反应在 22℃下搅拌 2 小时。将该溶液加到 25%(wt/wt)碳酸钠水溶液(5 L)上并搅拌 30 分钟。分离有机层，用二氯甲烷(2 × 1 L)反萃取水层。将有机层合并并蒸发掉溶剂，得到标题化合物(134 g, 99%)。ES/MS m/z 158 $(M+1)^+$。

制备例 10

噻唑-2-甲酰胺

将噻唑-2-甲酸乙酯(150 g, 0.9 mol)加入到甲醇(75 mL)和 30%氢氧化铵水溶液(750 mL)的混合物中，将混合物在回流下加热 1 小时。然后冷却至 22℃，在真空下蒸发掉甲醇。将混合物在室温下搅拌 30 分钟，滤出固体。将分离出来的固体真空干燥，得到标题化合物(98 g, 85%)。ES/MS m/z 129 $(M+1)^+$。

制备例 11

1-甲基-5-噻唑-2-基-1H-[1,2,4]三唑

将 1,1-二甲氧基-*N*,*N*-二甲基-甲胺(240 mL)冷却至 10℃并分三份加入噻唑-2-甲酰胺(60 g, 421 mmol)。将混合物在 10℃下搅拌 30 分钟。然后将混合物在 45 分钟内逐渐加热至回流。蒸馏掉所形成的甲醇，然后将反应加热至 100℃达 1.5 小时。将混合物冷却至 60℃并通过真空蒸馏除去过量的 1,1-二甲氧基-N,N-二甲基-甲胺。将残余物冷却至 22℃，加入己烷(200 mL)。将混合物研磨 15 分钟，过滤，将固体干燥至恒重，然后用于下一步。

将上面分离出来的固体(68 g)加入到乙酸(680 mL)中并将混合物冷却至 10℃。以保持温度低于 15℃的速度加入 *N*-甲基-肼(27 mL, 509 mmol)。将混合物在 30 分钟内温热至 20℃，然后逐渐加热至 90℃。在 90℃下搅拌 30 分钟，然后冷却至 22℃。通过真空蒸馏除去乙酸。将残余物加到水上，通过加入 25%氢氧化钠水溶液调至 pH = 8。用甲基-叔丁基醚对水层进行萃取(3 × 600 mL)。将有机层合并，蒸发掉溶剂。用硅胶色谱对所得的残余物进行纯化，用己烷/异丙醇(9/1)进行洗脱，得到标题化合物(49 g, 70%)。ES/MS m/z 167 $(M+1)^+$。

制备例 12

5-(5-溴-噻唑-2-基)-1-甲基-1*H*-[1,2,4]三唑

历经 1 小时分三批向甲基-5-噻唑-2-基-1H-[1,2,4]三唑(6.55 g; 39.4 mmol)和二甲基甲酰胺(32 mL)的混合物中加入 N-溴琥珀酰亚胺(14 g, 78.8 mmol)。将混合物在 22℃下搅拌 18 小时，然后加入到被冷却至 0-5℃的水

(300 mL)中。分离出水层，用甲基-叔丁基醚(2 × 200 mL)萃取。将有机层合并，用 7%碳酸氢钠水溶液(100 mL)洗涤，然后用硫酸钠干燥。过滤并蒸发掉溶剂，得到标题化合物(9.5 g, 93%)。ES/MS m/z (^{79}Br/^{81}Br) 245/247 $(M+1)^+$。

制备例 13

2,5-二甲基-3-[2-(2-甲基-2*H*-[1,2,4]三唑-3-基)-噻唑-5-基]-7-(1-丙基-丁基)-吡唑并[1,5-*a*]嘧啶

将 5-(5-溴-噻唑-2-基)-1-甲基-1H-[1,2,4]三唑(6.5 g, 23.8 mmol)和 2,5-二甲基-7-(1-丙基-丁基)-吡唑并[1,5-*a*]嘧啶(6 g, 24.5 mmol)合并到 N-甲基吡咯烷酮(58 mL)中并将其在氮气下搅拌至完全形成溶液。然后，加入溴化四-N-丁基铵(5.47 g, 16.7 mmol)和醋酸钾(11.8 g, 119 mmol)并将混合物在氮气气氛下加热至 100℃。通过用真空/氮气清洁三个循环对该热混合物进行脱气。然后加入醋酸钯(216 mg, 0.94 mmol)和三(2,4-二-叔丁基-苯基)-磷烷(787 mg, 1.2 mmol)。将混合物在 125℃下在氮气下加热 4 小时。将混合物冷却至 22℃并加入到水(750 mL)中。用甲基-叔丁基醚(3 × 200 mL)对水层进行萃取，将有机部分合并，蒸发。通过用硅胶垫过滤纯化残余物，用己烷/乙酸乙酯(4/1)进行洗脱。将包含产物的级分合并，蒸发掉溶剂，得到标题化合物(7 g, 72%)。ES/MS m/z 410 $(M+1)^+$。

制备例 14

2,5-二甲基-7-(1-丙基-丁基)-3-噻唑-5-基-吡唑并[1,5-*a*]嘧啶

向一个烘箱干燥的烧瓶中加入被溶解于无水 THF(30 mL)中的 2-三甲基硅烷基噻唑(1.765 g, 11.24 mmol)并将其在惰性气氛下冷却至-78℃。缓慢加入正丁基锂(2.5 M 己烷溶液, 4.5 mL, 11.24 mmol)并在-78℃下搅拌 30 分钟。一次性加入无水氯化锌(2.26 g, 16.58 mmol)并在-78℃下搅拌 30 分钟。使反应升至室温，搅拌 30 分钟，加入 7-(1-丙基-丁基)-3-碘-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(1.624 g, 5.18 mmol)和二氯[1,1'-双(二苯基膦基)二茂铁]钯

(II)二氯甲烷(0.423 g, 0.518 mmol)。在油浴(90℃)中在惰性气氛下回流过夜。将反应冷却至室温，用饱和碳酸氢钠淬灭，用乙酸乙酯(150 mL)稀释。将水相分离出来并用乙酸乙酯(75 mL)萃取。将有机相合并，用无水硫酸镁干燥，过滤，减压浓缩。将所得残余物用快速色谱进行纯化，用 100%己烷/0%(30% THF/己烷)至 0%己烷/100%(30% THF/己烷)以 10%的增量逐步进行梯度洗脱，得到白色固体(0.720 g, 42%)。ES/MS m/z 329.0$(M+1)^+$。

基本如制备例 14 中所述的那样来制备下面的化合物。

制备例号	化学名	物理数据
15	7-(1-乙基-丙基)-2,5-二甲基-3-噻唑-5-基-吡唑并[1,5-*a*]嘧啶	1H NMR(400 MHz, $CDCl_3$): d 8.75(s, 1H), 8.75(s, 1H), 8.28(s, 1H), 6.47(s, 1H), 3.62-3.55(m, 1H), 2.65(s, 3H), 2.61(s, 3H), 1.89-1.75(m, 4H), 0.85(t, 6H, *J* = 7.5 Hz), 0.85(t, 6H, *J* = 7.5 Hz)。

制备例 15 的另一种操作:

在-78℃下，在氮气下，将正丁基锂(76.5 mL, 191 mmol, 2.5 M 的己烷溶液)加入到 2-三甲基硅烷基噻唑(30 g, 191 mmol)在 THF(450 mL)中的溶液中，在加入期间保持温度低于-74℃。将该混合物在-78℃下搅拌 30 分钟，然后一次性加入氯化锌干粉(39.9 g, 286 mmol)并将混合物历经 1 小时温热至 22℃。加入 7-(1-乙基-丙基)-3-碘-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(30 g, 87 mmol)和 1,1'-双(二苯基膦基)二茂铁氯化钯(II)(6.5 g, 8 mmol)并将混合物在氮气下加热至回流达 8 小时。将混合物冷却至 22℃并加入 10%氯化铵水溶液(450 mL)。分离有机层并用甲基-叔丁基醚对水层进行洗涤(2 × 100 mL)。将有机部分合并，用硫酸钠干燥，过滤，蒸发掉溶剂，得到标题化合物(20.4 g, 78%)。ES/MS m/z 301$(M+1)^+$。

制备例 16

7-(1-乙基-丙基)-3-(2-碘-噻唑-5-基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶

在-78℃下，在氮气气氛下，将新制备的二-异丙基氨基锂溶液(150 ml; 62.4 mmol, 0.6 M 的 THF 溶液)加入到 7-(1-乙基-丙基)-2,5-二甲基-3-噻唑-5-基-吡唑并[1,5-*a*]嘧啶(17.8 g, 62.4 mmol)在 THF(100 mL)中的混合物中，在加入期间保持温度低于-74℃。将该混合物在-78℃下搅拌 1 小时，然后加入 N-碘琥珀酰亚胺(15 g, 63 mmol)在 THF(100 mL)中的溶液，同时保持温度低于-74℃。将反应逐渐温热至 22℃，然后加入 10%氯化铵水溶液(300 mL)。分离有机层，用甲基-叔丁基醚对水层进行洗涤(2 × 200 mL)。将有机层合并，用硫酸钠干燥，过滤并蒸发掉溶剂。用硅胶色谱对所得的残余物进行纯化，用己烷/丙酮(5/1)进行洗脱，得到标题化合物(15 g, 60%)。ES/MS m/z 427 $(M+1)^+$。

实施例 1

7-(1-乙基-丙基)-2,5-二甲基-3-(4-甲基-噻唑-5-基)-吡唑并[1,5-*a*]嘧啶

将 Rieke®锌(10 g，位于 100 mL THF 中, 13.2 mL, 18.48 mmol)加入到 5-溴-4-甲基噻唑(2.13 g, 18.48 mmol)中并在回流下加热 2 小时。将混合物冷却至室温，通过离心使锌沉降。向位于干燥四氢呋喃(10 mL)中的 7-(1-乙基-丙基)-3-碘-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(900 mg, 2.62 mmol)中用氮气鼓泡，加入有机溴化锌溶液，然后加入[1,1'-双(二苯基膦基)二茂铁]-二氯钯(II)(106 mg, 0.13 mmol)。将反应混合物在回流下搅拌过夜，然后冷却至室温。向反应混合物中加入氯化铵溶液并用二氯甲烷萃取。将有机部分用硫酸钠干燥，过滤，真空除去溶剂。用硅胶柱色谱对粗产物进行纯化，用己烷/乙酸乙酯(3/1)进行洗脱，得到标题化合物(652 mg, 79%)。^{1}H NMR (400 MHz, $CDCl_3$): δ 8.80(s, 1H), 6.48(s, 1H), 3.63(m, 1H), 2.57(s, 3H), 2.43 (s, 3H), 2.40(s, 3H), 1.85(m, 4H), 0.90(t, 6H, J = 7.3Hz)。ES/MS m/z 315 $(M+1)^+$。

制备例 17

3-(2,4-二溴-噻唑-5-基)-2,5-二甲基-7-(1-丙基-丁基)-吡唑并[1,5-*a*]嘧啶

将 2,5-二甲基-7-(1-丙基-丁基)-3-噻唑-5-基-吡唑并[1,5-*a*]嘧啶(3.15 g, 9.59 mmol)溶解于乙腈(100 mL)中并一次性加入 N-溴琥珀酰亚胺(4.27 g, 24.0 mmol)。在惰性气氛下搅拌过夜并用 TLC 证实反应进行完全。减压浓缩，用二氯甲烷(150 mL)稀释油状物，用水(75 mL)洗涤。将有机相用无水硫酸镁干燥，过滤，减压浓缩。将所得的油状物用快速色谱进行纯化，用 100%己烷/0%(30% THF/己烷)至 0%己烷/100%(30% THF/己烷)逐步梯度洗脱(0-10-15-20-25-30-35-40-45-50-100%的 30%THF/己烷)，得到黄色晶体(3.70 g, 79%)。ES/MS m/z ($^{79}Br^{81}Br$) 486.7 $(M+1)^+$。


基本如制备 17 中所述的那样制备下面的化合物，不同的是用二氯甲烷作为溶剂。

实施例编号	化学名	物理数据
2	3-(2,4-二溴-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶	MS (APCI) m/z ($^{79}Br^{81}Br$) 459.1 $(M+1)^+$
3*	3-(2-溴-4-甲基-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶	ES/MS m/z (^{79}Br) 393 $(M+1)^+$

*使用 1.1 eq NBS，搅拌 3 天。

实施例 4

3-(4-溴-2-吗啉-4-基-噻唑-5-基)-2,5-二甲基-7-(1-丙基-丁基)-吡唑并[1,5-*a*]嘧啶



向一个烘箱干燥的烧瓶中加入 3-(2,4-二溴噻唑-5-基)-2,5-二甲基-7-(1-

丙基-丁基)-吡唑并[1,5-*a*]嘧啶(0.973 g, 2.00 mmol)、无水二噁烷(20 mL)、吗啉(0.872 g, 10.0 mmol)和碳酸铯(1.95 g, 6.00 mmol)。在油浴(105℃)中在惰性气氛下回流过夜。用 LC/MS 证实反应完全。用乙酸乙酯(100 mL)稀释，用水(50 mL)洗涤，用乙酸乙酯(50 mL)反萃取水相。将有机相合并，用硫酸镁干燥，过滤，减压浓缩。将所得残余物用快速色谱进行纯化，用 100%己烷/0%(40%二氯甲烷/20%乙酸乙酯/2% 7 N 氨的甲醇溶液/38%己烷)至 0%己烷/100%(40%二氯甲烷/20%乙酸乙酯/2% 7 N 氨的甲醇溶液/38%己烷)以 10%的增量逐步梯度洗脱，得到灰白色固体(0.878 g, 89%)。ES/MS m/z (^{79}Br) 491.7$(M+1)^+$。

基本如实施例 4 中所述的那样用 2.0 二甲基胺/THF 或吗啉作为胺、用 THF 或二噁烷作为溶剂制备下面的实施例。这些反应是在密封的容器或 Schlenk 管中进行的。


实施例号	化学名	物理数据
5*	{4-溴-5-[2,5-二甲基-7-(1-丙基-丁基)-吡唑并[1,5-*a*]嘧啶-3-基]-噻唑-2-基}-二甲基胺	ES/MS (^{79}Br) 449.8 $(M+1)^+$。
6	3-(4-溴-2-吗啉-4-基-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶	MS (APCI) m/z (^{81}Br) 466.5 $(M+1)^+$
7	{4-溴-5-[7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶-3-基]-噻唑-2-基}-二甲基-胺	MS (APCI) m/z (^{81}Br) 424.4 $(M+1)^+$
8	{5-[7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶-3-基]-4-甲基-噻唑-2-基}-二甲基-胺	ES/MS m/z 358 $(M+1)^+$
9	7-(1-乙基-丙基)-2,5-二甲基-3-(4-甲基-2-吗啉-4-基-噻唑-5-基)-吡唑并[1,5-*a*]嘧啶	ES/MS m/z 400 $(M+1)^+$

*使用 6 eq 碳酸铯。

实施例 10

3-[4-溴-2-(2-甲基-2*H*-[1,2,4]三唑-3-基)-噻唑-5-基]-2,5-二甲基-7-(1-丙基-丁基)-吡唑并[1,5-*a*]嘧啶

0548




向一个烘箱干燥的烧瓶中加入 1-甲基-1,2,4-三唑(0.498, 6.00 mmol)和无水 THF(20 mL)，在惰性气氛下冷却至-78℃。缓慢加入正丁基锂(2.5M 己烷溶液, 2.4 mL, 6.0 mmol)并搅拌 30 分钟。一次性加入无水氯化锌(1.36 g, 10.0 mmol)并在-78℃下搅拌 30 分钟。使反应温热至室温，搅拌 30 分钟，加入 3-(2,4-二溴噻唑-5-基)-2,5-二甲基-7-(1-丙基-丁基)-吡唑并[1,5-*a*]嘧啶(0.973 g, 2.00 mmol)和二氯[1,1'-双(二苯基膦基)二茂铁]钯(II)二氯甲烷(0.163 g, 0.200 mmol)。将反应在油浴(90℃)中在惰性气氛下回流过夜。将反应冷却至室温，用水淬灭，用乙酸乙酯(100 mL)稀释。分离出含水部分，用二氯甲烷(50 mL)萃取。将有机相合并，用无水硫酸镁干燥，过滤，减压浓缩。将所得残余物用快速色谱进行纯化，用 100%己烷/0%(10%乙腈/40% THF/50%己烷)至 0%己烷/100%(10%乙腈/40% THF/50%己烷)以 10%的增量逐步梯度洗脱，得到白色固体(0.090 g, 9%)。ES/MS m/z (^{79}Br) 487.7 $(M+1)^+$。

另一种制备方法：

向 2,5-二甲基-3-[2-(2-甲基-2H-[1,2,4]三唑-3-基)-噻唑-5-基]-7-(1-丙基-丁基)-吡唑并[1,5-*a*]嘧啶(6 g, 14.65 mmol)在乙腈(60 mL)中的溶液中一次性加入 N-溴琥珀酰亚胺(2.74 g, 15.4 mmol)并在 22℃下搅拌 10 小时。蒸发掉溶剂，将残余物溶解于水(50 mL)和甲基-叔丁基醚(100 mL)的混合物中。分离有机层，用另外的甲基-叔丁基醚对水层进行萃取(2 × 50 mL)。将有机部分合并，蒸发掉溶剂。通过用硅胶垫过滤来对所得物质进行纯化，用己烷/乙酸乙酯(3/1)进行洗脱。将包含产物的级分合并，蒸发掉溶剂。加入庚烷(25 mL)并对固体进行研磨。将固体滤出，真空干燥，得到标题化合物(5.5 g, 77%)。ES/MS m/z (^{79}Br/^{81}Br) 488/490$(M+1)^+$。

实施例 10a

3-[4-溴-2-(2-甲基-2*H*-[1,2,4]三唑-3-基)-噻唑-5-基]-2,5-二甲基-7-(1-丙基-丁基)-吡唑并[1,5-*a*]嘧啶，盐酸盐



将 3-[4-溴-2-(2-甲基-2*H*-[1,2,4]三唑-3-基)-噻唑-5-基]-2,5-二甲基-7-(1-丙基-丁基)-吡唑并[1,5-*a*]嘧啶(750 mg, 1.54 mmol)溶解于丙酮(5 mL)中并加入 1 M HCl 的乙醚溶液(1.84 mL, 1.84 mmol)。将混合物在室温下搅拌 3 小时并真空浓缩。将残余物溶解于乙醚/己烷= 1/1(5 mL)中，使所需的 HCl 盐结晶(526 mg, 65%)。ES/MS m/z (^{81}Br) 490 $(M+1)^+$; ^{1}H-NMR ($CDCl_3$): 8.20(s, 1H), 6.82(s, 1H), 4.21(s, 3H), 3.64(m, 1H), 2.49(m, 3H), 2.44(s, 3H), 1.75(m, 4H), 1.96(m, 4H), 0.81(m, 6H)。


基本如实施例 10 中所述的那样来制备下面的化合物。

实施例编号	化学名	物理数据
11*	7-(1-乙基-丙基)-2,5-二甲基-3-[4-甲基-2-(2-甲基-2H-[1,2,4]三唑-3-基)-噻唑-5-基]-吡唑并[1,5-*a*]嘧啶	ES/MS m/z 396 $(M+1)^+$

* 用 0.5 M 位于 THF 中的氯化锌代替无水氯化锌。在 80℃下加热 3 天。

实施例 12

3-(4-溴-2-(2-甲基-2H-[1,2,4]三唑-3-基)-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶



在-78℃下，在氮气气氛下，将正丁基锂(2.5M 己烷溶液, 0.6 mL, 1.5 mmol)加入到 1-甲基-1,2,4-三唑(124.5 mg, 1.5 mmol)在 THF(3 mL)中的溶液中并搅拌 30 分钟。加入无水氯化锌(409 mg, 3.0 mmol)，继续搅拌 30 分钟，温热至室温并搅拌 2 小时。加入 3-(2,4-二溴-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(229 mg, 0.5 mmol)，然后加入四(三苯基膦)钯(58 mg, 0.05 mmol)并回流过夜。冷却至室温，用乙酸乙酯稀释，用饱和氯化铵洗涤。将有机部分用硫酸钠干燥，过滤，浓缩，获得残余物。用快速色谱对粗品物质进行纯化，用己烷:乙酸乙酯(10:2.5)进行洗脱，得到黄色泡沫形式的标题化合物(77 mg)。MS (APCI) m/z (^{79}Br) 460.4 $(M+1)^+$。

从实施例 21 开始的另一种制备方法:

将乙酸(1 mL)和 N-溴琥珀酰亚胺(4.1 g, 22 mmol)加入到 7-(1-乙基-丙基)-2,5-二甲基-3-[2-(2-甲基-2H-[1,2,4]三唑-3-基)-噻唑-5-基]-吡唑并[1,5-*a*]嘧啶(8 g, 21 mmol)在乙腈(80 mL)中的溶液中。将混合物在 22℃下搅拌 2 小时。然后蒸发掉溶剂，向所得的残余物中加入水(50 mL)和甲基-叔丁基醚(100 mL)。将有机部分分离出来，用硫酸钠干燥，过滤，蒸发掉溶剂。将所得的残余物用异丙醇重结晶，得到标题化合物(8.7 g, 90%)。ES/MS (m/z): (^{79}Br/^{81}Br) 460/462 $(M+1)^+$。

实施例 12a

3-(4-溴-2-(2-甲基-2H-[1,2,4]三唑-3-基)-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶, 对-甲苯磺酸

将 3-(4-溴-2-(2-甲基-2H-[1,2,4]三唑-3-基)-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(50 mg, 0.109 mmol)溶解于丙酮(3 mL)

中。加入 0.25 M 对-甲苯磺酸水溶液(434.4 μL, 0.109 mmol)，将所得混合物蒸发至干。加入乙酸乙酯(12 mL)以使固体部分溶解。加入甲醇(1 mL)以获得澄清溶液。通过缓慢蒸发来对该溶液进行浓缩，直至观察到晶体。通过过滤分离出晶体并在 25℃下真空干燥，得到约 50 mg 标题化合物。

用使用下列 HPLC 条件的离子色谱测定该盐的化学计量：柱：Phenomenex Phenosphere SAX, 4.6 × 150 mm，30℃；流动相：50%乙腈/50% 0.025 M 磷酸钠缓冲液, pH = 4.5；流速= 1.5 mL/min；检测：UV, 205 nm；进样体积= 5 μL；运行时间= 3 分钟。理论量计算值：27.2%甲苯磺酸根；实测值：28.4%甲苯磺酸根(三次 HPLC 运行的均值)。

实施例 13

{4-氯-5-[2,5-二甲基-7-(1-丙基-丁基)-吡唑并[1,5-*a*]嘧啶-3-基]-噻唑-2-基}-二甲基胺

向一个烘箱干燥的烧瓶中加入{4-溴-5-[2,5-二甲基-7-(1-丙基-丁基)-吡唑并[1,5-*a*]嘧啶-3-基]-噻唑-2-基-二甲基胺(0.20, 0.44 mmol)和无水 THF (3.0 mL)并在惰性气氛下冷却至-78℃。缓慢加入正丁基锂(1.6 M 己烷溶液, 0.42 mL, 0.67 mmol)并搅拌 30 分钟。一次性加入 N-氯琥珀酰亚胺(0.120 g, 0.889 mmol)并在-78℃下搅拌 30 分钟。使反应温热至室温，搅拌 5 小时，用 LC/MS 检查反应进程。用乙酸乙酯(100 mL)稀释，用饱和氯化铵(50 mL)洗涤，用二氯甲烷(50 mL)反萃取水相。将有机相合并，用无水硫酸镁干燥，过滤，减压浓缩。将所得残余物用快速色谱进行纯化，用 100%己烷/0%(25% THF/己烷)至 0%己烷/100%(25% THF/己烷)以 10%的增量逐步梯度洗脱，得到白色固体(0.087 g, 48%)。ES/MS m/z (^{35}Cl) 406.0 $(M+1)^+$。

基本如实施例 13 所述的那样用上面制得的适宜溴代噻唑来制备下面的实施例。

实施例号	化学名	物理数据
14	3-(4-氯-2-吗啉-4-基-噻唑-5-基)-2,5-二甲基-7-(1-丙基-丁基)-吡唑并[1,5-*a*]嘧啶	ES/MS m/z (^{35}Cl) 448.0 $(M+1)^+$
15	{4-氯-5-[7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶-3-基]-噻唑-2-基}-二甲基-胺	MS (APCI) m/z (^{35}Cl) 378.0 $(M+1)^+$

制备例 18

2,4-二氯噻唑

将噻唑烷-2,4-二酮(50 g, 0.43 mol)在三氯氧化磷(240 mL)中的混合物冷却至5℃，历经15分钟加入吡啶(34 mL, 0.43 mol)。将混合物加热至125℃达4小时，然后冷却至22℃。通过真空蒸馏除去过量的三氯氧化磷并将残余物加入到被冷却至5℃的水(1 L)中。将混合物用二氯甲烷(3 × 400 mL)萃取。将有机部分合并，蒸发掉溶剂，得到标题化合物(50 g, 76%)。EI/MS m/z: (^{35}Cl^{35}Cl/^{35}Cl^{37}Cl/^{37}Cl^{37}Cl) 153/155/157 $(M+1)^+$。

制备例 19


4-氯-2-吗啉代-噻唑

向2,4-二氯噻唑(34 g, 0.22 mol)在乙腈(425 mL)中的混合物中加入碳酸钾(60.9 g, 0.44 mol)，然后历经30分钟滴加吗啉(21.2 mL, 0.225 mol)。将混合物在40℃下回流，然后冷却至22℃。对混合物过滤并蒸发滤液。将残余物用异丙醇(60 mL)在22℃下研磨1小时。将固体滤出并真空干燥至恒重，得到标题化合物(34.5 g, 76%)。ES/MS m/z (^{35}Cl) 205 $(M+1)^+$。

实施例 16

3-(4-氯-2-吗啉-4-基-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶

0553



在氮气气氛下，将 3-(4-溴-2-吗啉-4-基-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(116 mg, 0.25 mmol)溶解于 THF(1.5 mL)中并冷却至-78℃。加入正丁基锂(0.1 mL. 2.5 M 己烷溶液, 0.25 mmol)并在-78℃下搅拌 30 分钟。加入 N-氯琥珀酰亚胺(33.4 mg, 0.25 mmol)并再搅拌 30 分钟，同时缓慢温热至室温。在搅拌过夜后，通过加入饱和氯化铵溶液将反应淬灭，用乙酸乙酯萃取。用盐水洗涤有机层，用硫酸钠干燥，过滤，浓缩，获得残余物。用快速色谱对该粗品物质进行纯化，用己烷:二氯甲烷:乙酸乙酯(5:5:2)洗脱，得到标题化合物(54 mg)。MS (APCI) m/z (^{35}Cl) 420.6 $(M+1)^+$; ^{1}H NMR (400 MHz, $CDCl_3$): 6.44(s, 1H), 3.79(t, 4H, *J*=4.8 Hz), 3.63-3.56(m, 1H), 3.47(t, 4H, *J*=4.8 Hz), 2.55(s, 3H), 2.45(s, 3H), 1.88-1.75(m, 4H), 0.87(t, 6H, *J*=7.5 Hz)。

从制备例 6 开始的另一种制备方法:

将 7-(1-乙基-丙基)-3-碘-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(9 g, 26.2 mmol)和 4-氯-2-吗啉代-噻唑(7.5 g, 36.7 mmol)合并到之前用氮气进行了脱气的二甲基甲酰胺(90 mL)中。加入碳酸铯(17.8 g, 55 mmol)、碘化亚铜(250 mg, 1.31 mmol)、三苯基膦(550 mg, 2.09 mmol)和醋酸钯(117 mg, 0.52 mmol)。将混合物加热至 125℃达 16 小时，然后冷却至 22℃。加入水(900 mL)并用甲基-叔丁基醚(3 × 200 mL)萃取。将有机部分合并，蒸发掉溶剂。用硅胶色谱进行纯化，用己烷/乙酸乙酯(4/1)进行洗脱，得到标题化合物(6.4 g, 62%)。ES/MS m/z (^{35}Cl) 420 $(M+1)^+$。

实施例 16a

3-(4-氯-2-吗啉-4-基-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-

吡唑并[1,5-*a*]嘧啶，盐酸盐

在 50℃下，将 3-(4-氯-2-吗啉-4-基-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(1.40 g, 3.33 mmol)溶解于丙酮(10 mL)中并冷却至室温。加入氯化氢(2M 乙醚溶液, 2.0 mL, 4.0 mmol)并在超声波仪中充分搅拌。将溶液浓缩少量，加入最低限度的乙醚以使 HCl 盐结晶。将混合物在冷藏器中冷却过夜。加入另外的氯化氢(2M 乙醚溶液, 2.0 mL, 4.0 mmol)，在冷藏器中冷却。将结晶性物质滤出，干燥，得到标题化合物(1.15 g, 75%)。ES/MS m/z (^{35}Cl) 420 $(M+1)^+$; ^{1}H NMR (CDCl3): 9.18(br, 1H), 6.86(s, 1H), 3.72(m, 4H), 3.49(m, 1H), 3.39(m, 4H), 2.48(s, 3H), 2.38(s, 3H), 1.79(m, 4H), 0.79(m, 6H)。

实施例 17

3-(4-溴-2-丁基-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶

在-78℃下，在氮气气氛下，将正丁基锂(2.5M 己烷溶液, 0.2 mL, 0.5 mmol)加入到 3-(2,4-二溴-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(230 mg, 0.5 mmol)在 THF(3 mL)中的溶液中。在 30 分钟后，加入 1-碘丁烷(138 mg, 0.75 mmol)并继续搅拌 1 小时。温热至室温并搅拌 1 小时。通过加入饱和氯化铵溶液来将反应淬灭并用乙酸乙酯萃取。将有机部分用硫酸钠干燥，过滤，浓缩，获得残余物。用快速色谱对该粗品物质进行纯化，用己烷/乙酸乙酯(10/1.5)进行洗脱，得到橙色泡沫形式的标题化合物(78 mg)。ES/MS m/z (^{81}Br) 437.4 $(M+1)^+$。

基本如实施例 17 所述的那样制备下面的实施例。

实施例号	化学名	物理数据
18	3-(4-溴-2-甲氧基甲基-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶	MS (APCI) m/z (^{81}Br) 424.6 $(M+1)^+$

实施例 19

7-(1-乙基-丙基)-3-(2-甲氧基甲基-噻唑-5-基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶

在-78℃下，在氮气气氛下，将正丁基锂(2.5M 己烷溶液, 0.4 mL, 1.0 mmol)加入到 7-(1-乙基-丙基)-2,5-二甲基-3-噻唑-5-基-吡唑并[1,5-a]嘧啶(300 mg, 1.0 mmol)在 THF(3 mL)中的溶液中。搅拌 30 分钟，加入 1-碘甲基甲基醚(205 mg, 1.2 mmol)。继续搅拌 1 小时，然后缓慢温热至室温并搅拌过夜。通过加入饱和氯化铵溶液来将反应淬灭，用乙酸乙酯萃取。将有机层用盐水洗涤，用硫酸钠干燥，过滤，真空浓缩，获得残余物。用快速色谱对该粗品物质进行纯化，用己烷/乙酸乙酯(10/2)进行洗脱，得到黄色泡沫形式的标题化合物(184 mg)。MS (APCI) m/z 345.3 $(M+1)^+$。

实施例 20

3-(4-氯-2-甲氧基甲基-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶

在-78 °C 下，将正丁基锂(2.5 M 己烷溶液, 174 mL, 0.43 mmol)加入到进行着搅拌的 7-(1-乙基-丙基)-3-(2-甲氧基甲基-噻唑-5-基)-2,5-二甲基-吡唑并[1,5-a]嘧啶(150 mg, 0.43 mmol)在 THF(3 mL)中的溶液中。搅拌 30 分钟并加入 N-氯琥珀酰亚胺(87 mg, 0.653 mmol)。搅拌 30 分钟，然后将反应缓慢温热至室温，使反应继续进行过夜。通过加入饱和氯化铵溶液来将反应淬灭，用乙酸乙酯萃取，用硫酸钠干燥，过滤，浓缩，获得残余物。用快速色谱进行纯化，用己烷/乙酸乙酯(10/2)进行洗脱，得到标题化合物(7 mg)。MS (APCI) m/z (^{35}Cl) 379.3 $(M+1)^+$。

实施例 21

7-(1-乙基-丙基)-2,5-二甲基-3-[2-(2-甲基-2H-[1,2,4]三唑-3-基)-噻唑-5-基)-吡唑并[1,5-*a*]嘧啶

将 3-(4-溴-2-(2-甲基-2H-[1,2,4]三唑-3-基)-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(175 mg, 0.38 mmol)和氯化亚铜(I)(132

mg, 1.33 mmol)在 DMF(5 mL)中进行混合并加热至 120℃达 24 小时。冷却至室温，用乙酸乙酯稀释并用盐水洗涤。将有机层用硫酸钠干燥，过滤，真空浓缩，得到残余物。用快速色谱进行纯化，用己烷、然后用己烷/EtOAc (10/1.8)进行洗脱，得到黄色-橙色固体(45 mg)。ES/MS m/z 382.0$(M+1)^+$。

另一种制备方法：

在-78℃下，在氮气气氛下，将正丁基锂(2.5 M 己烷溶液, 57.6 mL, 144 mmol)加入到 *N*-甲基三唑(11.95 g, 144 mmol)在 THF(600 mL)中的溶液中，在加入期间保持温度低于-74℃。然后一次性加入氯化锌干粉(26 g, 192 mmol)并将混合物在 1 小时内温热至 22℃。一次性加入 7-(1-乙基-丙基)-3-(2-碘-噻唑-5-基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(12.5 g, 29 mmol)和四(三苯基)膦钯催化剂(1.15 g, 0.01 mol)，将混合物在氮气下加热至回流达 8 小时。将混合物冷却至 22℃并加入水(300 mL)。分离有机层并用甲基-叔丁基醚萃取水层(2 × 200 mL)。将有机部分合并，用硫酸钠干燥，过滤，蒸发掉溶剂。通过硅胶垫来进行纯化，用己烷/乙酸乙酯(4/1)进行洗脱，得到标题化合物(8 g, 72%)。ES/MS m/z 382 $(M+1)^+$。

实施例 22

3-(4-氯-2-(2-甲基-2H-[1,2,4]三唑-3-基)-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶

将 7-(1-乙基-丙基)-2,5-二甲基-3-[2-(2-甲基-2H-[1,2,4]三唑-3-基)-噻唑-5-基)-吡唑并[1,5-*a*]嘧啶(20 mg, 0.052 mmol)和 N-氯琥珀酰亚胺(7.6 mg, 0.0569 mmol)在二氯甲烷(0.5 mL)和乙腈(0.5 mL)中的混合物在室温下在一个小瓶中搅拌过夜。浓缩，获得残余物。用快速色谱进行纯化，用己烷、然后用己烷/乙酸乙酯(10/1.5)洗脱，得到标题化合物(16 mg)。ES/MS m/z (^{35}Cl) 416.0 $(M+1)^+$。

实施例 23

7-(1-乙基-丙基)-3-(4-甲氧基-2-吗啉-4-基-噻唑-5-基)-2,5-二甲基-

0557

吡唑并[1,5-*a*]嘧啶

将 3-(4-溴-2-吗啉-4-基-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(162 mg, 0.35 mmol)、甲醇钠(57 mg, 1.05 mmol)和碘化亚铜(I)(67 mg, 0.35 mmol)在甲醇(3 mL)中的混合物在一个密封的 4-mL 小瓶中在 120℃下搅拌 15 小时。冷却至室温，通过过滤除去固体，将滤液真空浓缩。用快速色谱对残余物进行纯化，用己烷/THF(10/2)进行洗脱。用甲醇将该物质重结晶，得到标题化合物(20 mg)。ES/MS m/z 416.0 $(M+1)^+$。

制备例 20

4-溴-5-[7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶-3-基]-噻唑-2-甲醛

在-78℃下，在氮气气氛下，将正丁基锂(1.6 M 己烷溶液, 0.312 mL, 0.50 mmol)加入到 3-(2,4-二溴-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(230 mg, 0.50 mmol)的 THF 溶液(2.5 mL)中并搅拌 30 分钟。加入 N-甲酰基吗啉(58 mg, 0.50 mmol)的 THF(0.5 mL)溶液。搅拌 1 小时，然后将反应在-20℃下储存过夜。将反应温热至室温，用醚稀释，通过加入 4 N HCl (4 mL)将其淬灭。将有机相分离出来并用 4 N HCl (2 × 4 mL)萃取。将含水部分合并，用碳酸氢钠固体处理至 pH = 8 至 9，然后用乙醚萃取。将所有的有机层合并，用盐水洗涤，用硫酸钠干燥，过滤，浓缩，获得残余物。用快速色谱对该粗品物质进行纯化，用己烷/二氯甲烷/乙酸乙酯(5/5/1)洗脱，得到标题化合物(154 mg)。MS (APCI) m/z (^{81}Br) 409.0 $(M+1)^+$。

实施例 24

3-(4-溴-2-吗啉-4-基-甲基-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶

将 4-溴-5-[7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶-3-基]-噻唑-2-甲醛(150 mg, 0.368 mmol)、吗啉(35 mg, 0.405 mmol)和三乙酰氧基硼氢化钠(97 mg, 0.46 mmol)合并到二氯甲烷(3 mL)和甲醇(0.5 mL)中。搅拌过夜，再加入一些吗啉(35 mg, 0.405 mmol)和三乙酰氧基硼氢化钠(97 mg,

0.46 mmol)，再搅拌 4 小时。真空除去溶剂，用二氯甲烷稀释，用盐水洗涤。将有机相用硫酸钠干燥，过滤并真空浓缩。将所得的物质用快速色谱进行纯化，用二氯甲烷:2 M 氨的甲醇溶液(10:1)洗脱，得到一种混合物。用反相柱对混合物进行纯化，用水/乙腈(80/20)至水/乙腈(10/90)洗脱，得到标题化合物(20 mg)。ES/MS m/z (^{81}Br) 480.0 $(M+1)^+$。

实施例 25

3-(4-溴-2-吡啶-4-基-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-a]嘧啶

在-78℃下，在氮气气氛下，将正丁基锂(1.6 M 己烷溶液, 0.312 mL, 0.5 mmol)加入到 3-(2,4-二溴-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(229 mg, 0.5 mmol)在 THF(4 mL)中的溶液中。搅拌 30 分钟后，加入无水氯化锌(264 mg, 1.5 mmol)，继续搅拌 30 分钟。将反应温热至室温并搅拌 1 小时。加入 4-碘吡啶(103 mg, 0.5 mmol)，然后加入 1,1'-双(二苯基膦基)二茂铁氯化钯(II)(二氯甲烷加合物)(0.40.8 mg, 0.05 mmol)。将反应加热至回流过夜。冷却至室温，用乙酸乙酯稀释，用水和盐水洗涤。将有机层用硫酸钠干燥，过滤，浓缩，获得残余物。用快速色谱对该粗品物质进行纯化，用二氯甲烷:2 N 氨的甲醇溶液(10:0.75)洗脱，得到一种混合物。用反相柱对混合物进行纯化，用水:乙腈= 80:20 至水:乙腈= 10:90 进行洗脱，得到标题化合物(19 mg)。ES/MS m/z (^{79}Br) 456.0 $(M+1)^+$。

制备例 21

4-三氟甲基-噻唑-2-基胺

将硫脲(4.0 g, 52.3 mmol)和 3-溴-1,1,1-三氟丙-2-酮(5.5 mL, 10 g, 52.3 mmol)加入到乙醇(100 mL)中并在 50℃下加热 2 小时。冷却至室温，浓缩至干。将残余物溶解于水中并用 2M NaOH 将 pH 调至>12。用乙醚萃取(4×)。将合并的有机萃取物用硫酸钠干燥，过滤并真空浓缩。用硅胶色谱对所得材料进行纯化(CH_2Cl_2)，得到标题化合物(6.9 g, 79%)。ES/MS m/z

169 $(M+1)^+$。

制备例 22

5-溴-4-三氟甲基-噻唑-2-基胺，氢溴酸盐

将溴(2.0 mL, 6.28 g, 39.3 mmol)滴加到冰浴冷却的 4-三氟甲基-噻唑-2-基胺(6.0 g, 35.7 mmol)在乙醚(60 mL)中的溶液中。在完全加入后搅拌 1 小时，然后温热至室温。通过过滤收集固体并用乙醚洗涤，得到标题化合物(10.5 g, 90%)。ES/MS m/z ($^{79}Br/^{81}Br$) 247/249 $(M+1)^+$。


制备例 23

5-溴-2-(2,5-二甲基-吡咯-1-基)-4-三氟甲基-噻唑

将己烷-2,5-二酮(3.5 mL, 3.4 g, 30.2 mmol)加入到 5-溴-4-三氟甲基-噻唑-2-基胺氢溴酸盐(9.0 g, 27.4 mmol)在甲醇(60 mL)中的溶液中。在室温下搅拌过夜。加入磷酸盐缓冲液(50 mL, pH = 7)。通过过滤收集沉淀，用水洗涤。将滤饼溶解于 CH_2Cl_2 中，用硫酸钠干燥。过滤并真空浓缩，得到标题化合物(8.2 g, 92%)。^1H NMR (400 MHz, $CDCl_3$) δ 5.91(s, 2H), 2.27(s, 6H)。

实施例 26

3-[2-(2,5-二甲基-吡咯-1-基)-4-三氟甲基-噻唑-5-基]-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶



将 5-溴-2-(2,5-二甲基-吡咯-1-基)-4-三氟甲基-噻唑(2.2 g, 6.6 mmol)在 THF(25 mL)中的溶液在干冰浴中进行冷却。滴加叔丁基锂(1.7 M 的戊烷溶

液, 8.5 mL, 14.5 mmol)。搅拌 45 分钟，然后滴加氯化锌(0.5 M 的 THF 溶液, 14.6 mL, 7.3 mmol)。搅拌 5 分钟并除去冷却浴。搅拌 30 分钟，然后加入 7-(1-乙基-丙基)-3-碘-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(1.5 g, 4.4 mmol)和双(三-叔丁基膦)钯(0)(450 mg, 0.9 mmol)。回流 24 小时。将反应冷却，将混合物倾倒到乙醚中，用水(2×)洗涤。将合并的水层用乙醚洗涤。将合并的有机部分用硫酸钠干燥，过滤，真空浓缩至干。用硅胶色谱对所得的残余物进行纯化(75-100% CH_2Cl_2 的己烷溶液)，得到标题化合物(1.47 g, 72%)。HR-ToF-MS m/z $C_{23}H_{26}F_3N_5S+H^+$的计算值：462.1939，实测值：462.1915。

实施例 27

5-[7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶-3-基]-4-三氟甲基-噻唑-2-基胺

将羟胺(2 mL, 50%的水溶液)加入到 3-[2-(2,5-二甲基-吡咯-1-基)-4-三氟甲基-噻唑-5-基]-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(1.1 g, 2.3 mmol)在乙酸(10 mL)中的溶液中。将反应加热至 80℃达 6 小时。冷却至室温。倾倒到乙醚中，用 2 M NaOH 洗涤 2 次，然后用水洗涤一次。将有机部分用硫酸钠干燥，过滤，浓缩，真空浓缩至干。用硅胶色谱对所得的残余物进行纯化(40%乙酸乙酯的己烷溶液)，得到标题化合物(0.76 g, 87%)。ES/MS m/z 384 $(M+1)^+$。

制备例 24

3-(2-溴-4-三氟甲基-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶

将溴化铜(II)(540 mg, 2.4 mmol)和亚硝酸叔丁酯(0.36 mL, 310 mg, 3.0 mmol)在乙腈(20 mL)中的混合物加热至 60℃。加入固体形式的 5-[7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-a]嘧啶-3-基]-4-三氟甲基-噻唑-2-基胺(755 mg, 2.0 mmol)。将反应加热至 80℃达 2 小时。将反应冷却，倾倒到乙醚中，

用水萃取(3×)。将有机层用硫酸钠干燥，过滤，浓缩，真空浓缩至干。用硅胶色谱对所得的残余物进行纯化(CH_2Cl_2)，得到标题化合物(0.77 g, 87%)。ES/MS m/z ($^{79}Br/^{81}Br$) 447, 449 $(M+1)^+$。

实施例 28

{5-[7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶-3-基]-4-三氟甲基-噻唑-2-基}-二甲基-胺

将一个包含位于甲醇(4 mL)中的 3-(2-溴-4-三氟甲基-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(313 mg, 0.7 mmol)和二甲胺(2 M 的 THF 溶液, 4 mL, 8 mmol)的密封管加热至 80℃达 2 小时。将反应冷却并真空浓缩。用硅胶色谱对所得的残余物进行纯化，用 0-30%乙酸乙酯的 CH_2Cl_2 溶液洗涤，得到标题化合物(0.28 g, 97%)。HR-ToF-MS m/z $C_{19}H_{24}F_3N_5S+H^+$的计算值: 412.1770, 实测值: 412.1783。

基本如实施例 28 中所述的那样制备下面的实施例，不同的是将反应回流 8 小时。

实施例号	化学名	物理数据
29	7-(1-乙基-丙基)-2,5-二甲基-3-(2-吗啉-4-基-4-三氟甲基-噻唑-5-基)-吡唑并[1,5-*a*]嘧啶	HR-ToF-MS m/z $C_{21}H_{26}F_3N_5OS+H^+$ 的计算值: 454.1873, 实测值: 454.1888

实施例 30


N-{5-[7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶-3-基]-4-三氟甲基-噻唑-2-基}-乙酰胺

将羟胺(50%的水溶液, 5 mL)加入到 3-[2-(2,5-二甲基-吡咯-1-基)-4-三氟甲基-噻唑-5-基]-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(2.4 g, 5.2 mmol)在乙酸(25 mL)中的溶液中。将反应加热至 80℃达 72 小时。将反应冷却至室温，倾倒到乙醚中，用 2 M NaOH(2×)洗涤，然后用水洗涤一次。

将有机部分用硫酸钠干燥，过滤并浓缩至干。用柱色谱对所得残余物进行纯化，用 40%乙酸乙酯的己烷溶液洗脱，得到标题化合物(0.28 g, 13%)。HR-ToF-MS m/z $C_{19}H_{22}F_3N_5OS+H^+$ 的计算值：426.1575，实测值：426.1565。

实施例 31

(2-{5-[7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶-3-基]-4-三氟甲基-噻唑-2-基氨基}-乙基)-氨基甲酸叔丁酯



将(2-氨基-乙基)-氨基甲酸叔丁酯(0.5 mL, 506 mg, 3.2 mmol)加入到3-(2-溴-4-三氟甲基-噻唑-5-基)-7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶(100 mg, 0.22 mmol)和三乙胺(0.3 mL, 222 mg, 2.2 mmol)在甲醇(1 mL)中的溶液中。蒸发掉甲醇并加热至 80℃过夜。将反应冷却至室温并真空浓缩。用柱色谱对所得残余物进行纯化，用 10-50%乙酸乙酯的 CH_2Cl_2 溶液洗脱，得到标题化合物(0.11 g, 97%)。ES/MS m/z 527.2 $(M+1)^+$。

用适宜的胺基本如实施例 31 中所述的那样制备下面的化合物。

制备例或实施例号	化学名	物理数据
制备例 25*	[2-({5-[7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶-3-基]-4-三氟甲基-噻唑-2-基}-丙基-氨基)-乙基]-氨基甲酸叔丁酯	ES/MS m/z 569.3$(M+1)^+$
制备例 26**	(S)-(1-{5-[7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶-3-基]-4-三氟甲基-噻唑-2-基}-吡咯烷-3-基)-氨基甲酸叔丁酯	ES/MS m/z 553.3$(M+1)^+$

0563

实施例 32***	*N*-{5-[7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶-3-基]-4-三氟甲基-噻唑-2-基}-*N*,*N*'-二丙基-乙烷-1,2-二胺，盐酸盐	ES/MS m/z 511.2(M+1)$^+$

* 在 EtOH 中在回流下加热过夜。蒸发掉 EtOH，在 110℃下加热 24 小时。

** 在 EtOH 中在 80℃下加热过夜。

*** 制备该 HCl 盐，用 EtOAc/己烷重结晶。

实施例 33

N^1-{5-[7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶-3-基]-4-三氟甲基-噻唑-2-基}-乙烷-1,2-二胺，盐酸盐

将(2-{5-[7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶-3-基]-4-三氟甲基-噻唑-2-基氨基}-乙基)-氨基甲酸叔丁酯(101 mg,0.192 mmol)加入到 1 M HCl 的甲醇溶液(1 mL)中。将反应在 70℃下加热过夜。将反应冷却并由甲醇/乙酸乙酯真空浓缩。用乙酸乙酯对所得的残余物进行研磨，得到标题化合物(64 mg, 78%)。ES/MS m/z 427.0 (M+1)$^+$。

基本如实施例 33 中所述的那样制备下面的实施例。

实施例号	化学名	物理数据
34	N^1-{5-[7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-*a*]嘧啶-3-基]-4-三氟甲基-噻唑-2-基}-N^1-丙基-乙烷-1,2-二胺，盐酸盐	ES/MS m/z 469.2(M+1)$^+$
35	(*S*)-1-{5-[7-(1-乙基-丙基)-2,5-二甲基-吡唑并[1,5-a]嘧啶-3-基]-4-三氟甲基-噻唑-2-基}-吡咯烷-3-基胺，盐酸盐	ES/MS m/z 453.0(M+1)$^+$

实施例 A

用离体结合进行的体内效力评估

为了评估体内效力，用离体结合对本发明的化合物进行评价。使用 D.

R. Gehlert 等人, *EJP* 509: 145-153(2005)中所提供的操作，通过口服途径将化合物施用于大鼠。然后如 Gehlert 等人所述的那样对 ^{125}I-蛙皮降压肽与小脑的离体结合进行评估。例如，实施例 15 在 10 mg/kg 下提供 65%的抑制。

实施例 B

CRF1 滤膜结合测定法

在产生具有足够受体密度以开展结合测定法的重组细胞系方面，通过使用由 Stanford 许可的 Phoenix 逆转录病毒表达系统克服了以质粒为基础的人 CRF1 表达的限制。用稳定的 HEK-hCRF1 细胞系制备膜，如下建立结合反应(200 μL): 50 μL ^{125}I-蛙皮降压肽(终浓度为 0.2 nM)、50 μL 化合物和 100 μL CRF1 膜(25 μg/反应)。将反应在室温下孵育 2 小时，然后通过用预处理的 FB 微孔玻璃纤维滤板(96 孔)过滤来终止反应。将板用冰冷的测定缓冲液(50 mM tris, 12.5 mM NaCl, 1 mM EDTA, 10 mM $MgCl_2$, 0.05% BSA, pH 7.2)洗涤两次，风干过夜，用 100 μL Microscint 40 在 MicroBeta 计数器中进行计数。在存在 0.5 μM 未标记的蛙皮降压肽的情况下测定非特异性结合(NSB)。通常一式三份地进行测定，用 Graph Pad Prism 对中值数据点作图。

用这种测定法，本发明具体给出的化合物以低于 1 μM 的 Ki(抑制常数)抑制滚动(roller)/粘附细胞中 ^{125}I-蛙皮降压肽(4 nM)的结合。例如，实施例 15 表现出 6.2 nM 的 Ki。

实施例 C

CRF2 滤膜结合测定法

在产生具有足够受体密度以开展结合测定法的重组细胞系方面，通过使用由 Stanford 许可的 Phoenix 逆转录病毒表达系统克服了以质粒为基础的人 CRF2 表达的限制。用稳定的 HEK-hCRF2 细胞系制备膜，如下建立结合反应(200 μL): 50 μL ^{125}I-蛙皮降压肽(终浓度为 0.2 nM)、50 μL 化合物和 100 μL CRF2 膜(25 μg/反应)。将反应在室温下孵育 2 小时，然后通过用预处理的 FB 微孔玻璃纤维滤板(96 孔)过滤来终止反应。将板用冰冷的

测定缓冲液(50 mM tris, 12.5 mM NaCl, 1 mM EDTA, 10 mM $MgCl_2$, 0.05% BSA, pH 7.2)洗涤两次，风干过夜，用 100 μL Microscint 40 在 MicroBeta 计数器中进行计数。在存在 0.5 μM 未标记的蛙皮降压肽的情况下测定非特异性结合(NSB)。或者，用闪烁亲近测定法来对化合物进行评价。如下建立该测定法：50 μL ^{125}I-蛙皮降压肽(终浓度为 0.2 nM)、50 μL 化合物或未标记的蛙皮降压肽(NSB)和 100 μL 含 250 μg 麦胚凝集素(WGA)的 SPA 小珠和 CRF2 膜(1.5 μg/反应)。将板在室温下孵育 4-5 小时，然后在 200 X g 下离心 10 分钟。用 Wallac Trilux 闪烁计数器来对结合的放射性进行评估。通常使用一式三份的测定来对结合进行评估，用 Graph Pad Prism 对中值数据点作图。首先在固定浓度下对化合物进行筛选，如果注意到足够的活性，则随后产生浓度-响应曲线。

在所述 CRF2 结合测定法中对本发明的具体给出的化合物进行了试验，它们对 CRF2 受体表现出弱亲合性。例如，实施例 15 在 50 μM 的浓度下表现出 11%的抑制。这一结果表明本发明的化合物对 CRF1 受体具有选择性(相对于 CRF2 而言)。

实施例 D

生物利用度和药动学性质

分布容积(Vdist)是指药物在机体中的量与药物在血液或血浆中的浓度之比。分布容积指的是在与血液或血浆中的浓度相同的浓度下，包含机体中的全部药物量所需的体液体积：Vdist = 机体中的药物量/血液或血浆中的药物浓度(Goodman and Gillman's)。对于 10 mg 的剂量和 10 mg/L 的血浆浓度而言，分布容积将为 1 升。分布容积反映了药物在血管外组织中的存在程度。大的分布容积反映了与血浆蛋白结合相比化合物倾向于与组织组分结合。在临床情况中，可以用 Vdist 来确定获得稳态浓度的负荷剂量。

为了测定分布容积，给雄性 Sprague Dawley 大鼠(N=3)施用 1 mg/kg 的化合物静脉内单剂量。在给药后 0.08 至 24 小时，在一些时间点收集多个血浆样品。用 LC/MS/MS 对血浆样品进行分析以测定血浆浓度。进行血浆药动学计算以确定包括 Vdist 和血浆清除率(Clp)在内的药动学参数。

本发明的化合物优选具有良好的生物利用度。例如，大部分可商购的CNS和心血管药物表现出<10 L/Kg的人Vdist。与CRF拮抗剂CP154526(Schulz等人, *Proc. Natl. Acad. Sci. (USA)*, 93:10477 (1996))和NBI30775(Chen等人, *Drug Development Research*, 65:216 (2005))相比(当单独进行分析时，CP154526和NBI30775分别表现出114 L/Kg和76 L/Kg的大鼠Vdist)，当单独进行分析时，本发明的实施例15在给予1 mg/kg的静脉内单剂量后仅表现出7.2 L/Kg的大鼠Vdist。

此外，血浆清除率(CLp)是药物由机体除去速率的量度。按照静脉内剂量和一级动力学，可以用下列方程确定血浆清除率：CLp = 剂量/AUC，其中AUC是描述血浆药物浓度与从0至无穷大时间的函数关系的曲线下总面积。当单独进行分析时，在单次静脉内剂量后，参比物CRF拮抗剂CP154526和NBI37582分别表现出83和306 mL/min/kg的大鼠清除率(CLp)，而当单独进行分析时，本发明的实施例15仅表现出23.6 mL/min/kg的大鼠CLp。

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 239/94, A61K 31/505, C07D 239/88, 239/93, 413/12, A61K 31/535, C07D 403/12, 401/12, 417/12, A61K 31/54

A1

(11) International Publication Number: **WO 97/30035**

(43) International Publication Date: 21 August 1997 (21.08.97)

(21) International Application Number: PCT/GB97/00365

(22) International Filing Date: 10 February 1997 (10.02.97)

(30) Priority Data:
96400293.5 13 February 1996 (13.02.96) EP
(34) Countries for which the regional or international application was filed: FR et al.
96401756.0 8 August 1996 (08.08.96) EP
(34) Countries for which the regional or international application was filed: FR et al.
96402764.3 17 December 1996 (17.12.96) EP
(34) Countries for which the regional or international application was filed: FR et al.

(71) Applicants (*for all designated States except US*): ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB). ZENECA PHARMA S.A. [FR/FR]; "Le Galien", 1, rue des Chauffours, Boîte postale 27, F-95022 Cergy Cédex (FR).

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): THOMAS, Andrew Peter [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). JOHNSTONE, Craig [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). HENNEQUIN, Laurent, François, André [FR/FR]; Zeneca Pharma S.A., Centre de Recherches, Z.I. La Pompelle, Chemin de Vrilly, Boîte postale 1050, F-51689 Reims Cédex 2 (FR).

(74) Agent: MACK, John, Richard; Zeneca Pharmaceuticals, Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS

(57) Abstract

The invention relates to quinazoline derivatives of formula (I) [wherein: Z represents -O-, -NH- or -S-; m is an integer from 1 to 5; R^1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkylthio, or $-NR^5R^6$ (wherein R^5 and R^6, which may be the same or different, each represents hydrogen or C_{1-3}alkyl); R^2 represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro; R^3 represents hydroxy, halogeno, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X^1 represents -O-, $-CH_2-$, -S-, -SO-, $-SO_2-$, $-NR^7-$, $-NR^8CO-$, $-CONR^9-$, $-SO_2NR^{10}-$ or $-NR^{11}SO_2-$, (wherein R^7, R^8, R^9, R^{10} and R^{11} each represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl); R^4 represents a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry a terminal optionally substituted 5 or 6 membered saturated carbocyclic or heterocyclic group] and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.



(I)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	**GB**	United Kingdom	**MW**	Malawi
AT	Austria	**GE**	Georgia	**MX**	Mexico
AU	Australia	**GN**	Guinea	**NE**	Niger
BB	Barbados	**GR**	Greece	**NL**	Netherlands
BE	Belgium	**HU**	Hungary	**NO**	Norway
BF	Burkina Faso	**IE**	Ireland	**NZ**	New Zealand
BG	Bulgaria	**IT**	Italy	**PL**	Poland
BJ	Benin	**JP**	Japan	**PT**	Portugal
BR	Brazil	**KE**	Kenya	**RO**	Romania
BY	Belarus	**KG**	Kyrgystan	**RU**	Russian Federation
CA	Canada	**KP**	Democratic People's Republic of Korea	**SD**	Sudan
CF	Central African Republic			**SE**	Sweden
CG	Congo	**KR**	Republic of Korea	**SG**	Singapore
CH	Switzerland	**KZ**	Kazakhstan	**SI**	Slovenia
CI	Côte d'Ivoire	**LI**	Liechtenstein	**SK**	Slovakia
CM	Cameroon	**LK**	Sri Lanka	**SN**	Senegal
CN	China	**LR**	Liberia	**SZ**	Swaziland
CS	Czechoslovakia	**LT**	Lithuania	**TD**	Chad
CZ	Czech Republic	**LU**	Luxembourg	**TG**	Togo
DE	Germany	**LV**	Latvia	**TJ**	Tajikistan
DK	Denmark	**MC**	Monaco	**TT**	Trinidad and Tobago
EE	Estonia	**MD**	Republic of Moldova	**UA**	Ukraine
ES	Spain	**MG**	Madagascar	**UG**	Uganda
FI	Finland	**ML**	Mali	**US**	United States of America
FR	France	**MN**	Mongolia	**UZ**	Uzbekistan
GA	Gabon	**MR**	Mauritania	**VN**	Viet Nam

QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS

The present invention relates to quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability, to their use as medicaments and to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans.

Normal angiogenesis plays an important role in a variety of processes including embryonic development, wound healing and several components of female reproductive function. Undesirable or pathological angiogenesis has been associated with disease states including diabetic retinopathy, psoriasis, cancer, rheumatoid arthritis, atheroma, Kaposi's sarcoma and haemangioma (Fan et al, 1995, Trends Pharmacol. Sci. 16: 57-66; Folkman, 1995, Nature Medicine 1: 27-31). Alteration of vascular permeability is thought to play a role in both normal and pathological physiological processes (Cullinan-Bove et al, 1993, Endocrinology 133: 829-837; Senger et al, 1993, Cancer and Metastasis Reviews, 12: 303-324). Several polypeptides with in vitro endothelial cell growth promoting activity have been identified including, acidic and basic fibroblast growth factors (aFGF & bFGF) and vascular endothelial growth factor (VEGF). By virtue of the restricted expression of its receptors, the growth factor activity of VEGF, in contrast to that of the FGFs, is relatively specific towards endothelial cells. Recent evidence indicates that VEGF is an important stimulator of both normal and pathological angiogenesis (Jakeman et al, 1993, Endocrinology, 133: 848-859; Kolch et al, 1995, Breast Cancer Research and Treatment, 36:139-155) and vascular permeability (Connolly et al, 1989, J. Biol. Chem. 264: 20017-20024). Antagonism of VEGF action by sequestration of VEGF with antibody can result in inhibition of tumour growth (Kim et al, 1993, Nature 362: 841-844).

Receptor tyrosine kinases (RTKs) are important in the transmission of biochemical signals across the plasma membrane of cells. These transmembrane molecules characteristically consist of an extracellular ligand-binding domain connected through a segment in the plasma membrane to an intracellular tyrosine kinase domain. Binding of ligand to the receptor results in stimulation of the receptor-associated tyrosine kinase activity


which leads to phosphorylation of tyrosine residues on both the receptor and other intracellular molecules. These changes in tyrosine phosphorylation initiate a signalling cascade leading to a variety of cellular responses. To date, at least nineteen distinct RTK subfamilies, defined by amino acid sequence homology, have been identified. One of these subfamilies is presently comprised by the fms-like tyrosine kinase receptor, Flt or Flt1, the kinase insert domain-containing receptor, KDR (also referred to as Flk-1), and another fms-like tyrosine kinase receptor, Flt4. Two of these related RTKs, Flt and KDR, have been shown to bind VEGF with high affinity (De Vries et al, 1992, Science 255: 989-991; Terman et al, 1992, Biochem. Biophys. Res. Comm. 1992, 187: 1579-1586). Binding of VEGF to these receptors expressed in heterologous cells has been associated with changes in the tyrosine phosphorylation status of cellular proteins and calcium fluxes.

Compounds which have good activity against epidermal growth factor (EGF) receptor tyrosine kinase are disclosed in the European Patent Publication No 0566226, but there is no disclosure or suggestion that the compounds inhibit the effects of VEGF. European Patent Publication No. 0326330 discloses certain quinoline, quinazoline and cinnoline plant fungicides. Certain of these plant fungicides are also stated to possess insecticidal and miticidal activity. There is however no disclosure or any suggestion that any of the compounds disclosed may be used for any purpose in animals such as humans. In particular, the European Patent Publication contains no teaching whatsoever concerning angiogenesis and/or increased vascular permeability mediated by growth factors such as VEGF.

The present invention is based on the discovery of compounds that surprisingly inhibit the effects of VEGF, a property of value in the treatment of disease states associated with angiogenesis and/or increased vascular permeability such as cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation and ocular diseases with retinal vessel proliferation. Compounds of the present invention possess higher potency against VEGF receptor tyrosine kinase whilst possessing some activity against EGF receptor tyrosine kinase. Furthermore, compounds of the present invention, possess substantially higher potency against VEGF receptor tyrosine kinase than against EGF receptor tyrosine kinase or FGF R1 receptor tyrosine kinase. Thus compounds of the invention which have

been tested possess activity against VEGF receptor tyrosine kinase such that they may be used in an amount sufficient to inhibit VEGF receptor tyrosine kinase whilst demonstrating no significant activity against EGF receptor tyrosine kinase or FGF R1 receptor tyrosine kinase.

According to one aspect of the present invention there is provided a quinazoline derivative of the formula I:



(I)

[wherein:

Z represents -O-, -NH- or -S-;

m is an integer from 1 to 5 with the proviso that where Z is -NH- m is an integer from 3 to 5;

R^1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkylthio, or $-NR^5R^6$ (wherein R^5 and R^6, which may be the same or different, each represents hydrogen or C_{1-3}alkyl);

R^2 represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro;

R^3 represents hydroxy, halogeno, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkanoyloxy, trifluoromethyl, cyano, amino or nitro;

X^1 represents -O-, $-CH_2-$, -S-, -SO-, $-SO_2-$, $-NR^7-$, $-NR^8CO-$, $-CONR^9-$, $-SO_2NR^{10}-$ or $-NR^{11}SO_2-$, (wherein R^7, R^8, R^9, R^{10} and R^{11} each represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl);

R^4 is selected from one of the following seven groups:

1) hydrogen, C_{1-5}alkyl, C_{1-5}hydroxyalkyl, (preferably C_{2-5}hydroxyalkyl), C_{1-5}fluoroalkyl, C_{1-5}aminoalkyl;

2) C_{1-5}alkylX^2COR^{12} (wherein X^2 represents -O- or $-NR^{13}-$ (in which R^{13} represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{12} represents C_{1-3}alkyl, $-NR^{14}R^{15}$ or $-OR^{16}$ (wherein R^{14}, R^{15} and R^{16} which may be the same or different each represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl));

3) C_{1-5}alkylX^3R^{17} (wherein X^3 represents -O-, -S-, -SO-, $-SO_2$-, -OCO-, $-NR^{18}CO$-, $-CONR^{19}$-, $-SO_2NR^{20}$-, $-NR^{21}SO_2$- or $-NR^{22}$- (wherein R^{18}, R^{19}, R^{20}, R^{21} and R^{22} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{17} represents hydrogen, C_{1-3}alkyl, cyclopentyl, cyclohexyl or a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which C_{1-3}alkyl group may bear one or two substituents selected from oxo, hydroxy, halogeno and C_{1-4}alkoxy and which cyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C_{1-4}alkyl, C_{1-4}hydroxyalkyl and C_{1-4}alkoxy);

4) C_{1-5}alkylR^{23} (wherein R^{23} is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C_{1-4}alkyl, C_{1-4}hydroxyalkyl and C_{1-4}alkoxy);

5) C_{2-5}alkenylR^{23} (wherein R^{23} is as defined hereinbefore);

6) C_{2-5}alkynylR^{23} (wherein R^{23} is as defined hereinbefore); and

7) C_{1-5}alkylX^4C_{1-5}alkylX^5R^{24} (wherein X^4 and X^5 which may be the same or different are each -O-, -S-, -SO-, $-SO_2$-, $-NR^{25}CO$-, $-CONR^{26}$-, $-SO_2NR^{27}$-, $-NR^{28}SO_2$- or $-NR^{29}$- (wherein R^{25}, R^{26}, R^{27}, R^{28} and R^{29} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{24} represents hydrogen or C_{1-3}alkyl)];

and salts thereof.

Z is advantageously -S-, preferably -O-, but especially -NH-.

Where Z is -S- or -O- m is advantageously an integer from 2 to 5, preferably 2 or 3.

Where Z is -NH- m is preferably 3.

R^1 is advantageously hydrogen, hydroxy, cyano, nitro, trifluoromethyl, C_{1-3} alkyl, C_{1-3} alkoxy or amino.

R^1 is preferably hydrogen, hydroxy, cyano, nitro, trifluoromethyl, methyl, ethyl, methoxy, or ethoxy, more preferably hydrogen, cyano, nitro, trifluoromethyl, hydroxy, methyl or methoxy, but especially methoxy.


Where X^1 is $-NR^8CO$-, R^1 is preferably hydrogen.

R^2 is preferably hydrogen, fluoro, amino or nitro, but especially hydrogen.

In one embodiment of the present invention R^3 represents hydroxy, halogeno, C_{1-3}alkyl, C_{1-3}alkoxy, trifluoromethyl, cyano, amino or nitro, preferably hydroxy, halogeno or C_{1-2} alkyl, especially hydroxy or halogeno.

Advantageously in another embodiment of the present invention one R^3 substituent is advantageously hydroxy, preferably meta-hydroxy, and the other one or more are each selected from halogeno, methyl and methoxy.

In another embodiment of the invention the phenyl group bearing $(R^3)_m$ is preferably of the formula II:



(II)

wherein:

R^a represents hydrogen, methyl, fluoro or chloro, preferably hydrogen, fluoro or chloro, especially fluoro;

R^b represents hydrogen, methyl, methoxy, bromo, fluoro or chloro;

R^c represents hydrogen or hydroxy, especially hydroxy;

R^d represents hydrogen, fluoro or chloro, especially hydrogen or fluoro.

Preferably in another embodiment of the invention two R^3 substituents are halogeno, especially ortho,ortho'- difluoro, and the other one or more are each selected from halogeno, hydroxy and methyl, especially from halogeno and methyl.

In a particular aspect of the present invention, the phenyl group bearing $(R^3)_m$ is the 2-fluoro-5-hydroxy-4-methylphenyl group, the 4-bromo-2,6-difluorophenyl group, the 4-chloro-2-fluoro-5-hydroxyphenyl group, the 4-chloro-2,6-difluorophenyl group or the 2,4-difluoro-5-hydroxyphenyl group or, where Z is O or S, the 4-chloro-2-fluorophenyl group.

Preferably the phenyl group bearing $(R^3)_m$ is the 4-chloro-2-fluoro-5-hydroxyphenyl group or the 2-fluoro-5-hydroxy-4-methylphenyl group or, where Z is O or S, the 4-chloro-2-

fluorophenyl group. The 4-chloro-2-fluoro-5-hydroxyphenyl group is an especially preferred value for the phenyl group bearing $(R^3)_m$.

Conveniently X^1 represents -O-, -S-, $-CH_2-$, $-NR^8CO-$, $-CONR^9-$, $-NR^{11}SO_2-$ or $-NR^7-$ (wherein R^7, R^8, R^9 and R^{11} each independently represents hydrogen, C_{1-3}alkyl (especially C_{1-2}alkyl) or C_{1-2}alkoxyethyl).

Advantageously X^1 represents -O-, -S-, $-NR^8CO-$, $-NR^{11}SO_2-$ or $-NR^7-$ (wherein R^7, R^8 and R^{11} each independently represents hydrogen, C_{1-2}alkyl or C_{1-2}alkoxyethyl).

Preferably X^1 represents -O-, -S-, $-NR^8CO-$, $-NR^{11}SO_2-$ (wherein R^8 and R^{11} each independently represents hydrogen or C_{1-2}alkyl) or NH.

More preferably X^1 represents -O-, -S-, $-NR^8CO-$ (wherein R^8 represents hydrogen or methyl) or NH.

Particularly X^1 represents -O- or -NHCO-, especially -O-.

Advantageously X^2 represents -O- or $-NR^{13}-$ (wherein R^{13} represents hydrogen, C_{1-3}alkyl or C_{1-2}alkoxyethyl).

Advantageously X^3 represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{18}CO-$, $-NR^{21}SO_2-$ or $-NR^{22}-$ (wherein R^{18}, R^{21} and R^{22} each independently represents hydrogen, C_{1-2}alkyl or C_{1-2}alkoxyethyl).

Preferably X^3 represents -O-, -S-, -SO-, $-SO_2-$ or $-NR^{22}-$ (wherein R^{22} represents hydrogen, C_{1-2}alkyl or C_{1-2}alkoxyethyl).

More preferably X^3 represents -O- or $-NR^{22}-$ (wherein R^{22} represents hydrogen or C_{1-2}alkyl).

Advantageously X^4 and X^5 which may be the same or different each represents -O-, -S-, -SO-, $-SO_2-$ or $-NR^{29}-$ (wherein R^{29} represents hydrogen, C_{1-3}alkyl or C_{1-2}alkoxyethyl).

Preferably X^4 and X^5 which may be the same or different each represents -O-, -S- or $-NR^{29}-$ (wherein R^{29} represents hydrogen, C_{1-2}alkyl or C_{1-2}alkoxyethyl).

More preferably X^4 and X^5 which may be the same or different each represents -O- or -NH-.

Conveniently R^4 is selected from one of the following nine groups:

1) C_{1-5}alkyl, C_{2-5}hydroxyalkyl, C_{1-5}fluoroalkyl, C_{1-5}aminoalkyl;

2) C_{1-5}alkylX^2COR^{12} (wherein X^2 is as hereinbefore defined and R^{12} represents C_{1-3}alkyl, $-NR^{14}R^{15}$ or $-OR^{16}$ (wherein R^{14}, R^{15} and R^{16} which may be the same or different each represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl));

3) C_{1-5}alkylX^3R^{17} (wherein X^3 is as hereinbefore defined and R^{17} represents hydrogen, C_{1-3}alkyl, cyclopentyl, cyclohexyl or a 5 or 6 membered saturated heterocyclic group with one or

two heteroatoms, selected independently from O, S and N, which C_{1-3}alkyl group may bear one or two substituents selected from oxo, hydroxy, halogeno and C_{1-3}alkoxy and which cyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C_{1-4}alkyl, C_{1-4}hydroxyalkyl and C_{1-4}alkoxy);

4) C_{1-5}alkylR^{30} (wherein R^{30} is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group is linked to C_{1-5}alkyl through a carbon atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C_{1-4}alkyl, C_{1-4}hydroxyalkyl and C_{1-4}alkoxy) or C_{2-5}alkylR^{31} (wherein R^{31} is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms of which one is N and the other is selected independently from O, S and N, which heterocyclic group is linked to C_{2-5}alkyl through a nitrogen atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C_{1-4}alkyl, C_{1-4}hydroxyalkyl and C_{1-4}alkoxy);

5) C_{3-4}alkenylR^{30} (wherein R^{30} is as defined hereinbefore);

6) C_{3-4}alkynylR^{30} (wherein R^{30} is as defined hereinbefore);

7) C_{3-4}alkenylR^{31} (wherein R^{31} is as defined hereinbefore);

8) C_{3-4}alkynylR^{31} (wherein R^{31} is as defined hereinbefore); and

9) C_{1-5}alkylX^4C_{1-5}alkylX^5R^{24} (wherein X^4 and X^5 are as hereinbefore defined and R^{24} represents hydrogen or C_{1-3}alkyl).

Advantageously R^4 is selected from one of the following nine groups:

1) C_{1-5}alkyl, C_{2-5}hydroxyalkyl, C_{1-5}fluoroalkyl, C_{2-4}aminoalkyl;

2) C_{2-3}alkylX^2COR^{12} (wherein X^2 is as hereinbefore defined and R^{12} represents C_{1-3}alkyl, -$NR^{14}R^{15}$ or -OR^{16} (wherein R^{14}, R^{15} and R^{16} which may be the same or different are each C_{1-2}alkyl or C_{1-2}alkoxyethyl));

3) C_{2-4}alkylX^3R^{17} (wherein X^3 is as hereinbefore defined and R^{17} is a group selected from C_{1-3}alkyl, cyclopentyl, cyclohexyl, pyrrolidinyl and piperidinyl which group is linked to X^3 through a carbon atom and which C_{1-3}alkyl group may bear one or two substituents selected from oxo, hydroxy, halogeno and C_{1-2}alkoxy and which cyclopentyl, cyclohexyl, pyrrolidinyl or piperidinyl group may carry one substituent selected from oxo, hydroxy, halogeno, C_{1-2}alkyl, C_{1-2}hydroxyalkyl and C_{1-2}alkoxy);

4) C_{1-4}alkylR^{30} (wherein R^{30} is a group selected from pyrrolidinyl, piperazinyl, piperidinyl, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl and 1,3-dithian-2-yl, which group is linked to C_{1-4}alkyl through a carbon atom and which group may carry one or two substituents selected from oxo, hydroxy, halogeno, C_{1-2}alkyl, C_{1-2}hydroxyalkyl and C_{1-2}alkoxy) or C_{2-4}alkylR^{31} (wherein R^{31} is a group selected from morpholino, thiomorpholino, pyrrolidin-1-yl, piperazin-1-yl and piperidino which group may carry one or two substituents selected from oxo, hydroxy, halogeno, C_{1-2}alkyl, C_{1-2}hydroxyalkyl and C_{1-2}alkoxy);

5) C_{3-4}alkenylR^{30} (wherein R^{30} is as defined hereinbefore);

6) C_{3-4}alkynylR^{30} (wherein R^{30} is as defined hereinbefore);

7) C_{3-4}alkenylR^{31} (wherein R^{31} is as defined hereinbefore);

8) C_{3-4}alkynylR^{31} (wherein R^{31} is as defined hereinbefore); and

9) C_{2-3}alkylX^4C_{2-3}alkylX^5R^{24} (wherein X^4 and X^5 are as hereinbefore defined and R^{24} represents hydrogen or C_{1-3}alkyl).

Preferably R^4 is selected from one of the following five groups:

1) C_{1-3}alkyl, C_{2-3}hydroxyalkyl, C_{1-3}fluoroalkyl, C_{2-3}aminoalkyl;

2) 2-(3,3-dimethylureido)ethyl, 3-(3,3-dimethylureido)propyl, 2-(3-methylureido)ethyl, 3-(3-methylureido)propyl, 2-ureidoethyl, 3-ureidopropyl, 2-(N,N-dimethylcarbamoyloxy)ethyl, 3-(N,N-dimethylcarbamoyloxy)propyl, 2-(N-methylcarbamoyloxy)ethyl, 3-(N-methylcarbamoyloxy)propyl, 2-(carbamoyloxy)ethyl, 3-(carbamoyloxy)propyl;

3) C_{2-3}alkylX^3R^{17} (wherein X^3 is as hereinbefore defined and R^{17} is a group selected from C_{1-2}alkyl, cyclopentyl, cyclohexyl, pyrrolidinyl and piperidinyl which group is linked to X^3 through a carbon atom and which C_{1-2}alkyl group may bear one or two substituents selected from hydroxy, halogeno and C_{1-2}alkoxy and which cyclopentyl, cyclohexyl, pyrrolidinyl or piperidinyl group may carry one substituent selected from oxo, hydroxy, halogeno, C_{1-2}alkyl, C_{1-2}hydroxyalkyl and C_{1-2}alkoxy);

4) C_{1-2}alkylR^{30} (wherein R^{30} is a group selected from pyrrolidinyl, piperazinyl, piperidinyl, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl and 1,3-dithian-2-yl, which group is linked to C_{1-2}alkyl through a carbon atom and which group may carry one substituent selected from oxo, hydroxy, halogeno, C_{1-2}alkyl, C_{1-2}hydroxyalkyl and C_{1-2}alkoxy) or C_{2-3}alkylR^{31} (wherein R^{31} is a group selected from morpholino, thiomorpholino, piperidino, piperazin-1-yl

and pyrrolidin-1-yl which group may carry one substituent selected from oxo, hydroxy, halogeno, C_{1-2}alkyl, C_{1-2}hydroxyalkyl and C_{1-2}alkoxy); and

5) C_{2-3}alkylX^4C_{2-3}alkylX^5R^{24} (wherein X^4 and X^5 are as hereinbefore defined and R^{24} represents hydrogen or C_{1-2}alkyl).

More preferably R^4 represents methyl, ethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl, 3-methoxypropyl, 2-(methylsulphinyl)ethyl, 2-(methylsulphonyl)ethyl, 2-(N,N-dimethylsulphamoyl)ethyl, 2-(N-methylsulphamoyl)ethyl, 2-sulphamoylethyl, 2-(N,N-dimethylamino)ethyl, 3-(N,N-dimethylamino)propyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, 2-(piperazin-1-yl)ethyl, 3-(piperazin-1-yl)propyl, 2-(pyrrolidin-1-yl)ethyl, 3-(pyrrolidin-1-yl)propyl, (1,3-dioxolan-2-yl)methyl, 2-(1,3-dioxolan-2-yl)ethyl, 2-(2-methoxyethylamino)ethyl, 2-(2-hydroxyethylamino)ethyl, 3-(2-methoxyethylamino)propyl, 3-(2-hydroxyethylamino)propyl, 2-thiomorpholinoethyl, 3-thiomorpholinopropyl, 2-(4-methylpiperazin-1-yl)ethyl, 3-(4-methylpiperazin-1-yl)propyl or 2-(2-methoxyethoxy)ethyl.

Particularly R^4 represents 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl, 3-methoxypropyl, 2-(methylsulphinyl)ethyl, 2-(methylsulphonyl)ethyl, 2-(N,N-dimethylamino)ethyl, 3-(N,N-dimethylamino)propyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, 2-(piperazin-1-yl)ethyl, 3-(piperazin-1-yl)propyl, 2-(pyrrolidin-1-yl)ethyl, 3-(pyrrolidin-1-yl)propyl, (1,3-dioxolan-2-yl)methyl, 2-(1,3-dioxolan-2-yl)ethyl, 2-(2-methoxyethylamino)ethyl, 2-(2-hydroxyethylamino)ethyl, 3-(2-methoxyethylamino)propyl, 3-(2-hydroxyethylamino)propyl, 2-thiomorpholinoethyl, 3-thiomorpholinopropyl, 2-(4-methylpiperazin-1-yl)ethyl, 3-(4-methylpiperazin-1-yl)propyl or 2-(2-methoxyethoxy)ethyl.

Preferred compounds are:

4-(4-bromo-2,6-difluoroanilino)-6,7-dimethoxyquinazoline,

4-(4-bromo-2-fluoro-5-hydroxyanilino)-6,7-dimethoxyquinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-thiomorpholinoethoxy)quinazoline,

6,7-dimethoxy-4-(3-hydroxy-4-methylphenoxy)quinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-7-(2-hydroxyethoxy)-6-methoxyquinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-7-(2-methoxyethoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(2-(methylsulphinyl)ethoxy)quinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6,7-dimethoxyquinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-6,7-dimethoxyquinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,

7-(2-acetoxyethoxy)-4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxyquinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-morpholinoethoxy)quinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-piperidinoethoxy)quinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-(pyrrolidin-1-yl)ethoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-7-(2-methoxyethylamino)quinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-cyclopentyloxyethoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(2-methylthioethoxy)quinazoline,

4-(2,4-difluoro-5-hydroxyanilino)-6,7-dimethoxyquinazoline,

4-(2,4-difluoro-5-hydroxyanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-7-methoxyacetamidoquinazoline,

4-(4-bromo-2,6-difluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline

and salts thereof especially the hydrochloride salts thereof.

More preferred compounds are:

4-(4-bromo-2-fluoro-5-hydroxyanilino)-6,7-dimethoxyquinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-thiomorpholinoethoxy)quinazoline,

6,7-dimethoxy-4-(3-hydroxy-4-methylphenoxy)quinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-7-(2-hydroxyethoxy)-6-methoxyquinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-7-(2-methoxyethoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(2-(methylsulphinyl)ethoxy)quinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6,7-dimethoxyquinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-6,7-dimethoxyquinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,

7-(2-acetoxyethoxy)-4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxyquinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-morpholinoethoxy)quinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-piperidinoethoxy)quinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-(pyrrolidin-1-yl)ethoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-7-(2-methoxyethylamino)quinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-cyclopentyloxyethoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(2-methylthioethoxy)quinazoline,

4-(2,4-difluoro-5-hydroxyanilino)-6,7-dimethoxyquinazoline,

4-(2,4-difluoro-5-hydroxyanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-7-methoxyacetamidoquinazoline,

4-(4-bromo-2,6-difluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline

and salts thereof especially the hydrochloride salts thereof.

Particularly preferred compounds are:

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6,7-dimethoxyquinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-6,7-dimethoxyquinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,

7-(2-acetoxyethoxy)-4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxyquinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-morpholinoethoxy)quinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-piperidinoethoxy)quinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-(pyrrolidin-1-yl)ethoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-7-(2-methoxyethylamino)quinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-cyclopentyloxyethoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(2-methylthioethoxy)quinazoline,

4-(2,4-difluoro-5-hydroxyanilino)-6,7-dimethoxyquinazoline,

4-(2,4-difluoro-5-hydroxyanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-7-methoxyacetamidoquinazoline,

4-(4-bromo-2,6-difluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline

and salts thereof especially the hydrochloride salts thereof.

More particularly preferred compounds are:

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-(pyrrolidin-1-yl)ethoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(2-methylthioethoxy)quinazoline,

4-(4-chloro-2-fluoro-5-hydroxyanilino)-6,7-dimethoxyquinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-6,7-dimethoxyquinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-7-methoxyacetamidoquinazoline,

4-(4-bromo-2,6-difluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline

and salts thereof especially the hydrochloride salts thereof.

Especially preferred compounds are:

4-(2-fluoro-5-hydroxy-4-methylanilino)-6,7-dimethoxyquinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline,

4-(2-fluoro-5-hydroxy-4-methylanilino)-7-methoxyacetamidoquinazoline,

4-(4-bromo-2,6-difluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline

and salts thereof especially the hydrochloride salts thereof.

For the avoidance of doubt it is to be understood that where in this specification a group is qualified by 'hereinbefore defined' or 'defined hereinbefore' the said group encompasses the first occurring and broadest definition as well as each and all of the preferred definitions for that group.

In this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. An analogous convention applies to other generic terms. Unless otherwise stated the term "alkyl" advantageously refers to chains with 1-6 carbon atoms, preferably 1-4 carbon atoms. In this specification the term "alkoxy" means an alkyl group as

defined hereinbefore linked to an oxygen atom. In this specification the term "aryl" includes C_{6-10}aromatic groups which may, if desired, carry one or more substituents selected from halogeno, alkyl, alkoxy, cyano, nitro or trifluoromethyl (wherein alkyl and alkoxy are as hereinbefore defined). The term "aryloxy" means an aryl group as defined hereinbefore linked to an oxygen atom. In this specification the term "sulphonyloxy" includes alkylsulphonyloxy and arylsulphonyloxy wherein "alkyl" and "aryl" are as defined hereinbefore. The term "alkanoyl" as used herein unless otherwise stated includes alkylC=O groups in which "alkyl" is as defined hereinbefore, for example ethanoyl refers to CH_3C=O. In this specification unless stated otherwise the term "alkenyl" includes both straight and branched chain alkenyl groups but references to individual alkenyl groups such as 2-butenyl are specific for the straight chain version only. Unless otherwise stated the term "alkenyl" advantageously refers to chains with 2-5 carbon atoms, preferably 3-4 carbon atoms. In this specification unless stated otherwise the term "alkynyl" includes both straight and branched chain alkynyl groups but references to individual alkynyl groups such as 2-butynyl are specific for the straight chain version only. Unless otherwise stated the term "alkynyl" advantageously refers to chains with 2-5 carbon atoms, preferably 3-4 carbon atoms.

In formula I, as hereinbefore defined, hydrogen will be present at positions 2 and 8 of the quinazoline group.

Within the present invention it is to be understood that a quinazoline of the formula I or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which inhibits VEGF receptor tyrosine kinase activity and is not to be limited merely to any one tautomeric form utilised within the formulae drawings.

It is also to be understood that certain quinazolines of the formula I and salts thereof can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which inhibit VEGF receptor tyrosine kinase activity.

For the avoidance of any doubt, it is to be understood that when X^1 is, for example, a group of formula $-NR^8CO-$, it is the nitrogen atom bearing the R^8 group which is attached to the quinazoline ring and the carbonyl (CO) group is attached to R^4, whereas when X^1 is, for

example, a group of formula -$CONR^9$-, it is the carbonyl group which is attached to the quinazoline ring and the nitrogen atom bearing the R^9 group is attached to R^4. A similar convention applies to the other two atom X^1 linking groups such as -$NR^{11}SO_2$- and -SO_2NR^{10}-. When X^1 is -NR^7- it is the nitrogen atom bearing the R^7 group which is linked to the quinazoline ring and to R^4. An analogous convention applies to other groups. It is further to be understood that when X^1 represents -NR^7- and R^7 is C_{1-3}alkoxyC_{2-3}alkyl it is the C_{2-3}alkyl moiety which is linked to the nitrogen atom of X^1 and an analogous convention applies to other groups.

For the avoidance of any doubt, it is to be understood that in a compound of the formula I when R^4 is, for example, a group of formula C_{1-5}alkylR^{23}, it is the terminal C_{1-5}alkyl moiety which is bound to X^1, similarly when R^4 is, for example, a group of formula C_{2-5}alkenylR^{23} it is the C_{2-5}alkenyl moiety which is bound to X^1 and an analogous convention applies to other groups. When R^4 is a group 1-R^{23}prop-1-en-3-yl it is the first carbon to which the group R^{23} is attached and it is the third carbon which is linked to X^1 and an analogous convention applies to other groups.


The present invention relates to the compounds of formula I as hereinbefore defined as well as to the salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula I and their pharmaceutically acceptable salts. Pharmaceutically acceptable salts of the invention may, for example, include acid addition salts of the compounds of formula I as hereinbefore defined which are sufficiently basic to form such salts. Such acid addition salts include for example salts with inorganic or organic acids affording pharmaceutically acceptable anions such as with hydrogen halides (especially hydrochloric or hydrobromic acid of which hydrochloric acid is particularly preferred) or with sulphuric or phosphoric acid, or with trifluoroacetic, citric or maleic acid. In addition where the compounds of formula I are sufficiently acidic, pharmaceutically acceptable salts may be formed with an inorganic or organic base which affords a pharmaceutically acceptable cation. Such salts with inorganic or organic bases include for example an alkali metal salt, such as a sodium or potassium salt, an alkaline earth metal salt such as a calcium or magnesium salt, an ammonium salt or for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

A compound of the formula I, or salt thereof, and other compounds of the invention (as hereinafter defined) may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Such processes include, for example, those illustrated in European Patent Applications, Publication Nos. 0520722, 0566226, 0602851 and 0635498. Such processes, are provided as a further feature of the invention and are as described hereinafter. Necessary starting materials may be obtained by standard procedures of organic chemistry. The preparation of such starting materials is described within the accompanying non-limiting Examples. Alternatively necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist.

Thus the following processes (a) to (g) and (i) to (v) constitute further features of the present invention.


Synthesis of Compounds of Formula I

(a) Compounds of the formula I and salts thereof may be prepared by the reaction of a compound of the formula III:



(III)

(wherein R^1, R^2, X^1 and R^4 are as defined hereinbefore and L^1 is a displaceable moiety), with a compound of the formula IV:




(IV)

(wherein Z, R^3 and m are as defined hereinbefore) whereby to obtain compounds of the formula I and salts thereof. A convenient displaceable moiety L^1 is, for example, a halogeno, alkoxy (preferably C_{1-4}alkoxy), aryloxy or sulphonyloxy group, for example a chloro, bromo, methoxy, phenoxy, methanesulphonyloxy or toluene-4-sulphonyloxy group.

The reaction is advantageously effected in the presence of either an acid or a base. Such an acid is, for example, an anhydrous inorganic acid such as hydrogen chloride. Such a base is, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene, or for example, an alkali metal or alkaline earth metal carbonate or hydroxide, for example sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide. Alternatively such a base is, for example, an alkali metal hydride, for example sodium hydride, or an alkali metal or alkaline earth metal amide, for example sodium amide or sodium bis(trimethylsilyl)amide. The reaction is preferably effected in the presence of an inert solvent or diluent, for example an alkanol or ester such as methanol, ethanol, isopropanol or ethyl acetate, a halogenated solvent such as methylene chloride, trichloromethane or carbon tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxan, an aromatic hydrocarbon solvent such as toluene, or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide. The reaction is conveniently effected at a temperature in the range, for example, 10 to 150°C, preferably in the range 20 to 80°C.


The compound of the invention may be obtained from this process in the form of the free base or alternatively it may be obtained in the form of a salt with the acid of the formula H-L^1 wherein L^1 has the meaning defined hereinbefore. When it is desired to obtain the free base from the salt, the salt may be treated with a base as defined hereinbefore using a conventional procedure.

(b) Where the group of formula IIa:



(IIa)

(wherein R^3 and m are as hereinbefore defined) represents a phenyl group carrying one or more hydroxy groups, a compound of the formula I and salts thereof can be prepared by the deprotection of a compound of formula V:




(V)

(wherein X^1, m, R^1, R^2, R^3, R^4 and Z are as hereinbefore defined, P represents a phenolic hydroxy protecting group and p^1 is an integer from 1 to 5 equal to the number of protected hydroxy groups and such that $m\text{-}p^1$ is equal to the number of R^3 substituents which are not protected hydroxy). The choice of phenolic hydroxy protecting group P is within the standard knowledge of an organic chemist, for example those included in standard texts such as "Protective Groups in Organic Synthesis" T.W. Greene and R.G.M.Wuts, 2nd Ed. Wiley 1991, including ethers (for example, methyl, methoxymethyl, allyl and benzyl), silyl ethers (for example, t-butyldiphenylsilyl and t-butyldimethylsilyl), esters (for example, acetate and benzoate) and carbonates (for example, methyl and benzyl). The removal of such a phenolic hydroxy protecting group may be effected by any of the procedures known for such a transformation, including those reaction conditions indicated in standard texts such as that indicated hereinbefore, or by a related procedure. The reaction conditions preferably being such that the hydroxy derivative is produced without unwanted reactions at other sites within the starting or product compounds. For example, where the protecting group P is acetate, the transformation may conveniently be effected by treatment of the quinazoline derivative with a base as defined hereinbefore and including ammonia, and its mono and di-alkylated derivatives, preferably in the presence of a protic solvent or co-solvent such as water or an alcohol, for example methanol or ethanol. Such a reaction can be effected in the presence of

an additional inert solvent or diluent as defined hereinbefore and at a temperature in the range 0 to 50°C, conveniently at about 20°C.

(c) Production of those compounds of formula I and salts thereof wherein the substituent X^1 is -O-, -S- or -NR^7- can be achieved by the reaction, conveniently in the presence of a base as defined hereinbefore, of a compound of the formula VI:




(VI)

(wherein m, X^1, R^1, R^2, R^3, and Z are as hereinbefore defined) with a compound of formula VII:

$$R^4\text{-}L^1 \qquad \text{(VII)}$$

(wherein R^4 and L^1 are as hereinbefore defined); L^1 is a displaceable moiety for example a halogeno or sulphonyloxy group such as a bromo or methanesulphonyloxy group. The reaction is preferably effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously in the presence of an inert solvent or diluent (as defined hereinbefore in process (a)), advantageously at a temperature in the range, for example 10 to 150°C, conveniently at about 50°C.

(d) Compounds of the formula I and salts thereof may be prepared by the reaction of a compound of the formula VIII:



(VIII)

with a compound of the formula IX:

$$R^4\text{-}X^1\text{-}H \qquad (IX)$$

(wherein L^1, R^1, R^2, R^3, R^4, Z, m and X^1 are all as hereinbefore defined). The reaction may conveniently be effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously in the presence of an inert solvent or diluent (as defined hereinbefore in process (a)), advantageously at a temperature in the range, for example 10 to 150°C, conveniently at about 100°C.

(e) Compounds of the formula I and salts thereof wherein R^4 is $C_{1-5}alkylR^{32}$, [wherein R^{32} is selected from one of the following four groups:


1) $X^6C_{1-3}alkyl$ (wherein X^6 represents -O-, -S-, $-SO_2-$, $-NR^{33}CO-$ or $-NR^{34}SO_2-$ (wherein R^{33} and R^{34} are each independently hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$);

2) $NR^{35}R^{36}$ (wherein R^{35} and R^{36} which may be the same or different are each hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$);

3) $X^7C_{1-5}alkylX^5R^{24}$ (wherein X^7 represents -O-, -S-, $-SO_2-$, $-NR^{37}CO-$, $-NR^{38}SO_2-$ or $-NR^{39}-$ (wherein R^{37}, R^{38} and R^{39} are each independently hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$) and X^5 and R^{24} are as defined hereinbefore); and

4) R^{31} (wherein R^{31} is as defined hereinbefore);]

may be prepared by reacting a compound of the formula X:



(X)

(wherein L^1, X^1, R^1, R^2, R^3, Z and m are as hereinbefore defined and R^{40} is C_{1-5}alkyl) with a compound of the formula XI:

$$R^{32}\text{-}H \qquad \text{(XI)}$$

(wherein R^{32} is as defined hereinbefore) to give a compound of the formula I. The reaction may conveniently be effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously in the presence of an inert solvent or diluent (as defined hereinbefore in process (a)), and at a temperature in the range, for example 0 to 150°C, conveniently at about 50°C.


(f) The production of those compounds of the formula I and salts thereof wherein the substituent R^1 is represented by NR^5R^6, where one or both of R^5 and R^6 are C_{1-3}alkyl, may be effected by the reaction of compounds of formula I wherein the substituent R^1 is an amino group and an alkylating agent, preferably in the presence of a base as defined hereinbefore. Such alkylating agents are C_{1-3}alkyl moieties bearing a displaceable moiety as defined hereinbefore such as C_{1-3}alkyl halides for example C_{1-3}alkyl chloride, bromide or iodide. The reaction is preferably effected in the presence of an inert solvent or diluent (as defined hereinbefore in process (a)) and at a temperature in the range, for example, 10 to 100°C, conveniently at about ambient temperature. This process can also be used for preparing compounds in which R^4-X^1 is an alkylamino or dialkylamino group.

(g) The production of compounds of formula I and salts thereof wherein one or more of the substituents R^1, R^2 or R^3 is an amino group or where R^4-X^1 is amino may be effected by the reduction of a corresponding compound of formula I wherein the substituent(s) at the corresponding position(s) of the quinazoline and/or phenyl ring is/are a nitro group(s). The

reduction may conveniently be effected as described in process (i) hereinafter. The production of a compound of formula I and salts thereof wherein the substituent(s) at the corresponding position(s) of the quinazoline and/or phenyl ring is/are a nitro group(s) may be effected by the processes described hereinbefore and hereinafter in processes (a-e) and (i-v) using a quinazoline compound selected from the compounds of the formulae (I-XXVII) in which the substituent(s) at the corresponding position(s) of the quinazoline and/or phenyl ring is/are a nitro group(s).

Synthesis of Intermediates

(i) The compounds of formula III and salts thereof, constitute a further feature of the present invention. Such compounds in which L^1 is halogeno may for example be prepared by halogenating a compound of the formula XII:




(XII)

(wherein R^1, R^2, R^4 and X^1 are as hereinbefore defined).

Convenient halogenating agents include inorganic acid halides, for example thionyl chloride, phosphorus(III)chloride, phosphorus(V)oxychloride and phosphorus(V)chloride. The halogenation reaction is conveniently effected in the presence of an inert solvent or diluent such as for example a halogenated solvent such as methylene chloride, trichloromethane or carbon tetrachloride, or an aromatic hydrocarbon solvent such as benzene or toluene. The reaction is conveniently effected at a temperature in the range, for example 10 to 150°C, preferably in the range 40 to 100°C.


The compounds of formula XII and salts thereof which constitute a further feature of the present invention may for example be prepared by reacting a compound of the formula XIII:



(XIII)

(wherein R^1, R^2 and L^1 are as hereinbefore defined) with a compound of the formula IX as hereinbefore defined. The reaction may conveniently be effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously in the presence of an inert solvent or diluent (as defined hereinbefore in process (a)), advantageously at a temperature in the range, for example 10 to 150°C, conveniently at about 100°C.

The compounds of formula XII and salts thereof may also be prepared by cyclising a compound of the formula XIV:




(XIV)

(wherein R^1, R^2, R^4 and X^1, are as hereinbefore defined, and A^1 is an hydroxy, alkoxy (preferably C_{1-4}alkoxy) or amino group) whereby to form a compound of formula XII or salt thereof. The cyclisation may be effected by reacting a compound of the formula XIV, where A^1 is an hydroxy or alkoxy group, with formamide or an equivalent thereof effective to cause cyclisation whereby a compound of formula XII or salt thereof is obtained, such as [3-(dimethylamino)-2-azaprop-2-enylidene]dimethylammonium chloride. The cyclisation is conveniently effected in the presence of formamide as solvent or in the presence of an inert solvent or diluent such as an ether for example 1,4-dioxan. The cyclisation is conveniently effected at an elevated temperature, preferably in the range 80 to 200°C. The compounds of formula XII may also be prepared by cyclising a compound of the formula XIV, where A^1 is an amino group, with formic acid or an equivalent thereof effective to cause cyclisation whereby a compound of formula XII or salt thereof is obtained. Equivalents of formic acid

effective to cause cyclisation include for example a tri-C_{1-4}alkoxymethane, for example triethoxymethane and trimethoxymethane. The cyclisation is conveniently effected in the presence of a catalytic amount of an anhydrous acid, such as a sulphonic acid for example p-toluenesulphonic acid, and in the presence of an inert solvent or diluent such as for example a halogenated solvent such as methylene chloride, trichloromethane or carbon tetrachloride, an ether such as diethylether or tetrahydrofuran, or an aromatic hydrocarbon solvent such as toluene. The cyclisation is conveniently effected at a temperature in the range, for example 10 to 100°C, preferably in the range 20 to 50°C.


Compounds of formula XIV and salts thereof, which constitute a further feature of the present invention, may for example be prepared by the reduction of the nitro group in a compound of the formula XV:



(XV)

(wherein R^1, R^2, R^4, X^1 and A^1 are as hereinbefore defined) to yield a compound of formula XIV as hereinbefore defined. The reduction of the nitro group may conveniently be effected by any of the procedures known for such a transformation. The reduction may be carried out, for example, by the hydrogenation of a solution of the nitro compound in the presence of an inert solvent or diluent as defined hereinbefore in the presence of a metal effective to catalyse hydrogenation reactions such as palladium or platinum. A further reducing agent is, for example, an activated metal such as activated iron (produced for example by washing iron powder with a dilute solution of an acid such as hydrochloric acid). Thus, for example, the reduction may be effected by heating the nitro compound and the activated metal in the presence of a solvent or diluent such as a mixture of water and alcohol, for example methanol or ethanol, to a temperature in the range, for example 50 to 150°C, conveniently at about 70°C.


Compounds of the formula XV and salts thereof which constitute a further feature of the present invention, may for example be prepared by the reaction of a compound of the formula XVI:



(XVI)

(wherein R^1, R^2, L^1 and A^1 are as hereinbefore defined) with a compound of the formula IX as hereinbefore defined to give a compound of the formual XV. The reaction of the compounds of formulae XVI and IX is conveniently effected under conditions as described for process (d) hereinbefore.


Compounds of formula XV and salts thereof, may for example also be prepared by the reaction of a compound of the formula XVII:



(XVII)

(wherein R^1, R^2, X^1 and A^1 are as hereinbefore defined with the proviso that X^1 is not $-CH_2-$) with a compound of the formula VII as hereinbefore defined to yield a compound of formula XV as hereinbefore defined. The reaction of the compounds of formulae XVII and VII is conveniently effected under conditions as described for process (c) hereinbefore.

The compounds of formula III and salts thereof may also be prepared for example by reacting a compound of the formula XVIII:




(XVIII)

(wherein R^1, R^2 and X^1 are as hereinbefore defined with the proviso that X^1 is not $-CH_2-$ and L^2 represents a displaceable protecting moiety) with a compound of the formula VII as hereinbefore defined, whereby to obtain a compound of formula III in which L^1 is represented by L^2.

A compound of formula XVIII is conveniently used in which L^2 represents a phenoxy group which may if desired carry up to 5 substituents, preferably up to 2 substituents, selected from halogeno, nitro and cyano. The reaction may be conveniently effected under conditions as described for process (c) hereinbefore.

The compounds of formula XVIII and salts thereof as hereinbefore defined may for example be prepared by deprotecting a compound of the formula XIX:




(XIX)

(wherein R^1, R^2, P, X^1 and L^2 are as hereinbefore defined with the proviso that X^1 is not $-CH_2-$). Deprotection may be effected by techniques well known in the literature, for example where P represents a benzyl group deprotection may be effected by hydrogenolysis or by treatment with trifluoroacetic acid.

One compound of formula III may if desired be converted into another compound of formula III in which the moiety L^1 is different. Thus for example a compound of formula III in which L^1 is other than halogeno, for example optionally substituted phenoxy, may be converted to a compound of formula III in which L^1 is halogeno by hydrolysis of a compound of formula III (in which L^1 is other than halogeno) to yield a compound of formula XII as

hereinbefore defined, followed by introduction of halide to the compound of formula XII, thus obtained as hereinbefore defined, to yield a compound of formula III in which L^1 represents halogen.


(ii) The compounds of formula V and salts thereof, constitute a further feature of the present invention, and may for example be prepared by the reaction of a compound of formula III as hereinbefore defined with a compound of the formula XX:



(XX)

(wherein R^3, m, p^1, P and Z are as hereinbefore defined). The reaction may for example be effected as described for process (a) hereinbefore.


The compounds of formula V and salts thereof may also be prepared by reacting a compound of formula XXI:



(XXI)

(wherein R^1, R^2, L^1, Z, R^3, m, p^1 and P are as hereinbefore defined) with a compound of formula IX as hereinbefore defined. The reaction may for example be effected as described for process (d) above.


The compounds of formula V and salts thereof may also be prepared by reacting a compound of formula XXII:



(XXII)

(wherein R^1, R^2, R^3, X^1, Z, P, p^1 and m are as hereinbefore defined with the proviso that X^1 is not $-CH_2-$) with a compound of the formula VII as hereinbefore defined. The reaction may for example be effected as described for process (c) hereinbefore.


The compounds of formula XXI and salts thereof may for example be prepared by reaction of a compound of formula XXIII:



(XXIII)

(wherein R^1, R^2, and L^1 are as hereinbefore defined, and L^1 in the 4- and 7- positions may be the same or different) with a compound of the formula XX as hereinbefore defined. The reaction may be effected for example by a process as described in (a) above.


Compounds of the formula XXII and salts thereof may be made by reacting compounds of the formulae XIX and XX as hereinbefore defined, under conditions described in (a) hereinbefore, to give a compound of formula XXIV:



(XXIV)

(wherein R^1, R^2, R^3, P, Z, X^1, p^1 and m are as hereinbefore defined with the proviso that X^1 is not $-CH_2-$) and then deprotecting the compound of formula XXIV for example as described in (i) above.

(iii) Compounds of the formula VI as hereinbefore defined and salts thereof may be made by deprotecting the compound of formula XXV:



(XXV)

(wherein R^1, R^2, R^3, P, Z, X^1 and m are as hereinbefore defined) by a process for example as described in (i) above.

Compounds of the formula XXV and salts thereof may be made by reacting compounds of the formulae XIX and IV as hereinbefore defined, under the conditions described in (a) hereinbefore, to give a compound of the formula XXV or salt thereof.

(iv) Compounds of the formula VIII and salts thereof as hereinbefore defined may be made by reacting compounds of the formulae XXIII and IV as hereinbefore defined, the reaction for example being effected by a process as described in (a) above.


(v) Compounds of the formula X as defined hereinbefore and salts thereof may for example be made by the reaction of a compound of formula VI as defined hereinbefore with a compound of the formula XXVI:

$$L^1\text{-}R^{40}\text{-}L^1$$

(XXVI)

(wherein L^1 and R^{40} are as hereinbefore defined) to give a compound of the formula X. The reaction may be effected for example by a process as described in (c) above.

Compounds of the formula X and salts thereof may also be made for example by deprotecting a compound of the formula XXVII:



(XXVII)

(wherein L^1, R^{40}, X^1, R^1, R^2, R^3, Z, P, m and p^1 are as defined hereinbefore) by a process for example as described in (b) above.

Compounds of the formula XXVII and salts thereof may be made for example by reacting compounds of the formulae XXII and XXVI as defined hereinbefore, under the conditions described in (c) above.

When a pharmaceutically acceptable salt of a compound of the formula I is required, it may be obtained, for example, by reaction of said compound with, for example, an acid using a conventional procedure, the acid having a pharmaceutically acceptable anion.

Many of the intermediates defined herein are novel, for example, those of the formulae III, V, XII, XIV and XV, and these are provided as a further feature of the invention.

Intermediates of the formulae VIII, X, XXI, XXII, XXIV, XXV and XXVII are also provided as a further feature of the invention.

The identification of compounds which potently inhibit the tyrosine kinase activity associated with the VEGF receptors such as Flt and/or KDR and which inhibit angiogenesis and/or increased vascular permeability is desirable and is the subject of the present invention. These properties may be assessed, for example, using one or more of the procedures set out below:

(a) In Vitro Receptor Tyrosine Kinase Inhibition Test

This assay determines the ability of a test compound to inhibit tyrosine kinase activity. DNA encoding VEGF or epidermal growth factor (EGF) receptor cytoplasmic domains may be obtained by total gene synthesis (Edwards M, International Biotechnology

Lab 5(3), 19-25, 1987) or by cloning. These may then be expressed in a suitable expression system to obtain polypeptide with tyrosine kinase activity. For example VEGF and EGF receptor cytoplasmic domains, which were obtained by expression of recombinant protein in insect cells, were found to display intrinsic tyrosine kinase activity. In the case of the VEGF receptor Flt (Genbank accession number X51602), a 1.7kb DNA fragment encoding most of the cytoplasmic domain, commencing with methionine 783 and including the termination codon, described by Shibuya et al (Oncogene, 1990, 5: 519-524), was isolated from cDNA and cloned into a baculovirus transplacement vector (for example pAcYM1 (see The Baculovirus Expression System: A Laboratory Guide, L.A. King and R. D. Possee, Chapman and Hall, 1992) or pAc360 or pBlueBacHis (available from Invitrogen Corporation)). This recombinant construct was co-transfected into insect cells (for example Spodoptera frugiperda 21(Sf21)) with viral DNA (eg Pharmingen BaculoGold) to prepare recombinant baculovirus. (Details of the methods for the assembly of recombinant DNA molecules and the preparation and use of recombinant baculovirus can be found in standard texts for example Sambrook et al, 1989, Molecular cloning - A Laboratory Manual, 2nd edition, Cold Spring Harbour Laboratory Press and O'Reilly et al, 1992, Baculovirus Expression Vectors - A Laboratory Manual, W. H. Freeman and Co, New York). For other tyrosine kinases for use in assays, cytoplasmic fragments starting from methionine 806 (KDR, Genbank accession number L04947) and methionine 668 (EGF receptor, Genbank accession number X00588) may be cloned and expressed in a similar manner.

For expression of cFlt tyrosine kinase activity, Sf21 cells were infected with plaque-pure cFlt recombinant virus at a multiplicity of infection of 3 and harvested 48 hours later. Harvested cells were washed with ice cold phosphate buffered saline solution (PBS) (10mM sodium phosphate pH7.4, 138mM sodium chloride, 2.7mM potassium chloride) then resuspended in ice cold HNTG/PMSF (20mM Hepes pH7.5, 150mM sodium chloride, 10% v/v glycerol, 1% v/v Triton X100, 1.5mM magnesium chloride, 1mM ethylene glycol-bis(βaminoethyl ether) N,N,N',N'-tetraacetic acid (EGTA), 1mM PMSF (phenylmethylsulphonyl fluoride); the PMSF is added just before use from a freshly-prepared 100mM solution in methanol) using 1ml HNTG/PMSF per 10 million cells. The suspension was centrifuged for 10 minutes at 13,000 rpm at 4°C, the supernatant (enzyme stock) was removed and stored in aliquots at -70°C. Each new batch of stock enzyme was titrated in the

assay by dilution with enzyme diluent (100mM Hepes pH 7.4, 0.2mM sodium orthovanadate, 0.1% v/v Triton X100, 0.2mM dithiothreitol). For a typical batch, stock enzyme is diluted 1 in 2000 with enzyme diluent and 50µl of dilute enzyme is used for each assay well.

A stock of substrate solution was prepared from a random copolymer containing tyrosine, for example Poly (Glu, Ala, Tyr) 6:3:1 (Sigma P3899), stored as 1 mg/ml stock in PBS at -20°C and diluted 1 in 500 with PBS for plate coating.

On the day before the assay 100µl of diluted substrate solution was dispensed into all wells of assay plates (Nunc maxisorp 96-well immunoplates) which were sealed and left overnight at 4°C.

On the day of the assay the substrate solution was discarded and the assay plate wells were washed once with PBST (PBS containing 0.05% v/v Tween 20) and once with 50mM Hepes pH7.4.

Test compounds were diluted with 10% dimethylsulphoxide (DMSO) and 25µl of diluted compound was transferred to wells in the washed assay plates. "Total" control wells contained 10% DMSO instead of compound. Twenty five microlitres of 40mM manganese(II)chloride containing 8µM adenosine-5'-triphosphate (ATP) was added to all test wells except "blank" control wells which contained manganese(II)chloride without ATP. To start the reactions 50µl of freshly diluted enzyme was added to each well and the plates were incubated at room temperature for 20 minutes. The liquid was then discarded and the wells were washed twice with PBST. One hundred microlitres of mouse IgG anti-phosphotyrosine antibody (Upstate Biotechnology Inc. product 05-321), diluted 1 in 6000 with PBST containing 0.5% w/v bovine serum albumin (BSA), was added to each well and the plates were incubated for 1 hour at room temperature before discarding the liquid and washing the wells twice with PBST. One hundred microlitres of horse radish peroxidase (HRP)-linked sheep anti-mouse Ig antibody (Amersham product NXA 931), diluted 1 in 500 with PBST containing 0.5% w/v BSA, was added and the plates were incubated for 1 hour at room temperature before discarding the liquid and washing the wells twice with PBST. One hundred microlitres of 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) solution, freshly prepared using one 50mg ABTS tablet (Boehringer 1204 521) in 50ml freshly prepared 50mM phosphate-citrate buffer pH5.0 + 0.03% sodium perborate (made with 1 phosphate citrate buffer with sodium perborate (PCSB) capsule (Sigma P4922) per 100ml

distilled water), was added to each well. Plates were then incubated for 20-60 minutes at room temperature until the optical density value of the "total" control wells, measured at 405nm using a plate reading spectrophotometer, was approximately 1.0. "Blank" (no ATP) and "total" (no compound) control values were used to determine the dilution range of test compound which gave 50% inhibtion of enzyme activity.

(b) In Vitro HUVEC Proliferation Assay

This assay determines the ability of a test compound to inhibit the growth factor-stimulated proliferation of human umbilical vein endothelial cells (HUVEC).

HUVEC cells were isolated in MCDB 131 (Gibco BRL) + 7.5% v/v foetal calf serum (FCS) and were plated out (at passage 2 to 8), in MCDB 131 + 2% v/v FCS + 3μg/ml heparin + 1μg/ml hydrocortisone, at a concentration of 1000 cells/well in 96 well plates. After a minimum of 4 hours they were dosed with the appropriate growth factor (i.e. VEGF 3ng/ml, EGF 3ng/ml or b-FGF 0.3ng/ml) and compound. The cultures were then incubated for 4 days at 37°C with 7.5% carbon dioxide. On day 4 the cultures were pulsed with 1μCi/well of tritiated-thymidine (Amersham product TRA 61) and incubated for 4 hours. The cells were harvested using a 96-well plate harvester (Tomtek) and then assayed for incorporation of tritium with a Beta plate counter. Incorporation of radioactivity into cells, expressed as cpm, was used to measure inhibition of growth factor-stimulated cell proliferation by compounds.

(c) In Vivo Rat Uterine Oedema Assay

This test measures the capacity of compounds to reduce the acute increase in uterine weight in rats which occurs in the first 4-6 hours following oestrogen stimulation. This early increase in uterine weight has long been known to be due to oedema caused by increased permeability of the uterine vasculature and recently Cullinan-Bove and Koos (Endocrinology, 1993,133:829-837) demonstrated a close temporal relationship with increased expression of VEGF mRNA in the uterus. We have found that prior treatment of the rats with a neutralising monoclonal antibody to VEGF significantly reduces the acute increase in uterine weight, confirming that the increase in weight is substantially mediated by VEGF.

Groups of 20 to 22-day old rats were treated with a single subcutaneous dose of oestradiol benzoate (2.5μg/rat) in a solvent, or solvent only. The latter served as unstimulated controls. Test compounds were orally administered at various times prior to the

administration of oestradiol benzoate. Five hours after the administration of oestradiol benzoate the rats were humanely sacrificed and their uteri were dissected, blotted and weighed. The increase in uterine weight in groups treated with test compound and oestradiol benzoate and with oestradiol benzoate alone was compared using a Student T test. Inhibition of the effect of oestradiol benzoate was considered significant when $p<0.05$.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula I as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier.

The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) for example as a sterile solution, suspension or emulsion, for topical administration for example as an ointment or cream or for rectal administration for example as a suppository. In general the above compositions may be prepared in a conventional manner using conventional excipients.

The compositions of the present invention are advantageously presented in unit dosage form. The compound will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000mg per square metre body area of the animal, i.e. approximately 0.1-100mg/kg. A unit dose in the range, for example, 1-100mg/kg, preferably 1-50mg/kg is envisaged and this normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-250mg of active ingredient.

According to a further aspect of the present invention there is provided a compound of the formula I or a pharmaceutically acceptable salt thereof as defined hereinbefore for use in a method of treatment of the human or animal body by therapy.

We have found that compounds of the present invention inhibit VEGF receptor tyrosine kinase activity and are therefore of interest for their antiangiogenic effects and/or their ability to cause a reduction in vascular permeability.

A further feature of the present invention is a compound of formula I, or a pharmaceutically acceptable salt thereof, for use as a medicament, conveniently a compound of formula I, or a pharmaceutically acceptable salt thereof, for use as a medicament for

producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human being.

Thus according to a further aspect of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human being.

According to a further feature of the invention there is provided a method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof as defined hereinbefore.

As stated above the size of the dose required for the therapeutic or prophylactic treatment of a particular disease state will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. Preferably a daily dose in the range of 1-50mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.

The antiangiogenic and/or vascular permeability reducing treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. In the field of medical oncology it is normal practice to use a combination of different forms of treatment to treat each patient with cancer. In medical oncology the other component(s) of such conjoint treatment in addition to the antiangiogenic and/or vascular permeability reducing treatment defined hereinbefore may be: surgery, radiotherapy or chemotherapy. Such chemotherapy may cover three main categories of therapeutic agent:

(i) other antiangiogenic agents that work by different mechanisms from those defined hereinbefore (for example linomide, inhibitors of integrin $\alpha v\beta 3$ function, angiostatin, razoxin, thalidomide);

(ii) cytostatic agents such as antioestrogens (for example tamoxifen,toremifene, raloxifene, droloxifene, iodoxyfene), progestogens (for example megestrol acetate), aromatase inhibitors (for example anastrozole, letrazole, vorazole, exemestane), antiprogestogens, antiandrogens (for example flutamide, nilutamide, bicalutamide, cyproterone acetate), LHRH agonists and antagonists (for example goserelin acetate, luprolide), inhibitors of testosterone 5α-dihydroreductase (for example finasteride), anti-invasion agents (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function) and inhibitors of growth factor function, (such growth factors include for example EGF, FGFs, platelet derived growth factor and hepatocyte growth factor such inhibitors include growth factor antibodies, growth factor receptor antibodies, tyrosine kinase inhibitors and serine/threonine kinase inhibitors); and

(iii) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as antimetabolites (for example antifolates like methotrexate, fluoropyrimidines like 5-fluorouracil, purine and adenosine analogues, cytosine arabinoside); antitumour antibiotics (for example anthracyclines like doxorubicin, daunomycin, epirubicin and idarubicin, mitomycin-C, dactinomycin, mithramycin); platinum derivatives (for example cisplatin, carboplatin); alkylating agents (for example nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotepa); antimitotic agents (for example vinca alkaloids like vincristine and taxoids like taxol, taxotere); topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan).

As stated above the compounds defined in the present invention are of interest for their antiangiogenic and/or vascular permeability reducing effects. Such compounds of the invention are expected to be useful in a wide range of disease states including cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation and ocular diseases with retinal vessel proliferation. In particular such compounds of the invention are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the colon, breast, prostate, lungs and skin. More particularly such compounds of the invention are expected to inhibit the growth of those primary and recurrent solid tumours which are associated with VEGF, especially those tumours which are

significantly dependent on VEGF for their growth and spread, including for example, certain tumours of the colon, breast, prostate, lung, vulva and skin.

In addition to their use in therapeutic medicine, the compounds of formula I and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of VEGF receptor tyrosine kinase activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.

It is to be understood that where the term "ether" is used anywhere in this specification it refers to diethyl ether.

The invention will now be illustrated in the following non-limiting Examples in which, unless otherwise stated:-

[(i) evaporations were carried out by rotary evaporation in vacuo and work-up procedures were carried out after removal of residual solids such as drying agents by filtration;

(ii) operations were carried out at ambient temperature, that is in the range 18-25°C and under an atmosphere of an inert gas such as argon;

(iii) column chromatography (by the flash procedure) and medium pressure liquid chromatography (MPLC) were performed on Merck Kieselgel silica (Art. 9385) or Merck Lichroprep RP-18 (Art. 9303) reversed-phase silica obtained from E. Merck, Darmstadt, Germany;

(iv) yields are given for illustration only and are not necessarily the maximum attainable;

(v) melting points are uncorrected and were determined using a Mettler SP62 automatic melting point apparatus, an oil-bath apparatus or a Koffler hot plate apparatus.

(vi) the structures of the end-products of the formula I were confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectral techniques; proton magnetic resonance chemical shift values were measured on the delta scale and peak multiplicities are shown as follows: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad; q, quartet;

(vii) intermediates were not generally fully characterised and purity was assessed by thin layer chromatography (TLC), high-performance liquid chromatography (HPLC), infra-red (IR) or NMR analysis;

(viii) the following abbreviations have been used:-

DMF N,N-dimethylformamide

DMSO dimethylsulphoxide

DMA N,N-dimethylacetamide

TFA trifluoroacetic acid.]

Example 1

Isopropanolic hydrogen chloride (0.1ml of a 5M solution) was added to a solution of 4-chloro-6,7-dimethoxyquinazoline (202mg, 0.9mmol) and 4-bromo-2-fluoro-5-hydroxyaniline (as described in EP 61741 A2) (206mg, 1mmol) in 2-butanol (8ml). The mixture was heated at reflux for 45 minutes, then allowed to cool. The precipitated product was collected by filtration, washed with 2-butanol, and then with ether, and dried under vacuum to give **4-(4-bromo-2-fluoro-5-hydroxyanilino)-6,7-dimethoxyquinazoline** hydrochloride hydrate (340mg, 87%) as a white solid.

m.p. 265-270°C

^{1}H NMR Spectrum: ($DMSOd_6$) 4.0(2s, 6H); 7.13(d, 1H); 7.32(s, 1H); 7.64(d, 1H); 8.17(s, 1H); 8.8(s, 1H); 10.6(s, 1H); 11.3(s, 1H)

MS - ESI: 394-396 $[MH]^+$

Elemental analysis:	Found	C 43.42	H 3.68	N 9.33
$C_{16}H_{13}BrFN_3O_3$ 1HCl 1.05H_2O	Requires	C 42.75	H 3.61	N 9.35%

The starting material was prepared as follows:

A mixture of 4,5-dimethoxyanthranilic acid (19.7g) and formamide (10ml) was stirred and heated to 190°C for 5 hours. The mixture was allowed to cool to approximately 80°C and water (50ml) was added. The mixture was stored at ambient temperature for 3 hours. The precipitate was isolated, washed with water and dried to give 6,7-dimethoxy-3,4-dihydroquinazolin-4-one (3.65g).

A mixture of a portion (2.06g) of the material so obtained, thionyl chloride (20ml) and DMF (1 drop) was stirred and heated to reflux for 2 hours. The mixture was evaporated and the residue was partitioned between ethyl acetate and a saturated aqueous sodium

hydrogen carbonate solution. The organic phase was washed with water, dried ($MgSO_4$) and evaporated. The residue was purified by column chromatography using increasingly polar mixtures of methylene chloride and ethyl acetate as eluant to give 4-chloro-6,7-dimethoxyquinazoline (0.6g, 27%).

Example 2

Solid potassium hydroxide (71mg, 1.2mmol) and then 4-chloro-6,7-dimethoxyquinazoline (0.25g, 1.1mmol), (prepared as described for the starting material in Example 1), were added to a melt of 2,4-dihydroxytoluene (0.6g, 4.8mmol) at 140°C. The mixture was stirred at 140°C for 15 minutes, then allowed to cool. The mixture was diluted with water, and acidified to pH4 then extracted with ethyl acetate. The organic layer was washed with brine, dried ($MgSO_4$) and the solvent removed by evaporation. The crude product was first purified by flash chromatography eluting with petroleum ether/ethyl acetate (1/9) and then by absorption HPLC eluting with trichloromethane/acetonitrile (85/15) to give **6,7-dimethoxy-4-(3-hydroxy-4-methylphenoxy)quinazoline** (116mg, 34%).

m.p. 213-216°C

^{1}H NMR Spectrum: ($CDCl_3$) 2.22(s, 3H); 4.05(s, 6H); 6.6(s, 1H); 6.69(dd, 1H); 7.2(d, 1H); 7.3(s, 1H); 7.52(s, 1H); 8.35(br s, 1H); 8.65(s, 1H)

MS - ESI: 313 $[MH]^+$

Elemental analysis:	Found	C 65.36	H 5.53	N 8.92
$C_{17}H_{16}N_2O_4$	Requires	C 65.38	H 5.16	N 8.97%

The starting material was prepared as follows:

Boron tribromide (3.1ml, 3.2mmol) was added to a solution of 2,4-dimethoxytoluene (1g, 6.5mmol) in pentane (10ml) at -70°C. The reaction mixture was allowed to warm to ambient temperature and the mixture stirred for a further 2 hours. Ice water and ethyl acetate were then added and the aqueous layer basified to pH9.5 with 2M aqueous sodium hydroxide. After stirring for 10 minutes, the organic layer was separated and the aqueous layer extracted with ethyl acetate. The combined organic extract was washed with brine, dried ($MgSO_4$) and the solvent removed by evaporation. The residue was purified by flash chromatography

eluting with methylene chloride/ethyl acetate (9/1) to give 2,4-dihydroxytoluene (759mg, 94%) as a white solid.

Example 3

As part of the procedure described in Example 2 a second compound was extracted during the absorption HPLC by eluting with trichloromethane/acetonitrile (75/25) to give **6,7-dimethoxy-4-(5-hydroxy-2-methylphenoxy)quinazoline** (123mg, 36%).

m.p. 231-239°C

^{1}H NMR Spectrum: ($CDCl_3$) 2.1(s, 3H); 4.05(s, 6H); 6.6(s, 1H); 6.72(dd, 1H); 7.15(d, 1H); 7.32(s, 1H); 7.58(s, 1H); 8.65(s, 1H)

MS - ESI: 313 $[MH]^+$

Elemental analysis:	Found	C 65.05	H 5.68	N 8.6
$C_{17}H_{16}N_2O_4$ $0.1H_2O$	Requires	C 65.00	H 5.20	N 8.92%

Example 4

A mixture of 4-(4-chloro-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (160mg, 0.5mmol), 2-bromoethyl methyl ether (83mg, 0.6mmol) and potassium carbonate (207mg, 1.5mmol) in DMF (3ml) was heated at 180°C for 45 minutes. The reaction mixture was allowed to cool, diluted with water and acidified to pH3.5. This aqueous mixture was extracted with ethyl acetate and the organic extract was washed with water and brine, dried ($MgSO_4$) and the solvent removed by evaporation. The residue was purified by flash chromatography eluting with methylene chloride/ether (7/3) to give **4-(4-chloro-2-fluorophenoxy)-7-(2-methoxyethoxy)-6-methoxyquinazoline** (130mg, 68%).

m.p. 167-168°C

^{1}H NMR Spectrum: ($DMSOd_6$) 3.76(t, 2H); 3.99(s, 3H); 4.34(t, 2H); 7.4(d, 1H); 7.44(s, 1H); 7.56(t, 1H); 7.57(s, 1H); 7.70(dd, 1H); 8.56(s, 1H)

MS - ESI: 379 $[MH]^+$

Elemental analysis :	Found	C 57.03	H 4.53	N 7.41
$C_{18}H_{16}FClN_2O_4$ $0.1H_2O$	Requires	C 56.81	H 4.29	N 7.36%

The starting material was prepared as follows:

A mixture of 2-amino-4-benzyloxy-5-methoxybenzamide (J. Med. Chem. 1977, vol 20, 146-149, 10g, 0.04mol) and Gold's reagent (7.4g, 0.05mol) in dioxane (100ml) was stirred and heated at reflux for 24 hours. Sodium acetate (3.02g, 0.037mol) and acetic acid (1.65ml, 0.029mol) were added to the reaction mixture and it was heated for a further 3 hours. The mixture was evaporated, water was added to the residue, the solid was filtered off, washed with water and dried. Recrystallisation from acetic acid gave 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (8.7g, 84%).

A mixture of 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (2.82g, 0.01mol), thionyl chloride (40ml) and DMF (0.28ml) was stirred and heated at reflux for 1 hour. The mixture was evaporated and azeotroped with toluene to give 7-benzyloxy-4-chloro-6-methoxyquinazoline hydrochloride (3.45g).

4-Chloro-2-fluoro-phenol (264mg, 1.8mmol) was added to a solution of 7-benzyloxy-4-chloro-6-methoxyquinazoline hydrochloride (506mg, 1.5mmol) in pyridine (8ml) and the mixture heated at reflux for 45 minutes. The solvent was removed by evaporation and the residue partitioned between ethyl acetate and water. The organic layer was washed with 0.1M HCl, water and brine, dried ($MgSO_4$) and the solvent removed by evaporation. The solid residue was triturated with petroleum ether and the crude product collected by filtration and purified by flash chromatography eluting with methylene chloride/ether (9/1) to give 7-benzyloxy-4-(4-chloro-2-fluorophenoxy)-6-methoxyquinazoline (474mg, 77%) as a cream solid.

m.p. 179-180°C

^{1}H NMR Spectrum: ($DMSOd_6$) 3.99(s, 3H); 5.36(s, 2H); 7.35-7.5(m, 4H); 7.55-7.65(m, 5H); 7.72(d, 1H); 8.6(s, 1H)

MS - ESI: 411 $[MH]^+$

Elemental analysis: Found C 63.38 H 4.07 N 6.78

$C_{22}H_{16}ClFN_2O_3$ $0.06H_2O$ $0.05CH_2Cl_2$ Requires C 63.64 H 3.93 N 6.73%

A solution of 7-benzyloxy-4-(4-chloro-2-fluorophenoxy)-6-methoxyquinazoline (451mg, 1.1mmol) in TFA (4.5ml) was heated at reflux for 3 hours. The mixture was diluted with toluene and the volatiles removed by evaporation. The residue was triturated with methylene chloride, collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (320mg, 90%).

^{1}H NMR Spectrum: ($DMSOd_6$) 4.0(s, 3H); 7.27(s, 1H); 7.43(dd, 1H); 7.56(t, 1H); 7.57(s, 1H); 7.72(dd, 1H); 8.5(s, 1H)

MS - ESI: 321 $[MH]^+$

Example 5

4-Chloro-6,7-dimethoxyquinazoline (200mg, 0.89mmol), (prepared as described for the starting material in Example 1), was added to a solution of 3-hydroxybenzenethiol (168mg, 1.3mmol) and N,N-diisopropylethylamine (233µl, 1.3mmol) in DMF (5ml). After heating at 40°C for 10 minutes, the reaction mixture was allowed to cool, diluted with water, acidified to pH3 and the mixture extracted with ethyl acetate. The organic extract was washed with brine, dried ($MgSO_4$) and the solvent removed by evaporation. The residue was recrystallised from a mixture of ethanol and ether to give **6,7-dimethoxy-4-(3-hydroxyphenylthio)quinazoline** (259mg, 93%) as a white solid.

m.p. 221-230°C

^{1}H NMR Spectrum: ($DMSOd_6$) 4.0(2s, 6H); 6.9(dd, 1H); 7.05(s, 1H); 7.07(d, 1H); 7.34(t, 1H); 7.35(s, 1H); 7.38(s, 1H); 8.7(s, 1H); 9.8(br s, 1H)

MS - ESI: 315 $[MH]^+$

Elemental analysis:	Found	C 61.06	H 4.61	N 8.95
$C_{16}H_{14}N_2O_3S$	Requires	C 61.13	H 4.49	N 8.91%

The starting material was prepared as follows:

Boron tribromide (1.4ml, 14mmol) was added to a solution of 3-methoxybenzenethiol (1g, 7.1mmol) in methylene chloride (10ml) at 0°C. The mixture was allowed to warm to ambient temperature and stirred for a further 60 minutes. The reaction mixture was diluted with ethyl acetate and water and basified with aqueous 2M sodium hydroxide solution to pH9. The mixture was then extracted with ethyl acetate, the combined extract washed with brine, dried ($MgSO_4$) and the solvent removed by evaporation. The residue was purified by flash chromatography eluting with petroleum ether/ethyl acetate (8/2) to give 3-hydroxybenzenethiol (819mg, 91%).

^{1}H NMR Spectrum: ($CDCl_3$) 3.42(s, 1H); 4.85(br s, 1H); 6.6(d, 1H); 6.75(s, 1H); 6.85(d, 1H); 7.1(t, 1H)

Example 6

Concentrated aqueous ammonia (5ml) was added to a solution of 4-(5-acetoxy-4-chloro-2-fluoroanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline (180mg, 0.4mmol) in methanol (50ml). The mixture was stirred at ambient temperature for 3 hours, and then diluted with water. Most of the methanol was removed by evaporation and the resulting precipitate collected by filtration, washed with water and dried to give **4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline** (73mg, 45%).

m.p. >250°C

^{1}H NMR Spectrum: ($DMSOd_6$) 3.29(s, 3H); 3.74(t, 2H); 3.94(s, 3H); 4.28(t, 2H); 7.15(d, 1H); 7.19(s, 1H); 7.38(d, 1H); 7.77(s, 1H); 8.36(s, 1H); 9.40(s, 1H)

MS - ESI: 394 $[MH]^-$

Elemental analysis :	Found	C 51.1	H 4.6	N 9.8
$C_{18}H_{17}N_3ClFO_4$ $1.6H_2O$	Requires	C 51.2	H 4.8	N 9.9%

The starting material was prepared as follows:

A mixture of 4-chloro-2-fluoro-5-hydroxyaniline (2.5g, 15mmol), (as described in EP 61741 A2), and 7-benzyloxy-4-chloro-6-methoxyquinazoline (4.2g, 14mmol), (prepared as described for the starting material in Example 4 but with an aqueous work up), in isopropanol was heated at reflux for 2 hours. The mixture was then allowed to cool and the solid product collected by filtration, washed with isopropanol and dried to give 7-benzyloxy-4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxyquinazoline hydrochloride (4.8g, 81%).

^{1}H NMR Spectrum: ($DMSOd_6$) 3.98(s, 3H); 5.18(s, 2H); 7.05(d, 1H); 7.18-7.27(m, 7H); 8.06(s, 1H); 8.38(s, 1H)

Triethylamine (216ml, 1.5mmol) and then acetic anhydride (133ml, 1.4mmol) were added to a stirred suspension of 7-benzyloxy-4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy quinazoline hydrochloride (600mg, 1.4mmol) in methylene chloride (7ml). The mixture was stirred at ambient temperature for 3 hours and insoluble material removed by filtration. Volatiles were removed from the filtrate by evaporation and the residue purified by flash chromatography eluting with methylene chloride/methanol (100/0 increasing in polarity

to 97/3) to give 4-(5-acetoxy-4-chloro-2-fluoroanilino)-7-benzyloxy-6-methoxyquinazoline (340mg, 52%) as a solid.

^{1}H NMR Spectrum: ($DMSOd_6$) 2.34(s, 3H); 3.94(s, 3H); 5.28(s, 2H); 7.28(s, 1H); 7.35-7.44(m, 2H); 7.50(d, 2H); 7.58(d, 1H); 7.70(d, 1H); 7.80(s, 1H); 8.37(s, 1H); 9.30(s,1H)

MS - ESI: 468 $[MH]^+$

A solution of 4-(5-acetoxy-4-chloro-2-fluoroanilino)-7-benzyloxy-6-methoxyquinazoline (250mg, 0.54mmol) in methanol (5ml), trichloromethane (5ml) and DMF (1ml) was stirred under hydrogen at 1 atmosphere with 5% palladium-on-charcoal catalyst (100mg) for 4 hours. The catalyst was removed by filtration through diatomaceous earth and the solvent removed by evaporation. The residue was dissolved in ethyl acetate, washed with water and brine, and dried ($MgSO_4$). Most of the solvent was removed by evaporation, the mixture was cooled and hexane added to obtain solid product which was collected by filtration, washed with hexane/ethyl acetate and dried to give 4-(5-acetoxy-4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (170mg, 45%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.37(s, 3H); 3.95(s, 3H); 7.08(s, 1H); 7.59(d, 1H); 7.68(d, 1H); 7.78(s, 1H); 8.34(s, 1H); 9.48(s,1H)

1-1'-(Azodicarbonyl)dipiperidine (413mg, 1.6mmol) was added portionwise to a stirred mixture of 4-(5-acetoxy-4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (250mg, 0.66mmol), 2-methoxyethanol (63ml, 0.8mmol) and tributylphosphine (405ml, 1.6mmol) in methylene chloride at 0°C. The resulting solution was allowed to warm to ambient temperature and stirred for 2 hours. The precipitated solid was removed by filtration, the solvent removed from the filtrate by evaporation and the residue purified by flash chromatography eluting with acetonitrile/methylene chloride (1/9 increasing in polarity to 4/6) to give 4-(5-acetoxy-4-chloro-2-fluoroanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline (180mg, 62%) as a solid.

^{1}H NMR Spectrum: ($DMSOd_6$) 2.35(s, 3H); 3.33(s, 3H); 3.75(t, 2H); 3.95(s, 3H); 4.28(t, 2H); 7.22(s, 1H); 7.60(d, 1H); 7.72(d, 1H); 7.80(s, 1H); 8.39(s, 1H); 9.60(s,1H)

MS - ESI: 436 $[MH]^+$

Example 7

A mixture of 4-chloro-6,7-dimethoxyquinazoline hydrochloride (2.1g, 8mmol), (prepared as described for the starting material in Example 1 but without the aqueous work up), and 4-chloro-2-fluoro-5-hydroxyaniline (1.43g, 8.9mmol), (as described in EP 61741 A2), in isopropanol (150ml) was heated at reflux for 2 hours. The mixture was allowed to cool, the solid product collected by filtration, washed with isopropanol and dried to give **4-(4-chloro-2-fluoro-5-hydroxyanilino)-6,7-dimethoxyquinazoline** hydrochloride (1.45g, 47%).

m.p. >250°C

^{1}H NMR Spectrum: ($DMSOd_6$) 4.0(s, 6H); 7.17(d, 1H); 7.34(s, 1H); 7.50(d, 1H); 8.22(s, 1H); 8.80(s, 1H)

MS - ESI: 350 $[MH]^+$

Elemental analysis :	Found	C 49.2	H 3.7	N 10.9
$C_{16}H_{13}N_3ClFO_3$ 1HCl	Requires	C 49.7	H 3.6	N 10.9%

Example 8

A mixture of 4-chloro-6,7-dimethoxyquinazoline hydrochloride (2.5g, 9.6mmol), (prepared as described for the starting material in Example 1 but without the aqueous work up), and 2-fluoro-5-hydroxy-4-methylaniline (1.48g, 10.5mmol) in isopropanol (150ml) was heated at reflux for 2 hours. The mixture was allowed to cool, the solid product collected by filtration, washed with isopropanol and dried to give **4-(2-fluoro-5-hydroxy-4-methylanilino)-6,7-dimethoxyquinazoline** hydrochloride (2.2g, 71%).

m.p. >250°C

^{1}H NMR Spectrum: ($DMSOd_6$) 2.15(s, 3H); 3.99(s, 6H); 6.88(d, 1H); 7.10(d, 1H); 7.32(s, 1H); 8.20(s, 1H); 8.78(s, 1H) 9.66(s, 1H)

Elemental analysis:	Found	C 56.3	H 5.4	N 10.4
$C_{17}H_{16}N_3FO_3$ 1HCl 0.65C_3H_8O	Requires	C 56.3	H 5.5	N 10.4%

The starting material was prepared as follows:

Methyl chloroformate (6.8ml, 88mmol) was added over 30 minutes to a solution of 4-fluoro-2-methylphenol (10g, 79mmol) in 6% aqueous sodium hydroxide solution at 0°C. The mixture was stirred for 2 hours, then extracted with ethyl acetate (100ml). The ethyl

acetate extract was washed with water (100ml) and dried ($MgSO_4$) and the solvent removed by evaporation to give 4-fluoro-2-methylphenyl methyl carbonate (11.4g, 78%) as an oil.

^{1}H NMR Spectrum: ($DMSOd_6$) 2.14(s, 3H); 3.81(s, 3H); 7.05(m, 1H); 7.1-7.25(m, 2H)

A mixture of concentrated nitric acid (6ml) and concentrated sulphuric acid (6ml) was added slowly to a solution of 4-fluoro-2-methylphenyl methyl carbonate (11.34g, 62mmol) in concentrated sulphuric acid (6ml) such that the temperature of the reaction mixture was kept below 50°C. The mixture was stirred for 2 hours, then ice/water was added and the precipitated product collected by filtration. The crude product was purified by chromatography on silica eluting with methylene chloride/hexane progressing through increasingly polar mixtures to methanol/methylene chloride (1:19) to give 4-fluoro-2-methyl-5-nitrophenol (2.5g, 22%) as a solid.

^{1}H NMR Spectrum: ($DMSOd_6$, CD_3CO_2D) 2.31(s, 3H); 7.38(d, 1H); 7.58(d, 1H)

MS - ESI: 171 $[MH]^+$

A mixture of 4-fluoro-2-methyl-5-nitrophenol (2.1g, 13mmol), iron powder (1g, 18mmol) and iron(II)sulphate (1.5g, 10mmol) in water (40ml) was refluxed for 4 hours. The reaction mixture was allowed to cool, neutralised with 2M aqueous sodium hydroxide and extracted with ethyl acetate (100ml). The ethyl acetate extract was dried ($MgSO_4$) and the solvent removed by evaporation to give 2-fluoro-5-hydroxy-4-methylaniline (0.8g, 47%) as a solid.

^{1}H NMR Spectrum: ($DMSOd_6$) 1.94(s, 3H); 4.67(s, 2H); 6.22(d, 1H); 6.65(d, 1H); 8.68(s, 1H)

MS - ESI: 142 $[MH]^+$

Example 9

A mixture of 4-chloro-6-methoxy-7-(2-methoxyethoxy)quinazoline (76mg, 0.28mmol) and 2-fluoro-5-hydroxy-4-methylaniline (40mg, 0.28mmol), (prepared as described for the starting material in Example 8), in isopropanol (2.5ml) was stirred and heated at reflux for 7 hours. The reaction mixture was allowed to cool and the precipitated product collected by filtration, washed with isopropanol and dried to give **4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline** hydrochloride (79mg 66%) as a white solid.

m.p. >275°C

^{1}H NMR Spectrum: ($DMSOd_6$) 2.19(s, 3H); 3.36(s, 3H); 3.80(m, 2H); 4.00(s, 3H); 4.33(m, 2H); 6.90(d, 1H); 7.10(d, 1H); 7.37(s, 1H); 8.20(s, 1H); 8.75(s, 1H) 9.65(br s, 1H); 11.25(br s, 1H)

MS - ESI: 374 $[MH]^+$

Elemental analysis :	Found	C 55.7	H 4.8	N 10.1
$C_{19}H_{20}N_3FO_4$ 1HCl	Requires	C 55.7	H 5.2	N 10.3%

The starting material was prepared as follows:

A mixture of ethyl 4-hydroxy-3-methoxybenzoate (9.8g, 50mmol), 2-bromoethyl methyl ether (8.46ml, 90mmol) and potassium carbonate (12.42g, 90mmol) in acetone (60ml) was heated at reflux for 30 hours. The mixture was allowed to cool and the solids removed by filtration. The volatiles were removed from the filtrate by evaporation and the residue triturated with hexane to give ethyl 3-methoxy-4-(2-methoxyethoxy)benzoate (11.3g, 89%) as a white solid.

m.p. 57-60°C

^{1}H NMR Spectrum: ($DMSOd_6$) 1.31(t, 3H); 3.29(s, 3H); 3.32(s, 3H); 3.68(m, 2H); 4.16(m, 2H); 4.28(q, 2H); 7.06(d, 1H); 7.45(d, 1H); 7.56(dd, 1H)

MS - FAB: 255 $[MH]^+$

Ethyl 3-methoxy-4-(2-methoxyethoxy)benzoate (9.5g, 37mmol) was added portionwise to stirred concentrated nitric acid (75ml) at 0°C. The mixture was allowed to warm to ambient temperature and stirred for a further 90 minutes. The mixture was diluted with water and extracted with methylene chloride, dried ($MgSO_4$) and the solvent removed by evaporation. The residue was triturated with hexane to give ethyl 5-methoxy-4-(2-methoxyethoxy)-2-nitrobenzoate (10.6g, 95%) as an orange solid.

m.p. 68-69°C

^{1}H NMR Spectrum: ($DMSOd_6$) 1.27(t, 3H); 3.30(s, 3H); 3.69(m, 2H); 3.92(s, 3H); 4.25(m, 2H); 4.29(q, 2H); 7.30(s, 1H); 7.65(s, 1H)

MS - CI: 300 $[MH]^+$

A mixture of ethyl 5-methoxy-4-(2-methoxyethoxy)-2-nitrobenzoate (10.24g, 34mmol), cyclohexene (30ml) and 10% palladium-on-charcoal catalyst (2.0g) in methanol

(150ml) was heated at reflux for 5 hours. The reaction mixture was allowed to cool and diluted with methylene chloride. The catalyst was removed by filtration and the volatiles removed from the filtrate by evaporation. The residue was recrystallised from ethyl acetate/hexane to give ethyl 2-amino-5-methoxy-4-(2-methoxyethoxy) benzoate (8.0g) as a buff solid. Formamide (80ml) was added to this product and the mixture heated at 170°C for 18 hours. About half the solvent was removed by evaporation under high vacuum and the residue was left to stand overnight. The solid product was collected by filtration, washed with ether and dried to give 6-methoxy-7-(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one (5.3g, 62% over two steps) as a grey solid.

^{1}H NMR Spectrum: ($DMSOd_6$) 3.35(s, 3H); 3.74(m, 2H); 3.89(s, 3H); 4.26(m, 2H); 7.15(s, 1H); 7.47(s, 1H); 7.98(s, 1H); 12.03(br s, 1 H)

MS - CI: 251 $[MH]^+$

DMF (0.5ml) was added to a mixture of 6-methoxy-7-(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one (5.1g, 20mmol) in thionyl chloride (50ml). The mixture was stirred and heated at reflux for 3 hours, allowed to cool and the excess thionyl chloride removed by evaporation. The residue was suspended in methylene chloride and washed with aqueous sodium hydrogen carbonate solution. The aqueous phase was extracted with methylene chloride and the combined extracts dried ($MgSO_4$). The crude product was recrystallised from methylene chloride/hexane to give 4-chloro-6-methoxy-7-(2-methoxyethoxy)quinazoline (2.8g, 51%) as a fine white solid.

^{1}H NMR Spectrum: ($DMSOd_6$) 3.37(s, 3H); 3.77(m, 2H); 4.01(s, 3H); 4.37(m, 2H); 7.40(s, 1H); 7.49(s, 1H); 8.88(s, 1H)

MS - CI: 269 $[MH]^+$

Example 10

A mixture of 4-chloro-6,7-dimethoxyquinazoline hydrochloride, (152mg, 0.6mmol), (prepared as described for the starting material in Example 1 but without the aqueous work up), and 4-bromo-2,6-difluoroaniline (121mg, 0.6mmol) in isopropanol (7ml) was heated at reflux for 2 hours. The mixture was allowed to cool, the solid product collected by filtration, washed with isopropanol and dried to give **4-(4-bromo-2,6-difluoroanilino)-6,7-dimethoxyquinazoline** hydrochloride (81mg, 35%).

^{1}H NMR Spectrum: ($DMSOd_6$) 4.0(s x 2, 3H each); 7.2(s, 1H); 7.35(d, 2H); 8.2(s, 1H); 8.9(s, 1H); 11.8(br s, 1H)

MS - ESI: 396 $[MH]^+$

Example 11

4-Chloro-6,7-dimethoxyquinazoline hydrochloride (300mg, 1.15mmol), (prepared as described for the starting material in Example 1 but without the aqueous work up), and 2,4-difluoro-5-hydroxyaniline (184mg, 0.90mmol) in isopropanol (10ml) were heated at reflux for 2 hours. The reaction mixture was then allowed to cool, the precipitated product collected by filtration, washed with isopropanol and dried to give **4-(2,4-difluoro-5-hydroxyanilino)-6,7-dimethoxyquinazoline** hydrochloride (250mg, 65%).

^{1}H NMR Spectrum: ($DMSOd_6$) 3.99(s, 6H); 7.05(dd, 1H); 7.17(s, 1H); 7.40(dd, 1H); 8.10(s, 1H); 8.68(s, 1H)

MS - ESI: 334 $[MH]^+$

Elemental analysis:	Found	C 51.8	H 3.9	N 11.3
$C_{16}H_{13}N_3O_3F_2$ 1HCl	Requires	C 52.0	H 3.8	N 11.4%

The starting material was prepared as follows:

Methyl chloroformate (16.35ml, 0.173mol) was added to a solution of 2,4-difluorophenol (25g, 0.192mol) and sodium hydroxide (8.1g, 0.203mol) in water (140ml). The mixture was stirred at ambient temperature for 2 hours and then extracted with ethyl acetate. The extract was washed with water, dried ($MgSO_4$) and the volatiles removed by evaporation to give 2,4-difluoro-1-methoxycarbonyloxybenzene (32g, 89%).

^{1}H NMR Spectrum: ($DMSOd_6$) 3.85(s, 3H); 7.64(d, 2H); 7.72(d,1H)

A mixture of concentrated nitric acid (4ml) and concentrated sulphuric acid (4ml) was added slowly to a cooled mixture of 2,4-difluoro-1-methoxycarbonyloxybenzene (5.0g, 0.027mol) in concentrated sulphuric acid (4ml) such that the reaction temperature was maintained below 30°C. The mixture was stirred for a further 3 hours, diluted with ice/water and the precipitated product collected by filtration washed with water and dried to give 2,4-difluoro-5-methoxycarbonyloxy-1-nitrobenzene (2.8g, 45%).

^{1}H NMR Spectrum: ($DMSOd_6$) 3.85(s, 3H); 7.97(dd, 1H); 8.44(dd, 1H)

A mixture of 2,4-difluoro-5-methoxycarbonyloxy-1-nitrobenzene (2.7g, 0.012mol) and 10% palladium-on-charcoal catalyst (500mg) in ethanol (20ml) and ethyl acetate (10ml) was stirred under 1 atmosphere of hydrogen for 4 hours. The catalyst was removed by filtration through diatomaceous earth and the solvent removed by evaporation to give 2,4-difluoro-5-methoxycarbonyloxyaniline (2.3g, 97%).

^{1}H NMR Spectrum: ($DMSOd_6$) 3.82(s, 3H); 5.20(s, 2H); 6.65(dd,1H); 7.20(dd, 1H)

MS - ESI: 204 $[MH]^+$

Concentrated aqueous ammonia (20ml) was added to a solution of 2,4-difluoro-5-methoxycarbonyloxyaniline (2.0g, 9.85mmol) in ethanol (100ml) and the mixture stirred at ambient temperature for 3 hours. The reaction mixture was diluted with water and most of the organic volatiles were removed by evaporation. The aqueous residue was neutralised to pH7 and extracted with ethyl acetate. The extracts were washed with water, dried (MgSO4) and the solvent removed by evaporation to give 2,4-difluoro-5-hydroxyaniline (1.2g, 85%).

^{1}H NMR Spectrum: ($DMSOd_6$) 4.78(s, 2H); 6.34(t,1H); 6.87(t, 1H); 9.23(s, 1H)

MS - ESI: 145 $[MH]^+$

Example 12

6-Methoxy-7-(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one (200mg, 0.8mmol), (prepared as described for the starting material in Example 9), and DMF (0.1ml) in thionyl chloride (20ml) were heated at reflux for 2 hours. Excess thionyl chloride was removed by evaporation and the residue azeotroped with toluene. The residue was dissolved in isopropranol (15ml), 2,4-difluoro-5-hydroxyaniline (128mg, 0.88mmol), (prepared as described for the starting material in Example 11), added, and the mixture heated at reflux for 2 hours. The reaction mixture was then allowed to cool, the precipitated product collected by filtration, washed with isopropanol and dried to give **4-(2,4-difluoro-5-hydroxyanilino)-6-methoxy-7-(2-methoxyethoxy)quinazoline** hydrochloride (83mg, 28%).

^{1}H NMR Spectrum: ($DMSOd_6$) 3.35(s, 3H); 3.77(t, 2H); 4.00(s, 3H); 4.30(t, 2H); 7.10)(dd, 1H); 7.36(s, 1H); 7.40(t, 2H); 8.20(s, 1H); 8.78(d, 2H)

MS - ESI: 378 $[MH]^+$

Elemental analysis:	Found	C 51.8	H 4.2	N 10.1
$C_{18}H_{17}N_3O_4F_2$ 1HCl	Requires	C 52.2	H 4.4	N 10.2%

Example 13

A mixture of 7-(2-acetoxyethoxy)-4-(5-benzyloxy-2-fluoro-4-methylanilino)-6-methoxyquinazoline (133mg, 0.27mmol) and 10% palladium-on-charcoal catalyst (50mg) in ethyl acetate (8ml) was stirred under 1 atmosphere of hydrogen at ambient temperature for 18 hours. The catalyst was removed by filtration through diatomaceous earth and most of the solvent removed by evaporation and hexane added to the residue. The resulting precipitated product was collected by filtration and dried to give **7-(2-acetoxyethoxy)-4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxyquinazoline** (16mg, 15%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.05(s, 3H); 2.13(s, 3H); 3.91 (s, 3H); 4.3-4.4(m, 4H); 6.90(d, 1H); 6.98(d, 1H); 7.18(s, 1H); 7.79(s, 1H); 8.30(s, 1H); 9.15(s, 2H)

MS - ESI: 402 $[MH]^+$

The starting material was prepared as follows:

A mixture of 4-fluoro-2-methyl-5-nitrophenol (4.69g, 27mmol), (prepared as described for the starting material in Example 8), benzyl bromide (3.59ml, 30mmol) and potassium carbonate (7.58g, 55mmol) in DMF (100ml) was heated at 80°C for 4 hours. The reaction mixture was allowed to cool and diluted with water and stirred for 15 minutes. The precipitated product was collected by filtration, washed with water and dried to give 5-benzyloxy-2-fluoro-4-methyl-1-nitrobenzene (6.4g, 89%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.28(s, 3H); 5.22(s, 2H); 7.3-7.5(m, 6H); 7.70(s, 1H)

5-Benzyloxy-2-fluoro-4-methyl-1-nitrobenzene (500mg, 1.9mmol) in methanol (10ml) was added to a suspension of Raney nickel (75mg) and hydrazine hydrate (465ml, 9.5mmol) in methanol (10ml) and heated at reflux. The mixture was maintained under reflux for 15 minutes and then the insoluble materials removed by filtration through diatomaceous earth. The filter pad was washed with methanol and the solvent removed from the filtrate by evaporation to give 5-benzyloxy-2-fluoro-4-methylaniline (440mg, 99%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.02(s, 3H); 4.88(s, 2H); 4.98(s, 2H); 6.44(d, 1H); 6.76(d, 1H); 7.3-7.5(m, 5H)

A mixture of 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (5.0g, mmol), (prepared as described for the starting material in Example 4), acetic anhydride (200ml),

sodium acetate (12g), 10% palladium-on-charcoal catalyst (1.5g) in toluene (100ml) was stirred under an atmosphere of hydrogen for 3 hours. The mixture was filtered and the filtrate was evaporated. The residue was partitioned between a mixture of ethyl acetate (500ml), methanol (20ml) and water (300ml). The organic phase was separated, dried ($MgSO_4$) and the solvent removed by evaporation. The residue was triturated with hexane to give 7-acetoxy-6-methoxy-3,4-dihydroquinazolin-4-one (1.1 g, 27%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.29(s, 3H); 3.84(s, 3H); 7.42(s, 1H); 7.62(s, 1H); 8.1(br s, 1H)

MS - ESI: 235 $[MH]^+$

A mixture of 7-acetoxy-6-methoxy-3,4-dihydroquinazolin-4-one (1.69g, 7.2mmol), thionyl chloride (50ml) and DMF (3 drops) was heated at reflux for 2 hours. The excess thionyl chloride was removed by evaporation and the residue azeotroped with toluene. The residue was partitioned between methylene chloride and saturated aqueous sodium hydrogen carbonate solution. The organic phase was separated, dried ($MgSO_4$) and the solvent removed by evaporation. 5-Benzyloxy-2-fluoro-4-methylaniline (1.8g, 7.8mmol) in isopropanol (50ml) was added to the residue and the mixture heated at reflux for 2 hours. The mixture was allowed to cool, hexane added and the precipitated product collected by filtration to give 7-acetoxy-4-(5-benzyloxy-2-fluoro-4-methylanilino)-6-methoxyquinazoline (1.34g, 43%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.24(s, 3H); 2.38(s, 3H); 4.00(s, 3H); 5.10(s, 2H); 7.1-7.5(m, 7H); 7.75(s, 1H); 8.39(s, 1H); 8.77(s, 1H)

Concentrated aqueous ammonia (25ml) was added to a solution of 7-acetoxy-4-(5-benzyloxy-2-fluoro-4-methylanilino)-6-methoxyquinazoline (1.5g, 3.4mmol) in methanol (100ml). The mixture was stirred at ambient temperature for 30 minutes, and most of the organic volatiles were then removed by evaporation. Further water was added and the precipitate was collected by filtration, washed with water and dried to give 4-(5-benzyloxy-2-fluoro-4-methylanilino)-7-hydroxy-6-methoxyquinazoline (1.2g, 89%) which was used without further characterisation.

A mixture of 4-(5-benzyloxy-2-fluoro-4-methylanilino)-7-hydroxy-6-methoxyquinazoline (440mg, 1mmol), 2-bromoethanol (77ml, 1mmol) and potassium carbonate (150mg, 1.1mmol) in DMF (5ml) was heated at 50°C for 1 hour, further 2-bromoethanol (42ml, 0.6mmol) and potassium carbonate (150mg, 1.1mmol) was added and

the mixture was maintained at 50°C for 2 hours. The reaction mixture was diluted with water, neutralised with 2M hydrochloric acid and extracted with ethyl acetate. The extracts were dried ($MgSO_4$), the solvent removed by evaporation and the residue triturated with ether and hexane to give 4-(5-benzyloxy-2-fluoro-4-methylanilino)-7-(2-hydroxyethoxy)-6-methoxyquinazoline (200mg, 41%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.21(s, 3H); 3.80(t, 2H); 3.94(s, 3H); 4.14(t, 2H); 4.90(s, 1H); 5.10(s, 2H); 7.05-7.2(m, 2H); 7.25-7.45(m, 5H); 7.79(s, 1H); 8.30(s, 1H); 9.20(s, 1H)

Acetic anhydride (55ml, 0.58mmol) was added to a mixture of 4-(5-benzyloxy-2-fluoro-4-methylanilino)-7-(2-hydroxyethoxy)-6-methoxyquinazoline (233mg, 0.52mmol), triethylamine (80ml, 0.57mmol) and 4-(N,N-dimethylamino)pyridine (5mg) in ethyl acetate (50ml). The mixture was stirred for 2 hours at ambient temperature, water was added, the organic layer separated, washed with water and brine and dried ($MgSO_4$). Most of the solvent was removed by evaporation and hexane added. The precipitated product was collected by filtration to give 7-(2-acetoxyethoxy)-4-(5-benzyloxy-2-fluoro-4-methylanilino)-6-methoxyquinazoline (110mg, 43%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.03(s, 3H); 2.22(s, 3H); 3.92(s, 3H); 4.3-4.4(m, 4H); 5.08(s, 2H); 7.13(d, 1H); 7.18(d, 1H); 7.3-7.45(m, 5H); 7.80(s, 1H); 8.30(s, 1H); 9.42(s, 1H)

Example 14

A mixture of 4-(5-benzyloxy-2-fluoro-4-methylanilino)-7-(2-hydroxyethoxy)-6-methoxyquinazoline (150mg, 0.33mmol), (prepared as described for the starting material in Example 13), and 10% palladium-on-charcoal catalyst (20mg) in ethyl acetate (8ml) was stirred under 1 atmosphere of hydrogen at ambient temperature for 18 hours. The catalyst was removed by filtration through diatomaceous earth and most of the solvent removed by evaporation and hexane added to the residue. The resulting precipitate was collected by filtration and dried to give **4-(2-fluoro-5-hydroxy-4-methylanilino)-7-(2-hydroxyethoxy)-6-methoxyquinazoline** (50mg, 41%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.14(s, 3H); 3.80(q, 2H); 3.94(s, 3H); 4.15(t, 2H); 4.90(t, 1H); 6.90(d, 1H); 7.00(d, 1H); 7.17(s, 1H); 7.80(s, 1H); 8.33(s, 1H); 9.32(s, 1H); 9.37(s, 1H)

MS - ESI: 360 $[MH]^+$

Example 15

4-Chloro-6,7-dimethoxyquinazoline hydrochloride (210mg, 0.8mmol), (prepared as described for the starting material in Example 1 but without the aqueous work up), and 4-chloro-2,6-difluoroaniline hydrochloride (177mg, 0.89mmol) in isopropanol (8ml) were heated at reflux for 2 hours. The reaction mixture was then allowed to cool, hexane added and the precipitated product collected by filtration, washed with isopropanol and dried to give **4-(4-chloro-2,6-difluoroanilino)-6,7-dimethoxyquinazoline** hydrochloride (45mg, 16%).

m.p. >250°C

^{1}H NMR Spectrum: ($DMSOd_6$) 4.00(s, 3H); 4.01(s, 3H); 7.35(s, 1H); 7.63(d, 2H); 8.22(s, 1H); 8.81(s, 1H)

MS - ESI: 352 $[MH]^+$

The starting material was prepared as follows:

A solution of 3,5-difluoronitrobenzene (20g,126mmol) and ethyl dichloroacetate (15.8ml, 129mmol) in DMF (60ml) was added to potassium t-butoxide (31.8g, 283mmol) in DMF (500ml) at -25°C over 30 minutes. The mixture was stirred for 15 minutes at -25°C then poured on to a mixture of ice (600g) and 2M hydrochloric acid (500ml). The aqueous mixture was extracted with ethyl acetate, the combined extracts were washed with water and sodium hydrogen carbonate solution and dried ($MgSO_4$) and the solvent removed by evaporation to give ethyl 2-chloro-2-(2,6-difluoro-4-nitrophenyl)ethanoate (34g, 97%).

^{1}H NMR Spectrum: ($DMSOd_6$) 1.15(t, 3H); 4.1-4.3(m, 2H); 6.44(s, 1H); 8.17(d, 2H)

2.5M Aqueous sodium hydroxide solution (300ml) was added over 5 minutes to a solution of ethyl 2-chloro-2-(2,6-difluoro-4-nitrophenyl)ethanoate (34.86g 125mmol) in ethanol (300ml) at 5°C such that the reaction temperature was kept below 25°C. The mixture was cooled to 18°C and 30% hydrogen peroxide (40ml) was added. The mixture was stirred at 20°C for 2.5 hours. Sodium sulphite was added until the peroxide test was negative, the mixture was acidified to pH1 with 6M hydrochloric acid and extracted with ethyl acetate. The organic extracts were back extracted with saturated aqueous sodium hydrogen carbonate solution, the aqueous extracts were acidified with concentrated hydrochloric acid and extracted with ethyl acetate. The extracts were dried ($MgSO_4$) and the solvent removed by evaporation to give 2,6-difluoro-4-nitrobenzoic acid (4.89g, 19%).

^{1}H NMR Spectrum: ($DMSOd_6$) 8.14(d, 2H)

A mixture of 2,6-difluoro-4-nitrobenzoic acid (2.5g, 12mmol) and 10% palladium-on-charcoal catalyst (500mg) in ethanol (150ml) was stirred under 1 atmosphere of hydrogen at ambient temperature for 3 hours. The catalyst was removed by filtration through diatomaceous earth, the filter pad washed with ethanol and the solvent removed by evaporation to give 4-amino-2,6-difluorobenzoic acid (3.8g, 91%).

^{1}H NMR Spectrum: ($DMSOd_6$) 6.12(d, 2H); 6.28(s, 2H)

MS - ESI: 174 $[MH]^+$

A solution of sodium nitrite (220mg, 3.18mmol) in concentrated sulphuric acid (2ml) was added over 15 minutes to a suspension of 4-amino-2,6-difluorobenzoic acid (550mg, 3.18mmol) in acetic acid (6ml) at 15°C. The mixture was stirred at 15°C for 1 hour then heated to 90°C and poured into a solution of copper(I)chloride (800mg) in concentrated hydrochloric acid (11ml) at 95°C. The mixture was heated at 95°C for 45 minutes and then allowed to cool. The mixture was diluted with water, extracted with ethyl acetate, the organic extracts dried ($MgSO_4$) and the solvent removed by evaporation to give 4-chloro-2,6-difluorobenzoic acid (600mg, 98%)

^{1}H NMR Spectrum: ($DMSOd_6$) 7.50(d, 2H)

MS - ESI: 192 $[MH]^-$

4-Chloro-2,6-difluorobenzoic acid (500mg, 2.6mmol) was added to a solution of diphenylphosphoryl azide (737mg, 3mmol) in t-butanol (8ml) followed by triethylamine (477ml, 6mmol) and the mixture heated at reflux for 2 hours. The reaction mixture was allowed to cool and the solvent removed by evaporation. The residue was dissolved in ethyl acetate, washed with water, dried ($MgSO_4$) and purified by column chromatography eluting with increasingly polar mixtures of methylene chloride, hexane and methanol (1/1/0 to 95/0/5) to give N-t-butoxycarbonyl-4-chloro-2,6-difluoroaniline (170mg, 25%).

^{1}H NMR Spectrum: ($DMSOd_6$) 1.41(s, 9H); 7.39(d, 2H); 8.86(s, 1H)

A saturated solution of hydrogen chloride in ethyl acetate (4ml) was added to N-t-butoxycarbonyl-4-chloro-2,6-difluoroaniline (330mg, 1.3mmol) and the mixture stirred at ambient temperature for 2 hours. The precipitate was collected by filtration to give 4-chloro-2,6-difluoroaniline hydrochloride (140mg, 56%).

^{1}H NMR Spectrum: ($DMSOd_6$) 6.12(s, 2H); 7.08(d, 2H)

Example 16

A mixture of 6-methoxy-7-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one (370mg, 1.16mmol), thionyl chloride (5ml) and DMF (3 drops) was heated at reflux for 2 hours and allowed to cool. The excess thionyl chloride was removed by evaporation and the residue was azeotroped with toluene. A solution of 2-fluoro-5-hydroxy-4-methylaniline (220mg, 1.56mmol) in isopropanol (10ml) was added to the solid residue and the mixture was heated at reflux for 2 hours and then allowed to cool. The resulting precipitate was collected by filtration, washed with methylene chloride and dried. The impure solid product was treated with aqueous sodium hydrogen carbonate, to give a suspension and the product was recollected by filtration and purified by column chromatography eluting with methylene chloride/methanol (9/1) to give **4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline** (140mg, 27%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.0(m, 2H); 2.15(s, 3H); 2.35-2.55(m, 6H); 3.55(br t, 4H); 3.90(s, 3H); 4.20(t, 2H); 6.85-6.95(m, 2H); 7.10(s, 1H); 7.75(s, 1H); 8.25(s, 1H); 9.20(s, 2H)

Elemental analysis:	Found	C 62.2	H 6.1	N 12.4
$C_{23}H_{27}N_4O_4F$	Requires	C 62.4	H 6.2	N 12.7%

The starting material was prepared as follows:

Sodium hydride (400mg of an 80% suspension in paraffin oil, 13.3mmol) was added to a solution of phenol (1.26g, 13.3mmol) in dry 1-methyl-2-pyrrolidinone (20ml) and the mixture stirred for 10 minutes. 7-Benzyloxy-4-chloro-6-methoxyquinazoline (1.6g, 5.3mmol), (prepared as described for the starting material in Example 4 but with an aqueous work up), was then added and the reaction mixture heated at 110°C for 2 hours. The mixture was allowed to cool, water was added and the mixture extracted with ethyl acetate (3 x 100ml). The combined extracts were then washed with 2M sodium hydroxide solution, water and brine. Removal of the solvent under reduced pressure gave 7-benzyloxy-6-methoxy-4-phenoxyquinazoline (1.6g, 84%) as a yellowish solid.

^{1}H NMR Spectrum: ($DMSOd_6$) 3.98(s, 3H); 5.37(s, 2H); 7.25-7.6(m, 11H); 7.60(s, 1H); 8.54(s, 1H)

MS - ESI: 300 $[MH]^+$

7-Benzyloxy-6-methoxy-4-phenoxyquinazoline (160mg, 0.44mmol) in TFA (3ml) was heated at reflux for 30 minutes. The solvent was removed by evaporation and the residue treated with aqueous sodium hydrogen carbonate solution. The precipitated product was collected by filtration, washed with water and dried to give 7-hydroxy-6-methoxy-4-phenoxyquinazoline (105mg, 88%).

^{1}H NMR Spectrum: ($DMSOd_6$) 4.00(s, 3H); 7.20(s, 1H); 7.25-7.35(m, 3H); 7.4-7.55(m, 2H); 7.58(s, 1H); 10.73(s, 1 H)

MS - ESI: 269 $[MH]^+$

4-(3-Chloropropyl)morpholine (0.9g, 4.5mmol), (J. Am. Chem. Soc. 1945, 67, 736, 174mg, 1.06mmol), was added to 7-hydroxy-6-methoxy-4-phenoxyquinazoline (1.0g, 3.7mmol), potassium carbonate (2.6g, 18.8mmol) in DMF (30ml). The mixture was heated at 110°C for 4 hours and then allowed to cool. The solids were removed by filtration, and the volatiles were removed from the filtrate by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol, (96/4) to give 6-methoxy-7-(3-morpholinopropoxy)-4-phenoxyquinazoline (1.0g, 68%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.0 (m, 2H); 2.35-2.55(m, 6H); 3.6(br s, 4H); 3.95(s, 3H); 4.25(t, 2H); 7.25-7.35(m, 3H); 7.40(s, 1H); 7.45-7.55(m, 2H); 7.55(s, 1H); 8.50(s, 1H)

MS - ESI: 396 $[MH]^+$

A mixture of 6-methoxy-7-(3-morpholinopropoxy)-4-phenoxyquinazoline (980mg, 2.48mmol) and 2M hydrochloric acid (25ml) was heated at 100°C for 2 hours and allowed to cool. The solution was basified with solid sodium hydrogen carbonate, and the product was extracted with methylene chloride. The organic phase was passed through phase separating paper and the solvent removed by evaporation to give 6-methoxy-7-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one (750mg, 95%) as a pale brown solid which was used without further purification.

MS - ESI: 320 $[MH]^-$

Example 17

A mixture of 6-methoxy-7-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one (370mg, 1.16mmol), (prepared as described for the starting material in Example 16), thionyl chloride (5ml) and DMF (3 drops) was heated at reflux for 2 hours and allowed to cool. The

excess thionyl chloride was removed by evaporation and the residue was azeotroped with toluene. A solution of 4-chloro-2-fluoro-5-hydroxyaniline (210mg, 1.30mmol), (as described in EP 61741 A2), in isopropanol (10ml) was added to the solid residue and the mixture was heated at reflux for 2 hours and then allowed to cool. The mixture was diluted with acetone and the precipitate collected by filtration. The crude solid product was suspended in aqueous sodium hydrogen carbonate, collected again by filtration and purified by column chromatography eluting with methylene chloride/methanol/ammonia (100/10/1) to give **4-(4-chloro-2-fluoro-5-hydroxyaniline)-6-methoxy-7-(3-morpholinopropoxy)quinazoline** (160mg, 30%).

^{1}H NMR Spectrum: (DMSOd_6) 2.0(m, 2H); 2.35-2.55(m, 6H); 3.6(t, 4H); 3.95(s, 3H); 4.15(t, 2H); 7.15(m, 2H); 7.35(d, 1H); 7.75(s, 1H); 8.35(s, 1H); 9.35(s, 1H); 10.15(s, 1H)

MS - ESI: 463 $[MH]^+$

Elemental analysis:	Found	C 57.1	H 5.3	N 12.0
$C_{22}H_{24}N_4O_4FCl$	Requires	C 57.1	H 5.2	N 12.1%

Example 18

1M Ethereal hydrogen chloride (3.1ml, 3.1mmol) was added to 4-chloro-6-methoxy-7-(2-methylthioethoxy)quinazoline (0.8g, 2.8mmol) and 2-fluoro-5-hydroxy-4-methylaniline (0.44g, 3.12mmol), (prepared as described for the starting material in Example 8), in isopropanol (25ml). The mixture was heated at reflux for 2 hours, then allowed to cool. The resulting suspension was diluted with acetone and the precipitate collected by filtration and purified by column chromatography eluting with methylene chloride/methanol/ammonia (100/8/1) to give **4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(2-methylthioethoxy)quinazoline** (580mg, 52%).

^{1}H NMR Spectrum: (DMSOd_6) 2.15 (s, 3H); 2.23(s, 3H); 2.94 (t, 2H); 3.95(s, 3H); 4.33(t, 2H); 6.92(d, 1H); 7.00(d, 1H); 7.20(s, 1H); 7.83(s, 1H); 8.38(s, 1H); 9.30(s, 1H); 9.33(s, 1H)

MS - ESI: 390 $[MH]^+$

Elemental analysis:	Found	C 57.4	H 5.1	N 10.5
$C_{19}H_{20}N_3O_3FS$ 0.5H_2O	Requires	C 57.3	H 5.3	N 10.5%

The starting material was prepared as follows:

2-Chloroethyl methyl sulphide (1.2g, 10.9mmol) was added to 7-hydroxy-6-methoxy-4-phenoxyquinazoline (2.25g, 8.4mmol), (prepared as described for the starting material in Example 16), and potassium carbonate (6.0g, 43.4mmol) in DMF (70ml). The mixture was heated at 110°C for 4 hours and allowed to cool. The mixture was filtered, and the volatiles were removed from the filtrate by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (96/4) to give 6-methoxy-7-(2-methylthioethoxy)-4-phenoxyquinazoline (1.55g, 54%).

A mixture of 6-methoxy-7-(2-methylthioethoxy)-4-phenoxyquinazoline (1.5g, 4.4mmol) and 2M hydrochloric acid (25ml) was heated at 100°C for 2 hours. The mixture was allowed to cool, and methylene chloride was added with stirring to give a white precipitate. The precipitate was collected by filtration, washed with water and methylene chloride and dried to give 6-methoxy-7-(2-methylthioethoxy)-3,4-dihydroquinazolin-4-one hydrochloride (1.1g, 83%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.22(s, 3H); 2.94(t, 2H); 3.92(s, 3H); 4.30(t, 2H); 7.36(s, 1H); 7.49(s, 1H); 8.80(s, 1H)

MS - ESI: 267 $[MH]^+$

Elemental analysis:	Found	C 46.4	H 5.2	N 8.8
$C_{12}H_{14}N_2O_3S$ 1HCl	Requires	C 47.6	H 5.0	N 9.3%

A mixture of 6-methoxy-7-(2-methylthioethoxy)-3,4-dihydroquinazolin-4-one (1.07g, 4.0mmol), thionyl chloride (20ml) and DMF (4 drops) was heated at reflux for 2 hours and then allowed to cool. The excess thionyl chloride was removed by evaporation and the residue was azeotroped with toluene. The solid residue was partitioned between aqueous sodium hydrogen carbonate and methylene chloride, the organic phase was separated and washed with brine. The organic phase was passed through phase separating paper, and the solvent removed by evaporation to give 4-chloro-6-methoxy-7-(2-methylthioethoxy)quinazoline (810mg, 71%).

MS - ESI: 285 $[MH]^+$

Examples 19 and 20

3-Chloroperoxybenzoic acid (wet, 50-60%, 500mg), (3-CPBA), was added to a solution of 4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(2-

methylthioethoxy)quinazoline (485mg, 1.2mmol), (prepared as described for Example 18), in methylene chloride (90ml) and DMA (6ml). After 2 hours, 2 further portions of 3-CPBA were added (total 160mg). The mixture was checked for remaining oxidant, and the volatiles were removed by evaporation. The 2 products were separated by column chromatography eluting with methylene chloride/methanol (9/1) to give **4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(2-(methylsulphonyl)ethoxy)quinazoline** (94mg, 19%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.15(s, 3H); 3.18(s, 3H); 3.70(t, 2H); 3.95(s, 3H); 4.50(t, 2H); 6.92(d, 1H); 6.97(d, 1H); 7.25(s, 1H); 7.83(s, 1H); 8.33(s, 1H); 9.27(s, 1H); 9.30(s, 1H)

MS - ESI: 422 $[MH]^+$

Elemental analysis:	Found	C 53.0	H 4.9	N 9.7
$C_{19}H_{20}N_3O_5SF$ $0.5H_2O$	Requires	C 53.0	H 4.9	N 9.8%

and **4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(2-(methylsulphinyl)ethoxy)quinazoline** (120mg, 25%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.16(s, 3H); 2.69(s, 3H); 3.15(m, 1H); 3.37(m, 1H); 3.94(s, 3H); 4.53(m, 2H); 6.92(d, 1H); 6.97(d, 1H); 7.83(s, 1H); 8.32(s, 1H); 9.27(s, 1H); 9.30(s, 1H)

MS - ESI: 406 $[MH]^+$

Elemental analysis:	Found	C 55.5	H 5.0	N 10.0
$C_{19}H_{20}N_3O_4SF$	Requires	C 56.0	H 5.4	N 10.3%

Example 21

A mixture of 6-methoxy-7-(2-(pyrrolidin-1-yl)ethoxy)-3,4-dihydroquinazolin-4-one (260mg, 0.90mmol), thionyl chloride (5ml) and DMF (2 drops) was heated at reflux for 45 minutes and allowed to cool. The excess thionyl chloride was removed by evaporation, and the residue azeotroped with toluene. A solution of 4-chloro-2-fluoro-5-hydroxyaniline (160mg, 1.0mmol), (as described in EP 61741 A2), in isopropanol (5ml) was added to the residue and the mixture was heated at reflux for 1 hour and then allowed to cool. The mixture was diluted with acetone, and the solid product collected by filtration, washed with acetone and dried to give **4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-(pyrrolidin-1-yl)ethoxy)quinazoline** hydrochloride(381mg, 83%).

^{1}H NMR Spectrum: ($DMSOd_6$) 1.85-2.15(br m, 4H); 3.20(br s, 2H); 3.5-3.7(br m, 4H); 4.05(s, 3H); 4.65(t, 2H); 7.20(d, 1H); 7.5(m, 2H); 8.45(s, 1H); 8.80(s, 1H); 10.5(br s, 1H); 11.35(br s, 1H); 11.75(br s, 1H)

MS - ESI: 433 $[MH]^-$

Elemental analysis:	Found	C 49.7	H 5.0	N 10.6
$C_{21}H_{22}N_4O_3ClF$ 2HCl 0.17isopropanol	Requires	C 50.1	H 5.0	N 10.9%

The starting material was prepared as follows:

1-(2-Chloroethyl)pyrrolidine hydrochloride (1.27g, 7.5mmol) was added to 7-hydroxy-6-methoxy-4-phenoxyquinazoline (1.0g, 3.7mmol), (prepared as described for the starting material in Example 16), and potassium carbonate (3.9g, 28.3mmol) in DMF (30ml). The mixture was heated at 110°C for 4 hours and allowed to cool. The mixture was filtered, and the volatiles were removed from the filtrate by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol/ammonia, (100/8/1) to give an oil which was triturated with ethyl acetate to give 6-methoxy-4-phenoxy-7-(2-(pyrrolidin-1-yl)ethoxy)quinazoline (200mg, 15%) as a white solid.

^{1}H NMR Spectrum: ($DMSOd_6$) 1.65(m, 4H); 2.55(m, 4H); 2.85(t, 2H); 3.95(s, 3H); 4.25(t, 2H); 7.30(m, 3H); 7.38(s, 1H); 7.50(m, 2H); 7.55(s, 1H); 8.5(s, 1H)

MS - ESI: 366 $[MH]^-$

A mixture of 6-methoxy-4-phenoxy-7-(2-(pyrrolidin-1-yl)ethoxy)quinazoline (565mg, 1.55mmol) and 2M hydrochloric acid (5ml) was heated at 90°C for 90 minutes and allowed to cool. The solution was neutralised with aqueous sodium hydrogen carbonate, and the water removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol/ammonia (100/8/1) to give 6-methoxy-7-(2-(pyrrolidin-1-yl)ethoxy)-3,4-dihydroquinazolin-4-one (480mg). This material was used without further characterisation.

Example 22

1M Ethereal hydrogen chloride (0.72ml, 0.72mmol) was added to 4-chloro-6-methoxy-7-(2-morpholinoethoxy)quinazoline (210mg, 0.65mmol) and 4-chloro-2-fluoro-5-hydroxyaniline (115mg, 0.71mmol), (as described in EP 61741 A2), in isopropanol (5ml) and

the mixture heated at reflux for 2 hours and then allowed to cool. The mixture was diluted with acetone and the precipitated product collected by filtration. The impure product was dissolved in methylene chloride/ammonia (100/1) and methanol, the insolubles removed by filtration and the volatiles were removed from the filtrate by evaporation. The solid residue was washed with water and dried to give **4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-morpholinoethoxy)quinazoline** (60mg, 21%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.45-2.60(m, 4H); 2.78(t, 2H); 3.58(t, 4H); 3.94(s, 3H); 4.26(t, 2H); 7.17(d, 1H); 7.23(s, 1H); 7.38(d, 1H); 7.79(s, 1H); 8.37(s, 1H); 9.43(s, 1H); 10.17(s, 1H)

MS - ESI: 449 $[MH]^+$

Elemental analysis:	Found	C 53.5	H 5.2	N 11.6
$C_{21}H_{22}N_4O_4ClF\ 1.25H_2O$	Requires	C 53.5	H 5.3	N 11.9%

The starting material was prepared as follows:

1,2-Dibromoethane (1.6ml, 18.6mmol) was added to 7-hydroxy-6-methoxy-4-phenoxyquinazoline (0.5g, 1.86mmol), (prepared as described for the starting material in Example 16), and potassium carbonate (1.2g, 8.7mmol) in DMF (60ml) and the mixture was heated at 85°C for 2 hours, and was then allowed to cool. The insolubles were removed by filtration, and the volatiles were removed from the filtrate by evaporation to give a residue which was purified by column chromatography eluting with methylene chloride/methanol (97/3) to give 7-(2-bromoethoxy)-6-methoxy-4-phenoxyquinazoline (440mg, 63%).

MS - ESI: 375 $[MH]^+$

A mixture of morpholine (8ml) and 7-(2-bromoethoxy)-6-methoxy-4-phenoxyquinazoline (450mg, 1.2mmol) was stirred at ambient temperature for 3 hours. The excess morpholine was removed by evaporation and the residue was partitioned between aqueous sodium hydrogen carbonate and methylene chloride. The organic phase was separated, passed through phase separating paper and the solvent removed by evaporation. Trituration of the residue with isohexane gave a solid which was collected by filtration and dried to give 6-methoxy-7-(2-morpholinoethoxy)-4-phenoxyquinazoline (410mg, 90%).

MS - ESI: 382 $[MH]^+$

A mixture of 6-methoxy-7-(2-morpholinoethoxy)-4-phenoxyquinazoline (400mg, 1.05mmol) and 2M hydrochloric acid (10ml) was heated at 100°C for 2 hours and then

allowed to cool. The mixture was neutralised with solid sodium hydrogen carbonate. Addition of methylene chloride gave a white precipitate which was collected by filtration, washed with acetone and dried to give 6-methoxy-7-(2-morpholinoethoxy)-3,4-dihydroquinazolin-4-one (320mg, 100%).

MS - ESI: 306 $[MH]^+$

A mixture of 6-methoxy-7-(2-morpholinoethoxy)-3,4-dihydroquinazolin-4-one (310mg, 1.02mmol), thionyl chloride (10ml) and DMF (2 drops) was heated at reflux for 4 hours and allowed to cool. Excess thionyl chloride was removed by evaporation and the residue was azeotroped with toluene. The residue was partitioned between aqueous sodium hydrogen carbonate and methylene chloride. The organic layer was separated, washed with brine and filtered through phase separating paper. The volatiles were removed by evaporation and the residue purified by column chromatography eluting with methylene chloride/methanol (96/4) to give 4-chloro-6-methoxy-7-(2-morpholinoethoxy)quinazoline (225mg, 68%).

MS - ESI: 324 $[MH]^+$

Example 23

1M Ethereal hydrogen chloride (0.34ml, 0.34mmol) was added to 4-chloro-6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline (115mg, 0.34mmol) and 4-chloro-2-fluoro-5-hydroxyaniline (61mg, 0.38mmol), (as described in EP 61741 A2), in isopropanol (5ml) and the mixture was heated at reflux for 90 minutes and then allowed to cool. The mixture was diluted with acetone, and the solid product collected by filtration. The impure solid was treated with methylene chloride/methanol/ammonia (100/8/1) (5ml), and water was added. The reprecipitated product was collected by filtration and dried to give **4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline** (32%).

^1H NMR Spectrum: ($DMSOd_6$) 2.28(s, 3H); 2.53(m, 4H); 2.60(m, 4H); 2.81(t, 2H); 3.95(s, 3H); 4.25(t, 2H); 7.18(d, 1H); 7.20(s, 1H); 7.36(d, 1H); 7.80(s, 1H); 8.35(s, 1H); 9.43(s, 1H); 10.18(br s, 1H)

MS - ESI: 462 $[MH]^+$

Elemental analysis:	Found	C 54.1	H 5.3	N 14.0
$C_{22}H_{25}N_5O_3ClF\ 1.3H_2O$	Requires	C 54.4	H 5.7	N 14.4%

The starting material was prepared as follows:

A mixture of 1-methylpiperazine (7ml) and 7-(2-bromoethoxy)-6-methoxy-4-phenoxyquinazoline (1.0g, 2.67mmol), (prepared as described for the starting material in Example 22), was stirred at ambient temperature for 5 hours. The excess 1-methylpiperazine was removed by evaporation and the residue was partitioned between aqueous sodium hydrogen carbonate and methylene chloride. The organic phase was separated, passed through phase separating paper and the volatiles removed by evaporation to give 6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)-4-phenoxyquinazoline (970mg, 92%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.21(s, 3H); 2.38(m, 4H); 2.58(m, 4H); 2.85(t, 2H); 4.02(s, 3H); 4.35(t, 2H); 7.39(m, 3H); 7.46(s, 1H); 7.55(m, 2H); 7.61(s, 1H); 8.59(s, 1H)

A mixture of 6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)-4-phenoxyquinazoline (960mg, 2.4mmol) and 2M hydrochloric acid (20ml) was heated at 95°C for 2 hours and allowed to cool. The solution was basified with solid sodium hydrogen carbonate, the water removed by evaporation and the residue azeotroped with toluene. The residue was washed exhaustively with methylene chloride, the washings were combined, insolubles removed by filtration and the solvent removed by evaporation to give 6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)-3,4-dihydroquinazolin-4-one (500mg, 66%).

MS - ESI: 319 $[MH]^-$

A mixture of 6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)-3,4-dihydroquinazolin-4-one (500mg, 1.57mmol), thionyl chloride (20ml) and DMF (3 drops) was heated at reflux for 3 hours and allowed to cool. The excess thionyl chloride was removed by evaporation, and the residue was azeotroped with toluene. The residue was treated with aqueous sodium hydrogen carbonate and the product was extracted with methylene chloride. The combined extracts were washed with brine, passed through phase separating paper and the solvent removed by evaporation to give 4-chloro-6-methoxy-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline (120mg, 23%).

MS - ESI: 337 $[MH]^-$

Example 24

A mixture of 6-methoxy-7-(2-piperidinoethoxy)-3,4-dihydroquinazolin-4-one (440mg, 1.45mmol), thionyl chloride (15ml) and DMF (3 drops) was heated at reflux for 3 hours then allowed to cool. The excess thionyl chloride was removed by evaporation and the residue was azeotroped with toluene to give a crude 4-chloro-6-methoxy-7-(2-piperidinoethoxy)quinazoline hydrochloride (640mg).

A sample (320mg, 0.89mmol) of this material was added to a solution of 4-chloro-2-fluoro-5-hydroxyquinazoline (130mg, 0.8mmol), (as described in EP 61741 A2), in isopropanol (10ml) and the mixture heated at reflux for 90 minutes and allowed to cool. The mixture was diluted with acetone, and the precipitated product was collected by filtration and dried. The residue was purified by column chromatography eluting with methylene chloride/methanol/ammonia, (100/8/1). The pure product was dissolved in acetone and 1M ethereal hydrogen chloride (1ml, 1mmol) added. The resulting precipitate was collected by filtration and dried to give **4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-piperidinoethoxy)quinazoline** hydrochloride (137mg, 32%).

^{1}H NMR Spectrum: ($DMSOd_6$) 1.75(br m, 6H); 4.00(s, 3H); 4.65(t, 2H); 7.15(d, 1H); 7.35(s, 1H); 7.42(d, 1H); 8.15(s, 1H); 8.60(s, 1H); 10.4(s, 1H); 10.6(br s, 2H)

MS - ESI: 447 $[MH]^+$

Elemental analysis:	Found	C 51.0	H 5.4	N 10.6
$C_{22}H_{24}N_4O_3ClF$ 2HCl	Requires	C 50.8	H 5.0	N 10.8%

The starting material was prepared as follows:

1-(2-Chloroethyl)piperidine hydrochloride (0.83g, 4.5mmol) was added to 7-hydroxy-6-methoxy-4-phenoxyquinazoline (1.0g, 3.73mmol), (prepared as described for the starting material in Example 16), and potassium carbonate (2.6g, 18.8mmol) in DMF (30ml), and the mixture heated at 110°C for 2.5 hours and allowed to cool. The insolubles were removed by filtration, and the volatiles were removed from the filtrate by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (9/1) to give 6-methoxy-4-phenoxy-7-(2-piperidinoethoxy)quinazoline (1.2g, 85%).

^{1}H NMR Spectrum: ($DMSOd_6$) 1.38(m, 2H); 1.50(m, 4H); 2.4-2.5(m, 4H); 2.75(t, 2H); 3.95(s, 3H); 4.27(t, 2H); 7.30(m, 3H); 7.40(s, 1H); 7.46(m, 2H); 7.54(s, 1H); 8.52(s, 1H)

MS - ESI: 380 $[MH]^+$

A mixture of 6-methoxy-4-phenoxy-7-(2-piperidinoethoxy)quinazoline (1.15g, 3.0mmol) and 2M hydrochloric acid (20ml) was heated at 90°C for 2 hours and allowed to cool. The mixture was neutralised with solid sodium hydrogen carbonate and extracted with methylene chloride. The organic phase was separated, passed through phase separating paper and the volatiles removed by evaporation to give a solid product (230mg). The aqueous phase was adjusted to pH10, the resulting precipitate was collected by filtration, washed with water and dried to give a second crop of product (220mg). The products were combined to give 6-methoxy-7-(2-piperidinoethoxy)-3,4-dihydroquinazolin-4-one (450mg, 50%).

MS - ESI: 304 $[MH]^+$

Example 25

A mixture of 7-(2-cyclopentyloxyethoxy)-6-methoxy-3,4-dihydroquinazolin-4-one (260mg, 0.85mmol), thionyl chloride (5ml) and DMF (2 drops) was heated at reflux for 2 hours and allowed to cool. The excess thionyl chloride was removed by evaporation, and the residue was azeotroped with toluene. To the residue was added a solution of 4-chloro-2-fluoro-5-hydroxyaniline (140mg, 0.87mmol), (as described in EP 61741 A2), in isopropanol (5ml) and the mixture was heated at reflux for 1 hour and allowed to cool. The suspension was diluted with acetone, and the precipitate collected by filtration. The crude product was dissolved in methylene chloride/methanol/ammonia (100/8/1, 2ml), the insoluble material removed by filtration and the solvent removed from the filtrate by evaporation. The residue was dissolved in acetone, 1M ethereal hydrogen chloride (1ml, 1mmol) added and the resultant precipitate collected by filtration and dried to give **4-(4-chloro-2-fluoro-5-hydroxyanilino)-7-(2-cyclopentyloxyethoxy)-6-methoxyquinazoline** hydrochloride (50mg, 12%).

^{1}H NMR Spectrum: ($DMSOd_6$) 1.5-1.75(m, 8H); 3.75(m, 2H); 3.9-4.1(m, 1H); 4.00(s, 3H); 4.80(t, 2H); 7.20(m, 1H); 7.35(s, 1H); 7.50(d, 1H); 8.25(s, 1H); 8.75(s, 1H); 10.5(br s, 1H); 11.4(br s, 1H)

MS - ESI: 448 $[MH]^+$

Elemental analysis: Found C 54.1 H 4.8 N 8.5

$C_{22}H_{23}N_3O_4ClF$ 1HCl 0.1H_2O Requires C 54.4 H 5.0 N 8.6%

The starting material was prepared as follows:

2-Cyclopentyloxyethanol (4.3g, 33.1mmol) in pyridine (18ml) was added dropwise to a solution of 3-toluenesulphonyl chloride (6.8g, 35.7mmol) in pyridine (27ml) at 5°C. The mixture was allowed to warm to ambient temperature, and stirred overnight. The mixture was poured onto ice containing concentrated hydrochloric acid (46ml) and the product was extracted with ether. The organic phase was washed with 2M hydrochloric acid, dried ($MgSO_4$) and the solvent removed by evaporation to give 2-cyclopentyloxyethyl 4-toluenesulphonate (6.9g, 73%) which was used without further purification.

7-Hydroxy-6-methoxy-4-phenoxyquinazoline (1.11g, 4.2mmol), (prepared as described for the starting material in Example 16), in DMF (17ml) was added to a suspension of sodium hydride (184 mg of a 60% suspension in oil, 4.6mmol) in DMF (3ml). The mixture was stirred until evolution of gas ceased, and then 2-cyclopentyloxyethyl 4-toluenesulphonate (1.25g, 4.45mmol) in DMF (3ml) was added dropwise. The mixture was stirred at ambient temperature for 30 minutes, then heated at 60°C for 2 hours, and then at 80°C for a further 4 hours before being allowed to cool. The mixture was poured onto ice and extracted with methylene chloride. The combined extracts were washed with brine, passed through phase separating paper and the solvent removed by evaporation. The residue was purified by column chromatography eluting with ethyl acetate. The purified product was triturated with isohexane to give 7-(2-cyclopentyloxyethoxy)-6-methoxy-4-phenoxyquinazoline (480mg, 28%).

^{1}H NMR Spectrum: ($DMSOd_6$) 1.2-1.7m, (8H); 3.77(m, 2H); 3.95(s, 3H); 4.0(m, 1H); 4.25(m, 2H); 7.30(m, 3H); 7.38(s, 1H); 7.45(m, 2H); 7.55(s, 1H); 8.50 (s, 1H)

MS - ESI: 381 $[MH]^+$

A mixture of 7-(2-cyclopentyloxyethoxy)-6-methoxy-4-phenoxyquinazoline (470mg, 1.2mmol) and 2M hydrochloric acid (6ml) was heated at 90°C for 2 hours and allowed to cool. Water was added, and the product was extracted with methylene chloride. The combined extracts were washed with aqueous sodium hydrogen carbonate, passed through phase separating paper and the solvent was removed by evaporation. Trituration with ethyl acetate give 7-(2-cyclopentyloxyethoxy)-6-methoxy-3,4-dihydroquinazolin-4-one (270mg, 74%).

MS - ESI: 305 $[MH]^+$

Example 26

1M Aqueous sodium hydroxide solution (4ml, 4mmol) was added to a solution of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline (820mg, 2.2mmol) in methanol (20ml) and the mixture stirred for 1 hour at ambient temperature. Concentrated hydrochloric acid (0.8ml) was added, the volatiles removed by evaporation and the residue purified by column chromatography eluting with methylene chloride/methanol (60/40) to give **4-(2-fluoro-5-hydroxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline** (313mg, 45%).

m.p. 276-278°C

^{1}H NMR Spectrum: ($DMSOd_6$; CF_3COOD) 2.18(s, 3H); 4.0(s, 3H); 6.88(d, 1H); 7.12(d, 1H); 7.26(s, 1H); 8.08(s, 1H); 8.76(s, 1H)

MS - ESI: 316 $[MH]^+$

Elemental analysis:	Found	C 54.4	H 4.4	N 11.5
$C_{16}H_{14}N_3O_3F$ 1HCl 0.1H_2O	Requires	C 54.4	H 4.3	N 11.9%

The starting material was prepared as follows:

A solution of (4-fluoro-2-methyl-5-nitrophenyl) methyl carbonate (3g, 13mmol), (prepared as described in EP 0307777 A2), in ethanol (60ml) containing platinum(IV)oxide (300mg) was stirred under hydrogen at 0.3 atmosphere for 1 hour. After filtration and evaporation of the solvent, 2-fluoro-5-methoxycarbonyloxy-4-methylaniline was isolated as a solid (2.6g, 100%).

^{1}H NMR Spectrum: ($CDCl_3$) 2.07(s, 3H); 3.87(s, 3H); 6.52(d, 1H); 6.80(d, 1H)

A solution of 7-benzyloxy-4-chloro-6-methoxyquinazoline (800mg, 2.6mmol), (prepared as described for the starting material in Example 4 but with an aqueous work up), and 2-fluoro-5-methoxycarbonyloxy-4-methylaniline (570mg, 2.89 mmol) in isopropanol (20ml) was refluxed for 2 hours. After cooling to ambient temperature, the solid was filtered, washed with isopropanol and dried under vacuum to give 7-benzyloxy-4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-6-methoxyquinazoline (1.0g, 77%).

^{1}H NMR Spectrum: ($DMSOd_6$; CF_3COOD) 2.2(s, 3H); 3.85(s, 3H); 4.0(s, 3H); 5.37(s, 2H); 7.3-7.55(m, 8H); 8.13(s, 1H); 8.86(s, 1H)

MS - ESI: 464 $[MH]^-$

A solution of 7-benzyloxy-4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-6-methoxyquinazoline (700mg, 1.4mmol) in DMF (10ml), methanol (10ml) and trichloromethane (10ml) containing 10% palladium-on-charcoal (100 mg) was stirred under 1 atmosphere of hydrogen for 1 hour. After filtration and evaporation of the solvent, the residue was triturated with ether, filtered and dried under vacuum to give 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline (570mg, 98%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.23(s, 3H); 3.87(s, 3H); 4.01(s, 3H); 7.37(s, 1H); 7.45(d, 1H); 7.5(d, 1H); 8.20(s, 1H); 8.77(s, 1H); 11.35(s, 1H); 11.79(s, 1H)

MS - ESI: 374 $[MH]^+$

Example 27

A solution of 4-chloro-7-(2-methoxyethoxy)quinazoline hydrochloride (275mg, 1mmol) and 2-fluoro-5-hydroxy-4-methylaniline (170mg, 1.2mmol), (prepared as described for the starting material in Example 8), in 2-pentanol (5ml) was heated at reflux for 2 hours. The mixture was allowed to cool and the precipitate was collected by filtration, washed with isopropanol and ether, and dried under vacuum at 70°C to give **4-(2-fluoro-5-hydroxy-4-methylanilino)-7-(2-methoxyethoxy)quinazoline** hydrochloride(295mg, 78%) as a cream solid.

m.p. 217-220°C

^{1}H NMR Spectrum: ($DMSOd_6$) 2.17(s, 3H); 3.36(s, 3H); 3.75(t, 2H); 4.34(t, 2H); 6.89(d, 1H); 7.11(d, 1H); 7.30(d, 1H); 7.52(dd, 1H); 8.66(d, 1H); 8.82(s, 1H); 9.68(s, 1H); 11.40(s, 1H)

MS - ESI: 344 $[MH]^+$

Elemental analysis:	Found	C 56.8	H 5.2	N 11.1	
$C_{18}H_{18}N_3O_3F$ 1HCl	Requires	C 56.9	H 5.0	N 11.1%	

The starting material was prepared as follows:

A solution of 2-amino-4-fluorobenzoic acid (3g, 19.3mmol) in formamide (30ml) was heated at 150°C for 6 hours. The reaction mixture was poured onto ice/water 1/1 (250ml). The precipitated solid was collected by filtration, washed with water and dried to give 7-fluoro-3,4-dihydroquinazolin-4-one (2.6g, 82%).

Sodium (400mg, 17mmol) was added carefully to 2-methoxyethanol (10ml) and the mixture heated at reflux for 30 minutes. 7-Fluoro-3,4-dihydroquinazolin-4-one (750mg, 4.57mmol) was added to the resulting solution and the mixture heated at reflux for 15 hours. The mixture was cooled and poured into water (250ml). The mixture was acidified to pH4 with concentrated hydrochloric acid. The resulting solid product was collected by filtration, washed with water and then with ether, and dried under vacuum to give 7-(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one (580mg, 58%).

A solution of 7-(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one (500mg, 2.2mmol) in thionyl chloride (15ml) and DMF (0.1ml) was heated at reflux for 3 hours. The volatiles were removed by evaporation to give 4-chloro-7-(2-methoxyethoxy)quinazoline hydrochloride as a cream solid (520mg, 83%).

Example 28

A solution of 4-chloro-7-(2-methoxyethoxy)quinazoline hydrochloride (275mg, 1.0mmol), (prepared as described for the starting material in Example 27), and 4-chloro-2-fluoro-5-hydroxyaniline (193mg, 1.2mmol), (as described in EP 61741 A2), in 2-pentanol (5ml) was heated at reflux for 2 hours. The mixture was allowed to cool and the precipitate was collected by filtration, washed with isopropanol and ether, and dried under vacuum at 70°C to give **4-(4-chloro-2-fluoro-5-hydroxyanilino)-7-(2-methoxyethoxy)quinazoline** hydrochloride (178mg, 45%) as a cream solid.

m.p. 224-227°C

^{1}H NMR Spectrum: ($DMSOd_6$) 3.36(s, 3H); 3.76(t, 2H); 4.34(t, 2H); 7.14(d, 1H); 7.3(d, 1H); 7.53(m, 2H); 8.66(d, 1H); 8.85(s, 1H); 10.58(s, 1H); 11.40(s, 1H)

MS - ESI: 364 $[MH]^+$

Elemental analysis: Found C 50.8 H 4.1 N 10.4

$C_{17}H_{15}N_3O_3FCl$ 1HCl Requires C 51.0 H 4.0 N 10.5%

Example 29

A solution of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-methoxyacetamidoquinazoline (201mg, 0.5mmol) in methanol (5ml) and 2M aqueous sodium hydroxide solution (0.5ml) was stirred at ambient temperature for 1 hour. The mixture was

diluted with water and adjusted to pH6 with 2M hydrochloric acid. The precipitated solid was collected by filtration, washed with water, dried and then dissolved in a mixture of methylene chloride and methanol. A 5M solution of hydrogen chloride in isopropanol (0.3ml) was added and most of the solvent removed by evaporation. The precipitated solid was collected by filtration, washed with methylene chloride and dried under vacuum to give **4-(2-fluoro-5-hydroxy-4-methylanilino)-7-methoxyacetamidoquinazoline** hydrochloride (70mg, 36%) as a yellow solid.

m.p. 213-215°C

^{1}H NMR Spectrum: ($DMSOd_6$; CF_3COOD) 2.18(s, 3H); 3.43(s, 3H); 4.16(s, 2H); 6.90(d, 1H); 7.12(d, 1H); 7.95(d, 1H); 8.56(s, 1H); 8.62(d, 1H); 8.86(s, 1H)

MS - ESI: 357 $[MH]^+$

Elemental analysis:	Found	C 53.7	H 4.9	N 13.6
$C_{18}H_{17}N_4O_3F$ 1HCl $0.5H_2O$	Requires	C 53.8	H 4.8	N 13.9%

The starting material was prepared as follows:

A mixture of 7-nitro-3,4-dihydroquinazolin-4-one (5g, 26mmol) in thionyl chloride (50ml) and DMF (1ml) was heated at reflux for 1.5 hours. Excess thionyl chloride was removed by evaporation and the residue azeotroped with toluene. The residue was suspended in ether, collected by filtration and dried under vacuum to give 4-chloro-7-nitroquinazoline hydrochloride (6.4 g ; 100 %).

^{1}H NMR Spectrum: ($DMSOd_6$) 8.26(dd, 1H); 8.36(d, 1H); 8.40(s, 1H); 8.42(dd, 1H)

MS - ESI: 209 $[MH]^+$

A solution of 4-chloro-7-nitroquinazoline hydrochloride (2.46g, 10mmol) and 2-fluoro-5-methoxycarbonyloxy-4-methylaniline (2.2g, 11mmol), (prepared as described for the starting material in Example 26), in isopropanol (25ml) was heated at 50°C for 1 hour. The mixture was allowed to cool, the precipitated solid was collected by filtration recrystallised from methylene chloride/methanol/isopropanol, to give 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-nitroquinazoline hydrochloride (1.8g, 45%) as a yellow solid.

^{1}H NMR Spectrum: ($DMSOd_6$) 2.21(s, 3H); 3.86(s, 3H); 7.40(d, 1H); 7.46(d, 1H); 8.49(dd, 1H); 8.63(s, 1H); 8.84(s, 1H); 8.89(d, 1H)

MS - ESI: 373 $[MH]^+$

Elemental analysis:	Found	C 50.0	H 3.6	N 13.8
$C_{17}H_{13}N_4O_5F$ 1HCl	Requires	C 50.0	H 3.5	N 13.7%

A mixture of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-nitroquinazoline hydrochloride (5.3g, 13mmol) and 10% palladium-on-charcoal catalyst (1g) in ethanol (100ml), 7M ethanolic hydrogen chloride (1.8ml) and methanol (20ml) was stirred under hydrogen at 1.7atmospheres for 75 minutes. The catalyst was removed by filtration through diatomaceous earth and the filter pad thoroughly washed with methylene chloride, methanol and ether and the solvent was removed from the filtrate by evaporation to give 7-amino-4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)quinazoline hydrochloride (4.8g, 97%) as a yellow solid.

^{1}H NMR Spectrum: ($DMSOd_6$) 2.22(s, 3H); 3.87(s, 3H); 6.77(s, 1H); 7.08(dd, 1H); 7.15(m, 2H); 7.41(m, 2H); 8.35(d, 1H); 8.63(s, 1H); 11.03(s, 1H)

MS - ESI: 343 $[MH]^+$

Methoxyacetyl chloride (119mg, 1.1mmol) followed by triethylamine (232mg, 2.3mmol) were added to a suspension of 7-amino-4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)quinazoline hydrochloride (415mg, 1.1mmol) in methylene chloride (10ml) and the mixture stirred for 1 hour. The solvent was removed by evaporation and the residue partitioned between ethyl acetate and water. The organic layer was separated, washed with brine, dried ($MgSO_4$) and the solvent removed by evaporation. The resulting solid was purified by column chromatography eluting with methylene chloride/acetonitrile 50/50 followed by methylene chloride/acetonitrile/methanol 50/45/5 to give 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-methoxyacetamidoquinazoline (250mg, 60%) as a yellow solid.

^{1}H NMR Spectrum: ($DMSOd_6$) 2.18(s, 3H); 3.41(s, 3H); 3.85(s, 3H); 4.09(s, 2H); 7.30(d, 1H); 7.44(d, 1H); 7.84(d, 1H); 8.22(s, 1H); 8.36(d, 1H); 8.44(s, 1H); 9.74(s, 1H); 10.21(s, 1H)

MS - ESI: 437 $[MNa]^+$

Example 30

1M Aqueous sodium hydroxide solution (2.1ml, 2.1mmol) was added to a solution of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-hydroxyquinazoline hydrochloride (400mg, 1.05mmol), in methanol (10ml) and the mixture stirred for 50 minutes at ambient

temperature. The solvent was removed by evaporation, the residue dissolved in water and adjusted to pH7 with hydrochloric acid. The aqueous mixture was extracted with ethyl acetate, the extracts washed with brine, dried ($MgSO_4$) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol 95/5 and 80/20. The purified solid was dissolved in methanol and saturated methanolic hydrogen chloride was added. The volatiles were removed by evaporation, the residue was triturated with pentane to give **4-(2-fluoro-5-hydroxy-4-methylanilino)-7-hydroxyquinazoline** (149mg, 44%) as a yellow solid.

m.p. 274-278°C

^{1}H NMR Spectrum: ($DMSOd_6$) 2.16(s, 3H); 6.87(d, 1H); 7.10(d, 1H); 7.22(d, 1H); 7.32(ss, 1H); 8.57(d, 1H); 8.76(s, 1H); 9.66(s, 1H); 11.24(s, 1H); 11.70(s, 1H)

MS - ESI: 285 $[MH]^+$

Elemental analysis:		Found	C 54.2	H 4.1	N 12.3
$C_{15}H_{12}N_3O_2F$ 1HCl 0.3H_2O 0.05NaCl	Requires	C 54.6	H 4.2	N 12.7%	

The starting material was prepared as follows:

Sodium (368mg, 16mmol) was added to benzyl alcohol (10ml, 96mmol) and the mixture was heated at 148°C for 30 minutes, 7-fluoro-3,4-dihydroquinazolin-4-one (656mg, 4mmol), (J. Chem. Soc. section B 1967, 449), was added and the mixture maintained at 148°C for 24 hours. The reaction mixture was allowed to cool, the solution was poured on to water (170ml) and the aqueous mixture adjusted to pH3 with concentrated hydrochloric acid. The precipitate was collected by filtration, washed with water, ether and dried under vacuum to give 7-benzyloxy-3,4-dihydroquinazolin-4-one (890mg, 89%) as a white solid.

m.p. 267-269°C

^{1}H NMR Spectrum: ($DMSOd_6$; CF_3COOD) 5.32(s, 2H); 7.25(d, 1H); 7.32-7.52(m, 6H); 8.12(d, 1H); 8.99(s, 1H)

MS - ESI: 252 $[MH]^+$

Elemental analysis:	Found	C 71.4	H 4.9	N 10.7	
$C_{15}H_{12}N_2O_2$ 0.04H_2O	Requires	C 71.2	H 4.8	N 11.1	

A mixture of 7-benzyloxy-3,4-dihydroquinazolin-4-one (800mg, 3.17mmol) in thionyl chloride (20ml, 0.27mmol) and DMF (100µl) was heated at reflux for 3 hours. Excess

thionyl chloride was removed by evaporation and the residue azeotroped with toluene and dried under vacuum to give 7-benzyloxy-4-chloroquinazoline hydrochloride (835mg, 86%) as a cream solid.

m.p. 131-132°C

^{1}H NMR Spectrum: ($DMSOd_6$; CF_3COOD) 5.32(s, 2H); 7.29(d, 1H); 7.34-7.52(m, 6H); 8.12(d, 1H); 9.03(s, 1H)

MS - ESI: 270 $[MH]^+$

2-Fluoro-5-methoxycarbonyloxy-4-methylaniline (883mg, 4.4mmol), (prepared as described for the starting material in Example 26), was added to a solution of 7-benzyloxy-4-chloroquinazoline hydrochloride(1g, 3.7mmol) in 2-pentanol (15ml) at 120°C and the mixture was then heated at reflux for 4 hours. The precipitate was collected by filtration, washed with isopropanol followed by ether and dried under vacuum to give 7-benzyloxy-4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)quinazoline hydrochloride (1.65g, 97%) as a cream solid.

m.p. 219-220°C

^{1}H NMR Spectrum: ($DMSOd_6$) 2.22(s, 3H); 3.86(s, 3H); 5.37(s, 2H); 7.30-7.60(m, 9H); 8.60(d, 1H); 8.80(s, 1H); 11.2(s, 1H)

MS - ESI: 434 $[MH]^-$

Elemental analysis:	Found	C 60.1	H 4.9	N 8.5
$C_{24}H_{20}N_3O_4F$ 1HCl 0.5H_2O	Requires	C 60.2	H 4.6	N 8.8

7-Benzyloxy-4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)quinazoline hydrochloride (1.53g, 3.25mmol) and 10% palladium-on-charcoal catalyst (180mg) in a mixture of methanol/DMF/trichloromethane (75ml, 6ml, 30ml) was stirred under hydrogen at 1.5 atmospheres for 45 minutes. The catalyst was removed by filtration through diatomaceous earth and the solvent removed from the filtrate by evaporation. The residue was triturated with ether, the resulting solid collected by filtration and dried under vacuum to give 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-hydroxyquinazoline hydrochloride (1.23g, 84%) as an orange solid.

m.p. 205-210°C

^{1}H NMR Spectrum: ($DMSOd_6$) 2.22(s, 3H); 3.85(s, 3H); 7.24(d, 1H); 7.35(dd, 1H); 7.42(d, 1H); 7.45(d, 1H); 8.58(d, 1H); 8.81(s, 1H); 11.40(s, 1H); 11.76(s, 1H)

MS - ESI: 344 $[MH]^+$

Example 31

2M Aqueous sodium hydroxide solution (453µl, 0.9mmol) was added to a suspension of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-(3-morpholinopropionamido)quinazoline (219mg, 0.45mmol) in methanol (6ml) and the mixture stirred for 1 hour. The reaction mixture was diluted with water and then adjusted to pH6 with 2M hydrochloric acid. The resulting precipitate was collected by filtration, washed with water and ethanol and dried. The solid was dissolved in methylene chloride/methanol and a 5M solution of hydrogen chloride in isopropanol (0.3ml) added. The volatiles were removed by evaporation, the resulting solid was washed with ether, and dried under vacuum to give **4-(2-fluoro-5-hydroxy-4-methylanilino)-7-(3-morpholinopropionamido)quinazoline** (186mg, 80%) as a yellow solid.

m.p. 228-233°C

^1H NMR Spectrum: ($DMSOd_6$; CF_3COOD) 2.21(s, 3H); 3.1(t, 2H); 3.22(t, 2H); 3.5-3.6(m, 4H); 3.8(t, 2H); 4.05(d, 2H); 6.94(d, 1H); 7.10(d, 1H); 7.88(d, 1H); 8.55(s, 1H); 8.7(d, 1H); 8.9(s, 1H)

MS - ESI: 426 $[MH]^+$

Elemental analysis:	Found	C 52.1	H 5.8	N 13.4
$C_{22}H_{24}N_5O_3F$	Requires	C 52.5	H 5.6	N 13.5

1.9HCl $0.6H_2O$ 0.2isopropanol

The starting material was prepared as follows:

Potassium hydroxide (485mg, 8.6mmol) was added to a solution of methyl 3-morpholinopropionate (1g, 5.7mmol) in ethanol (20ml) and the mixture stirred for 2 hours at 80°C. The solution was allowed to cool and adjusted to pH1 with 6M hydrochloric acid. Insoluble material was removed by filtration and the volatiles removed from the filtrate by evaporation. The resulting oil was triturated with ether, the solid product collected by filtration, washed with methylene chloride and dried under vacuum to give 3-morpholinopropionic acid (993mg, 89%) as a white solid.

^{1}H NMR Spectrum: ($DMSOd_6$; CF_3COOD) 2.83(t, 2H); 3.13(t, 2H); 3.36(t, 2H); 3.46(d, 2H); 3.73(t, 2H); 3.97(d, 2H)

MS - ESI: 159 $[MH]^+$

1,3-Dicyclohexylcarbodiimide (343mg, 1.6mmol) was added to a suspension of 3-morpholinopropionic acid (325mg, 1.6mmol) in pyridine (12ml) and the mixture stirred for 10 minutes. 7-Amino-4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)quinazoline hydrochloride (370mg, 0.97mmol), (prepared as described for the starting material in Example 29), was added and the mixture stirred for 32 hours. 3-Morpholinopropionic acid (57mg, 0.29mmol) followed by 1,3-dicyclohexylcarbodiimide (100mg, 0.48mmol) was added and the mixture stirred for a further 18 hours. The solvent was removed by evaporation, the residue partitioned between water and ethyl acetate and the aqueous layer adjusted to pH8 with a saturated solution of sodium hydrogen carbonate. The organic layer was separated, washed with brine, dried ($MgSO_4$), and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (95/5) to give 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-(3-morpholinopropionamido)quinazoline (226mg, 48%) as a white solid.

^{1}H NMR Spectrum: ($DMSOd_6$) 2.18(s, 3H); 2.4-2.5(m, 4H); 2.5-2.6(m, 2H); 2.62-2.7(m, 2H); 3.58(t, 4H); 3.85(s, 3H); 7.30(d, 1H); 7.44(d, 1H); 7.7(d, 1H); 8.13(s, 1H); 8.35(d, 1H); 8.41(s, 1H); 9.7(s, 1H); 10.46(s, 1H)

Example 32

2M Aqueous sodium hydroxide solution (760µl, 1.5mmol) was added to a solution of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-(2-methoxyethylamino)quinazoline (304mg, 0.76mmol) in methanol (8ml) at 5°C and the mixture then stirred for 30 minutes at ambient temperature. The mixture was diluted with water and adjusted to pH6 with 2M hydrochloric acid. The precipitated solid was collected by filtration and then suspended in methylene chloride/methanol. A 5M solution of hydrogen chloride in isopropanol (0.4ml) was added and the volatiles were removed from the resulting solution by evaporation. The residue was triturated with ether, the solid product collected by filtration, washed with ether and dried under vacuum to give **4-(2-fluoro-5-hydroxy-4-methylanilino)-7-(2-methoxyethylamino)quinazoline** hydrochloride (260mg, 90%) as yellow solid.

m.p. 192-197°C

^{1}H NMR Spectrum: ($DMSOd_6$) 2.16(s, 3H); 3.32(s, 3H); 3.38(m, 2H); 3.58(m, 2H); 6.71(bs, 1H); 6.88(d, 1H); 7.1(d, 1H); 7.2(d, 1H); 7.73(m, 1H); 8.37(d, 1H); 8.61(s, 1H); 9.66(s, 1H); 10.95(s, 1H)

MS - ESI: 343 $[MH]^+$

The starting material was prepared as follows:

A solution of methoxyacetaldehyde dimethyl acetal (1.27g, 10mol) in water (7ml) and 2M hydrochloric acid (76µl) was heated at 50-60°C for 2 hours. The mixture was allowed to cool and adjusted to pH7.5 with saturated aqueous sodium hydrogen carbonate solution. This solution was added to a suspension of 7-amino-4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)quinazoline hydrochloride (400mg, 1mmol), (prepared as described for the starting material in Example 30), in ethanol (32ml) and acetic acid (95µl, 1.5mmol). The mixture was then stirred for 5 minutes, sodium cyanoborohydride (133mg, 2mmol) added and the solution adjusted to pH5.5 with glacial acetic acid. The mixture was stirred for 18 hours and the organic solvents removed by evaporation and the resulting aqueous mixture partitioned between ethyl acetate and water. The organic layer was separated, washed with brine, dried ($MgSO_4$) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (96/4 followed by 12/8) to give 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-(2-methoxyethylamino)quinazoline (308mg, 77%) as a yellow foam.

^{1}H NMR Spectrum: ($DMSOd_6$; CF_3COOD) 2.22(s, 3H); 3.33(s, 3H); 3.41(t, 2H); 3.60(t, 2H); 3.87(s, 3H); 6.68(br s, 1H); 7.22(dd, 1H); 7.37(d, 1H); 7.43(d, 1H); 8.30(d, 1H); 8.7(s, 1H)

Example 33

2M Aqueous sodium hydroxide solution (620µl) was added dropwise to a suspension of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-6-methoxy-7-methoxyacetamidoquinazoline (275mg, 0.62mmol) in methanol (8ml) at 5°C and the mixture then stirred for 90 minutes at ambient temperature. The reaction mixture was diluted with water and adjusted to pH7 with 2M hydrochloric acid. The precipitated solid was collected by filtration, resuspended in ethanol and a 5M solution of hydrogen chloride in isopropanol

(0.3ml) added. The volatiles were removed from the resulting solution by evaporation and the solid washed with ether collected by filtration and dried under vacuum to give **4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-methoxyacetamidoquinazoline** hydrochloride (216mg, 82%).

m.p. 300-306°C

^{1}H NMR Spectrum: ($DMSOd_6$) 2.18(s, 3H); 3.47(s, 2H); 4.13(s, 3H); 4.21(s, 3H); 6.92(d, 1H); 7.13(d, 1H); 8.41(s, 1H); 8.80(s, 1H); 8.90(s, 1H); 9.54(s, 1H); 9.72(s, 1H); 11.49(s, 1H)

MS - ESI: 387 $[MH]^+$

Elemental analysis:	Found	C 52.3	H 4.8	N 12.7
$C_{19}H_{19}N_4O_4F$ 1HCl 0.6H_2O	Requires	C 52.6	H 4.9	N 12.9

The starting material was prepared as follows:

Acetic anhydride (50ml) was added dropwise to a solution of 4-methoxy-2-methylaniline (49.7g, 360mmol) in DMA (200ml) at 5°C and the mixture stirred for 4.5 hours at ambient temperature. The solvent was removed by evaporation and the resulting solid washed with water and dried under vacuum to give N-(4-methoxy-2-methylphenyl)acetamide (57.3g, 88%).

^{1}H NMR Spectrum: ($CDCl_3$) 2.16(s, 3H); 2.21(s, 3H); 3.77(s, 3H); 6.7-6.75(m, 2H); 7.42(d, 1H)

A mixture of tin(IV)chloride (19.3ml) and 69.5% nitric acid (10.3ml) in methylene chloride (140ml) was added dropwise to a solution of N-(4-methoxy-2-methylphenyl)acetamide (28g, 0.14mol) in methylene chloride (500ml) cooled to and maintained at -30°C. The reaction mixture was stirred at -30°C for 1.5 hours, allowed to warm to ambient temperature then poured on to ice/water. The organic layer was separated and the aqueous layer extracted with ethyl acetate. The combined extracts were dried ($MgSO_4$), the solvent removed by evaporation and the residue purified by column chromatography eluting with petroleum ether/ethyl acetate (2/8) to give N-(4-methoxy-2-methyl-5-nitrophenyl)acetamide (17.8g, 51%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.06(s, 3H); 2.29(s, 3H); 3.9(s, 3H); 7.24(s, 1H); 7.99(s, 1H); 9.41(s, 1H)

Potassium permanganate (68g) was added portionwise to a solution of N-(4-methoxy-2-methyl-5-nitrophenyl)acetamide (35g, 0.156mol) and magnesium sulphate (38.5g) in water (2.3l) at 75°C. The mixture was maintained at 75°C for 3.5 hours, further magnesium sulphate (4g) and potassium permanganate (12g) were added and stirring continued for 30 minutes at 75°C. The insolubles were removed from the hot reaction mixture by filtration through diatomaceous earth, the filtrate cooled and was acidified to pH1 with concentrated hydrochloric acid. The precipitated solid was collected by filtration, washed with water and the aqueous filtrate extracted with ethyl acetate. The solid product and the ethyl acetate extract were combined and extracted with 2M aqueous sodium hydroxide solution. The basic aqueous layer was separated, washed with ethyl acetate, acidified with concentrated hydrochloric acid and re-extracted with ethyl acetate. The ethyl acetate extract was washed with brine, dried ($MgSO_4$) and the solvent removed by evaporation to give 2-acetamido-5-methoxy-4-nitrobenzoic acid (21.6g, 54%) as a yellow solid.

^{1}H NMR Spectrum: ($DMSOd_6$) 2.12(s, 3H); 3.93(s, 3H); 7.74(s, 1H); 8.75(s, 1H)

A solution of 2-acetamido-5-methoxy-4-nitrobenzoic acid (21.6g, 85mmol) in water (76ml) and concentrated hydrochloric acid (30.5ml) was heated at reflux for 3 hours. The reaction mixture was cooled to 0°C, the resulting solid was collected by filtration, washed with water and dried under vacuum to give 2-amino-5-methoxy-4-nitrobenzoic acid (16.6g, 92%).

^{1}H NMR Spectrum: ($DMSOd_6$) 3.79(s, 3H); 7.23(s, 1H); 7.52(s, 1H); 8.8(br s, 2H)

A solution of 2-amino-5-methoxy-4-nitrobenzoic acid (16.6g, 78mmol) in formamide (250ml) was heated at reflux for 4.5 hours. The reaction mixture was cooled to 0°C, diluted with water and the resulting precipitate collected by filtration, washed with water and dried under vacuum to give 6-methoxy-7-nitro-3,4-dihydroquinazolin-4-one (11.56g, 67%).

^{1}H NMR Spectrum: ($DMSOd_6$; CF_3COOD) 4.02(s, 3H); 7.8(s, 1H); 8.12(s, 1H); 8.18(s, 1H)

A suspension of 6-methoxy-7-nitro-3,4-dihydroquinazolin-4-one (8g, 36mmol) in thionyl chloride (150ml) and DMF (0.8ml) was heated at reflux for 3 hours. Excess thionyl chloride was removed by evaporation and the residue azeotroped with toluene. The resulting solid was triturated with ether, collected by filtration and dried under vacuum to give 4-chloro-6-methoxy-7-nitroquinazoline hydrochloride(7.5g, 75%).

^{1}H NMR Spectrum: ($DMSOd_6$) 4.13(s, 3H); 7.8(s, 1H); 8.7(s, 1H); 9.13(s, 1H)

A mixture of 4-chloro-6-methoxy-7-nitroquinazoline hydrochloride (784mg, 2.8mmol) and 2-fluoro-5-methoxycarbonyloxy-4-methylaniline (621mg, 3.1mmol), (prepared as described for the starting material in Example 26), in isopropanol (10ml) was heated at reflux for 2 hours. The mixture was allowed to cool, the precipitated product collected by filtration, washed with isopropanol, ether and dried under vacuum to give 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-6-methoxy-7-nitroquinazoline hydrochloride (1.12g, 90%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.22(s, 3H); 3.86(s, 3H); 4.10(s, 3H); 7.41(d, 1H); 7.46(d, 1H); 8.40(s, 1H); 8.55(s, 1H); 8.77(s, 1H); 11.4(br s, 1H)

MS - ESI: 403 $[MH]^+$

A mixture of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-6-methoxy-7-nitroquinazoline hydrochloride (1.1g, 25mmol) and 10% palladium-on-charcoal catalyst (220mg) in methanol (200ml) and ethanol (10ml) was stirred under hydrogen at 2.7 atmospheres for 7 hours. The catalyst was removed by filtration through diatomaceous earth, the solvent removed fom the filtrate by evaporation and the solid residue washed with ether, collected by filtration and dried under vacuum to give 7-amino-4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-6-methoxyquinazoline hydrochloride (930mg, 91%).

^{1}H NMR Spectrum: ($DMSOd_6$) 2.22(s, 3H); 3.87(s, 3H); 4.02(s, 3H); 6.9(s, 1H); 7.4-7.5(m, 2H); 7.99(s, 1H); 8.62(s, 1H)

MS - ESI: 372 $[MH]^+$

Methoxyacetyl chloride (62µl, 0.68mmol) was added dropwise to a solution of 7-amino-4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-6-methoxyquinazoline hydrochloride (215mg, 0.52mmol) in methylene chloride (5ml) and pyridine (1.5ml) at 0°C and the mixture stirred for 2 hours at 0°C. Further methoxyacetyl chloride (14µl, 0.15mmol) was added and the mixture stirred for 20 minutes at 0°C. The reaction mixture was partitioned between ethyl acetate and water and the aqueous layer adjusted to pH9 with saturated aqueous sodium hydrogen carbonate solution. The organic layer was separated, washed with brine, dried ($MgSO_4$) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/acetonitrile/methanol

(60/38/2) to give 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-6-methoxy-7-methoxyacetamidoquinazoline (175mg, 75%) as a white solid.

^{1}H NMR Spectrum: ($DMSOd_6$) 2.21(s, 3H); 3.47(s, 2H); 3.87(s, 3H); 4.07(s, 3H); 4.15(s, 3H); 7.35(d, 1H); 7.45(d, 1H); 7.96(s, 1H); 8.40(s, 1H); 8.65(s, 1H); 9.28(s, 1H); 9.65(s, 1H)

Example 34

A solution of ethereal hydrogen chloride (1.0ml of a 1.0M solution, 1.0mmol) was added to 4-chloro-6-methoxy-7-(2-thiomorpholinoethoxy)quinazoline (340mg, 1.0mmol) and 4-chloro-2-fluoro-5-hydroxyaniline (200mg, 1.2mmol), (as described in EP 61741 A2), in t-butanol (15ml). The mixture was heated at 95°C for 1 hour and then stirred for 18 hours at ambient temperature. The reaction mixture was diluted with acetone and the precipitated product collected by filtration, washed with acetone and dried to give **4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-thiomorpholinoethoxy)quinazoline** hydrochloride hemihydrate (480mg, 88%) as beige powder.

^{1}H NMR Spectrum: ($DMSOd_6$) 3.67(t, 2H); 4.04(s, 3H); 4.70(t, 2H); 7.18(d, 1H); 7.4-7.5(m, 2H); 7.51(dd, 1H); 8.44(s, 1H); 8.82(s, 1H); 10.6(br s, 1H); 11.7(br s, 1H)

MS - ESI: 465 $[MH]^+$

Elemental analysis :	Found	C 45.8	H 4.4	N 10.0
$C_{21}H_{22}N_4ClFO_3S$ 2HCl 0.5H_2O	Requires	C 46.1	H 4.6	N 10.2%

The starting material was prepared as follows:

1,2-Dibromoethane (19.2ml, 286mmol) was added to 7-hydroxy-6-methoxy-4-phenoxyquinazoline (6.0g, 22mmol), (prepared as described for the starting material in Example 16), and potassium carbonate (14.4g, 107mmol) in DMF. The mixture was stirred at 85°C for 2.5 hours, allowed to cool and insoluble material was removed by filtration. The solvent was removed by evaporation and the residue purified by column chromatography eluting with methylene chloride/methanol (93/7). The product was trituated with ethyl acetate to give 7-(2-bromoethoxy)-6-methoxy-4-phenoxyquinazoline (5.3g, 63%).

A mixture of 7-(2-bromoethoxy)-6-methoxy-4-phenoxyquinazoline (2.0g, 5.3mmol) in thiomorpholine (15ml) was stirred at ambient temperature for 5 hours. The mixture was diluted with water and the resulting precipitate collected by filtration. The solid product was

dissolved in methylene chloride, washed with brine and passed through phase separating paper. The solvent was removed by evaporation to give 6-methoxy-4-phenoxy-7-(2-thiomorpholinoethoxy)quinazoline (2.0g, 94%) as a pale yellow solid.

MS - ESI: 398 $[MH]^+$

A mixture of 6-methoxy-4-phenoxy-7-(2-thiomorpholinoethoxy)quinazoline (2.0g, 5mmol) in 2M hydrochloric acid (25ml) was heated at 90°C for 1.5 hours. The mixture was allowed to cool and adjusted to pH7 with solid sodium hydrogen carbonate. Methylene chloride was added and the resulting semi-solid product was isolated by decanting and filtering the aqueous mixture. This product was dissolved in acetone and insoluble material was removed by filtration. The solvent was removed by evaporation and the residue azeotroped with toluene to give 6-methoxy-7-(2-thiomorpholinoethoxy)-3,4-dihydroquinazolin-4-one (1.5g, 92%) as a white solid.

MS - ESI: 322 $[MH]^+$

A mixture of 6-methoxy-7-(2-thiomorpholinoethoxy)-3,4-dihydroquinazolin-4-one (1.5g, 4.6mmol), thionyl chloride (25ml) and DMF (0.2 ml) was heated at reflux for 2 hours. Excess thionyl chloride was removed by evaporation and the residue azeotroped with toluene. The resulting gum was partitioned between aqueous sodium hydrogen carbonate solution and methylene chloride. The organic layer was separated and the aqueous layer extracted with methylene chloride (4x40ml). The combined extracts were passed through phase separating paper, the solvent removed by evaporation and the residue purified by column chromatography eluting with methylene chloride/methanol (95/5). The purified product was triturated with acetone to give 4-chloro-6-methoxy-7-(2-thiomorpholinoethoxy)quinazoline (400mg, 25%) as an orange/brown solid.

MS - ESI: 342 $[MH]^+$

Example 35

A solution of ethereal hydrogen chloride (1.0ml of a 1.0M solution, 1.0mmol) was added to 4-chloro-6-methoxy-7-(2-(2-methoxyethylamino)ethoxy)quinazoline (110mg, 3.5mmol) and 4-chloro-2-fluoro-5-hydroxyaniline (72mg, 4.5mmol), (as described in EP 61741 A2), in t-butanol (5ml). The mixture was heated at 95°C for 1 hour, allowed to cool and diluted with acetone. The precipitated product was collected by filtration, washed with

methylene chloride and acetone and dried to give **4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-(2-methoxyethylamino)ethoxy)quinazoline** hydrochloride hydrate (110mg, 59%) as a beige powder.

^{1}H NMR Spectrum: ($DMSOd_6$) 3.2-3.6(m, 4H); 3.38(s, 3H); 3.73(t, 2H); 4.09(s, 3H); 4.58(t, 2H); 7.24(d, 1H); 7.52(d, 1H); 7.55(s, 1H); 8.48(s, 1H); 7.85(s, 1H); 9.35(br s, 1H); 10.65(br s, 1H); 11.75(br s, 1H)

MS - ESI: 437 $[MH]^+$

Elemental analysis : Found C 45.1 H 4.6 N 10.1

$C_{20}H_{22}N_4ClFO_4$ 2HCl $1.2H_2O$ Requires C 45.2 H 5.0 N 10.5%

The starting material was prepared as follows:

A mixture of 7-(2-bromoethoxy)-6-methoxy-4-phenoxyquinazoline (1.1g, 2.9mmol), (prepared as described for the starting material in Example 22), in 2-methoxyethylamine (8ml) was stirred at ambient temperature for 4 hours. The mixture was diluted with water and extracted with methylene chloride (5x25ml). The combined extracts were washed with brine and passed through phase separating paper. The solvent was removed by evaporation and the residue purified by column chromatography eluting with methylene chloride/methanol/aqueous ammonia (100/8/1) to give 6-methoxy-4-phenoxy-7-(2-(2-methoxyethylamino)ethoxy)quinazoline (760mg, 70%) as a white solid.

MS - ESI: 370 $[MH]^+$

A mixture of 6-methoxy-4-phenoxy-7-(2-(2-methoxyethylamino)ethoxy)quinazoline (760mg, 2mmol) in 2M hydrochloric acid (5ml) was heated at 90°C for 1.5 hours. The mixture was allowed to cool and adjusted to pH7 with solid sodium hydrogen carbonate. The water was removed by evaporation and the residue extracted with methylene chloride/methanol/aqueous ammonia (100/8/1). The volatiles were removed from the extract by evaporation, the residue dissolved in methylene chloride, passed through phase separating paper and the solvent removed by evaporation to give 6-methoxy-7-(2-(2-methoxyethylamino)ethoxy)-3,4-dihydroquinazolin-4-one (600mg, 99%) as a white solid.

A mixture of 6-methoxy-7-(2-(2-methoxyethylamino)ethoxy)-3,4-dihydroquinazolin-4-one (300mg, 1mmol), thionyl chloride (5ml) and DMF (0.1ml) was heated at reflux for 45 minutes. Excess thionyl chloride was removed by evaporation and the

residue azeotroped with toluene. The resulting gum was partitioned between aqueous sodium hydrogen carbonate solution and methylene chloride. The organic layer was separated and the aqueous layer extracted with methylene chloride (4x40ml). The combined extracts were passed through phase separating paper and the solvent removed by evaporation to give 4-chloro-6-methoxy-7-(2-(2-methoxyethylamino)ethoxy)quinazoline (120mg, 38%) as a yellow solid.

Example 36

A solution of 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (202mg, 0.6mmol) and 5M isopropanolic hydrogen chloride (1.5ml) in isopropanol (5ml) was heated at 80°C for 18 hours. The mixture was allowed to cool and the volatiles were removed by evaporation. The residue was partitioned between methylene chloride and water and the aqueous layer was adjusted to pH6.5 with 0.1M aqueous sodium hydroxide. The organic layer was separated, washed with water and brine, dried ($MgSO_4$) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (95/5). The purified solid was dissolved in methylene chloride/methanol and 2.2M ethereal hydrogen chloride was added. The volatiles were removed by evaporation, the solid residue was suspended in ether, collected by filtration, washed with ether and dried under vacuum to give **4-(4-bromo-2,6-difluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline** hydrochloride (91mg, 26%).

^{1}H NMR Spectrum: ($DMSOd_6$; CF_3COOD) 2.3-2.4(m, 2H); 3.1-3.2(m, 2H); 3.3-3.4(m, 2H); 3.55(d, 2H); 3.75(t, 2H); 4.01(d, 2H); 4.03(s, 3H); 4.35(t, 2H); 7.43(s, 1H); 7.76(d, 2H); 8.21(s, 1H); 8.93(s, 1H)

MS - ESI: 511 $[MH]^+$

Elemental Analysis:	Found	C 45.4	H 4.7	N 9.2
$C_{22}H_{23}N_4O_3BrF_2$ 0.3H_2O 1.85 HCl 0.09 ether 0.05 CH_2Cl_2	Requires	C 45.4	H 4.5	N 9.4%

The starting material was prepared as follows:

Diethyl azodicarboxylate (2.67ml, 17mmol) was added dropwise to a solution of 3-morpholinopropan-1-ol (1.54g, 10mmol), 7-hydroxy-3,4-dihydro-6-methoxy-3-

((pivaloyloxy)methyl)quinazolin-4-one (2.6g, 8.5mmol) and triphenylphosphine (4.45g, 17mmol) in methylene chloride (40ml). After stirring for 2 hours at ambient temperature, the volatiles were removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (97/3 followed by 95/5) to give 3,4-dihydro-6-methoxy-3-((pivaloyloxy)methyl)-7-(3-morpholinopropoxy)quinazolin-4-one (3.6g, 97%).

^{1}H NMR Spectrum: (DMSOd_6; CF_3COOD) 1.12(s, 9H); 2.2-2.3(m, 2H); 3.1-3.2(m, 2H); 3.32(t, 2H); 3.55(d, 2H); 3.65-3.75(m, 2H); 3.92(s, 3H); 4.05(d, 2H); 4.25(t, 2H); 5.93(s, 2H); 7.23(s, 1H); 7.54(s, 1H); 8.41(s, 1H)

A solution of 3,4-dihydro-6-methoxy-3-((pivaloyloxy)methyl)-7-(3-morpholinopropoxy)quinazolin-4-one (4.93g, 11.4mmol) in a saturated solution of methanolic ammonia (70ml) was stirred at ambient temperature for 2 days. The volatiles were removed by evaporation. The solid residue was suspended in ether, collected by filtration, washed with ether and dried under vacuum to give 4-hydroxy-6-methoxy-7-(3-morpholinopropoxy)quinazoline (2.87g, 79%).

^{1}H NMR Spectrum: (DMSOd_6; CF_3COOD) 2.2-2.3(m, 2H); 3.15(t, 2H); 3.35(t, 2H); 3.55(d, 2H); 3.7(t, 2H); 3.94(s, 3H); 4.05(d, 2H); 4.26(t, 2H); 7.29(s, 1H); 7.56(s, 1H); 8.96(s, 1H)

A solution of 4-hydroxy-6-methoxy-7-(3-morpholinopropoxy)quinazoline (2.87g, 9mmol) and DMF (1ml) in thionyl chloride (35ml) was refluxed for 45 minutes. After addition of toluene, the volatiles were removed by evaporation. The residue was partitioned between ethyl acetate and water and the aqueous layer was adjusted to pH8 with 2M aqueous sodium hydroxide. The organic layer was washed with water and brine, dried ($MgSO_4$) and the volatiles were removed by evaporation. The solid residue was purified by column chromatography eluting with a mixture of methylene chloride, acetonitrile and methanol (50/47.5/2.5) to give 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (2g, 66%).

^{1}H NMR Spectrum: ($CDCl_3$) 2.13(m, 2H); 2.48(br s, 4H); 2.56(t, 2H); 3.72(t, 4H); 4.05(s, 3H); 4.29(t, 2H); 7.37(d, 2H); 8.86(s, 1H)

Example 37

The following illustrate representative pharmaceutical dosage forms containing the compound of formula I, or a pharmaceutically acceptable salt thereof (hereafter compound X), for therapeutic or prophylactic use in humans:

(a)	Tablet I	mg/tablet
	Compound X	100
	Lactose Ph.Eur	182.75
	Croscarmellose sodium	12.0
	Maize starch paste (5% w/v paste)	2.25
	Magnesium stearate	3.0

(b)	Tablet II	mg/tablet
	Compound X	50
	Lactose Ph.Eur	223.75
	Croscarmellose sodium	6.0
	Maize starch	15.0
	Polyvinylpyrrolidone (5% w/v paste)	2.25
	Magnesium stearate	3.0

(c)	Tablet III	mg/tablet
	Compound X	1.0
	Lactose Ph.Eur	93.25
	Croscarmellose sodium	4.0
	Maize starch paste (5% w/v paste)	0.75
	Magnesium stearate	1.0

(d)	Capsule	mg/capsule
	Compound X	10
	Lactose Ph.Eur	488.5
	Magnesium stearate	1.5

(e)	Injection I	(50 mg/ml)
	Compound X	5.0% w/v
	1N Sodium hydroxide solution	15.0% v/v
	0.1N Hydrochloric acid	